<SEC-DOCUMENT>0001213900-22-014672.txt : 20220324
<SEC-HEADER>0001213900-22-014672.hdr.sgml : 20220324
<ACCEPTANCE-DATETIME>20220324093836
ACCESSION NUMBER:		0001213900-22-014672
CONFORMED SUBMISSION TYPE:	20-F
PUBLIC DOCUMENT COUNT:		82
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220324
DATE AS OF CHANGE:		20220324

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Can-Fite BioPharma Ltd.
		CENTRAL INDEX KEY:			0001536196
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		20-F
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36203
		FILM NUMBER:		22764918

	BUSINESS ADDRESS:	
		STREET 1:		10 BAREKET STREET, KIRYAT MATALON
		STREET 2:		P.O. BOX 7537
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			4951778
		BUSINESS PHONE:		972 39241114

	MAIL ADDRESS:	
		STREET 1:		10 BAREKET STREET, KIRYAT MATALON
		STREET 2:		P.O. BOX 7537
		CITY:			PETACH TIKVA
		STATE:			L3
		ZIP:			4951778
</SEC-HEADER>
<DOCUMENT>
<TYPE>20-F
<SEQUENCE>1
<FILENAME>f20f2021_canfitebio.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 24 13:02:59 UTC 2022 -->
<html xmlns:canf="http://www.confite.com/20211231" xmlns:compsci="http://compsciresources.com" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://www.w3.org/1999/xhtml" xmlns:xml="http://www.w3.org/XML/1998/namespace"><head>
     <title> </title>

<meta content="text/html" http-equiv="Content-Type" />
</head>
<body><div style="font: 10pt Times New Roman, Times, Serif"><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="border-top: Black 2pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">SECURITIES AND EXCHANGE COMMISSION<br/>
Washington, D.C. 20549</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Form <ix:nonNumeric contextRef="c0" name="dei:DocumentType">20-F</ix:nonNumeric></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:DocumentRegistrationStatement"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric>
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Or</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentAnnualReport"><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></ix:nonNumeric>
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">For the fiscal year ended <ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate"><ix:nonNumeric contextRef="c0" format="ixt:date-monthname-day-en" name="dei:CurrentFiscalYearEndDate">December 31</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric></ix:nonNumeric></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Or</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric>
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Or</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" format="ixt-sec:boolballotbox" name="dei:DocumentShellCompanyReport"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric>
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of event requiring this shell company report________________________</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>For the transition period from</b>__________
to ___________</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Commission File No. <ix:nonNumeric contextRef="c0" name="dei:EntityFileNumber">001-36203</ix:nonNumeric></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityRegistrantName">Can-Fite BioPharma Ltd.</ix:nonNumeric></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of Registrant as specified in
its charter)</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Can-Fite BioPharma Ltd., an Israeli Limited
Company</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Translation of Registrant&#8217;s name
into English)</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><i>&#160;</i><ix:nonNumeric contextRef="c0" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode">Israel</ix:nonNumeric></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Jurisdiction of incorporation or organization)</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine1">10 Bareket Street</ix:nonNumeric>,<br/>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine2">Kiryat Matalon</ix:nonNumeric>,<br/>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressAddressLine3">P.O. Box 7537</ix:nonNumeric>,<br/>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressCityOrTown">Petah-Tikva</ix:nonNumeric><br/>
<ix:nonNumeric contextRef="c0" name="dei:EntityAddressPostalZipCode">4951778</ix:nonNumeric>, <ix:nonNumeric contextRef="c0" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Israel</ix:nonNumeric></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal executive offices)</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelName">Motti Farbstein</ix:nonNumeric><br/>
Chief Operating and Financial Officer<br/>
Tel: +<ix:nonNumeric contextRef="c1" name="dei:CityAreaCode">972</ix:nonNumeric> <ix:nonNumeric contextRef="c1" name="dei:LocalPhoneNumber">(3) 924-1114</ix:nonNumeric><br/>
Fax: +<ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelFaxNumber">972 (3) 924-9378</ix:nonNumeric><br/>
<ix:nonNumeric contextRef="c1" name="dei:ContactPersonnelEmailAddress"><span style="text-decoration:underline;text-decoration: none">motti@canfite.co.il</span></ix:nonNumeric></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine1">10 Bareket Street</ix:nonNumeric>,<br/>
<ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine2">Kiryat Matalon</ix:nonNumeric>,<br/>
<ix:nonNumeric contextRef="c1" name="dei:EntityAddressAddressLine3">P.O. Box 7537</ix:nonNumeric>,<br/>
<ix:nonNumeric contextRef="c1" name="dei:EntityAddressCityOrTown">Petah-Tikva</ix:nonNumeric><br/>
<ix:nonNumeric contextRef="c1" name="dei:EntityAddressPostalZipCode">4951778</ix:nonNumeric>, <ix:nonNumeric contextRef="c1" format="ixt-sec:countrynameen" name="dei:EntityAddressCountry">Israel</ix:nonNumeric></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Name, Telephone, E-mail and/or Facsimile
number and Address of Company Contact Person)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Securities registered or to be registered pursuant
to Section 12(b) of the Act:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center">Title of each class</td> <td style="text-align: center; width: 2%; vertical-align: bottom">&#160;</td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 32%; text-align: center">Trading Symbol(s)</td> <td style="text-align: center; width: 2%; vertical-align: bottom">&#160;</td> <td style="vertical-align: bottom; width: 32%; border-bottom: black 1.5pt solid; text-align: center">Name of each exchange on which registered</td></tr> <tr style="vertical-align: top; background-color: #CCEEFF"> <td style="text-align: center; font-weight: bold"><ix:nonNumeric contextRef="c0" name="dei:Security12bTitle">American Depositary Shares, each representing 30 Ordinary Shares, par value NIS 0.25 per share</ix:nonNumeric>*</td> <td style="text-align: center">&#160;</td> <td style="text-align: center; font-weight: bold"><ix:nonNumeric contextRef="c0" name="dei:TradingSymbol">CANF</ix:nonNumeric></td> <td style="text-align: center; font-weight: bold">&#160;</td> <td style="text-align: center; font-weight: bold"><ix:nonNumeric contextRef="c0" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NYSE American</ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities registered or to be registered pursuant
to Section 12(g) of the Act:<br/>
<b>None</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Securities for which there is a reporting obligation
pursuant to Section 15(d) of the Act:<br/>
<b>None</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">* Ordinary shares not for trading, but only in
connection with the registration of the American Depositary Shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate the number of outstanding
shares of each of the issuer&#8217;s classes of capital or common stock as of the close of the period covered by the annual report (December
31, 2021): <ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="shares">815,746,293</ix:nonFraction> ordinary shares are outstanding.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark if
the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityWellKnownSeasonedIssuer">No</ix:nonNumeric>
<span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this report is an annual
or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934. Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;<ix:nonNumeric contextRef="c0" name="dei:EntityVoluntaryFilers">No</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such a shorter period that the registrant was required to file such reports), and (2) has been subject to
such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c0" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span>&#160;&#160;No
<span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T
(&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit
such files). <ix:nonNumeric contextRef="c0" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span>&#160;&#160;No <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or an emerging growth company. See definition
of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of
the Exchange Act.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="width: 23%; text-align: left">Large accelerated filer</td> <td style="vertical-align: top; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></td> <td style="width: 23%; text-align: left">Accelerated filer</td> <td style="vertical-align: top; width: 7%; text-align: center"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></td> <td style="width: 33%; text-align: left"><ix:nonNumeric contextRef="c0" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></td> <td style="vertical-align: top; width: 7%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">&#9746;</span></td></tr> <tr> <td style="vertical-align: top; text-align: left">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="vertical-align: top; text-align: left">&#160;</td> <td style="vertical-align: top; text-align: center">&#160;</td> <td style="text-align: left">Emerging growth company</td> <td style="vertical-align: top; text-align: right"><ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityEmergingGrowthCompany"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an emerging growth
company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected
not to use the extended transition period for complying with any new or revised financial accounting standards&#8224; provided
pursuant to Section 13(a) of the Exchange Act &#9744;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#1006; The term &#8220;new
or revised financial accounting standard&#8221; refers to any update issued by the Financial Accounting Standards Board to its Accounting
Standards Codification after April 5, 2012.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark whether
the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control
over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that
prepared or issued its audit report. <ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:IcfrAuditorAttestationFlag"><span style="font-family: Times New Roman, Times, Serif">&#9744;</span></ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Indicate by check mark which
basis of accounting the registrant has used to prepare the financial statements included in this filing:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="width: 25%; text-align: center"><ix:nonNumeric contextRef="c0" name="dei:DocumentAccountingStandard">U.S. GAAP</ix:nonNumeric> <span style="font-family: Times New Roman, Times, Serif">&#9746;</span></td> <td style="width: 50%; text-align: center">International Financial Reporting Standards</td> <td style="width: 25%; text-align: center">Other <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center">&#160;</td> <td style="text-align: center">as issued by the International Accounting Standards Board <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></td> <td style="text-align: center">&#160;</td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If &#8220;Other&#8221; has
been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to
follow. Item 17 <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;Item 18 <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If this is an annual report,
indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <span style="font-family: Times New Roman, Times, Serif">&#9744;</span>&#160;&#160;<ix:nonNumeric contextRef="c0" format="ixt:fixed-false" name="dei:EntityShellCompany">No</ix:nonNumeric>
<span style="font-family: Times New Roman, Times, Serif">&#9746;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><div style="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>


</div><!-- Field: Page; Sequence: 2 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="margin: 0pt">&#160;</p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-align: justify"><b><a href="#a_001">PART I</a></b></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: top; ">
    <td style="width: 13%; text-align: justify"><b>ITEM 1.</b></td>
    <td style="width: 75%; text-align: justify"><a href="#a_002">Identity of Directors, Senior Management and Advisers.</a></td>
    <td style="width: 12%; text-align: center">1</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><b>ITEM 2.</b></td>
    <td style="text-align: justify"><a href="#a_003">Offer Statistics and Expected Timetable</a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><b>ITEM 3.</b></td>
    <td style="text-align: justify"><a href="#a_004">Key Information</a></td>
    <td style="text-align: center">1</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><b>ITEM 4.</b></td>
    <td style="text-align: justify"><a href="#a_005">Information on the Company</a></td>
    <td style="text-align: center">29</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><b>ITEM 4A.</b></td>
    <td style="text-align: justify"><a href="#a_006">Unresolved Staff Comments</a></td>
    <td style="text-align: center">63</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><b>ITEM 5.</b></td>
    <td style="text-align: justify"><a href="#a_007">Operating and Financial Review and Prospects</a></td>
    <td style="text-align: center">63</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><b>ITEM 6.</b></td>
    <td style="text-align: justify"><a href="#a_008">Directors, Senior Management and Employees</a></td>
    <td style="text-align: center">74</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><b>ITEM 7.</b></td>
    <td style="text-align: justify"><a href="#a_009">Major Shareholders and Related Party Transactions</a></td>
    <td style="text-align: center">94</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><b>ITEM 8.</b></td>
    <td style="text-align: justify"><a href="#a_010">Financial Information</a></td>
    <td style="text-align: center">96</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><b>ITEM 9.</b></td>
    <td style="text-align: justify"><a href="#a_011">The Offer and Listing</a></td>
    <td style="text-align: center">96</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><b>ITEM 10.</b></td>
    <td style="text-align: justify"><a href="#a_012">Additional Information</a></td>
    <td style="text-align: center">97</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><b>ITEM 11.</b></td>
    <td style="text-align: justify"><a href="#a_013">Quantitative and Qualitative Disclosures About Market Risk</a></td>
    <td style="text-align: center">114</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><b>ITEM 12.</b></td>
    <td style="text-align: justify"><a href="#a_014">Description of Securities Other Than Equity Securities</a></td>
    <td style="text-align: center">114</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; ">
    <td colspan="2" style="text-align: justify"><b><a href="#a_014a">PART II</a></b></td>
    <td style="text-align: center">116</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><b>ITEM 13.</b></td>
    <td style="text-align: justify"><a href="#a_015">Defaults, Dividend Arrearages and Delinquencies</a></td>
    <td style="text-align: center">116</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><b>ITEM 14.</b></td>
    <td style="text-align: justify"><a href="#a_016">Material Modifications to the Rights of Security Holders and Use of Proceeds</a></td>
    <td style="text-align: center">116</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><b>ITEM 15.</b></td>
    <td style="text-align: justify"><a href="#a_017">Controls and Procedures</a></td>
    <td style="text-align: center">116</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><b>ITEM 16.</b></td>
    <td style="text-align: justify"><a href="#a_018">[RESERVED]</a></td>
    <td style="text-align: center">117</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><b>ITEM 16A.</b></td>
    <td style="text-align: justify"><a href="#a_019">Audit Committee Financial Expert</a></td>
    <td style="text-align: center">117</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><b>ITEM 16B.</b></td>
    <td style="text-align: justify"><a href="#a_020">Code of Ethics</a></td>
    <td style="text-align: center">117</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><b>ITEM 16C.</b></td>
    <td style="text-align: justify"><a href="#a_021">Principal Accountant Fees and Services</a></td>
    <td style="text-align: center">117</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><b>ITEM 16D.</b></td>
    <td style="text-align: justify"><a href="#a_022">Exemptions from the Listing Standards for Audit Committees</a></td>
    <td style="text-align: center">118</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><b>ITEM 16E.</b></td>
    <td style="text-align: justify"><a href="#a_023">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</a></td>
    <td style="text-align: center">118</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><b>ITEM 16F.</b></td>
    <td style="text-align: justify"><a href="#a_024">Change in Registrant&#8217;s Certifying Accountant</a></td>
    <td style="text-align: center">118</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><b>ITEM 16G.</b></td>
    <td style="text-align: justify"><a href="#a_025">Corporate Governance</a></td>
    <td style="text-align: center">118</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><b>ITEM 16H.</b></td>
    <td style="text-align: justify"><a href="#a_026">Mine Safety Disclosure</a></td>
    <td style="text-align: center">118</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><b>ITEM 16I.</b></td>
    <td style="text-align: justify"><a href="#a_027">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></td>
    <td style="text-align: center">118</td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="text-align: justify"><b><a href="#a_028">PART III</a></b></td>
    <td style="text-align: center">119</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><b>ITEM 17.</b></td>
    <td style="text-align: justify"><a href="#a_029">Financial Statements</a></td>
    <td style="text-align: center">119</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><b>ITEM 18.</b></td>
    <td style="text-align: justify"><a href="#a_030">Financial Statements</a></td>
    <td style="text-align: center">119</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: justify"><b>ITEM 19.</b></td>
    <td style="text-align: justify"><a href="#a_031">Exhibits</a></td>
    <td style="text-align: center">119</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 3 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">INTRODUCTION</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Can-Fite is a clinical-stage
biopharmaceutical company that develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and
inflammatory diseases and erectile dysfunction. We are also developing specific formulations of cannabis components for the treatment
of cancer, inflammatory, autoimmune, and metabolic diseases. Our platform technology utilizes the Gi protein associated A3 adenosine receptor,
or A3AR, as a therapeutic target. A3AR is highly expressed in pathological body cells such as inflammatory and cancer cells, and has a
low expression in normal cells, suggesting that the receptor could be a specific target for pharmacological intervention. Our pipeline
of drug candidates are synthetic, highly specific agonists and allosteric modulators targeting the A3AR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ordinary shares have been
trading on the Tel Aviv Stock Exchange, or TASE, under the symbol &#8220;CFBI&#8221; since October 2005. On October 2, 2012, our ADSs
began trading over the counter, or OTC, in the United States under the symbol &#8220;CANFY&#8221; and on November 19, 2013, our ADSs began
trading on the NYSE American under the symbol &#8220;CANF.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated, all references to the &#8220;Company,&#8221;
&#8220;we,&#8221; &#8220;our&#8221; and &#8220;Can-Fite&#8221; refer to Can-Fite BioPharma Ltd. and its consolidated subsidiary. References
to &#8220;ordinary shares&#8221;, &#8220;ADSs&#8221;, &#8220;warrants&#8221; and &#8220;share capital&#8221; refer to the ordinary shares,
ADSs, warrants and share capital, respectively, of Can-Fite.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">References to &#8220;U.S.
dollars&#8221;, &#8220;USD&#8221;, and &#8220;$&#8221; are to currency of the United States of America, and references to &#8220;NIS&#8221;
are to New Israeli Shekels. References to &#8220;ordinary shares&#8221; are to our ordinary shares, par value of NIS 0.25 per share. We
report financial information under generally accepted accounting principles in the United States, or U.S. GAAP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unless otherwise indicated,
U.S. dollar translations of NIS amounts presented in this Annual Report on Form 20-F for the year ended on December 31, 2021 are translated
using the rate of NIS 3.11 to $1.00, the exchange rate reported by the Bank of Israel on December 31, 2021, U.S. dollar translations of
NIS amounts presented in this Annual Report on Form 20-F for the year ended on December 31, 2020 are translated using the rate of NIS
3.215 to $1.00, the exchange rate reported by the Bank of Israel on December 31, 2020, and U.S. dollar translations of NIS amounts presented
in this Annual Report on Form 20-F for the year ended on December 31, 2019 are translated using the rate of NIS 3.456 to $1.00, the exchange
rate reported by the Bank of Israel on December 31, 2019.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 10, 2019, we effected
a change in the ratio of our ADSs to ordinary shares from one (1) ADS representing two (2) ordinary shares to a new ratio of one (1) ADS
representing thirty (30) ordinary shares. For ADS holders, the ratio change had the same effect as a one-for-fifteen reverse ADS split.
All ADS and related option and warrant information presented in this Annual Report on Form 20-F have been retroactively adjusted to reflect
the reduced number of ADSs and the increase in the ADS price which resulted from this action. Unless otherwise indicated, in this Annual
Report on Form 20-F fractional ADSs have been rounded to the nearest whole number.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 4 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">FORWARD LOOKING STATEMENTS</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Annual Report on Form
20-F contains forward-looking statements, about our expectations, beliefs or intentions regarding, among other things, our product development
efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives
have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking
words such as &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;may,&#8221; &#8220;should&#8221;
or &#8220;anticipate&#8221; or their negatives or other variations of these words or other comparable words or by the fact that these
statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited
to, various filings made by us with the U.S. Securities and Exchange Commission, or the SEC, press releases or oral statements made by
or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events,
activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred,
these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future
results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially
from the activities and results anticipated in forward-looking statements, including, but not limited to, the factors summarized below.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Annual Report on Form
20-F identifies important factors which could cause our actual results to differ materially from those indicated by the forward-looking
statements, particularly those set forth under the heading &#8220;Risk Factors.&#8221; The risk factors included in this Annual Report
on Form 20-F are not necessarily all of the important factors that could cause actual results to differ materially from those expressed
in any of our forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking
statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking statements
include, but are not limited to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our history of losses and needs for additional capital to fund our operations and our inability to obtain
additional capital on acceptable terms, or at all;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: 0in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">uncertainties of cash flows and inability to meet working
capital needs;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the initiation, timing, progress and results of our preclinical studies, clinical trials and other product
candidate development efforts;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our ability to advance our product candidates into clinical trials or to successfully complete our preclinical
studies or clinical trials;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings
and approvals;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the clinical development, commercialization and market acceptance of our product candidates;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">our ability to establish and maintain strategic partnerships and other corporate collaborations;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the implementation of our business model and strategic plans for our business and product candidates;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the scope of protection we are able to establish and maintain for intellectual property rights covering our
product candidates and our ability to operate our business without infringing the intellectual property rights of others;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">competitive companies, technologies and our industry;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">risks related to the COVID-19 pandemic and the Russian invasion of Ukraine;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">risks related to not satisfying the continued listing requirements of NYSE American; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">statements as to the impact of the political and security situation in Israel on our business.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">All forward-looking statements
attributable to us or persons acting on our behalf speak only as of the date of this Annual Report on Form 20-F and are expressly qualified
in their entirety by the cautionary statements included in this Annual Report on Form 20-F. We undertake no obligations to update or revise
forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated
events. In evaluating forward-looking statements, you should consider these risks and uncertainties.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 5 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">EXPLANATORY NOTE</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Market data and certain industry
data and forecasts used throughout this Annual Report on Form 20-F were obtained from sources we believe to be reliable, including market
research databases, publicly available information, reports of governmental agencies and industry publications and surveys. We have relied
on certain data from third-party sources, including internal surveys, industry forecasts and market research, which we believe to be reliable
based on our management&#8217;s knowledge of the industry. Forecasts are particularly likely to be inaccurate, especially over long periods
of time. In addition, we do not necessarily know what assumptions regarding general economic growth were used in preparing the third-party
forecasts we cite. Statements as to our market position are based on the most currently available data. While we are not aware of any
misstatements regarding the industry data presented in this Annual Report on Form 20-F, our estimates involve risks and uncertainties
and are subject to change based on various factors, including those discussed under the heading &#8220;Risk Factors&#8221; in this Annual
Report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 6 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="text-transform: uppercase"><b>PART
I</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_002"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
1. </span>Identity of Directors, Senior Management and Advisers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_003"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
2. </span>Offer Statistics and Expected Timetable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_004"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
3. </span>Key Information.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">A.
</span>[Reserved]</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">B.
</span>Capitalization and Indebtedness.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">C.
</span>Reasons for the Offer and Use of Proceeds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">D.
</span>Risk Factors</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You should carefully
consider the risks we describe below, in addition to the other information set forth elsewhere in this Annual Report on Form 20-F, including
our consolidated financial statements and the related notes beginning on page F-1, before deciding to invest in our ordinary shares and
American Depositary Shares, or ADSs. These material risks could adversely impact our results of operations, possibly causing the trading
price of our ordinary shares and ADSs to decline, and you could lose all or part of your investment.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Summary Risk Factors</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The principal factors and
uncertainties that make investing in our ordinary shares risky, include, among others:</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risks Related to Our Financial Position
and Capital Requirements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We have incurred operating losses since our inception and anticipate that we will continue to incur substantial
operating losses for the foreseeable future.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We will need to raise additional capital to meet our business requirements in the future, and such capital
raising may be costly or difficult to obtain and will dilute current shareholders&#8217; ownership interests.</td></tr></table><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risks Related to Our Business and
Regulatory Matters</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We have not yet commercialized any products or technologies, and we may never become profitable.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our product candidates are at various stages of clinical and preclinical development and may never be
commercialized.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Results of earlier clinical trials may not be predictive of the results of later-stage clinical trials.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We might be unable to develop product candidates that will achieve commercial success in a timely and
cost-effective manner, or ever.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our current pipeline is based on our platform technology utilizing the Gi protein associated A3AR, as
a potent therapeutic target and currently includes three molecules, Piclidenoson, Namodenoson and CF602 product candidates, of which Piclidenoson
is the most advanced. Failure to develop these molecules will have a material adverse effect on us.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Clinical trials are very expensive, time-consuming and difficult to design and implement, and, as a result,
we may suffer delays or suspensions in future trials which would have a material adverse effect on our ability to generate revenues.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The manufacture of our product candidates is a chemical synthesis process and if one of our materials
suppliers encounters problems manufacturing our products, our business could suffer.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We do not currently have sales, marketing or distribution capabilities or experience, and we are unable
to effectively sell, market or distribute our product candidates now and we do not expect to be able to do so in the future. The failure
to enter into agreements with third parties that are capable of performing these functions would have a material adverse effect on our
business and results of operations.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We depend on key members of our management and key consultants and will need to add and retain additional
leading experts. Failure to retain our management and consulting team and add additional leading experts could have a material adverse
effect on our business, results of operations or financial condition.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our product candidates will remain subject to ongoing regulatory requirements even if they receive marketing
approval, and if we fail to comply with these requirements, we could lose these approvals, and the sales of any approved commercial products
could be suspended.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We may not be able to successfully grow and expand our business. Failure to manage our growth effectively
will have a material adverse effect on our business, results of operations and financial condition.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our cannabinoid initiative is uncertain and may not yield commercial results and is subject to significant
regulatory risks.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We or the third parties upon whom we depend may be adversely affected by natural disasters and/or health
epidemics, and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our business may be adversely affected by the impact of COVID-19.</td></tr></table><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risks Related to Our Intellectual
Property</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The expiry of a patent that we licensed from the National
Institute of Health, or NIH, and the consequent loss of composition of matter exclusivity that we had by virtue of this license may diminish
our proprietary position.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We license from Leiden University intellectual property, which protects certain small molecules which
target the A3AR, in furtherance of our platform technology, and we could lose our rights to this license if a dispute with Leiden University
arises or if we fail to comply with the financial and other terms of the license.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The failure to obtain or maintain patents, licensing agreements, including our current licensing agreements,
and other intellectual property could impact our ability to compete effectively.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">International patent protection is particularly uncertain, and if we are involved in opposition proceedings
in foreign countries, we may have to expend substantial sums and management resources.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We may be unable to protect the intellectual property rights of the third parties from whom we license
certain of our intellectual property or with whom we have entered into other strategic relationships.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Under applicable U.S. and Israeli law, we may not be able to enforce covenants not to compete and therefore,
may be unable to prevent our competitors from benefiting from the expertise of some of our former employees. In addition, employees may
be entitled to seek compensation for their inventions irrespective of their agreements with us, which in turn could impact our future
profitability.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</td></tr></table><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risks Related to Our Industry</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We expect the healthcare industry to face increased limitations on reimbursement as a result of healthcare
reform, which could adversely affect third-party coverage of our products and how much or under what circumstances healthcare providers
will prescribe or administer our products.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our employees, principal investigators, consultants, commercial partners or vendors may engage in misconduct
or other improper activities, including non-compliance with regulatory standards.</td></tr></table><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risks Related to Our Operations in
Israel</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We conduct our operations in Israel and therefore our results may be adversely affected by political,
economic and military instability in Israel and its region.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Because a certain portion of our expenses is incurred in currencies other than U.S. dollars, our results
of operations may be harmed by currency fluctuations and inflation.</td></tr></table><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 8; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Risks Related to Our Ordinary Shares
and ADSs</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We are currently operating in a period of economic uncertainty and capital markets disruption, which has
been significantly impacted by geopolitical instability due to the ongoing military conflict between Russia and Ukraine</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our business could be negatively impacted by unsolicited takeover proposals, by shareholder activism or
by proxy contests relating to the election of directors or other matters.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Issuance of additional equity securities may adversely affect the market price of our ADSs or ordinary
shares.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The market price of our ordinary shares and ADSs is subject to fluctuation, which could result in substantial
losses by our investors.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We may not satisfy the NYSE American requirements for continued listing. If we cannot satisfy these requirements,
the NYSE American could delist our securities.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">As a foreign private issuer, we are permitted to follow certain home country corporate governance practices
instead of applicable SEC and NYSE American requirements, which may result in less protection than is accorded to investors under rules
applicable to domestic issuers.</td></tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Risks Related to Our Financial Position and
Capital Requirements</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have incurred
operating losses since our inception and anticipate that we will continue to incur substantial operating losses for the foreseeable future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage biopharmaceutical
company that develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases
and erectile dysfunction. Since our incorporation in 1994, we have been focused on research and development activities with a view to
developing our product candidates, CF101, also known as Piclidenoson, CF102, also known as Namodenoson, and CF602. We have financed our
operations primarily through the sale of equity securities (both in private placements and in public offerings on the TASE and NYSE American)
and payments received under out-licensing agreements and have incurred losses in each year since our inception in 1994. We have historically
incurred substantial net losses, including net losses of approximately $12.6 million in 2021, $14.4 million in 2020, and $12.6 million
in 2019. As of December 31, 2021, we had an accumulated deficit of approximately $140.7 million. We do not know whether or when we will
become profitable. To date, we have not commercialized any products or generated any revenues from product sales and accordingly we do
not have a revenue stream to support our cost structure. Our losses have resulted principally from costs incurred in development and discovery
activities. We expect to continue to incur losses for the foreseeable future, and these losses will likely increase as we:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">initiate and manage pre-clinical development and clinical trials for our current and new product candidates;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">seek regulatory approvals for our product candidates;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">implement internal systems and infrastructures;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">seek to license additional technologies to develop;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">hire management and other personnel; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">move towards commercialization.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our product candidates
fail in clinical trials or do not gain regulatory clearance or approval, or if our product candidates do not achieve market acceptance,
we may never become profitable. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly
or annual basis. Our inability to achieve and then maintain profitability would negatively affect our business, financial condition, results
of operations and cash flows. Moreover, our prospects must be considered in light of the risks and uncertainties encountered by an early-stage
company and in highly regulated and competitive markets, such as the biopharmaceutical market, where regulatory approval and market acceptance
of our products are uncertain. There can be no assurance that our efforts will ultimately be successful or result in revenues or profits.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 9; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will need to
raise additional capital to meet our business requirements in the future, and such capital raising may be costly or difficult to obtain
and will dilute current shareholders&#8217; ownership interests.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2021, we
had cash and cash equivalents of $4.4 million and short-term deposits of $14.5 million. We believe that our existing financial resources
will be sufficient to meet our requirements for the next twelve months from the date of issuance of this Annual Report on Form 20-F. We
have expended and believe that we will continue to expend substantial resources for the foreseeable future developing our product candidates.
These expenditures will include costs associated with research and development, manufacturing, conducting preclinical experiments and
clinical trials and obtaining regulatory approvals, as well as commercializing any products approved for sale. Because the outcome of
our planned and anticipated clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully
complete the development and commercialization of our product candidates. In addition, other unanticipated costs may arise. As a result
of these and other factors currently unknown to us, we will require additional funds, through public or private equity or debt financings
or other sources, such as strategic partnerships and alliances and licensing arrangements. In addition, we may seek additional capital
due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating
plans.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future capital requirements
will depend on many factors, including the progress and results of our clinical trials, the duration and cost of discovery and preclinical
development, and laboratory testing and clinical trials for our product candidates, the timing and outcome of regulatory review of our
product candidates, the number and development requirements of other product candidates that we pursue, and the costs of activities, such
as product marketing, sales, and distribution. Because of the numerous risks and uncertainties associated with the development and commercialization
of our product candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with
our anticipated clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our future capital requirements
depend on many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the level of research and development investment required
to develop our product candidates;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the failure to obtain regulatory approval or achieve commercial
success of our product candidates, including Piclidenoson, Namodenoson and CF602;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the results of our preclinical studies and clinical trials
for our earlier stage product candidates, and any decisions to initiate clinical trials if supported by the preclinical results;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the costs, timing and outcome of regulatory review of our
product candidates that progress to clinical trials;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">our ability to partner or sub-license any of our product candidates;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the costs of preparing, filing and prosecuting patent applications,
maintaining and enforcing our issued patents and defending intellectual property-related claims;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the cost of commercialization activities if any of our product
candidates are approved for sale, including marketing, sales and distribution costs;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the cost of manufacturing our product candidates and any products
we successfully commercialize;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">the timing, receipt and amount of sales of, or royalties on, our future products, if any;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">the expenses needed to attract and retain skilled personnel;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">any product liability or other lawsuits related to our products;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the extent to which we acquire or invest in businesses, products
or technologies and other strategic relationships;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the costs of financing unanticipated working capital requirements
and responding to competitive pressures; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">maintaining minimum shareholders&#8217; equity requirements
and complying with other continue listing standards under the NYSE American Company Guide</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additional funds may not be
available when we need them, on terms that are acceptable to us, or at all. General market conditions may make it very difficult for us
to seek financing from the capital markets and the COVID-19 outbreak and Russian invasion of Ukraine could impact the availability or
cost of future financings. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or
terminate preclinical studies, clinical trials or other research and development activities for one or more of our product candidates
or delay, limit, reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to
commercialize our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 10; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may incur substantial costs
in pursuing future capital financing, including investment banking fees, legal fees, accounting fees, securities law compliance fees,
printing and distribution expenses and other costs. We may also be required to recognize non-cash expenses in connection with certain
securities we issue, such as convertible notes and warrants, which may adversely impact our financial condition.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Raising additional
capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies
or product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may seek additional capital
through a combination of private and public equity offerings, debt financings, strategic partnerships and alliances and licensing arrangements.
To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of existing
shareholders will be diluted, and the terms may include liquidation or other preferences that adversely affect shareholder rights. Debt
financing, if available, may involve agreements that include covenants limiting or restricting our ability to take certain actions, such
as incurring debt, making capital expenditures or declaring dividends. If we raise additional funds through strategic partnerships and
alliances and licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies or product candidates,
or grant licenses on terms that are not favorable to us. If we are unable to raise additional funds through equity or debt financing when
needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to
develop and market product candidates that we would otherwise prefer to develop and market ourselves.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Risks Related to Our Business and Regulatory
Matters</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not yet
commercialized any products or technologies, and we may never become profitable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not yet commercialized
any products or technologies, and we may never be able to do so. We do not know when or if we will complete any of our product development
efforts, obtain regulatory approval for any product candidates incorporating our technologies or successfully commercialize any approved
products. Even if we are successful in developing products that are approved for marketing, we will not be successful unless these products
gain market acceptance for appropriate indications at favorable reimbursement rates. The degree of market acceptance of these products
will depend on a number of factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the timing of regulatory approvals in the countries, and for
the uses, we seek;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the competitive environment;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the establishment and demonstration in the medical community
of the safety and clinical efficacy of our products and their potential advantages over existing therapeutic products;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">our ability to enter into distribution and other strategic
agreements with pharmaceutical and biotechnology companies with strong marketing and sales capabilities;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the adequacy and success of distribution, sales and marketing
efforts; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the pricing and reimbursement policies of government and third-party
payors, such as insurance companies, health maintenance organizations and other plan administrators.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Physicians, patients, thirty-party
payors or the medical community in general may be unwilling to accept, utilize or recommend, and in the case of third-party payors, cover
any of our products or products incorporating our technologies. As a result, we are unable to predict the extent of future losses or the
time required to achieve profitability, if at all. Even if we successfully develop one or more products that incorporate our technologies,
we may not become profitable.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates
are at various stages of clinical and preclinical development and may never be commercialized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates are
at various stages of clinical development and may never be commercialized. The progress and results of any future pre-clinical testing
or future clinical trials are uncertain, and the failure of our product candidates to receive regulatory approvals will have a material
adverse effect on our business, operating results and financial condition to the extent we are unable to commercialize any products. None
of our product candidates has received regulatory approval for commercial sale. In addition, we face the risks of failure inherent in
developing therapeutic products. Our product candidates are not expected to be commercially available for several years, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 11; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to receive FDA approval
or approval from foreign regulatory authorities to market a product candidate or to distribute our products, we must demonstrate thorough
pre-clinical testing and thorough human clinical trials that the product candidate is safe and effective for its intended uses (e.g.,
treatment of a specific condition in a specific way subject to contraindications and other limitations). If the FDA, or foreign regulatory
authorities, determine that data from our pre-clinical testing and clinical trials are not sufficient to support approval, the FDA, or
foreign regulatory authorities, may require additional pre-clinical testing or clinical trials for our product candidates. Even if we
comply with all FDA requests, the FDA may ultimately reject one or more of our New Drug Applications, or NDA, or grant approval for a
narrowly intended use that is not commercially feasible. We might not obtain regulatory approval for our drug candidates in a timely manner,
if at all. Failure to obtain FDA approval of any of our drug candidates in a timely manner or at all will severely undermine our business
by reducing the number of salable products and, therefore, corresponding product revenues.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Results of earlier
clinical trials may not be predictive of the results of later-stage clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The results of preclinical
studies and early clinical trials of product candidates may not be predictive of the results of later-stage clinical trials. Also, interim
results, if at all, during a clinical trial do not necessarily predict final results. Product candidates in later stages of clinical trials
may fail to show the desired safety and efficacy results despite having progressed through preclinical studies and initial clinical trials.
For example, our former subsidiary OphthaliX Inc, or OphthaliX, announced top-line results of a Phase III study with Piclidenoson for
dry-eye syndrome in which Piclidenoson did not meet the primary efficacy endpoint of complete clearing of corneal staining, nor the secondary
efficacy endpoints, OphthaliX released top-line results from its Phase II clinical trial of Piclidenoson for the treatment of glaucoma
in which no statistically significant differences were found between the Piclidenoson treated group and the placebo group in the primary
endpoint of lowering intraocular pressure, or IOP. In addition, two Phase IIb studies in rheumatoid arthritis, utilizing Piclidenoson
in combination with methotrexate, a generic drug commonly used for treating rheumatoid arthritis patients, or MTX, failed to reach their
primary endpoints and we ended our Phase III ACROBAT study after the independent data monitoring committee, or IDMC recommended in a pre-planned
interim analysis not to continue this study. A Phase II/III study of Piclidenoson for psoriasis did not meet its primary endpoint although
positive data from further analysis of the Phase II/III study suggests Piclidenoson as a potential systemic therapy for patients with
moderate-severe psoriasis. Furthermore, a Phase II study for advanced HCC in subjects with Child-Pugh B who failed Nexavar as a first
line treatment did not meet its primary endpoint although it showed superiority in overall survival in the largest study subpopulation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many companies in the pharmaceutical
industry have suffered significant setbacks in advanced clinical trials due to adverse safety profiles or lack of efficacy, notwithstanding
promising results in earlier studies. Any delay in, or termination or suspension of, our clinical trials will delay the requisite filings
with the FDA, the EMA or other foreign regulatory authorities and, ultimately, our ability to commercialize our product candidates and
generate product revenues. If the clinical trials do not support our product claims, the completion of development of such product candidates
may be significantly delayed or abandoned, which will significantly impair our ability to generate product revenues and will materially
adversely affect our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This drug candidate development
risk is heightened by any changes in the planned clinical trials compared to the completed clinical trials. As product candidates are
developed from preclinical through early to late stage clinical trials towards approval and commercialization, it is customary that various
aspects of the development program, such as manufacturing and methods of administration, are altered along the way in an effort to optimize
processes and results. While these types of changes are common and are intended to optimize the product candidates for late stage clinical
trials, approval and commercialization, such changes do carry the risk that they will not achieve these intended objectives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes in our planned clinical
trials or future clinical trials could cause our product candidates to perform differently, including causing toxicities, which could
delay completion of our clinical trials, delay approval, if any, of our product candidates, and/or jeopardize our ability to commence
product sales and generate revenues.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We might be unable
to develop product candidates that will achieve commercial success in a timely and cost-effective manner, or ever.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if regulatory authorities
approve our product candidates, they may not be commercially successful. Our product candidates may not be commercially successful because
government agencies and other third-party payors may not cover the product or the coverage may be too limited to be commercially successful;
physicians and others may not use or recommend our products, even following regulatory approval. A product approval, assuming one issues,
may limit the uses for which the product may be distributed thereby adversely affecting the commercial viability of the product. Third
parties may develop superior products or have proprietary rights that preclude us from marketing our products. We also expect that at
least some of our product candidates will be expensive, if approved. Patient acceptance of and demand for any product candidates for which
we obtain regulatory approval or license will depend largely on many factors, including but not limited to the extent, if any, of reimbursement
of costs by government agencies and other third-party payors, pricing, the effectiveness of our marketing and distribution efforts, the
safety and effectiveness of alternative products, and the prevalence and severity of side effects associated with our products. If physicians,
government agencies and other third-party payors do not accept our products, we will not be able to generate significant revenue. In addition,
government regulators and legislative bodies in the U.S. are considering numerous proposals that may result in limitations on the prices
at which we could charge customers for our products if we have products that are ultimately approved for sale. At this time, we are unable
to predict how these potential legislative changes might affect our business.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 12; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current pipeline
is based on our platform technology utilizing the Gi protein associated A3AR, as a potent therapeutic target and currently includes three
molecules, Piclidenoson, Namodenoson and CF602 product candidates, of which Piclidenoson is the most advanced. Failure to develop these
molecules will have a material adverse effect on us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our current pipeline is based
on a platform technology where we target the A3AR with highly selective ligands, or small signal triggering molecules that bind to specific
cell surface receptors, such as the A3AR, including Piclidenoson, Namodenoson and CF602. A3ARs are structures found in cell surfaces that
record and transfer messages from small molecules or ligands, such as Piclidenoson, Namodenoson and CF602 to the rest of the cell. Piclidenoson
is the most advanced of our drug candidates. As such, we are currently dependent on only three molecules for our potential commercial
success, and any safety or efficacy concerns related to such molecules would have a significant impact on our business. Failure to develop
our drug candidates, in whole or in part, will have a material adverse effect on us.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials
are very expensive, time-consuming and difficult to design and implement, and, as a result, we may suffer delays or suspensions in future
trials which would have a material adverse effect on our ability to generate revenues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Human clinical trials are
very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Regulatory
authorities, such as the FDA, may preclude or prohibit clinical trials from proceeding. Additionally, the clinical trial process is time-consuming,
failure can occur at any stage of the trials, and we may encounter problems that cause us to abandon or repeat clinical trials. The commencement
and completion of clinical trials may be delayed by several factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">unforeseen safety issues;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">non-acceptance of an IND by the FDA;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">determination of dosing issues;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">lack of effectiveness or efficacy during clinical trials;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">inability to manufacture sufficient quantities of drug candidate;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">changes in formulation or manufacturing changes;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">failure of third-party suppliers to perform final manufacturing steps for the drug substance;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">slower than expected rates of patient recruitment and enrollment;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">inability to retain patients in clinical trials;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">lack of healthy volunteers and patients to conduct trials;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">inability to monitor patients adequately during or after treatment;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">failure to reach an agreement with contract research organizations or clinical trial sites;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">failure of institutional review boards, or IRBs, to approve
our clinical trial protocols or suspension or termination of our clinical trial by the IRB, DSMB, or the FDA;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">failure of institutional review boards to approve our clinical trial protocols;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">inability or unwillingness of clinical investigators and institutional
review boards to follow our clinical trial protocols;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">failure of clinical investigators or sites to maintain necessary
licenses or permits or comply with good clinical practices, or GCP, or other regulatory requirements;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">debarment of a clinical investigator by FDA or other similar
suspension or exclusion by a regulatory authority; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">lack of sufficient funding to finance the clinical trials.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 13; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have experienced the risks
involved with conducting clinical trials, including but not limited to, increased expense and delay and failure to meet end points of
the trial. For example, OphthaliX, announced top-line results of a Phase III study with Piclidenoson for dry-eye syndrome in which Piclidenoson
did not meet the primary efficacy endpoint of complete clearing of corneal staining, nor the secondary efficacy endpoints and OphthaliX
released top-line results from its Phase II clinical trial of Piclidenoson for the treatment of glaucoma in which no statistically significant
differences were found between the Piclidenoson treated group and the placebo group in the primary endpoint of lowering IOP. In addition,
two Phase IIb studies in rheumatoid arthritis, utilizing Piclidenoson in combination with MTX failed to reach their primary end points
and we ended our Phase III ACROBAT study after the IDMC recommended in a pre-planned interim analysis not to continue this study. A Phase
II/III study of Piclidenoson for psoriasis did not meet its primary endpoint although positive data from further analysis of the Phase
II/III study suggests Piclidenoson as a potential systemic therapy for patients with moderate-severe psoriasis. Furthermore, a Phase II
study of Namodenoson for advanced HCC in subjects with Child-Pugh B who failed Nexavar as a first line treatment did not meet its primary
endpoint although it showed superiority in overall survival in the largest study subpopulation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, we or regulatory
authorities may suspend our clinical trials at any time if it appears that we are exposing participants to unacceptable health risks or
if the regulatory authorities find deficiencies in our regulatory submissions or the conduct of these trials. Any suspension of clinical
trials will delay possible regulatory approval, if any, increase costs, and adversely impact our ability to develop products and generate
revenue.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We seek to partner
with third-party collaborators with respect to the development and commercialization of Piclidenoson and for any other product candidate,
and we may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability to develop
and commercialize our product candidates successfully, if at all.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business strategy relies
in part on partnering with pharmaceutical companies to complement our internal development efforts. We will be competing with many other
companies as we seek partners for Piclidenoson, Namodenoson and for any other product candidate and we may not be able to compete successfully
against those companies. If we are not able to enter into collaboration arrangements for Piclidenoson, Namodenoson and for any other product
candidate, we may be required to undertake and fund further development, clinical trials, manufacturing and commercialization activities
solely at our own expense and risk. If we are unable to finance and/or successfully execute those expensive activities, or we delay such
activities due to capital availability, our business could be materially and adversely affected, and potential future product launch could
be materially delayed, be less successful, or we may be forced to discontinue clinical development of these product candidates. The process
of establishing and maintaining collaborative relationships is difficult, time-consuming and involves significant uncertainty, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">a collaboration partner may shift its priorities and resources away from our product candidates due to a
change in business strategies, or a merger, acquisition, sale or downsizing;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">a collaboration partner may seek to renegotiate or terminate their relationships with us due to unsatisfactory
clinical results, manufacturing issues, a change in business strategy, a change of control or other reasons;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">a collaboration partner may cease development in therapeutic areas which are the subject of our strategic
collaboration</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">a collaboration partner may not devote sufficient capital or resources towards our product candidates;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">a collaboration partner may change the success criteria for a drug candidate thereby delaying or ceasing
development of such candidate;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">a significant delay in initiation of certain development activities by a collaboration partner will also
delay payment of milestones tied to such activities, thereby impacting our ability to fund our own activities;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">a collaboration partner could develop a product that competes, either directly or indirectly, with our drug
candidate;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">a collaboration partner with commercialization obligations may not commit sufficient financial or human resources
to the marketing, distribution or sale of a product;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">a collaboration partner with manufacturing responsibilities may encounter regulatory, resource or quality
issues and be unable to meet demand requirements;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">a partner may exercise a contractual right to terminate a strategic alliance;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">a dispute may arise between us and a partner concerning the research, development or commercialization of
a drug candidate resulting in a delay in milestones, royalty payments or termination of an alliance and possibly resulting in costly litigation
or arbitration which may divert management attention and resources; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">a partner may use our products or technology in such a way as to invite litigation from a third party.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 14; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any collaborative partners
we enter into agreements with in the future may shift their priorities and resources away from our product candidates or seek to renegotiate
or terminate their relationships with us. If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, our
research, clinical development, manufacturing or commercialization efforts related to that collaboration could be delayed or terminated,
or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have been the responsibility of
our collaborator. If we are unable to establish and maintain collaborative relationships on acceptable terms or to successfully transition
terminated collaborative agreements, we may have to delay or discontinue further development of one or more of our product candidates,
undertake development and commercialization activities at our own expense or find alternative sources of capital.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we acquire
or license additional technology or product candidates, we may incur a number of costs, may have integration difficulties and may experience
other risks that could harm our business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may acquire and license
additional product candidates and technologies. Any product candidate or technology we license from others or acquire will likely require
additional development efforts prior to commercial sale, including extensive pre-clinical or clinical testing, or both, and approval by
the FDA and applicable foreign regulatory authorities, if any. All product candidates are prone to risks of failure inherent in pharmaceutical
product development, including the possibility that the product candidate or product developed based on licensed technology will not be
shown to be sufficiently safe and effective for approval by regulatory authorities. In addition, we cannot assure you that any product
candidate that we develop based on acquired or licensed technology that is granted regulatory approval will be manufactured or produced
economically, successfully commercialized or widely accepted in the marketplace. Moreover, integrating any newly acquired product candidates
could be expensive and time-consuming. If we cannot effectively manage these aspects of our business strategy, our business may not succeed.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The manufacture
of our product candidates is a chemical synthesis process and if one of our materials suppliers encounters problems manufacturing our
products, our business could suffer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA and foreign regulators
require manufacturers to register manufacturing facilities. The FDA and foreign regulators also inspect these facilities to confirm compliance
with requirements that the FDA or foreign regulators establish. We do not intend to engage in the manufacture of our products other than
for pre-clinical and clinical studies, but we or our materials suppliers may face manufacturing or quality control problems causing product
production and shipment delays or a situation where we or the supplier may not be able to maintain compliance with the FDA&#8217;s or
foreign regulators&#8217; requirements necessary to continue manufacturing our drug substance. Drug manufacturers are subject to ongoing
periodic unannounced inspections by the FDA, the U.S. Drug Enforcement Agency, or DEA, and corresponding foreign regulators to ensure
strict compliance with requirements and other governmental regulations and corresponding foreign standards. Any failure to comply with
DEA requirements or FDA or foreign regulatory requirements could adversely affect our clinical research activities and our ability to
develop our product candidates, and delay possible regulatory approval.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently
have sales, marketing or distribution capabilities or experience, and we are unable to effectively sell, market or distribute our product
candidates now and we do not expect to be able to do so in the future. The failure to enter into agreements with third parties that are
capable of performing these functions would have a material adverse effect on our business and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently have,
and we do not expect to develop, sales, marketing and distribution capabilities. If we are unable to enter into agreements with third
parties to perform these functions, we will not be able to successfully market any of our platforms or product candidates. In order to
successfully market any of our platform or product candidates, we must make arrangements with third parties to perform these services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As we do not intend to develop
a marketing and sales force with technical expertise and supporting distribution capabilities, we will be unable to market any of our
product candidates directly. To promote any of our potential products through third parties, we will have to locate acceptable third parties
for these functions and enter into agreements with them on acceptable terms, and we may not be able to do so. Any third-party arrangements
we are able to enter into may result in lower revenues than we could achieve by directly marketing and selling our potential products.
In addition, to the extent that we depend on third parties for marketing and distribution, any revenues we receive will depend upon the
efforts of such third parties, as well as the terms of our agreements with such third parties, which cannot be predicted in most cases
at this time. As a result, we might not be able to market and sell our products in the United States or overseas, which would have a material
adverse effect on us.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will to some
extent rely on third parties to implement our manufacturing and supply strategies. Failure of these third parties in any respect could
have a material adverse effect on our business, results of operations and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our current and future
manufacturing and supply strategies are unsuccessful, then we may be unable to conduct and complete any future pre-clinical or clinical
trials or commercialize our product candidates in a timely manner, if at all. Completion of any potential future pre-clinical or clinical
trials and commercialization of our product candidates will require access to, or development of, facilities to manufacture a sufficient
supply of our product candidates. We do not have the resources, facilities or experience to manufacture our product candidates for commercial
purposes on our own and do not intend to develop or acquire facilities for the manufacture of product candidates for commercial purposes
in the foreseeable future. We may rely on contract manufacturers to produce sufficient quantities of our product candidates necessary
for any pre-clinical or clinical testing we undertake in the future. Such contract manufacturers may be the sole source of production
and they may have limited experience at manufacturing, formulating, analyzing, filling and finishing our types of product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 15; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also intend to rely on
third parties to supply the requisite materials needed for the manufacturing of our active pharmaceutical ingredients, or API. There may
be a limited supply of these requisite materials. We might not be able to enter into agreements that provide us assurance of availability
of such components in the future from any supplier. Our potential suppliers may not be able to adequately supply us with the components
necessary to successfully conduct our pre-clinical and clinical trials or to commercialize our product candidates. In particular, the
continued spread of COVID-19 globally could result in the inability of our suppliers to deliver components or raw materials on a timely
basis or at all. If we cannot acquire an acceptable supply of the requisite materials to produce our product candidates, we will not be
able to complete pre-clinical and clinical trials delaying possible regulatory approval, and adversely impacting our ability to develop
products, and will not be able to market or commercialize our product candidates, if approved.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We depend on key
members of our management and key consultants and will need to add and retain additional leading experts. Failure to retain our management
and consulting team and add additional leading experts could have a material adverse effect on our business, results of operations or
financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are highly dependent on
our executive officers and other key management and technical personnel. Our failure to retain our Chief Executive Officer, Pnina Fishman,
Ph.D., who has developed much of the technology we utilize today, or any other key management and technical personnel, could have a material
adverse effect on our future operations. Our success is also dependent on our ability to attract, retain and motivate highly trained technical,
and management personnel, among others, to continue the development and commercialization, if approved, of our current and future product
candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success also depends on
our ability to attract, retain and motivate personnel required for the development, maintenance and expansion of our activities. There
can be no assurance that we will be able to retain our existing personnel or attract additional qualified employees or consultants. The
loss of key personnel or the inability to hire and retain additional qualified personnel in the future could have a material adverse effect
on our business, financial condition and results of operation.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We face significant
competition and continuous technological change, and developments by competitors may render our products or technologies obsolete or non-competitive.
If we cannot successfully compete with new or existing products, our marketing and sales will suffer and we may not ever be profitable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will compete against fully
integrated pharmaceutical and biotechnology companies and smaller companies that are collaborating with larger pharmaceutical companies,
academic institutions, government agencies and other public and private research organizations. In addition, many of these competitors,
either alone or together with their collaborative partners, operate larger research and development programs than we do, and have substantially
greater financial resources than we do, as well as significantly greater experience in:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">developing drugs;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">undertaking pre-clinical testing and human clinical trials;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">obtaining FDA approval, addressing various regulatory matters and other regulatory approvals of drugs;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">formulating and manufacturing drugs; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">launching, marketing and selling drugs.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our competitors develop
and commercialize products faster than we do, or develop and commercialize products that are superior to our product candidates, our commercial
opportunities will be reduced or eliminated. The extent to which any of our product candidates achieve market acceptance will depend on
competitive factors, many of which are beyond our control. Competition in the biotechnology and biopharmaceutical industry is intense
and has been accentuated by the rapid pace of technology development. Our competitors include large integrated pharmaceutical companies,
biotechnology companies that currently have drug and target discovery efforts, universities, and public and private research institutions.
Almost all of these entities have substantially greater research and development capabilities and financial, scientific, manufacturing,
marketing and sales resources than we do. These organizations also compete with us to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">attract parties for acquisitions, joint ventures or other collaborations;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">license proprietary technology that is competitive with the technology we are developing;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">attract funding; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">attract and hire scientific talent and other qualified personnel.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 16; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our competitors may succeed
in developing and commercializing products earlier and obtaining regulatory approvals from the FDA or foreign regulators more rapidly
than we do. Our competitors may also develop products or technologies that are superior to those we are developing, and render our product
candidates or technologies obsolete or non-competitive. If we cannot successfully compete with new or existing products, our marketing
and sales will suffer and we may not ever be profitable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our competitors currently
include companies with marketed products and/or an advanced research and development pipeline. The major competitors in the psoriasis
therapeutic field include Amgen, J&amp;J, Pfizer, Novartis, Abbvie, Eli Lilly, Bristol-Myers Squibb, and more. Competitors in the HCC
field include companies such as Bayer, Exelixis, Merck, Roche, and Bristol-Myers Squibb. Competitors in the NASH field include companies
such as Gilead, Genfit, Galmed, Intercept, Madrigal, Akero, 89Bio, Viking, and Terns. Competitors in the erectile dysfunction field include
Pfizer, Eli Lilly, Bayer, and Petros Pharmaceuticals. See &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Competition.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, several companies
have reported the commencement of research projects related to the A3AR. Such companies include CV Therapeutics Inc. (which was acquired
by Gilead), King Pharmaceuticals R&amp;D Inv. (which was acquired by Pfizer), Hoechst Marion Roussel Inc. (which was acquired by Aventis),
Novo Nordisk A/S and Inotek Pharmaceuticals. However, to the best of our knowledge, there is no approved drug currently on the market,
which is similar to our A3AR agonists, nor are we aware of any allosteric modulator in the A3AR product pipeline similar to our allosteric
modulator with respect to chemical profile and mechanism of action.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may suffer
losses from product liability claims if our product candidates cause harm to patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any of our product candidates
could cause adverse events. Although a pooled safety analysis from clinical trials encompassing more than 1,300 humans dosed with Piclidenoson
through the completion of our Phase II rheumatoid arthritis and psoriasis trials indicated that Piclidenoson is generally well-tolerated
at doses up to 4.0 mg administered twice daily for up to 12-48 weeks, there were incidences (less than or equal to 5%) of adverse events
in eight completed and fully analyzed trials in inflammatory disease. Such adverse events included nausea, diarrhea, abdominal pain, vomiting,
constipation, common bacterial and viral syndromes (such as tonsillitis, otitis and respiratory and urinary tract infections), abdominal
pain, vomiting, myalgia, arthralgia, dizziness, headache and pruritus. We observed an even lower incidence (less than or equal to 2%)
of serious adverse events, although only one type of event was reported in more than a single Piclidenoson-treated subject, which was
exacerbation of chronic obstructive lung disease reported in two subjects. Notwithstanding the foregoing, the placebo group in such studies
had a higher incidence of overall adverse events than the pooled Piclidenoson groups. In addition, in normal volunteers, Piclidenoson
at doses 3-4-fold higher than those to be used in therapeutic trials, but not at therapeutic doses, was associated with prolongation of
the electrocardiographic QT intervals. No new safety concerns have been identified and no novel or unexpected safety concerns have appeared
over 48 weeks of treatment in more recent trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There is also a risk that
certain adverse events may not be observed in clinical trials, but may nonetheless occur in the future. If any of these adverse events
occur, they may render our product candidates ineffective or harmful in some patients, and our sales would suffer, materially adversely
affecting our business, financial condition and results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, potential adverse
events caused by our product candidates could lead to product liability lawsuits. If product liability lawsuits are successfully brought
against us, we may incur substantial liabilities and may be required to limit the marketing and commercialization of our product candidates.
Our business exposes us to potential product liability risks, which are inherent in the testing, manufacturing, marketing and sale of
pharmaceutical products. We may not be able to avoid product liability claims. Product liability insurance for the pharmaceutical and
biotechnology industries is generally expensive, if available at all. If, at any time, we are unable to obtain sufficient insurance coverage
on reasonable terms or to otherwise protect against potential product liability claims, we may be unable to clinically test, market or
commercialize our product candidates. A successful product liability claim brought against us in excess of our insurance coverage, if
any, may cause us to incur substantial liabilities, and, as a result, our business, liquidity and results of operations would be materially
adversely affected.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates
will remain subject to ongoing regulatory requirements even if they receive marketing approval, and if we fail to comply with these requirements,
we could lose these approvals, and the sales of any approved commercial products could be suspended.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even if we receive regulatory
approval to market a particular product candidate, the product will remain subject to extensive regulatory requirements, including requirements
relating to manufacturing, labelling, packaging, adverse event reporting, storage, advertising, promotion, distribution and recordkeeping.
Even if regulatory approval of a product is granted, the approval may be subject to limitations on the uses for which the product may
be marketed or the conditions of approval, or may contain requirements for costly post-marketing testing and surveillance to monitor the
safety or efficacy of the product, which could negatively impact us or our collaboration partners by reducing revenues or increasing expenses,
and cause the approved product candidate not to be commercially viable. In addition, as clinical experience with a drug expands after
approval, typically because it is used by a greater number and more diverse group of patients after approval than during clinical trials,
side effects and other problems may be observed after approval that were not seen or anticipated during pre-approval clinical trials or
other studies. Any adverse effects observed after the approval and marketing of a product candidate could result in limitations on the
use of or withdrawal of any approved products from the marketplace. Absence of long-term safety data may also limit the approved uses
of our products, if any. If we fail to comply with the regulatory requirements of the FDA and other applicable U.S. and foreign regulatory
authorities, or previously unknown problems with any approved commercial products, manufacturers or manufacturing processes are discovered,
we could be subject to administrative or judicially imposed sanctions or other setbacks, including the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">Restrictions on the products, manufacturers or manufacturing process;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 17; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">Warning or other enforcement letters;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">Civil or criminal penalties, fines and injunctions;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">Product seizures or detentions;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">Import or export bans or restrictions;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Voluntary or mandatory product recalls and related publicity requirements;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">Suspension or withdrawal of regulatory approvals;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">Total or partial suspension of production; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Refusal to approve pending applications for marketing approval of new products or supplements to approved
applications.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we or our collaborators
are slow or unable to adapt to changes in existing regulatory requirements or adoption of new regulatory requirements or policies, marketing
approval for our product candidates may be lost or cease to be achievable, resulting in decreased revenue from milestones, product sales
or royalties, which would have a material adverse effect on our results of operations.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We deal with hazardous
materials and must comply with environmental, health and safety laws and regulations, which can be expensive and restrict how we do business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our activities and those of
our third-party manufacturers on our behalf involve the controlled storage, use and disposal of hazardous materials, including corrosive,
explosive and flammable chemicals and other hazardous compounds. We and our manufacturers are subject to U.S. federal, state, and local,
and Israeli and other foreign laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials.
Although we believe that our safety procedures for handling and disposing of these materials comply with the standards prescribed by these
laws and regulations, we cannot eliminate the risk of accidental contamination or injury from these materials. In addition, if we develop
a manufacturing capacity, we may incur substantial costs to comply with environmental regulations and would be subject to the risk of
accidental contamination or injury from the use of hazardous materials in our manufacturing process.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of an accident,
government authorities may curtail our use of these materials and interrupt our business operations. In addition, we could be liable for
any civil damages that result, which may exceed our financial resources and may seriously harm our business. Although our Israeli insurance
program covers certain unforeseen sudden pollutions, we do not maintain a separate insurance policy for any of the foregoing types of
risks. In addition, although the general liability section of our life sciences policy covers certain unforeseen, sudden environmental
issues, pollution in the United States and Canada is excluded from the policy. In the event of environmental discharge or contamination
or an accident, we may be held liable for any resulting damages, and any liability could exceed our resources. In addition, we may be
subject to liability and may be required to comply with new or existing environmental laws regulating pharmaceuticals or other medical
products in the environment.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business and
operations may be materially adversely affected in the event of computer system failures or security breaches.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite the implementation
of security measures, our internal computer systems, and those of our contract research organizations, or CROs, and other third parties
on which we rely, are vulnerable to damage from computer viruses, unauthorized access, cyber-attacks, natural disasters, fire, terrorism,
war, and telecommunication and electrical failures. If such an event were to occur and interrupt our operations, it could result in a
material disruption of our drug development programs. For example, the loss of clinical trial data from ongoing or planned clinical trials
could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the
extent that any disruption or security breach results in a loss of or damage to our data or applications, loss of trade secrets or inappropriate
disclosure of confidential or proprietary information, including protected health information or personal data of employees or former
employees, access to our clinical data, or disruption of the manufacturing process, we could incur liability and the further development
of our drug candidates could be delayed. We may also be vulnerable to cyber-attacks by hackers or other malfeasance. This type of breach
of our cybersecurity may compromise our confidential information and/or our financial information and adversely affect our business or
result in legal proceedings. Further, these cybersecurity breaches may inflict reputational harm upon us that may result in decreased
market value and erode public trust.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 18; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be
able to successfully grow and expand our business. Failure to manage our growth effectively will have a material adverse effect on our
business, results of operations and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able to successfully
grow and expand. Successful implementation of our business plan will require management of growth, including potentially rapid and substantial
growth, which will result in an increase in the level of responsibility for management personnel and place a strain on our human and capital
resources. To manage growth effectively, we will be required to continue to implement and improve our operating and financial systems
and controls to expand, train and manage our employee base. Our ability to manage our operations and growth effectively requires us to
continue to expend funds to enhance our operational, financial and management controls, reporting systems and procedures and to attract
and retain sufficient numbers of talented personnel. If we are unable to scale up and implement improvements to our control systems in
an efficient or timely manner, or if we encounter deficiencies in existing systems and controls, then we will not be able to make available
the products required to successfully commercialize our technology. Failure to attract and retain sufficient numbers of talented personnel
will further strain our human resources and could impede our growth or result in ineffective growth. Moreover, the management, systems
and controls currently in place or to be implemented may not be adequate for such growth, and the steps taken to hire personnel and to
improve such systems and controls might not be sufficient. If we are unable to manage our growth effectively, it will have a material
adverse effect on our business, results of operations and financial condition.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable
to obtain adequate insurance, our financial condition could be adversely affected in the event of uninsured or inadequately insured loss
or damage. Our ability to effectively recruit and retain qualified officers and directors could also be adversely affected if we experience
difficulty in obtaining adequate directors&#8217; and officers&#8217; liability insurance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not be able to obtain
insurance policies on terms affordable to us that would adequately insure our business and property against damage, loss or claims by
third parties. To the extent our business or property suffers any damages, losses or claims by third parties, which are not covered or
adequately covered by insurance, our financial condition may be materially adversely affected.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be unable to maintain
sufficient insurance as a public company to cover liability claims made against our officers and directors. Our insurance costs have increased
for directors&#8217; and officers&#8217; liability insurance, and we may be required to incur further substantial increased costs to maintain
the same or similar coverage or be forced to accept reduced coverage in future. If we are unable to adequately ensure our officers and
directors, we may not be able to retain or recruit qualified officers and directors to manage us.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our cannabinoid
initiative is uncertain and may not yield commercial results and is subject to significant regulatory risks.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are developing formulations
of cannabis components for the treatment of diseases in which there is an overexpression of A3AR. While we believe there are substantial
business opportunities for us in this field, there can be no assurance that our activities will be successful, or that any research and
development and product testing efforts will result in commercially saleable products, or that the market will accept or respond positively
to our products. In addition, our current and potential involvement in cannabis-related activity may expose us to legal and reputational
risks. Such risks include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Medical-use cannabis remains illegal under U.S. federal law, and therefore, strict enforcement of federal
laws regarding medical -use cannabis would likely result in our inability to market any products;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">FDA has not approved a marketing application for the treatment of any disease or condition;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Changes in laws, regulations and guidelines related to cannabis may result in significant additional compliance
costs for us or limit our ability to operate in certain jurisdictions;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Certain banks will not accept deposits from or provide other bank services to businesses involved with cannabis
and U.S. federal money laundering laws make it a federal crime to engage in financial transactions involving the proceeds of some form
of unlawful activity; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Third parties with whom we do business may perceive that they are exposed to reputational risk as a result
of our cannabis-related business activities and may ultimately elect not to do business with us.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Complying with laws and regulations
relating to cannabinoids is evolving, complex and expensive, and may divert management&#8217;s attention and resources from other aspects
of our business. Failure to maintain compliance with such laws and regulations may result in regulatory action that could have a material
adverse effect on our business, results of operations and financial condition. The DEA, FDA or state agencies may seek civil penalties,
refuse to renew necessary registrations, or initiate proceedings to revoke those registrations. In certain circumstances, violations could
lead to criminal proceedings.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 19; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We or the third
parties upon whom we depend may be adversely affected by natural disasters and/or health epidemics, and our business continuity and disaster
recovery plans may not adequately protect us from a serious disaster.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Natural disasters could severely
disrupt our operations and have a material adverse effect on our business, results of operations, financial condition and prospects. If
a natural disaster, power outage, health epidemic or other event occurred that prevented us from using all or a significant portion of
our office, manufacturing and/or lab spaces, that damaged critical infrastructure, such as the manufacturing facilities of our third-party
contract manufacturers, CROs, clinical sites, third parties ongoing activities and schedules or that otherwise disrupted operations, it
may be difficult or, in certain cases, impossible for us to continue our plans and business for a substantial period of time.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In late 2019, a novel strain
of COVID-19, also known as coronavirus, was reported in Wuhan, China and began spreading to various parts of the world. In particular,
our clinical trial sites are based in areas currently affected by COVID-19. Epidemics such as this can adversely impact our business as
they can cause disruptions, such as travel bans, quarantines, and interruptions to access the trial sites and supply chain, which could
result in material delays and complications with respect to our research and development programs and clinical trials. Moreover, as a
result of COVID-19, there is a general unease of conducting unnecessary activities in medical centers. It is too early to assess the full
impact of the COVID-19 outbreak on our clinical trials however COVID-19 may affect our ability to complete recruitment in our original
timeframe and could materially affect the operations of key governmental agencies, such as the FDA. The extent to which COVID-19 impacts
our operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration
and severity of the outbreak, and the actions that may be required to contain COVID-19 or treat its impact. A health epidemic or other
outbreak, including the current COVID-19 outbreak, may materially and adversely affect our business, financial condition and results of
operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The disaster recovery and
business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial
expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse
effect on our business.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business may
be adversely affected by the impact of COVID-19.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Public health epidemics or
outbreaks could adversely impact our business. In late 2019, a novel strain of COVID-19, also known as coronavirus, was reported in Wuhan,
China. Initially the outbreak was largely concentrated in China, but it rapidly spread to countries across the globe, including in Israel
and the United States. Many countries around the world, including in Israel and the United States, implemented significant governmental
measures to control the spread of the virus, including temporary closure of businesses, severe restrictions on travel and the movement
of people, and other material limitations on the conduct of business. In response, we implemented remote working and workplace protocols
for our employees in accordance Israeli Ministry of Health requirements to ensure employee safety. The extent to which COVID-19 impacts
our operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration
and severity of the outbreak, and the actions that may be required to contain COVID-19 or treat its impact. In particular, the continued
spread of the coronavirus globally, could adversely impact our operations and workforce, including our research and clinical trials and
our ability to raise capital, could affect the operations of key governmental agencies, such as the FDA, which may delay the development
of our product candidates and could result in the inability of our suppliers to deliver components or raw materials on a timely basis
or at all, each of which in turn could have an adverse impact on our business, financial condition and results of operation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Risks Related to Our Intellectual Property</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The expiry of
a patent that we licensed from the National Institute of Health, or NIH, and the consequent loss of composition of matter exclusivity
that we had by virtue of this license may diminish our proprietary position.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result of the expiry
in June 2015 of a patent that provided composition of matter protection over Piclidenoson and Namodenoson, that we licensed from the NIH,
we no longer enjoy composition of matter patent exclusivity relating to Piclidenoson and Namodenoson. Nevertheless, because Piclidenoson
and Namodenoson may each be a new chemical entity, or NCE, following approval of an NDA, we, if we are the first applicant to obtain NDA
approval, may be entitled to five years of data exclusivity in the United States with respect to such NCEs. Analogous data and market
exclusivity provisions, of varying duration, may be available in Europe and other foreign jurisdictions. We also have rights under our
pharmaceutical use issued patents with respect to Piclidenoson and Namodenoson and under our Piclidenoson manufacturing process patents,
which provide patent exclusivity within our field of activity until the mid- to late-2020s. While we believe that we may be able to protect
our exclusivity through such use patent portfolio and such period of exclusivity, the lack of composition of matter patent protection
may diminish our ability to maintain a proprietary position for our intended uses of Piclidenoson or Namodenoson. Moreover, we cannot
be certain that we will be the first applicant to obtain an FDA approval for any indication of Piclidenoson or Namodenoson and we cannot
be certain that we will be entitled to NCE exclusivity. In addition, we have discontinued the prosecution of a family of pending patent
applications under joint ownership of us and NIH pertaining to the use of A3AR agonists for the treatment of uveitis. Such diminution
of our proprietary position could have a material adverse effect on our business, results of operation and financial condition.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 20; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We license from
Leiden University intellectual property, which protects certain small molecules which target the A3AR, in furtherance of our platform
technology, and we could lose our rights to this license if a dispute with Leiden University arises or if we fail to comply with the financial
and other terms of the license.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have licensed intellectual
property from Leiden University pursuant to a license agreement. The license agreement imposes certain payment, reporting, confidentiality
and other obligations on us. In the event that we were to breach any of the obligations and fail to cure, Leiden University would have
the right to terminate the license agreement. In addition, Leiden University has the right to terminate the license agreement upon our
bankruptcy, insolvency, or receivership. If any dispute arises with respect to our arrangements with Leiden University, such dispute may
disrupt our operations and may have a material adverse impact on us if resolved in a manner that is unfavorable to us.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The failure to
obtain or maintain patents, licensing agreements, including our current licensing agreements, and other intellectual property could impact
our ability to compete effectively.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To compete effectively, we
need to develop and maintain a proprietary position with regard to our own technologies, intellectual property, licensing agreements,
product candidates and business. Legal standards relating to the validity and scope of claims in the biotechnology and biopharmaceutical
fields are still evolving. Therefore, the degree of future protection for our proprietary rights in our core technologies and any products
that might be made using these technologies is also uncertain. The risks and uncertainties that we face with respect to our patents and
other proprietary rights include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">while some of our patents or patents that we in-licensed have issued, the pending patent applications we
have filed may not result in issued patents or may take longer than we expect to result in issued patents;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">a third party may initiate an inter parties review, or IPR, proceedings in the U.S.;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">we may be subject to interference proceedings in the U.S.;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">a third party may initiate opposition proceedings in foreign countries;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">any patents that are issued may not provide meaningful protection;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">we may not be able to develop additional proprietary technologies that are patentable;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">other companies may challenge patents licensed or issued to us;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">other companies may independently develop similar or alternative technologies, or duplicate our technologies;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">other companies may design around patents we have in-licensed or developed; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">enforcement of patents is complex, uncertain and expensive.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If patent rights covering
our products and methods are not sufficiently broad or not issued at all by the United States Patent and Trademark Office, or the USPTO,
or by foreign patent offices, we may not have adequate protection against competitors with similar products and technologies. Furthermore,
if the USPTO or foreign patent offices issue patents to us or our licensors, others may challenge the patents or design around the patents,
or the patent office or the courts may invalidate the patents. Thus, any patents we own or license from third parties may not provide
any protection against our competitors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We cannot be certain that
patents will be issued as a result of any pending applications, and we cannot be certain that any of our issued patents will give us adequate
protection from competing products. For example, issued patents, including the patents in-licensed by us, may be circumvented or challenged,
declared invalid or unenforceable, or narrowed in scope. In addition, since publication of discoveries in the scientific or patent literature
often lags behind actual discoveries, we cannot be certain that we were the first to make our inventions or to file patent applications
covering those inventions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It is also possible that others
may obtain issued patents that could prevent us from commercializing our products or require us to obtain licenses requiring the payment
of significant fees or royalties in order to enable us to conduct our business. As to those patents that we have in-licensed, our rights
depend on maintaining our obligations to the licensor under the applicable license agreement, and we may be unable to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to patents and
patent applications, we depend upon trade secrets and proprietary know-how to protect our proprietary technology. We require our employees,
consultants, advisors and collaborators to enter into confidentiality agreements that prohibit the disclosure of confidential information
to any other parties. We require our employees and consultants to disclose and assign to us their ideas, developments, discoveries and
inventions. These agreements may not, however, provide adequate protection for our trade secrets, know-how or other proprietary information
in the event of any unauthorized use or disclosure.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 21; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Costly litigation
may be necessary to protect our intellectual property rights and we may be subject to claims alleging the violation of the intellectual
property rights of others.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may face significant expense
and liability as a result of litigation or other proceedings relating to patents and other intellectual property rights of others. In
the event that another party has also filed a patent application or been issued a patent relating to an invention or technology claimed
by us in pending applications, we may be required to participate in an interference proceeding declared by the USPTO to determine priority
of invention, which could result in substantial uncertainties and costs for us, even if the eventual outcome were favorable to us. We,
or our licensors, also could be required to participate in interference proceedings involving issued patents and pending applications
of another entity. An adverse outcome in an interference proceeding could require us to cease using the technology or to license rights
from prevailing third parties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost to us of any patent
litigation or other proceeding relating to our own or in-licensed patents or patent applications, even if resolved in our favor, could
be substantial. Our ability to enforce our patent protection could be limited by our financial resources, and may be subject to lengthy
delays. If we are unable to effectively enforce our proprietary rights, or if we are found to infringe the rights of others, we may be
in breach of our License Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A third party may claim that
we are using inventions claimed by their patents and may go to court to stop us from engaging in our normal operations and activities,
such as research, development and the sale of any future products. Such lawsuits are expensive and would consume time and other resources.
There is a risk that the court will decide that we are infringing the third party&#8217;s patents and will order us to stop the activities
claimed by the patents, redesign our products or processes to avoid infringement or obtain licenses (which may not be available on commercially
reasonable terms). In addition, there is a risk that a court will order us to pay the other party damages for having infringed their patents
and possibly also their legal fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, there is no guarantee
that any prevailing patent owner would offer us a license so that we could continue to engage in activities claimed by the patent, or
that such a license, if made available to us, could be acquired on commercially acceptable terms. In addition, third parties may, in the
future, assert other intellectual property infringement claims against us with respect to our product candidates, technologies or other
matters.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We rely on confidentiality
agreements that could be breached and may be difficult to enforce, which could result in third parties using our intellectual property
to compete against us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we believe that we
take reasonable steps to protect our intellectual property, including the use of agreements relating to the non-disclosure of confidential
information to third parties, as well as agreements that purport to require the disclosure and assignment to us of the rights to the ideas,
developments, discoveries and inventions of our employees and consultants while we employ them, the agreements can be difficult and costly
to enforce. Although we seek to obtain these types of agreements from our contractors, consultants, advisors and research collaborators,
to the extent that employees and consultants utilize or independently develop intellectual property in connection with any of our projects,
disputes may arise as to the intellectual property rights associated with our products. If a dispute arises, a court may determine that
the right belongs to a third party. In addition, enforcement of our rights can be costly and unpredictable. We also rely on trade secrets
and proprietary know-how that we seek to protect in part by confidentiality agreements with our employees, contractors, consultants, advisors
or others. Despite the protective measures we employ, we still face the risk that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">these agreements may be breached;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">these agreements may not provide adequate remedies for the applicable type of breach;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">our trade secrets or proprietary know-how will otherwise become known; or</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">our competitors will independently develop similar technology or proprietary information.</td></tr></table><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">International
patent protection is particularly uncertain, and if we are involved in opposition proceedings in foreign countries, we may have to spend
substantial sums and management resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Patent law outside the United
States is different than in the United States. Further, the laws of some foreign countries may not protect our intellectual property rights
to the same extent as the laws of the United States, if at all. A failure to obtain sufficient intellectual property protection in any
foreign country could materially and adversely affect our business, results of operations and future prospects. Moreover, we may participate
in opposition proceedings to determine the validity of our foreign patents or our competitors&#8217; foreign patents, which could result
in substantial costs and divert management&#8217;s resources and attention.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 22; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although most jurisdictions
in which we have applied for, intend to apply for, or have been issued patents have patent protection laws similar to those of the United
States, some of them do not. For example, we expect to do business in Brazil and India in the future. However, the Brazilian drug regulatory
agency, ENVISA, has the authority to nullify patents on the basis of its perceived public interest and the Indian patent law does not
allow patent protection for new uses of pharmaceuticals (many of our current patent applications are of such nature). Additionally, due
to uncertainty in patent protection law, we have not filed applications in many countries where significant markets exist, including Indonesia,
Pakistan, Russia, African countries and Taiwan.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be unable
to protect the intellectual property rights of the third parties from whom we license certain of our intellectual property or with whom
we have entered into other strategic relationships.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of our intellectual
property rights are currently licensed from Leiden University, and, in the future, we wish to continue to license intellectual property
from Leiden University and/or other universities and/or strategic partners. Such third parties may determine not to protect the intellectual
property rights that we license from them and we may be unable to defend such intellectual property rights on our own or we may have to
undertake costly litigation to defend the intellectual property rights of such third parties. There can be no assurances that we will
be able to obtain licenses to such third party intellectual property or otherwise have the right to use through similar strategic relationships.
Any loss or limitations on use with respect to our right to use such intellectual property licensed from third parties or otherwise obtained
from third parties with whom we have entered into strategic relationships could have a material adverse effect on our business, results
of operations and financial condition.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under applicable
U.S. and Israeli law, we may not be able to enforce covenants not to compete and therefore, may be unable to prevent our competitors from
benefiting from the expertise of some of our former employees. In addition, employees may be entitled to seek compensation for their inventions
irrespective of their agreements with us, which in turn could impact our future profitability.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We generally enter into confidentiality
and non-competition agreements with our employees and certain key consultants, or our employment and consulting agreements contain confidentiality
and non-competition provisions. These agreements, to the extent they are in place and in effect, prohibit our employees and certain key
consultants, if they cease working for us, from competing directly with us or working for our competitors or clients for a limited period
of time and maintain confidentiality of our know-how and trade secrets, as long as they do not enter the public domain. We may be unable
to enforce these agreements under the laws of the jurisdictions in which our employees work and it may be difficult for us to restrict
our competitors from benefitting from the expertise our former employees or consultants developed while working for us. For example, Israeli
courts have required employers seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive activities
of the former employee will harm one of a limited number of material interests of the employer which have been recognized by the courts,
such as the secrecy of a company&#8217;s confidential commercial information or the protection of its intellectual property. If we cannot
demonstrate that such interests will be harmed, we may be unable to prevent our competitors from benefiting from the expertise of our
former employees or consultants and our ability to remain competitive may be diminished.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Chapter 8 to
the Israeli Patents Law, 5727-1967, or the Patents Law, deals with inventions made in the course of an employee&#8217;s service and during
his or her term of employment, whether or not the invention is patentable, or service inventions. Section 134 of the Patents Law provides
that if there is no agreement that explicitly determines whether the employee is entitled to compensation for the service inventions and
the extent and terms of such compensation, such determination will be made by the Compensation and Rewards Committee, a statutory committee
of the Israeli Patents Office. Although our employees have agreed to assign to us service invention rights, we may face claims demanding
remuneration in consideration for assigned inventions. As a consequence of such claims, we could be required to pay additional remuneration
or royalties to our current and/or former employees, or be forced to litigate such claims, which could negatively affect our business.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Intellectual property
rights do not necessarily address all potential threats to our competitive advantage.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The degree of future protection
afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately
protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Others may be able to make compounds that are the same as or similar to our product candidates but that are
not covered by the claims of the patents that we own or have exclusively licensed;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We or our licensors or any future strategic partners might not have been the first to make the inventions
covered by the issued patent or pending patent application that we own or have exclusively licensed;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">We or our licensors or any future strategic partners might not have been the first to file patent applications
covering certain of our inventions;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 23; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Others may independently develop similar or alternative technologies or duplicate any of our technologies
without infringing our intellectual property rights;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">It is possible that our pending patent applications will not lead to issued patents;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Issued patents that we own or have exclusively licensed may not provide us with any competitive advantages,
or may be held invalid or unenforceable, as a result of legal challenges by our competitors;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Our competitors might conduct research and development activities in countries where we do not have patent
rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;
and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">We may not develop additional proprietary technologies that are patentable.</td></tr></table><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject
to claims challenging the inventorship of our patents and other intellectual property.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be subject to claims
that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor
or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved
in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If
we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such
as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our
business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction
to management and other employees.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Risks Related to Our Industry</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject
to government regulations and we may experience delays in obtaining required regulatory approvals in the United States to market our proposed
product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Various aspects of our operations
are subject to federal, state or local laws, and rules and regulations, any of which may change from time to time. Costs arising out of
any regulatory developments could be time-consuming and expensive and could divert management resources and attention and, consequently,
could adversely affect our business operations and financial performance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Delays in regulatory approval,
limitations in regulatory approval and withdrawals of regulatory approval may have a material adverse effect on us. If we experience significant
delays in testing or receiving approvals or sign-offs to conduct clinical trials, our product development costs, or our ability to license
product candidates, will increase. If the FDA grants regulatory approval to market a product, this approval will be limited to those disease
states and conditions and populations for which the product has demonstrated, through clinical trials, to be safe and effective. Any product
approvals that we receive in the future could also include significant restrictions on the use or marketing of our products. Product approvals,
if granted, can be withdrawn for failure to comply with regulatory requirements or upon the occurrence of adverse events following commercial
introduction of the products. Failure to comply with applicable FDA or other applicable regulatory requirements may result in criminal
prosecution, civil penalties, recall or seizure of products, total or partial suspension of production or injunction, as well as other
regulatory action against our product candidates or us. If approval is withdrawn for a product, or if a product were seized or recalled,
we would be unable to sell or license that product and our revenues would suffer. In addition, outside the United States, our ability
to market any of our potential products is contingent upon receiving market application authorizations from the appropriate regulatory
authorities and these foreign regulatory approval processes include all of the risks associated with the FDA approval process described
above.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect the
healthcare industry to face increased limitations on reimbursement as a result of healthcare reform, which could adversely affect third-party
coverage of our products and how much or under what circumstances healthcare providers will prescribe or administer our products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In both the United States
and other countries, sales of our products will depend in part upon the availability of reimbursement from third-party payors, which include
governmental authorities, managed-care organizations and other private-health insurers. Third-party payors are increasingly challenging
the price and examining the cost effectiveness of medical products and services.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Increasing expenditures for
healthcare have been the subject of considerable public attention in the United States. Both private and government entities are seeking
ways to reduce or contain healthcare costs. Numerous proposals that would effect changes in the U.S. healthcare system have been introduced
or proposed in Congress and in some state legislatures, including reducing reimbursement for prescription products and reducing the levels
at which consumers and healthcare providers are reimbursed for purchases of pharmaceutical products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 24; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2010, the U.S. congress
enacted the Patient Protection and Affordable Care Act of 2010, or the Affordable Care Act. The Affordable Care Act seeks to reduce the
federal deficit and the rate of growth in healthcare spending through, among other things, stronger prevention and wellness measures,
increased access to primary care, changes in healthcare delivery systems and the creation of health insurance exchanges. Enrollment in
the health insurance exchanges began in October 2013. The Affordable Care Act requires the pharmaceutical industry to share in the costs
of reform, by, among other things, increasing Medicaid rebates and expanding Medicaid rebates to cover Medicaid managed-care programs.
Other components of healthcare reform include funding of pharmaceutical costs for Medicare patients in excess of the prescription drug
coverage limit and below the catastrophic coverage threshold. Under the Affordable Care Act, pharmaceutical companies are now obligated
to fund 50% of the patient obligation for branded prescription pharmaceuticals in this gap, or &#8220;donut hole.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There have been judicial and
congressional challenges to the Affordable Care Act. If a law is enacted, many if not all of the provisions of the Affordable Care Act
may no longer apply to prescription drugs. While we are unable to predict what changes may ultimately be enacted, to the extent that future
changes affect how any future products are paid for and reimbursed by government and private payers, our business could be adversely impacted.
On December 14, 2018, a federal district court in Texas ruled that the Affordable Care Act is unconstitutional as a result of the Tax
Cuts and Jobs Act and the federal income tax reform legislation previously passed by Congress and signed by President Trump on December
22, 2017, that eliminated the individual mandate portion of the Affordable Care Act. The case, Texas, et al. v. United States of America,
et al., (N.D. Texas), is an outlier, but in 2019, the Fifth Circuit Court of Appeals subsequently upheld the lower court decision, which
was then appealed to the U.S. Supreme Court. On June 17, 2021, the U.S. Supreme Court held that the plaintiffs did not have standing to
challenge the individual mandate because they have not shown a past or future injury. In November 2020, Joseph Biden was elected President
and, in January 2021, the Democratic Party obtained control of the Senate. As a result of these electoral developments, it is unlikely
that continued legislative efforts will be pursued to repeal PPACA. Instead, it is possible that legislation will be pursued to enhance
or reform PPACA. We are not able to state with certainty what the impact of potential legislation will be on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, other legislative
changes have been proposed and adopted since the Affordable Care Act was enacted. In August 2011, President Obama signed into law the
Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress
proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of an amount greater than $1.2
trillion for the years 2013 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This
includes aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per fiscal year, starting in 2013. In January
2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to
several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments
to providers from three to five years. If we ever obtain regulatory approval and commercialization of our products, these laws may result
in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on our customers and accordingly,
our financial operations. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales
and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether
the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our
products may be. Further, the Deficit Reduction Act of 2010, directed Centers for Medicare &amp; Medicaid Services to contract a vendor
to determine &#8220;retail survey prices for covered outpatient drugs that represent a nationwide average of consumer purchase prices
for such drugs, net of all discounts and rebates (to the extent any information with respect to such discounts and rebates is available).&#8221;
This survey information can be used to determine the National Average Drug Acquisition Cost, or NADAC. Some states have indicated that
they will reimburse based on the NADAC and this can result in further reductions in the prices paid for various outpatient drugs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As part of its reform of the
340B discount drug program, on October 31, 2018, the Health Resources and Services Administration, or HRSA, at the HHS, issued a notice
of proposed rulemaking to move up the effective date of a final rule that would give HHS authority to impose Civil Monetary Penalties
on pharmaceutical manufacturers who knowingly and intentionally charged a covered entity more than the statutorily allowed ceiling price
for a covered outpatient drug. The final rule is intended to encourage compliance by manufacturers in offering the mandatory 340B ceiling
purchase price to eligible purchasers, such as certain qualified health systems or individual hospitals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Various states, such as California,
have also taken steps to consider and enact laws or regulations that are intended to increase the visibility of the pricing of pharmaceutical
products with the goal of reducing the prices at which we are able to sell our products. Because these various actual and proposed legislative
changes are intended to operate on a state-by-state level rather than a national one, we cannot predict what the full effect of these
legislative activities may be on our business in the future.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Although we cannot predict
the full effect on our business of the implementation of existing legislation, including the Affordable Care Act or the enactment of additional
legislation, we believe that legislation or regulations that reduce reimbursement for or restrict coverage of our products could adversely
affect how much or under what circumstances healthcare providers will prescribe or administer our products. This could materially and
adversely affect our business by reducing our ability to generate revenue, raise capital, obtain additional collaborators and market our
products, following marketing approval. In addition, we believe the increasing emphasis on managed care in the United States has and will
continue to put pressure on the price and usage of pharmaceutical products, which may adversely impact any future product sales.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 25; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we or any of
our independent contractors, consultants, collaborators, manufacturers, or service providers fail to comply with healthcare and data privacy
laws and regulations, we or they could be subject to enforcement actions, which could result in penalties and affect our ability to develop,
market and sell our product candidates and may harm our reputation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are or may in the future
be subject to federal, state, and foreign healthcare and data privacy laws and regulations pertaining to, among other things, fraud and
abuse of patients&#8217; rights. These laws and regulations include:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The federal Anti-Kickback Statute prohibits, among other things, knowingly and willfully soliciting, offering,
receiving, or paying any remuneration, directly or indirectly, in cash or in kind, to induce or reward purchasing, ordering or arranging
for or recommending the purchase or order of any item or service for which payment may be made, in whole or in part, under a federal healthcare
program such as Medicare and Medicaid. Liability may be established without a person or entity having actual knowledge of the federal
Anti-Kickback Statute or specific intent to violate it. This statute has been interpreted to apply broadly to arrangements between pharmaceutical
manufacturers on the one hand and prescribers, patients, purchasers and formulary managers on the other. In addition, the Affordable Care
Act amended the Social Security Act to provide that the U.S. government may assert that a claim including items or services resulting
from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False
Claims Act, or the FCA. A conviction for violation of the Anti-Kickback Statute requires mandatory exclusion from participation in federal
healthcare programs. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities
from prosecution, the exemptions and safe harbors are drawn narrowly, and those activities may be subject to scrutiny or penalty if they
do not qualify for an exemption or safe harbor;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The FCA prohibits, among other things, knowingly presenting, or causing to be presented claims for payment
of government funds that are false or fraudulent, or knowingly making, using or causing to be made or used a false record or statement
material to such a false or fraudulent claim, or knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing
an obligation to pay money to the federal government. This statute also permits a private individual acting as a &#8220;whistleblower&#8221;
to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. The FCA prohibits
anyone from knowingly presenting, conspiring to present, making a false statement in order to present, or causing to be presented, for
payment to federal programs (including Medicare and Medicaid) claims for items or services, including drugs, that are false or fraudulent,
claims for items or services not provided as claimed, or claims for medically unnecessary items or services. This law also prohibits anyone
from knowingly underpaying an obligation owed to a federal program. Increasingly, U.S. federal agencies are requiring nonmonetary remedial
measures, such as corporate integrity agreements in FCA settlements. The U.S. Department of Justice announced in 2016 its intent to follow
the &#8220;Yates Memo,&#8221; taking a far more aggressive approach in pursuing individuals as FCA defendants in addition to the corporations.
FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and mandatory penalties
of $5,500 to $11,000 per false claim or statement ($10,781 to $21,563 per false claim or statement for penalties assessed after August
1, 2016 for violations occurring after November 2, 2015, and $10,957 to $21,916 per false claim or statement for penalties assessed after
February 3, 2017 for violations occurring after November 2, 2015). Government enforcement agencies and private whistleblowers have investigated
pharmaceutical companies for or asserted liability under the FCA for a variety of alleged promotional and marketing activities, such as
providing free product to customers with the expectation that the customers would bill federal programs for the product; providing consulting
fees and other benefits to physicians to induce them to prescribe products; engaging in promotion for &#8220;off-label&#8221; uses; and
submitting inflated best price information to the Medicaid Rebate Program;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The federal False Statements Statute prohibits knowingly and willfully falsifying, concealing, or covering
up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false
writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry, in connection with
the delivery of or payment for healthcare benefits, items, or services;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The federal Civil Monetary Penalties Law authorizes the imposition of substantial civil monetary penalties
against an entity, such as a pharmaceutical manufacturer, that engages in activities including, among others (1) knowingly presenting,
or causing to be presented, a claim for services not provided as claimed or that is otherwise false or fraudulent in any way; (2) arranging
for or contracting with an individual or entity that is excluded from participation in federal healthcare programs to provide items or
services reimbursable by a federal healthcare program; (3) violations of the federal Anti-Kickback Statute; or (4) failing to report and
return a known overpayment;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and
civil liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or
knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with
the delivery of, or payment for, healthcare benefits, items or services; similar to the federal Anti-Kickback Statute, a person or entity
does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 26; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, which imposes
requirements on certain types of people and entities relating to the privacy, security, and transmission of individually identifiable
health information, and requires notification to affected individuals and regulatory authorities of certain breaches of security of individually
identifiable health information;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologics
and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, to report
annually to the Centers for Medicare &amp; Medicaid Services information related to payments and other transfers of value to physicians,
other healthcare providers and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers
and their immediate family members, which is published in a searchable form on an annual basis;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">State laws comparable to each of the above federal laws, such as, for example, anti-kickback and false
claims laws that may be broader in scope and also apply to commercial insurers and other non-federal payor;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Requirements for mandatory corporate regulatory compliance programs, and laws relating to patient data
privacy and security. Other state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance
guidelines and the relevant compliance guidance promulgated by the federal government; require drug manufacturers to report information
related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and state and
foreign laws govern the privacy and security of health information in some circumstances, many of which differ from each other in significant
ways and often are not preempted by HIPAA, thus complicating compliance efforts; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">In the European Union, the General Data Protection Regulation, or the GDPR&#8212;Regulation EU 2016/679&#8212;which
was adopted in May 2016 and has become applicable on May 25, 2018. The GDPR is further intended to harmonize data protection requirements
across the European Union member states by establishing new and expanded operational requirements for entities that collect, process or
use personal data generated in the European Union, including consent requirements for disclosing the way personal information will be
used, information retention requirements, and notification requirements in the event of a data breach.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The California Consumer Privacy Act of 2018, or CCPA, effective as of January 1, 2020, gives California
residents expanded rights to access and require deletion of their personal information, opt out of certain personal information sharing,
and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as
well as a private right of action for data breaches, that is expected to increase data breach litigation.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">In addition, failure to comply with the Israeli Privacy Protection Law of 1981, and its regulations, as
well as the guidelines of the Israeli Privacy Protection Authority, may expose us to administrative fines, civil claims (including class
actions) and in certain cases criminal liability. Current pending legislation may result in a change of the current enforcement measures
and sanctions.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If our operations are found
to be in violation of any such healthcare laws and regulations, we may be subject to penalties, including administrative, civil and criminal
penalties, monetary damages, disgorgement, imprisonment, the curtailment or restructuring of our operations, loss of eligibility to obtain
approvals from the FDA or foreign regulatory authorities, or exclusion from participation in government contracting, healthcare reimbursement
or other government programs, including Medicare and Medicaid, any of which could adversely our financial results. Any action against
us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#8217;s attention
from the operation of our business, even if our defense is successful. In addition, achieving and sustaining compliance with applicable
laws and regulations may be costly to us in terms of money, time and resources.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our employees,
principal investigators, consultants, commercial partners or vendors may engage in misconduct or other improper activities, including
non-compliance with regulatory standards.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also exposed to the
risk of employees, independent contractors, principal investigators, consultants, commercial partners or vendors engaging in fraud or
other misconduct. Misconduct by employees, independent contractors, principal investigators, consultants, commercial partners and vendors
could include intentional failures to comply with EU regulations, to provide accurate information to the EMA or EU Member States authorities
or to comply with manufacturing or quality standards we have or will have established. In particular, sales, marketing and business arrangements
in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing
and other abusive practices such as promotion of products by medical practitioners. The EU Member States in which we operate have different
statutory provisions regulating the cooperation of pharmaceutical companies with healthcare professionals. In addition to these statutory
provisions, codes of conduct issued by business associations or other non-statutory standards may be applicable to our activities. Both
statutory provisions and non-statutory codes or standards restrict payments or other benefits provided to healthcare professionals, and
in case of non-compliance, may result in severe sanctions such as bans, administrative fines, criminal fines or even imprisonment. The
advertising of medicinal products for human use in the EU is regulated by Title VIII of European Directive 2001/83/EC. These provisions
have been implemented into the law of the EU member States. Such laws inter alia restrict or prohibit a wide range of pricing, discounting,
marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct could also involve
the improper use of information obtained in the course of clinical studies, which could result in regulatory sanctions and serious and
irreparable harm to our reputation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 27; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This could also apply with
respect to data privacy. In the EU, the EU Directive 95/46/EEC was replaced by the GDPR on May 25, 2018. The GDPR as an EU regulation
does not have to be implemented into Member States&#8217; national law, but applies directly in all Member States since May 25, 2018.
It applies to companies with an establishment in the European Economic Area (EEA) and to certain other companies not in the EEA that offer
or provide goods or services to individuals located in the EEA or monitor individuals located in the EEA. The GDPR implements more stringent
operational requirements for controllers of personal data, including, for example, expanded disclosures about how personal information
is to be used, limitations on retention of information, increased requirements pertaining to health data and pseudonymized (i.e., key-coded)
data, increased cyber security requirements, mandatory data breach notification requirements and higher standards for controllers to demonstrate
that they have obtained a valid legal basis for certain data processing activities. The GDPR provides that EU Member States may continue
to make their own further laws and regulations in relation to the processing of genetic, biometric or health data, which could result
in continued or new differences between Member States, limit our ability to use and share personal data or could cause our costs to increase,
and harm our business and financial condition. We are also subject to evolving and strict rules on the transfer of personal data out of
the European Union to the United States. Further prospective revision of the Directive on privacy and electronic communications (Directive
2002/58/EC), or ePrivacy Directive, may affect our marketing communications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our actual or alleged failure
to comply with this regulation, or to protect personal data, could result in enforcement actions and significant penalties against us,
which could result in negative publicity, increase our operating costs, subject us to claims or other remedies and have a material adverse
effect on our business, financial condition, and results of operations. It is not always possible to identify and deter misconduct by
employees or other parties. The precautions we take to detect and prevent such activity may not protect us from legal or regulatory action
resulting from a failure to comply with applicable laws or regulations. Misconduct by our employees, principal investigators, consultants,
commercial partners or vendors could result in significant financial penalties, criminal sanctions, civil law claims and/or negative media
coverage, and thus have a material adverse effect on our business, including through the imposition of significant fines or other sanctions,
and our reputation. In particular, failure to comply with EU laws, including failure under the GDPR, ePrivacy Directive and other laws
relating to the security of personal data may result in fines up to &#8364;20,000,000 or up to 4% of the total worldwide annual turnover
of the preceding financial year, if greater, and other administrative penalties including criminal liability, which may be onerous and
adversely affect our business, financial condition, results of operations and prospects. Failure to comply with the GDPR and related laws
may also give risk to increase risk of private actions, including a new form of class action that is available under the GDPR.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Risks Related to Our Operations in Israel</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conduct our
operations in Israel and therefore our results may be adversely affected by political, economic and military instability in Israel and
its region.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our headquarters, all of our
operations and some of our suppliers and third party contractors are located in central Israel and our key employees, officers and most
of our directors are residents of Israel. Accordingly, political and economic instability, war or acts of terrorism or natural disasters,
emergence of a pandemic, or other widespread health emergencies (or concerns over the possibility of such an emergency, including for
example, the COVID-19 outbreak), may directly affect our business. Since the establishment of the State of Israel in 1948, a number of
armed conflicts have taken place between Israel and its Arab neighbors. Any hostilities involving Israel or the interruption or curtailment
of trade within Israel or between Israel and its trading partners could adversely affect our operations and results of operations and
could make it more difficult for us to raise capital. During the winter of 2008, winter of 2012 and the summer of 2014, Israel was engaged
in an armed conflict with Hamas, a militia group and political party operating in the Gaza Strip, and during the summer of 2006, Israel
was engaged in an armed conflict with Hezbollah, a Lebanese Islamist Shiite militia group and political party. Israel faces political
tension with respect to its relationships with Turkey, Iran and certain Arab neighbor countries. In addition, recent conflicts involved
missile strikes against civilian targets in various parts of Israel, and negatively affected business conditions in Israel. Recent political
uprisings and social unrest in various countries in the Middle East and North Africa are affecting the political stability of those countries.
This instability may lead to deterioration of the political relationships that exist between Israel and these countries, and have raised
concerns regarding security in the region and the potential for armed conflict. Any armed conflicts, terrorist activities or political
instability in the region could adversely affect business conditions and could harm our results of operations. For example, any major
escalation in hostilities in the region could result in a portion of our employees and service providers being called up to perform military
duty for an extended period of time. Parties with whom we do business have sometimes declined to travel to Israel during periods of heightened
unrest or tension, forcing us to make alternative arrangements when necessary. In addition, the political and security situation in Israel
may result in parties with whom we have agreements involving performance in Israel claiming that they are not obligated to perform their
commitments under those agreements pursuant to force majeure provisions in such agreements. Any future deterioration in the political
and security situation in Israel will negatively impact our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our commercial insurance does
not cover losses that may occur as a result of events associated with the security situation in the Middle East. Although the Israeli
government currently covers the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, we cannot assure
you that this government coverage will be maintained. Any losses or damages incurred by us could have a material adverse effect on our
business. Any armed conflicts or political instability in the region would likely negatively affect business conditions and could harm
our results of operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further, in the past, the
State of Israel and Israeli companies have been subjected to an economic boycott. Several countries still restrict business with the State
of Israel and with Israeli companies. These restrictive laws and policies may have an adverse impact on our operating results, financial
condition or the expansion of our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The legislative power of the
State resides in the Knesset, a unicameral parliament that consists of 120 members elected by nationwide voting under a system of proportional
representation. Actual or perceived political instability in Israel or any negative changes in the political environment, may individually
or in the aggregate adversely affect the Israeli economy and, in turn, our business, financial condition, results of operations and prospects.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 28; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our operations
may be disrupted as a result of the obligation of Israeli citizens to perform military service.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Many Israeli citizens, including
Motti Farbstein, our Chief Operating and Financial Officer, are obligated to perform one month, and in some cases more, of annual military
reserve duty until they reach the age of 40 (or older, for reservists with certain occupations) and, in the event of a military conflict,
may be called to active duty. In response to increases in terrorist activity, there have been periods of significant call-ups of military
reservists. It is possible that there will be military reserve duty call-ups in the future. Our operations could be disrupted by such
call-ups, which may include the call-up of Motti Farbstein. Such disruption could materially adversely affect our business, financial
condition and results of operations.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because a certain
portion of our expenses is incurred in currencies other than U.S. dollars, our results of operations may be harmed by currency fluctuations
and inflation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From our inception through
January 1, 2018, our functional and presentation currency was the NIS. Management conducted a review of the functional currency and decided
to change its functional and presentation currency to U.S. dollars from the NIS effective January 1, 2018. These changes were based on
an assessment by our management that U.S. dollars is the primary currency of the economic environment in which we operate. Part of our
expenses are payable in U.S. dollars or in Euros as well as the revenues from our licensing arrangements that are payable in U.S. dollars
and Canadian dollars, we expect our revenues from future licensing arrangements to be denominated in U.S. dollars or in Euros. To date,
we have not engaged in hedging transactions. Although the Israeli rate of inflation has not had a material adverse effect on our financial
condition during 2019, 2020 or 2021 to date, we may, in the future, decide to enter into currency hedging transactions to decrease the
risk of financial exposure from fluctuations in the exchange rates of the currencies mentioned above in relation to U.S. dollars. These
measures, however, may not adequately protect us from material adverse effects.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">It may be difficult
to enforce a U.S. judgment against us and our officers and directors named in this Annual Report on Form 20-F in Israel or the United
States, or to serve process on our officers and directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated in Israel.
All of our executive officers and directors listed in this Annual Report on Form 20-F reside outside of the United States, and all of
our assets and most of the assets of our executive officers and directors are located outside of the United States. Therefore, a judgment
obtained against us or most of our executive officers and all of our directors in the United States, including one based on the civil
liability provisions of the U.S. federal securities laws, may not be collectible in the United States and may not be enforced by an Israeli
court. It also may be difficult for you to effect service of process on these persons in the United States or to assert U.S. securities
law claims in original actions instituted in Israel.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Your rights and
responsibilities as a shareholder will be governed by Israeli law which may differ in some respects from the rights and responsibilities
of shareholders of U.S. companies.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are incorporated under
Israeli law. The rights and responsibilities of the holders of our shareholders are governed by our Amended and Restated Articles of Association
and Israeli law. These rights and responsibilities differ in some respects from the rights and responsibilities of shareholders in typical
U.S.-based corporations. In particular, a shareholder of an Israeli company has a duty to act in good faith toward the company and other
shareholders and to refrain from abusing its power in the company, including, among other things, in voting at the general meeting of
shareholders on matters such as amendments to a company&#8217;s articles of association, increases in a company&#8217;s authorized share
capital, mergers and acquisitions and interested party transactions requiring shareholder approval. In addition, a shareholder who knows
that it possesses the power to determine the outcome of a shareholder vote or to appoint or prevent the appointment of a director or executive
officer in the company has a duty of fairness toward the company. There is limited case law available to assist us in understanding the
implications of these provisions that govern shareholders&#8217; actions. These provisions may be interpreted to impose additional obligations
and liabilities of our shareholders that are not typically imposed on shareholders of U.S. corporations.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions of
Israeli law may delay, prevent or otherwise impede a merger with, or an acquisition of, our Company, which could prevent a change of control,
even when the terms of such a transaction are favorable to us and our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli corporate law regulates
mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving
directors, officers or significant shareholders and regulates other matters that may be relevant to these types of transactions. For example,
a merger may not be consummated unless at least 50 days have passed from the date that a merger proposal was filed by each merging company
with the Israel Registrar of Companies and at least 30 days from the date that the shareholders of both merging companies approved the
merger. In addition, a majority of each class of securities of the target company must approve a merger. Moreover, a full tender offer
can only be completed if the acquirer receives at least 95% of the issued share capital; provided that, pursuant to an amendment to the
Companies Law, 5759-1999, as amended, or the Israeli Companies Law, effective as of May 15, 2011, a majority of the offerees that do not
have a personal interest in such tender offer shall have approved the tender offer; except that, if the total votes to reject the tender
offer represent less than 2% of our issued and outstanding share capital, in the aggregate, approval by a majority of the offerees that
do not have a personal interest in such tender offer is not required to complete the tender offer, and the shareholders, including those
who indicated their acceptance of the tender offer, may, at any time within six months following the completion of the tender offer, petition
the court to alter the consideration for the acquisition (unless the acquirer stipulated in the tender offer that a shareholder that accepts
the offer may not seek appraisal rights).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 29; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, Israeli tax considerations
may make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty with Israel
exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent
as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent
on the fulfillment of numerous conditions, including a holding period of two years from the date of the transaction during which sales
and dispositions of shares of the participating companies are restricted. Moreover, with respect to certain share swap transactions, the
tax deferral is limited in time, and when such time expires, the tax becomes payable even if no actual disposition of the shares has occurred.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These and other similar provisions
could delay, prevent or impede an acquisition of us or our merger with another company, even if such an acquisition or merger would be
beneficial to us or to our shareholders. See &#8220;Description of the Offered Securities&#8212;Articles of Association.&#8221;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Risks Related to Our Ordinary Shares and ADSs</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>We are currently operating
in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability
due to the ongoing military conflict between Russia and Ukraine.</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. and global markets are
experiencing volatility and disruption following the escalation of geopolitical tensions and the start of the military conflict between
Russia and Ukraine. In February 2022, Russia launched a full-scale military invasion of Ukraine. Although the length and impact of the
ongoing military conflict is highly unpredictable, the conflict in Ukraine could lead to market disruptions, including significant volatility
in commodity prices, credit and capital markets. Additionally, Russia&#8217;s prior annexation of Crimea, recent recognition of two separatist
republics in the Donetsk and Luhansk regions of Ukraine and subsequent military interventions in Ukraine have led to sanctions and other
penalties being levied by the United States, European Union and other countries against Russia, Belarus, the Crimea Region of Ukraine,
the so-called Donetsk People&#8217;s Republic, and the so-called Luhansk People&#8217;s Republic, including agreement to remove certain
Russian financial institutions from the Society for Worldwide Interbank Financial Telecommunication (SWIFT) payment system. Additional
potential sanctions and penalties have also been proposed and/or threatened. Russian military actions and the resulting sanctions could
adversely affect the global economy and financial markets and lead to instability and lack of liquidity in capital markets, potentially
making it more difficult for us to obtain additional funds. Any of the abovementioned factors could affect our business, prospects, financial
condition, and operating results. The extent and duration of the military action, sanctions and resulting market disruptions are impossible
to predict, but could be substantial. Any such disruptions may also magnify the impact of other risks described in this Annual Report
on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no
assurance that we will not be a passive foreign investment company, or PFIC, for U.S. federal income tax purposes in 2022 or in any subsequent
year. If we are a PFIC, there may be negative tax consequences for U.S. taxpayers that are holders of our ordinary shares, ADSs, Warrants,
or Pre-funded Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will be treated as a PFIC
for U.S. federal income tax purposes in any taxable year in which either (i) at least 75% of our gross income is &#8220;passive income&#8221;
or (ii) on average at least 50% of our assets by value produce passive income or are held for the production of passive income. Passive
income for this purpose generally includes, among other things, certain dividends, interest, royalties, rents and gains from commodities
and securities transactions and from the sale or exchange of property that gives rise to passive income. Passive income also includes
amounts derived by reason of the temporary investment of funds, including those raised in a public offering. In determining whether a
non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly,
at least a 25% interest (by value) is taken into account.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our analysis of our
income, assets, and operations, we believe that we were not a PFIC for 2021. Because the PFIC determination is highly fact intensive,
there can be no assurance that we will not be a PFIC in 2022 or in any other taxable year. If we were to be characterized as a PFIC for
U.S. federal income tax purposes in any taxable year during which a U.S. shareholder owns our ordinary shares, ADSs, Warrants, or Pre-funded
Warrants, then &#8220;excess distributions&#8221; to such U.S. shareholder, and any gain realized on the sale or other disposition of
our ordinary shares, ADSs, Warrants, or Pre-funded Warrants, as applicable, will be subject to special rules. Under these rules: (i) the
excess distribution or gain would be allocated ratably over the U.S. shareholder&#8217;s holding period for the ordinary shares (or ADSs,
Warrants, or Pre-funded Warrants, as the case may be); (ii) the amount allocated to the current taxable year and any period prior to the
first day of the first taxable year in which we were a PFIC would be taxed as ordinary income; and (iii) the amount allocated to each
of the other taxable years would be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that
year, and an interest charge for the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such
other taxable year. Certain of the adverse consequences of PFIC status can be mitigated if a U.S. shareholder makes an election to treat
us as a &#8220;qualified electing fund,&#8221; or QEF, or makes a &#8220;mark-to-market&#8221; election. A QEF election is unavailable
with respect to our Warrants, and a mark-to-market election is unavailable with respect to our Warrants and Pre-funded Warrants. In addition,
if the U.S. Internal Revenue Service, or IRS, determines that we are a PFIC for a year with respect to which we have determined that we
were not a PFIC, it may be too late for a U.S. shareholder to make a timely QEF or mark-to-market election. U.S. shareholders who hold
our ordinary shares, ADSs, Warrants or Pre-funded Warrants during a period when we are a PFIC will be subject to the foregoing rules,
even if we cease to be a PFIC in subsequent years, subject to exceptions for U.S. shareholders who made a timely QEF or mark-to-market
election (to the extent available). A U.S. shareholder can make a QEF election by completing the relevant portions of and filing IRS Form
8621 in accordance with the instructions thereto. Upon request, we intend to annually furnish U.S. shareholders with information needed
in order to complete IRS Form 8621 (which form would be required to be filed with the IRS on an annual basis by the U.S. shareholder)
and to make and maintain a valid QEF election for any year in which we or any of our subsidiaries that we control is a PFIC.</p><div>
</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 30; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions of
our charter documents and Israeli law may discourage, delay, prevent or otherwise impede a merger with, or an acquisition of, our Company,
which could prevent a change of control, even when the terms of such a transaction are favorable to us and our shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Provisions in articles of
association may discourage, delay, prevent or otherwise impede a merger, acquisition or other change in control of us that shareholders
may consider favorable, including transactions in which they might otherwise receive a premium for their ADSs. On February 20, 2020, we
amended our articles of association to establish a staggered Board of Directors, which divides the board into three groups, with directors
in each group serving a three-year term. The existence of a staggered board can make it more difficult for shareholders to replace or
remove incumbent members of our Board of Directors. As such, these provisions could also limit the price that investors might be willing
to pay in the future for our ADSs, thereby depressing the market price of our ADSs. In addition, because our Board of Directors is responsible
for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our shareholders to replace
or remove our current management by making it more difficult for shareholders to replace members of our Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, Israeli corporate
law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions
involving directors, officers or significant shareholders and regulates other matters that may be relevant to these types of transactions.
For example, a merger may not be consummated unless at least 50 days have passed from the date that a merger proposal was filed by each
merging company with the Israel Registrar of Companies and at least 30 days from the date that the shareholders of both merging companies
approved the merger. In addition, a majority of each class of securities of the target company must approve a merger. Moreover, a full
tender offer can only be completed if the acquirer receives at least 95% of the issued share capital; provided that, pursuant to an amendment
to the Companies Law, 5759-1999, as amended, or the Israeli Companies Law, effective as of May 15, 2011, a majority of the offerees that
do not have a personal interest in such tender offer shall have approved the tender offer; except that, if the total votes to reject the
tender offer represent less than 2% of our issued and outstanding share capital, in the aggregate, approval by a majority of the offerees
that do not have a personal interest in such tender offer is not required to complete the tender offer, and the shareholders, including
those who indicated their acceptance of the tender offer, may, at any time within six months following the completion of the tender offer,
petition the court to alter the consideration for the acquisition (unless the acquirer stipulated in the tender offer that a shareholder
that accepts the offer may not seek appraisal rights).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Furthermore, Israeli tax considerations
may make potential transactions unappealing to us or to our shareholders whose country of residence does not have a tax treaty with Israel
exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent
as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent
on the fulfillment of numerous conditions, including a holding period of two years from the date of the transaction during which sales
and dispositions of shares of the participating companies are restricted. Moreover, with respect to certain share swap transactions, the
tax deferral is limited in time, and when such time expires, the tax becomes payable even if no actual disposition of the shares has occurred.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business could
be negatively impacted by unsolicited takeover proposals, by shareholder activism or by proxy contests relating to the election of directors
or other matters.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business could be negatively
affected as a result of an unsolicited takeover proposal, by shareholder activism or a proxy contest. During 2019, an activist shareholder
sought to make changes to our Board of Directors, among other matters, which ultimately resulted in us entering into a settlement agreement
with the shareholder, and for which considerable costs were incurred and absorbed significant time and attention by management and the
Board of Directors. A future proxy contest, unsolicited takeover proposal, or other shareholder activism relating to the election of directors
or other matters would most likely require us to incur significant legal fees and proxy solicitation expenses and require significant
time and attention by management and our Board of Directors. The potential of a proxy contest, unsolicited takeover proposal, or other
shareholder activism could interfere with our ability to execute our strategic plan, give rise to perceived uncertainties as to our future
direction, result in the loss of potential business opportunities or make it more difficult to attract and retain qualified personnel,
any of which could materially and adversely affect our business and operating results.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Issuance of additional
equity securities may adversely affect the market price of our ADSs or ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently authorized
to issue 5,000,000,000 ordinary shares. As of the date of this Annual Report, we had 815,746,293 ordinary shares issued and outstanding
and we had no preferred shares outstanding. As of the date of this Annual Report, we also had warrants to purchase 377,947,640 ordinary
shares and options to purchase 19,422,700 ordinary shares outstanding, of which options to purchase 7,899,575 ordinary shares are currently
fully vested or vest within the next 60 days.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that ADSs or
ordinary shares are issued or options and warrants are exercised, holders of our ADSs and our ordinary shares will experience dilution.
In addition, in the event of any future issuances of equity securities or securities convertible into or exchangeable for ADSs or ordinary
shares, holders of our ADSs or our ordinary shares may experience dilution. We also consider from time to time various strategic alternatives
that could involve issuances of additional ADSs or ordinary shares, including but not limited to acquisitions and business combinations,
but do not currently have any definitive plans to enter into any of these transactions.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 31; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have no plans
to pay dividends on our ordinary shares, and you may not receive funds without selling our ADSs or ordinary shares.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have not declared or paid
any cash dividends on our ordinary shares, nor do we expect to pay any cash dividends on our ordinary shares for the foreseeable future.
We currently intend to retain any additional future earnings to finance our operations and growth and for future stock repurchases and,
therefore, we have no plans to pay cash dividends on our ordinary shares at this time. Any future determination to pay cash dividends
on our ordinary shares will be at the discretion of our Board of Directors and will be dependent on our earnings, financial condition,
operating results, capital requirements, any contractual restrictions, and other factors that our Board of Directors deems relevant. Accordingly,
you may have to sell some or all of our ADSs or ordinary shares in order to generate cash from your investment. You may not receive a
gain on your investment when you sell our ADSs or ordinary shares and may lose the entire amount of your investment.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The market price
of our ordinary shares and ADSs is subject to fluctuation, which could result in substantial losses by our investors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The stock market in general
and the market price of our ordinary shares on the TASE and our ADSs on the NYSE American is subject to fluctuation, and changes in our
share price may be unrelated to our operating performance. The market price of our ordinary shares and ADSs are and will be subject to
a number of factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">announcements of technological innovations or new products by us or others;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">announcements by us of significant strategic partnerships, out-licensing, in-licensing, joint ventures, acquisitions
or capital commitments;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">expiration or terminations of licenses, research contracts or other collaboration agreements;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">public concern as to the safety of drugs we, our licensees or others develop;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">general market conditions;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">the volatility of market prices for shares of biotechnology companies generally;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">success of research and development projects;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">success in clinical and preclinical studies;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">departure of key personnel;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">developments concerning intellectual property rights or regulatory approvals;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">variations in our and our competitors&#8217; results of operations;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">changes in earnings estimates or recommendations by securities analysts, if our ordinary shares or ADSs are
covered by analysts;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">changes in government regulations or patent decisions;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">developments by our licensees; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">general market conditions and other factors, including factors unrelated to our operating performance, such
as natural disasters and political and economic instability, including wars, terrorism, political unrest, results of certain elections
and votes, emergence of a pandemic, or other widespread health emergencies (or concerns over the possibility of such an emergency, including
for example, the COVID-19 outbreak), boycotts, adoption or expansion of government trade restrictions, and other business restrictions.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These factors and any corresponding
price fluctuations may materially and adversely affect the market price of our ordinary shares and our ADSs and result in substantial
losses by our investors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, market prices
for securities of biotechnology and pharmaceutical companies historically have been very volatile. The market for these securities has
from time to time experienced significant price and volume fluctuations for reasons unrelated to the operating performance of any one
company. See also Risk Factors&#8212;Risks Relating to Ownership of Our Ordinary Shares and ADSs &#8220;<i>We are currently operating
in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability
due to the ongoing military conflict between Russia and Ukraine</i>.&#8221; In the past, following periods of market volatility, shareholders
have often instituted securities class action litigation and we have been named in the past in a lawsuit requesting recognition as a class
action, in which we ultimately prevailed. If we were involved in securities litigation, it could have a substantial cost and divert resources
and attention of management from our business, even if we are successful.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Future sales of our ordinary
shares or ADSs could reduce the market price of our ordinary shares and ADSs.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 32; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Substantial sales
of our ordinary shares or our ADSs either on the TASE or on the NYSE American, as applicable, may cause the market price of our ordinary
shares or our ADSs to decline.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Sales by us or our security-holders
of substantial amounts of our ordinary shares or our ADSs, or the perception that these sales may occur in the future, could cause a reduction
in the market price of our ordinary shares or our ADSs. The issuance of any additional ordinary shares or ADSs, or any securities that
are exercisable for or convertible into our ordinary shares or our ADSs, may have an adverse effect on the market price of our ordinary
shares or our ADSs, as applicable, and will have a dilutive effect on our shareholders.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may not satisfy
the NYSE American requirements for continued listing. If we cannot satisfy these requirements, the NYSE American could delist our securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ADSs are listed on the
NYSE American under the symbol &#8220;CANF.&#8221; To continue to be listed on the NYSE American, we are required to satisfy a number
of conditions, including maintaining a share price and shareholders&#8217; equity above certain thresholds. If we are delisted from the
NYSE American, trading in our securities may be conducted, if available, on the OTC Markets or, if available, via another market. In the
event of such delisting, our shareholders would likely find it significantly more difficult to dispose of, or to obtain accurate quotations
as to the value of our securities, and our ability to raise future capital through the sale of our securities could be severely limited.
In addition, if our securities were delisted from the NYSE American, our ADSs could be considered a &#8220;penny stock&#8221; under the
U.S. federal securities laws. Additional regulatory requirements apply to trading by broker-dealers of penny stocks that could result
in the loss of an effective trading market for our securities. Moreover, if our ADSs were delisted from the NYSE American, we will no
longer be exempt from certain provisions of the Israeli Securities Law, and therefore will have increased disclosure requirements.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ADS holders are
not shareholders and do not have shareholder rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bank of New York Mellon,
as Depositary, delivers our ADSs. Each ADS represents two of our ordinary shares. ADS holders will not be treated as shareholders and
do not have the rights of shareholders. The Depositary will be the holder of the shares underlying our ADSs. Holders of ADSs will have
ADS holder rights. A deposit agreement among us, the Depositary, ADS holders and the beneficial owners of ADSs sets out ADS holder rights
as well as the rights and obligations of the Depositary. New York law governs the deposit agreement and our ADSs. Our shareholders have
shareholder rights. Israeli law and our Amended and Restated Articles of Association govern shareholder rights. ADS holders do not have
the same voting rights as our shareholders. Shareholders are entitled to our notices of general meetings and to attend and vote at our
general meetings of shareholders. At a general meeting, every shareholder present (in person or by proxy, attorney or representative)
and entitled to vote has one vote. This is subject to any other rights or restrictions which may be attached to any shares. ADS holders
may instruct the Depositary how to vote the number of deposited shares their ADSs represent.&#160;<i>Otherwise, you won&#8217;t be able
to exercise your right to vote unless you withdraw the shares. However, you may not know about the meeting enough in advance to withdraw
the shares. Th</i>e Depositary will notify ADS holders of shareholders&#8217; meetings and arrange to deliver our voting materials to
them if we ask it to. Those materials will describe the matters to be voted on and explain how ADS holders may instruct the Depositary
how to vote. For instructions to be valid, they must reach the Depositary by a date set by the Depositary. The Depositary will try, as
far as practical, subject to the laws of Israel and our Amended and Restated Articles of Association or similar documents, to vote or
to have its agents vote the shares or other deposited securities as instructed by ADS holders. The Depositary will only vote or attempt
to vote as instructed. We cannot assure you that you will receive the voting materials in time to ensure that you can instruct the Depositary
to vote your shares. In addition, the Depositary and its agents are not responsible for failing to carry out voting instructions or for
the matter of carrying out voting instructions. Th<i>is means that you may not be able to exercise your right to vote and there may be
nothing you can do if your shares are not voted as requested.</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">ADS holders do not have the
same rights to receive dividends or other distributions as our shareholders. Subject to any special rights or restrictions attached to
a share, the directors may determine that a dividend will be payable on a share and fix the amount, the time for payment and the method
for payment (although we have never declared or paid any cash dividends on our ordinary shares and we do not anticipate paying any cash
dividends in the foreseeable future). Dividends and other distributions payable to our shareholders with respect to our ordinary shares
generally will be payable directly to them. Any dividends or distributions payable with respect to ordinary shares deposited in the ADS
facility will be paid to the Depositary, which has agreed to pay to ADS holders the cash dividends or other distributions it or the custodian
receives on shares or other deposited securities, after deducting its fees and expenses. ADS holders will receive these distributions
in proportion to the number of ordinary shares their ADSs represent. In addition, there may be certain circumstances in which the Depositary
may not pay ADS holder&#8217;s amounts distributed by us as a dividend or distribution.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ordinary shares
and our ADSs are traded on different markets and this may result in price variations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ordinary shares have traded
on the TASE since October 2005 and our ADSs have been listed on the NYSE American since November 2013. Trading on these markets will take
place in different currencies (U.S. dollars on the NYSE American and NIS on the TASE), and at different times (resulting from different
time zones, different trading days and different public holidays in the United States and Israel). The trading prices of our securities
on these two markets may differ due to these and other factors. Any decrease in the price of our securities on one of these markets could
cause a decrease in the trading price of our securities on the other market.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 33; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have incurred
significant additional increased costs as a result of the listing of our ADSs for trading on the NYSE American, and our management is
required to devote substantial time to new compliance initiatives as well as to compliance with ongoing U.S. and Israeli reporting requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a public company in the
United States, we incur additional significant accounting, legal and other expenses that we did not incur before becoming a reporting
company in the United States. We also incur costs associated with corporate governance requirements of the SEC and the NYSE American Company
Guide, as well as requirements under Section 404 and other provisions of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act as
a result of our ADSs being listed on the NYSE American. These rules and regulations have increased our legal and financial compliance
costs, introduced new costs such as investor relations, stock exchange listing fees and shareholder reporting, and made some activities
more time consuming and costly. Since we are no longer an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business
Startups Act of 2012, and are no longer able to take advantage of certain exemptions from various reporting requirements that are applicable
to public companies that are &#8220;emerging growth companies&#8221; and that were applicable to us prior to January 1, 2020, we may incur
additional compliance costs in the future. The implementation and testing of such processes and systems may require us to hire outside
consultants and incur other significant costs. Any future changes in the laws and regulations affecting public companies in the United
States and Israel, including Section 404 and other provisions of the Sarbanes-Oxley Act, the rules and regulations adopted by the SEC
and the NYSE American Company Guide, as well as applicable Israeli reporting requirements, for so long as they apply to us, may result
in increased costs to us as we respond to such changes. These laws, rules and regulations could make it more difficult or more costly
for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to accept reduced
policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these requirements
could also make it more difficult for us to attract and retain qualified persons to serve on our Board of Directors, our Board committees
or as executive officers.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private
issuer, we are permitted to follow certain home country corporate governance practices instead of applicable SEC and NYSE American requirements,
which may result in less protection than is accorded to investors under rules applicable to domestic issuers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we will be permitted to follow certain home country corporate governance practices instead of those otherwise required under the NYSE
American Company Guide for domestic issuers. For instance, we may follow home country practice in Israel with regard to, among other things,
composition and function of the audit committee and other committees of our Board of Directors and certain general corporate governance
matters. In addition, in certain instances we will follow our home country law, instead of the NYSE American Company Guide, which requires
that we obtain shareholder approval for certain dilutive events, such as an issuance that will result in a change of control of the company,
certain transactions other than a public offering, involving issuances of a 20% or more interest in the company and certain acquisitions
of the stock or assets of another company. We comply with the director independence requirements of the NYSE American Company Guide, including
the requirement that a majority of the Board of Directors be independent. Following our home country governance practices as opposed to
the requirements that would otherwise apply to a U.S. company listed on the NYSE American may provide less protection than is accorded
to investors under the NYSE American Company Guide applicable to domestic issuers.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, as a foreign
private issuer, we are exempt from the rules and regulations under the U.S. Securities Exchange Act of 1934, as amended, or the Exchange
Act, related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from
the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we will not be required
under the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly
as domestic companies whose securities are registered under the Exchange Act.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we became
a reporting company under the Exchange Act by means of filing a Form 20-F, we may have difficulty attracting the attention of research
analysts at major brokerage firms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because we did not become
a reporting company by conducting an underwritten initial public offering in the United States, we may have difficulty attracting the
attention of security analysts at major brokerage firms in order for them to provide coverage of our company. The failure to receive research
coverage or support in the market for our shares will have an adverse effect on our ability to develop a liquid market for our ADSs.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are unable
to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act as they apply to a foreign private issuer that is listed on a U.S.
exchange, or our internal control over financial reporting is not effective, the reliability of our financial statements may be questioned
and our share price and the ADS price may suffer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the requirements
of the Sarbanes-Oxley Act. Section 404 of the Sarbanes-Oxley Act requires companies subject to the reporting requirements of the U.S.
securities laws to do a comprehensive evaluation of its and its subsidiaries&#8217; internal control over financial reporting. To comply
with this statute, we must document and test our internal control procedures and our management and issue a report concerning our internal
control over financial reporting. In addition, as long as we do not become an accelerated or large accelerated filer, we are exempt from
the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act. Under this exemption, our auditor will not be required
to attest to and report on our management&#8217;s assessment of our internal control over financial reporting until the date we are no
longer a non-accelerated filer. We will need to prepare for compliance with Section 404 by strengthening, assessing and testing our system
of internal controls to provide the basis for our report. However, the continuous process of strengthening our internal controls and complying
with Section 404 is complicated and time-consuming. Furthermore, as our business continues to grow both domestically and internationally,
our internal controls will become more complex and will require significantly more resources and attention to ensure our internal controls
remain effective overall. During the course of the testing, our management may identify material weaknesses or significant deficiencies,
which may not be remedied in a timely manner to meet the deadline imposed by the Sarbanes-Oxley Act. If our management cannot favorably
assess the effectiveness of our internal control over financial reporting, or our independent registered public accounting firm identifies
material weaknesses in our internal controls, investor confidence in our financial results may weaken, and the market price of our securities
may suffer.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 34; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_005"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
4. </span>Information on the Company</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">A.
</span>History and Development of the Company</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our legal name is Can-Fite
BioPharma Ltd. and our commercial name is &#8220;Can-Fite.&#8221; We are a company limited by shares organized under the laws of the State
of Israel. Our principal executive offices are located at 10 Bareket Street, Kiryat Matalon, Petah-Tikva 4951778 Israel. Our telephone
number is +972 (3) 924-1114.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We were founded on September
11, 1994 by Pnina Fishman, Ph.D., our Chief Executive Officer and a director, and Ilan Cohn, Ph.D., our Chairman of the Board of Directors,
under the name Can-Fite Technologies Ltd. On January 7, 2001, we changed our name to Can-Fite BioPharma Ltd. We completed our initial
public offering in Israel in October 2005 and our ordinary shares are traded on the TASE under the symbol &#8220;CFBI.&#8221; On October
2, 2012, our ADSs began trading over the counter in the United States under the symbol &#8220;CANFY&#8221; and on November 19, 2013, our
ADSs began trading on the NYSE American under the symbol &#8220;CANF.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2011, through
a series of transactions, we spun-off our activity in the ophthalmic field to our now former subsidiary, OphthaliX, a Delaware corporation
and successor-in-interest to Denali Concrete Management, Inc., a Nevada corporation, whose common shares were traded in the United States
on OTC under the symbol &#8220;OPLI.&#8221; In the spin-off transactions, we granted an exclusive license for the use of our Piclidenoson
drug candidate in the ophthalmic field, or the License Agreement, to Eye-Fite Ltd., an Israel limited company, or Eye-Fite, and transferred
our issued and outstanding ordinary shares in Eye-Fite to OphthaliX in exchange for an 86.7% interest in OphthaliX. In connection with
the spin-off transactions, OphthaliX completed a series of private placement financing transactions. Following the spin-off transactions
and the private placement financing transactions, we held approximately 82% interest in OphthaliX. In July 2016, OphthaliX released top-line
results from its Phase II clinical trial of Piclidenoson for the treatment of glaucoma. In this trial, no statistically significant differences
were found between the Piclidenoson treated group and the placebo group in the primary endpoint of lowering IOP. High IOP is a characteristic
of glaucoma. Piclidenoson was found to have a favorable safety profile and was generally well-tolerated. Based on these overall results,
OphthaliX saw no immediate path forward in glaucoma and ceased active business operations. Subsequently, on May 21, 2017, OphthaliX and
a wholly owned private Israeli subsidiary of OphthaliX, Bufiduck Ltd, or the Merger Sub, and Wize Pharma Ltd., or Wize Israel, an Israeli
company formerly listed on the TASE entered into an Agreement and Plan of Merger, or the Merger Agreement, providing for the merger of
the Merger Sub with and into Wize Israel, with Wize Israel becoming a wholly-owned subsidiary of OphthaliX and the surviving corporation
of the merger, or the Merger. On November 16, 2017, the Merger was completed. As a result of the Merger, our ownership of OphthaliX, immediately
post-Merger, became approximately 8% of the outstanding shares of common stock. In addition, immediately prior to the Merger, OphthaliX
sold on an &#8220;as is&#8221; basis to us all the ordinary shares of Eye-Fite in exchange for the irrevocable cancellation and waiver
of all indebtedness owed by OphthaliX and Eye-Fite to us, including approximately $5 million of deferred payments owed by OphthaliX and
Eye-Fite to us and, as part of the purchase of Eye-Fite, we also assumed certain accrued milestone payments in the amount of $175,000
under a license agreement previously entered into with NIH. In addition, that certain License Agreement granted to OphthaliX by us and
a related services agreement was terminated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our capital expenditures for
the years ended December 31, 2021, 2020 and 2019 were $11,000, $26,000 and $3,000, respectively. Our current capital expenditures are
made solely within Israel and primarily consist of the acquisition of computers and related communications equipment. Such capital expenditures
are financed internally.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We use our website (<i>http://www.canfite.com</i>)
as a channel of distribution of Company information. The information we post on our website may be deemed material. Accordingly, investors
should monitor the website, in addition to following our press releases, SEC filings and public conference calls and webcasts. The contents
of our website are not, however, a part of this Annual Report on Form 20-F.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">B.
</span>Business Overview</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage biopharmaceutical
company that develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases
and erectile dysfunction. We are also developing specific formulations of cannabis components for the treatment of cancer, inflammatory,
autoimmune, and metabolic diseases. Our platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is highly
expressed in pathological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting that
the receptor could be a specific target for pharmacological intervention. Our pipeline of drug candidates are synthetic, highly specific
agonists and allosteric modulators targeting the A3AR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research further suggests
that A3AR affects pathological and normal cells differently. While specific A3AR agonists, such as Piclidenoson and Namodenoson, and allosteric
modulators, such as CF602, appear to inhibit growth and induce apoptosis of cancer and inflammatory cells, normal cells are refractory,
or unresponsive to the effects of these drugs. To date, the A3AR agonists have had a positive safety profile as a result of this differential
effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product pipeline is based
on the research of Dr. Pnina Fishman, who investigated a clinical observation that tumor metastasis can be found in most body tissues,
but are rarely found in striated muscle tissue, which constitutes approximately 60% of human body weight. Dr. Fishman&#8217;s research
revealed that one reason that striated muscle tissue is resistant to tumor metastasis is that muscle cells release small molecules which
bind with high selectivity to the A3AR. As part of her research, Dr. Fishman also discovered that A3ARs have significant expression in
tumor and inflammatory cells, whereas normal cells have low or no expression of this receptor. The A3AR agonists and allosteric modulators,
currently our pipeline drug candidates, bind with high selectivity and affinity to the A3ARs and initiating down-stream signal transduction
pathways resulting in apoptosis, or programmed cell death, of tumors and inflammatory cells and inhibition of inflammatory cytokines.
Cytokines are proteins produced by body cells and affect the immune system in order to maintain homeostasis. Overproduction or inappropriate
production of certain cytokines by the body can result in disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 35; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates, CF101,
CF102 and CF602, are being developed to treat cancer, liver and inflammatory diseases, as well as erectile dysfunction. CF101, also known
as Piclidenoson, is in an advanced stage of clinical development for the treatment of psoriasis. During 2021, we decided to end our Phase
II COVID-19 trial of Piclidenoson for the treatment of COVID-19 to focus on other clinical programs. CF102, also known as Namodenoson,
is being developed for the treatment of HCC and has an orphan drug designation for this indication in the United States and Europe. Namodenoson
was granted Fast Track designation by the FDA as a second line treatment for patients with advanced HCC who failed first line therapy.
Namodenoson is also being developed for the treatment of NASH, a disease for which no FDA approved therapies currently exist. CF602 is
our second-generation allosteric drug candidate for the treatment of erectile dysfunction, which has shown efficacy in the treatment of
erectile dysfunction in preclinical studies and we are investigating additional compounds, targeting A3AR, for the treatment of erectile
dysfunction. Preclinical studies revealed that our drug candidates have potential to treat liver diseases, additional inflammatory diseases,
oncological diseases, viral diseases, such as the JC virus, and obesity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe our pipeline of
drug candidates represent a significant market opportunity. For instance, according to iHealthcareAnalyst, the psoriasis drug market is
forecasted to be worth $11.3 billion by 2025. According to DelveInsight, the HCC drug market in the G8 countries (U.S., Germany, France,
Italy, Spain, UK, Japan and China) is expected to reach $3.8 billion by 2027.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have out-licensed the following
product candidates for indications that we are currently pursuing:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Piclidenoson for the treatment of (i) psoriasis to Cipher Pharmaceuticals, or Cipher, for Canada, (ii)
psoriasis to Gebro Holding, or Gebro, for Spain, Switzerland and Austria, (iii) psoriasis to CMS Medical, or CMS, for China (including
Hong Kong, Macao and Taiwan), (iv) psoriasis to Kyongbo Pharm Co. Ltd., or Kyongbo Pharm, for South Korea, (v) psoriasis to Ewopharma
AG, or Ewopharma, for Central Eastern Europe, and (vi) osteoarthritis in companion animals including dogs and cats to Vetbiolix.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Namodenoson for the treatment of (i) liver cancer and NASH to Chong Kun Dang Pharmaceuticals, or CKD,
for South Korea, (ii) advanced liver cancer and NAFLD/NASH to CMS for China (including Hong Kong, Macao and Taiwan), and (iii) HCC and
NASH to Ewopharma, for Central Eastern Europe and Switzerland.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently: (i) completed
enrollment in our Phase III trial for Piclidenoson in the treatment of psoriasis, with topline results expected in the second quarter
of 2022, (ii) preparing to commence a Phase III trial for Namodenoson in the treatment of advanced liver cancer and expect to commence
patient enrollment in the second quarter of 2022, (iii) conducting a Phase IIb study of Namodenoson in the treatment of NASH, having recently
commenced enrollment, (iv) investigating additional compounds, targeting the A3 adenosine receptor, for the treatment of erectile dysfunction,
and (v) developing formulations of cannabis components for the treatment of diseases in which there is an overexpression of A3AR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, we believe characteristics
of Piclidenoson, as exhibited in our clinical studies to date, including its good safety profile, clinical activity, simple and less frequent
delivery through oral administration and its low cost of production, position it well against the competition in psoriasis markets, where
treatments, when available, often include injectable drugs, many of which can be highly toxic, expensive and not always effective.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Like Piclidenoson, Namodenoson
has a good safety profile, is orally administered and has a low cost of goods, which we believe may position it well in the HCC market,
where no drug has yet been approved by the FDAn for patients with advanced liver cancer disease defined as Child Pugh B7. In addition,
pre-clinical studies show Namodenoson&#8217;s novel mechanism of action which entails de-regulation of three key signaling pathways which
mediate the etiology and pathology of NAFLD/NASH and are responsible for the anti-inflammatory and anti-fibrogenic effect in the liver.
Most recently, pre-clinical data support Namodenoson&#8217;s potential utilization as an anti-obesity drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nevertheless, other drugs
on the market, new drugs under development (including drugs that are in more advanced stages of development in comparison to our drug
candidates) and additional drugs that were originally intended for other purposes, but were found effective for purposes targeted by us,
may all be competitive to the current drugs in our pipeline. In fact, some of these drugs are well established and accepted among patients
and physicians in their respective markets, are orally bioavailable, can be efficiently produced and marketed, and are relatively safe.
None of our product candidates have been approved for sale or marketing and, to date, there have been no commercial sales of any of our
product candidates.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Our Strategy</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our strategy is to build a
fully integrated biotechnology company that discovers, in-licenses and develops an innovative and effective small molecule drug portfolio
of ligands that bind to a specific therapeutic target for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction.
We continue to develop and test our existing pipeline, while also testing other indications for our existing drugs and examining, from
time to time, the potential of other small molecules that may fit our platform technology of utilizing small molecules to target the A3AR.
We generally focus on drugs with global market potential and we seek to create global partnerships to effectively assist us in developing
our portfolio and to market our products. Our approach allows us to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">continue to advance our clinical and preclinical pipeline;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">test our products for additional indications which fit our molecules&#8217; mechanism of action;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 36; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">identify other small molecule drugs or ligands;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">focus on our product candidates closest to realizing their potential; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">avoid dependency on a small number of small molecules and indications.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Using this approach, we have
successfully advanced our product candidates for a number of indications into various stages of clinical development. Specific elements
of our current strategy include the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Successful development
of our existing portfolio of small molecule orally bioavailable drugs for the treatment of various diseases</b>. We intend to continue
to develop our existing portfolio of small molecule orally bioavailable drugs, both for existing targeted diseases, as well as other potential
indications. Our drug development will continue to focus on cancer, liver and inflammatory diseases and erectile dysfunction. We intend
to focus most prominently on advancing our product candidates that are in the most advanced stages, i.e., psoriasis with respect to Piclidenoson,
and HCC and NASH with respect to Namodenoson.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Use our expertise with
our platform technology to evaluate in-licensing opportunities</b>. We continuously seek attractive product candidates and innovative
technologies to in-license or acquire. We intend to focus on product candidates that would be synergistic with our A3AR expertise. We
believe that by pursuing selective acquisitions of technologies in businesses that complement our own, we will be able to enhance our
competitiveness and strengthen our market position. We intend to utilize our expertise in A3AR and our pharmacological expertise to validate
new classes of small molecule orally bioavailable drugs. We will then seek to grow our product candidate portfolio by attempting to in-license
those various candidates and to develop them for a variety of indications.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Primarily develop products
that target major global markets</b>. Our existing product candidates are almost all directed at diseases that have major global markets.
Our intent is to continue to develop products that target diseases that affect significant populations using our platform technology.
We believe these arrangements will allow us to share the high development cost, minimize the risk of failure and enjoy our partners&#8217;
marketing capabilities, while also enabling us to treat a more significant number of persons. We believe further that this strategy will
increase the likelihood of advancing clinical development and potential commercialization of our product candidates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b>Commercialize our product
candidates throughout-licensing arrangements</b>. We have entered into several out-licensing arrangements with leading pharmaceutical
companies in the Far East, Canada and Europe. We intend to continue to commercialize our product candidates throughout-licensing arrangements
with third parties who may perform any or all of the following tasks: completing development, securing regulatory approvals, manufacturing,
marketing and sales. We do not intend to develop our own manufacturing facilities or sales forces. If appropriate, we may enter into co-development
and similar arrangements with respect to any product candidate with third parties or commercialize a product candidate ourselves. We believe
these arrangements will allow us to share the high development cost, minimize the risk of failure and enjoy our partners&#8217; marketing
capabilities. We believe further that this strategy will increase the likelihood of advancing clinical development and potential commercialization
of our product candidates.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Our Product Pipeline</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The table below sets forth
our current pipeline of product candidates, including the target indication and status of each.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-top: black 1.5pt solid; padding-left: 2pt; border-left: Black 1.5pt solid; white-space: nowrap; text-align: left; font-size: 10pt"><b>Clinical Application/Drug</b></td>
    <td colspan="2" style="border-top: black 1.5pt solid; white-space: nowrap; text-align: center; font-size: 10pt"><b>Pre-Clinical</b></td>
    <td style="border-top: black 1.5pt solid; white-space: nowrap; text-align: center; font-size: 10pt"><b>Phase I</b></td>
    <td colspan="2" style="border-top: black 1.5pt solid; white-space: nowrap; text-align: center; font-size: 10pt"><b>Phase II</b></td>
    <td colspan="2" style="border-top: black 1.5pt solid; border-right: black 1.5pt solid; white-space: nowrap; text-align: center; font-size: 10pt"><b>Phase
    III</b></td></tr>
  <tr>
    <td style="border-left: Black 1.5pt solid; padding-left: 2pt; text-align: left; font-size: 10pt"><b>Autoimmune-Inflammatory</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-right: black 1.5pt solid">&#160;</td></tr>
  <tr>
    <td style="border-left: Black 1.5pt solid; width: 58%">&#160;</td>
    <td style="width: 6%">&#160;</td>
    <td style="width: 6%">&#160;</td>
    <td style="width: 6%">&#160;</td>
    <td style="width: 6%">&#160;</td>
    <td style="width: 6%">&#160;</td>
    <td style="width: 4%">&#160;</td>
    <td style="border-right: black 1.5pt solid; width: 8%">&#160;</td></tr>
  <tr>
    <td style="border-left: Black 1.5pt solid; padding-left: 0.125in; text-align: left; font-size: 10pt">Psoriasis - Piclidenoson (1)</td>
    <td style="background-color: #16365C">&#160;</td>
    <td style="background-color: #16365C">&#160;</td>
    <td style="background-color: #16365C">&#160;</td>
    <td style="background-color: #16365C">&#160;</td>
    <td style="background-color: #16365C">&#160;</td>
    <td style="background-color: #BDD6EE">&#160;</td>
    <td style="border-right: black 1.5pt solid; background-color: #BDD6EE">&#160;</td></tr>
  <tr>
    <td style="border-left: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-right: black 1.5pt solid">&#160;</td></tr>
  <tr>
    <td style="border-left: Black 1.5pt solid; text-align: left; font-size: 10pt"><b>Liver diseases</b></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-right: black 1.5pt solid">&#160;</td></tr>
  <tr>
    <td style="border-left: Black 1.5pt solid; padding-left: 0.125in; text-align: left; font-size: 10pt">HCC &#8211; Namodenoson (2)</td>
    <td style="background-color: #16365C">&#160;</td>
    <td style="background-color: #16365C">&#160;</td>
    <td style="background-color: #16365C">&#160;</td>
    <td style="background-color: #16365C">&#160;</td>
    <td style="background-color: #16365C">&#160;</td>
    <td style="background-color: #DDD9C3">&#160;</td>
    <td style="border-right: black 1.5pt solid">&#160;</td></tr>
  <tr>
    <td style="border-left: Black 1.5pt solid">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-right: black 1.5pt solid">&#160;</td></tr>
  <tr>
    <td style="border-left: Black 1.5pt solid; padding-left: 0.125in; text-align: left; font-size: 10pt">NASH &#8211; Namodenoson (3)</td>
    <td style="background-color: #1F3864">&#160;</td>
    <td style="background-color: #1F3864">&#160;</td>
    <td style="vertical-align: top; background-color: #1F3864">&#160;</td>
    <td style="vertical-align: top; background-color: #1F3864">&#160;</td>
    <td style="background-color: #BDD6EE">&#160;</td>
    <td>&#160;</td>
    <td style="border-right: black 1.5pt solid">&#160;</td></tr>
  <tr>
    <td style="border-left: Black 1.5pt solid; vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="border-right: black 1.5pt solid">&#160;</td></tr>
  <tr>
    <td style="border-left: Black 1.5pt solid; padding-left: 2pt; vertical-align: bottom; text-align: left; font-size: 10pt"><b>Erectile Dysfunction</b> - CF602 (4)</td>
    <td style="background-color: #BDD5EE">&#160;</td>
    <td style="background-color: #BDD5EE">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-right: black 1.5pt solid">&#160;</td></tr>
  <tr>
    <td style="border-left: Black 1.5pt solid; vertical-align: bottom">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="3" style="border-right: black 1.5pt solid">&#160;</td></tr>
  <tr>
    <td style="border-left: Black 1.5pt solid; padding-left: 2pt; vertical-align: bottom; text-align: left; font-size: 10pt"><b>Cannabinoid-Based Pharmaceuticals</b> (5)</td>
    <td style="background-color: #BDD5EE">&#160;</td>
    <td style="background-color: #BDD5EE">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="border-right: black 1.5pt solid">&#160;</td></tr>
  <tr>
    <td style="border-bottom: black 1.5pt solid; border-left: Black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border: black 1.5pt solid; width: 0.15in; background-color: #16365C">&#160;&#160;&#160;&#160;</td>
    <td style="width: 0.1in">&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">Completed</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="border: black 1.5pt solid; background-color: #95B3D7; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">On-going</td></tr>
  <tr>
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">&#160;</td></tr>
  <tr>
    <td style="border: black 1.5pt solid; background-color: #BFBFBF; text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td style="vertical-align: bottom; text-align: justify">Preparatory work</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">We competed enrollment in our Phase III trial for Piclidenoson
in the treatment of psoriasis and are expecting topline data in the second quarter of 2022.</td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">We are preparing to commence a Phase III trial for Namodenoson
in the treatment of advanced liver cancer. We expect to commence patient enrollment in the first half of 2022.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt"></p><div>

</div><!-- Field: Page; Sequence: 37; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: justify">We are conducting a Phase IIb trial for Namodenoson for the
treatment of NASH having recently commenced patient enrollment.</td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(4)</td><td style="text-align: justify">We are investigating additional compounds, targeting the A3AR,
for the treatment of erectile dysfunction.</td>
</tr></table><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(5)</td><td style="text-align: justify">We are developing formulations of cannabis components for the
treatment of diseases in which there is an overexpression of A3AR.</td>
</tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Piclidenoson (CF101)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Piclidenoson, our lead therapeutic
product candidate, is in development for the treatment of autoimmune-inflammatory diseases. Piclidenoson is a highly-selective, orally
bioavailable small molecule synthetic drug, which targets the A3AR. Based on our clinical studies to date, we believe that Piclidenoson
has a favorable safety profile and significant anti-inflammatory effects as a result of its capability to inhibit the production of inflammatory
cytokines, such as TNF-&#945;, IL-6 and IL-1, chemokines and MMPs, by modulating key proteins such as NF-&amp;kcy;B and PKB/AKT. Overall,
these up-stream events result in apoptosis of inflammatory cells. See Figure 1 below. Piclidenoson&#8217;s anti-inflammatory effect is
mediated via the A3AR, which is highly expressed in inflammatory cells.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="img_002.jpg"/></b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Figure 1: Piclidenoson anti-inflammatory mechanism
of action</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Psoriasis is an autoimmune
hereditary disease that affects the skin. In psoriasis, immune cells move from the dermis to the epidermis, where they stimulate keratinocytes,
or skin cells, to proliferate. DNA acts as an inflammatory stimulus to stimulate receptors which produce cytokines, such as IL-1, IL-6,
and TNF-&#945;, and antimicrobial peptides. These cytokines and antimicrobial peptides signal more inflammatory cells to arrive and produce
further inflammation. In other words, psoriasis occurs when the immune system overreacts and mistakes the skin cells as a pathogen, and
sends out faulty signals that speed up the growth cycle of skin cells. Normally, skin cells grow gradually and flake off approximately
every four weeks. New skin cells grow to replace the outer layers of the skin as they shed. But in psoriasis, new skin cells move rapidly
to the surface of the skin in days rather than weeks. They build up and form thick patches called plaques.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are five types of psoriasis:
plaque, guttate, inverse, pustular and erythrodermic. The most common form, plaque psoriasis, is commonly seen as red and white hues of
scaly patches appearing on the top first layer of the epidermis, or skin. In plaque psoriasis, skin rapidly accumulates at these sites,
which gives it a silvery-white appearance. Plaques frequently occur on the skin of the lower back, elbows and knees, but can affect any
area, including the scalp, palms of hands, soles of feet and genitals. The plaques range in size from small to large. In contrast to eczema,
psoriasis is more likely to be found on the outer side of the joint. Some patients, though, have no dermatological symptoms.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Psoriasis is a chronic recurring
condition that varies in severity from minor localized patches to complete body coverage. Fingernails and toenails are frequently affected,
known as psoriatic nail dystrophy, and can be seen as an isolated symptom. Psoriasis can also cause inflammation of the joints, which
is known as psoriatic arthritis.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 38; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Pre-Clinical Studies with Piclidenoson</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information below is based
on the various studies conducted with Piclidenoson, including preclinical studies. All of the studies were conducted by Can-Fite and/or
by Can-Fite&#8217;s partners or affiliates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pre-clinical studies are a
set of experiments carried out in animals to show that a certain drug does not evoke toxicity. Based on the animal studies and safety
data, one can approach the FDA and request permission to conduct a Phase I study in human beings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The toxicity of Piclidenoson
has been evaluated following 28-day, 90-day, six-month and nine-month good laboratory practice repeated-dose toxicity studies in male
and female mice (28-day, 90-day and six-month), dogs (single-dose only), and monkeys (28-day, 90-day and nine-month). Even though the
dose of Piclidenoson in these studies was escalated to an exposure that is many folds higher than the dose used in human clinical studies,
no toxic side effects were identified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Effects on cardiovascular
parameters were evaluated in conscious instrumented monkeys and anesthetized dogs. These studies demonstrated no significant cardiovascular
risk.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Genotoxicity studies were
conducted in bacterial and mammalian mutation assays&#160;<i>in vitro</i>&#160;(i.e., laboratory) and in an&#160;<i>in vivo</i>&#160;(i.e.,
animal) mouse micronucleus assay. These studies were all negative, indicating no deleterious action on cellular genetic material.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Reproductive toxicology studies
that we completed in mice and rabbits did not reveal evidence of negative effects on male or female fertility. In mouse teratology studies,
or studies for abnormalities of physiological developments, craniofacial and skeletal abnormalities were observed at doses greater than
10 mg/kg; however, no such effects were observed at 3 mg/kg demonstrating the safety of the drug in this concentration range. Teratogenicity,
or any developmental anomaly in a fetus, was not observed in rabbits given doses (greater than 13 mg/kg) that induced severe maternal
toxicity in such rabbits.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Studies of P450 enzymes, or
enzymes that participate in the metabolism of drugs, showed that Piclidenoson caused no P450 enzyme inhibition, or increased drug activity,
or induction, or reduced drug activity. Studies carried out with radiolabeled (C<sup>14</sup>) Piclidenoson in rats showed that the drug
is excreted essentially unchanged. These studies also showed that the drug is widely distributed in all body parts, except the central
nervous system.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In pre-clinical studies with
skin cells, modeling psoriasis in humans, Piclidenoson destroyed pathological skin cells. We observed that in a cell culture of human
HaCaT cells, incubated with Piclidenoson, cell apoptosis was induced with an increase in the caspase protein, known to mediate apoptotic
responses.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Clinical Studies with Piclidenoson</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information below is based
on the various studies conducted with Piclidenoson, including clinical studies in patients with autoimmune-inflammatory and ophthalmic
diseases. All of the studies were conducted by Can-Fite and/or by Can-Fite&#8217;s partners or affiliates.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Phase I Clinical
Studies of Piclidenoson</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Piclidenoson has been studied
comprehensively in normal volunteer trials to assess safety, pharmacokinetic metabolism and food interaction. Two Phase I studies in 40
healthy volunteers, single dose and repeated dose, indicated that Piclidenoson is rapidly absorbed (reaching a maximal concentration within
one to two hours) with a half-life of eight to nine hours. Some mild adverse events (principally, increased heart rate) were observed
at doses higher than single doses of 10.0 mg and twice-daily doses of 5.0 mg. Such increase in heart rate was not accompanied by any change
in QT intervals. The drug showed linear kinetics, in that the concentration that results from the dose is proportional to the dose and
the rate of elimination of the drug is proportional to the concentration, and low inter-subject variability, meaning that the same dose
of the drug does not produce large differences in pharmacological responses in different individuals. A fed-fast Phase I study (with and
without food) demonstrated that food causes some attenuation in Piclidenoson absorption; accordingly, Piclidenoson is administered to
patients on an empty stomach in our trials. An additional Phase I study of the absorption, metabolism, excretion and mass balance of 4.0
mg (C<sup>14</sup>) Piclidenoson was conducted in six healthy male subjects and demonstrated that Piclidenoson was generally well-tolerated
in this group.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the findings from
Phase I clinical studies, 4.0 mg twice daily, or BID, was selected as the upper limit for initial Phase II clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Additionally, in preparation
for Phase III studies of Piclidenoson to establish cardiac safety in humans prior to registration for marketing approval, we conducted
a cardiodynamic trial that was a placebo-controlled crossover study using precise methodology to determine the effect of Piclidenoson
on electrocardiograms of healthy volunteers. The primary objective of the trial was to assess whether Piclidenoson causes a delay in cardiac
repolarization, as manifested by prolongation of the QT interval of the electrocardiogram. A drug-induced delay in cardiac repolarization
creates an electrophysiological environment that can lead to the development of ventricular cardiac arrhythmias. In this study, Piclidenoson
doses were up to 3-fold higher than the highest dose expected to be used in our registration-directed clinical trials. Trial results showed
that our highest projected Piclidenoson dose had no clinically significant adverse electrocardiographic effects.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 39; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Phase II, Phase
II/III and Phase III Clinical Studies of Piclidenoson</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Piclidenoson has completed
ten Phase II studies, one Phase II/III study and two Phase III studies in different clinical indications including psoriasis, rheumatoid
arthritis, glaucoma and dry eye syndrome, or DES, in approximately 1,700 patients. These studies indicate that Piclidenoson has a favorable
safety profile at doses up to 4.0 mg BID for up to 48 weeks. In these studies, we did not observe a dose-response relationship between
Piclidenoson and adverse events. Moreover, we did not observe any clinically significant changes in vital signs, electrocardiograms, blood
chemistry or hematology. Furthermore, no new emergent safety signals have been observed in the completed or ongoing Phase III rheumatoid
arthritis and psoriasis trials.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Piclidenoson given as a standalone
therapy reached the primary endpoint in Phase II clinical studies in DES; however, a Phase III study of Piclidenoson for DES failed to
reach the primary endpoint. We have observed positive data utilizing Piclidenoson as a standalone drug in a Phase IIa clinical study in
rheumatoid arthritis. In this study, we also observed a significant direct correlation between A3AR expression prior to treatment and
the patients&#8217; responses to Piclidenoson. However, we did not fully attain the primary endpoint in this study as we did not observe
a significant difference in responses between Piclidenoson and the placebo (which for this study was 0.1 mg of Piclidenoson). Moreover,
two Phase IIb studies in rheumatoid arthritis utilizing Piclidenoson in combination with MTX, also failed to reach the primary endpoints.
Based on this data, we believe that the failures in the Phase IIb studies in rheumatoid arthritis may have been due to low A3AR expression
in the MTX-treated patients. A Phase IIb of Piclidenoson given as a standalone therapy in patients with A3AR expression levels above a
certain threshold reached the primary endpoint in rheumatoid arthritis in December 2013. Piclidenoson has been tested in Phase II trials
to establish dose and activity (first, orally administered capsules and then tablets in formulations of 1.0, 2.0 and 4.0 mg of Piclidenoson
BID) in psoriasis (moderate to severe plaque psoriasis), rheumatoid arthritis and DES (moderate to severe). A Phase II/III study of Piclidenoson
for psoriasis did not meet its primary endpoint although positive data from further analysis of the Phase II/III study suggests Piclidenoson
as a potential systemic therapy for patients with moderate-severe psoriasis. In addition, a Phase II study of Piclidenoson for glaucoma
showed no statistically significant differences between the Piclidenoson treated group and the placebo group in the primary endpoint of
lowering IOP.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Psoriasis</i>: The rationale
for utilizing Piclidenoson to treat psoriasis stems from our pre-clinical pharmacology studies showing that Piclidenoson acts as an anti-inflammatory
agent via the inhibition of inflammatory cytokines, including TNF-&#945;, which plays a major role in the pathogenesis of psoriasis.
In addition, the A3AR is over-expressed in the tissue and PBMCs of patients with psoriasis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We completed an exploratory
Phase II trial in ten European and Israeli medical centers involving 76 patients. This study was a randomized, double-blind, placebo controlled
and included four cohorts of 1.0, 2.0, and 4.0 mg of Piclidenoson and a placebo for a 12-week period. The study objectives were efficacy
and safety of daily doses of Piclidenoson administered orally in patients with moderate-to-severe plaque-type psoriasis and the efficacy
endpoints were improvements in both the Psoriasis Area Sensitivity Index score, or PASI score, and the Physicians&#8217; Global Assessment
score, or PGA score. We concluded that Piclidenoson met such efficacy endpoints and was well-tolerated and effective in ameliorating disease
manifestations in these patients. The patient group receiving 2.0 mg Piclidenoson BID showed progressive improvement over the course of
the 12-week study in the PGA and PASI scores. Analysis of the mean change from baseline in the PASI score at week 12 revealed a statistically
significant difference between the 2.0 mg Piclidenoson BID treated group and the placebo group (p&lt;0.001 versus baseline and p=0.031
versus placebo). Analysis of the PGA score revealed that 23.5% of the patients treated with the 2.0 mg Piclidenoson BID achieved a score
of 0 or 1, in comparison to 0% in the placebo group (p&lt;0.05). The study also demonstrated linear improvement in patients in both PASI
and PGA. See Figure 2. No drug-related serious adverse events were evident during the study.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="img_003.jpg"/></b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Figure 2: Psoriasis efficacy by PGA and PASI</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below are representative
pictures of a patient with plaque-type psoriasis on the upper and lower back treated with 2.0 mg Piclidenoson BID, both baseline and week
12.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 40; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><img alt="" src="img_004.jpg"/></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">A comparison between baseline and week 12
of a patient treated with 2.0 mg CF101</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2015, we completed
a Phase II/III randomized, double-blind, placebo-controlled, dose-finding study of the efficacy and safety of Piclidenoson administered
daily orally in patients with moderate-to-severe plaque psoriasis. This clinical trial enrolled 326 patients in 17 clinical centers in
the United States, Europe and Israel, of which 103 patients were enrolled in the first study cohort and were treated for 6 months and
223 patients were enrolled in the second study cohort and were treated for 8 months. The first study cohort was comprised of three arms
with patients receiving: 1.0 mg of Piclidenoson; 2.0 mg of Piclidenoson; and placebo. All patients receiving placebo were switched to
either 1.0 mg or 2.0 mg of Piclidenoson after 12 weeks. Based on a positive safety and efficacy interim analysis of the first 103 patients
who completed 24 weeks of treatment in the trial, we decided to continue patient enrollment for the second stage of the study and the
study protocol was amended to extend the Piclidenoson 2.0 mg BID and placebo administration for a period of 32 weeks. The positive clinical
effects of the Piclidenoson 2.0 mg BID dose relative to a placebo were observed in a variety of standard psoriasis assessment parameters,
including PASI 75 and PGA scores, with the responses accumulating steadily over the 24-week treatment period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2015, we announced
the study did not meet its primary endpoint of a statistically significant improvement in the PASI 75 score relative to placebo after
12 weeks of treatment. Further analysis of the entire study period revealed that by 32 weeks of treatment with Piclidenoson, 33% of the
patients achieved PASI 75 while the mean percent of improvement in PASI score was 57% (p&lt;0.001). This was a statistically significant
cumulative and linear improvement during weeks 16 to 32. Most significantly, by week 32 of the study, 20% of the study patients reached
PASI 90, a result demonstrating a response rate of 90% clearing of skin lesions. PASI 90 is one of the most stringent and difficult to
meet clinical endpoints for measuring responses to psoriasis treatments. Moreover, the PASI 90 subset analysis further suggests a higher
and significant (p=0.026) Piclidenoson response rate of 27% among patients previously untreated with systemic psoriasis therapy compared
to patients pre-treated with systemic drugs. We believe this presents the opportunity that Piclidenoson can be developed as a first-line
systemic therapy for patients with moderate-severe psoriasis and for patients who do not want to be treated with the current systemic
drugs due to safety issues.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="img_005.jpg"/></b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 8pt">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><i>Figure 3: Linear Effect of Piclidenoson
on PASI Scores through 32 Weeks of Treatment</i></p><div>

</div><!-- Field: Page; Sequence: 41; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>



</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently conducting
our pivotal COMFORT Phase III trial for Piclidenoson for the treatment of psoriasis. The trial is a randomized, double-blind, placebo-
and active-controlled study that is investigating the efficacy and safety of daily Piclidenoson 2.0 mg or 3.0 mg administered twice daily
orally as compared to placebo as its primary endpoint and as compared to apremilast (Otezla&#174;) as a secondary endpoint in approximately
400 patients with moderate-to-severe plaque psoriasis. Medication is to be taken orally twice daily for 32 weeks in a double-blinded fashion.
The primary end point is the proportion of subjects who achieve a PASI score response of &#8805;75% (PASI 75) vs. placebo at week 16. The
secondary endpoints include non-inferiority to Otezla&#174; on weeks 16 and 32, achievement of PASI 50 at week 16 and efficacy and safety
data for Piclidenoson through the extension period of up to 48 weeks of treatment. Patients are being selected to the study based on over
expression of the A3AR biomarker. In September 2021, we announced that we completed enrollment of all patients. We expect COMFORT will
serve as the first of two pivotal studies required for EMA-drug approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2020, an independent
data monitoring committee which conducted an interim analysis of the our Phase III Comfort&#8482; trial of Piclidenoson in the treatment
of moderate-to-severe plaque psoriasis, recommended, based on the positive data, to continue the study with the original sample size and
drop one dose group. This means that an optimal dose has been found and that the study can be concluded earlier than has been originally
planned.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2021, we completed
enrollment of all patients in the COMFORT Phase III trial and currently expect to announce top line data in the second quarter of 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Rheumatoid Arthritis:&#160;</i>We
previously conducted a Phase IIa blinded to dose study in 74 patients with rheumatoid arthritis, randomized to receive Piclidenoson as
a monotherapy in one of three doses&#8212;0.1 mg, 1.0 mg and 4.0 mg. The primary efficacy endpoint was ACR20 response at week 12, a criterion
determined by the American College of Rheumatology that reflects 20% improvement in inflammation parameters. The study data revealed maximal
response at the 1.0 mg group, showing 55.6% with ACR20, 33.3% with 50% improvement, or ACR50, and 11.5% with 70% improvement, or ACR70.
Piclidenoson administered BID for 12 weeks resulted in improvement in signs and symptoms of rheumatoid arthritis and was well-tolerated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subsequently, two Phase IIb
studies with Piclidenoson in combination with MTX were conducted. The study protocols were multicenter, randomized, double-blind, placebo-controlled,
parallel-group and dose-finding to determine the safety and efficacy of daily Piclidenoson administered orally when added to weekly MTX
in patients with active rheumatoid arthritis. The objectives of both studies were improvement in ACR20, ACR50, ACR70 and DAS28, or the
Disease Activity Score of 28 Joints, and EULAR, or the European League Against Rheumatism, response criteria, as well as a positive safety
profile. The trials&#8217; primary endpoints were both ACR20. The first Phase IIb trial showed that the combined treatment had an excellent
safety profile, but no significant ACR20 response was observed between the rheumatoid arthritis group treated with Piclidenoson and MTX
and the group treated with MTX alone (the placebo group). However, the ACR50, ACR70 and the EULAR Good Values in the combined treatment
group were higher than those of the MTX placebo group. The study also indicated that the 1.0 mg Piclidenoson dose was the most favorable
dose, i.e., the dose yielded the highest ACR50 and EULAR Good Values as compared to the MTX placebo group. The most commonly reported
adverse events in this study included nausea, dizziness, headache and common bacterial and viral infections and infestations. Following
a decision of our Clinical Advisory Board in October 2007, an additional Phase IIb study was initiated. This study was conducted in medical
centers in Europe and Israel and included 230 patients who received the drug orally BID (0.1 and 1.0 mg Piclidenoson tablets plus MTX
versus a placebo, which was MTX alone) for 12 weeks. On April 30, 2009, we published preliminary results of the Phase IIb study, which
were later confirmed as the final results, also indicating that the study&#8217;s objectives were not achieved. The most commonly reported
adverse events in this study included nausea, myalgia and dizziness. The two Phase IIb studies failed to achieve the primary endpoint
of ACR20. A cross study analysis of the three rheumatoid arthritis clinical studies revealed that in the first Phase IIa study, where
Piclidenoson had been administered as a standalone drug, A3AR had been over-expressed in the patients&#8217; PBMCs prior to Piclidenoson
treatment, whereas A3AR had not been over-expressed in the Phase IIb patient population. We believe, based on the foregoing data, that
there may be a direct and statistically significant correlation between A3AR over-expression at baseline and patients&#8217; response
to Piclidenoson, and that Piclidenoson should be administered as a standalone drug and not in combination with MTX. Furthermore, the
correlation between A3AR expression levels prior to treatment and patients&#8217; response to the drug suggest that the A3AR may be a
predictive biomarker to be analyzed prior to Piclidenoson treatment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on the results of the
two Phase IIb studies, we conducted an additional Phase IIb clinical study with Piclidenoson as a stand-alone, monotherapy treatment and
not in combination with MTX. The trial was a 12-week multicenter, randomized, double-blind, placebo-controlled, parallel-group study involving
79 patients to determine the safety and efficacy of Piclidenoson administered orally daily in patients with active rheumatoid arthritis
and elevated baseline expression levels of the A3AR in PBMCs. Enrolled patients had high baseline A3AR biomarker expression (determined
at 1.5-fold over a predetermined age-matched standard). This selection criteria was made following the findings during previous Phase
IIa and IIb rheumatoid arthritis studies showing a positive correlation between A3AR expression at baseline and patients&#8217; response
to the drug, potentially rendering A3AR expression as a predictive biomarker. The primary objectives of this study were to determine the
efficacy of oral Piclidenoson when administered daily as a standalone treatment for 12 weeks to patients with active rheumatoid arthritis
and elevated baseline expression levels of the A3AR in the patients&#8217; PBMCs, in comparison to a placebo treatment, and to assess
the safety of daily oral Piclidenoson under the circumstances of the trial. In December 2013, we announced the results of the study in
which Piclidenoson met all primary efficacy endpoints, showing statistically significant superiority over placebo in reducing signs and
symptoms of rheumatoid arthritis as compared to the placebo. The treatment had an ACR20 response rate of 49% for Piclidenoson compared
to 25% for placebo (p=0.035), an ACR50 response rate of 19% for Piclidenoson compared to 9% for placebo, and an ACR70 response rate of
11% for Piclidenoson compared to 3% for placebo. Similar to our observations in the previously reported Piclidenoson psoriasis trials,
the response of patients with rheumatoid arthritis was cumulative over time, suggesting a consistent anti-inflammatory effect of Piclidenoson.
Moreover, half of the rheumatoid arthritis patients treated with Piclidenoson showed clinically meaningful improvement. Piclidenoson was
very well-tolerated and showed no evidence of immunosuppression, and there were no severe treatment-emergent adverse events during the
study. A subgroup analysis of 16 patients with no prior systemic therapy showed a dramatic increase in the response showing ACR20 of 75%,
ACR50 of 50%, and ACR70 of 50%. See Figure 7. We believe this may be related to the fact that in this patient population there is a full
receptor expression since they had not been treated earlier with any systemic drugs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 42; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">At the end of 2017, we initiated
the pivotal ACRobat Phase III trial of Piclidenoson to evaluate Piclidenoson as a first line treatment and replacement for MTX. The trial
was a randomized, double-blind, active and placebo-controlled, parallel-group study in approximately 500 patients in Europe, Israel and
Canada. The primary endpoint of ACRobat was low disease activity after 12 weeks of treatment in patients dosed with Piclidenoson compared
to those dosed with MTX. Piclidenoson at 1.0 mg and 2.0 mg, or placebo, will be administered twice daily, and MTX or placebo will be administered
once weekly. Secondary endpoints include disease activity remission at week 24, ACR 20/50/70 response rates, European League Against Rheumatism
good and moderate response rates and change from baseline for disease activity and ACR responses. The total study duration was to be 24
weeks in order to provide more data on long term efficacy and safety. In October 2020, an independent data monitoring committee for an
interim analysis recommended not to continue this study. Subsequently, we conducted a detailed analysis of the interim results which showed
that although Piclidenoson efficacy was significantly superior to placebo, the study missed the primary endpoint which was non-inferiority
vs. the comparator methotrexate. Accordingly, we decided to stop developing Piclidenoson for the treatment of rheumatoid arthritis to
focus on other indications.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Additional Developments with Piclidenoson</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">COVID-19<span style="font-style: normal; font-weight: normal">	</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">&#160;</span></p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-style: normal; font-weight: normal">In
2020, with the aim of developing a much-needed drug to treat manifestations of COVID-19, mainly the Cytokine Release Syndrome, we initiated
a Phase II COVID-19 study of Piclidenoson, with patient enrollment in Israel and Europe. With the anticipated launch of Pfizer&#8217;s
oral COVID-19 antiviral drug candidate, in November 2021, we made a strategic decision to end our COVID-19 program and to focus our resources
on our other clinical programs, all in advanced clinical trials.</span></p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Osteoarthritis</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Arthritis
Foundation, osteoarthritis, or OA, is the most common arthritic disease. Currently, there is a shortage of effective drugs for treating
OA patients. Piclidenoson has induced a significant anti-inflammatory effect in experimental animal models with respect to the treatment
of OA. We have not yet filed an IND for this indication as Piclidenoson for the treatment of OA is not currently being clinically tested
in the United States and there are no near-term plans to do so.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2019, we announced
that the U.S. Patent and Trademark Office, or the PTO, has issued to us Patent #10,265,337 titled &#8220;Use of A3 Adenosine Receptor
Agonist in Osteoarthritis Treatment&#8221; for Piclidenoson for the treatment of osteoarthritis in mammals. We are evaluating potential
partnerships with companies in the animal health pharmaceutical market that may in-license and develop Piclidenoson for the companion
animal market, a substantial and rapidly growing global market.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2021, we signed a
development and commercialization agreement with Vetbiolix, a France-based veterinary biotech company, for the development of Piclidenoson
for the treatment of osteoarthritis in companion animals including dogs and cats. In November 2021, we announced that Vetbiolix commenced
a safety and efficacy study of Piclidenoson for the treatment of osteoarthritis in dogs. Safety and efficacy results are expected in the
second quarter of 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Namodenoson (CF102)</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Namodenoson is our second
drug candidate and is under development for the treatment of HCC, hepatitis C virus, or HCV, or NAFLD, the precursor to NASH. Namodenoson
is also a small, orally bioavailable molecule, and an A3AR agonist, with high affinity and selectivity to the A3AR. In comparison to the
expression in adjacent normal liver tissue, the A3AR is over-expressed in tumor tissues of patients with HCC, and the over-expression
is also reflected in the patients&#8217; PBMCs. A3AR over-expression in the patients&#8217; tumor cells and PBMCs is attributed to high
expression of certain A3AR transcription factors. The binding of Namodenoson to the A3AR results in down-regulation, or a decrease in
the quantity of a cellular component, such as the number of receptors on a cell&#8217;s surface, of certain A3AR transcription factors.
Our studies have shown that this down-regulation leads to apoptosis of HCC cells. In our pre-clinical and clinical studies, Namodenoson
demonstrated anti-cancer, anti-viral and liver protective effects. As a result, we believe that Namodenoson can be used to treat a variety
of oncological and liver-related diseases and viruses.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2012, the FDA
granted an orphan drug status for the active moiety, or the part of the drug that is responsible for the physiological or pharmacological
action of the drug substance, of Namodenoson for the treatment of HCC. Subsequently, in October 2015, the EMA granted Namodenoson orphan
drug designation for the treatment of HCC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An orphan drug designation
is a special designation for drug approval and marketing. The special designation is granted to companies that develop a given drug for
unique populations and for incurable and relatively rare diseases. The FDA orphan drug designation program provides orphan status to drugs
and biologics, which are intended for the safe and effective treatment, diagnosis or prevention of rare diseases or disorders that affect
fewer than 200,000 people in the United States and in the EU not more than 5 per 10,000. Orphan drug designations have enabled companies
to achieve medical breakthroughs that may not have otherwise been achieved due to the economics of drug research and development as this
status lessens some of the regulatory burdens, for approval, including statistical requirements for efficacy, safety and stability, in
an effort to maintain development momentum. Orphan drug designation also results in additional marketing exclusivity and could result
in certain financial incentives.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 43; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2015, the FDA
granted Fast Track designation to Namodenoson as a second line treatment to improve survival for patients with advanced HCC who have previously
received Nexavar (sorafenib). Fast Track, aimed at getting important new drugs that meet an unmet need to patients earlier, is expected
to expedite the development of Namodenoson. Drugs that receive Fast Track designation benefit from more frequent meetings and communications
with the FDA to review the drug&#8217;s development plan to support approval. It also allows us to submit parts of the NDA on a rolling
basis for review as data becomes available.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israel&#8217;s Ministry of
Health has previously approved Namodenoson for Compassionate Use for HCC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below are general
descriptions of the diseases with respect to which Namodenoson has underwent or is currently undergoing or being prepared for clinical
trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>HCC:&#160;</i>HCC is an
oncological disease characterized by malignant tumors that grow on the surface or inside of the liver. This type of tumor is refractory
to chemotherapy and to other anti-cancer agents. HCC, like any other cancer, develops when there is a mutation to the cellular machinery
that causes the cell to replicate at a higher rate and/or results in the cell avoiding apoptosis. Chronic infections of Hepatitis B and/or
C can aid the development of HCC by repeatedly causing the body&#8217;s own immune system to attack the liver cells, some of which are
infected by the virus. While this constant cycle of damage followed by repair can lead to mistakes during repair which in turn lead to
carcinogenesis, this hypothesis is more applicable, at present, to HCV. Chronic HCV causes HCC through cirrhosis. In chronic Hepatitis
B, however, the integration of the virus into infected cells can directly induce a non-cirrhotic liver to develop HCC. Alternatively,
repeated consumption of large amounts of ethanol can have a similar effect.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Hepatitis C:</i>&#160;HCV
is an infectious disease affecting primarily the liver, caused by the Hepatitis C virus. The infection is often asymptomatic, but chronic
infection can lead to scarring of the liver and ultimately to cirrhosis, which is generally apparent after many years, and chronic liver
disease. The virus also increases the chance for HCC development. In some cases, those with cirrhosis will develop liver failure, liver
cancer or life-threatening esophageal and gastric varices, or dilated submucosal veins, which can be life-threatening. HCV is spread primarily
by blood-to-blood contact often associated with intravenous drug use, poorly sterilized medical equipment, transfusions, and erectile
intercourse.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>NAFLD/NASH</i>: NASH, also
called &#8220;fatty liver,&#8221; is a condition in which fat builds up inside the liver causing inflammation. Prior to the presence of
inflammation, the disease is simply referred to as NAFLD, the most common form of liver disorder in the United States. The accumulation
of macroglobular fat inside the liver causes oxidative stress that reduces the efficiency of the liver and can lead to increased liver
enzymes such as alanine aminotransferase and aspartate aminotransferase. Loss of liver efficiency and oxidative stress leads to inflammation,
liver cell ballooning, and the development of NASH. Prolonged inflammation results in cirrhosis (scar tissue), liver failure, or liver
cancer. There are currently no drugs approved for the treatment of NASH.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Pre-Clinical Studies with Namodenoson</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In pre-clinical pharmacology
studies, Namodenoson inhibited the growth of HCC via the induction of tumor cell apoptosis. In addition, in collaboration with leading
virology labs, we observed that Namodenoson inhibited viral replication of HCV through the down-regulation of viral proteins. Both of
these findings served as a basis to further explore development of this drug for HCC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted several pre-clinical
studies demonstrating robust anti-inflammatory, anti-fibrogenic and anti-steatotic effects, supporting the development of Namodenoson
for the NAFLD/NASH indication. Furthermore, the results indicated that Namodenoson was very well-tolerated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In pre-clinical studies, we
evaluated the toxicity, stability, metabolism and other safety parameters of Namodenoson at doses much higher than the doses that we currently
administer to humans in our clinical trials of Namodenoson.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In preclinical studies, Namodenoson
revealed its capability to act as an anti NAFLD/NASH agent and data has shown as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">In the STAM model, Namodenoson significantly decreased the
non-alcoholic fatty liver disease (NAFLd) activity score, NAS, demonstrating anti-inflammatory and anti steatotic effects.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">In the carbon tetrachloride (ccl4) model, Namodenoson reversed
alanine aminotransferase (ALT) to normal values and significantly improved liver inflammation and fibrosis, as well as the adiponectin
and leptin levels; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Namodenoson mechanism of action entailed de-regulation of
the Wnt/&#946;-catenin pathway in the liver extracts of the ccl4 model mice and in the LX2 HScs, manifested by a decreasing the expression
of phosphoinositide 3-kinase (PI3K), NF-&#954;B.</td>
</tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Clinical Studies of Namodenoson</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information discussed
below is based on the various studies conducted by Can-Fite with Namodenoson, including clinical studies in patients with oncological
and liver-related diseases and viruses.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 44; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Phase I Clinical Study</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Namodenoson completed a Phase
I double-blind, randomized, placebo-controlled, ascending single dose trial to evaluate the safety, tolerability, and pharmacokinetics
of orally administered Namodenoson in healthy volunteers. The study was conducted in the United States under an open IND. Namodenoson
was found to be safe and well-tolerated with a half-life time of 12 hours. See Figure 8.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b><img alt="" src="img_006.jpg"/></b></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Figure 8: Half-life of orally administered
Namodenoson &#8211; Phase I Clinical Study</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Phase I/II and Phase II Clinical Studies</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">HCC</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Namodenoson completed two
Phase I/II studies in Israel, one in patients with HCC and another in patients with HCV. The HCC Phase I/II study was an open-label, dose-escalation
study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered Namodenoson in patients with advanced
HCC. The primary objectives of the study were to determine the safety and tolerability, dose-limiting toxicities, maximum tolerated dose,
and recommended Phase II dose of orally administered Namodenoson in patients with advanced HCC; and to assess the repeat-dose pharmacokinetics
behavior of Namodenoson in those patients. The secondary objectives were to document any observed therapeutic effect of Namodenoson in
patients with HCC and to evaluate the relationship between PBMCs and the A3AR expression at baseline, as a biomarker, and the effects
of Namodenoson in patients with HCC. The study included 18 patients, nine of which were also carriers of HCV. The initial dose of Namodenoson
was 1.0 mg BID, with planned dose escalations in subsequent cohorts to 5.0 and 25.0 mg BID. This Phase I/II study achieved its objectives,
showing a good safety profile, or no material differences versus a placebo with respect to observed and patient-indicated side effects,
for Namodenoson and a linear pharmacokinetic drug profile, with no dose-limiting toxicities at any dose level. The median overall survival
time for the patients in this study was 7.8 months, which is encouraging data considering that (i) 67% of the patient population in the
study had previously progressed on Nexavar, produced by Onyx Pharmaceuticals and Bayer, and that Namodenoson was a second line therapy
for these patients and (ii) 28% of the patient population were Child-Pugh Class B patients (patients classified on the Child Pugh scoring
system for chronic liver disease as having significantly impaired liver function) whose overall survival time is usually 3.5 to 5.5 months.
Accordingly, we may also consider Namodenoson as a drug to be developed for this patient sub-population of Child-Pugh Class B patients.
Namodenoson had no adverse effect on routine measures of liver function over a six-month period in 12 patients treated for at least that
duration. These findings are consistent with our pre-clinical Namodenoson data which demonstrated a protective effect on normal liver
tissue in an experimental model of liver inflammation. As such, Namodenoson may potentially be a safer alternative to patients with cirrhosis
and/or hepatic impairment. The study also demonstrated a direct relationship between A3AR expression at baseline and patients&#8217; response
to Namodenoson, suggesting A3AR as a predictive biological marker. We also observed a decrease in the viral load of seven out of nine
patients who were also carriers of HCV. The most commonly reported adverse events included loss of appetite, ascites, nausea, diarrhea,
constipation and pain. However, many of these events are expected in a population of patients with advanced HCC. The most frequently reported
drug-related adverse events included diarrhea, fatigue, loss of appetite, pain and weakness.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 45; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our second Phase I/II study
was a randomized, double-blind, placebo-controlled, dose-escalation study evaluating the safety, tolerability, biological activity, and
pharmacokinetics of orally administered Namodenoson in 32 subjects with chronic HCV genotype 1. Eligible subjects were assigned in a 3:1
ratio (eight subjects in each cohort) to receive QD or BID treatment (1.0, 5.0 and 25.0 mg of Namodenoson) for 15 days with oral Namodenoson
or with a placebo. Dose escalation occurred in four sequential cohorts. The study&#8217;s primary objectives were to determine the safety
and tolerability of orally administered Namodenoson in patients with chronic HCV genotype 1, to assess the effects on HCV load during
15 days of treatment with Namodenoson and to assess the repeat-dose pharmacokinetic behavior of Namodenoson under the conditions of this
trial. The secondary objective of this trial was to perform an exploratory evaluation of the relationship between A3AR in PBMCs at baseline
and the clinical effects of Namodenoson on the study&#8217;s patients. Following the decrease in HCV load that had been observed in HCV
patients treated with Namodenoson in the parallel HCC study and the good safety profile of Namodenoson, we received Israeli Institutional
Review Board, or IRB, approval to extend the treatment period of the Phase I/II in patients with HCV to four months with the 1.0 mg dose
vs. the placebo. The results of this Phase I/II HCV study demonstrated a good safety profile and a linear pharmacokinetic drug profile,
however, no significant decrease in the viral load was observed. Notwithstanding, we did observe in the parallel HCC study that seven
out of the nine patients with both HCC and HCV experienced a decrease in viral load and that these seven patients were treated with higher
Namodenoson dosages than what was administered to the patients with chronic HCV genotype 1 only, and not HCC, possibly explaining the
difference in results. The most commonly reported adverse events included loss of appetite, ascites, nausea, diarrhea, constipation and
pain. However, many of these events are expected in a population of patients with advanced HCV. The most frequently reported drug-related
adverse events included diarrhea, fatigue, loss of appetite, pain and weakness.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2019, we completed a Phase
II study in HCC patients. In January 2013, as part of our preparatory work for such study, we announced that we believe that the optimal
drug dose for the upcoming study is Namodenoson 25.0 mg. This dose was found to be the most effective dose out of the three dosages tested
(1.0 mg, 5.0 mg and 25.0 mg) in the previous Phase I/II study. We filed a patent application protecting such optimal dose of Namodenoson
for HCC. A publication summarizing the results of the Phase I/II study was published in &#8220;The Oncologist,&#8221; a leading oncology
scientific journal. We also highlighted that one patient has been treated with Namodenoson for over five years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Phase II study was a randomized,
double-blind, placebo controlled trial conducted in the United States, Europe and Israel to evaluate the efficacy and safety of Namodenoson
as a second-line treatment for advanced HCC in subjects with Child-Pugh B who failed Nexavar as a first line treatment. Advanced HCC in
patients with underlying cirrhosis is categorized into three subclasses based on the severity of cirrhosis, starting with Child Pugh A,
or CPA, mostly treated with Nexavar and progressing to Child Pugh B, or CPB, and Child Pugh C, or CPC, for which there are no drugs on
market with proven efficacy. In the study, we enrolled only patients with CPB stage liver cancer with CBP stage patients being further
divided into three categories of increasing severity, namely CPB7, CPB8, and CPB9. These patients already failed first line Nexavar and
were treated with Namodenoson (25mg), or placebo, as a second line treatment, twice daily, using a 2:1 randomization. The primary endpoint
of the study was median overall survival. Secondary endpoints included progression free survival, partial response, and disease control
rate. In March 2014, the study protocol was approved by the IRB at the Rabin Medical Center in Israel and in December 2014, we dosed the
first patient at the study&#8217;s Israeli site. In the third quarter of 2017, we announced that we completed enrollment and randomization
of all 78 patients and in March 2019, we announced top-line results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While the study did not achieve
the primary end point of overall survival in the whole population (n=78), superiority in overall survival was found in the largest study
subpopulation of CPB7 (n=56) and in secondary end points in the whole population, including objective response measured by CT or MRI.
Findings from the study include the following: (i) for the whole population (n=78), median overall survival was 4.1 months for Namodenoson
vs. 4.3 months for placebo (HR: 0.82), (ii) pre-planned subpopulation analysis of the CPB7 patients (n=56), revealed that the Namodenoson
treated group (n=34) showed median overall survival of 6.8 months vs 4.3 months in placebo (n=22) [HR: 0.77 (95% CI 0.49-1.40)]; similarly,
for this subgroup of patients, progression free survival was 3.5 months for the Namodenoson treated group vs 1.9 (HR: 0.87) in the placebo
group; (iv) 1-year survival in the CPB7 population was 44% for the Namodenoson treated group, as compared to 18% for patients dosed with
placebo (p=0.028); (v) objective response in the whole patient population measured by CT or MRI, demonstrated that 9% treated by Namodenoson
achieved partial response vs 0% in the placebo group, (vi) consistent with safety results from previously completed clinical trials, Namodenoson
was generally well-tolerated, with no treated patients being withdrawn for toxicity and no cases of treatment-related deaths, (vii) disease
control rate was 18.0% in the Namodenoson group vs 7.1% in the placebo group (p=0.013) after four months of treatment, (viii) 32.0% of
patients treated with Namodenoson completed at least 12 months of treatment vs 14.3% who were treated with placebo (p=0.058), (vii) as
of March 27, 2019, two patients in the Namodenoson group are ongoing after 30 months of treatment; these patients will continue to receive
Namodenoson, and (ix) all nine patients with CBP9 cirrhosis, the most severe grade allowed into the trial, were randomly assigned to the
Namodenoson treatment group (OS=3.5 months), a fact which has distorted the results in the whole population. Subgroup analyses using a
variety of demographic and baseline disease characteristics, such as sex, performance status, and HCC disease status indicate the overall
survival advantage of Namodenoson over placebo persists in the vast majority of the subgroups.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A paper titled &#8220;Namodenoson
in Advanced Hepatocellular Carcinoma and Child&#8211;Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial&#8221; was published
in the peer reviewed journal&#160;<i>Cancers</i> with respect to the Phase II HCC trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 46; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2021, we announced
that two patients continued to receive Namodenoson treatment from our Phase II study of HCC after nearly four years under an open label
extension. Additional findings show disappearance of ascites, normal liver function and good quality of life. In one patient stable disease
has been recorded with disappearance of peritoneal carcinomatosis. Namodenoson continued to demonstrate a good safety profile and was
well tolerated with no severe adverse events reported. Furthermore, in December 2021, we reported that the last patient treated under
the open label extension experienced a complete response. Under treatment with Namodenoson, we reported that the patient survived five
years, during which time the clinical benefits of treatment have included the disappearance of ascites, normal liver function, and the
disappearance of peritoneal carcinomatosis leading to complete clearance of all cancer lesions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In October 2019, we held an
End-of-Phase II Meeting with the FDA regarding our Phase II study of Namodenoson in the treatment of HCC. The purpose of the meeting was
to review the Phase II study data with the FDA and to present our proposed Phase III study design to the regulatory agency. The FDA agreed
with our proposed pivotal Phase III trial design to support an NDA submission and approval. Subsequently in June 2020, we concluded a
meeting with the Scientific Advice Working Party of the EMA to discuss our planned Phase III study. Based on the input received from the
FDA and EMA, we plan on conducting a Phase III, randomized, double blind, placebo controlled trial of Namodenoson, that will enroll approximately
450 patients with HCC and underlying CPB7 cirrhosis at multiple centers worldwide. Patients will be randomized to oral treatment with
either Namodenoson 25 mg or matching placebo given twice daily. The primary efficacy endpoint of the trial is overall survival (OS), based
on the favorable OS response seen in the Phase II trial in patients with HCC and CPB7 cirrhosis. Other oncology trial efficacy outcomes,
such as tumor radiographic response rates and median progression-free survival, as well as standard safety parameters, will be assessed.
The study is designed to support an NDA submission in the U.S. and a marketing authorization application, or MAA, in Europe. We plan on
commencing patient enrollment in the first half of 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2019, we initiated
a compassionate use program for Namodenoson in the treatment of HCC, the most common form of liver cancer. Our compassionate use program
has enrolled and continues to treat patients. The compassionate use program, which enables liver cancer patients not enrolled in our clinical
study to be treated with Namodenoson, is being administered by Dr. Salomon Stemmer, the Principal Investigator of the Company&#8217;s
prior Phase II liver cancer study, and Professor at the Institute of Oncology, Rabin Medical Center, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">NAFLD/NASH</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted a Phase II double-blind,
placebo-controlled, dose-finding efficacy and safety study that enrolled 60 patients with NAFLD with or without NASH in three clinical
sites in Israel including Hadassah Medical Center, Jerusalem; Rabin Medical Center, Petach Tikva; and Holy Family Hospital, Nazareth;
with Prof. Rifaat Safadi as the Principal Investigator. Patients with evidence of an active inflammation were treated twice daily with
12.5 mg (n=21) or 25 mg (n=19) of oral Namodenoson vs. placebo (n=20). The patients were treated for 12 weeks and followed-up until week
16. The study&#8217;s end points included among others alanine aminotransferase (ALT) and aspartate aminotransferase (AST) blood level,
% of liver fat, liver stiffness, serum adiponectin, leptin and patient&#8217;s weight loss. In April 2020 we announced top-line data and
in June 2020 we announced our final data analysis. As a whole, the data show that Namodenoson at the 25 mg dose produced statistically
significant results in all measures of efficacy, while also having a strong safety profile and well tolerated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Therapeutically significant
positive data and trends were found as follows:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Anti-Inflammatory Effect</i>:
Namodenoson significantly reduced two liver enzymes, AST and ALT, which are elevated in a damaged liver, and increased the anti-inflammatory
cytokine adiponectin known also to act as an anti-fibrotic factor. Serum adiponectin levels increased in the 25 mg dose group by 220 ng/mL
and the 12.5 mg dose group by 539 ng/mL (p=0.03). Adiponectin is a cytokine with robust anti-inflammatory and anti-fibrotic effects that
is used as a biomarker in NAFLD/NASH trials. In addition, a dose response decrease compared to placebo was observed, indicating a reduction
of hepatic inflammation was achieved: (i) % of patients who reached ALT normalization at follow up was 36.8% in the 25 mg dose vs. 10%
in the placebo (p=0.038). In the 12.5 mg dose, 23.8% was recorded at follow up, (ii) ALT change from baseline (CFB) and % change from
baseline (PCFB) - in the 25 mg group, CFB decreased by 15.4 U/L (p=0.066) and PCFB by 22% (p=0.079) compared to placebo (1.7 U/L, 3.0%,
respectively); in the 12.5 mg group, a decrease CFB of 10.4 U/L and PCFB of 8.2% was recorded; and, (iii) AST CFB and PCFB - in the 25
mg group, CFB decreased by 8.1 U/L (p=0.03) and PCFB by 17.9% (p=0.05) compared to placebo (increase of 0.3 U/L, decrease of 1.3%, respectively).
In the 12.5 mg group, a decrease in CFB of 7.4 U/L and PCFB of 8.1 % was recorded.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Reduction of Liver&#160;</i>Steatosis:
In the Namodenoson 25 mg treated group, the proportion of patients with high steatosis scores declined from 37.5% to 13.3% of the population,
as compared to the placebo treated group in which the proportion of patients with high steatosis scores decreased from 37.5% to 35.3%
of the population, with p=0.08. Steatosis was assessed by Controlled Attenuation Parameter (CAP) measurement of the FibroScan, a non-invasive
marker of hepatic steatosis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>NASH &#8211; All Cases
Resolved</i>: 25% of patients randomized into the Namodenoson 25 mg dosed group had NASH at baseline, as compared to none in the placebo
group, which comprised of patients who had NAFLD without NASH at baseline. Following 12 weeks of treatment, all NASH cases were resolved
in patients treated with 25 mg of Namodenoson, as compared to new NASH that developed in the placebo group representing 5% of that population,
with p&lt;0.009. NASH was evaluated by FibroScan-AST (FAST) score, a noninvasive marker of NASH, the severe form of NAFLD (equivalent
to biopsy findings of NAS&#8805;4, F&#8805;2), measured by FibroScan elastography, CAP and serum AST.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Decrease in Body&#160;</i>weight:
A linear decrease in body weight was recorded in the 25 mg and 12.5 mg Namodenoson groups.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 47; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>A3 Adenosine Receptor (A3AR)</i>:
The A3AR biomarker was stable, demonstrating the presence of the receptor after chronic treatment and reflecting the validity of the target.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Safety</i>: Namodenoson
continued to be safe and very well tolerated with no drug emergent severe adverse effects and no hepatotoxicity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently conducting
a Phase IIb study Namodenoson in the treatment of NASH, having announced first patient enrollment in January 2022. The Phase IIb trial
is a multicenter, randomized, double-blind, placebo-controlled study in subjects with biopsy-confirmed NASH. The primary efficacy objective
of the trial is to evaluate the efficacy of Namodenoson as compared to placebo in 140 subjects with NASH, as determined by a histological
endpoint. Eligible subjects are randomly assigned in a 2:1 ratio to oral doses of Namodenoson 25 mg every 12 hours or a matching placebo
for 36 weeks. . The protocol was developed in conjunction with Dr. Scott Friedman, Chief of the Division of Liver Diseases at the Icahn
School of Medicine at Mount Sinai in New York, and Dr. Stephen A. Harrison, Medical Director of Pinnacle Clinical Research, both of whom
were involved in the design of Namodenoson&#8217;s Phase II study in NAFLD/NASH.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Additional Developments with Namodenoson</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Anti-Obesity</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2019, we announced
new pre-clinical findings demonstrating that Namodenoson, inhibits lipid production and fat accumulation in adipocytes (lipid producing
cells). More specifically, Namodenoson showed a significant decrease in lipid production and fat accumulation utilizing 3T3-L1 adipocytes,
functioning as lipid producing cells and are also responsible for fat storage. Namodenoson was also shown to inhibit the proliferation
of adipocytes, further hampering the expansion of fat producing cells. These findings, together with the safety profile of Namodenoson,
support its potential utilization as an anti-obesity drug. A patent application for the utilization of Namodenoson as an anti-obesity
drug has been filed. In January 2020, we announced further pre-clinical data generated at the Hadassah Medical Center by Dr. Rifaat Safadi&#8217;s
lab that demonstrated that Namodenoson induces weight loss in experimental models and normalizes glucose levels.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">JC Virus</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2011, we announced
that, in laboratory study, Namodenoson inhibited the reproduction of the JC virus, a type of polyomavirus, which is dormant in approximately
70% to 90% of the world population. However, in patients treated with biological drugs, including monoclonal antibody therapeutics, such
as anti-TNFs or anti-CD20, JC virus replication may occur, resulting in development of progressive multifocal leukoencephalopathy, or
PML, which is characterized by progressive damage or inflammation of the white matter of the brain and, eventually, death. The ability
of Namodenoson to suppress the JC virus culture, as indicated in the laboratory study, may indicate that it may be used for the treatment
of PML as a combination therapy with biological drugs. As Namodenoson is already in various stages of clinical development for other indications,
its efficacy for this new application may be tested in clinical trials.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">CF602</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The allosteric modulator,
CF602, is our third drug candidate in its pipeline. CF602 is an orally bioavailable small molecule, which enhances the affinity of the
natural ligand, adenosine, to its A3AR. The advantage of this molecule is its capability to target specific areas where adenosine levels
are increased. Normal body cells and tissues are refractory to allosteric modulators. This approach complements the basic platform technology
of Can-Fite, utilizing the Gi coupled protein A3AR as a potent target in inflammatory diseases. CF602 has demonstrated proof of concept
for anti-inflammatory activity in&#160;<i>in vitro</i>&#160;and&#160;<i>in vivo</i>&#160;studies performed by us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">During clinical studies conducted
with our product candidates, other than CF602, patients suffering from erectile dysfunction reported that they returned to normal functioning
following the treatment with such drugs. We believe that these findings are correlated with our platform technology, which is the targeting
of the A3AR. Adenosine, like nitric oxide, is a potent and short-lived vaso-relaxant that functions via intracellular signaling (in particular,
through cAMP) to promote smooth muscle relaxation. Recent studies conducted by others show that adenosine functions to relax the corpus
cavernosum and thereby promote penile erection.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">CF602 was tested in an experimental
animal model of diabetic rats, which similar to diabetic patients, suffer from erectile dysfunction. Erectile dysfunction was assessed
by monitoring the ratio between intra-cavernosal pressure, or ICP, and mean arterial pressure, or MAP, as a physiological index of erectile
function. The ICP/MAP for the CF602 treated group improved by 118% over the placebo group. This data is similar to that achieved earlier
by sildenafil (Viagra) in preclinical studies. In addition, treatment with CF602 reversed smooth muscle and endothelial damage, in a dose
dependent manner, leading to the improvement in erectile dysfunction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Further studies of CF602 have
revealed that CF602 restores the impaired vascular endothelial growth factor system in the penis of diabetes mellitus rats, thereby inducing
an increase in nitric oxide resulting in significant improvement of penile erection compared to placebo. This mechanism of action is similar
to that of sildenafil, with CF602 demonstrating effects on erection superior to that demonstrated by sildenafil in animal studies. Among
the most important factors to affect erectile function is nitric oxide, which is released by endothelial cells that line the corpus cavernosum
and control smooth muscle relaxation and vascular inflow. It has been well established that release of nitric oxide is diminished in diabetes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 48; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, CF602 induced
a dose-dependent, linear effect in a diabetic mellitus rat model after treatment with one single dose of CF602. One hour after dosing,
erectile function was measured. Statistically significant full recovery from erectile dysfunction took place in rats treated with a 500
&#181;/kg dose.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2021, we announced
new data from a preclinical study of CF602 in the treatment of erectile dysfunction, or ED, in a diabetes experimental model. The study
evaluated the efficacy of topically applied CF602 in a 4-cohort study with diabetic Sprague-Dawley (SD) rats receiving placebo; 100nM
CF602; 500nM CF602. Na&#239;ve rats served as a comparative negative control. ED was assessed by tracing ICP under cavernous nerve stimulation.
Treatment with CF602 at a dose of 500 nM resulted in statistically significant improvement of erectile dysfunction compared to vehicle
treated controls when measured in a two-way ANOVA followed by Bonferroni multiple comparisons post-hoc analysis (p&lt;0.001). The improvement
was even better than recorded for the na&#239;ve animals group. Efficacy was dose-dependent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the American
Diabetes Association, approximately 30 million children and adults have diabetes mellitus in the United States. It is estimated that 35-75%
of men with diabetes mellitus suffer from erectile dysfunction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In November 2016, a Notice
of Allowance was granted to us by the USPTO for our patent covering A3AR ligands for use in the treatment of erectile dysfunction. The
patent addresses methods for treating erectile dysfunction with different A3AR ligands including our erectile dysfunction drug candidate,
CF602. With this new broader patent protection, we made a strategic decision to investigate additional compounds, owned by us, for the
most effective and safest profile in this indication and we are seeking to partner development of CF602.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Cannabinoid-Based Pharmaceuticals</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In September 2019, we entered
into a collaboration agreement with Univo, a medical cannabis company, to identify and co-develop specific formulations of cannabis components
for the treatment of diseases in which there is an overexpression of A3AR. Based on our recent scientific findings, we have filed patents
for the use of cannabinoid-based drugs to treat cancer, autoimmune, inflammatory and metabolic diseases. Our most recent pre-clinical
research revealed that cannabis derived CBD enriched fractions, supplied by Univo, inhibit the expansion of human fat cells (pre-adipocytes)
by 60%, a result that points towards the potential anti-obesity effect of this agent. Although it is already documented that cannabis
derived compounds possess anti-obesity effect, the novel data presented by us demonstrates the anti-obesity effect at low nano-molar concentrations.
Low CBD concentrations are known to be safe and well accepted in humans. Previously, we announced pre-clinical findings demonstrating
CBD&#8217;s robust anti-neoplastic effect in pre-clinical studies against liver cancer. The studies were carried out on human liver cancer
cells and utilized cannabinoid fractions enriched for CBD, in nano and pico molar concentrations. Marked inhibition of Hep-3b, liver cancer
cell proliferation was noted and was mediated via the A3 adenosine receptor. As of December 31, 2020, our collaboration agreement with
Univo expired.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2020, we completed
the development of a biological cell-based in vitro assay which can identify clinically active cannabis derived compounds that bind to
and activate A3AR, thus enabling the development of pharmaceuticals that use a specific cannabis derived compound to treat a variety of
diseases.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In December 2020, we received
approval from the Medical Cannabis Unit of Israel&#8217;s Ministry of Health to conduct pre-clinical studies on the effect of nanomolar
concentrations of cannabinoid fractions on the proliferation and functionality of cancer, inflammatory and adipocyte cells (fat cells).
This regulatory approval allows us to advance our cannabinoid program by evaluating the effect of cannabis fractions at nanomolar concentrations
binding with A3AR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2021, we announced
the completion of a set of pre-clinical studies demonstrating that cannabis derived compounds bind to A3AR, mediating therapeutic effects.
CBD rich T3/C15 cannabis fraction inhibited the proliferation of LX-2 hepatic-stellate cells, the liver cell type mediating the development
of fibrosis. This inhibitory response was neutralized by an antagonist to the A3AR, demonstrating that the anti-fibrotic effect was mediated
via the A3AR.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In April 2021, we announced
the completion of a set of pre-clinical studies demonstrating that a CBD rich T3/C15 cannabis fraction inhibited the growth of liver HEP-3b
hepatocellular carcinoma cells via the A3AR by inhibiting Wnt- and NF-kappa B-related regulatory pathways. The Wnt signaling pathway is
known to be highly active in controlling the growth of liver cancer cells. An A3AR antagonist, MRS1523 reversed this effect demonstrating
that the inhibitory effect is mediated via our target, A3AR.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Commercial Biomarker Test</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2015, we completed
the development of a commercial predictive biomarker blood test kit for A3AR. The biomarker test can be used at any molecular biology
lab, where a small blood sample from a prospective patient would be tested and within just a few hours, results indicate if the patient
would benefit from treatment with our drugs, which are currently in clinical trials for rheumatoid arthritis, psoriasis, and liver cancer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The USPTO previously issued
to us a patent for the utilization of A3AR as a biomarker to predict patient response to our drug Piclidenoson in autoimmune inflammatory
indications.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 49; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">In-Licensing Agreements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
description of our in-licensing agreement with Leiden University. Our previously granted license with NIH expired in June 2015 with the
expiration of certain patents. The description provided below does not purport to be complete and is qualified in its entirety by the
complete agreement, which is attached as an exhibit to this Annual Report on Form 20-F.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Leiden University Agreements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On November 2, 2009, we entered
into a license agreement, or the Leiden University Agreement, with Leiden University. Leiden University is affiliated with NIH and is
the joint owner with NIH of the patents licensed pursuant to the Leiden University Agreement. The Leiden University Agreement grants an
exclusive license for the use of the patents of several compounds, including CF602, that comprise certain allosteric compound drugs, and
for the use, sale, production and distribution of products derived from such patents in the territory, i.e., China and certain countries
in Europe (Austria, Belgium, Denmark, France, Germany, Italy, Spain, Sweden, Switzerland, Holland and England). Subject to certain conditions,
we may sublicense the Leiden University Agreement. However, the U.S. government has an irrevocable, royalty-free, paid-up right to practice
the patent rights throughout the territory on behalf of itself or any foreign government or international organization pursuant to any
existing or future treaty or agreement to which the U.S. government is a signatory and the U.S. government may require us to grant sublicenses
when necessary to fulfill health or safety needs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Leiden University
Agreement, we are committed to make the following payments: (i) a one-time concession commission of 25,000 Euros; (ii) annual royalties
of 10,000 Euros until clinical trials commence; (iii) 2% to 3% of net sales value, as defined in the Leiden University Agreement, received
by us; (iv) royalties of up to 850,000 Euros based on certain progress milestones in the clinical stages of the products which are the
subject of the patent under the Leiden University Agreement; and (v) if we sublicense the agreement, we will provide Leiden University
royalties at a rate of 2-3% of net sales value, as defined in the Leiden University Agreement, and 10% of certain consideration received
for granting the sublicense. In the event that we transfer to a transferee the aspect of our business involving the Leiden University
Agreement, we must pay to Leiden University an assignment royalty of 10% of the consideration received for the transfer of the agreement.
However, a merger, consolidation or any other change in ownership will not be viewed as an assignment of the agreement. In addition, we
have agreed to bear all costs associated with the prosecution of the patents and patent applications to which we are granted a license
under the Leiden University Agreement. As of December 31, 2021, we have paid approximately 145,000 Euros in royalties to Leiden University
in connection with the Leiden University Agreement.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Leiden University Agreement
expires when the last of the patents expires in each country of the territory, unless earlier terminated in accordance with the terms
of the Leiden University Agreement. The last of such patents is set to expire on 2027. The termination rights of the parties include,
but are not limited to, (i) the non-defaulting party&#8217;s right to terminate if the defaulting party does not cure within 90 days of
written notice identifying the default and requesting remedy of the same; and (ii) Leiden University&#8217;s right to terminate if we
become insolvent, have a receiver appointed over our assets or initiate a winding-up. In addition, Leiden University may terminate the
agreement when it is determined, in consultation with NIH, that termination is necessary to alleviate health and safety needs and certain
other similar circumstances.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Out-Licensing and Distribution Agreements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following are summary
descriptions of certain out-licensing and distribution agreements of Piclidenoson and Namodenoson for the indications we are currently
investigating.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Cipher Pharmaceuticals Agreement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On March 20, 2015, we entered
into a Distribution and Supply Agreement with Cipher granting Cipher the exclusive right to distribute Piclidenoson in Canada for the
treatment of psoriasis and rheumatoid arthritis. In 2020, we ended our development of Piclidenoson for rheumatoid arthritis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Distribution and
Supply Agreement, we are entitled to CAD 1.65 million upon execution of the agreement plus milestone payments upon receipt of regulatory
approval by the Therapeutic Products Directorate of Health Canada, or Health Canada, for Piclidenoson and the first delivery of commercial
launch quantities as follows (i) CAD 1 million upon the first approved indication for either psoriasis or rheumatoid arthritis, and (ii)
CAD 1 million upon the second approved indication for either psoriasis or rheumatoid arthritis. In addition, following regulatory approval,
we shall be entitled to a royalty of 16.5% of net sales of Piclidenoson in Canada and reimbursement for the cost of manufacturing Piclidenoson.
We are also entitled to a royalty payment for any authorized generic of Piclidenoson that Cipher distributes in Canada. To date, we have
received a total of $1.3 million from Cipher in an upfront payment.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 50; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are responsible for supplying
Cipher with finished product for distribution and conducting product development activities while Cipher is responsible for distributing,
marketing and obtaining applicable regulatory approvals in Canada. The Distribution and Supply Agreement has an initial term of fifteen
years, automatically renewable for additional five-year periods and may be terminated in certain limited circumstances including certain
breaches of the agreement and failure to achieve certain minimum quantities of sales during the contract period.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The timeline to regulatory
submissions to Health Canada will be determined by the completion of the remaining clinical trial program.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">CKD Agreement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 25, 2016, we entered
into an exclusive Distribution Agreement with CKD for the exclusive right to distribute Namodenoson for the treatment of liver cancer
in South Korea, upon receipt of regulatory approvals. On February 25, 2019, the Distribution Agreement was amended to expand the exclusive
right to distribute Namodenoson for the treatment of NASH in South Korea. The Distribution Agreement further provides that we will deliver
finished product to CKD and grant CKD a right of first refusal to distribute Namodenoson for other indications for which we develop Namodenoson.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Distribution Agreement
provides for up to $3,000,000 in upfront and milestone payments payable with respect to the liver cancer indication and up to $3,000,000
with respect to the NASH indication. In addition, we are entitled to a transfer price of the higher of the manufacturing cost plus 10%
or 23% of net sales of Namodenoson following commercial launch in South Korea. To date, we have received a total of $2,000,000 from CKD,
$1,500,000 in upfront payments for the expansion of CKD&#8217;s existing agreement with us to include the rights to distribute Namodenoson
for the treatment of NASH in South Korea, and a further $500,000 for a milestone payment received in the third quarter of 2017 upon receipt
by CKD of a positive result from the preliminary review by the MFDS on obtaining orphan drug designation in South Korea.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Distribution Agreement
has an initial term of 10 years from first commercial sale of Namodenoson for the treatment of liver cancer or NASH and is renewable for
additional 3-year periods unless either party gives notice of termination at least 6 months prior to the then current term. The Distribution
Agreement may be terminated by CKD upon 30 days prior written notice if we fail to successfully complete our ongoing Phase II clinical
trial for Namodenoson and we may terminate the Distribution Agreement upon 30 days prior written notice if certain commercialization milestones
are not met by CKD or certain minimum quantities of sales are not made during the contract period. In addition, either party may terminate
the Distribution Agreement in the event of an uncured material breach or insolvency.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Gebro Agreement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 8, 2018, we entered
into a Distribution and Supply Agreement with Gebro, granting Gebro the exclusive right to distribute Piclidenoson in Spain, Switzerland,
Liechtenstein and Austria for the treatment of psoriasis and rheumatoid arthritis. In 2020, we ended our development of Piclidenoson for
rheumatoid arthritis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Distribution and
Supply Agreement, we are entitled to &#8364;1,500,000 upon execution of the agreement plus milestone payments upon achieving certain clinical,
launch and sales milestones, as follows: (i) &#8364;300,000 upon initiation of the ACRobat Phase III clinical trial for the treatment of
rheumatoid arthritis and &#8364;300,000 upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii)
between &#8364;750,000 and &#8364;1,600,000 following first delivery of commercial launch quantities of Piclidenson for either the treatment
of rheumatoid arthritis or psoriasis, and (iii) between &#8364;300,000 and up to &#8364;4,025,000 upon meeting certain net sales. In addition,
following regulatory approval, we shall be entitled to double digit percentage royalties on net sales of Piclidenoson in the territories
and payment for the manufacturing Piclidenoson. To date, we have received a total of &#8364;2,100,000 from Gebro in upfront and milestone
payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are initially responsible
for supplying Gebro with finished product for distribution and obtaining EMA and Swissmedic marketing approval while Gebro is responsible
for distributing, marketing and obtaining pricing and reimbursement approvals in the territories. The Distribution and Supply Agreement
has an initial term of fifteen years, automatically renewable for additional five-year periods and may be terminated in certain limited
circumstances including certain breaches of the agreement and failure to achieve certain minimum quantities of sales during the contract
period.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">CMS Medical Agreement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 6, 2018, we entered
into a License, Collaboration and Distribution Agreement with CMS for the exclusive right to develop, manufacture and commercialize Piclidenoson
for the treatment of rheumatoid arthritis and psoriasis and Namodenoson for the treatment of HCC and NAFLD/NASH in China (including Hong
Kong, Macau and Taiwan).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 51; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the License, Collaboration
and Distribution Agreement, we are entitled to $2,000,000 upon execution of the agreement plus milestone payments of up to $14,000,000
upon achieving certain regulatory milestones and payments of up to $58,500,000 upon achieving certain sales milestones, as follows: (i)
$500,000 upon the granting of the marketing authorization of Piclidenoson in the United States for rheumatoid arthritis; (ii) $500,000
upon the granting of the marketing authorization of Piclidenoson in the European Union for rheumatoid arthritis; (iii) $500,000 upon the
granting of the marketing authorization of Piclidenoson in the United States for psoriasis; (iv) $500,000 upon the granting of the marketing
authorization of Piclidenoson in the European Union for psoriasis; (v) $500,000 upon the granting of the marketing authorization of Namodenoson
in the United States for HCC; (vi) $500,000 upon the granting of the marketing authorization of Namodenoson in the European Union for
HCC; (vii) $500,000 upon the granting of the marketing authorization of Namodenoson in the United States for NAFLD/NASH; (viii) $500,000
upon the granting of the marketing authorization of Namodenoson in the European Union for NAFLD/NASH; (ix) $2,500,000 upon the issuance
of an imported drug license permitting the product to be imported into and marketed in China, or the IDL and granting of marketing authorization
of Piclidenoson in China for rheumatoid arthritis; (x) $2,500,000 upon the issuance of the IDL and granting of marketing authorization
of Piclidenoson in China for psoriasis; (xi) $2,500,000 upon the issuance of the IDL and granting of marketing authorization of Namodenoson
in China for HCC; (xii) $2,500,000 upon the issuance of the IDL and granting of marketing authorization of Namodenoson in China for NAFLD/NASH;
and (xiii) between $1,000,000 and up to $30,000,000 upon meeting certain net sales. In addition, following regulatory approval, we shall
be entitled to double-digit percentage royalties on net sales of Piclidenoson and Namodenoson in the licensed territories. To date, we
have received a total of $2,000,000 from CMS in upfront and milestone payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the agreement,
CMS will be responsible for the development of Piclidenoson and Namodenoson to obtain regulatory approval in China and shall be further
responsible for obtaining and maintaining regulatory approval in China for the indications described above. We may, at the option of CMS,
supply finished product to CMS.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The License, Collaboration
and Distribution Agreement shall continue in force unless earlier terminated and may be terminated in certain limited circumstances including
certain breaches of the agreement and failure to achieve certain minimum quantities of sales during the contract period. Following expiration
of the term of the agreement, the license granted shall become non-exclusive, fully paid, royalty free and irrevocable.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Kyongbo Pharm Agreement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2019, we entered
into a License and Distribution Agreement with Kyongbo Pharm. Under the terms of agreement, Kyongbo Pharm, in exchange for exclusive distribution
rights to sell Piclidenoson in the treatment of psoriasis in South Korea, made a total upfront payment of $750,000 to us, with additional
payments of up to $3,250,000 upon achievement of certain milestones. We will also be entitled to a transfer price for delivering finished
product to Kyongbo Pharm. To date, we have received a total of $750,000 from Kyongbo Pharm in upfront and milestone payments.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Ewopharma Agreement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2021, we signed an
exclusive distribution agreement with Switzerland-based Ewopharma for Piclidenoson in the treatment of psoriasis and Namodenoson in the
treatment of liver diseases namely, HCC, the most common form of liver cancer, and NASH. Under the terms of the distribution agreement,
Ewopharma we received $2.25 million upfront and are entitled to up to an additional $40.45 million payable upon the achievement of regulatory
and sales milestones plus 17.5% royalties on net sales. In exchange, Ewopharma will have the exclusive right to market and sell Piclidenoson
in Central Eastern European (CEE) countries and Namodenoson in CEE countries and Switzerland. Ewopharma has the right to extend the distribution
agreement to new indications that we may identify for its drug candidates. We will also be entitled to a transfer price for delivering
finished product to Ewopharma. To date, we have received a total of $2.25 million from Ewopharma in upfront, milestone and royalty payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"><b>Vetbiolix Agreement</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2021, we signed a
development and commercialization agreement with Vetbiolix, a France-based veterinary biotech company, for the development of Piclidenoson
for the treatment of osteoarthritis in companion animals including dogs and cats. Vetbiolix will have the exclusive right to Piclidenoson
in the veterinary osteoarthritis market for two years, during which time Vetbiolix will conduct proof-of-concept studies and cover all
associated costs. If the studies yield positive data and Vetbiolix exercises its option to obtain the license from Can-Fite, then Vetbiolix
will be obligated to pay Can-Fite upfront and milestone payments, in addition to royalties on sales upon regulatory approval for veterinary
use.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Total Revenues by Category of Activity and Geographic
Markets</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Historically, we have generated
revenues from payments received pursuant to our out-licensing agreements with respect to Piclidenoson and Namodenoson. See &#8220;Item
4. Information on the Company&#8212;B. Business Overview&#8212;Out-Licensing and Distribution Agreements&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 52; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended December
31, 2021, we recorded the following revenues: (i) $0.19 million as a result of recognition of a portion of an advance payment
received in January 2018 under the distribution agreement with Gebro; (ii) $0.20 million under the Distribution Agreement with CKD which
was due to the recognition of a portion of the advance payment received in December 2016 and April 2019 under the Distribution Agreement
with CKD; and (iii) $0.11 million under the Distribution Agreement with Cipher; and (iv) $0.35 million under the Distribution Agreement
with Ewopharma.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended December
31, 2020, we recorded the following revenues: (i) $0.26 million for the as a result of recognition of a portion of an advance payment
received in January 2018 under the distribution agreement with Gebro; (ii) $0.35 million under the Distribution Agreement with CKD which
was due to the recognition of a portion of the advance payment received in December 2016 and April 2019 under the Distribution Agreement
with CKD; and (iii) $0.15 million under the Distribution Agreement with Cipher.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For the year ended December
31, 2019, we recorded the following revenues: (i) $0.75 million as a result of an upfront payment from Kyongbo Pharm, (i) $0.59 million
for the as a result of recognition of a portion of an advance payment received in January 2018 under the distribution agreement with Gebro;
(iii) $0.34 million under the Distribution Agreement with CKD which was due to the recognition of a portion of the advance payment received
in December 2016 and April 2019 under the Distribution Agreement with CKD; and (iv) $0.35 million under the Distribution Agreement with
Cipher.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect to generate future
revenues through our current and potential future out-licensing arrangements with respect to Piclidenoson and Namodenoson based on the
progress we make in our clinical trials.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Seasonality</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our business and operations
are generally not affected by seasonal fluctuations or factors.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Raw Materials and Suppliers</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the raw materials
that we require to manufacture Piclidenoson, Namodenoson and CF602 are widely available from numerous suppliers and are generally considered
to be generic industrial chemical supplies. We do not rely on a single or unique supplier for the current production of any therapeutic
small molecule in our pipeline.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Manufacturing</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently manufacturing
our API through a leading CRO. The relevant suppliers of our drug products are compliant with both current Good Manufacturing Practices,
or cGMP, and current Good Laboratory Practices, or cGLP, and allow us to manufacture drug products for our current clinical trials. We
anticipate that we will continue to rely on third parties to produce our drug products for clinical trials and commercialization.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There can be no assurance
that our drug candidates, if approved, can be manufactured in sufficient commercial quantities, in compliance with regulatory requirements
and at an acceptable cost. We and our contract manufacturers are, and will be, subject to extensive governmental regulation in connection
with the manufacture of any pharmaceutical products or medical devices. We and our contract manufacturers must ensure that all of the
processes, methods and equipment are compliant with cGMP for drugs on an ongoing basis, as mandated by the FDA and other regulatory authorities,
and conduct extensive audits of vendors, contract laboratories and suppliers.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Contract Research Organizations</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We outsource certain preclinical
and clinical development activities to CROs, which in pre-clinical studies work according to cGMP and cGLP. We believe our clinical CROs
comply with guidelines from the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals
for Human Use, which attempt to harmonize the FDA and the EMA regulations and guidelines. We create and implement the drug development
plans and, during the preclinical and clinical phases of development, manage the CROs according to the specific requirements of the drug
candidate under development.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Marketing and Sales</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not currently have any
marketing or sales capabilities. We intend to license to, or enter into strategic alliances with, larger companies in the pharmaceutical
business, which are equipped to market and/or sell our products, if any, through their well-developed marketing capabilities and distribution
networks. We intend to out-license some or all of our worldwide patent rights to more than one party to achieve the fullest development,
marketing and distribution of any products we develop.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Intellectual Property</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our success depends in part
on our ability to obtain and maintain proprietary protection for our product candidates, technology and know-how, to operate without infringing
the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy is to seek to protect our proprietary
position by, among other filing U.S. and foreign patent applications related to our proprietary technology, inventions and improvements
that we believe are important to the development of our business. We also rely on trade secrets, know-how and continuing technological
innovation to develop and maintain our proprietary position.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 53; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Patents</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of March 20, 2022, we owned
or exclusively licensed (from Leiden University) 15 patent families that, collectively, contain approximately 194 issued patents and pending
patent applications in various countries around the world relating to our two clinical candidates, Piclidenoson and Namodenoson, and our
preclinical candidate, CF602. Patents related to our drug candidates may provide future competitive advantages by providing exclusivity
related to the composition of matter, formulation and method of administration of the applicable compounds and could materially improve
their value. The patent positions for our leading drug candidates are described below. In addition, we filed a patent application in Israel
concerning the use of cannabinoids for treatment of conditions associated with elevated expression of the A<sub>3</sub>&#160;adenosine
receptor.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">With respect to our product
candidates, we currently own patents and/or have patent applications pending in several countries around the world for the following families
of patents:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A3AR ligands to treat viral diseases &#8211; a family of patents which pertain to use of substances that bind to the A3AR for the treatment of viral diseases, such as AIDS and hepatitis, and which inhibit viral replication. Such patents were granted in the United States, in Europe (by the EPO and validated in France, Germany, Italy, Switzerland and the United Kingdom), Australia, China, Israel, Japan, Singapore, Canada and Hong Kong. These patents have a filing date of January 1, 2002 and a priority date of January 16, 2001 and expired in January 2022, other than the U.S. patent that will expire in 2023.</span></td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">A3AR ligands to treat RA &#8211; a patent which pertains to the use of A3AR agonists for the treatment
of inflammatory arthritis, in particular rheumatoid arthritis. This patent was granted in the United States and is set to expire in 2023.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">A3AR as a predictive and follow up biomarker &#8211; a family of patents and patent applications which
pertain to a method of identifying inflammation, determining its severity, and determining and monitoring the efficacy of the anti-inflammatory
treatment by determining the level of A3AR expression in white blood cells as a biological marker for inflammation. These patents were
granted in the United States, Europe (by the EPO and validated in France, Germany, Italy, Spain, Switzerland and the United Kingdom),
Australia, Israel, Japan, China, Mexico and Canada. The patents are set to expire in 2025. There is a patent application pending in Brazil.
Each of the patents and the patent application has a filing date of November 30, 2005 and a priority date of December 2, 2004;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Specific dose to protect from psoriasis &#8211; a family of patents and patent applications which pertains
to the use of a specific dose level of Piclidenoson (total daily dose of 4.0 mg) for the treatment of psoriasis. Such a patent was granted
in Israel, Japan, the United States, South Korea and Europe (by the EPO and validated in in Austria, Belgium, Denmark, France, Germany,
Italy, the Netherlands, Spain, Sweden, Switzerland and the United Kingdom). The patent is set to expire in 2030, and in 2031 in the U.S.
The patent applications are pending in China, Hong Kong, and India each with a filing date of September 6, 2010 and a priority date of
September 6, 2009.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Piclidenoson method of synthesis &#8211; a family of patents which pertain to the method for producing
Piclidenoson. Such patents were granted in the United States, India, China, Japan, Israel and Europe (by the EPO and validated in Austria,
Belgium, Denmark, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Luxembourg, Monaco, the Netherlands, Norway, Poland, Portugal,
Spain, Sweden, Switzerland, Turkey and the United Kingdom). These patents are set to expire in 2028 and in 2031 in the U.S. Each patent
has a filing date of March 13, 2008 and a priority date of March 14, 2007.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Osteoarthritis (OA) indication - a family of patents and patent applications which pertain to the use
of A3AR agonists for the treatment of OA. Such patents were granted in Europe (by the EPO and validated in Austria, Belgium, Denmark,
France, Germany, Italy, Spain, Sweden, Switzerland, Netherlands and the United Kingdom), U.S., Australia, Canada, South Korea, China,
Israel, Japan and Mexico. The patents are set to expire in 2026. A patent application is pending in Brazil. These patents and patent applications
have a filing date of November 29, 2006 and a priority date of November 30, 2005.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Liver protection&#8211; a family of patents which pertains to the use of A3AR agonists for increasing
liver cell division, intended to induce liver regeneration following injury or surgery. Such patents were granted in China, Israel, Japan,
U.S. and Europe (by the EPO and validated in Austria, Belgium, Denmark, France, Germany, Italy, the Netherlands, Poland, Spain, Sweden,
Switzerland, United Kingdom and Turkey). Each patent in this family has a filing date of October 22, 2008 and a priority date of October
15, 2007.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Erectile dysfunction &#8211; a family of patents and patent applications which pertain to treatment of
erectile dysfunction. This family includes granted patents in the United States, Australia, China, Hong Kong, Canada, South Korea, Israel
and Japan and patent applications in Brazil, Europe, and Mexico, the latter application in Mexico recently allowed. The patents and patent
applications have a filing date of August 8, 2013 with priority dates of August 8, 2012 and November 12, 2012.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">CAR T induced cytokine release syndrome &#8211; a family of patent applications which pertains to the
use of A3AR ligands for managing cytokine release syndrome. This family includes a patent applications in Israel and in the U.S., China,
EP and HK claiming priority from this Israeli application. The US, China, EP and HK patent applications have a filing date of September
16, 2018 and the Israeli patent application has a filing date of September 17, 2017.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 54; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">NAFLD/NASH - a family of patents and patent applications which pertain to the use of A3AR ligands for
treatment of ectopic fat accumulation. This family includes granted patents in U.S., Israel, Europe, South Korea, Hong Kong, and Mexico,
and patent applications in China, Brazil, Canada, and Japan. The patent applications have a filing date of November 22, 2016.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Obesity - a family of patent applications which pertains to the use of A3AR ligand for reducing level
of adipocytes and specifically, for treating obesity. This family includes a patent application in Israel and a PCT application claiming
priority from this Israeli application. The PCT patent application has a filing date of January 6, 2020 while the Israeli patent application
has a filing date of January 6, 2019.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Cannabinoids &#8211; a family of patent applications pertaining to the use of cannabinoids for treating
conditions and diseases that involve elevated expression of the A3AR. This family includes a patent application in Israel and a PCT application
claiming priority from this Israeli application. The PCT patent application has a filing date of January 16, 2021 while the Israeli patent
application has a filing date of January 16, 2020.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">PD-1/PD-L1 - an Israeli patent application pertaining to the use of PD-1/PD-L1 axis inhibitor in combination
with an A3AR. This Israeli patent application has a filing date of January 29, 2020.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Treatment of advanced cancer &#8211; a family of patent applications that makes use of A3AR ligands, particularly
Namodenoson, for the treatment of advanced solid cancer, including advanced liver cancer. This family includes patent applications in
the US, Australia, Brazil, Canada, Turkey, Japan, South Korea and Mexico. The US application (which is a provisional application) was
filed on December 29, 2021, and the other patent applications where filed on the same date or a few days later.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We currently hold an exclusive
license from Leiden University of the Netherlands to a family of patents and patent applications that relate to the allosteric modulators
of the A3AR, which includes the allosteric modulator CF602. This exclusive license relates to patents that were granted in the United
States, China, Japan, South Korea, India and in Europe (validated in, Austria, Belgium, Denmark, France, Germany, Italy, the Netherlands,
Spain, Sweden, Switzerland and United Kingdom). These granted patents are set to expire in 2028.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our owned
and licensed patents provide broad and comprehensive coverage of our technology, and we intend to aggressively enforce our intellectual
property rights if necessary to preserve such rights and to gain the benefit of our investment. However, as a result of the termination
of the NIH license agreement between Can-Fite and NIH in June 2015 due to patent expiration, we no longer hold rights to a family of composition
of matter patents relating to Piclidenoson and Namodenoson that were licensed from NIH. Nevertheless, because Piclidenoson or Namodenoson
may be a NCE following approval of an NDA, we, if we are the first applicant to obtain NDA approval, may be entitled to five years of
data exclusivity in the United States with respect to such NCEs. Analogous data and market exclusivity provisions, of varying duration,
may be available in Europe and other foreign jurisdictions. However, we cannot be certain that we will be the first applicant to obtain
an FDA approval for any indication of Piclidenoson or Namodenoson and we cannot be certain that we will be entitled to NCE exclusivity.
In addition, we have discontinued the prosecution of a family of pending patent applications under joint ownership of Can-Fite and NIH
pertaining to the use of A3AR agonists for the treatment of uveitis. Such diminution of our proprietary position could have a material
adverse effect on our business, results of operation and financial condition.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The patent positions of companies
like ours are generally uncertain and involve complex legal and factual questions. Our ability to maintain and solidify our proprietary
position for our technology will depend on our success in obtaining effective claims and enforcing those claims once granted. We do not
know whether any of our patent applications or those patent applications that we license will result in the issuance of any patents. Our
issued patents and those that may issue in the future, or those licensed to us, may be challenged, narrowed, circumvented or found to
be invalid or unenforceable, which could limit our ability to stop competitors from marketing related products or the length of term of
patent protection that we may have for our products. Neither we nor our licensors can be certain that we were the first to invent the
inventions claimed in our owned or licensed patents or patent applications. In addition, our competitors may independently develop similar
technologies or duplicate any technology developed by us, and the rights granted under any issued patents may not provide us with any
meaningful competitive advantages against these competitors. Furthermore, because of the extensive time required for development, testing
and regulatory review of a potential product, before any of our products can be commercialized, any related patent may expire or remain
in force for only a short period following commercialization, thereby reducing any advantage of the patent.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Trade Secrets</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may rely, in some circumstances,
on trade secrets to protect our technology. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology
and processes, in part, by confidentiality agreements and assignment of inventions agreements with our employees, consultants, scientific
advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical
security of our premises and physical and electronic security of our information technology systems. While we have confidence in these
individuals, organizations and systems, such agreements or security measures may be breached, and we may not have adequate remedies for
any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors or others.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Scientific Advisory Board</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We seek advice from our Scientific
Advisory Board on scientific and medical matters generally. We call for Scientific Advisory Board meetings on an as-needed basis. The
following table sets forth certain information with respect to our Scientific Advisory Board member.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 40%; text-align: left; font-weight: bold">Name</td>
    <td style="width: 2%; text-align: left">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 58%; text-align: left; font-weight: bold">Position/Institutional Affiliation</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">Nabil Hanna, Ph.D.</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: left">Former Chief Science Officer of Biogen-Idec</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 55; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Clinical Advisory Board</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Clinical Advisory Board,
which consists of seven members, a leading U.S.-based rheumatologist, oncologist, dermatologist, and three hepatologists, who play an
active role in consulting with us with respect to clinical drug development. We call for Clinical Advisory Board meetings on an as-needed
basis. The following table sets forth certain information with respect to our Clinical Advisory Board members.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 40%; text-align: left; font-weight: bold">Name</td>
    <td style="width: 2%; text-align: left; font-weight: bold">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 58%; text-align: justify; font-weight: bold">Position/Institutional Affiliation</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">Dr. Michael Weinblatt</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">Head, Division of Rheumatology, Immunology and Allergy, Brigham and Women&#8217;s Hospital</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">Dr. Keith Stuart</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">Chairman, Department of Hematology and Oncology; Professor of Medicine, Tufts University School of Medicine; Lahey Clinic Medical Center</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">Dr. Jonathan Wilkin</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">Former Head, Dermatology Division, FDA</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">Dr. Scott Friedman</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">Dean for Therapeutic Discovery and Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai in New York</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">Dr. Arun Sanyal</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">Professor of Medicine, Physiology and Molecular Pathology at Virginia Commonwealth University School of Medicine</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">Dr. Rifaat Safadi</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">Head of the Liver Unit, Gastroenterology and Liver Diseases, Division of Medicine at Hadassah Medical Center and Professor of Internal Medicine, Bowel, Liver Disease, and Metabolic Syndrome at Hadassah University in Israel</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: left">Dr. Stephen Harrison</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">Dr. Harrison is currently a Visiting Professor of Hepatology at the Radcliffe Department of Medicine, University of Oxford.</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Competition</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The pharmaceutical industry
is characterized by rapidly evolving technology, intense competition and a highly risky, costly and lengthy research and development process.
Adequate protection of intellectual property, successful product development, adequate funding and retention of skilled, experienced and
professional personnel are among the many factors critical to success in the pharmaceutical industry.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our technology platform is
based on the finding that the A3AR is highly expressed in pathological cells, such as various tumor cell types and inflammatory cells.
We believe that targeting the A3AR with synthetic and highly selective A3AR agonists, such as Piclidenoson and Namodenoson, and allosteric
modulators, such as CF602, induces anti-cancer and anti-inflammatory effects. Currently, our drug candidates, Piclidenoson, Namodenoson
and CF602 are being developed to treat autoimmune inflammatory indications, oncology and liver diseases as well as erectile dysfunction,
including but not limited to psoriasis, HCC and NASH. Preclinical studies have also indicated that our drug candidates have the potential
to treat additional inflammatory diseases, such as erectile dysfunction, Crohn&#8217;s disease, oncological diseases and viral diseases,
such as the JC virus, and obesity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Despite the competition, however,
we believe that our drug candidates have unique characteristics and advantages over certain drugs currently available on the market and
under development to treat these indications. We believe that our pipeline of drug candidates has exhibited a potential for therapeutic
success with respect to the treatment of autoimmune-inflammatory, oncological and liver diseases. We believe that targeting the A3AR with
synthetic and highly selective A3AR agonists, such as Piclidenoson and Namodenoson, and allosteric modulators, such as CF602, induces
anti-cancer and anti-inflammatory effects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe the characteristics
of Piclidenoson, as exhibited in our clinical studies to date, including its good safety profile, clinical activity, simple and less frequent
delivery through oral administration and its low cost of production, position it well against the competition in the autoimmune-inflammatory
markets, including the psoriasis markets, where treatments, when available, often include injectable drugs, many of which can be highly
toxic, expensive and not always effective. For example, while TNF inhibitor therapies transformed the treatment for many patients, a substantial
percentage of patients (40% to 60%) do not respond to either a DMARD or biologic therapies (Simsek, 2010).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pre-clinical pharmacology
studies in different experimental animal models revealed that Piclidenoson acts as a DMARD, which, when coupled with its good safety profile,
makes it competitive in the psoriasis market. Our recent findings suggest that Piclidenoson might offer a superior efficacy and tolerability
profile, allowing patients to stay on drug longer and potentially leading to an improvement in response rate. Like Piclidenoson, Namodenoson
has a good safety profile, is orally administered and has a low cost of production, which we believe positions it well in the HCC market,
where only a handful of drugs have been approved by the FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 56; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, our human clinical
data suggests that A3AR may be a biological marker in that high A3AR expression prior to treatment has been predictive of good patient
response to our drug treatment. In fact, as a result of our research we have developed a simple blood assay to test for A3AR expression
as a predictive biological marker. We hold a patent with respect to the intellectual property related to such assay and are currently
analyzing A3AR expression levels in our Phase III psoriasis trial.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On the other hand, other drugs
on the market, new drugs under development (including drugs that are in more advanced stages of development in comparison to our drug
pipeline) and additional drugs that were originally intended for other purposes, but were found effective for purposes targeted by us,
may all be competitive to the current drug candidates in our pipeline. In fact, some of these drugs are well established and accepted
among patients and physicians in their respective markets, are orally bioavailable, can be efficiently produced and marketed, and are
relatively safe. Moreover, other companies of various sizes engage in activities similar to ours. Most, if not all, of our competitors
have substantially greater financial and other resources available to them. Competitors include companies with marketed products and/or
an advanced research and development pipeline. The major competitors in the psoriasis therapeutic field include Amgen, J&amp;J, Pfizer,
Novartis, Abbvie, Eli Lilly, Bristol-Myers, and more. Competitors in the HCC field include companies such as Bayer, Exelixis, Merck, Roche,
and Bristol-Myers. Competitors in the NASH field include companies such as Gilead, Genfit, Galmed, Intercept, Madrigal, Akero, 89Bio,
Viking, and Terns. Competitors in the erectile dysfunction field include Pfizer, Eli Lilly, Bayer, and Petros Pharmaceuticals.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Moreover, several companies
have reported the commencement of research projects related to the A3AR. Such companies include CV Therapeutics Inc. (which was acquired
by Gilead), King Pharmaceuticals R&amp;D Inv. (which was acquired by Pfizer), Hoechst Marion Roussel Inc., Novo Nordisk A/S and Inotek
Pharmaceuticals. However, to the best of our knowledge, there is no approved drug currently on the market which is similar to our A3AR
agonists, nor are we aware of any allosteric modulator in the A3AR product pipeline similar to our allosteric modulator with respect to
chemical profile and mechanism of action.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Piclidenoson for the Treatment of Psoriasis</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Psoriasis is a skin condition
that affects 2% to 3% of the general population according to the National Psoriasis Foundation. The disease is manifested by scaly plaques
on the skin and in the severe form has a major effect on the physical and emotional well-being of the patients. Topical agents are typically
used for mild disease, phototherapy for moderate disease, and systemic agents for severe disease. For moderate to severe cases, systemic
biologic drugs, delivered via intravenous injection, or IV, have dominated the market. According to the National Psoriasis Foundation,
common side effects of biologics include respiratory infections, flu-like symptoms, and injection site reactions while rare side effects
include serious nervous system disorders, such as multiple sclerosis, seizures, or inflammation of the nerves of the eyes, blood disorders,
and certain types of cancer. We believe a significant need remains for novel oral and safe drugs for patients who do not respond to existing
therapies or for whom these therapies are unsuitable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The psoriasis therapeutic market is dominated by biological drugs that
are primarily administered via IV and have potential side effects. Recently, a new oral small molecule inhibitor of phosphodiesterase
4, Celgene&#8217;s Otezla, has gained sizable market share as a result in part due to its convenience of oral dose and comparable efficacy
to the biologic drugs. In January 2015, the FDA approved Cosentyx (secukinumab) by Novartis. In March 2016, the FDA approved Taltz (ixekizumab)
by Eli Lilly. The psoriasis drug market is forecast to grow to $11.3 billion by 2025, according to estimates of iHealthcareAnalyst.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The current common treatments
for psoriasis include topical and systemic drugs, steroids, immunosuppressive drugs such as Cyclosporine A by Novartis, MTX and biological
drugs.] Biological drugs, such as Enbrel (etanercept) by Amgen and Pfizer, Remicade (infliximab) by Centocor, Humira (adalimumab) by Abbvie,
Stelara (ustekinumab) by Janssen, Otezla (aprelimast) byAmgen, Cosentyx (secukinumab) by Novartis and Taltz (ixekizumab) by Eli Lilly
have significant side effects, are expensive and patients are often not responsive. For example, some of these drugs have received an
FDA &#8220;black box&#8221; warning for increased risk of cancer in children and adolescents and risk of infection with Legionella and
Listeria bacteria.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Namodenoson for the Treatment of HCC</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the American
Cancer Society, HCC is the fifth most common form of cancer death in the U.S., the most common form of liver cancer in adults and the
third most common cause of cancer-related mortality worldwide, particularly in Asia. According to the American Cancer Society, more than
700,000 people are diagnosed with liver cancer each year throughout the world and more than 600,000 persons die from liver cancer each
year. Despite several new approvals in the HCC market, including immunotherapy agents, this remains a significant unmet medical need where
five year survival rates remain less than 20%. According to Grand View Research, the HCC drug market is expected to reach $1.5 billion
by 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Several therapies are in advanced
clinical development for HCC. Some drugs under development act as a single agent and some act in combination with Nexavar or approved
checkpoint inhibitors pembrolizumab and/or nivolumab. Moreover, some are first line treatments while others are second line treatments.
In addition, many existing approaches are used in the treatment of unresectable liver cancer, including alcohol injection, radiofrequency
ablation, chemoembolization, cryoablation and radiation therapy.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 57; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Namodenoson for the Treatment of NASH</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Rates of NAFLD and NASH are
increasing in the United States in concert with increasing rates of obesity and diabetes. In fact, NASH is now the third leading cause
of liver transplant in the United States. It is estimated that 17-33% of Americans have fatty liver, with approximately one-third going
on to develop NASH. NASH is believed to affect 2-5% of adult Americans. Despite the progression of several interesting clinical-stage
candidates by companies such as Gilead, Genfit, Madrigal, Conatus, Galmed, Intercept, Akero, 89Bio, Viking, and Terns as well as others,
there are currently no FDA approved treatment options for NASH.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2019, Intercept
Pharmaceuticals announced its Phase 3 results of their OCA drug for the treatment of liver fibrosis due to NASH and Intercept reported
that it submitted an NDA to the FDA seeking accelerated approval of OCA for NASH and an MAA to the EMA. In June 2020, the FDA issued a
complete response letter, or the CRL, regarding the NDA of OCA for the treatment of NASH. Recently, Intercept reported that it is in discussions
with the FDA with respect to the potential resubmission of its NDA. If approved, OCA will become the first approved NASH drug.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">By 2028, Vantage Market Research estimates the addressable pharmaceutical
market for NASH will reach $21.9 billion in size.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">CF602 for the Treatment of Erectile Dysfunction</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Massachusetts
Male Aging Study in 1994, 52% of the respondents between the ages of 40 and 70 years old reported some degree of erectile dysfunction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The most popular class of
drug to treat erectile dysfunction is the phosphodiesterase type 5, or PDE5, inhibitors. These drugs block the degradative action of cyclic
guanosine monophosphate, or GMP, specific PDE5 on cyclic GMP in the smooth muscle cells lining the blood vessels supplying the corpus
cavernosum of the penis. An erection is caused by increased blood flow into the penis resulting from the relaxation of penile arteries
and corpus cavernosal smooth muscle. This response is mediated by the release of nitric oxide from nerve terminals and endothelial cells,
which stimulates the synthesis of cyclic GMP in smooth muscle cells. The inhibition of PDE5 enhances erectile function by increasing the
concentration of cyclic GMP in the corpus cavernosum and pulmonary arteries.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Unfortunately, the systemic
side effects of PDE5 inhibitors include a decrease in sitting blood pressure. This has resulted in warnings and precautions and contraindications
of use in patients already taking antihypertensive agents like nitrates or alpha-blockers. A study published in the American Journal of
Medicine (Selvin E., et al., 2007) found that persons with a history of heart disease, hypertension, and diabetes had a higher probability
of impotence. A second study published in the same journal (Shah NP., et al, 2015) notes that vascular erectile dysfunction is a powerful
marker of increased cardiovascular risk. We believe a significant market opportunity exists targeting erectile dysfunction patients contraindicated
for use of the market leading products, Viagra and Cialis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Grand View Research Inc. estimates
the value of the erectile dysfunction therapeutic market to be approximately $3.2 billion by 2022.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Insurance</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain insurance for
our offices and laboratory in Petah-Tikva, Israel. Our insurance program covers approximately $0.85 million of equipment and lease improvements
against risk of loss. In addition, we maintain the following insurance: employer liability with coverage of approximately $5.7 million;
third party liability with coverage of approximately $0.87 million; fire insurance coverage of approximately $0.43 million; natural disaster
coverage of approximately $1.3 million; all risk coverage of approximately $0.02 million for electronic equipment and machinery insurance
for laboratory refrigerators; and directors&#8217; and officers&#8217; liability insurance with coverage of $5.0 million per claim and
$5.0 million in the aggregate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also maintain worldwide
product and clinical trial liability insurance with coverage of approximately $5 million with respect to the Piclidenoson and Namodenoson
drugs used in clinical trials. We also procure additional insurance for each specific clinical trial which covers a certain number of
trial participants and which varies based on the particular clinical trial. Certain of such policies are based on the Declaration of Helsinki,
which is a set of ethical principles regarding human experimentation developed for the medical community by the World Medical Association,
and certain protocols of the Israeli Ministry of Health.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We procure cargo marine coverage
when we ship substances for our clinical studies. Such insurance is custom-fit to the special requirements of the applicable shipment,
such as temperature and/or climate sensitivity. If required, we ensure the substances to the extent they are stored in central depots
and at clinical sites.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that our insurance
policies are adequate and customary for a business of our kind. However, because of the nature of our business, we cannot assure you that
we will be able to maintain insurance on a commercially reasonable basis or at all, or that any future claims will not exceed our insurance
coverage.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 58; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Environmental Matters</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to various
environmental, health and safety laws and regulations, including those governing air emissions, water and wastewater discharges, noise
emissions, the use, management and disposal of hazardous, radioactive and biological materials and wastes and the cleanup of contaminated
sites. We believe that our business, operations and facilities are being operated in compliance in all material respects with applicable
environmental and health and safety laws and regulations. Our laboratory personnel in Israel have ongoing communication with the Israeli
Ministry of Environmental Protection in order to verify compliance with relevant instructions and regulations. In addition, all of our
laboratory personnel participate in instruction on the proper handling of chemicals, including hazardous substances before commencing
employment, and during the course of their employment with us. In addition, all information with respect to any chemical substance that
we use is filed and stored as a Material Safety Data Sheet, as required by applicable environmental regulations. Based on information
currently available to us, we do not expect environmental costs and contingencies to have a material adverse effect on us. The operation
of our testing facilities, however, entails risks in these areas. Significant expenditures could be required in the future if these facilities
are required to comply with new or more stringent environmental or health and safety laws, regulations or requirements. See &#8220;Item
4. Information on the Company&#8212;B. Business Overview&#8212;Government Regulation and Funding&#8212;Israel Ministry of the Environment&#8212;Toxin
Permit.&#8221;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Government Regulation and Funding</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We operate in a highly controlled
regulatory environment. Stringent regulations establish requirements relating to analytical, toxicological and clinical standards and
protocols in respect of the testing of pharmaceuticals. Regulations also cover research, development, manufacturing and reporting procedures,
both pre- and post-approval. In many markets, especially in Europe, marketing and pricing strategies are subject to national legislation
or administrative practices that include requirements to demonstrate not only the quality, safety and efficacy of a new product, but also
its cost-effectiveness relating to other treatment options. Failure to comply with regulations can result in stringent sanctions, including
product recalls, withdrawal of approvals, seizure of products and criminal prosecution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before obtaining regulatory
approvals for the commercial sale of our product candidates, we must demonstrate through preclinical studies and clinical trials that
our product candidates are safe and effective. Historically, the results from preclinical studies and early clinical trials often have
not accurately predicted results of later clinical trials. In addition, a number of pharmaceutical products have shown promising results
in clinical trials but subsequently failed to establish sufficient safety and efficacy results to obtain necessary regulatory approvals.
We have incurred, and will continue to incur substantial expense for and devote a significant amount of time to, preclinical studies and
clinical trials. Many factors can delay the commencement and rate of completion of clinical trials, including the inability to recruit
patients at the expected rate, the inability to follow patients adequately after treatment, the failure to manufacture sufficient quantities
of materials used for clinical trials, and the emergence of unforeseen safety issues and governmental and regulatory delays. If a product
candidate fails to demonstrate safety and efficacy in clinical trials, this failure may delay development of other product candidates
and hinder our ability to conduct related preclinical studies and clinical trials. Additionally, as a result of these failures, we may
also be unable to obtain additional financing.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Governmental authorities in
all major markets require that a new pharmaceutical product be approved or exempted from approval before it is marketed, and have established
high standards for technical appraisal which can result in an expensive and lengthy approval process. The time to obtain approval varies
by country and some products are never approved. The lengthy process of conducting clinical trials, seeking approval and subsequent compliance
with applicable statutes and regulations, if approval is obtained, are very costly and require the expenditure of substantial resources.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A summary of the United States,
European Union and Israeli regulatory processes follow below.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">United States</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the United States, the
Public Health Service Act and the Federal Food, Drug, and Cosmetic Act (FDCA), as amended, and the regulations promulgated thereunder,
and other federal and state statutes and regulations govern, among other things, the safety and effectiveness standards for our products
and the raw materials and components used in the production of, testing, manufacture, labeling, storage, record keeping, approval, advertising
and promotion of our products on a product-by-product basis.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preclinical tests include&#160;<i>in
vitro</i>&#160;and&#160;<i>in vivo</i>&#160;evaluation of the product candidate, its chemistry, formulation and stability, and animal
studies to assess potential safety and efficacy. Certain preclinical tests must be conducted in compliance with good laboratory practice,
or GLP, regulations. Violations of these regulations can, in some cases, lead to invalidation of the studies, requiring them to be replicated.
After laboratory analysis and preclinical testing, a sponsor files an IND application including the results of the preclinical testing,
manufacturing information and analytical data, with FDA. An IND is a request for authorization from FDA to administer an investigational
new drug or biological product to humans.to begin human testing. An IND becomes effective 30 days after FDA receives it, unless the FDA
notifies the sponsor that the clinical trial is subject to a clinical hold. FDA also may impose a clinical hold at any time during a clinical
trial. A sponsor may not proceed with a clinical trial that is subject to a clinical hold until the clinical hold has been lifted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 59; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Typically, a manufacturer
conducts a three-phase human clinical testing program which itself is subject to numerous laws and regulatory requirements, including
good clinical practice requirements, or GCP, which include adequate monitoring, reporting, record keeping and informed consent. In Phase
I, small clinical trials are conducted, typically in healthy human volunteers, to determine the safety and proper dose ranges of product
candidates. In Phase II, clinical trials are conducted in patients with the targeted disease or condition to assess safety and gain preliminary
evidence of the efficacy of product candidates. In Phase III, clinical trials are conducted in an expanded population of patients with
the targeted disease or condition to further evaluate clinical efficacy and safety. Phase III trials are designed to provide sufficient
data for the statistically valid evidence of safety and efficacy to support approval, and if approved, the basis for product labeling.
Post-approval studies, sometimes referred to as Phase IV trials, may be conducted, voluntarily or as a condition of approval, after initial
product approval to obtain additional information about the drugs risks and benefits in patients with the targeted disease or condition.
The time and expense required for us to perform this clinical testing can vary and is substantial. We cannot be certain that we will successfully
complete Phase I, Phase II or Phase III testing of our product candidates within any specific time period, if at all. Furthermore, the
FDA, the Institutional Review Board responsible for approving and monitoring the clinical trials at a given site, the Data Safety Monitoring
Board, where one is used, or we may suspend the clinical trials at any time on various grounds, including a finding that subjects or patients
are exposed to unacceptable health risk.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the clinical data from
these clinical trials (Phases I, II and III) are deemed to support the safety and effectiveness of the candidate product for its intended
use, then we may proceed to seek to file with the FDA an NDA seeking approval to market a new drug for one or more specified intended
uses. We have not completed our clinical trials for any candidate product for any intended use and therefore, we cannot ascertain whether
the clinical data will support and justify filing an NDA. Nevertheless, if and when we are able to ascertain that the clinical data supports
and justifies filing an NDA, we intend to make such appropriate filings.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The purpose of the NDA is
to provide the FDA with sufficient information so that it can assess whether it ought to approve the candidate product for marketing for
specific intended uses. Under PDUFA, the submission of an NDA requires the payment of substantial user fees, unless a waiver is granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The NDA normally contains,
among other things, sections describing the chemistry, manufacturing, and controls, non-clinical pharmacology and toxicology, human pharmacokinetics
and bioavailability, microbiology, the results of the clinical trials, and the proposed labeling which contains, among other things, the
intended uses of the candidate product. FDA reviews the information submitted under the NDA to determine, among other things, whether
a product is safe and effective for its intended use and whether its manufacturing is compliant with cGMP requirements to assure and preserve
the product&#8217;s identity, strength, quality and purity. Before accepting an NDA for filing, FDA conducts a preliminary review of the
NDA, within 60 days of submission, to determine whether it is sufficiently complete to permit substantive review. Generally, under PDUFA
guidelines, FDA has a goal of ten months from the date of acceptance of a standard NDA for a new molecular entity to review and act on
the submission. Because of the 60 day review FDA is permitted prior to accepting an NDA for filing, this review typically takes 12 months
from the date the NDA is submitted to FDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The FDA may refer an application
for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific
experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions.
The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.
Before approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an
application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate
to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect
one or more clinical trial sites to assure compliance with GCP requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Manufacturers cannot take
any action to market any new drug or biologic product in the United States until an appropriate marketing application has been approved
by the FDA. The FDA has substantial discretion over the approval process and may disagree with a manufacturer&#8217;s interpretation of
the data submitted. The process may be significantly extended by requests for additional information or clarification regarding information
already provided. As part of this review, the FDA may refer the application to an appropriate advisory committee. An advisory committee
is a panel comprised of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a
recommendation as to whether an application should be approved and under what conditions. FDA is not bound by the recommendations of an
advisory committee; however, it takes into consideration the advisory committee&#8217;s recommendations when making decisions., typically
a panel of clinicians. As part of the approval process, FDA determines whether the manufacturer&#8217;s facilities and manufacturing processes
are in compliance with cGMP requirements and sufficient to ensure consistent production of the product within required specifications.
Prior to approving an NDA, FDA also may inspect one or more clinical trial sites to assure compliance with GCP requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the completion of
its evaluation of an NDA, FDA will issue an approval letter or a Complete Response Letter, or CRL. An approval letter authorizes commercialization
of the drug for specified indications. A CRL informs the manufacturer that the review cycle for an application is complete and that the
application is not ready for approval in its present form. A CRL typically identifies specific deficiencies in the NDA that may require
additional clinical data or other significant requirements related to clinical trials or manufacturing. If FDA issues a CRL, the manufacturer
must resubmit the NDA with all deficiencies addressed or withdraw the NDA. Even if all requested data and information are submitted, FDA
ultimately may not approve the NDA.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 60; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Satisfaction of these and
other regulatory requirements typically takes several years, and the actual time required may vary substantially based upon the type,
complexity and novelty of the product. Government regulation may delay or prevent marketing of potential products for a considerable period
of time and impose costly procedures on our activities. We cannot be certain that the FDA or other regulatory agencies will approve any
of our products on a timely basis, if at all. Success in preclinical or early stage clinical trials does not assure success in later-stage
clinical trials. Even if a product receives regulatory approval, the approval may be significantly limited to specific indications or
uses and these limitations may adversely affect the commercial viability of the product. Delays in obtaining, or failures to obtain regulatory
approvals, would have a material adverse effect on our business.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Even after we obtain FDA approval,
we may be required to conduct further clinical trials (i.e., Phase IV trials) and provide additional data on safety and effectiveness.
FDA also may impose other conditions on approval including the requirement for a risk evaluation and mitigation strategy, or REMS, designed
to ensure the safe use of the drug. A REMS could include, among other things, medication guides, physician communication plans, restricted
distribution methods, and patient registries. Any of these limitations on approval or marketing could restrict our ability to successfully
commercialize products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also required to gain
separate approval for the use of an approved product as a treatment for indications other than those initially approved. In addition,
side effects or adverse events that are reported during clinical trials can delay, impede or prevent marketing approval. Similarly, adverse
events that are reported after marketing approval can result in additional limitations being placed on the product&#8217;s use and, potentially,
withdrawal of the product from the market. Any adverse event, either before or after marketing approval, can result in product liability
claims against us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As an alternate path for FDA
approval of new indications or new formulations of previously-approved products, a company may file a Section 505(b)(2) NDA, instead of
a &#8220;stand-alone&#8221; or &#8220;full&#8221; NDA. Section 505(b)(2) of the FDCA, was enacted as part of the Drug Price Competition
and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Amendments. Section 505(b)(2) permits the submission of an
NDA where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which
the applicant has not obtained a right of reference. Some examples of products that may be allowed to follow a 505(b)(2) path to approval
are drugs that have a new dosage form, strength, route of administration, formulation or indication. The Hatch-Waxman Amendments permit
the applicant to rely upon certain published nonclinical or clinical studies conducted for an approved product or the FDA&#8217;s conclusions
from prior review of such studies. The FDA may require companies to perform additional studies or measurements to support any changes
from the approved product. The FDA may then approve the new product for all or some of the labeled indications for which the reference
product has been approved, as well as for any new indication supported by the NDA. While references to nonclinical and clinical data not
generated by the applicant or for which the applicant does not have a right of reference are allowed, all development, process, stability,
qualification and validation data related to the manufacturing and quality of the new product must be included in an NDA submitted under
Section 505(b)(2).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that the Section
505(b)(2) applicant is relying on the FDA&#8217;s conclusions regarding studies conducted for an already approved product, the applicant
is required to certify to the FDA concerning any patents listed for the approved product in the FDA&#8217;s Orange Book publication. Specifically,
the applicant must certify that: (i) the required patent information has not been filed; (ii) the listed patent has expired; (iii) the
listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or (iv) the listed
patent is invalid or will not be infringed by the new product. The Section 505(b)(2) application also will not be approved until any non-patent
exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the reference product
has expired. Thus, the Section 505(b)(2) applicant may invest a significant amount of time and expense in the development of its products
only to be subject to significant delay and patent litigation before its products may be commercialized.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to regulating
and auditing human clinical trials, the FDA regulates and inspects equipment, facilities, laboratories and processes used in the manufacturing
and testing of such products prior to providing approval to market a product. If, after receiving FDA approval, we make a material change
in manufacturing equipment, location or process, additional regulatory review and approval may be required. We also must adhere to cGMP
regulations and product-specific regulations enforced by the FDA through its facilities inspection program. The FDA also conducts regular,
periodic visits to re-inspect our equipment, facilities, laboratories and processes following the initial approval. If, as a result of
these inspections, the FDA determines that our equipment, facilities, laboratories or processes do not comply with applicable FDA regulations
and conditions of product approval, the FDA may seek civil, criminal or administrative sanctions and/or remedies against us, including
the suspension of our manufacturing operations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have currently received
no approvals to market our products from the FDA or other foreign regulators.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are also subject to various
federal, state and international laws pertaining to healthcare &#8220;fraud and abuse,&#8221; including anti-kickback laws and false claims
laws. The federal anti-kickback law, which governs federal healthcare programs (e.g., Medicare, Medicaid), makes it illegal to solicit,
offer, receive or pay any remuneration in exchange for, or to induce, the referral of business, including the purchase or prescription
of a particular drug. Many states have similar laws that are not restricted to federal healthcare programs. Federal and state false claims
laws prohibit anyone from knowingly and willingly presenting, or causing to be presented for payment to third party payers (including
Medicare and Medicaid), claims for reimbursement, including claims for the sale of drugs or services, that are false or fraudulent, claims
for items or services not provided as claimed, or claims for medically unnecessary items or services. If the government or a whistleblower
were to allege that we violated these laws there could be a material adverse effect on us, including our stock price. Even an unsuccessful
challenge could cause adverse publicity and be costly to respond to, which could have a materially adverse effect on our business, results
of operations and financial condition. A finding of liability under these laws can have significant adverse financial implications for
us and can result in payment of large penalties and possible exclusion from federal healthcare programs. We will consult counsel concerning
the potential application of these and other laws to our business and our sales, marketing and other activities and will make good faith
efforts to comply with them. However, given their broad reach and the increasing attention given by law enforcement authorities, we cannot
assure you that some of our activities will not be challenged or deemed to violate some of these laws.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 61; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Orphan Drug Designation</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Orphan Drug
Act, FDA may grant special status, or orphan designation, to a drug intended to treat a rare disease or condition, which is a defined
as a disease or condition that affects fewer than 200,000 individuals in the United States, or there is no reasonable expectation that
the sales of the product will offset the cost of developing and making the drug available in the United States. A request for orphan drug
designation must be filed before the NDA is filed. Following the grant of orphan designation, FDA will publicly disclose the identity
of the therapeutic drug candidate and its potential orphan use. Orphan designation does not shorten the duration of the regulatory review
and approval process. The fact that the FDA has designated a drug as an orphan drug for a particular intended use does not mean that the
drug has been approved for marketing. Only after an NDA has been approved by the FDA is marketing appropriate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a drug candidate with orphan
designation subsequently receives the first FDA approval for the disease or condition for which it has orphan designation, the drug is
entitled to a seven-year period of market exclusivity subject to certain exceptions (e.g., clinical superiority of a subsequent product).
This means that FDA may not approve another drug application authorizing another manufacturer to market the same drug for the same indication
for seven years. This does not preclude competitors from receiving approval of the same product that has orphan exclusivity for a different
indication or a different product for the same indication for which the orphan product has exclusivity. The orphan designation of a drug
also provides the sponsor with certain financial incentives including tax credits, waiver of PDUFA fees, and access to certain grant funding
for orphan products.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2012, the FDA
granted orphan drug status for the active moiety, or the part of the drug that is responsible for the physiological or pharmacological
action of the drug substance, of Namodenoson for the treatment of HCC. Subsequently, in October 2015, the EMA granded Namodenoson orphan
drug designation for the treatment of HCC. See &#8220;Item 4. Information on the Company&#8212;B. Business&#8212;Overview&#8212;Namodenoson.&#8221;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">European Union</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Regulation and Marketing Authorization
in the European Union</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The process governing approval
of medicinal products in the European Union follows essentially the same lines as in the United States and, likewise, generally involves
satisfactorily completing each of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">preclinical laboratory tests, animal studies and formulation studies all performed in accordance with the
applicable E.U. Good Laboratory Practice regulations;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">submission to the relevant national authorities of a clinical trial application, or CTA, which must be approved
before human clinical trials may begin;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">performance of adequate and well-controlled clinical trials to establish the safety and efficacy of the product
for each proposed indication;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">submission to the relevant competent authorities of an MAA, which includes the data supporting safety and
efficacy as well as detailed information on the manufacture and composition of the product in clinical development and proposed labelling;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">satisfactory completion of an inspection by the relevant national authorities of the manufacturing facility
or facilities, including those of third parties, at which the product is produced to assess compliance with strictly enforced current
cGMP;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">potential audits of the non-clinical and clinical trial sites that generated the data in support of the MAA;
and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">review and approval by the relevant competent authority of the MAA before any commercial marketing, sale
or shipment of the product.</td></tr></table><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Preclinical Studies</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Preclinical tests include
laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animal studies, in
order to assess the potential safety and efficacy of the product. The conduct of the preclinical tests and formulation of the compounds
for testing must comply with the relevant E.U. and/or Member States&#8217; regulations and requirements. The results of the preclinical
tests, together with relevant manufacturing information and analytical data, are submitted as part of the CTA.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 62; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Clinical Trial Approval</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Requirements for the conduct
of clinical trials in the European Union including Good Clinical Practice, or GCP, are implemented in the Clinical Trials Directive 2001/20/EC
and the GCP Directive 2005/28/EC. Pursuant to Directive 2001/20/EC and Directive 2005/28/EC, as amended, a system for the approval of
clinical trials in the European Union has been implemented through national legislation of the member states. Under this system, approval
must be obtained from the competent national authority of an E.U. member state in which a study is planned to be conducted or in multiple
member states if the clinical trial is to be conducted in a number of member states. To this end, a CTA is submitted, which must be supported
by an investigational medicinal product dossier, or IMPD, and further supporting information prescribed by Directive 2001/20/EC and Directive
2005/28/EC and other applicable guidance documents. Furthermore, a clinical trial may only be started after a competent ethics committee
has issued a favorable opinion on the clinical trial application in that country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Clinical trials in the EU
are now regulated under Regulation (EU) 536/2014, or the CTR. As opposed to the former law, Directive 2001/20/EC, or CTD, which as an
EU directive was not directly applicable in the member states, the CTR has immediate effect and does not have to be transposed into national
law. While national law transposing the CTD varied to a great extent, the CTR aims at significant further harmonization of the law governing
clinical trials in the EU. After significant delay, the CTR has now become applicable on January 31, 2022. The CTR further harmonizes
the assessment and supervision processes for clinical trials throughout the EU via a Clinical Trials Information System, or CTIS, which
includes a centralized EU portal and database for clinical trials. The exact timing of the Regulation&#8217;s application depends on confirmation
of full functionality of CTIS through an independent audit. The CTR will become applicable six months after the European Commission publishes
notice of this confirmation. The CTR provides inter alia:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">Consistent rules for conducting clinical trials throughout the EU;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Making information on the authorization, conduct and results of each clinical trial carried out in the EU
publicly available;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Harmonized electronic submission and assessment process for clinical trials conducted in multiple member
states;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Improved collaboration, information sharing and decision-making between and within member states;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">Increased transparency of information on clinical trials; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">Higher standards of safety for all participants in EU clinical trials.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The authorization of a clinical
trial (Phase I-III) in an EU member state requires the submission of a clinical trial application (CTA) via the EU Portal. The application
will be reviewed by the competent authorities of the member states where the trial is supposed to take place. The application and approval
process is conducted by the member states under the cooperation system set forth in the CTR. Particularities under member states&#8217;
national law still apply to some extent. In general, the CTA should include, among other documents, the study protocol, results of the
nonclinical studies and manufacturing information and analytical results. Also, the sponsor has to suggest one of the concerned member
states as reporting member state. The CTR aims at speeding up the validation and review of clinical trial applications and therefore provides
strict deadlines.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Marketing Authorization</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Authorization to market a
product in the member states of the European Union proceeds under one of four procedures: a centralized authorization procedure, a mutual
recognition procedure, a decentralized procedure or a national procedure.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Centralized Authorization Procedure</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The centralized procedure
enables applicants to obtain a marketing authorization that is valid in all E.U. member states based on a single application. Certain
medicinal products, including products developed by means of biotechnological processes, must undergo the centralized authorization procedure
for marketing authorization which, if granted by the European Commission, is automatically valid in all 28 E.U. member states. The EMA
and the European Commission administer this centralized authorization procedure pursuant to Regulation (EC) No 726/2004.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Regulation (EC)
No 726/2004, this procedure is inter alia mandatory for:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">medicinal products developed by means of one of the following biotechnological processes:</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">recombinant DNA technology;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">controlled expression of genes coding for biologically active proteins in prokaryotes and eukaryotes including
transformed mammalian cells; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">hybridoma and monoclonal antibody methods;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 63; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">advanced therapy medicinal products as defined in Article
2 of Regulation (EC) No. 1394/2007 on advanced therapy medicinal products;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">medicinal products for human use containing a new active substance
that, on the date of effectiveness of this regulation, was not authorized in the European Union, and for which the therapeutic indication
is the treatment of any of the following diseases:</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">acquired immune deficiency syndrome;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">cancer;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">neurodegenerative disorder;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">diabetes;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">auto-immune diseases and other immune dysfunctions;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.75in"></td><td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">viral diseases; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">&#9679;</span></td><td style="text-align: justify">medicinal products that are designated as orphan medicinal
products pursuant to Regulation (EC) No 141/2000.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The centralized authorization
procedure is optional for other medicinal products if they contain a new active substance or if the applicant shows that the medicinal
product concerned constitutes a significant therapeutic, scientific or technical innovation or that the granting of authorization is in
the interest of patients in the European Union.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Administrative Procedure</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the centralized authorization
procedure, the EMA&#8217;s Committee for Human Medicinal Products, or CHMP, serves as the scientific committee that renders opinions about
the safety, efficacy and quality of medicinal products for human use on behalf of the EMA. The CHMP is composed of experts nominated by
each member state&#8217;s national authority for medicinal products, with expert appointed to act as Rapporteur for the co-ordination
of the evaluation with the possible assistance of a further member of the Committee acting as a Co-Rapporteur. After approval, the Rapporteur(s)
continue to monitor the product throughout its life cycle. The CHMP has 210 days to adopt an opinion as to whether a marketing authorization
should be granted. The process usually takes longer in case additional information is requested, which triggers clock-stops in the procedural
timelines. The process is complex and involves extensive consultation with the regulatory authorities of member states and a number of
experts. When an application is submitted for a marketing authorization in respect of a drug that is of major interest from the point
of view of public health and in particular from the viewpoint of therapeutic innovation, the applicant may pursuant to Article 14(9) Regulation
(EC) No 726/2004 request an accelerated assessment procedure. If the CHMP accepts such request, the time-limit of 210 days will be reduced
to 150 days but it is possible that the CHMP can revert to the standard time-limit for the centralized procedure if it considers that
it is no longer appropriate to conduct an accelerated assessment. Once the procedure is completed, a European Public Assessment Report,
or EPAR, is produced. If the opinion is negative, information is given as to the grounds on which this conclusion was reached. After the
adoption of the CHMP opinion, a decision on the MAA must be adopted by the European Commission, after consulting the E.U. member states.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Conditional Approval</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In specific circumstances,
E.U. legislation (Article 14(7) Regulation (EC) No 726/2004 and Regulation (EC) No 507/2006 on Conditional Marketing Authorisations for
Medicinal Products for Human Use) enables applicants to obtain a conditional marketing authorization prior to obtaining the comprehensive
clinical data required for an application for a full marketing authorization. Such conditional approvals may be granted for product candidates
(including medicines designated as orphan medicinal products) if (1) the risk-benefit balance of the product candidate is positive, (2)
it is likely that the applicant will be in a position to provide the required comprehensive clinical trial data, (3) the product fulfills
unmet medical needs and (4) the benefit to public health of the immediate availability on the market of the medicinal product concerned
outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization may contain specific
obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or
new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year,
and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified
conditions and/or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review
by the CHMP of applications for a conditional marketing authorization.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Marketing Authorization under Exceptional
Circumstances</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Article 14(8) Regulation
(EC) No 726/2004, products for which the applicant can demonstrate that comprehensive data (in line with the requirements laid down in
Annex I of Directive 2001/83/EC, as amended) cannot be provided (due to specific reasons foreseen in the legislation) might be eligible
for marketing authorization under exceptional circumstances. This type of authorization is reviewed annually to reassess the risk-benefit
balance. The fulfillment of any specific procedures/obligations imposed as part of the marketing authorization under exceptional circumstances
is aimed at the provision of information on the safe and effective use of the product and will normally not lead to the completion of
a full dossier/approval.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 64; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Market Authorizations Granted by Authorities
of E.U. Member States</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, if the centralized
procedure is not followed, there are three alternative procedures as prescribed in Directive 2001/83/EC:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The decentralized procedure allows applicants to file identical applications to several E.U. member states
and receive simultaneous national approvals based on the recognition by E.U. member states of an assessment by a reference member state;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">The national procedure is only available for products intended to be authorized in a single E.U. member state;
and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">A mutual recognition procedure similar to the decentralized procedure is available when a marketing authorization
has already been obtained in at least one E.U. member state.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A marketing authorization
may be granted only to an applicant established in the European Union.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pediatric Studies</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Prior to obtaining a marketing
authorization in the European Union, applicants have to demonstrate compliance with all measures included in an EMA-approved Paediatric
Investigation Plan, or PIP, covering all subsets of the paediatric population, unless the EMA has granted a product-specific waiver, a
class waiver, or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization
procedures are set forth in Regulation (EC) No 1901/2006, which is referred to as the Pediatric Regulation. This requirement also applies
when a company wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized.
The Pediatric Committee of the EMA, or PDCO, may grant deferrals for some medicines, allowing a company to delay development of the medicine
in children until there is enough information to demonstrate its effectiveness and safety in adults. The PDCO may also grant waivers when
development of a medicine in children is not needed or is not appropriate, such as for diseases that only affect the elderly population.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Before a marketing authorization
application can be filed, or an existing marketing authorization can be amended, the EMA determines that companies actually comply with
the agreed studies and measures listed in each relevant PIP.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Periods of Authorization and Renewals</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A marketing authorization
is valid for five years in principle and the marketing authorization may be renewed after five years on the basis of a re-evaluation of
the risk-benefit balance by the competent authority of the authorizing member state. To this end, the marketing authorization holder must
provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including
all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases
to be valid. Once renewed, the marketing authorization is valid for an unlimited period, unless the European Commission or the competent
authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any authorization
which is not followed by the actual placing of the drug on the E.U. market (in case of centralized procedure) or on the market of the
authorizing member state within three years after authorization ceases to be valid (the so-called sunset clause).</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Orphan Drug Designation and Exclusivity</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Regulation (EC)
No 141/2000 and Regulation (EC) No. 847/2000, the European Commission can grant such orphan medicinal product designation to products
for which the sponsor can establish that it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically
debilitating condition affecting not more than five in 10,000 people in the European Union, or a life threatening, seriously debilitating
or serious and chronic condition in the European Union and with regards to that without incentives it is unlikely that sales of the drug
in the European Union would generate a sufficient return to justify the necessary investment. In addition, the sponsor must establish
that there is no other satisfactory method approved in the European Union of diagnosing, preventing or treating the condition, or if such
a method exists, the proposed orphan drug will be of significant benefit to patients.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Orphan drug designation is
not a marketing authorization. It is a designation that provides a number of benefits, including fee reductions, regulatory assistance,
and the possibility to apply for a centralized E.U. marketing authorization, as well as ten years of market exclusivity following a marketing
authorization. During this market exclusivity period, neither the EMA, the European Commission nor the member states can accept an application
or grant a marketing authorization for a &#8220;similar medicinal product.&#8221; A &#8220;similar medicinal product&#8221; is defined
as a medicinal product containing a similar active substance or substances as those contained in an authorized orphan medicinal product
and that is intended for the same therapeutic indication. The market exclusivity period for the authorized therapeutic indication may
be reduced to six years if, at the end of the fifth year, it is established that the orphan designation criteria are no longer met, including
where it is shown that the product is sufficiently profitable not to justify maintenance of market exclusivity. In addition, a competing
similar medicinal product may in limited circumstances be authorized prior to the expiration of the market exclusivity period, including
if the marketing authorization holder is unable to supply sufficient quantities of the product or if the competing product is shown to
be safer, more effective or otherwise clinically superior to the already approved orphan drug. Furthermore, a product can lose orphan
designation, and the related benefits, prior to us obtaining a marketing authorization if it is demonstrated that the orphan designation
criteria are no longer met.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 65; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regulatory Data Protection</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">E.U. legislation also provides
for a system of regulatory data and market exclusivity. According to Article 14(11) of Regulation (EC) No 726/2004, as amended, and Article
10(1) of Directive 2001/83/EC, as amended, upon receiving marketing authorization, new chemical entities approved on the basis of a complete
independent data package benefit from eight years of data exclusivity and an additional two years of market exclusivity. Data exclusivity
prevents regulatory authorities in the European Union from referencing the innovator&#8217;s data to assess a generic (abbreviated) application.
During the additional two-year period of market exclusivity, a generic marketing authorization can be submitted, and the innovator&#8217;s
data may be referenced, but no generic medicinal product can be marketed until the expiration of the market exclusivity. The overall ten-year
period will be extended to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder,
or MAH, obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization,
are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical
entity and the innovator is able to gain the period of data exclusivity, another company nevertheless could also market another version
of the drug if such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical
tests, preclinical tests and clinical trials. However, products designated as orphan medicinal products enjoy, upon receiving marketing
authorization, a period of ten years of orphan market exclusivity&#8212;see also&#160;<i>Orphan Drug Designation and Exclusivity</i>.
Depending upon the timing and duration of the E.U. marketing authorization process, products may be eligible for up to five years&#8217;
supplementary protection certificates, or SPCs, pursuant to Regulation (EC) No 469/2009. Such SPCs extend the rights under the basic patent
for the drug (see below sub&#160;<i>Patent Term Extension</i>).</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Regulatory Requirements After a Marketing
Authorization has been Obtained</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we obtain authorization
for a medicinal product in the European Union, we will be required to comply with a range of requirements applicable to the manufacturing,
marketing, promotion and sale of medicinal products:</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pharmacovigilance and other requirements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We will, for example, have
to comply with the E.U.&#8217;s stringent pharmacovigilance or safety reporting rules, pursuant to which post-authorization studies and
additional monitoring obligations can be imposed. Other requirements relate, for example, to the manufacturing of products and APIs in
accordance with good manufacturing practice standards. E.U. regulators may conduct inspections to verify our compliance with applicable
requirements, and we will have to continue to expend time, money and effort to remain compliant. Non-compliance with E.U. requirements
regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population,
can also result in significant financial penalties in the European Union. Similarly, failure to comply with the E.U.&#8217;s requirements
regarding the protection of individual personal data can also lead to significant penalties and sanctions. Individual E.U. member states
may also impose various sanctions and penalties in case we do not comply with locally applicable requirements.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Manufacturing</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The manufacturing of authorized
drugs, for which a separate manufacturer&#8217;s license is mandatory, must be conducted in strict compliance with the EMA&#8217;s Good
Manufacturing Practices, or cGMP, requirements and comparable requirements of other regulatory bodies in the European Union, which mandate
the methods, facilities and controls used in manufacturing, processing and packing of drugs to assure their safety and identity. The EMA
enforces its current cGMP requirements through mandatory registration of facilities and inspections of those facilities. The EMA may have
a coordinating role for these inspections while the responsibility for carrying them out rests with the member states competent authority
under whose responsibility the manufacturer falls. Failure to comply with these requirements could interrupt supply and result in delays,
unanticipated costs and lost revenues, and could subject the applicant to potential legal or regulatory action, including but not limited
to warning letters, suspension of manufacturing, seizure of product, injunctive action or possible civil and criminal penalties.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Marketing and Promotion</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The marketing and promotion
of authorized drugs, including industry-sponsored continuing medical education and advertising directed toward the prescribers of drugs
and/or the general public, are strictly regulated in the European Union under Directive 2001/83/EC. The applicable regulations aim to
ensure that information provided by holders of marketing authorizations regarding their products is truthful, balanced and accurately
reflects the safety and efficacy claims authorized by the EMA or by the competent authority of the authorizing member state. Failure to
comply with these requirements can result in adverse publicity, warning letters, corrective advertising and potential civil and criminal
penalties.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 66; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Patent Term Extension</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to compensate the
patentee for delays in obtaining a marketing authorization for a patented product, a supplementary certificate, or SPC, may be granted
extending the exclusivity period for that specific product by up to five years. Applications for SPCs must be made to the relevant patent
office in each E.U. member state and the granted certificates are valid only in the member state of grant. An application has to be made
by the patent owner within six months of the first marketing authorization being granted in the European Union (assuming the patent in
question has not expired, lapsed or been revoked) or within six months of the grant of the patent (if the marketing authorization is granted
first). In the context of SPCs, the term &#8220;product&#8221; means the active ingredient or combination of active ingredients for a
medicinal product and the term &#8220;patent&#8221; means a patent protecting such a product or a new manufacturing process or application
for it. The duration of an SPC is calculated as the difference between the patent&#8217;s filing date and the date of the first marketing
authorization, minus five years, subject to a maximum term of five years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A six month pediatric extension
of an SPC may be obtained where the patentee has carried out an agreed pediatric investigation plan, the authorized product information
includes information on the results of the studies and the product is authorized in all member states of the European Union.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">United Kingdom</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The withdrawal of the United
Kingdom (U.K.) from the E.U. took effect on January 1, 2021, and there are 27 member states remaining in the E.U. As of January 1, 2021,
the U.K. is a &#8220;third country&#8221; with regard to the EU (subject to the terms of the EU UK Trade Agreement) and EU law ceased
to apply directly in the UK. However, the U.K. has retained the E.U. regulatory regime with certain modifications as standalone U.K. legislation.
Therefore, the U.K. regulatory regime is currently similar to E.U. regulations, but the U.K. may adopt changed regulations that may diverge
from the E.U. legislative regime for medicines and their research, development and commercialization. For a two-year period starting January
1, 2021, the U.K. has adopted transitional provisions, which&#160;<i>inter alia</i>&#160;apply to the importation of medicines into the
U.K. and rely on certain EMA marketing authorization application procedures.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Israel</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Israel Ministry of the Environment &#8212;
Toxin Permit</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In accordance with the Israeli
Dangerous Substance Law &#8212; 1993, the Ministry of the Environment may grant a permit in order to use toxic materials. Because we utilize
toxic materials in the course of operation of our laboratories, we were required to apply for a permit to use these materials. Our current
toxin permit will remain in effect until March 9, 2023 and is in the process of being renewed.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Other Licenses and Approvals</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have a business license
from the municipality of Petah-Tikva for a drug development research laboratory located at our offices in Petah Tikva, Israel. In order
to obtain this license, we also received approval from the Petah-Tikva Association of Towns Fire Department. The business license is valid
until December 31, 2025 and is in the process of being renewed. We also have a radioactive materials or products containing radioactive
materials license, which is valid until July 25, 2022.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Clinical Testing in Israel</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In order to conduct clinical
testing on humans in Israel, special authorization must first be obtained from the ethics committee and general manager of the institution
in which the clinical studies are scheduled to be conducted, as required under the Guidelines for Clinical Trials in Human Subjects implemented
pursuant to the Israeli Public Health Regulations (Clinical Trials in Human Subjects), as amended from time to time, and other applicable
legislation. These regulations also require authorization from the Israeli Ministry of Health, except in certain circumstances, and in
the case of genetic trials, special fertility trials and similar trials, an additional authorization of the overseeing institutional ethics
committee. The institutional ethics committee must, among other things, evaluate the anticipated benefits that are likely to be derived
from the project to determine if it justifies the risks and inconvenience to be inflicted on the human subjects, and the committee must
ensure that adequate protection exists for the rights and safety of the participants as well as the accuracy of the information gathered
in the course of the clinical testing. Since we intend to perform a portion of the clinical studies on certain of our product candidates
in Israel, we will be required to obtain authorization from the ethics committee and general manager of each institution in which we intend
to conduct our clinical trials, and in most cases, from the Israeli Ministry of Health.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Israel Ministry of Health</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israel&#8217;s Ministry of
Health, which regulates medical testing, has adopted protocols that correspond, generally, to those of the FDA and the EMA, making it
comparatively straightforward for studies conducted in Israel to satisfy FDA and the European Medicines Agency requirements, thereby enabling
medical technologies subjected to clinical trials in Israel to reach U.S. and EU commercial markets in an expedited fashion. Many members
of Israel&#8217;s medical community have earned international prestige in their chosen fields of expertise and routinely collaborate,
teach and lecture at leading medical centers throughout the world. Israel also has free trade agreements with the United States and the
European Union.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 67; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Other Countries</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to regulations
in the United States, the EU and Israel, we are subject to a variety of other regulations governing clinical trials and commercial sales
and distribution of drugs in other countries. Whether or not our products receive approval from the FDA, approval of such products must
be obtained by the comparable regulatory authorities of countries other than the United States before we can commence clinical trials
or marketing of the product in those countries. The approval process varies from country to country, and the time may be longer or shorter
than that required for FDA approval. The requirements governing the conduct of clinical trials and product licensing vary greatly from
country to country.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The requirements that we and
our collaborators must satisfy to obtain regulatory approval by government agencies in other countries prior to commercialization of our
products in such countries can be rigorous, costly and uncertain. In Canada and Australia, regulatory requirements and approval processes
are similar in principle to those in the United States. For example, in Canada, pharmaceutical product candidates are regulated by the
Food and Drugs Act and the rules and regulations promulgated thereunder, which are enforced by Health Canada. Before commencing clinical
trials in Canada, an applicant must complete preclinical studies and file a clinical trial application with Health Canada. After filing
a clinical trial application, the applicant must receive different clearance authorizations to proceed with Phase 1 clinical trials, which
can then lead to Phase 2 and Phase 3 clinical trials. To obtain regulatory approval to commercialize a new drug in Canada, a new drug
submission, or NDS, must be filed with Health Canada. If the NDS demonstrates that the product was developed in accordance with the regulatory
authorities&#8217; rules, regulations and guidelines and demonstrates favorable safety and efficacy and receives a favorable risk/benefit
analysis, Health Canada issues a notice of compliance which allows the applicant to market the product. Facilities, procedures, operations
and/or testing of products are subject to periodic inspection by Health Canada and the Health Products and Food Branch Inspectorate. In
addition, Health Canada conducts pre-approval and post-approval reviews and plant inspections to determine whether systems are in compliance
with the good manufacturing practices in Canada, Drug Establishment Licensing requirements and other provisions of the Food and Drug Regulations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Foreign governments also have
stringent post-approval requirements including those relating to manufacture, labeling, reporting, record keeping and marketing. Failure
to substantially comply with these on-going requirements could lead to government action against the product, our company and/or our representatives.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Related Matters</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, legislation
is drafted, introduced and passed in governmental bodies that could significantly change the statutory provisions governing the approval,
manufacturing and marketing of products regulated by the FDA, the EMA, the Israeli Ministry of Health and other applicable regulatory
bodies to which we are subject. In addition, regulations and guidance are often revised or reinterpreted by the national agency in ways
that may significantly affect our business and our product candidates. It is impossible to predict whether such legislative changes will
be enacted, whether FDA, EMA or Israeli Ministry of Health regulations, guidance or interpretations will change, or what the impact of
such changes, if any, may be. We may need to adapt our business and product candidates and products to changes that occur in the future.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">C.
</span>Organizational Structure</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our corporate structure consists
of Can-Fite and our wholly owned subsidiary, Can-Fite Biopharma Europe, incorporated in France.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">D.
</span>Property, Plants and Equipment</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are headquartered in Petah-Tikva,
Israel. We lease one floor in one facility pursuant to a lease agreement with Eshkolit Nihul Nadlan LTD, an Israeli limited company. Pursuant
to a verbal agreement with the lessor, the lease expires on December 31, 2022. The Petah-Tikva headquarters consists of approximately
300 square meters of space. Lease payments are approximately NIS 20,447, or $6,197, per month. If our lease is terminated, we do not foresee
significant difficulty in leasing another suitable facility. The current facility houses our administrative, clinical and research operations.
The research laboratory consists of approximately 150 square meters and includes a tissue culture laboratory and a molecular biology laboratory.</p><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 68; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_006"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
4A. </span>Unresolved Staff Comments</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not Applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_007"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
5. </span>Operating and Financial Review and Prospects</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The information in this section
should be read in conjunction with our consolidated financial statements and related notes beginning on page F-1 and the related information
included elsewhere in this Annual Report on Form 20-F. Our financial statements are prepared in accordance with U.S. GAAP. We maintain
our accounting books and records in U.S. dollars and our functional currency is the U.S. dollar. Certain amounts presented herein may
not sum due to rounding.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Overview</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a clinical-stage biopharmaceutical
company that develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases
and erectile dysfunction. We are also developing specific formulations of cannabis components for the treatment of cancer, inflammatory,
autoimmune, and metabolic diseases. Our platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic
target. A3AR is highly expressed in pathological body cells such as inflammatory and cancer cells, and has a low expression in normal
cells, suggesting that the receptor could be a specific target for pharmacological intervention. Our pipeline of drug candidates are synthetic,
highly specific agonists and allosteric modulators targeting the A3AR.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product pipeline is based
on the research of Dr. Pnina Fishman, who investigated a clinical observation that tumor metastasis can be found in most body tissues,
but are rarely found in muscle tissue, which constitutes approximately 60% of human body weight. Dr. Fishman&#8217;s research revealed
that one reason that striated muscle tissue is resistant to tumor metastasis is that muscle cells release small molecules which bind with
high selectivity to the A3AR. As part of her research, Dr. Fishman also discovered that A3ARs have significant expression in tumor and
inflammatory cells, whereas normal cells have low or no expression of this receptor. The A3AR agonists and allosteric modulators, currently
our pipeline of drug candidates, bind with high selectivity and affinity to the A3ARs and upon binding to the receptor initiate down-stream
signal transduction pathways resulting in apoptosis, or programmed cell death, of tumors and inflammatory cells and to the inhibition
of inflammatory cytokines. Cytokines are proteins produced by cells that interact with cells of the immune system in order to regulate
the body&#8217;s response to disease and infection. Overproduction or inappropriate production of certain cytokines by the body can result
in disease.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our product candidates, CF101,
CF102 and CF602, are being developed to treat cancer, liver and inflammatory diseases, as well as erectile dysfunction. CF101, also known
as Piclidenoson, is in an advance stage of clinical development for the treatment of autoimmune-inflammatory diseases, including psoriasis.
During 2021, we decided to stop developing Piclidenoson for the treatment of COVID-19 to focus on other indications. CF102, also known
as Namodenoson, is being developed for the treatment of HCC and has orphan drug designation for the treatment of HCC in the United States
and Europe. Namodenoson was granted Fast Track designation by the FDA as a second line treatment to improve survival for patients with
advanced HCC who have previously received Nexavar (sorafenib). Namodenoson is also being developed for the treatment of NASH, a disease
for which no FDA approved therapies currently exist. CF602 is our second-generation allosteric drug candidate for the treatment of erectile
dysfunction, which has shown efficacy in the treatment of erectile dysfunction in preclinical studies and we are investigating additional
compounds, targeting A3AR, for the treatment of erectile dysfunction. Preclinical studies revealed that our drug candidates have potential
to treat additional inflammatory diseases, such as Crohn&#8217;s disease, oncological diseases, viral diseases, such as the JC virus,
and obesity.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe our pipeline of
drug candidates represent a significant market opportunity. For instance, according to iHealthcareAnalyst, the psoriasis drug market is
forecasted to be worth $11.3 billion by 2025. According to DelveInsight, the HCC drug market in the G8 countries (U.S., Germany, France,
Italy, Spain, UK, Japan and China) is expected to reach $3.8 billion by 2027.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have in-licensed an allosteric
modulator of the A3AR, CF602 from Leiden University. In addition, we have out-licensed the following product candidates for indications
that we are currently pursuing:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Piclidenoson for the treatment of (i) psoriasis to Cipher Pharmaceuticals, or Cipher, for Canada, (ii) psoriasis
to Gebro Holding, or Gebro, for Spain, Switzerland and Austria, (iii) psoriasis to CMS Medical, or CMS, for China (including Hong Kong,
Macao and Taiwan), (iv) psoriasis to Kyongbo Pharm Co. Ltd., or Kyongbo Pharm, for South Korea, (v) psoriasis to Ewopharma AG, or Ewopharma,
for Central Eastern Europe, and (vi) osteoarthritis in companion animals including dogs and cats to Vetbiolix.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">Namodenoson for the treatment of (i) liver cancer and NASH to Chong Kun Dang Pharmaceuticals, or CKD, for
South Korea, (ii) advanced liver cancer and NAFLD/NASH to CMS for China (including Hong Kong, Macao and Taiwan), and (iii) HCC and NASH
to Ewopharma, for Central Eastern Europe and Switzerland.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 69; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are currently: (i) completed enrollment in our Phase III trial for
Piclidenoson in the treatment of psoriasis, with topline results expected in the second quarter of 2022, (ii) preparing to commence a
Phase III trial for Namodenoson in the treatment of advanced liver cancer and expect to commence patient enrollment in the first half
of 2022, (ii) conducting a Phase IIb study of Namodenoson in the treatment of NASH, having recently commenced enrollment, (iv) investigating
additional compounds, targeting the A3 adenosine receptor, for the treatment of erectile dysfunction, and (v) developing formulations
of cannabis components for the treatment of diseases in which there is an overexpression of A3AR.Since inception, we have incurred significant
losses in connection with our research and development. As of December 31, 2021, we had an accumulated deficit of approximately $140.7
million. Although we have recognized revenues in connection with our existing out-licensing agreements with KD, Cipher, CKD, Gebro, CMS,
Kyongbo and Ewopharma and our historic out-licensing agreement with SKK, we expect to generate losses in connection with the research
and development activities relating to our pipeline of drug candidates. Such research and development activities are budgeted to expand
over time and will require further resources if we are to be successful. As a result, we expect to incur operating losses, which may be
substantial over the next several years, and we will need to obtain additional funds to further develop or research and development programs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have funded our operations
primarily through the sale of equity securities (both in private placements and in public offerings) and payments received under our existing
out-licensing agreements with KD, Cipher, CKD Gebro, CMS, and Kyongbo and our historic out-licensing agreement with SKK. We expect to
continue to fund our operations over the next several years through our existing cash resources, potential future milestone payments that
we expect to receive from our licensees, interest earned on our investments, if any, and additional capital to be raised through public
or private equity offerings or debt financings. As of December 31, 2021, we had approximately $4.4 million of cash and cash equivalents
and $14.5 million of short-term deposits. A substantial part of this amount is designated for payments to be made in relation to the ongoing
treatment of patients who are currently enrolled in the Company&#8217;s on-going trials.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Revenues</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our revenues to date have
been generated primarily from payments under our existing out-licensing agreements with Kwang Dong, Cipher, CKD, Gebro, CMS and Kyongbo,
and our historic out-licensing agreement with SKK and Ewopharma.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Kwang Dong License
Agreement, we are entitled to up-front and milestone payments of up to $1.5 million. In accordance with the Kwang Dong License Agreement,
we received an up-front payment of $0.3 million and a payment of $0.048 million as consideration for Kwang Dong&#8217;s purchase of our
ordinary shares in 2009 and a milestone payment of $0.2 million in 2010. Under the terms of the Kwang Dong License Agreement, in addition
to the payments mentioned above, we are entitled to certain additional payments based on the sale of raw materials, subject to the terms
and conditions of the respective agreements. To date, we have received a total of $0.5 million from Kwang Dong in an upfront payment.
See &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Out-Licensing and Distribution Agreements&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Distribution and
Supply Agreement with Cipher we received CAD 1.65 million upon execution of the agreement and are entitled to milestone payments upon
receipt of regulatory approval by Health Canada for Piclidenoson and the first delivery of commercial launch quantities as follows (i)
CAD 1 million upon the first approved indication for either psoriasis or rheumatoid arthritis, and (ii) CAD 1 million upon the second
approved indication for either psoriasis or rheumatoid arthritis. In addition, following regulatory approval, we shall be entitled to
a royalty of 16.5% of net sales of Piclidenoson in Canada and reimbursement for the cost of manufacturing Piclidenoson. We are also entitled
to a royalty payment for any authorized generic of Piclidenoson that Cipher distributes in Canada. To date, we have received a total of
$1.3 million (CAD 1.65 million) from Cipher in an upfront payment. See &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Out-Licensing
and Distribution Agreements&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Distribution Agreement
with CKD provides for up to $3,000,000 in upfront and milestone payments payable with respect to the liver cancer indication and up to
$3,000,000 with respect to the NASH indication. In addition, we are entitled to a transfer price of the higher of (a) the manufacturing
cost plus 10% or (b) 23% of net sales of Namodenoson following commercial launch in South Korea. To date, we have received a total of
$2,000,000 from CKD, comprising $1,500,000 in upfront payments for the expansion of CKD&#8217;s existing agreement with us to include
the rights to distribute Namodenoson for the treatment of NASH in South Korea, and a further $500,000 for a milestone payment received
in the third quarter of 2017 upon receipt by CKD of a positive result from the preliminary review by the MFDS, on obtaining orphan drug
designation in South Korea. See &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Out-Licensing and Distribution
Agreements&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In January 2018, we entered
into a Distribution and Supply Agreement with Gebro. The Distribution and Supply Agreement with Gebro provides that we are entitled to
&#8364;1,500,000 upon execution of the agreement plus milestone payments upon achieving certain clinical, launch and sales milestones,
as follows: (i) &#8364;300,000 upon initiation of the ACRobat Phase III clinical trial for the treatment of rheumatoid arthritis and &#8364;300,000
upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis, (ii) between &#8364;750,000 and &#8364;1,600,000
following first delivery of commercial launch quantities of Piclidenson for either the treatment of rheumatoid arthritis or psoriasis,
and (iii) between &#8364;300,000 and up to &#8364;4,025,000 upon meeting certain net sales. In addition, following regulatory approval,
we shall be entitled to double digit percentage royalties on net sales of Piclidenoson in the territories and payment for the manufacturing
Piclidenoson. To date, we have received a total of &#8364;2,100,000 from Gebro in upfront and milestone payments. See &#8220;Item 4. Information
on the Company&#8212;B. Business Overview&#8212;Out-Licensing and Distribution Agreements&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 70; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In August 2018, we entered
into a License, Collaboration and Distribution Agreement with CMS. Under the License, Collaboration and Distribution Agreement, we are
entitled to $2,000,000 upon execution of the agreement plus milestone payments of up to $14,000,000 upon achieving certain regulatory
milestones and payments of up to $58,500,000 upon achieving certain sales milestones. In addition, following regulatory approval, we shall
be entitled to double-digit percentage royalties on net sales of Piclidenoson and Namodenoson in the licensed territories. To date, we
have received a total of $2,000,000 from CMS in upfront and milestone payments. See &#8220;Item 4. Information on the Company&#8212;B.
Business Overview&#8212;Out-Licensing and Distribution Agreements&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In July 2019, we entered
into a License and Distribution Agreement with Kyongbo Pharm. Under the terms of agreement, Kyongbo Pharm, in exchange for exclusive distribution
rights to sell Piclidenoson in the treatment of psoriasis in South Korea, made a total upfront payment of $750,000 to us, with additional
payments of up to $3,250,000 upon achievement of certain milestones. We will also be entitled to a transfer price for delivering finished
product to Kyongbo Pharm. To date, we have received a total of $750,000 from Kyongbo Pharm in upfront and milestone payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March 2021, we signed an
exclusive distribution agreement with Switzerland-based Ewopharma for Piclidenoson in the treatment of psoriasis and Namodenoson in the
treatment of liver diseases namely, HCC, the most common form of liver cancer, and NASH. Under the terms of the distribution agreement,
Ewopharma we received $2.25 million upfront and are entitled to up to an additional $40.45 million payable upon the achievement of regulatory
and sales milestones plus 17.5% royalties on net sales. We will also be entitled to a transfer price for delivering finished product to
Ewopharma. To date, we have received a total of $2,250,000 from Ewopharma in upfront, milestone and royalty payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the terminated SKK license
agreement we received an aggregate of approximately $8.5 million from SKK. See &#8220;Item 4. Information on the Company&#8212;B. Business&#8212;Out-Licensing
and Distribution Agreements&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain payments we have received
from SKK and KD have been subject to a 10% and 5% withholding tax in Japan and Korea, respectively, and certain payments we may receive
in the future, if at all, may also be subject to the same withholding tax in Korea. Receipt of any milestone payment under our out-licensing
agreements depends on many factors, some of which are beyond our control. We cannot assure you that we will receive any of these future
payments. We expect our revenues for the next several years, if any, to be derived primarily from payments under our current out-license
agreements and our public capital raising activities, as well as additional collaborations that we may enter into in the future with respect
to our drug candidates.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Research and Development</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our research and development
expenses consist primarily of salaries and related personnel expenses, fees paid to external service providers, up-front and milestone
payments under our license agreements, patent-related legal fees, costs of preclinical studies and clinical trials, drug and laboratory
supplies and costs for facilities and equipment. We charge all research and development expenses to operations as they are incurred. We
expect our research and development expense to remain our primary expense in the near future as we continue to develop our products. Increases
or decreases in research and development expenditures are attributable to the number and/or duration of the pre-clinical and clinical
studies that we conduct.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table identifies
our current major research and development projects:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 26%; text-align: left; font-weight: bold">Project</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 36%; text-align: center; font-weight: bold">Status</td>
    <td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 36%; text-align: center; font-weight: bold">Expected or Recent Near Term Milestone</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">Piclidenoson</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">COMFORT Phase III study in psoriasis</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Topline results expected in the second quarter of 2022</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">Namodenoson</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Phase III in HCC</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Expect to commence patient enrollment in the first half of 2022</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Phase IIb study in NASH</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Enrollment commenced in January 2022</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We record certain costs for
each development project on a &#8220;direct cost&#8221; basis, as they are recorded to the project for which such costs are incurred.
Such costs include, but are not limited to, CRO expenses, drug production for pre-clinical and clinical studies and other pre-clinical
and clinical expenses. However, certain other costs, including but not limited to, salary expenses (including salaries for research and
development personnel), facilities, depreciation, share-based compensation and other overhead costs are recorded on an &#8220;indirect
cost&#8221; basis, i.e., they are shared among all of our projects and are not recorded to the project for which such costs are incurred.
We do not allocate direct salaries to projects due to the fact that our project managers are generally involved in several projects at
different stages of development, and the related salary expense is not significant to the overall cost of the applicable projects. In
addition, indirect labor costs relating to our support of the research and development process, such as manufacturing, controls, pre-clinical
analysis, laboratory testing and initial drug sample production, as well as rent and other administrative overhead costs, are shared by
many different projects and have never been considered by management to be of significance in its decision-making process with respect
to any specific project. Accordingly, such costs have not been specifically allocated to individual projects.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 71; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Set forth below is a summary
of the gross direct costs allocated to our main projects on an individual basis, as well as the gross direct costs allocated to our less
significant projects on an aggregate basis, for the years ended December 31, 2019, 2020 and 2021; and on an aggregate basis since project
inception:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center">(USD in thousands)</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total Costs</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">Since&#160;Project</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Inception</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; text-indent: -9pt; padding-left: 9pt">Piclidenoson</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">7,348</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">6,046</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">4,041</p></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">43,797</p></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Namodenoson</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,217</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,261</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,991</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,027</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">CF602</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">20</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">31</p></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,734</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Other projects</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">201</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,199</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">-</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">4,129</p></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total gross direct project costs&#160;<sup>(1)</sup></td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9,585</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">9,506</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">8,063</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><p style="margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">65,687</p></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Does not include indirect project costs and overhead, such as
payroll and related expenses (including stock-based compensation), facilities, depreciation and impairment of intellectual property,
which are included in total research and development expenses in our financial statements.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From our inception through
December 31, 2021, we have incurred research and development expenses of approximately $132.45 million. We expect that a large percentage
of our research and development expense in the future will be incurred in support of our current and future preclinical and clinical development
projects. Due to the inherently unpredictable nature of preclinical and clinical development processes and given the early stage of our
preclinical product development projects, we are unable to estimate with any certainty the costs we will incur in the continued development
of the product candidates in our pipeline for potential commercialization. Clinical development timelines, the probability of success
and development costs can differ materially from expectations. We expect to continue to test our product candidates in preclinical studies
for toxicology, safety and efficacy, and to conduct additional clinical trials for each product candidate. If we are not able to enter
into an out-licensing arrangement with respect to any product candidate prior to the commencement of later stage clinical trials, we may
fund the trials for the product candidates ourselves.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While we are currently focused
on advancing each of our product development projects, our future research and development expenses will depend on the clinical success
of each product candidate, as well as ongoing assessments of each product candidate&#8217;s commercial potential. In addition, we cannot
forecast with any degree of certainty which product candidates may be subject to future out-licensing arrangements, when such out-licensing
arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As we obtain results from
clinical trials, we may elect to discontinue or delay clinical trials for certain product candidates or projects in order to focus our
resources on more promising product candidates or projects. Completion of clinical trials by us or our licensees may take several years
or more, but the length of time generally varies according to the type, complexity, novelty and intended use of a product candidate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of clinical trials
may vary significantly over the life of a project as a result of differences arising during clinical development, including, among others:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">the number of sites included in the clinical trials;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">the length of time required to enroll suitable patients;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">the number of patients that participate in the clinical trials;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">the duration of patient follow-up;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">the development stage of the product candidate; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">the efficacy and safety profile of the product candidate.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We expect our research and
development expenses to increase in the future from current levels as we continue the advancement of our clinical trials and preclinical
product development and to the extent we in-license new product candidates. The lengthy process of completing clinical trials and seeking
regulatory approval for our product candidates requires expenditure of substantial resources. Any failure or delay in completing clinical
trials, or in obtaining regulatory approvals, could cause a delay in generating product revenue and cause our research and development
expenses to increase and, in turn, have a material adverse effect on our operations. Because of the factors set forth above, we are not
able to estimate with any certainty when we would recognize any net cash inflows from our projects.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">General and Administrative Expenses</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses consist primarily of compensation for employees in executive and operational functions, including accounting, finance, legal,
business development, investor relations, information technology and human resources. Other significant general and administration costs
include facilities costs, professional fees for outside accounting and legal services, travel costs, insurance premiums and depreciation.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 72; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Financial Expense and Income</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial expense and income
consists of interest earned on our cash and cash equivalents; bank fees and other transactional costs; expense or income resulting from
fluctuations of the NIS and other currencies, in which a portion of our assets and liabilities are denominated, against the U.S. dollar
(our functional currency).</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Critical Accounting Policies and Estimates</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our accounting policies and
their effect on our financial condition and results of operations are more fully described in our audited consolidated financial statements
included elsewhere in this Annual Report on Form 20-F. The preparation of financial statements in conformity with U.S. GAAP as issued
by the Financial Accounting Standards Board (FASB) requires management to make estimates and assumptions that in certain circumstances
affect the reported amounts of assets and liabilities, revenues and expenses and disclosure of contingent assets and liabilities. These
estimates are prepared using our best judgment, after considering past and current events and economic conditions. While management believes
the factors evaluated provide a meaningful basis for establishing and applying sound accounting policies, management cannot guarantee
that the estimates will always be consistent with actual results. In addition, certain information relied upon by us in preparing such
estimates includes internally generated financial and operating information, external market information, when available, and when necessary,
information obtained from consultations with third party experts. Actual results could differ from these estimates and could have a material
adverse effect on our reported results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that the accounting
policies discussed below are critical to our financial results and to the understanding of our past and future performance, as these policies
relate to the more significant areas involving management&#8217;s estimates and assumptions. We consider an accounting estimate to be
critical if: (1) it requires us to make assumptions because information was not available at the time or it included matters that were
highly uncertain at the time we were making our estimate; and (2) changes in the estimate could have a material impact on our financial
condition or results of operations.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Functional and Presentation Currency</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our functional and presentation
currency is the U.S. dollar (&#8220;dollar&#8221;, &#8220;USD&#8221; or &#8220;$&#8221;) since the USD is the primary currency of the
economic environment in which we operate.</p><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Principles of Consolidation</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our financial statements
reflect the consolidation of the financial statements of companies that we control based on legal control or effective control. We fully
consolidate into our financial statements the results of operations of companies that we control. Legal control exists when we have the
power, directly or indirectly, to govern the financial and operating policies of an entity. The effect of potential voting rights that
are exercisable at the balance sheet date are considered when assessing whether we have legal control. In addition, we consolidate on
the basis of effective control even if we do not have voting control.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 73; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Revenue Recognition</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We generate income from distribution
agreements. See &#8220;Item 4. Information on the Company&#8212;B. Business&#8212;Out-Licensing and Distribution Agreements&#8221;. Such
income comprises of upfront license fees, milestone payments and potential royalty payments.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We recognize revenue in accordance
with ASC 606, &#8220;Revenue from Contracts with Customers&#8221; pursuant to which each required deliverable is evaluated to determine
whether it qualifies as a separate unit of accounting based on whether the deliverable has &#8220;stand-alone value&#8221; to the customer.
The arrangement&#8217;s consideration that is fixed or determinable is then allocated to each separate unit of accounting based on the
relative selling price of each deliverable which is based on the Estimated Selling Price.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our contracts generally include
three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of an exclusive
licensing to distribute the product, once available; and, (iii) participation in joint steering committee.&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our contracts also include
development milestones payments and future sales-based royalties. Development milestones payments are recognized only to the extent that
it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated
with those milestones is subsequently resolved. As such sales based royalties are recognized only when the subsequent sale occurs. We
have not yet received the required regulatory approvals for our products and we have not yet recognized any sales-based royalties.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenue from supply and distribution
agreements with customers are recognized over time as we satisfy the performance obligations. We usually accept long-term upfront payment
from our customers. Contract liabilities for those upfront payments are recognized as revenue over time.</p><div>
</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues from milestone payments:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Contingent payments related
to milestones will be recognized immediately upon satisfaction of the milestone and contingent payments related to royalties will be recognized
in the period that the related sales have occurred.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Revenues from royalties:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenues from royalties will
be recognized as they accrue in accordance with the terms of the relevant agreement.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Share-based Compensation</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We account for share-based
compensation arrangements in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221; (&#8220;ASC 718&#8221;), which requires
companies to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the
portion of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#8217;s
consolidated statement of comprehensive loss. We recognize compensation expenses for the value of its awards granted based on the vesting
attribution approach over the requisite service period of each of the awards, net of estimated forfeitures. ASC 718 requires forfeitures
to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We selected the binomial option
pricing model as the most appropriate method for determining the estimated fair value of our share-based awards without market conditions.
The determination of the grant date fair value of options using an option pricing model is affected by estimates and assumptions regarding
a number of complex and subjective variables. These variables include the expected volatility of our share price over the expected term
of the options, share option exercise and forfeiture rate, risk-free interest rates, expected dividends and the price of our ordinary
shares on the TASE. As our ordinary shares are publicly traded on the TASE, we do not need to estimate the fair value of our ordinary
shares. Rather, we use the actual closing market price of our ordinary shares on the date of grant, as reported by the TASE although in
the future may use the closing market price of our ADSs on the date of grant, as reported by the NYSE American.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If any of the assumptions
used in the binomial option pricing model change significantly, share-based compensation for future awards may differ materially compared
with the awards previously granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As for other service providers,
the cost of the transactions is measured at the fair value of the goods or services received as consideration for equity instruments.
In cases where the fair value of the goods or services received as consideration of equity instruments cannot be measured, they are measured
by reference to the fair value of the equity instruments granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The cost of equity-settled
transactions is recognized in profit or loss, together with a corresponding increase in equity, during the period which the service are
to be satisfied, ending on the date on which the relevant employees or other service providers become fully entitled to the award.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 74; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we modify the conditions
on which equity-instruments are granted, an additional expense is recognized for any modification that increases the total fair value
of the share-based payment arrangement or is otherwise beneficial to the employee or other service provider at the modification date.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Recently Issued Accounting Pronouncements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In June 2016, the FASB issued
ASU No. 2016-13, Financial Instruments &#8211; Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which
replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized
cost to be presented at the net amount expected to be collected. The adoption of the standard did not have material effect on our results.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="text-align: justify; margin: 0pt 0; font: 10pt Times New Roman, Times, Serif">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic
740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing a variety of exceptions
within the framework of ASC 740. These exceptions include the exception to the incremental approach for intraperiod tax allocation in
the event of a loss from continuing operations and income or a gain from other items (such as other comprehensive income), and the exception
to using general methodology for the interim period tax accounting for year-to-date losses that exceed anticipated losses. The adoption
of the standard did not have a material effect on our results.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Recent Offerings</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 18, 2019, we
sold to a single institutional investor an aggregate 149,206 ADSs in a registered direct offering at $15.75 per ADS, resulting in
gross proceeds of $2,350,000. In addition, we issued to the investor unregistered warrants to purchase 149,206 ADSs in a private
placement. The warrants are immediately exercisable from the date of issuance for a period of five and a half years and have an
exercise price of $19.50 per ADS, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if
six months after issuance there is no effective registration statement registering the ADSs underlying the warrants. We paid an
aggregate of $428,000 in placement agent fees and other expenses and issued unregistered placement agent warrants to purchase 7,460
ADS on the same terms as the warrants except they have a term of five years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On April 4, 2019, we sold
to certain institutional investors an aggregate 328,205 ADSs in a registered direct offering at $9.75 per ADS, resulting in gross proceeds
of $3,200,000. In addition, we issued to the investors unregistered warrants to purchase 328,205 ADSs in a private placement. The warrants
are immediately exercisable and will expire five years from issuance at an exercise price of $12.90 per ADS, subject to adjustment as
set forth therein. The warrants may be exercised on a cashless basis if six months after issuance there is no effective registration statement
registering the ADSs underlying the warrants. We paid an aggregate of $242,000 in placement agent fees and expenses and issued unregistered
placement agent warrants to purchase 16,410 ADS on the same terms as the warrants except they have a term of five years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On May 22, 2019, we sold to
certain institutional investors an aggregate of 1,500,000 ADSs in a registered direct offering at $4.00 per ADS, resulting in gross proceeds
of $6,000,000. In addition, we issued to the investors unregistered warrants to purchase an aggregate of 1,500,000 ADSs in a private placement.
The warrants are immediately exercisable and will expire five and one-half years from issuance at an exercise price of $4.00 per ADS,
subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if six months after issuance there is no
effective registration statement registering the ADSs underlying the warrants. We paid an aggregate of $410,000 in placement agent fees
and expenses and issued unregistered placement agent warrants to purchase 75,000 ADS on the same terms as the warrants except they have
a term of five years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On January 9, 2020, we entered
into warrant exercise agreements, or the Exercise Agreements, with several accredited investors who are the holders, or the Holders, of
warrants issued in September 2015, October 2015, March 2018, January 2019, and April 2019 or the Public Warrants, to purchase our ordinary
shares, represented by ADS, pursuant to which the Holders agreed to exercise in cash their Public Warrants to purchase up to an aggregate
of 22,278,540 ordinary shares represented by 742,618 ADSs having exercise prices ranging from $12.90 to $78.75 per ADS issued by us, at
a reduced exercise price of $3.25 per ADS, resulting in gross proceeds of approximately $2.4 million. Closing occurred on January 13,
2020. Under the Exercise Agreements, we also issued to the Holders new unregistered warrants to purchase up to 22,278,540 ordinary shares
represented by 742,618 ADSs, or the Private Placement Warrants. The Private Placement Warrants are immediately exercisable, expire five
and one-half years from issuance date and have an exercise price of $3.45 per ADS, subject to adjustment as set forth therein. The Private
Placement Warrants may be exercised on a cashless basis if six months after issuance there is no effective registration statement registering
the ADSs underlying the warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On February 12, 2020, we sold
to certain institutional investors an aggregate of (i) 1,825,000 units, or Units, each Unit consisting of one ADS, and one warrant to
purchase one ADS, or the Warrant, at a price of $1.50 per Unit, and (ii) 1,508,334 pre-funded units, or the Pre-funded Units, each Pre-funded
Unit consisting of one pre-funded warrant to purchase one ADS, or the Pre-funded Warrant, and one Warrant, at a price of $1.49 per Pre-funded
Unit, in a public offering, resulting in gross proceeds of approximately $5.0 million. Each Pre-funded Warrant contained in a Pre-funded
Unit is immediately exercisable for one ADS at an exercise price of $0.001 per share and remains exercisable until exercised in full.
The Warrants included in the Units and the Pre-funded Units are immediately exercisable at a price of $1.50 per ADS, subject to adjustment
in certain circumstances, and expire five years from the date of issuance. We paid an aggregate of $315,000 in placement agent fees and
expenses and issued placement agent warrants to purchase 250,000 ADS on the same terms as the warrants except they have a term of five
years and have an exercise price of $1.875.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In March, April and May 2020,
we issued an aggregate of 51,250,020 ordinary shares represented by 1,708,334 ADSs in exchange for exercise of warrants. Total consideration
received by us was approximately $2,562,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 75; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On June 12, 2020, we sold to several institutional and accredited investors
an aggregate of 117,073,200 ordinary shares represented by 3,902,440 ADSs in a registered direct offering at $2.05 per ADS, resulting
in gross proceeds of approximately $8.0 million. In addition, we issued to the investors unregistered warrants to purchase up to an aggregate
of 1,951,220 ADSs in a private placement. The warrants are immediately exercisable and will expire four and one-half years from the issuance
date at an exercise price of $2.50 per ADS, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis
if there is no effective registration statement registering the ADSs underlying the warrants. We paid an aggregate of $600,000 in placement
agent fees and expenses and issued unregistered placement agent warrants to purchase up to 292,683 ADS on the same terms as the warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On July 8, 2020, we sold to several institutional and accredited investors
an aggregate of 51,165,000 ordinary shares represented by 1,705,500 ADSs in a registered direct offering at $2.00 per ADS, resulting in
gross proceeds of approximately $3.4 million. In addition, we issued to the investors unregistered warrants to purchase up to an aggregate
of 852,750 ADSs in a private placement. The warrants are immediately exercisable and will expire four and one-half years from the issuance
date at an exercise price of $2.50 per ADS, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis
if there is no effective registration statement registering the ADSs underlying the warrants. We paid an aggregate of $255,825 in placement
agent fees and expenses and issued unregistered placement agent warrants to purchase up to 127,913 ADS on the same terms as the warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February and March 2021, we issued 50,926,830 ordinary shares represented
by 1,697,561 ADSs in exchange for exercise of warrants. Total consideration received by us was approximately $2,744,000.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 16, 2021, we sold
to an institutional investor an aggregate of (i) 57,000,000 ordinary shares represented by 1,900,000 ADSs at $2.00 per ADS, and (ii) 93,000,000
ordinary shares represented by 3,100,000 pre-funded warrant to purchase one ADS, or Pre-funded Warrants, at a price of $1.99 per Pre-funded
Warrant, in a registered direct offering. Each Pre-funded Warrant is immediately exercisable for one ADS at an exercise price of $0.001
per share and remains exercisable until exercised in full. In addition, we issued to the investors unregistered warrants to purchase 150,000,000
ordinary shares represented by 5,000,000 ADSs in a private placement. The warrants are immediately exercisable and will expire three years
from the effectiveness of an initial resale registration statement registering the ordinary shares issuable upon the exercise of the warrants.
We paid on aggregate of $700,000 in placement agent fees and expenses and issued placement agent warrants in an amount equal to 7.0% of
the aggregate number of ADSs sold in the offering (or warrants to purchase up to an aggregate of 350,000 ADSs), at an initial exercise
price equal to $2.00 per ADS, on substantially the same terms as the investor warrants, except that the placement agent warrants expire
on the earlier of (i) the third-year anniversary of the date on which an initial resale registration statement registering the ordinary
shares (or the ADSs) issuable upon the exercise of the warrants becomes effective and (ii) August 11, 2026.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On December 20, 2021, we entered
into a warrant exercise agreement, or the Exercise Agreement, with an institutional investor, or the Holder, of warrants issued in August
2021, or the Warrants, to purchase ordinary shares, represented by ADS, pursuant to which the Holder agreed to exercise in cash its Warrant
to purchase up to an aggregate of 150,000,000 ordinary shares represented by 5,000,000 ADSs having an exercise price of $2.00 per ADS,
at an exercise price of $2.00 per ADS, resulting in gross proceeds of $10.0 million. Closing occurred on December 23, 2021. Under the
Exercise Agreement, we also issued to the Holder new unregistered warrants to purchase up to 180,000,000 ordinary shares represented by
6,000,000 ADSs, or the Private Placement Warrants. The Private Placement Warrants are immediately exercisable, expire five years following
the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants and have
an exercise price of $2.00 per ADS, subject to adjustment as set forth therein. We paid an aggregate of $875,000 in placement agent fees
and expenses and issued unregistered placement agent warrants to purchase 350,000 ADS on the same terms as the warrant.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">A.
</span>Results of Operations</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Comparison of the Year Ended December 31, 2021
to Year Ended December 31, 2020</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenues</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenues for the year ended
December 31, 2021 were $0.85 million, an increase of $0.09 million, or 12%, compared to $0.76 million for the year ended December 31,
2020. The increase in revenues was mainly due to the recognition a portion of advance payment received under Ewopharma distribution agreement
entered in 2021 which was set off by recognition of a lower portion of advance payments received under distribution agreements from Gebro,
Chong Kun Dung Pharmaceuticals, and Cipher Pharmaceuticals.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
expenses</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
for the year ended December 31, 2021 were $9.85 million, a decrease of $2.1 million, or 17%, compared to $11.95 million for the year ended
December 31, 2020. Research and developments expenses for the year ended 2021 comprised primarily of expenses associated with two studies
for Piclidenoson, a Phase III study in the treatment of psoriasis and a Phase II study in COVID-19 and Phase II studies for Namodenoson
in the treatment of liver cancer and NASH. The decrease is primarily due to costs incurred in 2020 associated with Univo research project
which was completed by the end of that year, a Phase III study of Piclidenoson for the treatment of rheumatoid arthritis which was ongoing
during 2020, partially offset by pre-clinical projects and the two ongoing studies of Piclidenoson. We expect that the research and development
expenses will increase through 2022 and beyond.</p><div>
</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 76; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses were $3.84 million for the year ended December 31, 2021 an increase of $0.89 million, or 30%, compared to $2.95 million for the
year ended December 31, 2020. The increase is primarily due to the increase in salaries and related benefits due to the distribution of
bonuses to employees, increase in public relationship expenses and insurance expenses. We expect that general and administrative expenses
will remain at the same level through 2022.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial income
(expenses), net</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial income, net for
the year ended December 31, 2021 aggregated $0.23 million compared to financial expense, net of $0.3 million for the year ended December
31, 2020. The decrease in financial expense, net was mainly due to increase in the revaluation of our short-term investment.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Comparison of the Year Ended December 31, 2020
to Year Ended December 31, 2019</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenues</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Revenues for the year ended
December 31, 2020 were $0.76 million, a decrease of $1.27 million, or 63%, compared to $2.03 million for the year ended December 31, 2019.
The decrease in revenues was mainly due to the recognition of a lower portion of advance payments received under distribution agreements
from Gebro, Chong Kun Dung Pharmaceuticals, and Cipher Pharmaceuticals.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development
expenses</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Research and development expenses
for the year ended December 31, 2020 were $11.95 million, an increase of $0.98 million, or 8.9%, compared to $10.97 million for the year
ended December 31, 2019. Research and developments expenses for the year ended 2020 comprised primarily of expenses associated with the
Phase II studies for Namodenoson in the treatment of NASH and HCC, as well as expenses for ongoing Phase III studies of Piclidenoson in
the treatment of rheumatoid arthritis and psoriasis. The increase is primarily due to increased costs for the Phase III clinical trial
of Piclidenoson for the treatment of rheumatoid arthritis and for psoriasis. We expect that the research and development expenses will
increase through 2021 and beyond.</p><div>
</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">General and administrative
expenses were $2.95 million for the year ended December 31, 2020 a decrease of $0.11 million, or 3.6%, compared to $3.06 million for the
year ended December 31, 2019. The decrease is primarily due to the decrease is primarily due to is primarily due to a decrease in professional
services and travel expenses which was partly offset by an increase in salaries and related benefits and insurance expenses. We expect
that general and administrative expenses will remain at the same level through 2021.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial income,
net</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Financial expense, net for
the year ended December 31, 2020 aggregated $0.3 million compared to $0.6 million for the year ended December 31, 2019. The decrease in
financial expense, net was mainly due to decrease in the revaluation of our short-term investment.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 77; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">B.
</span>Liquidity and Capital Resources</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Since inception, we have funded
our operations primarily through public (in Israel and the United States) and private offerings of our equity securities and payments
received under our strategic licensing arrangements. As of December 31, 2021, we had approximately $4.39 million in cash and cash equivalents
and $14.51 million in short-term deposits. We have invested most of our available cash funds in ongoing cash accounts and short-term deposits.
In August 2021, we raised approximately $10.0 million from a registered direct offering, and in December 2021, we raised approximately
$10.0 million from the exercise of warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may be able to use U.S.
taxes withheld as credits against Israeli corporate income tax when we have income, if at all, but there can be no assurance that we will
be able to realize the credits. In addition, we believe that we may be entitled to a refund of such withholding tax from the U.S. government
but there can be no assurance that we will be entitled to such a refund. For information regarding the revenues and expenses associated
with our licensing agreements, see &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;Out-Licensing and Distribution
Agreements&#8221;, &#8220;Item 4. Information on the Company&#8212;B. Business Overview&#8212;In-Licensing Agreements&#8221; and &#8220;Item
5. Operating and Financial Review and Prospects&#8212;Revenues.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in operating activities was $9.85 million for the year
ended December 31, 2021, compared with net cash used in operating activities of $12.0 million and $11.0 million for the years ended December
31, 2020 and 2019, respectively. The $2.15 million decrease in the net cash used in operating activities during 2021, compared to 2020,
was primarily the result of $1.8 million decrease in net loss, $1.95 million change in trade payables, $1.7 million change in deferred
revenues and $0.8 change in other accounts payable, which were offset by a decrease of $4.1 million in prepaid expenses and other current
assets. The $1.0 million increase in the net cash used in operating activities during 2020, compared to 2019, was primarily the result
of $1.8 million increase in net loss, $2.7 million decrease in trade payables and $0.5 million decrease in deferred revenues which were
offset by an increase of $4.0 increase in prepaid expenses, and other current assets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash used in investing
activities for the year ended December 31, 2021 was $14.5 million compared to net cash used in investing activities of $0.03 million and
$0.003 million for the years ended December 31, 2020 and December 31, 2019, respectively. The changes in cash flows from investing activities
was primarily result of investment of $14.5 million in short-term deposits in 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Net cash provided by financing
activities for the year ended December 31, 2021 was $20.4 million, compared to $17.7 million for the year ended December 31, 2020 and
$10.1 million of net cash provided by financing activities for the year ended December 31, 2019. The increase in net cash provided by
financing activities during 2021 compared to 2020 was due to increase in issuance of shares and warrants, net of issuance expenses during
2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Developing drugs, conducting
clinical trials and commercializing products is expensive and we will need to raise substantial additional funds to achieve our strategic
objectives. Although we believe our existing financial resources as of the date of issuance of this Annual Report on Form 20-F, will be
sufficient to fund our projected cash requirements at least through the end of the next twelve months, we will require significant additional
financing to fund our operations. Additional financing may not be available on acceptable terms, if at all. Our future capital requirements
will depend on many factors, including:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the level of research and development investment required to develop our product candidates;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the failure to obtain regulatory approval or achieve commercial success of our product candidates, including
Piclidenoson, Namodenoson and CF602;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the results of our preclinical studies and clinical trials for our earlier stage product candidates, and
any decisions to initiate clinical trials if supported by the preclinical results;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the costs, timing and outcome of regulatory review of our product candidates that progress to clinical trials;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our issued
patents and defending intellectual property-related claims;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the cost of commercialization activities if any of our product candidates are approved for sale, including
marketing, sales and distribution costs;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the cost of manufacturing our product candidates and any products we successfully commercialize;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">the timing, receipt and amount of sales of, or royalties on, our future products, if any;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in"></p><div>

</div><!-- Field: Page; Sequence: 78; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">the expenses needed to attract and retain skilled personnel;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">any product liability or other lawsuits related to our products;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">the extent to which we acquire or invest in businesses, products or technologies and other strategic relationships;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the costs of financing unanticipated working capital requirements and responding to competitive pressures;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">maintaining minimum shareholders&#8217; equity requirements under the NYSE American Company Guide; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: justify">the impact of the COVID-19 outbreak and the Russian invasion of Ukraine, which may exacerbate the magnitude
of the factors discussed above.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Until we can generate significant
continuing revenues, we expect to satisfy our future cash needs through payments received under our license agreements, debt or equity
financings, or by out-licensing other product candidates. We cannot be certain that additional funding will be available to us on acceptable
terms, or at all. If funds are not available, we may be required to delay, reduce the scope of, or eliminate one or more of our research
or development programs or our commercialization efforts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">The following table summarizes
our significant contractual obligations in U.S. dollars as of December 31, 2021:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Total</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>Less than <br/>
1&#160;year</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>1-3&#160;years</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>3-5&#160;years</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-size: 10pt"><b>More than <br/>
5&#160;years</b></span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td><span style="font-size: 10pt">Contractual Obligations</span></td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 40%"><span style="font-size: 10pt">Leiden University milestones<sup>(1)</sup></span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">124,498</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">11,318</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">113,180</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 9%; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt"><span style="font-size: 10pt">Car lease obligations</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">155,430</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">66,526</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">88,903</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 4pt"><span style="font-size: 10pt">Total</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">279,928</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">77,844</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">202,083</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: black 4.5pt double">&#160;</td>
    <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-size: 10pt">-</span></td>
    <td style="padding-bottom: 4pt">&#160;</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 0px">&#160;</td>
    <td style="width: 24px"><span style="font-size: 10pt">(1)</span></td>
    <td style="text-align: justify"><span style="font-size: 10pt">Includes a &#8364;10,000 annual royalty and &#8364;50,000 upon the initiation of a Phase I study. We will update our milestone payment obligations upon releasing the Phase I data from such study. As such, the obligations above do not include a potential milestone payment of &#8364;100,000 upon the initiation of a Phase II study, &#8364;200,000 upon the initiation of a Phase III study or &#8364;500,000 upon marketing approval by any regulatory authority.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Other than as described above,
we did not have any material commitments for capital expenditures, including any anticipated material acquisition of plant and equipment
or interests in other companies, as of December 31, 2021.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">C.
</span>Research and Development, Patents and Licenses, Etc.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For information concerning
our research and development policies and a description of the amount spent during each of the last three fiscal years on company-sponsored
research and development activities, see &#8220;Item 5. Operating and Financial Review and Prospects&#8212; Results of Operation.&#8221;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">D.
</span>Trend Information</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a development stage
company and it is not possible for us to predict with any degree of accuracy the outcome of our research, development or commercialization
efforts. As such, it is not possible for us to predict with any degree of accuracy any known trends, uncertainties, demands, commitments
or events that are reasonably likely to have a material effect on our net sales or revenues, income from continuing operations, profitability,
liquidity or capital resources, or that would cause reported financial information to not necessarily be indicative of future operating
results or financial conditions. However, to the extent possible, certain trends, uncertainties, demands, commitments and events are in
this &#8220;Operating and Financial Review and Prospects.&#8221;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">E.
</span>Critical Accounting Estimates</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We prepare our financial statements
in accordance with U.S. GAAP. In doing so, we must make estimates and assumptions that affect our reported amounts of assets, liabilities
and expenses, as well as related disclosure of contingent assets and liabilities. In some cases, we could reasonably have used different
accounting policies and estimates. Changes in the accounting estimates are reasonably likely to occur from period to period. Accordingly,
actual results could differ materially from our estimates. To the extent that there are material differences between these estimates and
actual results, our financial condition or results of operations will be affected. Significant estimates include, but are not limited
to, those related to deferred revenue, revenue recognition, stock-based compensation and fair value of marketable debt securities. For
further significant accounting policies please see Note 2 to our audited consolidated financial statements of this annual report. We believe
that our accounting policies contained therein are critical in fully understanding and evaluating our financial condition and operating
results.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 79; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_008"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
6. </span>Directors, Senior Management and Employees</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">A.
</span>Directors and Senior Management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
our directors and senior management:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 36%; text-align: left; font-weight: bold">Member</td>
    <td style="width: 1%; text-align: justify">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 10%; text-align: center; font-weight: bold">Age</td>
    <td style="width: 1%; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; width: 52%; text-align: center; font-weight: bold">Position</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">Ilan Cohn, Ph.D.</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">66</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Chairman of the Board</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">Pnina Fishman, Ph.D.</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">73</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Chief Executive Officer, Director</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">Motti Farbstein</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">58</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Chief Operating and Financial Officer</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">Sari Fishman, Ph.D.</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">50</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">VP of Business Development</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">Guy Regev(1)(2)(3)(4)(5)</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">52</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Director</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">Abraham Sartani, M.D.(4)</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">75</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Director</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">Yoseph Bornstein</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">64</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Director</td></tr>
  <tr style="vertical-align: top; ">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: left">Yaacov Goldman (1)(2)(3)(4)(5)</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: center">66</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Director</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Member of the Compensation Committee</td>
</tr><tr style="vertical-align: top; text-align: justify">
<td><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 8pt">&#160;</span></td></tr>

<tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">Member of the Audit Committee</td>
</tr><tr style="vertical-align: top; text-align: justify">
<td><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 8pt">&#160;</span></td></tr>

<tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: justify">External Director under Israeli Law</td>
</tr><tr style="vertical-align: top; text-align: justify">
<td><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 8pt">&#160;</span></td></tr>

<tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(4)</td><td style="text-align: justify">Independent Director under Israeli Law</td>
</tr><tr style="vertical-align: top; text-align: justify">
<td><span style="font-size: 8pt">&#160;</span></td><td style="text-align: left"><span style="font-size: 8pt">&#160;</span></td><td style="text-align: justify"><span style="font-size: 8pt">&#160;</span></td></tr>

<tr style="vertical-align: top; text-align: justify">
<td style="width: 0in"></td><td style="width: 0.25in; text-align: left">(5)</td><td style="text-align: justify">Independent Director under the NYSE American rules</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Ilan Cohn, Ph.D.&#160;</i></b>Ilan
Cohn, Ph.D. is a patent attorney and a founding partner at the patent attorney firm Cohn, de Vries, Stadler &amp; Co. since December 2020.
Previously, Dr. Cohen was a senior partner at Reinhold Cohn and Partners, where he has been an attorney since 1986. Dr. Cohn co-founded
Can-Fite, served as its Chief Executive Officer until September 2004, served on our Board of Directors since 1994 and since May 30, 2013
serves as the Chairman of the Can-Fite Board of Directors. Dr. Cohn has also been a director of OphthaliX since November 21, 2011. Dr.
Cohn holds a Ph.D. in biology and is a patent attorney with many years of experience in the biopharmaceutical field. He has served on
the Board of Directors of a number of life science companies, including Discovery Laboratories Inc. (formerly Ansan Pharmaceuticals),
a U.S. public company. Dr. Cohn has also been involved in the past in management of venture capital funds focused on investments in the
life sciences industry. Dr. Cohn served a number of years as a co-chairman of the Biotech Committee of the US-Israeli Science and Technology
Commission. Dr. Cohn is also currently a member of the Board of Directors of I.C.R.C. Management Ltd, Famillion BVI Ltd. and Famillion
Ltd. (a subsidiary of Famillion BVI Ltd.). Dr. Cohn holds a Ph.D. in Biology from the Hebrew University of Jerusalem.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Pnina Fishman, Ph.D.</i></b>&#160;Pnina
Fishman, Ph.D. co-founded Can-Fite and has served as our Chief Executive Officer and served on our Board of Directors since September
2005. Dr. Fishman is the scientific founder of Can-Fite and was previously a professor of Life Sciences and headed the Laboratory of
Clinical and Tumor Immunology at the Felsenstein Medical Research Institute, Rabin Medical Center, Israel. Dr. Fishman has authored or
co-authored over 150 publications and presented the findings of her research at many major scientific meetings. Her past managerial experience
included seven years as Chief Executive Officer of Mor Research Application, the technology transfer arm of Clalit Health Services, the
largest healthcare provider in Israel. Mor Research Application was also the first clinical research organization in Israel. Dr. Fishman
currently also serves as a member of the Board of Directors of F.D Consulting Ltd., and Eye-Fite Ltd. Dr. Fishman holds a Ph.D. in Immunology
from the Bar Ilan University in Ramat Gan, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 80; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Motti Farbstein</i></b>.
Motti Farbstein has been with Can-Fite since 2003. Mr. Farbstein served as our Chief Operating Officer from August 2003 until May 2005
and from that date onwards he served as Chief Operating and Financial Officer. Mr. Farbstein also serves as a director of Eye-Fite Ltd.
since July 2011. Mr. Farbstein&#8217;s past managerial experience includes seven years as Vice President of Mor Research Application,
a company that managed the commercialization of the intellectual property of all hospitals and research centers affiliated with Clalit
Health Services, which is the largest healthcare provider in Israel and was Israel&#8217;s first clinical CRO. Mr. Farbstein also has
extensive experience in the data management of clinical trials.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Sari Fishman, Ph.D</i>.&#160;</b>Sari
Fishman, Ph.D. has served as our Director Clinical Affairs from 2004 to 2014, Director of Business Development from 2014 to 2017 and since
2017 serves as VP of Business Development. Dr. Fishman gained her Ph.D. at the Bar-Ilan University, Ramat-Gan, Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Abraham Sartani, M.D.</i></b>&#160;Abraham
Sartani has served on our Board of Directors since 2001. Dr. Sartani has over 30 years of experience in the pharmaceuticals industry and
currently acts as a consultant to pharmaceutical and medical device companies. Dr. Sartani is a member of a number of scientific and management
societies and the author or co-author of numerous publications and patents in the urology, pain treatment and hypertension fields. Dr.
Sartani previously served on the Board of Directors of Akkadeas Pharma Srl (formerly Arkadia Pharma) and was a co-founder. From 1985 until
2008, Dr. Sartani was the Vice-President of R&amp;D and Licensing and Group coordinator of B&amp;D of Recordati, a European specialty
pharmaceutical company. Prior to joining Recordati, from 1980 until 1985, Dr. Sartani was employed at Farmitalia-Carlo Erba, serving in
a number of capacities, including as the Medical Director for Europe. Currently, Dr. Sartani is a BoD member of BLV Pharma Group Srl,
a privately owned Italian food supplements company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Guy Regev.&#160;</i></b>Guy
Regev has over fourteen years of experience in accounting, financial management and control and general management of commercial enterprises.
He has served on our Board of Directors since July 2011 and has served as a member of our Audit Committee and Compensation Committee since
February 2014. Mr. Regev has also been a director of OphthaliX since November 2011. Mr. Regev is currently the Chief Executive Officer
of Gaon Holdings Ltd, a publicly traded Israeli holding company traded on the TASE which focuses on three areas of operation - Cleantech
/ Water, Financial Services, Retail/Trading. Mr. Regev is currently also the Chief Executive Officer of Middle East Tube Company Ltd a
publicly traded Israeli company traded on the TASE which focuses on steel pipe manufacturing and galvanization services. Mr. Regev was
the Chief Executive Officer of Shaked Global Group Ltd, a privately-held equity investment firm that provides value added capital to environmental-related
companies and technologies. Prior to joining Shaked, from 2001 to 2008, Mr. Regev was Vice President of Commercial Business at Housing
&amp; Construction Holding, or HCH, Israel&#8217;s largest infrastructure company. His duties included being responsible for the consolidation
and financial recovery of various business units within HCH. Prior to that, Mr. Regev carried several roles within the group including
as a Chief Financial Officer and later the Chief Executive Officer of Blue-Green Ltd., the environmental services subsidiary of HCH. Between
1999 and 2001, Mr. Regev was a manager at Deloitte &amp; Touche, Israel. Mr. Regev holds an LLB degree in Law (Israel) and is a licensed
attorney and has been a licensed CPA since 1999. Mr. Regev is also a director of, The Green Way Ltd, Shtang Construction and Engineering
Ltd, R.I.B.E. Consulting &amp; Investment Ltd., Middle East Tube Company Ltd, Middle East Tube - Industries 2001 Ltd, Middle East Tubes
- Galvanizing (1994) Ltd, I-Solar Greentech Ltd, Plassim Infrastructure Ltd, Plassim Advanced Solutions in Sanitation Ltd, Hakohav Valves
Industries Metal (1987) Ltd, Metzerplas Agriculture Cooperative Ltd, B. Gaon Retail &amp; Trading Ltd, Gaon Agro - Rimon Management Services
Ltd, B. Gaon Business (2004) Ltd, Gaon Antan Investments Ltd, Or Asaf Investments Ltd, Hamashbir Holdings (1999) Ltd, and AHAVA Holdings
LTD.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Yoseph Borenstein</i>.
</b>Yoseph Bornstein has played key roles in the Israeli biomed industry during the past 35 years. Mr. Bornstein is a co-founder of Microbot
Medical and has been a member of the Board of Directors since Microbot Israel was founded in November 2010. He is also serving as a compensation
committee member and Audit committee member at Microbot Medical. Mr. Bornstein founded Shizim Ltd., a life science holding group in October
2000 and has served as its president since then. Mr. Bornstein is the Chairman of GCP Clinical Studies Ltd., a provider of clinical research
services and educational programs in Israel since January 2002. He is the Chairman of Biotis Ltd., that supplies bio-pharmaceutical industry,
since June 2000. In addition, he is the Chairman of Dolphin Medical Ltd, that supplies medical device industry, since April 2012. Mr.
Bornstein is a co-founder and director of XACT Robotics, developing a novel platform technology for robotic needle steering in minimally
invasive interventional procedures, and is the founder of ShizimXL &amp; ShizimVS, Innovation Centers. In October 1992, Mr. Bornstein
founded Pharmateam Ltd., an Israeli company that specialized in representing international pharmaceutical companies which was sold in
2000. Mr. Bornstein is also a founder of a number of other privately held life-science companies. Mr. Bornstein served as the Biotechnology
Committee Chairman of the United States-Israel Science &amp; Technology Commission, or the USISTC, from September 2002 to February 2005
as well as a consultant for USISTF from September 2002 to February 2005. He is also the founder of ILSI-Israel Life Science Industry Organization
(who was integrated into Israel Advanced Technology Industries) and ITTN-Israel Tech Transfer Organization. Mr. Bornstein was the General
Manager of Bristol-Myers Squibb (Israel), until 1992. Mr. Bornstein holds a Bachelor of Science degree in Agriculture from the Hebrew
University of Jerusalem.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>&#160;</i></b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><b><i>Yaacov Goldman</i></b>.
Yaacov Goldman has served as external director since August 2017. Mr. Goldman provides consulting services to companies in strategic-financial
areas, through his wholly owned company, Maanit-Goldman Management &amp; Investments (2002) Ltd. Mr. Goldman also serves as a director
of Avgol Industries 1953 Ltd., Mivne Real Estate (K.D) Ltd., Fattal Properties (Europe) Ltd. and Prashkovsky Investments and Construction
Ltd. Mr. Goldman served as the Professional Secretary of the Peer Review Institute of the Certified Public Accountants Institute in Israel
from October 2004 until September 2008. Commencing in 1981, Mr. Goldman worked for Kesselman &amp; Kesselman (Israeli member firm of PricewaterhouseCoopers)
for 19 years, and from 1991 until 2000, as a partner and then senior partner of such firm. From September 2000 until November 2001, Mr.
Goldman served as managing director of Argoquest Holdings, LLC. Mr. Goldman holds a B.A. degree in Economics and Accounting from Tel Aviv
University and is a Certified Public Accountant (Israel).</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 81; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="margin: 0">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">B.
</span>Compensation.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Compensation of Directors and Senior Management</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
in the aggregate all compensation we paid to all of our office holders as a group</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term &#8216;office holder&#8217;
as defined in the Companies Law includes a general manager, chief business manager, deputy general manager, vice general manager, any
other person fulfilling or assuming the responsibilities of any of the foregoing positions without regard to such person&#8217;s title,
as well as a director, or a manager directly subordinate to the general manager or the chief executive officer. As of December 31, 2021,
in addition to the seven members of the Board of Directors (including the Company&#8217;s Chief Executive Officer), the Company considers
two other individuals, including its Chief Financial Officer and its VP Business Development to be office holders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="white-space: nowrap; text-align: center">&#160;</td><td style="white-space: nowrap; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="white-space: nowrap; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salaries, fees,<br/> commissions,<br/> bonuses and<br/> options<br/> (thousand USD)</td><td style="white-space: nowrap; padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: justify; text-indent: -9pt; padding-left: 9pt">All office holders as a group, consisting of 9 persons</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1,780</td><td style="width: 1%; text-align: left">*</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">This amount includes approximately $0.1 million set aside or accrued
to provide pension, severance, retirement or similar benefits or expenses, but does not include business travel, professional and business
association dues and expenses reimbursed to office holders, and other benefits commonly reimbursed or paid by companies in our industry.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table presents
information regarding compensation reflected in our financial statements for five most highly compensated office holders, as of December
31, 2021.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Salary</td>
    <td style="font-weight: bold; text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Bonus</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Value of<br/> Options<br/> Granted(4)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Other(5)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Name and Position</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="18" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(USD in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 35%; text-align: left; text-indent: -9pt; padding-left: 9pt">Pnina Fishman<br/> <i>Chief Executive Officer</i></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">448</td>
    <td style="width: 2%; text-align: left">(1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">180</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 12%; text-align: right">123</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">16</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">767</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Motti Farbstein<br/> <i>Chief Financial Officer</i></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">291</td>
    <td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">109</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">68</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">484</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Sari Fishman<br/> <i>VP Business Development</i></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">228</td>
    <td style="text-align: left">(2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">70</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">63</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">380</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Yaacov Goldman<br/> <i>External Director</i></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td>
    <td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 9pt">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td>
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Guy Regev<br/> <i>External Director</i></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td>
    <td style="text-align: left">(3)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">43</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Amount represents consulting fee.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">Salary includes gross salary plus payment of social benefits made
by us on behalf of such person. Such benefits may include, to the extent applicable, payments, contributions and/or allocations for savings
funds (e.g., managers&#8217; life insurance policy), education funds (referred to in Hebrew as &#8220;keren hishtalmut&#8221;), pension,
severance, risk insurances (e.g., life, or work disability insurance), payments for social security payments and tax gross-up payments,
vacation, medical insurance and benefits, convalescence or recreation pay and other benefits and perquisites consistent with our policies.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: justify">Amount represents fees for Board service.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">(4)</td><td style="text-align: justify">The value of options is the expense recorded in our financial
statements for the period ended December 31, 2021 with respect to all options granted to such person. Assumptions and key variables used
in the calculation of such amounts are discussed in Note 12 of our financial statements.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">(5)</td><td style="text-align: justify">Amount represents cost of use of company car.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 82; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each director other than our
Chief Executive Officer and Avraham Sartani, is entitled to the payment of annual fee of NIS 50,492 or $16,235 (based on the exchange
rate reported by the Bank of Israel on December 31, 2021), and payment of NIS 3,374 or $1,085 (based on the exchange rate reported by
the Bank of Israel on December 31, 2021) per meeting for participating in meetings of the Board and committees of the Board. The annual
fee shall not exceed the annual fee of an expert external director set forth in the Companies Regulations (Rules regarding Compensation
and Expenses of External Directors) 5760-2000 as adjusted by the Companies Regulations (Relief for Public Companies with Shares Listed
for Trading on a Stock Market Outside of Israel), 5760-2000. The compensation awarded for participating in resolutions that are adopted
without an actual convening (i.e., unanimous written resolutions) and for participating through telephone meetings will be reduced as
follows: (1) for resolutions that will be adopted without an actual convening, the participation compensation will be reduced by 50%;
and (2) for participation through telephone meetings, the participation compensation will be reduced by 40%. The participation compensation
and the annual fee is inclusive of all expenses incurred by our directors in connection with their participation in a meeting held at
our offices or with regard to resolutions resolved by written consent or teleconference. Avraham Sartani is entitled to a fee of $1,000
per meeting. In addition, our directors (other than our Chief Executive Officer and external directors) are entitled to reimbursement
for expenses related to their participation at meetings taking place not at our offices and outside their respective residency area.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Employment and Consulting Agreements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have entered into employment
or consulting agreements with our directors, senior management and key service providers. All of these agreements contain customary provisions
regarding noncompetition, confidentiality of information and assignment of proprietary information and inventions. However, the enforceability
of the noncompetition provisions may be limited under applicable law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following are summary
descriptions of certain agreements to which we are a party. The descriptions provided below do not purport to be complete and are qualified
in their entirety by the complete agreements, which are attached as exhibits to this Annual Report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Service Management Agreement
with F.D. Consulting:</i>&#160;On June 27, 2002, we entered into a Service Management Agreement with F.D. Consulting, a company partially
owned by Pnina Fishman, pursuant to which Dr. Fishman began serving as our Chief Scientific Officer and later became our Chief Executive
Officer and is a member of our Board of Directors and continues to be retained through this agreement. F.D. Consulting&#8217;s current
gross monthly fee is NIS 124,614 or $40,068 (based on the exchange rate reported by the Bank of Israel on December 31, 2021) which is
linked to the Israeli CPI and fluctuates accordingly. Dr. Fishman, through F.D. Consulting, is also entitled to reimbursement for reasonable
out-of-pocket expenses and use of a company automobile and mobile phone.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term of F.D. Consulting&#8217;s
service management agreement is indefinite, unless earlier terminated for cause by us or without cause by either party, subject to three
months&#8217; advanced notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dr. Fishman is also entitled
to receive options exercisable into our ordinary shares from time to time. As of the date of this Annual Report, Dr. Fishman has outstanding
options to purchase an aggregate of 5,600,000 ordinary shares, of which (i) 200,000 options to purchase 200,000 ordinary shares have an
exercise price of NIS 3.573 per ordinary share or $1.15 per ordinary share (based on the exchange rate reported by the Bank of Israel
on December 31, 2021), vesting on a quarterly basis over four years commencing October 22, 2015, and expire on October 22, 2025, (ii)
400,000 options to purchase 400,000 ordinary shares have an exercise price of NIS 2.344 per ordinary share or $0.75 per ordinary share
(based on the exchange rate reported by the Bank of Israel on December 31, 2021), vesting on a quarterly basis over three years commencing
January 7, 2019, and expire on January 7, 2029, (iii) 2,500,000 options to purchase 2,500,000 ordinary shares have an exercise price of
NIS 0.25 per ordinary share or $0.08 per ordinary share (based on the exchange rate reported by the Bank of Israel on December 31, 2021),
vesting on a quarterly basis over four years commencing May 27, 2020, and expire on May 27, 2030, (iv) 2,500,000 options to purchase 2,500,000
ordinary shares have an exercise price of NIS 0.25 per ordinary share or $0.08 per ordinary share (based on the exchange rate reported
by the Bank of Israel on December 31, 2021), vesting on a quarterly basis over four years commencing April 13, 2021, and expire on April
13, 2031.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 83; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Employment and Non-Competition
Agreement with Motti Farbstein:</i>&#160;On September 1, 2003 we entered into an employment and non-competition agreement with Motti Farbstein
pursuant to which Mr. Farbstein began serving as our Director of Clinical Operations and Administrative Affairs on September 1, 2003 and
is currently serving as our Chief Operating and Financial Officer. Mr. Farbstein&#8217;s current gross monthly salary is NIS 59,800 or
$19,228 (based on the exchange rate reported by the Bank of Israel on December 31, 2021). Mr. Farbstein is entitled to an allocation to
a manager&#8217;s insurance policy equivalent to an amount up to 13-1/3% of his gross monthly salary, up to 2-1/2% of his gross monthly
salary for disability insurance and 7-1/2% of his gross monthly salary for a study fund. The foregoing amounts are paid by us. Five percent
of his gross monthly salary is deducted for the manager&#8217;s insurance policy and 2-1/2% is deducted for the study fund. Mr. Farbstein
is also entitled to reimbursement for reasonable out-of-pocket expenses, including travel expenses, and use of a company automobile and
mobile phone.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term of Mr. Farbstein&#8217;s
employment and non-competition agreement is indefinite, unless earlier terminated for just cause by either party, upon the death, disability
or retirement age, or without cause by either party, subject to 60 days&#8217; advanced notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Mr. Farbstein is also entitled
to receive options exercisable into our ordinary shares from time to time. As of December 31, 2021, Mr. Farbstein has outstanding options
to purchase an aggregate of 2,978,000 ordinary shares, of which (i) 100,000 options are exercisable into 4,000 ordinary shares at an exercise
price of NIS 0.385 per option or $0.12 per option (based on the exchange rate reported by the Bank of Israel on December 31, 2021), are
fully vested, and expire on May 2, 2022, (ii) 100,000 options are exercisable into 4,000 ordinary shares at an exercise price of NIS 0.326
per option or $0.10 per option (based on the exchange rate reported by the Bank of Israel on December 31, 2021) are fully vested, and
expire on March 20, 2023, (iii) 10,000 options to purchase 10,000 ordinary shares at an exercise price of NIS 8.1205 per option or $2.61
per option (based on the exchange rate reported by the Bank of Israel on December 31, 2021), vesting on a quarterly basis over four years
commencing March 19, 2015, and expire on March 18, 2025, (iv) 60,000 options to purchase 60,000 ordinary shares at an exercise price of
NIS 4.317 per option or $1.38 per option (based on the exchange rate reported by the Bank of Israel on December 31, 2021), vesting on
a quarterly basis over four years commencing February 18, 2016 and expire on February 18, 2026, (v) 250,000 options to purchase 250,000
ordinary shares at an exercise price of NIS 2.513 per option or $0.80 per option (based on the exchange rate reported by the Bank of Israel
on December 31, 2021), vesting on a quarterly basis over four years commencing December 28, 2017 and expire on December 28, 2027, (vi)
150,000 options to purchase 150,000 ordinary shares at an exercise price of NIS 2.344 per option or $0.75 per option (based on the exchange
rate reported by the Bank of Israel on December 31, 2021), vesting on a quarterly basis over four years commencing January 7, 2019 and
expire on January 7, 2029, (vii) 1,000,000 options to purchase 1,000,000 ordinary shares at an exercise price of NIS 0.25 per option or
$0.08 per option (based on the exchange rate reported by the Bank of Israel on December 31, 2021), vesting on a quarterly basis over four
years commencing May 27, 2020 and expire on May 27, 2030, (viii) 1,500,000 options to purchase 1,500,000 ordinary shares at an exercise
price of NIS 0.25 per option or $0.08 per option (based on the exchange rate reported by the Bank of Israel on December 31, 2021), vesting
on a quarterly basis over four years commencing April 13, 2021 and expire on April 14, 2031.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Consulting Agreement with
BioStrategics:</i>&#160;On September 27, 2005, we entered into a consulting agreement with BioStrategics through its President, Michael
Silverman pursuant to which Dr. Silverman began serving as our Medical Director. Dr. Silverman has extensive experience in clinical development
acquired through his involvement in clinical development in large pharmaceutical and small biopharmaceutical companies. He was involved
in international clinical research, market-oriented strategic planning, and the challenges of managing research and development portfolios
in various capacities at Sterling Winthrop Research Institute and subsequently at Sandoz Research Institute.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">BioStrategics&#8217; current
fee is $400 per hour with a maximum daily fee of $2,600. In addition, BioStrategics is entitled to reimbursement for reasonable pre-approved
expenses. The term of the consulting agreement is currently on a year-to-year basis, unless earlier terminated by either party upon 30
days&#8217; prior written notice or immediately by either party if such termination is for cause.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 84; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Master Services Agreement
with Accellient Partners:</i>&#160;On May 10, 2010, we entered into a Master Services Agreement with Accellient Partners, a company owned
by William Kerns, who currently serves as our current Vice President of Drug Development. Dr. Kerns has over 20 years of experience in
Pharmaceutical Research and Development at SmithKline Beecham and Eisai Pharmaceuticals. As a Senior Executive he has participated in
the development of drugs for over 100 Phase I studies and 13 NDA&#8217;s and/or Marketing Authorization Applications. Dr. Kerns has chaired
an FDA committee on biomarkers and he is an expert in preclinical development and regulatory strategy.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the agreement,
consulting services are provided by Accellient Partners&#8217; personnel in accordance with individual work orders that are executed from
time to time. Each individual work order defines the scope of work to be provided and sets forth the fees to be paid to Accellient Partners.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Beginning on May 10, 2012,
the term of the master services agreement is on a month-to-month basis, unless terminated by us upon 30 days&#8217; prior written notice,
by us at any time if Accellient Partners commits a breach and fails to cure, or by Accellient Partners upon 30 days&#8217; prior written
notice if we commit a breach and fail to cure.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Cohn, De Vries, Stadler
&amp; Co.:</i>&#160;Cohn, De Vriew, Stadler &amp; Co. of which Ilan Cohn, Ph.D. is a partner provides intellectual property services to
us in the ordinary course of business. Previously, Dr. Cohn was a partner with Reinhold Cohn and Partners that provided intellectual property
services to us in the ordinary course of business.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">C.
</span>Board Practices</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">General</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the Israeli Companies
Law, the management of our business is vested in our Board of Directors. Our Board of Directors may exercise all powers and may take all
actions that are not specifically granted to our shareholders. Our executive officers are responsible for our day-to-day management and
have individual responsibilities established by our Board of Directors. Executive officers are appointed by and serve at the discretion
of our Board of Directors, subject to any applicable employment agreements we have entered into with the executive officers. See &#8220;Item
6. Directors, Senior Management and Employees&#8212;B. Compensation&#8212;Employment and Consulting Agreements.&#8221;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Election of Directors and Terms of Office</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated Articles
of Association provide that the maximum number of members of the Board of Directors is 13. The Board of Directors is presently comprised
of six members.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2020, a special
general meeting of our shareholders approved an amendment to the our Amended and Restated Articles of Association, according to which
the Board of Directors, excluding the external directors, if any (who shall be elected and serve in office in strict accordance with the
provisions of the Companies Law, if so required by the Companies Law), shall consist of three classes of directors as nearly equal in
number as practicable, which are appointed for fixed terms of office in accordance with the Israeli Companies Law and our Amended and
Restated Articles of Association, as follows: (i) the term of office of the initial Class I directors expired at the first annual general
meeting of our shareholders held in 2020 and when their successors are elected and qualified, (ii) the term of office of the initial Class
II directors shall expire at the first annual general meeting of our shareholders following the annual general meeting of our shareholders
referred to in clause (i) above and when their successors are elected and qualified, and (iii) the term of office of the initial Class
III directors shall expire at the first annual general meeting of our shareholders following the annual general meeting of our shareholders
referred to in clause (ii) above and when their successors are elected and qualified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors (other than external
directors), may be elected only in annual general meetings of our shareholders. At each annual general meeting of our shareholders, commencing
with the annual general meeting of our shareholders held in 2021, each of the successors elected to replace the directors of a class whose
term shall have expired at such annual general meeting of our shareholders shall be elected to hold office until the third annual general
meeting of our shareholders next succeeding his or her election and until his or her respective successor shall have been elected and
qualified. Notwithstanding anything to the contrary, each director shall serve until his or her successor is elected and qualified or
until such earlier time as such director&#8217;s office is vacated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 85; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the number of directors
(excluding external directors) that constitutes the Board of Directors is hereafter changed, the then-serving directors shall be re-designated
to other classes and/or any newly created directorships or decrease in directorships shall be apportioned by the Board of Directors among
the classes so as to make all classes as nearly equal in number as is practicable, provided that no decrease in the number of Directors
constituting the Board of Directors shall shorten the term of any incumbent director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors so elected may not
be dismissed from office by the shareholders or by a general meeting of our shareholders prior to the expiration of their term of office.
The directors do not receive any benefits upon the expiration of their term of office.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The three classes of directors
are Class I Directors, Class II Directors and Class III Directors. Dr. Pnina Fishman and Mr. Guy Regev serve as our Class III Directors
until the close of the annual meeting to be held in 2022; Abraham Sartani serves as our Class I Director until the close of the annual
meeting to be held in 2023; and Ilan Cohn serves as our Class II Director until the close of the annual meeting to be held in 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any amendment, replacement
or suspension of our Amended and Restated Articles of Association regarding the election of directors, as described above, require a majority
of 65% of the voting power represented at the general meeting of our shareholders in person or by proxy and voting thereon, disregarding
abstentions from the count of the voting power present and voting, provided that such majority constitutes more than 20% of our then issued
and outstanding share capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A nominee for service as a
director in a public company may not be elected without submitting a declaration to the company, prior to election, specifying that he
or she has the requisite qualifications to serve as a director, independent director or external director (if required), as applicable,
and the ability to devote the appropriate time to performing his or her duties as such.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A director, who ceases to
meet the statutory requirements to serve as a director, external director or independent director, as applicable, must notify the company
to that effect immediately and his or her service as a director will expire upon submission of such notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 1, 2017, at an annual
general meeting of our shareholders Yaacov Goldman was elected to serve as one of our external directors for a three-year term ending
July 31, 2020.&#160;On August 12, 2020 at an annual general meeting of our shareholders, Yaacov Goldman was elected to serve for an additional
three-year term ending July 24, 2023.&#160;On December 27, 2017, at a special meeting of our shareholders, Israel Shamay was elected to
serve for a three-year term ending December 26, 2020 as one of our external directors. On December 9, 2020, at an annual general meeting
of our shareholders, Israel Shamay was elected to serve for an additional three-year term ending December 30, 2023. On June 11, 2021,
Israel Shamay passed away. On August 5, 2021, at a special meeting of our shareholders Yoseph Bornstein was elected to serve as one of
our external directors for a three-year term ending July 29, 2024. On May 30, 2013, Ilan Cohn was appointed as Chairman of the Board.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">None of our directors or senior
management has any family relationship with any other director or senior management except that Sari Fishman is the daughter of Pnina
Fishman. None of our directors have service contracts that provide for benefits upon termination of his or her directorship with us, other
than the payment of salary due, accrued and unpaid as of and through the date of termination. See &#8220;Item 6. Directors, Senior Management
and Employees&#8212;B. Compensation&#8212;Employment and Consulting Agreements.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Chairman of the Board.
Un</i>der the Israeli Companies Law, without shareholder approval, a person cannot hold the role of both chairman of the Board of Directors
and chief executive officer of a company. Furthermore, a person who is directly or indirectly subordinate to a chief executive officer
of a company may not serve as the chairman of the Board of Directors of that company and the chairman of the Board of Directors may not
otherwise serve in any other capacity in a company or in a subsidiary of that company other than as the chairman of the Board of Directors
of such a subsidiary.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 86; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
provides that an Israeli company may, under certain circumstances, exculpate an office holder from liability with respect to a breach
of his duty of care toward the company if appropriate provisions allowing such exculpation are included in its articles of association.
Our Amended and Restated Articles of Association permit us to maintain directors&#8217; and officers&#8217; liability insurance and to
indemnify our directors and officers for actions performed on behalf of us, subject to specified limitations. We maintain a directors
and officers insurance policy which covers the liability of our directors and officers as allowed under the Israeli Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term office holder is
defined in the Israeli Companies Law as a director, general manager, chief business manager, deputy general manager, vice general manager,
executive vice president, vice president, any other manager directly subordinate to the general manager, director, or any other person
assuming the responsibilities of any of the foregoing positions, without regard to such person&#8217;s title.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">External and Independent Directors</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, the boards of directors of companies whose shares are publicly traded, either within or outside of Israel, are required to include
at least two members who qualify as external directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">External directors must be
elected by a majority vote of the shares present and voting at a shareholders meeting, provided that either:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the majority of the shares that are voted at the meeting,
shall include at least a majority of the shares held by non-controlling shareholders and shareholders who do not have a personal interest
in the election of the external director (other than a personal interest not deriving from a relationship with a controlling shareholder)
who voted at the meeting, excluding abstentions, vote in favor of the election of the external director; Anyone with a personal interest
will be subject to the provisions of section 276, mutatis mutandis; or</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the total number of shares held by non-controlling, disinterested
shareholders (as described in the preceding bullet point) that are voted against the election of the external director does not exceed
2% of the aggregate voting rights in the company.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term &#8220;controlling
shareholder&#8221; means a shareholder with the ability to direct the activities of the company, other than by virtue of being an office
holder. A shareholder is presumed to have &#8220;control&#8221; of the company and thus to be a controlling shareholder of the company
if the shareholder holds 50% or more of the &#8220;means of control&#8221; of the company. &#8220;Means of control&#8221; is defined as
(1) the right to vote at a general meeting of a company or a corresponding body of another corporation; or (2) the right to appoint directors
of the corporation or its general manager. For the purpose of approving related-party transactions, the term also includes any shareholder
that holds 25% or more of the voting rights of the company if the company has no shareholder that owns more than 50% of its voting rights.
For the purpose of determining the holding percentage stated above, two or more shareholders who have a personal interest in a transaction
that is brought for the company&#8217;s approval are deemed as joint holders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A person may not serve as
an external director of a company if (i) such person is a relative of a controlling shareholder of a company or (ii) at the date of such
person&#8217;s appointment or within the prior two years, such person, such person&#8217;s relative, partner, employer or any entity under
such person&#8217;s control or anyone to whom such person is subordinate, whether directly or indirectly, has or had any affiliation with
(a) the company, (b) the controlling shareholder or his relative, at the time of such person&#8217;s appointment or (c) any entity that
is either controlled by the company or by its controlling shareholder at the time of such appointment or during the prior two years. If
a company does not have a controlling shareholder or a group of shareholders who have a control block entitling them to vote at least
25% of the votes in a shareholders meeting, then a person may not serve as an external director if, such person or such person&#8217;s
relative, partner, employer or any entity under such person&#8217;s control, has or had, on or within the two years preceding the date
of the person&#8217;s appointment to serve as an external director, any affiliation with the chairman of our Board of Directors, chief
executive officer, a substantial shareholder who holds at least 5% of the issued and outstanding shares of the company or voting rights
which entitle him to vote at least 5% of the votes in a shareholders meeting, or the chief financial officer of the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 87; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term affiliation includes:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">an employment relationship;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a business or professional relationship even if not maintained
on a regular basis (excluding insignificant relationships);</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">control; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">service as an office holder, excluding service as a director
in a private company prior to the initial offering of its shares to the public if such director was appointed as a director of the private
company in order to serve as an external director following the public offering.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term relative is defined
as a spouse, sibling, parent, grandparent or descendant; a spouse&#8217;s sibling, parent or descendant; and the spouse of each of the
foregoing persons.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, no person may
serve as an external director if that person&#8217;s professional activities create, or may create, a conflict of interest with that person&#8217;s
responsibilities as a director or otherwise interfere with that person&#8217;s ability to serve as an external director or if the person
is an employee of the Israel Securities Authority, or the ISA, or of the TASE. Furthermore, a person may not continue to serve as an external
director if he or she received direct or indirect compensation from the company for his or her role as a director. This prohibition does
not apply to compensation paid or given in accordance with regulations promulgated under the Israeli Companies Law or amounts paid pursuant
to indemnification and/or exculpation contracts or commitments and insurance coverage. If, at the time an external director is appointed,
all current members of the Board of Directors not otherwise affiliated with the company are of the same gender, then that external director
must be of the other gender. In addition, a director of a company may not be elected as an external director of another company if, at
that time, a director of the other company is acting as an external director of the first company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Following the termination
of an external director&#8217;s service on a Board of Directors, such former external director and his or her spouse and children may
not be provided with a direct or indirect benefit by the company, its controlling shareholder or any entity under its controlling shareholder&#8217;s
control. This includes engagement to serve as an executive officer or director of the company or a company controlled by its controlling
shareholder, or employment by, or providing services to, any such company for consideration, either directly or indirectly, including
through a corporation controlled by the former external director, for a period of two years (and for a period of one year with respect
to relatives of the former external director).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
provides that an external director must meet certain professional qualifications or have financial and accounting expertise and that at
least one external director must have financial and accounting expertise. However, if at least one of our other directors (i) meets the
independence requirements of the Securities Exchange Act of 1934, as amended, (ii) meets the standards of the NYSE American rules for
membership on the audit committee and (iii) has financial and accounting expertise as defined in the Israeli Companies Law and applicable
regulations, then neither of our external directors is required to possess financial and accounting expertise as long as both possess
other requisite professional qualifications. Our Board of Directors is required to determine whether a director possesses financial and
accounting expertise by examining whether, due to the director&#8217;s education, experience and qualifications, the director is highly
proficient and knowledgeable with regard to business-accounting issues and financial statements, to the extent that the director is able
to engage in a discussion concerning the presentation of financial information in our financial statements, among others. The regulations
define a director with the requisite professional qualifications as a director who satisfies one of the following requirements: (i) the
director holds an academic degree in either economics, business administration, accounting, law or public administration; (ii) the director
either holds an academic degree in any other field or has completed another form of higher education in our primary field of business
or in an area which is relevant to the office of an external director; or (iii) the director has at least five years of experience serving
in any one of the following, or at least five years of cumulative experience serving in two or more of the following capacities: (a) a
senior business management position in a corporation with a substantial scope of business; (b) a senior position in our primary field
of business; or (c) a senior position in public administration. Yaacov Goldman, who is one of our external directors, meets the required
qualifications and has financial and accounting expertise as required by the Israeli Companies Law, while Guy Regev, an independent director,
also meets the required qualifications and has financial and accounting expertise as required by the Israeli Companies Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 88; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
defines an independent director as a director who complies with the following and was appointed as such in accordance with Chapter 1 of
Part 56 of the Israeli Companies Law: (1) the director complies with the qualification to serve as an external director as set out in
Sections 240 (b)-(f) of the Israeli Companies Law and the audit committee has approved such compliance; and (2) the director has not served
as a director of the company for more than nine consecutive years (which, for such purpose, does not include breaks in such service for
periods of less than two year).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an external directorship
becomes vacant and there are less than two external directors on the Board of Directors at the time, then the Board of Directors is required
under the Israeli Companies Law to call a shareholders&#8217; meeting as soon as possible to appoint a replacement external director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each committee of the Board
of Directors that is authorized to exercise the powers of the Board of Directors must include at least one external director, except that
the audit committee and compensation committee must each include all external directors then serving on the Board of Directors. Under
the Israeli Companies Law, external directors of a company are prohibited from receiving, directly or indirectly, any compensation for
their services as external directors, other than compensation and reimbursement of expenses pursuant to applicable regulations promulgated
under the Israeli Companies Law. Compensation of an external director is determined prior to his or her appointment and may not be changed
during his or her term subject to certain exceptions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yoseph Borenstein and Yaacov
Goldman serve as external directors on our Board of Directors pursuant to the provisions of the Israeli Companies Law. They both serve
on our audit committee and our compensation committee. Our Board of Directors has determined that Yaacov Goldman possesses accounting
and financial expertise, and that both of our external directors possess the requisite professional qualifications. In addition to our
external directors, Guy Regev and Abraham Sartani serve as independent directors on our Board of Directors. Guy Regev also serves on our
audit committee and our compensation committee.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Audit Committee</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
requires public companies to appoint an audit committee. The responsibilities of the audit committee include identifying irregularities
in the management of our business and approving related party transactions as required by law. An audit committee must consist of at least
three directors, including all of its external directors and a majority of independent directors. The chairman of the Board of Directors,
any director employed by or otherwise providing services to the company, and a controlling shareholder or any relative of a controlling
shareholder, may not be a member of the audit committee. An audit committee may not approve an action or a transaction with a controlling
shareholder, or with an office holder, unless at the time of approval two external directors are serving as members of the audit committee
and at least one of the external directors was present at the meeting in which an approval was granted.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee is currently
comprised of three independent non-executive directors. The audit committee is chaired by Yaacov Goldman, who serves as the audit committee
financial expert, with Yoseph Borenstein and Guy Regev as members. Our audit committee meets at least four times a year and monitors the
adequacy of our internal controls, accounting policies and financial reporting. It regularly reviews the results of the ongoing risk self-assessment
process, which we undertake, and our interim and annual reports prior to their submission for approval by the full Board of Directors.
The audit committee oversees the activities of the internal auditor, sets its annual tasks and goals and reviews its reports. The audit
committee reviews the objectivity and independence of the external auditors and also considers the scope of their work and fees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee provides
assistance to our Board of Directors in fulfilling its legal and fiduciary obligations in matters involving our accounting, auditing,
financial reporting, internal control and legal compliance functions by pre-approving the services performed by our independent accountants
and reviewing their reports regarding our accounting practices and systems of internal control over financial reporting. Our audit committee
also oversees the audit efforts of our independent accountants and takes those actions that it deems necessary to satisfy itself that
the accountants are independent of management.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 89; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, our audit committee is responsible for (i) determining whether there are deficiencies in the business management practices of our
company, including in consultation with our internal auditor or the independent auditor, and making recommendations to the Board of Directors
to improve such practices and amend such deficiencies, (ii) determining whether certain related party transactions (including transactions
in which an office holder has a personal interest) should be deemed as material or extraordinary, and to approve such transactions (which
may be approved according to certain criteria set out by our audit committee on an annual basis) (see &#8220;&#8212;Approval of Related
Party Transactions under the Israeli Companies Law&#8221;); (iii) establishing procedures to be followed in respect of related party transactions
with a controlling shareholder (where such are not extraordinary transactions), which may include, where applicable, the establishment
of a competitive process for such transaction, under the supervision of the audit committee, or individual, or other committee or body
selected by the audit committee, in accordance with criteria determined by the audit committee; (iv) determining procedures for approving
certain related party transactions with a controlling shareholder, which having been determined by the audit committee not to be extraordinary
transactions, were also determined by the audit committee not to be negligible transactions; (v) approving the working plan of the internal
auditor, to examine such working plan before its submission to the Board and proposing amendments thereto, (vi) examining our internal
controls and internal auditor&#8217;s performance, including whether the internal auditor has sufficient resources and tools to dispose
of its responsibilities, (vii) examining the scope of our auditor&#8217;s work and compensation and submitting a recommendation with respect
thereto to our Board of Directors or shareholders, depending on which of them is considering the appointment of our auditor, and (viii)
establishing procedures for the handling of employees&#8217; complaints as to the management of our business and the protection to be
provided to such employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a written
charter for our audit committee, setting forth its responsibilities as outlined by the regulations of the SEC. In addition, our audit
committee has adopted procedures for the receipt, retention and treatment of complaints we may receive regarding accounting, internal
accounting controls or auditing matters and the submission by our employees of concerns regarding questionable accounting or auditing
matters. In addition, SEC rules mandate that the audit committee of a listed issuer consist of at least three members, all of whom must
be independent, as such term is defined by rules and regulations promulgated by the SEC. We are in compliance with the independence requirements
of the SEC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any person who is not eligible
to serve on the audit committee is further restricted from participating in its meetings and votes, unless the chairman of the audit committee
determines that such person&#8217;s presence is necessary in order to present a certain matter; provided, however, that company employees
who are not controlling shareholders or relatives of such shareholders may be present in the meetings, but not for actual voting, and
likewise, company counsel and secretary who are not controlling shareholders or relatives of such shareholders may be present in the meetings
and for actual voting if such presence is requested by the audit committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition to the above,
all such committee&#8217;s members must apply with the following requirements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">All members shall be members of the Board of Directors of
the company.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">At least one of the committee&#8217;s members shall have financial
and accounting expertise and the rest of the committee&#8217;s members must have the ability to read and understand financial statements.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our company, through our audit
committee, is in full compliance with the above requirements.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Financial Statement Examination Committee</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, the Board of Directors of a public company must appoint a financial statement examination committee, which consists of members with
accounting and financial expertise or the ability to read and understand financial statements. According to a resolution of our Board
of Directors, the audit committee has been assigned the responsibilities and duties of a financial statements examination committee, as
permitted under relevant regulations promulgated under the Israeli Companies Law. From time to time as necessary and required to approve
our financial statements, the audit committee holds separate meetings, prior to the scheduled meetings of the entire Board of Directors
regarding financial statement approval. The function of a financial statements examination committee is to discuss and provide recommendations
to its Board of Directors (including the report of any deficiency found) with respect to the following issues: (i) estimations and assessments
made in connection with the preparation of financial statements; (ii) internal controls related to the financial statements; (iii) completeness
and propriety of the disclosure in the financial statements; (iv) the accounting policies adopted and the accounting treatments implemented
in material matters of the company; and (v) value evaluations, including the assumptions and assessments on which evaluations are based
and the supporting data in the financial statements. Our independent auditors and our internal auditors are invited to attend all meetings
of audit committee when it is acting in the role of the financial statements examination committee.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 90; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Compensation Committee</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Amendment no. 20 to the Israeli
Companies Law was published on November 12, 2012 and became effective on December 12, 2012, or Amendment no. 20. In general, Amendment
no. 20 requires public companies to appoint a compensation committee and to adopt a compensation policy with respect to its officers,
or the Compensation Policy. In addition, Amendment no. 20 addresses the corporate approval process required for a public company&#8217;s
engagement with its officers (with specific reference to a director, a non-director officer, a chief executive officer and controlling
shareholders and their relatives who are employed by the company).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The compensation committee
shall be nominated by the Board of Directors and be comprised of its members. The compensation committee must consist of at least three
members. All of the external directors must serve on the compensation committee and constitute a majority of its members. The remaining
members of the compensation committee must be directors who qualify to serve as members of the audit committee (including the fact that
they are independent) and their compensation should be identical to the compensation paid to the external directors of the company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Similar to the rules that
apply to the audit committee, the compensation committee may not include the chairman of the board, or any director employed by the Company,
by a controlling shareholder or by any entity controlled by a controlling shareholder, or any director providing services to the company,
to a controlling shareholder or to any entity controlled by a controlling shareholder on a regular basis, or any director whose primary
income is dependent on a controlling shareholder, and may not include a controlling shareholder or any of its relatives. Individuals who
are not permitted to be compensation committee members may not participate in the committee&#8217;s meetings other than to present a particular
issue; provided, however, that an employee that is not a controlling shareholder or relative may participate in the committee&#8217;s
discussions, but not in any vote, and our legal counsel and corporate secretary may participate in the committee&#8217;s discussions and
votes if requested by the committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The roles of the compensation
committee are, among others, to: (i) recommend to the Board of Directors the Compensation Policy for office holders and recommend to the
board once every three years the extension of a Compensation Policy that had been approved for a period of more than three years; (ii)
recommend to the directors any update of the Compensation Policy, from time to time, and examine its implementation; (iii) decide whether
to approve the terms of office and of employment of office holders that require approval of the compensation committee; and (iv) decide,
in certain circumstances, whether to exempt the approval of terms of office of a chief executive officer from the requirement of shareholder
approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Policy requires
the approval of the general meeting of shareholders with a &#8220;Special Majority&#8221;, which requires a majority of the shareholders
of the company who are not either a controlling shareholder or an &#8220;interested party&#8221; in the proposed resolution, or that shareholders
holding less than 2% of the voting power in the company voted against the proposed resolution at such meeting. However, under special
circumstances, the Board of Directors may approve the compensation policy without shareholder approval, if the compensation committee
and thereafter the Board of Directors decided, based on substantiated reasons after they have reviewed the Compensation Policy again,
that the Compensation Policy is in the best interest of the company. The Compensation Policy is required to be brought before the shareholders
of the Company once every three years for approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 91; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, our Compensation Policy must generally serve as the basis for corporate approvals with respect to the financial terms of employment
or engagement of office holders, including exemption, insurance, indemnification or any monetary payment or obligation of payment in respect
of employment or engagement. The Compensation Policy must relate to certain factors, including advancement of the company&#8217;s objective,
the company&#8217;s business plan and its long term strategy, and creation of appropriate incentives for office holders. It must also
consider, among other things, the company&#8217;s risk management, size and nature of its operations. The Compensation Policy must furthermore
consider the following additional factors:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The knowledge, skills, expertise, and accomplishments of the
relevant office holder;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The office holder&#8217;s roles and responsibilities and prior
compensation agreements with him or her;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The relationship between the terms offered and the average
compensation of the other employees of the company, including those employed through manpower companies;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The impact of disparities in salary upon work relationships
in the company;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The possibility of reducing variable compensation at the discretion
of the Board of Directors;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The possibility of setting a limit on the exercise value of
non-cash variable equity-based compensation; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">As to severance compensation, the period of service of the
office holder, the terms of his or her compensation during such service period, the company&#8217;s performance during that period of
service, the person&#8217;s contributions towards the company&#8217;s achievement of its goals and the maximization of its profits, and
the circumstances under which the person is leaving the company.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Policy must
also include the following principles:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the link between variable compensation and the long term performance
and measurable criteria;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the relationship between variable and fixed compensation,
and the ceiling for the value of variable compensation;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the conditions under which an office holder would be required
to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and
was required to be restated in the company&#8217;s financial statements;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the minimum holding or vesting period for variable, equity-based
compensation; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">maximum limits for severance compensation.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Policy was
approved by the general meeting of shareholders on January 19, 2017 after discussions and recommendation of the compensation committee
and approval by the Board of Directors. The Compensation Policy was amended by the general meeting of shareholders on June 7, 2021. Moreover,
the approval of the compensation committee is required in order to approve terms of office and/or employment of office holders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Yaacov Goldman is the chairman
of our compensation committee. Guy Regev and Yoseph Bornstein serve as the other members of our compensation committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Amendment no. 27 to
the Israeli Companies Law, which became effective as of February 17, 2016, the audit committee of an Israeli public company which has
been established and conducts itself also in accordance with provisions governing the composition of the compensation committee as set
forth in the Israeli Companies Law, may act in lieu of a compensation committee with respect to the responsibilities of a compensation
committee which are set forth in the Israeli Companies Law.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 92; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Approval of Related Party Transactions
under the Israeli Companies Law</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Fiduciary duties of
the office holders</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
imposes a duty of care and a duty of loyalty on all office holders of a company. The duty of care of an office holder is based on the
duty of care set forth in connection with the tort of negligence under the Israeli Torts Ordinance (New Version) 5728-1968. This duty
of care requires an office holder to act with the degree of proficiency with which a reasonable office holder in the same position would
have acted under the same circumstances. The duty of care includes a duty to use reasonable means, in light of the circumstances, to obtain:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">information on the advisability of a given action brought
for his or her approval or performed by virtue of his or her position; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">all other important information pertaining to these action.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The duty of loyalty requires
an office holder to act in good faith and for the benefit of the company, and includes the duty to:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">refrain from any act involving a conflict of interest between
the performance of his or her duties in the company and his or her other duties or personal affairs;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">refrain from any activity that is competitive with the business
of the company;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">refrain from exploiting any business opportunity of the company
for the purpose of gaining a personal advantage for himself or herself or others; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">disclose to the company any information or documents relating
to our affairs which the office holder received as a result of his or her position as an office holder.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may approve an act performed
in breach of the duty of loyalty of an office holder provided that the office holder acted in good faith, the act or its approval does
not harm the company, and the office holder discloses his or her personal interest, as described below.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disclosure of personal
interests of an office holder and approval of acts and transactions</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Compensation Policy requires
the approval of the general meeting of shareholders with a &#8220;Special Majority&#8221;, which requires a majority of the shareholders
of the company who are not either a controlling shareholder or an &#8220;interested party&#8221; in the proposed resolution, or that shareholders
holding less than 2% of the voting power in the company voted against the proposed resolution at such meeting. However, under special
circumstances, the Board of Directors may approve the compensation policy without shareholder approval, if the compensation committee
and thereafter the Board of Directors decided, based on substantiated reasons after they have reviewed the Compensation Policy again,
that the Compensation Policy is in the best interest of the company. The Compensation Policy is required to be brought before the shareholders
of the Company once every three years for approval.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The term personal interest
is defined under the Israeli Companies Law to include the personal interest of a person in an action or in the business of a company,
including the personal interest of such person&#8217;s relative or the interest of any corporation in which the person is an interested
party, but excluding a personal interest stemming solely from the fact of holding shares in the company. A personal interest furthermore
includes the personal interest of a person for whom the office holder holds a voting proxy or the interest of the office holder with respect
to his or her vote on behalf of the shareholder for whom he or she holds a proxy even if such shareholder itself has no personal interest
in the approval of the matter. An office holder is not, however, obliged to disclose a personal interest if it derives solely from the
personal interest of his or her relative in a transaction that is not considered an extraordinary transaction.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, an extraordinary transaction which requires approval is defined as any of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a transaction other than in the ordinary course of business;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a transaction that is not on market terms; or</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a transaction that may have a material impact on our profitability,
assets or liabilities.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, once an office holder has complied with the disclosure requirement described above, a company may approve a transaction between the
company and the office holder or a third party in which the office holder has a personal interest, or approve an action by the office
holder that would otherwise be deemed a breach of duty of loyalty. However, a company may not approve a transaction or action that is
adverse to our interest or that is not performed by the office holder in good faith.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 93; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->87<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, unless the articles of association of a company provide otherwise, a transaction with an office holder, a transaction with a third
party in which the office holder has a personal interest, and an action of an office holder that would otherwise be deemed a breach of
duty of loyalty requires approval by the Board of Directors. Our Amended and Restated Articles of Association do not provide otherwise.
If the transaction or action considered is (i) an extraordinary transaction, (ii) an action of an office holder that would otherwise be
deemed a breach of duty of loyalty and may have a material impact on a company&#8217;s profitability, assets or liabilities, (iii) an
undertaking to indemnify or insure an office holder who is not a director, or (iv) for matters considered an undertaking concerning the
terms of compensation of an office holder who is not a director, including, an undertaking to indemnify or insure such office holder,
then approval by the audit committee is required prior to approval by the Board of Directors. Arrangements regarding the compensation,
indemnification or insurance of a director require the approval of the audit committee, Board of Directors and shareholders, in that order.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A director who has a personal
interest in a matter that is considered at a meeting of the Board of Directors or the audit committee may generally not be present at
the meeting or vote on the matter, unless a majority of the directors or members of the audit committee have a personal interest in the
matter or the chairman of the audit committee or Board of Directors, as applicable, determines that he or she should be present to present
the transaction that is subject to approval. If a majority of the directors have a personal interest in the matter, such matter would
also require approval of the shareholders of the company.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Disclosure of personal
interests of a controlling shareholder and approval of transactions</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, the disclosure requirements that apply to an office holder also apply to a controlling shareholder of a public company. See &#8220;&#8212;
Audit Committee&#8221; for a definition of controlling shareholder. Extraordinary transactions with a controlling shareholder or in which
a controlling shareholder has a personal interest, including a private placement in which a controlling shareholder has a personal interest,
as well as transactions for the provision of services whether directly or indirectly by a controlling shareholder or his or her relative,
or a company such controlling shareholder controls, and transactions concerning the terms of engagement of a controlling shareholder or
a controlling shareholder&#8217;s relative, whether as an office holder or an employee, require the approval of the audit committee, the
Board of Directors and a majority of the shares voted by the shareholders of the company participating and voting on the matter in a shareholders&#8217;
meeting. In addition, such shareholder approval must fulfill one of the following requirements:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">at least a majority of the shares held by shareholders who
have no personal interest in the transaction and are voting at the meeting must be voted in favor of approving the transaction, excluding
abstentions; or</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the shares voted by shareholders who have no personal interest
in the transaction who vote against the transaction represent no more than 2% of the voting rights in the company.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent that any such
transaction with a controlling shareholder is for a period extending beyond three years, approval is required once every three years,
unless the audit committee determines that the duration of the transaction is reasonable given the circumstances related thereto.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Duties of shareholders</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, a shareholder has a duty to refrain from abusing its power in the company and to act in good faith and in an acceptable manner in
exercising its rights and performing its obligations to the company and other shareholders, including, among other things, voting at general
meetings of shareholders on the following matters:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">an amendment to the articles of association;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">an increase in our authorized share capital;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a merger; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the approval of related party transactions and acts of office
holders that require shareholder approval.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 94; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->88<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A shareholder also has a general
duty to refrain from discriminating against other shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The remedies generally available
upon a breach of contract will also apply to a breach of the above mentioned duties, and in the event of discrimination against other
shareholders, additional remedies are available to the injured shareholder.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, any controlling
shareholder, any shareholder that knows that its vote can determine the outcome of a shareholder vote and any shareholder that, under
a company&#8217;s articles of association, has the power to appoint or prevent the appointment of an office holder, or has another power
with respect to a company, is under a duty to act with fairness towards the company. The Israeli Companies Law does not describe the substance
of this duty except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach
of the duty to act with fairness, taking the shareholder&#8217;s position in the company into account.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Exculpation, Insurance and Indemnification
of Directors and Officers</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate
an office holder in advance from liability to us, in whole or in part, for damages caused to us as a result of a breach of duty of care
but only if a provision authorizing such exculpation is included in its articles of association. Our Amended and Restated Articles of
Association include such a provision. We may not exculpate in advance a director from liability arising out of a prohibited dividend or
distribution to shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law and the Israeli Securities Law, a company may indemnify, or undertake in advance to indemnify, an office holder, provided its articles
of association include a provision authorizing such indemnification, for the following liabilities and expenses imposed on an office holder
or incurred by office holder due to acts performed by him or her as an office holder:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Financial liability incurred by or imposed on him or her in
favor of another person pursuant to a judgment, including a settlement or arbitrator&#8217;s award approved by a court. However, if an
undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited
to events which, in the opinion of the Board of Directors, can be foreseen based on our activities when the undertaking to indemnify
is given, and to an amount or according to criteria determined by the Board of Directors as reasonable under the circumstances, and such
undertaking shall detail the abovementioned foreseen events and amount or criteria;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Reasonable litigation expenses, including attorneys&#8217;
fees, incurred by the office holder as a result of an investigation or proceeding instituted against him or her by an authority authorized
to conduct such investigation or proceeding, provided that (i) no indictment was filed against such office holder as a result of such
investigation or proceeding; and (ii) no financial liability was imposed upon him or her as a substitute for the criminal proceeding
as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense
that does not require proof of criminal intent or as a monetary sanction;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Reasonable litigation expenses, including attorneys&#8217;
fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by us, on our behalf, or by a
third party, or in connection with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for
an offense that does not require proof of criminal intent; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">Expenses, including reasonable litigation expenses and legal
fees, incurred by an office holder in relation to an administrative proceeding instituted against such office holder, or certain compensation
payments required to be made to an injured party, pursuant to certain provisions of the Israeli Securities Law.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 95; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->89<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder
if and to the extent provided in the Company&#8217;s articles of association:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a breach of the duty of loyalty to us, provided that the office
holder acted in good faith and had a reasonable basis to believe that the act would not harm us;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a breach of duty of care to us or to a third party; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a financial liability imposed on the office holder in favor
of a third party.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the provisions
of the Israeli Companies Law and the Israeli Securities Law, we may also enter into a contract to insure an office holder, in respect
of expenses, including reasonable litigation expenses and legal fees, incurred by an office holder in relation to an administrative proceeding
instituted against such office holder or payment required to be made to an injured party, pursuant to certain provisions of the Israeli
Securities Law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Nevertheless, under the Israeli
Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a breach of fiduciary duty, except for indemnification and
insurance for a breach of the duty of loyalty to us in the event office holder acted in good faith and had a reasonable basis to believe
that the act would not prejudice us;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a breach of duty of care committed intentionally or recklessly,
excluding a breach arising out of the negligent conduct of the office holder;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">an act or omission committed with intent to derive unlawful
personal benefit; or</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a fine, monetary sanction, penalty or forfeit levied against
the office holder.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, exculpation, indemnification and insurance of office holders require the approval of the compensation committee, Board of Directors
and, in certain circumstances, the shareholders. Our Amended and Restated Articles of Association permit us to exculpate, indemnify and
insure our office holders to the fullest extent permitted by the Israeli Companies Law.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Approval of Compensation to Our Officers</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
prescribes that compensation to officers must be approved by a company&#8217;s Board of Directors after obtaining the approval of the
compensation committee.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As detailed above, our compensation
committee consists of three independent directors: Yoseph Borenstein, Yaacov Goldman and Guy Regev. The responsibilities of the compensation
committee are to set our overall policy on executive remuneration and to decide the specific remuneration, benefits and terms of employment
for directors, officers and the Chief Executive Officer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The objectives of the compensation
committee&#8217;s policies are that such individuals should receive compensation which is appropriate given their performance, level of
responsibility and experience. Compensation packages should also allow us to attract and retain executives of the necessary caliber while,
at the same time, motivating them to achieve the highest level of corporate performance in line with the best interests of shareholders.
In order to determine the elements and level of remuneration appropriate to each executive director, the compensation committee reviews
surveys on executive pay, obtains external professional advice and considers individual performance.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 96; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->90<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Internal Auditor</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, the Board of Directors must appoint an internal auditor, nominated by the audit committee. The role of the internal auditor is to
examine, among other matters, whether our actions comply with the law and orderly business procedure. Under the Israeli Companies Law,
an internal auditor may not be:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a person (or a relative of a person) who holds more than 5%
of our ordinary shares;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a person (or a relative of a person) who has the power to
appoint a director or the general manager of the company;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">an executive officer or director of the company (or a relative
thereof); or</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a member of our independent accounting firm, or anyone on
his or her behalf.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We comply with the requirement
of the Israeli Companies Law relating to internal auditors. Our internal auditors examine whether our various activities comply with the
law and orderly business procedure. Our current internal auditor is Deloitte.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">D. Employees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2021, we
had eight employees, three of whom were employed in management and administration, four of whom were employed in research and development
and one of whom was employed in business development. All of these employees were located in Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">While none of our employees
are party to any collective bargaining agreements, certain provisions of the collective bargaining agreements between the Histadrut (General
Federation of Labor in Israel) and the Coordination Bureau of Economic Organizations (including the Industrialists&#8217; Associations)
are applicable to our employees by order of the Israel Ministry of Labor. These provisions primarily concern the length of the workday,
minimum daily wages for professional workers, pension fund benefits for all employees, insurance for work-related accidents, procedures
for dismissing employees, determination of severance pay and other conditions of employment. We generally provide our employees with benefits
and working conditions beyond the required minimums. We have never experienced any employment-related work stoppages and believe our relationship
with our employees is good.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">E. Share Ownership.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth
information regarding the beneficial ownership of our outstanding ordinary shares as of March 20, 2022 by the members of our senior management
and Board of Directors individually and as a group. The beneficial ownership of ordinary shares is based on the 815,746,293 ordinary shares
outstanding as of March 20, 2022 and is determined in accordance with the rules of the SEC and generally includes any ordinary shares
over which a person exercises sole or shared voting or investment power. For purposes of the table below, we deem shares subject to options
or warrants that are currently exercisable or exercisable within 60 days of March 20, 2022, to be outstanding and to be beneficially owned
by the person holding the options or warrants for the purposes of computing the percentage ownership of that person but we do not treat
them as outstanding for the purpose of computing the percentage ownership of any other person.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid">Name of Beneficial Owner</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of<br/> Ordinary Shares*</td>
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; border-bottom: Black 1.5pt solid">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Percentage<br/> of<br/> Class**</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: left">Senior Management and Directors</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td>
    <td style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 75%; text-align: left">Ilan Cohn, Ph.D.</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">444,067</td>
    <td style="padding-left: -0.125in; width: 1%; text-align: left">(1)</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">**</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Pnina Fishman, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,507,183</td>
    <td style="text-align: left">(2)</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">**</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Motti Farbstein</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,259,508</td>
    <td style="text-align: left">(3)</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">**</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Sari Fishman, Ph.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,194,000</td>
    <td style="text-align: left">(4)</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">**</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Guy Regev</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">344,740</td>
    <td style="text-align: left">(5)</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">**</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Abraham Sartani, M.D.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">314,500</td>
    <td style="text-align: left">(6)</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">**</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Yaacov Goldman</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">310,500</td>
    <td style="text-align: left">(7)</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">**</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Yoseph Borenstein</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">112,500</td>
    <td style="text-align: left">(8)</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">**</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Senior Management and Directors as a group (8 persons)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,486,998</td>
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">**</td><td style="text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">U.S. dollar translations of NIS amounts presented in the footnotes
to this table are translated using the exchange rate reported by the Bank of Israel on December 31, 2021.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">**</td><td style="text-align: justify">Denotes less than 1%</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Represents (i) 133,567 ordinary shares, (ii) 48,000 options to
purchase 48,000 ordinary shares at an exercise price of NIS 2.926 per option or $0.89 per option and expire on November 8, 2027, and
(iii) 262,500 options to purchase 262,500 ordinary shares at an exercise price of NIS 0.25 per option or $0.08 per option and expire
on June 14, 2030. Excludes 337,500 options to purchase 337,500 ordinary shares that vest in more than 60 days from March 20, 2022.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt"></p><div>

</div><!-- Field: Page; Sequence: 97; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->91<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">Represents (i) 263,433 ordinary shares, (ii) 200,000 options to
purchase 200,000 ordinary shares at an exercise price of NIS 3.573 per option or $1.09 per option and expire on October 22, 2025, (iii)
325,000 options to purchase 325,000 ordinary shares at an exercise price of NIS 2.344 per option or $0.72 per option and expire on January
7, 2029, and (iv) 1,093,750 options to purchase 1,093,750 ordinary shares at an exercise price of NIS 0.25 per option or $0.08 per option
and expire on May 27, 2030. (v) 625,000 options to purchase 625,000 ordinary shares at an exercise price of NIS 0.25 per option or $0.08
per option and expire on April 13, 2031. Excludes 3,356,250 options to purchase 3,356,250 ordinary shares that vest in more than 60 days
from March 20, 2022.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">(3)</td><td style="text-align: justify">Represents (i) 1,133 ordinary shares, (ii) 4,000 options to purchase
4,000 ordinary shares at an exercise price of NIS 0.326 per option or $0.10 per option and expire on March 20, 2023, (iii) 10,000 options
to purchase 10,000 ordinary shares at an exercise price of NIS 8.1205 per option or $2.49 per option and expire on March 18, 2025, (iv)
60,000 options to purchase 60,000 ordinary shares at an exercise price of NIS 4.317 per option or $1.32 per option and expire on February
18, 2026, (v) 250,000 options to purchase 250,000 ordinary shares at an exercise price of NIS 2.513 per option or $0.78 per option and
expire on December 28, 2027, (vi) 121,875 options to purchase 121,875 ordinary shares at an exercise price of NIS 2.344 per option or
$0.72 per option and expire on January 7, 2029, and (vii) 437,500 options to purchase 437,500 ordinary shares at an exercise price of
NIS 0.25 per option or $0.08 per option and expire on May 27, 2030. (viii) 375,000 options to purchase 375,000 ordinary shares at an
exercise price of NIS 0.25 per option or $0.08 per option and expire on April 13, 2031. Excludes 1,715,625 options to purchase 1,715,625
ordinary shares that vest in more than 60 days from March 20, 2022.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">(4)</td><td style="text-align: justify">Represents (i) 4,000 options to purchase 4,000 ordinary shares
at an exercise price of NIS 0.326 per option or $0.1 per option and expire on March 20, 2023, and (ii) 10,000 options to purchase 10,000
ordinary shares at an exercise price of NIS 8.1205 per option or $2.49 per option and expire on March 18, 2025, (iii) 40,000 options
to purchase 40,000 ordinary shares at an exercise price of NIS 4.317 per option or $1.32 per option and expire on February 18, 2026,
(iv) 80,000 options to purchase 80,000 ordinary shares at an exercise price of NIS 3.662 per option or $1.12 per option and expire on
March 30, 2027, (v) 150,000 options to purchase 150,000 ordinary shares at an exercise price of NIS 2.513 per option or $0.77 per option
and expire on December 30, 2027, (vi) 97,500 options to purchase 97,500 ordinary shares at an exercise price of NIS 2.344 per option
or $0.72 per option and expire on January 7, 2029, (vii) 437,500 options to purchase 437,500 ordinary shares at an exercise price of
NIS 0.25 per option or $0.08 per option and expire on May 27, 2030 and (viii) 375,000 options to purchase 375,000 ordinary shares at
an exercise price of NIS 0.25 per option or $0.08 per option and expire on April 13, 2031. Excludes 1,710,000 options to purchase 1,710,000
ordinary shares that vest in more than 60 days from March 20, 2022.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">(5)</td><td style="text-align: justify">Represents (i) 24,240 ordinary shares, (ii) 10,000 options to
purchase 10,000 ordinary shares at an exercise price of NIS 0.60 per option or $0.18 per option and expire on May 2, 2023, (iii) 48,000
options to purchase 48,000 ordinary shares at an exercise price of NIS 2.926 per option or $0.89 per option and expire on December 28,
2027, and (iv) 262,500 options to purchase 262,500 ordinary shares at an exercise price of NIS 0.25 per option or $0.08 per option and
expire on June 14, 2030. Excludes 337,500 options to purchase 337,500 ordinary shares that vest in more than 60 days from March 20,
2022.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">(6)</td><td style="text-align: justify">Represents (i) 4,000 options to purchase 4,000 ordinary shares
at an exercise price of NIS 0.60 per option or $0.18 per option and expire on August 14, 2022, (ii) 48,000 options to purchase 48,000
ordinary shares at an exercise price of NIS 2.926 per option or $0.88 per option and expire on November 8, 2027, and (iv) 262,500 options
are exercisable into 262,500 ordinary shares at an exercise price of NIS 0.25 per option or $0.08 per option and expire on June 14, 2030.
Excludes 337,500 options to purchase 337,500 ordinary shares that vest in more than 60 days from March 20, 2022.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">(7)</td><td style="text-align: justify">Represents (i) 48,000 options to purchase 48,000 ordinary shares
at an exercise price of NIS 2.926 per option or $0.89 per option and expire on November 8, 2027, (ii) 262,500 options to purchase 262,500
ordinary shares at an exercise price of NIS 0.25 per option or $0.08 per option and expire on June 14, 2030. Excludes 337,500 options
to purchase 337,500 ordinary shares that vest in more than 60 days from March 20, 2022.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">(8)</td><td style="text-align: justify">Represents 112,500 options to purchase 112,500 ordinary shares
at an exercise price of NIS 0.25 per option or $0.08 per option and expire on June 22, 2031. Excludes 487,500 options to purchase 487,500
ordinary shares that vest in more than 60 days from March 20, 2022.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">(9)</td><td style="text-align: justify">Based solely upon, and qualified in its entirety with reference
to, Schedule 13G filed with the SEC on January 29, 2021. Mitchell P. Kopin, or Mr. Kopin, and Daniel B. Asher, or Mr. Asher, each of
whom are managers of Intracoastal Capital, LLC, or Intracoastal, have shared voting control and investment discretion over the securities
reported herein that are held by Intracoastal. As a result, each of Mr. Kopin and Mr. Asher may be deemed to have beneficial ownership
(as determined under Section 13(d) of Exchange Act) of the securities reported herein that are held by Intracoastal. In the aggregate,
Mr. Kopin and Mr. Asher may be deemed to have beneficial ownership (as determined under Section 13(d) of the Exchange Act). Each of the
reporting persons may have been deemed to have beneficial ownership of 32,911,650 ordinary shares,&#160;which consisted of (i) 6,000,000
ordinary shares issuable upon exercise of a warrant held by Intracoastal (&#8220;Intracoastal Warrant 1&#8221;), (ii) 8,527,500 Ordinary
Shares issuable upon exercise of a second warrant held by Intracoastal (&#8220;Intracoastal Warrant 2&#8221;),&#160;(iii) 3,750,000 Ordinary
Shares issuable upon exercise of a third warrant held by Intracoastal (&#8220;Intracoastal Warrant 3&#8221;)&#160;and&#160;(iv) 14,634,150
Ordinary Shares issuable upon exercise of a fourth warrant held by Intracoastal (&#8220;Intracoastal Warrant 4&#8221;), and all such
ordinary shares represented beneficial ownership of approximately 6.4% of the Ordinary Shares. The foregoing excludes (I) 500,010 ordinary
shares issuable upon exercise of a fifth warrant held by Intracoastal (&#8220;Intracoastal Warrant 5&#8221;) because Intracoastal Warrant
5 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 5 to the extent
(but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder&#8217;s
affiliates, and any other persons acting as a group together with the holder or any of the holder&#8217;s affiliates, of more than 4.99%
of the ordinary shares and (II) 6,137,430 ordinary shares issuable upon exercise of a sixth warrant held by Intracoastal (&#8220;Intracoastal
Warrant 6&#8221;) because Intracoastal Warrant 6 contains a blocker provision under which the holder thereof does not have the right
to exercise Intracoastal Warrant 6 to the extent (but only to the extent) that such exercise would result in beneficial ownership by
the holder thereof, together with the holder&#8217;s affiliates, and any other persons acting as a group together with the holder or
any of the holder&#8217;s affiliates, of more than 4.99% of the Ordinary Shares. Without such blocker provisions, each of the reporting
persons may have been deemed to have beneficial ownership of 39,549,090 ordinary shares.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 98; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->92<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bank of New York Mellon,
or BNY, is the holder of record for our ADR program, pursuant to which each ADS represents 30 ordinary shares. As of March 20, 2022, BNY
held 606,796,860 ordinary shares representing approximately 74% of the outstanding ordinary shares at that date. Certain of these ordinary
shares were held by brokers or other nominees.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a result, the number of
holders of record or registered holders in the United States is not representative of the number of beneficial holders or of the residence
of beneficial holders.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Share Option Plans</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain the following
share option plans for our and our subsidiary&#8217;s employees, directors and consultants. In addition to the discussion below, see Note
11b of our consolidated financial statements, included elsewhere in this Annual Report on Form 20-F.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors administers
our share option plans and has the authority to designate all terms of the options granted under our plans including the grantees, exercise
prices, grant dates, vesting schedules and expiration dates, which may be no more than ten years after the grant date. Options may not
be granted with an exercise price of less than the fair market value of our ordinary shares on the date of grant, unless otherwise determined
by our Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of December 31, 2021, options
to purchase an aggregate of 18,422,700 ordinary shares, par value NIS 0.25, are outstanding pursuant to the 2003 and 2013 share option
plans.</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2003 Share Option Plan</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the 2003 Plan we granted
options during the period between 2003 and 2013, at exercise prices between NIS 0.25 and NIS 31.175 per ordinary share, par value NIS
0.25. There are no options to purchase ordinary shares, par value NIS 0.25, were available to be granted under the 2003 Plan. As of December
31, 2021, 1,030,000 options to purchase 41,200 ordinary shares were outstanding. Options granted to Israeli employees were in accordance
with section 102 of the Income Tax Ordinance, 1961, or the Tax Ordinance, under the capital gains option set forth in section 102(b)(2)
of the Tax Ordinance. The options are non-transferable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The option term is for a period
of ten years from the grant date. The options were granted for no consideration. The options vest over a four or two year period. As of
March 20, 2022, 41,200 options to purchase 41,200 ordinary shares, par value NIS 0.25, were fully vested.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2013 Share Option Plan</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the 2013 Plan we granted
options at exercise prices between NIS 0.25 and NIS 12 per ordinary share, par value NIS 0.25. As of December 31, 2021, options to purchase
up to 6,618,500 ordinary shares, par value NIS 0.25, were available to be granted under the 2013 Plan. As of December 31, 2021, 18,381,500
options to purchase 18,381,500 ordinary shares were outstanding. Options granted to Israeli employees were in accordance with the Tax
Ordinance under the capital gains option set forth in section 102(b)(2) of the Tax Ordinance. The options are non-transferable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The option term is for a period
of ten years from the grant date. The options were granted for no consideration. The options vest over a four year period. As of March
20, 2022, options to purchase 7,343,375 ordinary shares, par value NIS 0.25, were fully vested.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 99; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->93<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_009"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
7. </span>Major Shareholders and Related Party Transactions</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">A.
</span>Major Shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as set forth in &#8220;Item
6. Directors, Senior Management and Employees&#8212;E. Share Ownership,&#8221; to the best of our knowledge, no other person who we know
beneficially owns 5.0% or more of the Company&#8217;s ordinary shares outstanding as of March 20, 2022. None of our shareholders has different
voting rights from other shareholders. Other than as described herein, to the best of our knowledge, we are not owned or controlled, directly
or indirectly, by another corporation, by any foreign government or by any natural person or legal persons, severally or jointly, and
we are not aware of any arrangement that may, at a subsequent date, result in a change of control of our Company.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To our knowledge, other than
as disclosed in the table above, our other filings with the SEC and this Annual Report on Form 20-F, there has been no significant change
in the percentage ownership held by any major shareholder since January 1, 2019.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">B.
</span>Related Party Transactions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a description of the transactions with related parties
to which we, or our subsidiary, are party, and which were in effect since January 1, 2021. The descriptions provided below are summaries
of the terms of such agreements, do not purport to be complete and are qualified in their entirety by the complete agreements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We believe that we have executed
all of our transactions with related parties on terms no less favorable to us than those we could have obtained from unaffiliated third
parties. We are required by Israeli law to ensure that all future transactions between us and our officers, directors and principal shareholders
and their affiliates are approved by a majority of our Board of Directors, including a majority of the independent and disinterested members
of our Board of Directors, and that they are on terms no less favorable to us than those that we could obtain from unaffiliated third
parties.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 100; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->94<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Employment and Consulting Agreements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have or have had employment,
consulting or related agreements with each member of our senior management. See &#8220;Item 6. Directors, Senior Management and Employees&#8212;Compensation&#8221;.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We employ Zivit Harpaz as
Director of Regulatory and Clinical Operations. For fiscal years 2021 and 2020, Ms. Harpaz received salary, bonus and benefits totaling
approximately $262,000 and $229,000, respectively, and during fiscal years 2021 and 2020 we awarded to Ms. Harpaz options to purchase
1,000,000 and 750,000 ordinary shares, respectively. Ms. Harpaz is the daughter of Pnina Fishman.</p><div>
</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Options</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have granted options to
purchase our ordinary shares to certain of our senior management and directors. See &#8220;Item 6. B.&#8212;Compensation&#8221; and &#8220;Item
6. Directors, Senior Management and Employees&#8212;Share Ownership&#8221;. We describe our option plans under &#8220;Item 6. Directors,
Senior Management and Employees&#8212;Share Ownership&#8221;.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indemnification Agreements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated Articles
of Association permit us to exculpate, indemnify and insure our directors and officeholders to the fullest extent permitted by the Israeli
Companies Law. We have obtained directors&#8217; and officers&#8217; insurance for each of our officers and directors and have entered
into indemnification agreements with all of our current officers and directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">C.
</span>Interests of Experts and Counsel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 101; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->95<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_010"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
8. </span>Financial Information</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">A.
</span>Consolidated Financial Statements and Other Financial Information</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 18. Financial
Statements&#8221; for a list of all financial statements filed as part of this Annual Report on Form 20-F.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Legal Matters</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are not involved in any
legal or arbitration proceedings that may have or have had in the recent past, significant effects on our financial position or profitability.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividend Policy</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have never declared or
paid cash dividends to our shareholders. Currently we do not intend to pay cash dividends. We intend to reinvest any earnings in developing
and expanding our business. Any future determination relating to our dividend policy will be at the discretion of our Board of Directors
and will depend on a number of factors, including future earnings, our financial condition, operating results, contractual restrictions,
capital requirements, business prospects, applicable Israeli Companies Law and other factors our Board of Directors may deem relevant.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">B.
</span>Significant Changes</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Note 19:- Subsequent
Events&#8221; to our consolidated financial statements included in this Annual Report beginning on page F-1 for a discussion of significant
events that have occurred since December 31, 2021.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_011"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
9. </span>The Offer and Listing</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">A.
</span>Offer and Listing Details</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Ordinary Shares</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ordinary shares have been
trading on the TASE under the symbol &#8220;CFBI&#8221; since October 2005.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">ADSs</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On October 2, 2012, our ADSs
began trading OTC in the United States under the symbol &#8220;CANFY&#8221; and on November 19, 2013, our ADSs began trading on the NYSE
American under the symbol &#8220;CANF.&#8221; One ADS represents thirty (30) ordinary shares. See &#8220;Item 12. Description of Securities
Other Than Equity Securities&#8212;D. American Depositary Shares&#8221; for a description of the rights attaching to our ADSs. See &#8220;Item
12. Description of Securities Other Than Equity Securities&#8212;D. American Depositary Shares&#8221; for a description of the rights
attaching to our ADSs.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">B.
</span>Plan of Distribution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">C.
</span>Markets.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;&#8212;Offer and
Listing Details&#8221; above.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">D.
</span>Selling Shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">E.
</span>Dilution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">F.
</span>Expenses of the Issue.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 102; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->96<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_012"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
10. </span>Additional Information</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">A.
</span>Share Capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">B.
</span>Memorandum and Articles of Association.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our number with the Israeli
Registrar of Companies is 512022153. Our purpose is set forth in Section 3 of our Articles of Association and includes every lawful purpose.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our ordinary shares that are
fully paid for are issued in registered form and may be freely transferred under our Amended and Restated Articles of Association, unless
the transfer is restricted or prohibited by applicable law or the rules of a stock exchange on which the shares are traded. The ownership
or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our Amended and Restated Articles of Association
or the laws of the State of Israel, except for ownership by nationals of some countries that are, or have been, in a state of war with
Israel.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Israeli Companies
Law and our Amended and Restated Articles of Association, our Board of Directors may exercise all powers and take all actions that are
not required under law or under our Amended and Restated Articles of Association to be exercised or taken by our shareholders, including
the power to borrow money for company purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated Articles
of Association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Israeli Companies
Law and must be approved by a resolution duly passed by our shareholders at a general or special meeting by voting on such change in the
capital. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence
of sufficient retained earnings and profits and an issuance of shares for less than their nominal value, require a resolution of our Board
of Directors and court approval.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Dividends</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may declare a dividend
to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Israeli Companies Law, dividend
distributions are determined by the Board of Directors and do not require the approval of the shareholders of a company unless such company&#8217;s
articles of association provide otherwise. Our Amended and Restated Articles of Association do not require shareholder approval of a dividend
distribution and provide that dividend distributions may be determined by our Board of Directors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the Israeli Companies
Law, we may only distribute dividends from our profits accrued over the previous two years, as defined in the Israeli Companies Law, according
to our then last reviewed or audited financial reports, or we may distribute dividends with court approval. In each case, we are only
permitted to pay a dividend if there is no reasonable concern that payment of the dividend will prevent us from satisfying our existing
and foreseeable obligations as they become due.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Election of Directors</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated Articles
of Association provide that the maximum number of members of the Board of Directors is 13. The Board of Directors is presently comprised
of six members.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 103; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->97<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In February 2020, a special
general meeting of our shareholders approved an amendment to the our Amended and Restated Articles of Association, according to which
the Board of Directors, excluding the external directors, if any (who shall be elected and serve in office in strict accordance with the
provisions of the Companies Law, if so required by the Companies Law), shall consist of three classes of directors as nearly equal in
number as practicable, which are appointed for fixed terms of office in accordance with the Israeli Companies Law and our Amended and
Restated Articles of Association, as follows: (i) the term of office of the initial Class I directors shall expire at the first annual
general meeting of our shareholders held in 2020 and when their successors are elected and qualified, (ii) the term of office of the initial
Class II directors shall expire at the first annual general meeting of our shareholders following the annual general meeting of our shareholders
referred to in clause (i) above and when their successors are elected and qualified, and (iii) the term of office of the initial Class
III directors shall expire at the first annual general meeting of our shareholders following the annual general meeting of our shareholders
referred to in clause (ii) above and when their successors are elected and qualified.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors (other than external
directors), may be elected only in annual general meetings of our shareholders. At each annual general meeting of our shareholders, commencing
with the annual general meeting of our shareholders held in 2021, each of the successors elected to replace the directors of a class whose
term shall have expired at such annual general meeting of our shareholders shall be elected to hold office until the third annual general
meeting of our shareholders next succeeding his or her election and until his or her respective successor shall have been elected and
qualified. Notwithstanding anything to the contrary, each director shall serve until his or her successor is elected and qualified or
until such earlier time as such director&#8217;s office is vacated.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If the number of directors
(excluding external directors) that constitutes the Board of Directors is hereafter changed, the then-serving directors shall be re-designated
to other classes and/or any newly created directorships or decrease in directorships shall be apportioned by the Board of Directors among
the classes so as to make all classes as nearly equal in number as is practicable, provided that no decrease in the number of Directors
constituting the Board of Directors shall shorten the term of any incumbent director.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Directors so elected may not
be dismissed from office by the shareholders or by a general meeting of our shareholders prior to the expiration of their term of office.
The directors do not receive any benefits upon the expiration of their term of office.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The three classes of directors
are Class I Directors, Class II Directors and Class III Directors. Dr. Pnina Fishman and Mr. Guy Regev serve as our Class III Directors
until the close of the annual meeting to be held in 2022; Abraham Sartani serves as our Class I Director until the close of the annual
meeting to be held in 2023; and Ilan Cohn serves as our Class II Director until the close of the annual meeting to be held in 2024.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any amendment, replacement
or suspension of our Amended and Restated Articles of Association regarding the election of directors, as described above, require a majority
of 65% of the voting power represented at the general meeting of our shareholders in person or by proxy and voting thereon, disregarding
abstentions from the count of the voting power present and voting, provided that such majority constitutes more than 20% of our then issued
and outstanding share capital.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A nominee for service as a
director in a public company may not be elected without submitting a declaration to the company, prior to election, specifying that he
or she has the requisite qualifications to serve as a director, independent director or external director (if required), as applicable,
and the ability to devote the appropriate time to performing his or her duties as such.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A director, who ceases to
meet the statutory requirements to serve as a director, external director or independent director, as applicable, must notify the company
to that effect immediately and his or her service as a director will expire upon submission of such notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 6. Directors,
Senior Management and Employees&#8212;C. Board Practices&#8212;External Directors.&#8221;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Shareholder Meetings</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under Israeli Companies Law,
we are required to hold an annual general meeting of our shareholders once every calendar year that must be no later than 15 months after
the date of the previous annual general meeting. All meetings other than the annual general meeting of shareholders are referred to as
special meetings. Our Board of Directors may call special meetings whenever it sees fit, at such time and place, within or outside of
Israel, as it may determine. In addition, the Israeli Companies Law and our Amended and Restated Articles of Association provide that
our Board of Directors is required to convene a special meeting upon the written request of (i) any two of our directors or one quarter
of our Board of Directors or (ii) one or more shareholders holding, in the aggregate, either (1) 5% of our outstanding shares and 1% of
our outstanding voting power or (2) 5% of our outstanding voting power.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 104; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->98<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to the provisions
of the Israeli Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings
are the shareholders of record on a date to be decided by the Board of Directors, which may be between four and forty days prior to the
date of the meeting. Furthermore, the Israeli Companies Law and our Amended and Restated Articles of Association require that resolutions
regarding the following matters must be passed at a general meeting of our shareholders:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">amendments to our Amended and Restated Articles of Association;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">appointment or termination of our auditors;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">appointment of directors and appointment and dismissal of
external directors;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">approval of acts and transactions requiring general meeting
approval pursuant to the Israeli Companies Law;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">director compensation, indemnification and change of the principal
executive officer;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">increases or reductions of our authorized share capital;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">a merger; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the exercise of our Board of Director&#8217;s powers by a
general meeting, if our Board of Directors is unable to exercise its powers and the exercise of any of its powers is required for our
proper management.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
requires that a notice of any annual or special shareholders meeting be provided at least 21 days prior to the meeting and if the agenda
of the meeting includes the appointment or removal of directors, the approval of transactions with office holders or interested or related
parties, or an approval of a merger, notice must be provided at least 35 days prior to the meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
does not allow shareholders of publicly traded companies to approve corporate matters by written consent. Consequently, our Amended and
Restated Articles of Association does not allow shareholders to approve corporate matters by written consent.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to our Amended and
Restated Articles of Association, holders of our ordinary shares have one vote for each ordinary share held on all matters submitted to
a vote before the shareholders at a general meeting.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Quorum</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The quorum required for our
general meetings of shareholders consists of at least two shareholders present in person, by proxy or written ballot who hold or represent
between them at least 25% of the total outstanding voting rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A meeting adjourned for lack
of a quorum is adjourned to the same day in the following week at the same time and place or on a later date if so specified in the summons
or notice of the meeting. At the reconvened meeting, any number of our shareholders present in person or by proxy shall constitute a lawful
quorum.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Resolutions</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated Articles
of Association provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by applicable
law.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 105; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->99<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli law provides that
a shareholder of a public company may vote in a meeting and in a class meeting by means of a written ballot in which the shareholder indicates
how he or she votes on resolutions relating to the following matters:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">an appointment or removal of directors;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">an approval of transactions with office holders or interested or related parties;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">an approval of a merger or any other matter in respect of which there is a provision in the articles of association
providing that decisions of the general meeting may also be passed by written ballot;</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">authorizing the chairman of the Board of Directors or his relative to act as our chief executive officer
or act with such authority; or authorize our chief executive officer or his relative to act as the chairman of the Board of Directors
or act with such authority; and</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top">
<td style="width: 0.5in"></td><td style="width: 0.25in">&#9679;</td><td style="text-align: left">other matters which may be prescribed by Israel&#8217;s Minister of Justice.</td></tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The provision allowing the
vote by written ballot does not apply where the voting power of the controlling shareholder is sufficient to determine the vote. Our Amended
and Restated Articles of Association provide that our Board of Directors may prevent voting by means of a written ballot and this determination
is required to be stated in the notice convening the general meeting.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
provides that a shareholder, in exercising his or her rights and performing his or her obligations toward the company and its other shareholders,
must act in good faith and in a customary manner, and avoid abusing his or her power. This is required when voting at general meetings
on matters such as changes to the articles of association, increasing our registered capital, mergers and approval of related party transactions.
A shareholder also has a general duty to refrain from depriving any other shareholder of its rights as a shareholder. In addition, any
controlling shareholder, any shareholder who knows that its vote can determine the outcome of a shareholder vote and any shareholder who,
under such company&#8217;s articles of association, can appoint or prevent the appointment of an office holder, is required to act with
fairness towards the company. The Israeli Companies Law does not describe the substance of this duty except to state that the remedies
generally available upon a breach of contract will also apply to a breach of the duty to act with fairness, and, to the best of our knowledge,
there is no binding case law that addresses this subject directly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, unless provided otherwise in a company&#8217;s articles of association, a resolution at a shareholders meeting requires approval
by a simple majority of the voting rights represented at the meeting, in person, by proxy or written ballot, and voting on the resolution.
A resolution for the voluntary winding up of the company requires the approval of holders of 75% of the voting rights represented at the
meeting, in person, by proxy or by written ballot and voting on the resolution.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In the event of our liquidation,
after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary shares in proportion to
their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution
rights to the holders of a class of shares with preferential rights that may be authorized in the future.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Access to Corporate Records</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law, all shareholders of a company generally have the right to review minutes of our general meetings, its shareholders register and principal
shareholders register, articles of association, financial statements and any document it is required by law to file publicly with the
Israeli Companies Registrar and the Israel Securities Authority. Any of our shareholders may request access to review any document in
our possession that relates to any action or transaction with a related party, interested party or office holder that requires shareholder
approval under the Israeli Companies Law. We may deny a request to review a document if we determine that the request was not made in
good faith, that the document contains a commercial secret or a patent or that the document&#8217;s disclosure may otherwise prejudice
our interests.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 106; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->100<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Acquisitions under Israeli Law</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Full Tender Offer</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A person wishing to acquire
shares of a public Israeli company and who would as a result hold over 90% of the target company&#8217;s issued and outstanding share
capital is required by the Israeli Companies Law to make a tender offer to all of our shareholders for the purchase of all of the issued
and outstanding shares of the company. A person wishing to acquire shares of a public Israeli company and who would as a result hold over
90% of the issued and outstanding share capital of a certain class of shares is required to make a tender offer to all of the shareholders
who hold shares of the same class for the purchase of all of the issued and outstanding shares of the same class. If the shareholders
who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable class, all
of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law (provided that a majority
of the offerees that do not have a personal interest in such tender offer shall have approved the tender offer except that if the total
votes to reject the tender offer represent less than 2% of the company&#8217;s issued and outstanding share capital, in the aggregate,
approval by a majority of the offerees that do not have a personal interest in such tender offer is not required to complete the tender
offer). However, a shareholder that had its shares so transferred may petition the court within six months from the date of acceptance
of the full tender offer, whether or not such shareholder agreed to the tender or not, to determine whether the tender offer was for less
than fair value and whether the fair value should be paid as determined by the court unless the acquirer stipulated in the tender offer
that a shareholder that accepts the offer may not seek appraisal rights. If the shareholders who did not accept the tender offer hold
5% or more of the issued and outstanding share capital of the company or of the applicable class, the acquirer may not acquire shares
of the company that will increase its holdings to more than 90% of our issued and outstanding share capital or of the applicable class
from shareholders who accepted the tender offer.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Special Tender
Offer</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
provides that an acquisition of shares of a public Israeli company must be made by means of a special tender offer if as a result of the
acquisition the purchaser would become a holder of 25% or more of the voting rights in the company, unless one of the exemptions in the
Israeli Companies Law is met. This rule does not apply if there is already another holder of at least 25% of the voting rights in the
company. Similarly, the Israeli Companies Law provides that an acquisition of shares in a public company must be made by means of a tender
offer if as a result of the acquisition the purchaser would become a holder of 45% or more of the voting rights in the company, if there
is no other shareholder of the company who holds 45% or more of the voting rights in the company, unless one of the exemptions in the
Israeli Companies Law is met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A special tender offer must
be extended to all shareholders of a company but the offeror is not required to purchase shares representing more than 5% of the voting
power attached to our outstanding shares, regardless of how many shares are tendered by shareholders. A special tender offer may be consummated
only if (i) at least 5% of the voting power attached to our outstanding shares will be acquired by the offeror and (ii) the number of
shares tendered in the offer exceeds the number of shares whose holders objected to the offer.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a special tender offer
is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling
person or entity may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger
with the target company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to
effect such an offer or merger in the initial special tender offer.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Merger</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
permits merger transactions if approved by each party&#8217;s Board of Directors and, unless certain requirements described under the
Israeli Companies Law are met, a majority of each party&#8217;s shares voted on the proposed merger at a shareholders&#8217; meeting called
with at least 35 days&#8217; prior notice.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">For purposes of the shareholder
vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the shares represented at the shareholders
meeting that are held by parties other than the other party to the merger, or by any person who holds 25% or more of the outstanding shares
or the right to appoint 25% or more of the directors of the other party, vote against the merger. If the transaction would have been approved
but for the separate approval of each class or the exclusion of the votes of certain shareholders as provided above, a court may still
approve the merger upon the request of holders of at least 25% of the voting rights of a company, if the court holds that the merger is
fair and reasonable, taking into account the value of the parties to the merger and the consideration offered to the shareholders.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 107; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->101<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Upon the request of a creditor
of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern
that, as a result of the merger, the surviving company will be unable to satisfy the obligations of any of the parties to the merger,
and may further give instructions to secure the rights of creditors.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, a merger may
not be completed unless at least 50 days have passed from the date that a proposal for approval of the merger was filed by each party
with the Israeli Registrar of Companies and 30 days have passed from the date the merger was approved by the shareholders of each party.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Antitakeover Measures</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Israeli Companies Law
allows us to create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain
preferred rights, distributions or other matters and shares having preemptive rights. As of the date of this Annual Report on Form 20-F,
we do not have any authorized or issued shares other than our ordinary shares. In the future, if we do create and issue a class of shares
other than ordinary shares, such class of shares, depending on the specific rights that may be attached to them, may delay or prevent
a takeover or otherwise prevent our shareholders from realizing a potential premium over the market value of their ordinary shares. The
authorization of a new class of shares will require an amendment to our Amended and Restated Articles of Association which requires the
prior approval of the holders of a majority of our shares at a general meeting. In addition, the rules and regulations of the TASE also
limit the terms permitted with respect to a new class of shares and prohibit any such new class of shares from having voting rights. Shareholders
voting in such meeting will be subject to the restrictions provided in the Israeli Companies Law as described above.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Borrowing Powers</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the Israeli Companies
Law and our Amended and Restated Articles of Association, our Board of Directors may exercise all powers and take all actions that are
not required under law or under our amended and restated articles of association to be exercised or taken by our shareholders or other
corporate bodies, including the power to borrow money for company purposes.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Changes in Capital</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Amended and Restated Articles
of Association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Israeli Companies
Law and must be approved by a resolution duly passed by our shareholders at a general meeting by voting on such change in the capital.
In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of
sufficient retained earnings or profits and, in certain circumstances, an issuance of shares for less than their nominal value, require
the approval of both our Board of Directors and an Israeli court.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">C.
</span>Material Contracts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following are summary
descriptions of certain material agreements to which we are a party. The descriptions provided below do not purport to be complete and
are qualified in their entirety by the complete agreements, which may be attached as exhibits to this Annual Report on Form 20-F.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">License Agreements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 4. Information
on the Company&#8212;B. Business Overview&#8212;Out-Licensing and Distribution Agreements&#8221;.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">OphthaliX Merger Agreement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 7. Major Shareholders
and Related Party Transactions&#8212;B. Related Party Transactions&#8221;.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Employment and Consulting Agreements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">See &#8220;Item 6. Directors,
Senior Management and Employees&#8212;B. Compensation&#8212;Employment and Consulting Agreements&#8221;.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 108; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->102<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Univo Agreement</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On September 10, 2019, we
entered into a collaboration agreement with Univo, a medical cannabis company, to identify and co-develop specific formulations of cannabis
components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Under the collaboration agreement, Univo will
provide us with cannabis and cannabis components, as well as full access to its laboratories for both research and manufacturing. We agreed
to pay Univo a total of $500,000 through two installments and issued to Univo 19,934,355 ordinary shares through a private placement,
representing approximately 16.6% of Can-Fite&#8217;s ordinary shares outstanding after giving effect to the issuance. In addition, in
connection therewith, we issued 996,690 ordinary shares to a consultant. On February 17, 2020, the Company entered into an amendment to
Univo agreement, pursuant to which the parties expanded the collaboration to allow the testing of minute CBD concentrations/ dosages in
combination with Namodenoson on liver cancer and additional oncological indications. As part of the expansion, the Company agreed to fund
the research and development activities for the two new indications, to be jointly performed, for an amount of US $200 per indication.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The companies will initially
share ownership of intellectual property developed in this collaboration. Revenues derived from the collaboration will generally be shared
between us and Univo on the basis of each party&#8217;s contribution. Golan Bitton, Univo&#8217;s CEO, served as an observer to our board
of directors until his appointment to our board of directors on December 18, 2019. On February 27, 2020, Golan Bitton resigned from the
Company&#8217;s board of directors, effective immediately. As of December 31, 2020, our collaboration agreement with Univo expired.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">D.
</span>Exchange Controls</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There are no Israeli government laws, decrees or regulations that restrict
or that affect our export or import of capital or the remittance of dividends, interest or other payments to non-resident holders of our
securities, including the availability of cash and cash equivalents for use by us and our wholly-owned subsidiary, except or otherwise
as set forth under &#8220;Item 10. Additional Information&#8212;E. Taxation.&#8221;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">E.
</span>Taxation</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following description
is not intended to constitute a complete analysis of all tax consequences relating to the acquisition, ownership and disposition of our
ordinary shares, ADSs, Warrants or Pre-funded Warrants. You should consult your own tax advisor concerning the tax consequences of your
particular situation, as well as any tax consequences that may arise under the laws of any state, local, foreign, or other taxing jurisdiction.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Certain Israeli Tax Considerations</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a summary
of the material Israeli tax laws applicable to us. This section also contains a discussion of material Israeli tax consequences concerning
the ownership and disposition of our ordinary shares. This summary does not discuss all the aspects of Israeli tax law that may be relevant
to a particular investor in light of his or her personal investment circumstances or to some types of investors subject to special treatment
under Israeli law. Examples of this kind of investor include residents of Israel or traders in securities who are subject to special tax
regimes not covered in this discussion. Because certain parts of this discussion are based on new tax legislation that has not yet been
subject to judicial or administrative interpretation, we cannot assure you that the appropriate tax authorities or the courts will accept
the views expressed in this discussion. The discussion does not cover all possible tax consequences.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">You are urged to consult
your own tax advisor as to the Israeli and other tax consequences of the purchase, ownership and disposition of our ADSs, including, in
particular, the effect of any non-Israeli, state or local taxes.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">General Corporate Tax Structure in Israel</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Israeli companies are generally
subject to corporate tax, which has decreased in recent years, from a rate of 26.5% in 2014 and 2015 to 25% in 2016 and to 24% in 2017
to 23% for 2018, 2019, 2020 and 2021. However, the effective corporate tax rate payable by a company that derives income from an Approved
Enterprise, a Privileged Enterprise or a Preferred Enterprise (as discussed below) may be considerably less. Capital gains generated by
an Israeli company are generally subject to tax at the corporate tax rate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In 2006, transfer pricing
regulations came into force, following the introduction of Section 85A of the Israeli Tax Ordinance under Amendment 132. The transfer
pricing rules require that cross-border transactions between related parties be carried out implementing an arms&#8217; length principle
based on a transfer pricing study and reported and taxed accordingly.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 109; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->103<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Pre-Ruling from the Israeli Income Tax
Authorities</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In connection with the spin-off,
we received a pre-ruling decision from the Israeli Income Tax Authority which confirms: (i) that the grant of the license to Eye-Fite
is not liable for tax pursuant to the provisions of section 104a to the Income Tax Ordinance (New Version), 1961, or the Ordinance; (ii)
that OphthaliX is considered the receiving company pursuant to section 103c(7)(b) to the Ordinance; (iii) that the sale of Eye-Fite shares
to OphthaliX as consideration for OphthaliX shares does not create liability for tax pursuant to the provisions of section 103t to the
Ordinance, or change in structure; and (iv) the date for the change in structure was determined. According to the tax pre-ruling, the
date of change in structure shall also be the date of exchange of shares with respect to the spin-off and notification to the tax assessor.
We and Eye-Fite presented to the tax assessor and the merger and spin-off department of the tax assessor the forms required by the Ordinance
and the regulations thereunder. The tax pre-ruling further provides that the grant of a license to Eye-Fite as consideration for the issuance
of Eye-Fite shares to us does not create liability for tax pursuant to the provisions of section 104a to the Ordinance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to the pre-ruling,
we must not sell more than 10% of our common stock holdings in OphthaliX issued in connection with the change in structure for at least
two years from the date of the change (i.e., November 21, 2011), OphthaliX must not sell more than 10% of its ordinary share holdings
in Eye-Fite received in connection with the change in structure for at least two years from the date of the change and Eye-Fite must retain
the assets received from us in connection with the change in structure for at least two years from the date of the change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of Eye-Fite which
were transferred to OphthaliX in connection with the change in structure will be held in escrow. The sale of these shares will be deemed
as a sale by an Israeli company and will be taxed accordingly. The trustee will withhold tax at the source.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The shares of OphthaliX which
were transferred to us in connection with the change in structure will be held in escrow. The sale of these shares will be deemed as a
sale by an Israeli company and will be taxed accordingly. The trustee will withhold tax at the source.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any dividend distributed by
Eye-Fite to OphthaliX will be taxed in Israel in accordance with paragraph 125b(5) of the Israeli Tax Ordinance.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A description of the terms
of the pre-ruling is also included in the notes to the financial statements.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Tax Benefits and Grants for Research
and Development</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">According to section 20A of
the Israeli tax Ordinance, under certain conditions, a tax deduction for research and development expenditures, including capital expenditures,
for the year in which they are incurred. These expenses must relate to scientific research and development projects and must be approved
by the Office of the Chief Scientist, or the OCS, of the relevant Israeli government ministry, determined by the field of research. Furthermore,
the research and development must be for the promotion of the company and carried out by or on behalf of the company seeking such tax
deduction. The amount of such deductible expenses is reduced by the sum of any funds received through government grants for the funding
of the scientific research and development projects. No deduction under these research and development deduction rules is allowed if such
deduction is related to an expense invested in an asset depreciable under the general depreciation rules of the Tax Ordinance. Expenditures
not so approved are deductible in equal amounts over three years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On a yearly basis, we evaluate
the applicability of the above tax deduction for research and development expenditures and, based on our evaluation, determine whether
to apply to the OCS for approval of a tax deduction. There can be no assurance that any application for a tax deduction will be accepted.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 110; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->104<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Taxation of our Shareholders</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Capital Gains Taxes Applicable
to Non-Israeli Resident Shareholders</i>. Shareholders that are not Israeli residents are generally exempt from Israeli capital gains
tax on any gains derived from the sale, exchange or disposition of our ordinary shares, provided that such shareholders did not acquire
their shares prior to our initial public offering on the TASE and such gains were not derived from a permanent establishment or business
activity of such shareholders in Israel. However, non-Israeli corporations will not be entitled to the foregoing exemptions if an Israeli
resident (i) has a controlling interest of 25% or more in such non-Israeli corporation or (ii) is the beneficiary of or is entitled to
25% or more of the revenues or profits of such non-Israeli corporation, whether directly or indirectly.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, under the U.S.-Israel
Income Tax Treaty, 1995, or the U.S.-Israel Tax Treaty, the sale, exchange or disposition of our ordinary shares by a shareholder who
is a U.S. resident (for purposes of the U.S.-Israel Tax Treaty) holding the shares as a capital asset is exempt from Israeli capital gains
tax unless either (i) the shareholder holds, directly or indirectly, shares representing 10% or more of our voting capital during any
part of the 12-month period preceding such sale, exchange or disposition or (ii) the capital gains arising from such sale are attributable
to a permanent establishment of the shareholder located in Israel. In either case, the sale, exchange or disposition of the shares would
be subject to Israeli tax, to the extent applicable; however, under the U.S.-Israel Tax Treaty, the U.S. resident would be permitted to
claim a credit for the tax against the U.S. federal income tax imposed with respect to the sale, exchange or disposition, subject to the
limitations in U.S. laws applicable to foreign tax credits. The U.S.-Israel Tax Treaty does not relate to U.S. state or local taxes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Shareholders may be required
to demonstrate that they are exempt from tax on their capital gains in order to avoid withholding at source at the time of sale.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Taxation of Non-Israeli
Shareholders on Receipt of Dividends</i>. Non-residents of Israel are generally subject to Israeli income tax on the receipt of dividends
paid on our ordinary shares at the rate of 25%, which tax will be withheld at the source, unless a different rate is provided in a tax
treaty between Israel and the shareholder&#8217;s country of residence. With respect to a person who is a &#8220;substantial shareholder&#8221;
at the time receiving the dividend or on any date in the 12 months preceding such date, the applicable tax rate is 30%. A &#8220;substantial
shareholder&#8221; is generally a person who alone, or together with his relative or another person who collaborates with him on a permanent
basis, holds, directly or indirectly, at least 10% of any of the &#8220;means of control&#8221; of the corporation. &#8220;Means of control&#8221;
generally include the right to vote, receive profits, nominate a director or an officer, receive assets upon liquidation, or order someone
who holds any of the aforesaid rights how to act, and all regardless of the source of such right.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the U.S.-Israel Tax
Treaty, the maximum rate of tax withheld in Israel on dividends paid to a holder of our ordinary shares who is a U.S. resident (for purposes
of the U.S.-Israel Tax Treaty) is 25%. However, generally, the maximum rate of withholding tax on dividends paid shall be 12.5% in the
event that the U.S. corporation holding 10% or more of our outstanding voting capital throughout the tax year in which the dividend is
distributed as well as the previous tax year, and no more than 25% of the gross income of our income in such prior taxable year (if any)
consists of interest or dividends (excluding interest derived from the conduct of a banking, insurance, or financing business or interest
received from subsidiary corporations, 50 percent or more of the outstanding shares of the voting stock of which is owned us at the time
such dividends or interest is received). Note that 12.5% tax on dividend shall not apply in the event the dividend derives from income
that is entitled to the reduced tax rate applicable to an approved enterprise under Israel&#8217;s Encouragement of Capital Investments
Law (1959) (In such case, 15% tax rate shall apply).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A non-resident of Israel who
receives dividends from which tax was withheld is generally exempt from the duty to file returns in Israel in respect of such income,
provided such income was not derived from a business conducted in Israel by the taxpayer, and the taxpayer has no other taxable sources
of income in Israel.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Taxation of Israeli Shareholders on Receipt
of Dividends</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Residents of Israel are generally
subject to Israeli income tax on the receipt of dividends paid on our ordinary shares at the rate of 25%, which tax will be withheld at
the source. With respect to a person who is a &#8220;substantial shareholder&#8221; at the time of receiving the dividend or on any date
within the 12 months preceding such date, the applicable tax rate is 30%.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 111; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->105<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">U.S. Federal Income Tax Consequences</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following is a general
summary of certain material U.S. federal income tax consequences relating to the purchase, ownership and disposition of our ordinary shares,ADSs,
Warrants, and Pre-funded Warrants by U.S. Holders (as defined below) that hold such ordinary shares, ADSs, Warrants, or Pre-funded Warrants
as capital assets (generally, property held for investment). This summary is based on the Internal Revenue Code of 1986, as amended, or
the Code, the regulations of the U.S. Department of the Treasury issued pursuant to the Code, or the Treasury Regulations, administrative
and judicial interpretations thereof, and the U.S.-Israel Income Tax Treaty, all as in effect on the date hereof and all of which are
subject to change, possibly with retroactive effect, or to different interpretation. No ruling has been sought from the IRS, with respect
to any United States federal income tax consequences described below, and there can be no assurance that the IRS or a court will not take
a contrary position. This summary does not address all of the tax considerations that may be relevant to specific U.S. Holders in light
of their particular circumstances or to U.S. Holders subject to special treatment under U.S. federal income tax law, including but not
limited to, (1) a bank, insurance company, regulated investment company, or other financial institution or &#8220;financial services entity&#8221;;
(2) a broker or dealer in securities or foreign currency; (3) a person who acquired our ordinary shares, ADSs, Warrants, or Pre-funded
Warrants in connection with employment or other performance of services; (4) a U.S. Holder that is subject to the U.S. alternative minimum
tax; (5) a U.S. Holder that holds our ordinary shares, ADSs, Warrants, or Pre-funded Warrants as a hedge or as part of a hedging, straddle,
conversion or constructive sale transaction or other risk-reduction transaction for U.S. federal income tax purposes; (6) a retirement
plan or tax-exempt entity; (7) real estate investment trusts; (8) a U.S. Holder that expatriates out of the United States or a former
long-term resident of the United States; or (9) a U.S. Holder having a functional currency other than the U.S. dollar. This discussion
does not address the U.S. federal income tax treatment of a U.S. Holder that owns, directly or constructively, at any time, ordinary shares
or ADSs representing 10% or more of our voting power or value (including by treating U.S. Holders of Warrants, Pre-funded Warrants, or
other options to acquire our ordinary shares or ADSs as owning such ordinary shares or ADSs). Additionally, this summary does not address
any U.S. state or local or non-U.S. tax considerations or any U.S. federal estate, gift or alternative minimum tax considerations or any
U.S. federal tax consequences other than U.S. federal income tax consequences. In addition, this discussion assumes that a U.S. Holder
will not be entitled to a fractional share upon the exercise of a Warrant or Pre-funded Warrant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As used in this summary, the
term &#8220;U.S. Holder&#8221; means a beneficial owner of our ordinary shares, ADSs, Warrants, or Pre-funded Warrants that is, for U.S.
federal income tax purposes, (i) an individual citizen or resident of the United States, (ii) a corporation, or other entity taxable as
a corporation for U.S. federal income tax purposes, created or organized in or under the laws of the United States, any state thereof,
or the District of Columbia, (iii) an estate the income of which is subject to U.S. federal income tax regardless of its source or (iv)
a trust with respect to which a court within the United States is able to exercise primary supervision over its administration and one
or more U.S. persons have the authority to control all of its substantial decisions, or that has a valid election in effect under applicable
Treasury Regulations to be treated as a &#8220;United States person.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If an entity or arrangement
treated as a partnership for U.S. federal income tax purposes holds our ordinary shares, ADSs, Warrants, or Pre-funded Warrants, the tax
treatment of such partnership and each person or entity treated as a partner thereof will generally depend upon the status and activities
of the partnership and such partner. A holder that is treated as a partnership for U.S. federal income tax purposes should consult its
own tax advisor regarding the U.S. federal income tax considerations applicable to it and its partners of the purchase, ownership and
disposition of its ordinary shares, ADSs, Warrants, or Pre-funded Warrants.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This summary is not intended
to be, and should not be considered to be, legal or tax advice. Prospective investors should be aware that this summary does not address
the tax consequences to investors who are not U.S. Holders, except to the limited extent discussed below. Prospective investors should
consult their own tax advisors as to the particular tax considerations applicable to them relating to the purchase, ownership and disposition
of their ordinary shares, ADSs, Warrants, or Pre-funded Warrants, including the applicability of U.S. federal, state and local tax laws
and non-U.S. tax laws.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Taxation of U.S. Holders</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The discussions under &#8220;&#8212;
Distributions&#8221; and under &#8220;&#8212; Sale, Exchange or Other Disposition of Ordinary Shares, ADSs, Warrants, and Pre-funded Warrants&#8221;
below assume that we will not be treated as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes. Based
on our analysis of our income, assets, and operations, we believe that we were not a PFIC for 2021. Because the PFIC determination is
highly fact intensive, there can be no assurance that we will not be a PFIC for 2022 or for any other taxable year. For a discussion of
the rules that would apply if we are treated as a PFIC, see the discussion under &#8220;&#8212; Passive Foreign Investment Company.&#8221;</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 112; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->106<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Tax Characterization of
Pre-funded Warrants</i>. Although the appropriate characterization of Pre-funded Warrants under the tax law is unsettled, it is likely
that the Pre-funded Warrants will be treated as a class of our ordinary shares for U.S. federal income tax purposes. However, it is possible
that the IRS could treat the Pre-funded Warrants as warrants to acquire our ADSs. U.S. Holders should consult their own tax advisors regarding
the U.S. federal income tax consequences of an investment in our Pre-funded Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Allocation of Purchase
Price and Characterization of Units</i>. Each Unit and Pre-funded Unit should be treated for U.S. federal income tax purposes as an investment
unit consisting of one ADS (or Pre-funded Warrant, as the case may be), and one Warrant to purchase one ADS. For U.S. federal income tax
purposes, each U.S. Holder must allocate the purchase price of a Unit or Pre-funded Unit between that ADS (or Pre-funded Warrant, as applicable),
and the Warrant based on the relative fair market value of each at the time of issuance. The purchase price allocated to each ADS, Pre-funded
Warrant, and Warrant generally will be the U.S. Holder&#8217;s tax basis in such security, as the case may be. Each U.S. Holder should
consult its own tax advisor regarding the allocation of the purchase price for a Unit or Pre-funded Unit.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Distributions.&#160;</i>We
have no current plans to pay dividends. To the extent we pay any dividends, a U.S. Holder will be required to include in gross income
as a taxable dividend the amount of any distributions made on the ordinary shares or ADSs, including the amount of any Israeli taxes withheld,
to the extent that those distributions are paid out of our current and/or accumulated earnings and profits as determined for U.S. federal
income tax purposes. Any distributions in excess of our earnings and profits will be applied against and will reduce the U.S. Holder&#8217;s
tax basis in its shares or ADSs and to the extent they exceed that tax basis, will be treated as gain from the sale or exchange of those
shares or ADSs. If we were to pay dividends, we expect to pay such dividends in NIS with respect to the shares and in U.S. dollars with
respect to ADSs. A dividend paid in NIS, including the amount of any Israeli taxes withheld, will be includible in a U.S. Holder&#8217;s
income as a U.S. dollar amount calculated by reference to the exchange rate in effect on the date such dividend is received, regardless
of whether the payment is in fact converted into U.S. dollars. If the dividend is converted to U.S. dollars on the date of receipt, a
U.S. Holder generally will not recognize a foreign currency gain or loss. However, if the U.S. Holder converts the NIS into U.S. dollars
on a later date, the U.S. Holder must include, in computing its income, any gain or loss resulting from any exchange rate fluctuations.
The gain or loss will be equal to the difference between (i) the U.S. dollar value of the amount included in income when the dividend
was received and (ii) the amount received on the conversion of the NIS into U.S. dollars. Such gain or loss will generally be ordinary
income or loss and United States source for U.S. foreign tax credit purposes. U.S. Holders should consult their own tax advisors regarding
the tax consequences to them if we pay dividends in NIS or any other non-U.S. currency.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Subject to certain significant
conditions and limitations, including potential limitations under the U.S.-Israel Tax Treaty, any Israeli taxes paid on or withheld from
distributions from us and not refundable to a U.S. Holder may be credited against the investor&#8217;s U.S. federal income tax liability
or, alternatively, may be deducted from the investor&#8217;s taxable income. The election to credit or deduct foreign taxes is made on
a year-by-year basis and applies to all foreign taxes paid by a U.S. Holder or withheld from a U.S. Holder that year. Dividends paid on
the ordinary shares generally will constitute income from sources outside the United States and be categorized as &#8220;passive category
income&#8221; or, in the case of some U.S. Holders, as &#8220;general category income&#8221; for U.S. foreign tax credit purposes.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Because the rules governing
foreign tax credits are complex, U.S. Holders should consult their own tax advisor regarding the availability of foreign tax credits in
their particular circumstances.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Dividends paid on the ordinary
shares and ADSs will not be eligible for the &#8220;dividends-received&#8221; deduction generally allowed to corporate U.S. Holders with
respect to dividends received from U.S. corporations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 113; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->107<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain distributions treated
as dividends that are received by an individual U.S. Holder from &#8220;qualified foreign corporations&#8221; generally qualify for a
20% tax rate so long as certain holding period and other requirements are met. A non-U.S. corporation (other than a corporation that is
treated as a PFIC for the taxable year in which the dividend is paid or the preceding taxable year) generally will be considered to be
a qualified foreign corporation (i) if it is eligible for the benefits of a comprehensive tax treaty with the United States which the
Secretary of Treasury of the United States determines is satisfactory for purposes of this provision and which includes an exchange of
information program, or (ii) with respect to any dividend it pays on stock (or ADSs in respect of such stock) which is readily tradable
on an established securities market in the United States. Dividends paid by us in a taxable year in which we are not a PFIC and with respect
to which we were not a PFIC in the preceding taxable year are expected to be eligible for the 20% tax rate, although we can offer no assurances
in this regard. However, any dividend paid by us in a taxable year in which we are a PFIC or were a PFIC in the preceding taxable year
will be subject to tax at regular ordinary income rates. Because the PFIC determination is highly fact intensive, there can be no assurance
that we will not be a PFIC in 2021 or in any other taxable year. The additional 3.8% &#8220;net investment income tax&#8221; (described
below) may apply to dividends received by certain U.S. Holders who meet certain modified adjusted gross income thresholds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Adjustments with respect
to Warrants and Pre-funded Warrants</i>. The terms of the Warrants and Pre-funded Warrants provide for an adjustment to the number of
shares for which the warrant may be exercised or to the exercise price of the warrant in certain events. An adjustment that has the effect
of preventing dilution generally is not taxable. However, the U.S. Holders of the Warrants or Pre-funded Warrants would be treated as
receiving a constructive distribution from us if, for example, the adjustment increases the warrant holders&#8217; proportionate interest
in our assets or earnings and profits (e.g., through a decrease in the exercise price of the Warrants or Pre-funded Warrants) as a result
of a distribution of cash to the holders of our ordinary shares or ADSs, which is taxable to the U.S. Holders of such ordinary shares
or ADSs as described under &#8220;&#8212;Distributions&#8221; above. Such constructive distribution would be subject to tax as described
under that section in the same manner as if the U.S. Holders of the Warrants or Pre-funded Warrants received a cash distribution from
us equal to the fair market value of such increased interest. U.S. Holders of Warrants and Pre-funded Warrants are urged to consult their
own tax advisors on these issues<b>.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Sale, Exchange or Other
Disposition of Ordinary Shares, ADSs, Warrants, and Pre-funded Warrants.&#160;</i>Subject to the discussion under &#8220;&#8212; Passive
Foreign Investment Company&#8221; below, a U.S. Holder generally will recognize capital gain or loss upon the sale, exchange or other
taxable disposition of our ordinary shares, ADSs, Warrants, or Pre-funded Warrants in an amount equal to the difference between the amount
realized on the sale, exchange or other disposition and the U.S. Holder&#8217;s adjusted tax basis in such securities. This capital gain
or loss will be long-term capital gain or loss if the U.S. Holder&#8217;s holding period in our securities exceeds one year. Preferential
tax rates for long-term capital gain (currently, with a maximum rate of 20%) will apply to individual U.S. Holders. The deductibility
of capital losses is subject to limitations. The gain or loss will generally be income or loss from sources within the United States for
U.S. foreign tax credit purposes, subject to certain exceptions in the U.S.-Israel Tax Treaty. The additional 3.8% &#8220;net investment
income tax&#8221; (described below) may apply to gains recognized upon the sale, exchange, or other taxable disposition of our securities
by certain U.S. Holders who meet certain modified adjusted gross income thresholds.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders should consult
their own tax advisors regarding the U.S. federal income tax consequences of receiving currency other than U.S. dollars upon the disposition
of their ordinary shares, ADSs, Warrants, or Pre-funded Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Exercise or Lapse of a
Warrant and Pre-funded Warrants</i>. Subject to the discussion under &#8220;&#8212;Passive Foreign Investment Company&#8221; below, a
U.S. Holder generally will not recognize gain or loss upon the exercise of a Warrant or Pre-funded Warrant for cash. An ADS acquired pursuant
to the exercise of a Warrant or Pre-funded Warrant for cash generally will have a tax basis equal to the U.S. Holder&#8217;s tax basis
in the Warrant or Pre-funded Warrant, increased by the amount paid to exercise the Warrant or Pre-funded Warrant. The holding period of
such ADS generally would begin on the day after the date of exercise of the Warrant or Pre-funded Warrant. If a Warrant or Pre-funded
Warrant is allowed to lapse unexercised, a U.S. Holder generally will recognize a capital loss equal to such holder&#8217;s tax basis
in the warrant.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The tax consequences of a
cashless exercise of Warrants are unclear and could differ from the consequences described above. It is possible that a cashless exercise
could be a taxable event. U.S. Holders should consult their own tax advisors regarding the U.S. federal income tax consequences of the
cashless exercise of Warrants, including with respect to whether the exercise is a taxable event, and their holding period and tax basis
in the ADSs received.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 114; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->108<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Passive Foreign Investment Company</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, a corporation
organized outside the United States will be treated as a PFIC for U.S. federal income tax purposes in any taxable year in which either
(i) at least 75% of its gross income is &#8220;passive income&#8221; or (ii) on average at least 50% of its assets (by value) produce
passive income or are held for the production of passive income. Passive income for this purpose generally includes, among other things,
certain dividends, interest, royalties, rents and gains from commodities and securities transactions and from the sale or exchange of
property that gives rise to passive income. Passive income also includes amounts derived by reason of the temporary investment of funds,
including those raised in the public offering. Assets that produce or are held for the production of passive income may include cash,
even if held as working capital or raised in a public offering, as well as marketable securities and other assets that may produce passive
income. In determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in
which it owns, directly or indirectly, at least a 25% interest (by value) is taken into account.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the tests described
above, whether or not we are a PFIC will be determined annually based upon the composition of our income and the composition and valuation
of our assets, all of which are subject to change.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our analysis of our
income, assets, and operations, we believe that we were not a PFIC for 2021. Because the PFIC determination is highly fact intensive,
there can be no assurance that we will not be a PFIC in 2022 or in any other taxable year.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Default PFIC Rules</i>.
If we are a PFIC for any tax year, a U.S. Holder who does not make a timely QEF election or a mark-to-market election, referred to in
this disclosure as a &#8220;Non-Electing U.S. Holder,&#8221; will be subject to special rules with respect to (i) any &#8220;excess distribution&#8221;
(generally, the portion of any distributions received by the Non-Electing U.S. Holder on the ordinary shares or ADSs (or warrants, to
the extent applicable) in a taxable year in excess of 125% of the average annual distributions received by the Non-Electing U.S. Holder
in the three preceding taxable years, or, if shorter, the Non-Electing U.S. Holder&#8217;s holding period for the ordinary shares or ADSs),
and (ii) any gain realized on the sale or other disposition of ordinary shares, ADSs, Warrants, or Pre-funded Warrants. Under these rules:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the excess distribution or gain would be allocated ratably
over the Non-Electing U.S. Holder&#8217;s holding period for such ordinary shares, ADSs, Warrants, or Pre-funded Warrants;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the amount allocated to the current taxable year and any year
prior to us becoming a PFIC would be taxed as ordinary income; and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">the amount allocated to each of the other taxable years would
be subject to tax at the highest rate of tax in effect for the applicable class of taxpayer for that year, and an interest charge for
the deemed deferral benefit would be imposed with respect to the resulting tax attributable to each such other taxable year.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If a Non-Electing U.S. Holder
who is an individual dies while owning our ordinary shares, ADSs, Warrants, or Pre-funded Warrants, the Non-Electing U.S. Holder&#8217;s
successor would be ineligible to receive a step-up in tax basis of such ordinary shares, ADSs, Warrants, or Pre-funded Warrants. Non-Electing
U.S. Holders should consult their tax advisors regarding the application of the &#8220;net investment income tax&#8221; (described below)
to their specific situation.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To the extent a distribution
on our ordinary shares or ADSs (or warrants, to the extent applicable) does not constitute an excess distribution to a Non-Electing U.S.
Holder, such Non-Electing U.S. Holder generally will be required to include the amount of such distribution in gross income as a dividend
to the extent of our current and/or accumulated earnings and profits (as determined for U.S. federal income tax purposes) that are not
allocated to excess distributions. The tax consequences of such distributions are discussed above under &#8220;&#8212; Taxation of U.S.
Holders &#8212; Distributions.&#8221; Each U.S. Holder is encouraged to consult its own tax advisor with respect to the appropriate U.S.
federal income tax treatment of any distribution on our ordinary shares or ADSs (or warrants, to the extent applicable).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">If we are treated as a PFIC
for any taxable year during the holding period of a Non-Electing U.S. Holder, we will continue to be treated as a PFIC for all succeeding
years during which the Non-Electing U.S. Holder is treated as a direct or indirect Non-Electing U.S. Holder even if we are not a PFIC
for such years. A U.S. Holder is encouraged to consult its tax advisor with respect to any available elections that may be applicable
in such a situation, including the &#8220;deemed sale&#8221; election of Code Section 1298(b)(1) (which will be taxed under the adverse
tax rules described above).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 115; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->109<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We may invest in the equity
of foreign corporations that are PFICs or may own subsidiaries that own PFICs. If we are classified as a PFIC, under attribution rules
U.S. Holders will be subject to the PFIC rules with respect to their indirect ownership interests in such PFICs, such that a disposition
of the shares of the PFIC or receipt by us of a distribution from the PFIC generally will be treated as a deemed disposition of such shares
or the deemed receipt of such distribution by the U.S. Holder, subject to taxation under the PFIC rules. There can be no assurance that
a U.S. Holder will be able to make a QEF election or a mark-to-market election with respect to PFICs in which we invest. Each U.S. Holder
is encouraged to consult its own tax advisor with respect to tax consequences of an investment by us in a corporation that is a PFIC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="text-decoration:underline">QEF Election</span>. Certain
adverse consequences of PFIC status can be mitigated for holders of our ordinary shares, ADSs, and Pre-funded Warrants if a U.S. Holder
makes a QEF election. A U.S. Holder may not make a QEF election with respect to our Warrants. A U.S. Holder who makes a timely QEF election,
referred to in this disclosure as an &#8220;Electing U.S. Holder,&#8221; with respect to us must report for U.S. federal income tax purposes
his pro rata share of our ordinary earnings and net capital gain, if any, for our taxable year that ends with or within the taxable year
of the Electing U.S. Holder. The &#8220;net capital gain&#8221; of a PFIC is the excess, if any, of the PFIC&#8217;s net long-term capital
gains over its net short-term capital losses. The amount so included in income generally will be treated as ordinary income to the extent
of such Electing U.S. Holder&#8217;s allocable share of the PFIC&#8217;s ordinary earnings and as long-term capital gain to the extent
of such Electing U.S. Holder&#8217;s allocable share of the PFIC&#8217;s net capital gains. Such Electing U.S. Holder generally will be
required to translate such income into U.S. dollars based on the average exchange rate for the PFIC&#8217;s taxable year with respect
to the PFIC&#8217;s functional currency. Such income generally will be treated as income from sources outside the United States for U.S.
foreign tax credit purposes. Amounts previously included in income by such Electing U.S. Holder under the QEF rules generally will not
be subject to tax when they are distributed to such Electing U.S. Holder. The Electing U.S. Holder&#8217;s tax basis in our ordinary shares,
ADSs, or Pre-funded Warrants generally will increase by any amounts so included under the QEF rules and decrease by any amounts not included
in income when distributed.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">An Electing U.S. Holder will
be subject to U.S. federal income tax on such amounts for each taxable year in which we are a PFIC, regardless of whether such amounts
are actually distributed to such Electing U.S. Holder. However, an Electing U.S. Holder may, subject to certain limitations, elect to
defer payment of current U.S. federal income tax on such amounts, subject to an interest charge. If an Electing U.S. Holder is an individual,
any such interest will be treated as non-deductible &#8220;personal interest.&#8221;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Any net operating losses or
net capital losses of a PFIC will not pass through to the Electing U.S. Holder and will not offset any ordinary earnings or net capital
gain of a PFIC recognized by Electing U.S. Holder in subsequent years.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">So long as an Electing U.S.
Holder&#8217;s QEF election with respect to us is in effect with respect to the entire holding period for our ordinary shares, ADSs, or
Pre-funded Warrants, any gain or loss recognized by such Electing U.S. Holder on the sale, exchange or other disposition of such shares,
ADSs, or Pre-funded Warrants generally will be long-term capital gain or loss if such Electing U.S. Holder has held such shares, ADSs,
or Pre-funded Warrants for more than one year at the time of such sale, exchange or other disposition. Preferential tax rates for long-term
capital gain (currently, a maximum rate of 20%) will apply to individual U.S. Holders. The deductibility of capital losses is subject
to limitations.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, a U.S. Holder
must make a QEF election on or before the due date for filing its income tax return for the first year to which the QEF election is to
apply. A U.S. Holder makes a QEF election by completing the relevant portions of and filing IRS Form 8621 in accordance with the instructions
thereto. Upon request, we intend to annually furnish U.S. Holders with information needed in order to complete IRS Form 8621 (which form
would be required to be filed with the IRS on an annual basis by the U.S. Holder) and to make and maintain a valid QEF election for any
year in which we or any of our subsidiaries that we control is a PFIC. There is no assurance, however, that we will have timely knowledge
of our status as a PFIC, or that the information that we provide will be adequate to allow U.S. Holders to make a QEF election. A QEF
election will not apply to any taxable year during which we are not a PFIC, but will remain in effect with respect to any subsequent taxable
year in which we become a PFIC.</p><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 116; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->110<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A U.S. Holder may not make
a QEF election with respect to our Warrants. As a result, if a U.S. Holder sells or otherwise disposes of such Warrants (other than upon
exercise thereof), any gain recognized generally will be subject to special tax and interest charge rules treating the gain as an excess
distribution, as described above, if we were a PFIC at any time during the period the U.S. Holder held the Warrants. If a U.S. Holder
that exercises such Warrants properly makes a QEF election with respect to the newly acquired ADSs (or has previously made a QEF election
with respect to our ADSs), the QEF election will apply to the newly acquired ADSs, but the adverse tax consequences attributable to the
period prior to exercise of the Warrants, adjusted to take into account the current income inclusions resulting from the QEF election,
will continue to apply with respect to such newly acquired ADSs, unless the U.S. Holder makes a &#8220;purging election&#8221; that creates
a deemed sale of such ADSs at their fair market value. The gain recognized by the purging election will be subject to the special tax
and interest charge rules treating the gain as an excess distribution, as described above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Each U.S. Holder should consult
its own tax advisor with respect to the advisability of, the tax consequences of, and the procedures for making a QEF election with respect
to us.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>&#160;</i></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><i>Mark-to-Market Election.&#160;</i>Alternatively,
if our ordinary shares or ADSs are treated as &#8220;marketable stock,&#8221; a U.S. Holder would be allowed to make a &#8220;mark-to-market&#8221;
election with respect to our ordinary shares or ADSs, provided the U.S. Holder completes and files IRS Form 8621 in accordance with the
relevant instructions and related Treasury Regulations. A &#8220;mark-to-market&#8221; election will not be available with respect to
our Warrants and Pre-funded Warrants. If the election is made, the U.S. Holder generally would include as ordinary income in each taxable
year the excess, if any, of the fair market value of our ordinary shares or ADSs at the end of the taxable year over such holder&#8217;s
adjusted tax basis in such shares or ADSs. The U.S. Holder would also be permitted an ordinary loss in respect of the excess, if any,
of the U.S. Holder&#8217;s adjusted tax basis in our ordinary shares or ADSs over their fair market value at the end of the taxable year,
but only to the extent of the net amount previously included in income as a result of the mark-to-market election. A U.S. Holder&#8217;s
tax basis in our ordinary shares or ADSs would be adjusted to reflect any such income or loss amount. Gain realized on the sale, exchange
or other disposition of our ordinary shares or ADSs would be treated as ordinary income, and any loss realized on the sale, exchange or
other disposition of our ordinary shares or ADSs would be treated as ordinary loss to the extent that such loss does not exceed the net
mark-to-market gains previously included in income by the U.S. Holder, and any loss in excess of such amount will be treated as capital
loss. Amounts treated as ordinary income will not be eligible for the favorable tax rates applicable to qualified dividend income or long-term
capital gains.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, stock will be considered
marketable stock if it is &#8220;regularly traded&#8221; on a &#8220;qualified exchange&#8221; within the meaning of applicable Treasury
Regulations. A class of stock is regularly traded on an exchange during any calendar year during which such class of stock is traded,
other than in&#160;<i>de minimis&#160;</i>quantities, on at least 15 days during each calendar quarter. To be marketable stock, our ordinary
shares and ADSs must be regularly traded on a qualifying exchange (i) in the United States that is registered with the SEC or a national
market system established pursuant to the Exchange Act or (ii) outside the United States that is properly regulated and meets certain
trading, listing, financial disclosure and other requirements. Our ordinary shares should constitute &#8220;marketable stock&#8221; as
long as they remain listed on the TASE and are regularly traded. Our ADSs will be listed on the OTC and/or the NYSE American. While we
believe that our ordinary shares and ADSs may be treated as marketable stock for purposes of the PFIC rules so long as they are listed
on the TASE and the OTC and/or the NYSE American, as applicable, and are regularly traded, the IRS has not provided a list of the exchanges
that meet the foregoing requirements and thus no assurance can be provided that our ordinary shares and/or ADSs will be (or will remain)
treated as marketable stock for purposes of the PFIC rules.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A mark-to-market election
will not apply to our ordinary shares or ADSs held by a U.S. Holder for any taxable year during which we are not a PFIC, but will remain
in effect with respect to any subsequent taxable year in which we become a PFIC. Such election will not apply to any PFIC subsidiary that
we own. Each U.S. Holder is encouraged to consult its own tax advisor with respect to the availability and tax consequences of a mark-to-market
election with respect to our ordinary shares and ADSs.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, U.S. Holders
should consult their tax advisors regarding the IRS information reporting and filing obligations that may arise as a result of the ownership
of ordinary shares in a PFIC, including IRS Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or
Qualified Electing Fund.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The U.S. federal
income tax rules relating to PFICs, QEF elections, and mark-to market elections are complex. U.S. Holders are urged to consult their own
tax advisors with respect to the purchase, ownership and disposition of our ordinary shares, ADSs, Warrants, or Pre-funded Warrants, any
elections available with respect to such shares, ADSs, Warrants, or Pre-funded Warrants, and the IRS information reporting obligations
with respect to the purchase, ownership and disposition of our ordinary shares, ADSs, Warrants, or Pre-funded Warrants.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 117; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->111<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Tax Consequences for Non-U.S. Holders
of Ordinary Shares, ADSs, Warrants, or Pre-funded Warrants</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Except as provided below,
an individual, corporation, estate or trust that is not a U.S. Holder, referred to below as a non-U.S. Holder, generally will not be subject
to U.S. federal income or withholding tax on the payment of dividends on, and the proceeds from the disposition of, our ordinary shares,
ADSs, Warrants, or Pre-funded Warrants.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">A non-U.S. Holder may be subject
to U.S. federal income tax on a dividend paid on our ordinary shares or ADSs (or warrants, to the extent applicable) or gain from the
disposition of our ordinary shares, ADSs, Warrants, or Pre-funded Warrants if: (1) such item is effectively connected with the conduct
by the non-U.S. Holder of a trade or business in the United States and, if required by an applicable income tax treaty is attributable
to a permanent establishment or fixed place of business in the United States; or (2) in the case of a disposition of our ordinary shares,
ADSs, Warrants, or Pre-funded Warrants, the individual non-U.S. Holder is present in the United States for 183 days or more in the taxable
year of the disposition and other specified conditions are met.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In general, non-U.S. Holders
will not be subject to backup withholding with respect to the payment of dividends on our ordinary shares or ADSs (or warrants, to the
extent applicable) if payment is made through a paying agent, or office of a foreign broker outside the United States. However, if payment
is made in the United States or by a U.S. related person, non-U.S. Holders may be subject to backup withholding, unless the non-U.S. Holder
provides an applicable IRS Form W-8 (or a substantially similar form) certifying its foreign status, or otherwise establishes an exemption.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The amount of any backup withholding
from a payment to a non-U.S. Holder will be allowed as a credit against such holder&#8217;s U.S. federal income tax liability and may
entitle such holder to a refund, provided that the required information is timely furnished to the IRS.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain Reporting Requirements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain U.S. Holders may be
required to file IRS Form 926, Return by U.S. Transferor of Property to a Foreign Corporation, and IRS Form 5471, Information Return of
U.S. Persons With Respect to Certain Foreign Corporations, reporting transfers of cash or other property to us and information relating
to the U.S. Holder and us. Substantial penalties may be imposed upon a U.S. Holder that fails to comply. See also the discussion regarding
Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund, above.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, certain U.S.
Holders must report information on IRS Form 8938, Statement of Specified Foreign Financial Assets, with respect to their investments in
certain &#8220;specified foreign financial assets,&#8221; which would include an investment in our securities, if the aggregate value
of all of those assets exceeds $50,000 on the last day of the taxable year (and in some circumstances, a higher threshold). This reporting
requirement applies to individuals and certain U.S. entities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders who fail to report
required information could become subject to substantial penalties. U.S. Holders should consult their tax advisors regarding the possible
implications of these reporting requirements arising from their investment in our securities.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Backup Withholding Tax and Information
Reporting Requirements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Generally, information reporting
requirements will apply to distributions on our ordinary shares or ADSs (or warrants, to the extent applicable) or proceeds on the disposition
of our securities paid within the United States (and, in certain) proceeds on the disposition of our securities paid within the United
States (and, in certain cases, outside the United States) to U.S. Holders other than certain exempt recipients, such as corporations.
Furthermore, backup withholding (currently at 24%) may apply to such amounts if the U.S. Holder fails to (i) provide a correct taxpayer
identification number, (ii) report interest and dividends required to be shown on its U.S. federal income tax return, or (iii) make other
appropriate certifications in the required manner. U.S. Holders who are required to establish their exempt status generally must provide
such certification on IRS Form W-9.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></p><div>

</div><!-- Field: Page; Sequence: 118; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->112<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Backup withholding is not
an additional tax. Amounts withheld as backup withholding from a payment may be credited against a U.S. Holder&#8217;s U.S. federal income
tax liability and such U.S. Holder may obtain a refund of any excess amounts withheld by filing the appropriate claim for refund with
the IRS and furnishing any required information in a timely manner.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Tax on Net Investment
Income</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain U.S. persons, including
individuals, estates and trusts are generally subject to an additional 3.8% Medicare tax. For individuals, the additional Medicare tax
applies to the lesser of (i) &#8220;net investment income&#8221; or (ii) the excess of &#8220;modified adjusted gross income&#8221; over
$200,000 ($250,000 if married and filing jointly or $125,000 if married and filing separately). &#8220;Net investment income&#8221; generally
equals the taxpayer&#8217;s gross investment income reduced by the deductions that are allocable to such income. Investment income generally
includes passive income such as interest, dividends, annuities, royalties, rents, and capital gains. U.S. Holders are urged to consult
their own tax advisors regarding the implications of the additional Medicare tax resulting from their ownership and disposition of our
securities.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">U.S. Holders should
consult their own tax advisors concerning the tax consequences relating to the purchase, ownership and disposition of our ordinary shares,
ADSs, Warrants or Pre-funded Warrants.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">F.
</span>Dividends and Paying Agents.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">G.
</span>Statements by Experts.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">H.
</span>Documents on Display.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are subject to the information
reporting requirements of the Exchange Act, applicable to foreign private issuers and under those requirements will file reports with
the SEC. The SEC maintains an Internet website that contains reports and other information regarding issuers that file electronically
with the SEC. You may read and copy this annual report, including the related exhibits and schedules, and any document we file with the
SEC at http://www.sec.gov.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As a foreign private issuer,
we are exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors
and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange
Act. In addition, we are not required under the Exchange Act to file annual, quarterly and current reports and financial statements with
the SEC as frequently or as promptly as United States companies whose securities are registered under the Exchange Act. However, we file
with the SEC, within four months after the end of each fiscal year, or such applicable time as required by the SEC, an annual report on
Form 20-F containing financial statements audited by an independent registered public accounting firm, and submit to the SEC, on a Form
6-K, unaudited quarterly financial information for the first three quarters of each fiscal year within 60 days after the end of each such
quarter, or such applicable time as required by the SEC.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, because our ordinary
shares are traded on the TASE, we have filed Hebrew language periodic and immediate reports with, and furnish information to, the TASE
and the ISA, as required under Chapter Six of the Israel Securities Law. Copies of our filings with the ISA can be retrieved electronically
through the MAGNA distribution site of the ISA (<i>www.magna.isa.gov.il</i>) and the TASE website (<i>www.maya.tase.co.il</i>).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We maintain a corporate website
at&#160;<i>www.canfite.com. In</i>formation contained on, or that can be accessed through, our website does not constitute a part of this
Annual Report on Form 20-F. We have included our website address in this Annual Report on Form 20-F solely as an inactive textual reference.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 119; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->113<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">I.
</span>Subsidiary Information.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_013"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
11. </span>Quantitative and Qualitative Disclosures About Market Risk</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Market risk is the risk of
loss related to changes in market prices, including interest rates and foreign exchange rates, of financial instruments that may adversely
impact our consolidated financial position, results of operations or cash flows.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Interest Rate
Risk</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We do not anticipate undertaking
any significant long-term borrowings. At present, our investments consist primarily of cash and cash equivalents. We may invest in investment-grade
marketable securities with maturities of up to three years, including commercial paper, money market funds, and government/non-government
debt securities. The primary objective of our investment activities is to preserve principal while maximizing the income that we receive
from our investments without significantly increasing risk and loss. Our investments are exposed to market risk due to fluctuation in
interest rates, which may affect our interest income and the fair market value of our investments, if any. We manage this exposure by
performing ongoing evaluations of our investments. Due to the short-term maturities, if any, of our investments to date, their carrying
value has always approximated their fair value. If we decide to invest in investments other than cash and cash equivalents, it will be
our policy to hold such investments to maturity in order to limit our exposure to interest rate fluctuations.</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Foreign Currency
Exchange Risk</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our foreign currency exposures
give rise to market risk associated with exchange rate movements of the U.S dollar, our functional and reporting currency, mainly against
the NIS and the euro. Although the U.S dollar is our functional currency, a portion of our expenses are denominated in both NIS and euro
and currently all of our revenues are denominated in dollars. Our U.S. dollar and euro expenses consist principally of payments made to
sub-contractors and consultants for preclinical studies, clinical trials and other research and development activities, Our NIS expenses
consist principally of salary related payments. We anticipate that a sizable portion of our expenses will continue to be denominated in
currencies other than the NIS. If the U.S dollar fluctuates significantly against either the NIS or the euro, it may have a negative impact
on our results of operations. To date, fluctuations in the exchange rates have not materially affected our results of operations or financial
condition for the periods under review.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">To date, we have not engaged
in hedging transactions. In the future, we may enter into currency hedging transactions to decrease the risk of financial exposure from
fluctuations in the exchange rates of our principal operating currencies. These measures, however, may not adequately protect us from
the material adverse effects of such fluctuations.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_014"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
12. </span>Description of Securities Other Than Equity Securities</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">A.
</span>Debt Securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">B.
</span>Warrants and Rights.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">C.
</span>Other Securities.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 120; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->114<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif">D.
</span>American Depositary Shares</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Bank of New York Mellon,
as Depositary, will register and deliver American Depositary Shares, or ADSs. Each ADS will represent thirty (30) ordinary shares (or
a right to receive thirty (30) ordinary shares) deposited with the principal Tel Aviv office of Bank Hapoalim, as custodian for the Depositary.
Each ADS will also represent any other securities, cash or other property which may be held by the Depositary. The Depositary&#8217;s
corporate trust office at which the ADSs will be administered is located at 101 Barclay Street, New York, New York 10286. The Bank of
New York Mellon&#8217;s principal executive office is located at One Wall Street, New York, New York 10286.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The form of the deposit agreement
for our ADSs and the form of American Depositary Receipt that represents an ADS have been incorporated by reference as exhibits to this
Annual Report on Form 20-F.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Fees and Expenses</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; text-align: left; font-weight: bold">Persons depositing or withdrawing shares or ADS holders must pay:</td>
    <td style="text-align: left">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: left; font-weight: bold">For:</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 50%; text-align: left">$5.00 (or less) per 100 ADSs (or portion of 100 ADSs)</td>
    <td style="width: 3%; text-align: left">&#160;</td>
    <td style="width: 2%; text-align: left">&#9679;</td>
    <td style="width: 45%; text-align: justify">Issuance of ADSs, including issuances resulting from a distribution of shares or rights or other property</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#9679;</td>
    <td style="text-align: justify">Cancellation of ADSs for the purpose of withdrawal, including if the Deposit Agreement terminates</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">$.05 (or less) per ADS</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#9679;</td>
    <td style="text-align: justify">Any cash distribution to ADS holders</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">A fee equivalent to the fee that would be payable if securities distributed to you had been shares and the shares had been deposited for issuance of ADSs</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#9679;</td>
    <td style="text-align: justify">Distribution of securities distributed to holders of deposited securities which are distributed by the Depositary to ADS holders</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">$.05 (or less) per ADSs per calendar year</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#9679;</td>
    <td style="text-align: justify">Depositary services</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">Registration or transfer fees</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#9679;</td>
    <td style="text-align: justify">Transfer and registration of shares on our share register to or from the name of the Depositary or its agent when you deposit or withdraw shares</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">Expenses of the Depositary</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#9679;</td>
    <td style="text-align: justify">Cable, telex and facsimile transmissions (when expressly provided in the Deposit Agreement)</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#9679;</td>
    <td style="text-align: justify">Converting foreign currency to U.S. dollars</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">Taxes and other governmental charges the Depositary or the custodian have to pay on any ADS or share underlying an ADS, for example, stock transfer taxes, stamp duty or withholding taxes</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#9679;</td>
    <td style="text-align: justify">As necessary</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">Any charges incurred by the Depositary or its agents for servicing the deposited securities</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#9679;</td>
    <td style="text-align: justify">As necessary</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Depositary collects its
fees for delivery and surrender of ADSs directly from investors depositing shares or surrendering ADSs for the purpose of withdrawal or
from intermediaries acting for them. The Depositary collects fees for making distributions to investors by deducting those fees from the
amounts distributed or by selling a portion of distributable property to pay the fees. The Depositary may collect its annual fee for depositary
services by deduction from cash distributions, by directly billing investors or by charging the book-entry system accounts of participants
acting for them. The Depositary may generally refuse to provide fee-attracting services until its fees for those services are paid.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">From time to time, the Depositary
may make payments to us to reimburse us for expenses and/or share revenue with us from the fees collected from ADS holders, or waive fees
and expenses for services provided, generally relating to costs and expenses arising out of the establishment and maintenance of the ADS
program. In performing its duties under the Deposit Agreement, the Depositary may use brokers, dealers or other service providers that
are affiliates of the Depositary and that may earn or share fees or commissions.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 121; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->115<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_014a"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="text-transform: uppercase"><b>PART
II</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_015"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
13. </span>Defaults, Dividend Arrearages and Delinquencies</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_016"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
14. </span>Material Modifications to the Rights of Security Holders and Use of Proceeds</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_017"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
15. </span>Controls and Procedures</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Disclosure controls and procedures</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, including
our chief executive officer, or CEO, and our chief financial officer, or CFO, are responsible for establishing and maintaining our disclosure
controls and procedures (within the meaning of Rule 13a-15(e) of the Exchange Act). These controls and procedures were designed to ensure
that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized
and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated
to our management, including our CEO and CFO, as appropriate, to allow timely decisions regarding required disclosure. We evaluated these
disclosure controls and procedures under the supervision of our CEO and CFO as of December 31, 2021. Based upon that evaluation, our management,
including our CEO and CFO, concluded that our disclosure controls and procedures as of December 31, 2021 were effective.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Management&#8217;s annual report on internal
control over financial reporting</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our management, including
our CEO, and our CFO, is responsible for establishing and maintaining adequate internal control over our financial reporting, as defined
in Rules 13a-15(f) and 15d-15(f) of the Exchange Act of 1934, as amended. Our internal control over financial reporting is a process designed
to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles. Internal control over financial reporting includes policies and
procedures that:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">pertain to the maintenance of records that in reasonable detail
accurately and fairly reflect our transactions and asset dispositions;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">provide reasonable assurance that transactions are recorded
as necessary to permit the preparation of our financial statements in accordance with generally accepted accounting principles;</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">provide reasonable assurance that receipts and expenditures
are made only in accordance with authorizations of our management and board of directors (as appropriate); and</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">provide reasonable assurance regarding the prevention or timely
detection of unauthorized acquisition, use or disposition of assets that could have a material effect on our financial statements.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Due to its inherent limitations,
internal controls over financial reporting may not prevent or detect misstatements. In addition, projections of any evaluation of effectiveness
to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Under the supervision and
with the participation of our management, including our CEO, and our CFO, we assessed the effectiveness of our internal control over financial
reporting as of December 31, 2021 based on the framework for Internal Control-Integrated Framework set forth by The Committee of Sponsoring
Organizations of the Treadway Commission (COSO) (2013).</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Based on our assessment and
this framework, our management concluded that our internal control over financial reporting were effective as of December 31, 2021.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 122; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->116<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Attestation Report of Registered Public Accounting
Firm</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Changes in internal control over financial reporting</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">There were no changes in our
internal control over financial reporting, other than as described above, that occurred during the year ended December 31, 2021 that have
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_018"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
16. </span>[RESERVED]</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_019"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
16A. </span>Audit Committee Financial Expert</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our Board of Directors has
determined that Guy Regev and Yaacov Goldman are audit committee financial experts, as defined by applicable SEC regulations. Messrs.
Regev and Goldman qualified as an &#8220;independent director,&#8221; as that term is defined under NYSE American rules.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_020"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
16B. </span>Code of Ethics</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have adopted a code of
ethics, referred to as a Code of Business Conduct, applicable to our directors, officers and all other employees. Our code of ethics is
publicly available on our website at&#160;<i>www.canfite.com</i>. If we make any amendment to the code of ethics or grant any waivers,
including any implicit waiver, from a provision of the code of ethics, which applies to our chief executive officer, chief financial officer,
chief accounting officer or controller, or persons performing similar functions, we will disclose the nature of such amendment or waiver
on our website.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_021"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
16C. </span>Principal Accountant Fees and Services</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The following table sets forth,
for each of the years indicated, the fees billed by our independent registered public accounting firm.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#160;31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Services Rendered</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">(USD in thousands)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Audit (1)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">135</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">105</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Audit related services (2)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">21</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">61</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Tax</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">All other fees</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">166</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">170</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Audit fees consist of services that would normally be provided
in connection with statutory and regulatory filings or engagements, including services that generally only the independent accountant
can reasonably provide.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">(2)</td><td style="text-align: justify">Audit related services consist of services that were reasonably
related to the performance of the audit or reviews of our financial statements and not included under &#8220;Audit Fees&#8221; above,
including, principally, providing consents for registration statement filings.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Audit Committee Pre-Approval Policies and Procedures</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audit committee&#8217;s
specific responsibilities in carrying out its oversight of the quality and integrity of the accounting, auditing and reporting practices
of us include the approval of audit and non-audit services to be provided by the external auditor. The audit committee approves in advance
the particular services or categories of services to be provided to us during the following yearly period and also sets forth a specific
budget for such audit and non-audit services. Additional non-audit services may be pre-approved by the audit committee.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 123; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->117<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_022"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
16D. </span>Exemptions from the Listing Standards for Audit Committees</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_023"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
16E. </span>Purchases of Equity Securities by the Issuer and Affiliated Purchasers</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_024"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
16F. </span>Change in Registrant&#8217;s Certifying Accountant</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_025"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
16G. </span>Corporate Governance</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We are a foreign private issuer
whose ordinary shares are listed on the NYSE American. As such, we are required to comply with U.S. federal securities laws, including
the Sarbanes-Oxley Act, and the NYSE American rules, including the NYSE American corporate governance requirements. The NYSE American
rules provide that foreign private issuers may follow home country practice in lieu of certain qualitative listing requirements subject
to certain exceptions and except to the extent that such exemptions would be contrary to U.S. federal securities laws, so long as the
foreign issuer discloses that it does not follow such listing requirement and describes the home country practice followed in its reports
filed with the SEC. Below is a concise summary of the significant ways in which our corporate governance practices differ from the corporate
governance requirements of NYSE American applicable to domestic U.S. listed companies:</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">The NYSE American rules recommend that an issuer have a quorum
requirement for shareholders meetings of at least one-third of the outstanding shares of the issuer&#8217;s common voting stock. We have
chosen to follow home country practice with respect to the quorum requirements of our shareholders meeting and our adjourned shareholders
meeting. Our Amended and Restated Articles of Association, as permitted under the Israeli Companies Law and Israeli practice, provide
that the quorum requirements for a shareholders meeting are the presence of at least two shareholders who represent at least 25% of the
outstanding shares of the issuer&#8217;s common voting stock, and in the event of an adjourned meeting, the presence of a minimum of
two shareholders present in person.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: left; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.5in"></td><td style="width: 0.25in; text-align: left">&#9679;</td><td style="text-align: justify">We have chosen to follow our home country practice in lieu
of the requirements of the NYSE American rules relating to shareholder approval required prior to the issuance of securities (i) when
a stock option or purchase plan is to be established or materially amended or other equity compensation arrangement made or materially
amended, pursuant to which stock may be acquired by officers, directors, employees or consultants and (ii) in connection with a transaction,
other than a public offering, involving the issuance or potential issuance by the Company of ordinary shares (or their equivalent) equal
to 20% or more of the ordinary shares or 20% voting power outstanding before the issuance for or at a price less than the greater of
book or market value of the shares. We follow the provisions of the Israeli Companies Law with regard to transactions with our affiliates,
i.e., our controlling shareholder and our directors and officers, including private placement transactions.</td>
</tr></table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_026"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
16H. </span>Mine Safety Disclosure</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Not applicable.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_027"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
16I. </span>Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Not applicable.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"></p><div>

</div><!-- Field: Page; Sequence: 124; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->118<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="text-transform: uppercase"><b>&#160;</b></span></p><div>

</div><div><a id="a_028"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><span style="text-transform: uppercase"><b>PART
III</b></span></p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_029"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
17. </span>Financial Statements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have responded to Item
18 in lieu of responding to this item.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_030"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
18. </span>Financial Statements</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Please refer to the financial
statements beginning on page F-1.</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="text-transform: uppercase">&#160;</span></p><div>

</div><div><a id="a_031"></a></div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in"><span style="font-family: Times New Roman, Times, Serif; text-transform: uppercase">ITEM
19. </span>Exhibits</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Index to Exhibits</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; ">
    <td style="border-bottom: Black 1.5pt solid; width: 9%; font-weight: bold"><b>Exhibit No.</b></td>
    <td style="padding-bottom: 1.5pt; width: 1%; text-align: justify"><b>&#160;</b></td>
    <td style="border-bottom: Black 1.5pt solid; width: 90%; font-weight: bold"><b>Description</b></td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>1.1</b></td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/0001536196/000121390020003604/f6k021320ex99-1b_canfitbio.htm">Amended and Restated Articles of Association of Can-Fite BioPharma Ltd (1)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>2.1</b></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020007682/f20f2019ex2-1_canfite.htm">Description of Securities Registered under Section 12 (2)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>2.2</b></td>
    <td>&#160;</td>
    <td><a href="https://www.sec.gov/Archives/edgar/data/1536196/000114420413062206/v359878_ex4-2.htm">Form of Amended and Restated Deposit Agreement, by and among Can-Fite BioPharma Ltd., The Bank of New York Mellon and the Owners and Holders of American Depositary Shares, dated September 11, 2013 (3)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.1</b></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-3.htm">Employment and Non-Competition Agreement with Motti Farbstein, dated June 10, 2003 (4)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.2</b></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-4.htm">Consulting Agreement with BioStrategics Consulting, Ltd, dated September 27, 2005 (4)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.3</b></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-5.htm">Service Management Agreement with F.D. Consulting International and Marketing Ltd., dated June 27, 2002 (4)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.4</b></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-6.htm">Master Services Agreement with Accellient Partners, dated May 10, 2010 (4)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.5</b></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-10.htm">License Agreement, by and between The University of Leiden and Can-Fite BioPharma Ltd., dated November 2, 2009 (5)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.6</b></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1536196/000114420413050045/v354765_ex4-25.htm">Can-Fite BioPharma Ltd. 2003 Israeli Share Option Plan (4)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.7</b></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390015002133/f20f2014ex4xiii_canfitebio.htm">Can-Fite BioPharma Ltd. 2013 Israeli Share Option Plan (5)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.8</b></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/0001536196/000121390021030289/ea141961ex99-1_canfitebio.htm">Compensation Policy of Can-Fite BioPharma Ltd. (23)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.9</b></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390015002133/f20f2014ex4xxxiv_canfitebio.htm">Distribution and Supply Agreement between Can-Fite BioPharma Ltd. and Cipher Pharmaceuticals Inc. dated as of March 20, 2015 (5)&#8224;</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.10</b></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390016010259/ff32016ex4iv_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on September 21, 2015 (6)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.11</b></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390016010259/ff32016ex4v_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on October 15, 2015 (6)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.12</b></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390017003022/f20f2016ex4xxxi_canfitebio.htm">Distribution Agreement between Can-Fite BioPharma Ltd. and Chong Kun Dang Pharmaceutical Corp. dated as of October 25, 2016 (7)&#8224;</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.13</b></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390017000539/f6k012017ex10iii_canfitebio.htm">Form of Warrant issued by Can-Fite BioPharma Ltd. on January 18, 2017 (8)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.14</b></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390017005943/ff12017ex4iii_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on January 18, 2017 (9)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.15</b></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390018010490/ff12018ex4-3_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on March 13, 2018 (10)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.16</b></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390019002713/ff12019ex4-36_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on January 23, 2019 (11)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.17</b></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390019007796/ff12019ex4-6_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on April 4, 2019 (12)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.18</b></td>
    <td>&#160;</td>
    <td><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390019009378/f6k052219ex10-2_canfitebio.htm">Form of Warrant issued by Can-Fite BioPharma Ltd. on May 22, 2019 (13)</a></td></tr>
</table><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 125; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->119<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="width: 9%"><b>4.19</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390019009654/ff12019a1ex4-8_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on May 22, 2019 (14)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.20</b></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020000768/f6k010920bex10-1_canfitebio.htm">Form of Warrant Exercise Agreement dated as of January 9, 2020 between Can-Fite BioPharma Ltd. and the investors listed therein (16)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.21</b></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020000768/f6k010920bex10-2_canfitebio.htm">Form of Warrant issued by Can-Fite BioPharma Ltd. on January 13, 2020 (16)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.22</b></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020003406/f6k021220ex10-1_canfitebio.htm">Form of Securities Purchase Agreement dated as of February 10, 2020, between Can-Fite BioPharma Ltd. and the investors listed therein (17)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.23</b></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020003406/f6k021220ex4-1_canfitebio.htm">Form of Warrant issued by Can-Fite BioPharma Ltd. on February 12, 2020 (17)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.24</b></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020003406/f6k021220ex4-2_canfitebio.htm">Form of Pre-funded Warrant issued by Can-Fite BioPharma Ltd. on February 12, 2020 (17)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.25</b></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020003406/f6k021220ex4-3_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on February 12, 2020 (17)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.26</b></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020014760/ea122926ex10-2_canfitebio.htm">Form of Warrant issued by Can-Fite BioPharma Ltd. on June 12, 2020 (18)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.27</b></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020016932/ea123900ex10-2_canfitebio.htm">Form of Warrant issued by Can-Fite BioPharma Ltd. on July 8, 2020 (19)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.28</b></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020014760/ea122926ex10-3_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on June 12, 2020 (18)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.29</b></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020016932/ea123900ex10-3_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on July 8, 2020 (19)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.30</b></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020014760/ea122926ex10-1_canfitebio.htm">Form of Securities Purchase Agreement dated as of June 10, 2020 by and between Can-Fite BioPharma Ltd. and the Purchasers signatory thereto (18)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.31</b></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020016932/ea123900ex10-1_canfitebio.htm">Form of Securities Purchase Agreement dated as of July 5, 2020 by and between Can-Fite BioPharma Ltd. and the Purchasers signatory thereto (19)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.32</b></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020014760/ea122926ex10-2_canfitebio.htm">Form of Warrant issued by Can-Fite BioPharma Ltd. on June 12, 2020 (18)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.33</b></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020016932/ea123900ex10-2_canfitebio.htm">Form of Warrant issued by Can-Fite BioPharma Ltd. on July 8, 2020 (19)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.34</b></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020014760/ea122926ex10-3_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on June 12, 2020 (18)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.35</b></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="http://www.sec.gov/Archives/edgar/data/1536196/000121390020016932/ea123900ex10-3_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on July 8, 2020 (19)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.36</b></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/0001536196/000121390021042704/ea145842ex10-1_canfitebio.htm">Form of Securities Purchase Agreement dated as of August 11, 2021 between Can-Fite BioPharma Ltd. and the investor listed therein (20)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.37</b></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/0001536196/000121390021042704/ea145842ex10-2_canfitebio.htm">Form of Pre-Funded Warrant issued by Can-Fite BioPharma Ltd. on August 16, 2021 (20)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.38</b></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/0001536196/000121390021042704/ea145842ex10-3_canfitebio.htm">Form of Warrant issued by Can-Fite BioPharma Ltd. on August 16, 2021 (20)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.39</b></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/0001536196/000121390021042704/ea145842ex10-4_canfitebio.htm">Form of Placement Agent Warrant issued by Can-Fite BioPharma Ltd. on August 16, 2021 (20)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.40</b></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/0001536196/000121390021067180/ea152948ex10-1_canfitebio.htm">Form of Warrant Exercise Agreement issued by Can-Fite BioPharma Ltd. on December 23, 2021 (21)</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>4.41</b></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="https://www.sec.gov/Archives/edgar/data/0001536196/000121390021067180/ea152948ex10-2_canfitebio.htm">Form of Private Placement Warrants issued by Can-Fite BioPharma Ltd. on December 23, 2021 (21)</a></td></tr>
</table><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><!-- Field: Page; Sequence: 126; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->120<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>8.1</b></td>
    <td>&#160;</td>
    <td><a href="f20f2021ex8-1_canfitebio.htm">List of Subsidiaries of Can-Fite BioPharma Ltd.*</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>12.1</b></td>
    <td>&#160;</td>
    <td><a href="f20f2021ex12-1_canfitebio.htm">Certification by Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td><b>12.2</b></td>
    <td>&#160;</td>
    <td><a href="f20f2021ex12-2_canfitebio.htm">Certification by Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002*</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><b>13.1</b></td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="f20f2021ex13-1_canfitebio.htm">Certification by Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>

<tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="width: 9%"><b>13.2</b></td>
    <td style="width: 1%">&#160;</td>
    <td style="text-align: justify; width: 90%"><a href="f20f2021ex13-2_canfitebio.htm">Certification by Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002*</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><b>15.1</b></td>
    <td>&#160;</td>
    <td><a href="f20f2021ex15-1_canfitebio.htm">Consent of Independent Registered Public Accounting Firm.*</a></td></tr>
  <tr style="vertical-align: top; ">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td><b>101</b></td>
    <td>&#160;</td>
    <td style="text-align: justify">The following financial information from Can-Fite BioPharma Ltd.&#8217;s Annual Report on Form 20-F
    for the year ended December 31, 2021, formatted in Inline Extensible Business Reporting Language (IXBRL): (i) Consolidated
    Statements of Financial Position, (ii) Consolidated Statements of Comprehensive Loss, (iii) Consolidated Statements of Changes in
    Equity (Deficiency) (iv) the Consolidated Statements of Cash Flows, and (iv) Notes to Consolidated Financial Statements.*</td></tr>
  </table><div>
</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">*</td><td style="text-align: justify">Filed Herewith.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: -0.25in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0"></td><td style="width: 0.25in; text-align: left">&#8224;</td><td style="text-align: justify">Certain confidential information contained in this exhibit was
omitted by means of redacting a portion of the text and replacing it with [...]. This exhibit has been filed separately with the Commission
without the redaction pursuant to a Confidential Treatment Request under Rule 24b-2 of the Securities Exchange Act of 1934 and Rule 406
of the Securities Act.</td>
</tr></table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: justify; text-indent: -13.5pt">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0pt; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.25in; text-align: left">(1)</td><td style="text-align: justify">Incorporated herein by reference to the Current Report on Form
6-K filed with the SEC on February 13, 2020.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">(2)</td><td style="text-align: justify">Incorporated herein by reference to Annual Report on Form 20-F
filed with the SEC on March 27, 2020.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">(3)</td><td style="text-align: justify">Incorporated herein by reference to the Registration Statement
on Form 8-A filed with the SEC on November 15, 2013.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">(4)</td><td style="text-align: justify">Incorporated herein by reference to Amendment No. 1 to the Draft
Registration Statement on Form 20-F filed with the SEC on September 10, 2013.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">(5)</td><td style="text-align: justify">Incorporated herein by reference to Annual Report on Form 20-F
filed with the SEC on March 27, 2015.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">(6)</td><td style="text-align: justify">Incorporated herein by reference to Registration Statement on
Form F-3 filed with the SEC on January 19, 2016.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">(7)</td><td style="text-align: justify">Incorporated herein by reference to the Annual Report on Form
20- F filed with the SEC on March 30, 2017.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">(8)</td><td style="text-align: justify">Incorporated herein by reference to the Current Report on Form
6-K filed with the SEC on January 20, 2017.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">(9)</td><td style="text-align: justify">Incorporated herein by reference to Registration Statement on
Form F-1 filed with the SEC on May 30, 2017.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">(10)</td><td style="text-align: justify">Incorporated herein by reference to Registration Statement on
Form F-1 filed with the SEC on August 8, 2018.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">(11)</td><td style="text-align: justify">Incorporated herein by reference to Registration Statement on
Form F-1 filed with the SEC on February 15, 2019.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">(12)</td><td style="text-align: justify">Incorporated herein by reference to Registration Statement on
Form F-1 filed with the SEC on May 3, 2019.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">(13)</td><td style="text-align: justify">Incorporated herein by reference to Current Report on Form 6-K
filed with the SEC on May 22, 2019.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">(14)</td><td style="text-align: justify">Incorporated herein by reference to Registration Statement on
Form F-1 filed with the SEC on May 28, 2019.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">(15)</td><td style="text-align: justify">Incorporated herein by reference to Registration Statement on
Form F-1 filed with the SEC on October 18, 2019.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">(16)</td><td style="text-align: justify">Incorporated herein by reference to the Current Report on Form
6-K filed with the SEC on January 10, 2020.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">(17)</td><td style="text-align: justify">Incorporated herein by reference to the Current Report on Form
6-K filed with the SEC on February 12, 2020.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">(18)</td><td style="text-align: justify">Incorporated herein by reference to the Current Report on Form
6-K filed with the SEC on June 12, 2020.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">(19)</td><td style="text-align: justify">Incorporated herein by reference to the Current Report on Form
6-K filed with the SEC on July 8, 2020.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">(20)</td><td style="text-align: justify">Incorporated herein by reference to the Current Report on Form
6-K filed with the SEC on August 16, 2021.</td>
</tr>
<tr style="vertical-align: top; text-align: justify">
<td style="text-align: left">(21)</td><td style="text-align: justify">Incorporated herein by reference to the Current Report on Form
6-K filed with the SEC on December 23, 2021.</td>
</tr>
     </table><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>


</div><!-- Field: Page; Sequence: 127; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->121<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">SIGNATURES</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Registrant hereby certifies
that it meets all of the requirements for filing on Form 20-F and that it has duly caused and authorized the undersigned to sign this
Annual Report on its behalf.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td colspan="2" style="text-align: left; font-weight: bold">CAN-FITE BIOPHARMA LTD.</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2" style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%; text-align: left">Date: March 24, 2022</td>
    <td style="width: 4%; text-align: left">By:</td>
    <td style="width: 36%; border-bottom: black 1.5pt solid; text-align: left">/s/ Pnina Fishman, Ph.D.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Pnina Fishman, Ph.D.</td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td>
    <td style="text-align: left">Chief Executive Officer</td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>


</div><!-- Field: Page; Sequence: 128; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->122<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CONSOLIDATED FINANCIAL STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>AS OF DECEMBER 31, 2021</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>INDEX</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr> <td style="vertical-align: top; width: 90%">&#160;</td> <td style="vertical-align: bottom; width: 1%; text-align: center">&#160;</td> <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 9%; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Page</b></span></td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top"><a href="#f_001"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Report of Independent Registered Public Accounting Firm (PCAOB ID: <ix:nonNumeric contextRef="c0" name="dei:AuditorFirmId">1281</ix:nonNumeric>)</b></span></a></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-2 - F-3</b></span></td></tr> <tr> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top"><a href="#f_002"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Balance Sheets</b></span></a></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-4 - F-5</b></span></td></tr> <tr> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top"><a href="#f_003"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Statements of Comprehensive Loss</b></span></a></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-6</b></span></td></tr> <tr> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top"><a href="#f_004"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Statements of Changes in Equity</b></span></a></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-7 - F-8</b></span></td></tr> <tr> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top"><a href="#f_005"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Consolidated Statements of Cash Flows</b></span></a></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-9</b></span></td></tr> <tr> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center">&#160;</td></tr> <tr style="background-color: #CCEEFF"> <td style="vertical-align: top"><a href="#f_006"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Notes to Consolidated Financial Statements</b></span></a></td> <td style="vertical-align: top">&#160;</td> <td style="vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>F-10 - F-30</b></span></td></tr> </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">- - - - - - - - - - -</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p><div>

</div><!-- Field: Page; Sequence: 129; Options: NewSection; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="text-align: left; vertical-align: bottom; width: 20%"><span style="font-family: Sans-Serif; font-size: 9pt; color: Red"><b><img alt="" src="img_001.jpg"/></b></span></td>
    <td style="vertical-align: bottom; width: 30%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Kost Forer Gabbay &amp; Kasierer</b><br/>
144 Menachem Begin Road<br/>
Tel-Aviv 6492102, Israel&#160;</span></td>
    <td style="vertical-align: top; width: 1%; text-align: justify">&#160;</td>
    <td style="vertical-align: bottom; width: 49%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel: +972-3-6232525<br/>
Fax: +972-3-5622555<br/>
ey.com</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><div><a id="f_001"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>To the Shareholders and the Board of Directors
of</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CAN-FITE BIOPHARMA LTD.</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Opinion on the Financial
Statements</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We have audited the accompanying
consolidated balance sheets of Can-Fite Biopharma Ltd. and its subsidiary (the &#8220;Company&#8221;) as of December 31, 2021 and 2020,
the related consolidated statements of comprehensive loss, changes in equity and cash flows for each of the three years in the period
ended December 31, 2021, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our
opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December
31, 2021 and 2020, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2021,
in conformity with U.S. generally accepted accounting principles.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><b>Basis for Opinion</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">These financial statements
are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United
States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and
the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We conducted our audits in
accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to
have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required
to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness
of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our audits included performing
procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures
that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the
financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for
our opinion.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 130; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 104.45pt 0pt 0; text-align: justify"><b>Critical Audit Matters</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.8pt 0pt 0; text-align: justify; text-indent: 0.5in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.8pt 0pt 0; text-align: justify; text-indent: 0.5in">The critical audit
matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required
to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the financial statements
and (2) involved our especially challenging, subjective or complex judgments. The communication of the critical audit matter does not
alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical
audit matter below, providing a separate opinion on the critical audit matter or on the account or disclosure to which it relates.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.8pt 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="width: 17%; text-align: justify">&#160;</td>
    <td style="width: 1%; padding-right: 3.5pt; text-align: justify">&#160;</td>
    <td style="width: 82%; padding-right: 104.45pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Liquidity and Capital Resources</b></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: justify">&#160;</td>
    <td style="padding-right: 3.5pt; text-align: justify">&#160;</td>
    <td style="padding-right: 104.45pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Description of the Matter</i></span></td>
    <td style="padding-right: 3.5pt; text-align: justify">&#160;</td>
    <td style="padding-right: 3.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">As discussed in Note 1 to the consolidated financial statements, the Company has incurred losses, and its operations are dependent on its ability to raise additional funds from existing and/or new investors. This dependency will continue until the Company will be able to completely finance its operations by generating revenue from its product candidates. In addition, as of the date of approval of these financial statements, the Company has raised the necessary funding in order to continue its activity in the foreseeable future.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-right: 3.5pt; text-align: justify">&#160;</td>
    <td style="padding-right: 3.5pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-right: 3.5pt; text-align: justify">&#160;</td>
    <td style="padding-right: 3.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">We identified Liquidity and Capital Resources as a critical audit matter due to the subjective judgments required of management to conclude the Company would have sufficient liquidity to sustain itself for at least a year beyond the date of the issuance of the consolidated financial statements. This in turn led to a high degree of auditor subjectivity and judgment to evaluate the audit evidence supporting the liquidity conclusions. Additionally, the relevance of management&#8217;s liquidity conclusions to the users of the consolidated financial statements also impacted our assessment of these circumstances as a critical audit matter.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td style="padding-right: 3.5pt; text-align: justify">&#160;</td>
    <td style="padding-right: 3.5pt; text-align: justify">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>How We Addressed the Matter in Our Audit</i></span></td>
    <td style="padding-right: 3.5pt; text-align: justify">&#160;</td>
    <td style="padding-right: 3.5pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; ">Addressing the matter involved performing procedures and evaluating audit evidence in connection with our overall opinion on the consolidated financial statements. Our audit procedures to evaluate the significant judgments made by management included, among others, testing the reasonableness of the total liquid assets at December 31, 2021, evaluating the amount and timing of forecasted clinical trial expenses and related payments, including negotiated vendor payment terms, evaluating the fluctuations in forecasted clinical trial expenses and payments thereof as compared to historic amounts and the underlying management assumptions, evaluating the reasonableness of the amounts and timing of payments of forecasted general and administrative expenses and other income, net, reconsidering certain prior management forecasted amounts to evaluate whether those forecasted amounts approximated the ultimate actual results. This was performed in consideration of management&#8217;s ability to put forth reasonable estimates and evaluating the adequacy of the Company&#8217;s disclosure of these circumstances in the consolidated financial statements.</span></td></tr>
  </table><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.8pt 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2.8pt 0pt 0; text-align: justify">/s/ <ix:nonNumeric contextRef="c0" name="dei:AuditorName">Kost Forer Gabbay &amp; Kasierer</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">KOST FORER GABBAY&amp;
KASIERER</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">A Member of Ernst &amp;
Young Global</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We have served as the Company&#8217;s auditor
since at least 2001, but we are unable to determine the specific year.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><ix:nonNumeric contextRef="c0" name="dei:AuditorLocation">Tel-Aviv, Israel</ix:nonNumeric></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "><span>March
24, 2022</span></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 131; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><div><a id="f_002"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED BALANCE SHEETS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(U.S. dollars in thousands except for share and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">ASSETS</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">CURRENT ASSETS:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; padding-left: 9pt">Cash and cash equivalents</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">4,390</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" unitRef="usd">8,268</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 9pt">Short-term deposits</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepositsAssetsCurrent" scale="3" unitRef="usd">14,512</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-0">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Prepaid expenses, and other current assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">3</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">929</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" unitRef="usd">1,057</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">4</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" unitRef="usd">237</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" unitRef="usd">75</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="text-decoration:underline">Total</span> current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">20,068</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" unitRef="usd">9,400</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">NON-CURRENT ASSETS:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 9pt">Operating lease right of use assets</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">138</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" unitRef="usd">73</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 9pt">Property, plant and equipment, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">5</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">47</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">50</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="text-decoration:underline">Total</span> long-term assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd">185</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsNoncurrent" scale="3" unitRef="usd">123</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="text-decoration:underline">Total</span> assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">20,253</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" unitRef="usd">9,523</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 132; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED BALANCE SHEETS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(U.S. dollars in thousands except for share and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">CURRENT LIABILITIES:</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify; padding-left: 0.2in">Trade payables</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd">954</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableTradeCurrent" scale="3" unitRef="usd">561</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0.2in">Current maturity of operating lease liability</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">53</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" unitRef="usd">43</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0.2in">Deferred revenues</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="3" unitRef="usd">818</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueCurrent" scale="3" unitRef="usd">334</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.2in">Other accounts payable</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">6</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd">905</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" scale="3" unitRef="usd">331</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="text-decoration:underline">Total</span> current liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">2,730</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" unitRef="usd">1,269</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">NON-CURRENT LIABILITIES:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0.2in">Long-term operating lease liability</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">11</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd">71</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" unitRef="usd">24</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.2in">Deferred revenues</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" unitRef="usd">3,070</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredRevenueNoncurrent" scale="3" unitRef="usd">2,156</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="text-decoration:underline">Total</span> Long-term liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitRef="usd">3,141</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesNoncurrent" scale="3" unitRef="usd">2,180</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">CONTIGENT LIABILITIES AND COMMITMENTS</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-1">&#160;</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-2">&#160;</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">SHAREHOLDERS&#8217; EQUITY:</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">9</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; text-indent: -0.2in; padding-left: 0.4in">Ordinary shares of NIS <ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="ilsPershares"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="ilsPershares">0.25</ix:nonFraction></ix:nonFraction> par value - Authorized: <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">5,000,000,000</ix:nonFraction> and <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" unitRef="shares">1,000,000,000</ix:nonFraction> shares at December 31, 2021 and December 31, 2020, respectively; Issued and outstanding: <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">815,746,293</ix:nonFraction></ix:nonFraction> shares as of December 31, 2021; <ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="0" unitRef="shares"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" unitRef="shares">463,769,463</ix:nonFraction></ix:nonFraction> shares as of December 31, 2020</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">60,654</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CommonStockValue" scale="3" unitRef="usd">33,036</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 0.2in">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">93,275</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" unitRef="usd">97,380</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-left: 0.2in">Accumulated other comprehensive income</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0.2in">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">140,674</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" sign="-" unitRef="usd">125,469</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt"><span style="text-decoration:underline">Total</span> shareholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">14,382</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">6,074</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt"><span style="text-decoration:underline">Total</span> liabilities and shareholders&#8217; equity</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">20,253</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" unitRef="usd">9,523</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 133; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>&#160;</b></p><div>

</div><div><a id="f_003"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(U.S. dollars in thousands except for share and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Note</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="6" style="text-align: justify">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; padding-bottom: 1.5pt">Revenues</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="width: 9%; padding-bottom: 1.5pt; text-align: center">8</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">853</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">763</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Revenues" scale="3" unitRef="usd">2,032</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Research and development expenses</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">9,850</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">11,951</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" unitRef="usd">10,976</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">3,845</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">2,951</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" unitRef="usd">3,063</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Operating loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">12,842</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">14,139</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" sign="-" unitRef="usd">12,007</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total financial income (expense), net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">12</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" unitRef="usd">227</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd">304</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NonoperatingIncomeExpense" scale="3" sign="-" unitRef="usd">618</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Loss before taxes on income</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd">12,615</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd">14,443</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" sign="-" unitRef="usd">12,625</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Taxes on income</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">13</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-3">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-4">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-5">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,615</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">14,443</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,625</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Deemed dividend</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RedeemablePreferredStockDividends" scale="3" unitRef="usd">2,590</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RedeemablePreferredStockDividends" scale="3" unitRef="usd">715</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-6">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt">Total comprehensive loss</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd">15,205</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd">15,158</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="3" sign="-" unitRef="usd">12,625</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Basic and diluted net loss per share</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: center">14</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" sign="-" unitRef="usdPershares">0.03</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" sign="-" unitRef="usdPershares">0.04</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" sign="-" unitRef="usdPershares">0.14</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Weighted average number of ordinary shares used in computing basic and diluted net loss per share</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: center">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" unitRef="shares">553,079,638</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" unitRef="shares">358,411,297</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" unitRef="shares">85,909,859</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 134; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><div><a id="f_004"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(U.S. dollars in thousands except for share and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional<br/>
paid-in</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated&#160;other <br/>
comprehensive</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total shareholders&#8217;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">capital</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">deficit</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">equity</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-indent: -0.1in; padding-left: 0.1in">Balance as of January 1, 2019</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">40,399,290</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c6" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">2,635</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c7" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">96,939</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c8" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c9" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">97,686</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;<ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">3,015</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of share capital and warrants, net of issue expenses of $ <ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="canf:WarrantsNetOfIssueExpenses" scale="3" unitRef="usd">1,382</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" scale="0" unitRef="shares">79,256,703</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" scale="3" unitRef="usd">5,518</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" scale="3" unitRef="usd">6,149</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-7">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-8">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" scale="3" unitRef="usd">11,667</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.1in; padding-left: 0.1in">Issuance of share capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">996,690</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c11" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">72</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">43</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-9">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-10">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">115</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Share-based payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-11">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c12" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">270</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-12">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-13">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">270</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-14">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-15">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-16">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c14" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,625</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,625</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Balance as of December 31, 2019</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">120,652,683</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">8,225</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">103,401</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">110,311</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">2,442</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 135; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(U.S. dollars in thousands except for share and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Ordinary shares</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Additional<br/>
paid-in</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated&#160;other <br/>
comprehensive</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Accumulated</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Total shareholders&#8217;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">capital</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Income</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">deficit</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">equity</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; text-indent: -0.1in; padding-left: 0.1in">Balance as of January 1, 2020</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c15" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">120,652,683</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c15" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">8,225</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c16" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">103,401</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c17" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c18" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">110,311</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">2,442</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Deemed dividends related to the warrants exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-17">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" scale="3" unitRef="usd">715</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-18">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" scale="3" sign="-" unitRef="usd">715</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-19">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of share capital and warrants, net of issuance expenses of $ <ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:WarrantsNetOfIssueExpenses" scale="3" unitRef="usd">3,703</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" scale="0" unitRef="shares">341,766,780</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" scale="3" unitRef="usd">24,711</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" scale="3" sign="-" unitRef="usd">7,028</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-20">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-21">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" scale="3" unitRef="usd">17,683</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.1in; padding-left: 0.1in">Issuance of share capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">1,350,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c20" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">100</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" sign="-" unitRef="usd">25</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-22">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-23">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">75</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Share-based payments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-24">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c21" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">317</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-25">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-26">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">317</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Net loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-27">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-28">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-29">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c23" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">14,443</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">14,443</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.1in; padding-left: 0.1in">Balance as of December 31, 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c24" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">463,769,463</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c24" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">33,036</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c25" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">97,380</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c26" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c27" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">125,469</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">6,074</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of share capital due to warrants exercise, net of issuance expenses of $ <ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodValueNetOfIssueExpenses" scale="3" unitRef="usd">980</ix:nonFraction> (Note 9b(14), 9b(16) &#160;and 9b(17))</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" scale="0" unitRef="shares">293,926,830</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" scale="3" unitRef="usd">23,106</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" scale="3" sign="-" unitRef="usd">11,339</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-30">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-31">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" scale="3" unitRef="usd">11,767</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of share capital and warrants, net of issuance expenses of $ <ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:WarrantsNetOfIssueExpenses" scale="3" unitRef="usd">1,307</ix:nonFraction> (Note 9b(16))</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" scale="0" unitRef="shares">57,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" scale="3" unitRef="usd">4,432</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" scale="3" unitRef="usd">4,258</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-32">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" scale="3" unitRef="usd">8,690</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Issuance of share capital in exchange for services (Note 9b(15))</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">1,050,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c28" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">80</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" sign="-" unitRef="usd">12</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-33">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-34">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" unitRef="usd">68</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Deemed dividends related to the warrants exercise (Note 9b(17))</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-35">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" scale="3" unitRef="usd">2,590</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-36">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" scale="3" sign="-" unitRef="usd">2,590</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-37">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; text-indent: -0.1in; padding-left: 0.1in">Net loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-38">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-39">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-40">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c31" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,615</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,615</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.1in; padding-left: 0.1in">Share-based payment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-41">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c29" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">398</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-42">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-43">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" unitRef="usd">398</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-indent: -0.1in; padding-left: 0.1in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-indent: -0.1in; padding-left: 0.1in">Balance as of December 31, 2021</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c32" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="0" unitRef="shares">815,746,293</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c32" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">60,654</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c33" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">93,275</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c34" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">1,127</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c35" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" sign="-" unitRef="usd">140,674</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" unitRef="usd">14,382</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 3in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></p><div>

</div><!-- Field: Page; Sequence: 136; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><div><a id="f_005"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>(U.S. dollars in thousands except for share and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt"><span style="text-decoration:underline">Cash flows from operating activities:</span></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Net loss</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,615</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">14,443</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,625</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Adjustments required to reconcile net loss to net cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Depreciation of property, plant and equipment and amortization</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" unitRef="usd">14</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" unitRef="usd">12</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" unitRef="usd">14</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Decrease in operating lease right of use asset</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" sign="-" unitRef="usd">55</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" sign="-" unitRef="usd">9</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" sign="-" unitRef="usd">28</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Change in prepaid expenses, and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" sign="-" unitRef="usd">128</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" sign="-" unitRef="usd">4,275</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" sign="-" unitRef="usd">221</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Share-based payment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:IncreaseDecreaseInSharebasedPayment" scale="3" unitRef="usd">398</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:IncreaseDecreaseInSharebasedPayment" scale="3" unitRef="usd">355</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="canf:IncreaseDecreaseInSharebasedPayment" scale="3" unitRef="usd">385</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Share-based payment in exchange for services</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" unitRef="usd">68</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-44">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-45">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Changes in fair value of short-term investment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" scale="3" unitRef="usd">162</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" scale="3" unitRef="usd">11</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" scale="3" sign="-" unitRef="usd">209</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Decrease in operating lease liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd">63</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd">8</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" sign="-" unitRef="usd">33</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Interest on bank deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" scale="3" unitRef="usd">12</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-46">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-47">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">non-cash financial expenses (income), net</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" unitRef="usd">34</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" sign="-" unitRef="usd">23</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Increase (decrease) in trade payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" unitRef="usd">393</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" sign="-" unitRef="usd">1,595</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" scale="3" unitRef="usd">1,085</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Increase (decrease) in deferred revenues</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" unitRef="usd">1,398</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" sign="-" unitRef="usd">401</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInDeferredRevenue" scale="3" unitRef="usd">146</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Increase (decrease) in other accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" unitRef="usd">574</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" sign="-" unitRef="usd">279</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInOtherAccountsPayable" scale="3" sign="-" unitRef="usd">512</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">9,858</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">12,063</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" sign="-" unitRef="usd">11,084</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: justify">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Purchase of property, plant and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">11</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">26</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" unitRef="usd">3</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Investment in short-term deposits</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireOtherInvestments" scale="3" unitRef="usd">14,500</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-48">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-49">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Net cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">14,511</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">26</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" sign="-" unitRef="usd">3</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-decoration: underline; text-align: justify">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Issuance of share capital and warrants, net of issuance expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" unitRef="usd">20,457</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" unitRef="usd">17,683</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" unitRef="usd">10,167</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Net cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">20,457</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">17,683</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" unitRef="usd">10,167</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Exchange differences on balances of cash and cash equivalents</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="3" unitRef="usd">34</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="3" sign="-" unitRef="usd">23</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents" scale="3" unitRef="usd">2</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Increase (decrease) in cash and cash equivalents</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd">3,878</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" unitRef="usd">5,571</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" sign="-" unitRef="usd">918</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Cash and cash equivalents at the beginning of the year</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd">8,268</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd">2,697</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c10" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd">3,615</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Cash and cash equivalents at the end of the year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd">4,390</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd">8,268</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c19" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" unitRef="usd">2,697</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-decoration: underline; text-align: justify">Non-cash activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Lease liabilities arising from obtaining right-of-use-assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd">120</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd">29</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" unitRef="usd">76</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Deemed Dividend</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDividends" scale="3" unitRef="usd">2,590</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfDividends" scale="3" unitRef="usd">715</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-50">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Cash paid during the year for interest</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd">18</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd">23</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" unitRef="usd">29</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">The accompanying notes are an integral part of
the consolidated financial statements.</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 137; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><div><a id="f_006"></a></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1:-&#160;GENERAL</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company description:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Can-Fite Biopharma Ltd. (the &#8220;Company&#8221;)
was incorporated and started to operate in September 1994 as a private Israeli company. Can-Fite is a clinical-stage biopharmaceutical
company focused on developing orally bioavailable small molecule therapeutic products for the treatment of psoriasis, liver cancer, NASH
and erectile dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is highly expressed
in patholological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting that the receptor
could be a specific target for pharmacological intervention. The Company&#8217;s pipeline of drug candidates are synthetic, highly specific
agonists and allosteric modulators at the A3AR.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s ordinary shares
have been publicly traded on the Tel-Aviv Stock Exchange since October 2005 under the symbol &#8220;CFBI&#8221; and the Company&#8217;s
American Depositary Shares (&#8220;ADSs&#8221;) began public trading on the over the counter market in the U.S. in October 2012 and since
November 2013 the Company&#8217;s ADSs have been publicly traded on the NYSE American under the symbol &#8220;CANF&#8221;. Each ADS represents
<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">30</ix:nonFraction> ordinary shares of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company incurred net losses of USD&#160;<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" sign="-" unitRef="usd">12,615</ix:nonFraction> and it had negative cash flows from operating activities in the amount of USD&#160;<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:CashFlowsFromOperatingActivities" scale="3" sign="-" unitRef="usd">9,858</ix:nonFraction>.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_6" id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Furthermore, the Company intends to
continue to finance its operating activities by raising capital and seeking collaborations with multinational companies in the industry.
There are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research
and development activities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">If the Company will not have sufficient
liquidity resources, the Company may not be able to continue the development of all of its products or may be required to implement a
cost reduction and may be required to delay part of its development programs. The Company&#8217;s management and board of directors are
of the opinion that its current financial resources will be sufficient to continue the development of the Company&#8217;s products for
at least the next twelve months beyond the date of the filing date of the consolidated financial statements.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 138; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;<b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_1" escape="true" name="us-gaap:SignificantAccountingPoliciesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_2" id="_SignificantAccountingPoliciesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The consolidated financial
statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_3" id="_SignificantAccountingPoliciesTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" continuedAt="_UseOfEstimates-c0_cont_1" escape="true" name="us-gaap:UseOfEstimates"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of estimates:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_4" id="_SignificantAccountingPoliciesTextBlock-c0_cont_3"><ix:continuation id="_UseOfEstimates-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#8217;s
management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they
are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting
period. Actual results could differ from those estimates.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_5" id="_SignificantAccountingPoliciesTextBlock-c0_cont_4"><ix:nonNumeric contextRef="c0" continuedAt="_ConsolidationPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ConsolidationPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principles of consolidation:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_6" id="_SignificantAccountingPoliciesTextBlock-c0_cont_5"><ix:continuation id="_ConsolidationPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The consolidated financial statements
include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_7" id="_SignificantAccountingPoliciesTextBlock-c0_cont_6"><ix:nonNumeric contextRef="c0" continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency, reporting currency and foreign currency:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_8" id="_SignificantAccountingPoliciesTextBlock-c0_cont_7"><ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency and reporting currency:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_9" id="_SignificantAccountingPoliciesTextBlock-c0_cont_8"><ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_3" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">From the Company&#8217;s inception through
January 1, 2018, the Company&#8217;s functional and presentation currency was the New Israeli Shekel (&#8220;NIS&#8221;). In 2018, management
conducted a review of the functional currency of the Company and concluded that the Company&#8217;s functional currency has changed to the U.S
dollar (&#8220;dollar&#8221;, &#8220;USD&#8221; or &#8220;$&#8221;) effective January 1, 2018.These changes were based on an assessment
made by the Company&#8217;s management that the USD is the primary currency of the economic environment in which the Company operates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_10" id="_SignificantAccountingPoliciesTextBlock-c0_cont_9"><ix:continuation continuedAt="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_4" id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions, assets and liabilities in foreign currency:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt"><b>&#160;</b></span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_11" id="_SignificantAccountingPoliciesTextBlock-c0_cont_10"><ix:continuation id="_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Transactions and balances denominated
in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured
into dollars in accordance with ASC No.&#160;830, &#8220;Foreign Currency Matters&#8221;. All transaction gains and losses from the re-measurement
of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as
appropriate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_12" id="_SignificantAccountingPoliciesTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" continuedAt="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_13" id="_SignificantAccountingPoliciesTextBlock-c0_cont_12"><ix:continuation id="_CashAndCashEquivalentsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Cash equivalents are short-term, highly
liquid investments that are readily convertible to cash with a maturity of three months or less at the date of acquisition, to be cash
equivalents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_14" id="_SignificantAccountingPoliciesTextBlock-c0_cont_13"><ix:nonNumeric contextRef="c0" continuedAt="_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><ix:nonNumeric contextRef="c0" continuedAt="_DebtPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:DebtPolicyTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></ix:nonNumeric></td> <td><ix:continuation id="_DebtPolicyTextBlock-c0_cont_1"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Short-term bank deposits:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Short-term bank deposits are deposits with maturities of more than three months and less than one year. As of December 31, 2021 and 2020, the Company&#8217;s bank deposits are denominated mainly in U.S. dollars and bears yearly interest at weighted average rates of <ix:nonFraction contextRef="c2" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" unitRef="pure">0.53</ix:nonFraction>% and none. Short-term bank deposits are presented at their cost, including accrued interest.</p></ix:continuation></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 8pt">&#160;</span></td> <td><span style="font-size: 8pt">&#160;</span></td> <td><span style="font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: top"> <td style="padding-right: -6.55pt">&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses, and other current assets:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_15" id="_SignificantAccountingPoliciesTextBlock-c0_cont_14"><ix:continuation id="_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Prepaid expenses are composed mainly from prepayments to suppliers
and from active pharmaceutical ingredients and clinical trial drug-capsules which are expensed when designate to a clinical trial and
no longer have an alternative future use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_16" id="_SignificantAccountingPoliciesTextBlock-c0_cont_15"><ix:nonNumeric contextRef="c0" continuedAt="_OperatingLeaseLeaseIncomeTableTextBlock-c0_cont_1" escape="true" name="us-gaap:OperatingLeaseLeaseIncomeTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_17" id="_SignificantAccountingPoliciesTextBlock-c0_cont_16"><ix:continuation continuedAt="_OperatingLeaseLeaseIncomeTableTextBlock-c0_cont_2" id="_OperatingLeaseLeaseIncomeTableTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In accordance with ASU No. 2016-02,
"Leases (Topic 842)", the Company determines if an arrangement is a lease and the classification of that lease at inception
based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially
all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of
the asset. The Company elected to not recognize a lease liability and a right-of-use ("ROU") asset for leases with a term of
twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases.
ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum
lease payments arising from the lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;&#160;</span></p></ix:continuation></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 139; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_18" id="_SignificantAccountingPoliciesTextBlock-c0_cont_17"><ix:continuation id="_OperatingLeaseLeaseIncomeTableTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ROU assets are initially measured at amounts, which represents the
discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially
measured at lease commencement date based on the discounted present value of minimum lease payments over the lease term. The implicit
rate within the operating leases is generally not determinable, therefore the Company uses its Incremental Borrowing Rate ("IBR")
based on the information available at commencement date in determining the present value of lease payments. The Company's IBR is estimated
to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased
asset is located. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection
with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option
to terminate is considered unless it is reasonably certain that the Company will not exercise the option.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_19" id="_SignificantAccountingPoliciesTextBlock-c0_cont_18"><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_20" id="_SignificantAccountingPoliciesTextBlock-c0_cont_19"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Property and equipment are stated at
cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the
assets at the following annual rates:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_21" id="_SignificantAccountingPoliciesTextBlock-c0_cont_20"><ix:nonNumeric contextRef="c0" escape="true" name="canf:ScheduleOfUsefulLivesOfTheAssetsTableTextBlock"><ix:continuation continuedAt="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mainly<br/> %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Laboratory equipment and Leasehold improvements</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center"><ix:nonFraction contextRef="c36" decimals="2" format="ixt:num-dot-decimal" name="canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" scale="-2" unitRef="pure">10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c36" decimals="2" format="ixt:num-dot-decimal" name="canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" scale="-2" unitRef="pure">10</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 49.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c37" decimals="2" format="ixt:num-dot-decimal" name="canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" scale="-2" unitRef="pure">6</ix:nonFraction> - <ix:nonFraction contextRef="c38" decimals="2" format="ixt:num-dot-decimal" name="canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" scale="-2" unitRef="pure">33</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c39" decimals="2" format="ixt:num-dot-decimal" name="canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" scale="-2" unitRef="pure">33</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_22" id="_SignificantAccountingPoliciesTextBlock-c0_cont_21"><ix:continuation id="_PropertyPlantAndEquipmentPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including extension option held by the Company and intended to be exercised)
and the expected life of the improvement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_23" id="_SignificantAccountingPoliciesTextBlock-c0_cont_22"><ix:nonNumeric contextRef="c0" continuedAt="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of long-lived assets:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_24" id="_SignificantAccountingPoliciesTextBlock-c0_cont_23"><ix:continuation id="_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Property and equipment are reviewed
for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment,&#8221; whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair
value of the assets. As of December 31, 2021, and 2020, no impairment indicators have been identified.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_25" id="_SignificantAccountingPoliciesTextBlock-c0_cont_24"><ix:nonNumeric contextRef="c0" continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:RevenueRecognitionPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"></td><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td><td style="text-align: justify">Revenue recognition:</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_26" id="_SignificantAccountingPoliciesTextBlock-c0_cont_25"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_2" id="_RevenueRecognitionPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue in
accordance with ASC Topic&#160;606, Revenue from contracts with customers (&#8220;ASC 606&#8221;) and determines revenue recognition
through the following steps:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_27" id="_SignificantAccountingPoliciesTextBlock-c0_cont_26"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_3" id="_RevenueRecognitionPolicyTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
of the contract, or contracts, with a customer;</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_28" id="_SignificantAccountingPoliciesTextBlock-c0_cont_27"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_4" id="_RevenueRecognitionPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
of the performance obligations in the contract;</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_29" id="_SignificantAccountingPoliciesTextBlock-c0_cont_28"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_5" id="_RevenueRecognitionPolicyTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determination
of the transaction price;</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_30" id="_SignificantAccountingPoliciesTextBlock-c0_cont_29"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_6" id="_RevenueRecognitionPolicyTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation
of the transaction price to the performance obligations in the contract; and</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_31" id="_SignificantAccountingPoliciesTextBlock-c0_cont_30"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_7" id="_RevenueRecognitionPolicyTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"></td><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition
of revenue when, or as, the performance obligations are satisfied.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p></ix:continuation></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_32" id="_SignificantAccountingPoliciesTextBlock-c0_cont_31"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_8" id="_RevenueRecognitionPolicyTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates rev</span>enues from supply and distribution agreements. The consideration under these agreements comprise of upfront
license fees, milestone payments and potential royalty payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_33" id="_SignificantAccountingPoliciesTextBlock-c0_cont_32"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_9" id="_RevenueRecognitionPolicyTextBlock-c0_cont_8"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and
distribution agreements with customers is recognized when the control over the goods or services is transferred to the customer. The
transaction price is the amount of the consideration that is expected to be received based on the contract terms, excluding amounts
collected on behalf of third parties (such as taxes).<b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><b>&#160;</b></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 140; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_34" id="_SignificantAccountingPoliciesTextBlock-c0_cont_33"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_10" id="_RevenueRecognitionPolicyTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and distribution
agreements with customers are recognized over time as the Company satisfies the performance obligations. The Company usually accepts long-term
upfront payment from its customers. Contract liabilities for those upfront payments are recognized as revenue over time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_35" id="_SignificantAccountingPoliciesTextBlock-c0_cont_34"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_11" id="_RevenueRecognitionPolicyTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts generally
include three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of
an exclusive licensing to distribute the product, once available; and, (iii) participation in joint steering committee.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_36" id="_SignificantAccountingPoliciesTextBlock-c0_cont_35"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_12" id="_RevenueRecognitionPolicyTextBlock-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company has concluded that the
abovementioned contracts contain a single performance obligation satisfied over time. Consequently, revenue from these contracts is recorded
based on the term of the research and development services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_37" id="_SignificantAccountingPoliciesTextBlock-c0_cont_36"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_13" id="_RevenueRecognitionPolicyTextBlock-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts also
include development milestones payments and future sales-based royalties. Development milestones payments are recognized only to the extent
that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated
with those milestones is subsequently resolved. As such sales based royalties are recognized only when the subsequent sale occurs. As
of December 31, 2021, the Company has not yet received the required regulatory approvals for its products and has not yet recognized any
sales-based royalties .</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_38" id="_SignificantAccountingPoliciesTextBlock-c0_cont_37"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_14" id="_RevenueRecognitionPolicyTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The prepayments terms from the Company&#8217;s
contracts with customers do not include a significant financing component as the primary purpose of these payments is not to receive financing
from the customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_39" id="_SignificantAccountingPoliciesTextBlock-c0_cont_38"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_15" id="_RevenueRecognitionPolicyTextBlock-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="text-decoration:underline">Revenue Recognition &#8211; Contract
Balances </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_40" id="_SignificantAccountingPoliciesTextBlock-c0_cont_39"><ix:continuation continuedAt="_RevenueRecognitionPolicyTextBlock-c0_cont_16" id="_RevenueRecognitionPolicyTextBlock-c0_cont_15"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Contract liabilities, due to the upfront
payments, include amounts received from customers for which revenue has not yet been recognized. As of December 31, 2021 and December
31, 2020 contract liabilities amounted to $<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="canf:ContractLiabilities" scale="3" unitRef="usd">3,888</ix:nonFraction>&#160;and $<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="canf:ContractLiabilities" scale="3" unitRef="usd">2,490</ix:nonFraction>, respectively and are presented under deferred revenues. During the year
ended December 31, 2021, the Company recognized revenues in the amount of $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:Revenue" scale="3" unitRef="usd">853</ix:nonFraction>&#160;out of which $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:RevenuesIncludedInContractLiabilities" scale="3" unitRef="usd">507</ix:nonFraction> have been included in the contract
liabilities at December&#160;31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_41" id="_SignificantAccountingPoliciesTextBlock-c0_cont_40"><ix:continuation id="_RevenueRecognitionPolicyTextBlock-c0_cont_16"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Deferred revenue that is anticipated
to be recognized during the succeeding 12-months period is recorded as current deferred revenue and the remaining portion is recorded
as non-current deferred revenue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_42" id="_SignificantAccountingPoliciesTextBlock-c0_cont_41"><ix:nonNumeric contextRef="c0" continuedAt="_ResearchAndDevelopmentExpensePolicy-c0_cont_1" escape="true" name="us-gaap:ResearchAndDevelopmentExpensePolicy"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_43" id="_SignificantAccountingPoliciesTextBlock-c0_cont_42"><ix:continuation id="_ResearchAndDevelopmentExpensePolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Research and development costs are
expensed as incurred. Research and development costs include payroll and personnel expenses, consulting costs, external contract research
and development expenses, raw materials, drug product manufacturing costs, and allocated overhead including depreciation and amortization,
rent, and utilities. Research and development are generally expensed as incurred. Research and development costs that are paid in advance
of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_44" id="_SignificantAccountingPoliciesTextBlock-c0_cont_43"><ix:nonNumeric contextRef="c0" continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_45" id="_SignificantAccountingPoliciesTextBlock-c0_cont_44"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company applies ASC 820, &#8220;Fair
Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;). Under this standard, fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market
participants at the measurement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_46" id="_SignificantAccountingPoliciesTextBlock-c0_cont_45"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In determining fair value, the Company
uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable
inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs
are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent
from the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken
down into three levels based on the inputs as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_47" id="_SignificantAccountingPoliciesTextBlock-c0_cont_46"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 1 - Valuations based on quoted
prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are
not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active
market, valuation of these products does not entail a significant degree of judgment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_48" id="_SignificantAccountingPoliciesTextBlock-c0_cont_47"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 2 - Valuations based on one or
more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_49" id="_SignificantAccountingPoliciesTextBlock-c0_cont_48"><ix:continuation continuedAt="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6" id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 3 - Valuations based on inputs
that are unobservable and significant to the overall fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 141; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_50" id="_SignificantAccountingPoliciesTextBlock-c0_cont_49"><ix:continuation id="_FairValueMeasurementPolicyPolicyTextBlock-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The carrying amounts of cash and cash
equivalents, other accounts receivable and prepaid expenses, trade payables and other accounts payable and accrued expenses approximate
their fair value due to the short-term maturity of such instruments. The Company has an investment measured using Level 1 inputs. See
Note 4.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_51" id="_SignificantAccountingPoliciesTextBlock-c0_cont_50"><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><ix:nonNumeric contextRef="c0" continuedAt="_ConcentrationRiskCreditRisk-c0_cont_1" escape="true" name="us-gaap:ConcentrationRiskCreditRisk"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></ix:nonNumeric></td> <td><ix:continuation id="_ConcentrationRiskCreditRisk-c0_cont_1"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Concentration of Credit Risk:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents and short-term deposits. For cash and cash equivalents, the Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.</p></ix:continuation></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 8pt">&#160;</span></td> <td><span style="font-size: 8pt">&#160;</span></td> <td><span style="font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal and other contingencies</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_52" id="_SignificantAccountingPoliciesTextBlock-c0_cont_51"><ix:continuation continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for its contingent
liabilities in accordance with ASC 450, Contingencies (&#8220;ASC 450&#8221;). A provision is recorded when it is both probable that a liability
has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, the Company reviews the status
of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable
and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. As of December 31, 2021, and 2020,
the Company is not a party to any litigation that could have a material adverse effect on the Company&#8217;s business, financial position,
results of operations or cash flows. Legal costs incurred in connection with loss contingencies are expensed as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_53" id="_SignificantAccountingPoliciesTextBlock-c0_cont_52"><ix:continuation continuedAt="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_3" id="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Major customer data as a percentage
of total revenues:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_54" id="_SignificantAccountingPoliciesTextBlock-c0_cont_53"><ix:nonNumeric contextRef="c0" escape="true" name="canf:ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock"><ix:continuation id="_CommitmentsAndContingenciesPolicyTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cipher Pharmaceuticals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c40" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">12</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c41" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">20</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Chong Kun Dang Pharmaceuticals Corp.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c42" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">24</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c43" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">45</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Gebro Holding GmBH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c44" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">23</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c45" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">35</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Ewopharma AG</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c46" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">41</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">100</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="canf:RevenueContractWithCustomer" scale="-2" unitRef="pure">100</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></ix:continuation></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_55" id="_SignificantAccountingPoliciesTextBlock-c0_cont_54"><ix:nonNumeric contextRef="c0" continuedAt="_SeverancePayPolicyTextBlock-c0_cont_1" escape="true" name="canf:SeverancePayPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severance pay<span style="text-transform: uppercase">:</span></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_56" id="_SignificantAccountingPoliciesTextBlock-c0_cont_55"><ix:continuation continuedAt="_SeverancePayPolicyTextBlock-c0_cont_2" id="_SeverancePayPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s liability for severance
pay is pursuant to Section 14 of the Severance Compensation Act, 1963 (&#8220;Section 14&#8221;), pursuant to which all the Company&#8217;s
employees are included under Section 14, and are entitled only to monthly deposits, at a rate of <ix:nonFraction contextRef="c0" decimals="4" format="ixt:num-dot-decimal" name="canf:PercentageOfDepositsOnMonthlySalary" scale="-2" unitRef="pure">8.33</ix:nonFraction>% of their monthly salary, made in
the employee&#8217;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release the Company
from any future severance payments in respect of those employees. The fund is made available to the employee at the time the employer-employee
relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected
in the consolidated balance sheets as the severance pay risks have been irrevocably transferred to the severance funds.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_57" id="_SignificantAccountingPoliciesTextBlock-c0_cont_56"><ix:continuation id="_SeverancePayPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Severance pay expense for the year
ended December 31, 2021, 2020 and 2019 amounted to $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="3" unitRef="usd">53</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="3" unitRef="usd">46</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SeveranceCosts1" scale="3" unitRef="usd">42</ix:nonFraction>, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_58" id="_SignificantAccountingPoliciesTextBlock-c0_cont_57"><ix:nonNumeric contextRef="c0" continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1" escape="true" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions<span style="text-transform: uppercase">:</span></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_59" id="_SignificantAccountingPoliciesTextBlock-c0_cont_58"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for share-based
compensation in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221; (&#8220;ASC 718&#8221;), which requires companies
to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion
of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#8217;s
consolidated statement of comprehensive loss, based on acceleration method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_60" id="_SignificantAccountingPoliciesTextBlock-c0_cont_59"><ix:continuation continuedAt="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3" id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company recognizes compensation
expenses for the value of its awards granted based on the vesting attribution approach over the requisite service period of each of the
awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in
subsequent periods if actual forfeitures differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_61" id="_SignificantAccountingPoliciesTextBlock-c0_cont_60"><ix:continuation id="_ShareBasedCompensationOptionAndIncentivePlansPolicy-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company estimates the fair value
of share options granted using the Binomial option pricing model. The option-pricing model requires a number of assumptions, of which
the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated based upon
historical volatility of the Company. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term.
The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 142; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_62" id="_SignificantAccountingPoliciesTextBlock-c0_cont_61"><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_63" id="_SignificantAccountingPoliciesTextBlock-c0_cont_62"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_2" id="_IncomeTaxPolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for income taxes
in accordance with ASC No. 740, &#8220;Income Taxes&#8221;, (&#8220;ASC 740&#8221;) which prescribes the use of the liability method whereby
deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_64" id="_SignificantAccountingPoliciesTextBlock-c0_cont_63"><ix:continuation continuedAt="_IncomeTaxPolicyTextBlock-c0_cont_3" id="_IncomeTaxPolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company provides a valuation allowance,
if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2021, and 2020, a full valuation allowance
was provided by the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_65" id="_SignificantAccountingPoliciesTextBlock-c0_cont_64"><ix:continuation id="_IncomeTaxPolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ASC 740 contains a two-step approach
to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected
to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation
of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes.
The second step is to measure the tax benefit as the largest amount that is more than <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="canf:PercentageOfRealizationOnUltimateSettlement" scale="-2" unitRef="pure">50</ix:nonFraction>% likely to be realized upon ultimate settlement.
As of December 31, 2021, and 2020, no liability for unrecognized tax benefits was recorded.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_66" id="_SignificantAccountingPoliciesTextBlock-c0_cont_65"><ix:nonNumeric contextRef="c0" continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:EarningsPerSharePolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><ix:nonNumeric contextRef="c0" continuedAt="_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock-c0_cont_1" escape="true" name="canf:OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></ix:nonNumeric></td> <td><ix:continuation continuedAt="_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock-c0_cont_2" id="_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock-c0_cont_1"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ordinary share warrants classification and measurement:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></td></tr> <tr style="vertical-align: top"> <td><ix:continuation continuedAt="_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock-c0_cont_3" id="_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock-c0_cont_2">&#160;</ix:continuation></td> <td><ix:continuation continuedAt="_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock-c0_cont_4" id="_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock-c0_cont_3">&#160;</ix:continuation></td> <td><ix:continuation id="_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock-c0_cont_4"> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#8217;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.</p></ix:continuation></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net loss per share<span style="text-transform: uppercase">:</span></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_67" id="_SignificantAccountingPoliciesTextBlock-c0_cont_66"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_2" id="_EarningsPerSharePolicyTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Basic and diluted net loss per share
is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated
based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260,
&#8220;Earnings per Share&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_68" id="_SignificantAccountingPoliciesTextBlock-c0_cont_67"><ix:continuation continuedAt="_EarningsPerSharePolicyTextBlock-c0_cont_3" id="_EarningsPerSharePolicyTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">All outstanding share options and warrants
for the years ended December 31, 2021, 2020 and 2019 have been excluded from the calculation of the diluted net loss per share, because
all such securities are anti-dilutive for all periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_69" id="_SignificantAccountingPoliciesTextBlock-c0_cont_68"><ix:continuation id="_EarningsPerSharePolicyTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">To compute diluted loss per share for the years ended December 31,
2021, December 31, 2020 and December 31, 2019, the total number of <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">18,422,700</ix:nonFraction>, <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">11,923,400</ix:nonFraction> and <ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" unitRef="shares">2,673,400</ix:nonFraction> shares, respectively subject to
outstanding unlisted options have not been considered since they have anti-dilutive effect.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_SignificantAccountingPoliciesTextBlock-c0_cont_70" id="_SignificantAccountingPoliciesTextBlock-c0_cont_69"><ix:nonNumeric contextRef="c0" continuedAt="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1" escape="true" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 47px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recently adopted and recently issued accounting pronouncements</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#8211;
Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which replaces the existing incurred loss impairment
model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected
to be collected. The adoption of the standard did not have material effect on Company&#8217;s results.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><!-- Field: Page; Sequence: 143; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_SignificantAccountingPoliciesTextBlock-c0_cont_70"><ix:continuation id="_NewAccountingPronouncementsPolicyPolicyTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 47px">&#160;</td> <td style="width: 24px">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic
740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing a variety of exceptions
within the framework of ASC 740. These exceptions include the exception to the incremental approach for intra period tax allocation in
the event of a loss from continuing operations and income or a gain from other items (such as other comprehensive income), and the exception
to using general methodology for the interim period tax accounting for year-to-date losses that exceed anticipated losses. The adoption
of the standard did not have material effect on Company&#8217;s results.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><ix:nonNumeric contextRef="c0" continuedAt="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c0_cont_1" escape="true" name="canf:AccountingPronouncementsNotYetAdoptedPolicyTextBlock"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></ix:nonNumeric></td> <td style="text-align: justify"><ix:continuation continuedAt="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c0_cont_2" id="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c0_cont_1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting pronouncements not yet adopted:</span></ix:continuation></td></tr> <tr style="vertical-align: top"> <td><ix:continuation continuedAt="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c0_cont_3" id="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c0_cont_2">&#160;</ix:continuation></td> <td><ix:continuation continuedAt="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c0_cont_4" id="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c0_cont_3">&#160;</ix:continuation></td> <td style="text-align: justify"><ix:continuation continuedAt="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c0_cont_5" id="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c0_cont_4">&#160;</ix:continuation></td></tr> <tr style="vertical-align: top"> <td><ix:continuation continuedAt="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c0_cont_6" id="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c0_cont_5">&#160;</ix:continuation></td> <td><ix:continuation continuedAt="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c0_cont_7" id="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c0_cont_6">&#160;</ix:continuation></td> <td><ix:continuation id="_AccountingPronouncementsNotYetAdoptedPolicyTextBlock-c0_cont_7"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provides guidance to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. As a result, the Company will not be required to adopt ASU 2021-04 until January 1, 2022. The Company is currently evaluating the impact of the adoption of this principle on the Company&#8217;s unaudited consolidated financial statements.</p></ix:continuation> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p></td></tr> </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_OtherAccountsReceivableAndPrepaidExpensesTextBlock-c0_cont_1" escape="true" name="canf:OtherAccountsReceivableAndPrepaidExpensesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3:-&#160;OTHER ACCOUNTS RECEIVABLE AND
PREPAID EXPENSES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_OtherAccountsReceivableAndPrepaidExpensesTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="canf:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Government authorities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="canf:GovernmentAuthorities" scale="3" unitRef="usd">48</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="canf:GovernmentAuthorities" scale="3" unitRef="usd">18</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Prepaid expenses and others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="3" unitRef="usd">881</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssets" scale="3" unitRef="usd">1,039</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" unitRef="usd">929</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherReceivablesNetCurrent" scale="3" unitRef="usd">1,057</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_InvestmentTextBlock-c0_cont_1" escape="true" name="us-gaap:InvestmentTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4:-&#160;SHORT-TERM INVESTMENT</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_InvestmentTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company holds <ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares"><ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares">356,803</ix:nonFraction></ix:nonFraction> shares of
Mawson Infrastructure Group Inc. (formerly Wize Pharma Inc.) as of December 31, 2021 and December 31, 2020, which as of such dates represents
less than <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="canf:PercentageOfOutstandingShares" scale="-2" unitRef="pure">5</ix:nonFraction> percent of Mawson Infrastructure Group Inc.&#8217;s outstanding shares, respectively. The investments in marketable equity
securities are measured at fair value with the related gains and losses, including unrealized, recognized in finance income (expenses),
net.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 144; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5:-&#160;PROPERTY, PLANT AND EQUIPMENT,
NET </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Composition of assets, grouped by major classification,
is as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3" id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_2"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:PropertyPlantAndEquipmentTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">62</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">57</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">206</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">200</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">13</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">13</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">281</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" unitRef="usd">270</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c48" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">35</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c49" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">28</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c50" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">190</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c51" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">184</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c52" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">9</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c53" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">8</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">234</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" unitRef="usd">220</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">47</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" unitRef="usd">50</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p></ix:nonNumeric></ix:continuation><div>


</div><div>

</div><ix:continuation id="_PropertyPlantAndEquipmentDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Depreciation expenses for the year ended December 31, 2021, 2020 and
2019 amounted to $<ix:nonFraction contextRef="c5" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationExpenseOnReclassifiedAssets" scale="0" unitRef="usd">14</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationExpenseOnReclassifiedAssets" scale="0" unitRef="usd">12</ix:nonFraction> and $<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DepreciationExpenseOnReclassifiedAssets" scale="0" unitRef="usd">14</ix:nonFraction>, respectively.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6:-</b>&#160;<b>OTHER ACCOUNTS PAYABLE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Employees and payroll accruals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="canf:EmployeesAndPayrollAccruals" scale="0" unitRef="usd">603</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="canf:EmployeesAndPayrollAccruals" scale="0" unitRef="usd">96</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd">302</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" scale="0" unitRef="usd">235</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd">905</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:OtherAccountsPayableAndAccruedLiabilities" scale="0" unitRef="usd">331</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 145; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_FairValueDisclosuresTextBlock-c0_cont_1" escape="true" name="us-gaap:FairValueDisclosuresTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7:- FAIR VALUE MEASUREMENTS </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_2" id="_FairValueDisclosuresTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In accordance with ASC 820 &#8220;Fair
Value Measurements and Disclosures&#8221;, the Company measures its short-term investment at fair value. Short-term investments are classified
within Level 1 as the valuation inputs are valuations based on quoted prices in active markets for identical assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_3" id="_FairValueDisclosuresTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company&#8217;s financial assets
and liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of the following dates:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_FairValueDisclosuresTextBlock-c0_cont_4" id="_FairValueDisclosuresTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1" escape="true" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measurements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Description</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair value</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; width: 52%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c54" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" unitRef="usd">237</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c55" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" unitRef="usd">237</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation id="_FairValueDisclosuresTextBlock-c0_cont_4"><ix:continuation id="_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value measurements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Description</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair value</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 52%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c58" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" unitRef="usd">75</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c59" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShortTermInvestments" scale="3" unitRef="usd">75</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:continuation></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8:-&#160;CONTINGENT LIABILITIES AND COMMITMENTS
</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; padding-right: 0.9pt">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities to pay royalties:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According to the patent license agreement that the Company entered into with Leiden University in the Netherlands on November 2, 2009, which is affiliated with the National Institutes of Health (NIH), the Company was granted an exclusive license for the use of the patents of several compounds, including CF602 in certain territories.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company is committed to pay royalties
as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A one-time concession commission of &#8364;<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NoninterestExpenseCommissionExpense" scale="3" unitRef="eur">25</ix:nonFraction> thousand;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual royalties of &#8364;<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RoyaltyExpense" scale="3" unitRef="eur">10</ix:nonFraction> thousand until the clinical trials commence;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c62" decimals="2" format="ixt:num-dot-decimal" name="canf:PercentageOfNetSales" scale="-2" unitRef="pure">2</ix:nonFraction>%-<ix:nonFraction contextRef="c63" decimals="2" format="ixt:num-dot-decimal" name="canf:PercentageOfNetSales" scale="-2" unitRef="pure">3</ix:nonFraction>% of net sales (as defined in the agreement) received by the Company;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><ix:nonNumeric contextRef="c0" continuedAt="_PatentAgreementDescription-c0_cont_1" name="canf:PatentAgreementDescription"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></ix:nonNumeric></td> <td style="text-align: justify; font-size: 10pt"><ix:continuation continuedAt="_PatentAgreementDescription-c0_cont_2" id="_PatentAgreementDescription-c0_cont_1"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalties in a total amount of up to &#8364;<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdvanceRoyalties" scale="3" unitRef="eur">850</ix:nonFraction> thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) &#8364;50 thousand upon initiation of Phase I studies; (ii) &#8364;100 thousand upon initiation of Phase II studies; (iii) &#8364;200 thousand upon initiation of Phase III studies; and (iv) &#8364;500 thousand upon marketing approval by any regulatory authority.</span></ix:continuation></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_8"><ix:continuation continuedAt="_PatentAgreementDescription-c0_cont_3" id="_PatentAgreementDescription-c0_cont_2"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the agreement is sublicensed to another company, the Company will provide Leiden University royalties at a rate of <ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="canf:RoyaltyPaymentsPercentage" scale="-2" unitRef="pure">10</ix:nonFraction>%. A merger, consolidation or any other change in ownership will not be viewed as an assignment of the agreement as discussed in this paragraph.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_10" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_9"><ix:continuation continuedAt="_PatentAgreementDescription-c0_cont_4" id="_PatentAgreementDescription-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.25in">As of December
31 2021, no accrual has been recorded with respect to Leiden University.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 146; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8:-&#160;CONTINGENT LIABILITIES AND COMMITMENTS
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_11" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_10"><ix:continuation continuedAt="_PatentAgreementDescription-c0_cont_5" id="_PatentAgreementDescription-c0_cont_4"><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: top">
    <td style="width: 48px; padding-right: 0.9pt">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments and license agreements:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_12" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_11"><ix:continuation continuedAt="_PatentAgreementDescription-c0_cont_6" id="_PatentAgreementDescription-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2015, the Company signed a distribution agreement with Cipher Pharmaceuticals (&#8220;Cipher&#8221;). As part of the distribution agreement, Cipher will distribute Can-Fite&#8217;s lead drug candidate, Piclidenoson for the treatment of psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_13" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_12"><ix:continuation continuedAt="_PatentAgreementDescription-c0_cont_7" id="_PatentAgreementDescription-c0_cont_6"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under the terms of the agreement, Cipher
made an upfront payment of USD <ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="canf:UnfrontPaymentAmount" scale="3" unitRef="usd">1,292</ix:nonFraction> (CAD <ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="canf:UnfrontPaymentAmount" scale="3" unitRef="cad">1,650</ix:nonFraction> thousand) to the Company in March 2015. In addition, the agreement provides that additional
payments of up to CAD <ix:nonFraction contextRef="c64" decimals="-3" format="ixt:num-dot-decimal" name="canf:AdditionalPayments" scale="3" unitRef="usd">2,000</ix:nonFraction> thousand will be received by the Company upon the achievement of certain milestones plus royalty payments
of <ix:nonFraction contextRef="c64" decimals="3" format="ixt:num-dot-decimal" name="canf:RoyaltyPaymentsPercentage" scale="-2" unitRef="pure">16.5</ix:nonFraction>% of net sales of Piclidenoson in Canada.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_14" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_13"><ix:continuation continuedAt="_PatentAgreementDescription-c0_cont_8" id="_PatentAgreementDescription-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities. In addition, the Company agreed to form
a joint steering committee with Cipher which will oversee the progress of the clinical studies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_15" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_14"><ix:continuation continuedAt="_PatentAgreementDescription-c0_cont_9" id="_PatentAgreementDescription-c0_cont_8"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2016, the Company signed a distribution agreement with Chong Kun Dang Pharmaceuticals Corp. (&#8220;CKD&#8221;) for future sales in South Korea. As part of the distribution agreement, CKD will distribute Namodenoson for the treatment of liver cancer in the South Korean market upon receipt of regulatory approvals.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_16" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_15"><ix:continuation continuedAt="_PatentAgreementDescription-c0_cont_10" id="_PatentAgreementDescription-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under the terms of the agreement, CKD
made an upfront payment of USD <ix:nonFraction contextRef="c65" decimals="-3" format="ixt:num-dot-decimal" name="canf:UnfrontPaymentAmount" scale="3" unitRef="usd">500</ix:nonFraction> to the Company in December 2016 and in August 2017, the Company received a second milestone payment
in the amount of USD <ix:nonFraction contextRef="c66" decimals="-3" format="ixt:num-dot-decimal" name="canf:UnfrontPaymentAmount" scale="3" unitRef="usd">500</ix:nonFraction> from CKD, which has licensed the exclusive right to distribute Namodenoson for the treatment of liver cancer
in Korea upon receipt of regulatory approvals.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_17" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_16"><ix:continuation continuedAt="_PatentAgreementDescription-c0_cont_11" id="_PatentAgreementDescription-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In addition, the agreement provides that
additional payments of up to USD <ix:nonFraction contextRef="c67" decimals="-3" format="ixt:num-dot-decimal" name="canf:AdditionalPayments" scale="3" unitRef="usd">2,500</ix:nonFraction> will be received by the Company upon the achievement of certain milestones.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_18" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_17"><ix:continuation continuedAt="_PatentAgreementDescription-c0_cont_12" id="_PatentAgreementDescription-c0_cont_11"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 147; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8:-&#160;CONTINGENT LIABILITIES AND COMMITMENTS
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_19" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_18"><ix:continuation continuedAt="_PatentAgreementDescription-c0_cont_13" id="_PatentAgreementDescription-c0_cont_12"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On February 25, 2019, the Company&#8217;s
Distribution Agreement with CKD was amended to expand the exclusive right to distribute Namodenoson for the treatment of NASH in addition
to liver cancer in South Korea. CKD has agreed to pay the Company up to an additional USD <ix:nonFraction contextRef="c68" decimals="-3" format="ixt:num-dot-decimal" name="canf:UnfrontPaymentAmount" scale="3" unitRef="usd">6,000</ix:nonFraction> in upfront and milestone payments payable
with respect to the NASH indication. The Company will also be entitled to a transfer price for delivering finished product to CKD following
commercial launch. In April 2019, the Company received an upfront payment of USD <ix:nonFraction contextRef="c69" decimals="-3" format="ixt:num-dot-decimal" name="canf:UnfrontPaymentAmount" scale="3" unitRef="usd">1,000</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_20" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_19"><ix:continuation continuedAt="_PatentAgreementDescription-c0_cont_14" id="_PatentAgreementDescription-c0_cont_13"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 22, 2008, the Company signed an agreement
    regarding the provision of a license for Piclodenoson with a South Korean pharmaceutical company, Kwang Dong Pharmaceutical Co. Ltd. (&#8220;KD&#8221;).
    According to the license agreement, the Company granted the KD a license to use, develop and market its Piclodenoson for treating only
    rheumatoid arthritis only in the Republic of Korea.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_21" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_20"><ix:continuation continuedAt="_PatentAgreementDescription-c0_cont_15" id="_PatentAgreementDescription-c0_cont_14"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of December 31, 2021, the Company estimates
that such contingent payments are remote.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_22" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_21"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px"><ix:continuation continuedAt="_PatentAgreementDescription-c0_cont_16" id="_PatentAgreementDescription-c0_cont_15">&#160;</ix:continuation></td> <td style="width: 24px"><ix:continuation id="_PatentAgreementDescription-c0_cont_16"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></ix:continuation></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 8, 2018, the Company entered into a Distribution and Supply Agreement with Gebro Holding GmBH (&#8220;Gebro&#8221;), granting Gebro the exclusive right to distribute Piclidenoson in Spain, Switzerland, Liechtenstein and Austria for the treatment of psoriasis and rheumatoid arthritis.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_23" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_22"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under the Distribution and Supply Agreement,
<ix:nonNumeric contextRef="c70" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription">the Company is entitled to &#8364;1,500 thousand upon execution of the agreement plus milestone payments upon achieving certain clinical,
launch and sales milestones, as follows: (i) &#8364;300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment
of rheumatoid arthritis and &#8364;300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis,
(ii) between &#8364;750 thousand and &#8364;1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either
the treatment of rheumatoid arthritis or psoriasis, and (iii) between &#8364;300 thousand and up to &#8364;4,025 thousand upon meeting certain
net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson
in the territories and payment for the manufacturing Piclidenoson.&#160;On January 25, 2018 the Company received a first payment of approximately
USD 2,200 from Gebro and in August 2018 received approximately USD 350 upon reaching the first milestone.</ix:nonNumeric></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_24" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_23"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company estimates these services will
spread over a period ending December 2026. Component (iv) was not accounted as part of the research and development services and will
be recognized entirely upon the Company reaching sales stage.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_25" id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_24"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 6, 2018, the Company entered into a License, Collaboration and Distribution Agreement with CMS Medical Venture Investment Limited (&#8220;CMS Medical&#8221;) for the commercialization of Piclidenoson for the treatment of rheumatoid arthritis and psoriasis and Namodenoson for the treatment of advanced liver cancer and NAFLD/NASH in China (including Hong Kong, Macao and Taiwan). Under the License, Collaboration and Distribution Agreement, the Company received USD <ix:nonFraction contextRef="c71" decimals="-3" format="ixt:num-dot-decimal" name="canf:UnfrontPaymentAmount" scale="3" unitRef="usd">2,000</ix:nonFraction> upon execution of the agreement and is entitled to additional milestone payments upon achieving certain regulatory and sales milestones. In addition, following regulatory approval, the Company shall be entitled to future double digit royalties on net sales in the territories and payment for the manufacturing of Piclidenoson and Namodenoson.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 148; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8:-&#160;CONTINGENT LIABILITIES AND COMMITMENTS
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation id="_CommitmentsAndContingenciesDisclosureTextBlock-c0_cont_25"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 31, 2019, the Company signed a distribution agreement with Kyongbo Pharm Co., Ltd. (&#8220;Kyongbo Pharm&#8221;), to distribute Piclidenoson, for the treatment of psoriasis in South Korea, upon receipt of regulatory approvals. Under the terms of the distribution agreement, Kyongbo Pharm, in exchange for exclusive distribution rights to sell Piclidenoson in the treatment of psoriasis in South Korea, is required to make a total upfront payment of USD <ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="canf:UnfrontPaymentAmount" scale="3" unitRef="usd">750</ix:nonFraction> to the Company, with additional payments of up to USD <ix:nonFraction contextRef="c72" decimals="-3" format="ixt:num-dot-decimal" name="canf:AdditionalPayments" scale="3" unitRef="usd">3,250</ix:nonFraction> upon achievement of certain milestones. The Company will also be entitled to a transfer price for delivering finished product to Kyongbo Pharm upon commercial launch. In August 2019, the Company received the upfront payment of USD <ix:nonFraction contextRef="c73" decimals="-3" format="ixt:num-dot-decimal" name="canf:UnfrontPaymentAmount" scale="3" unitRef="usd">750</ix:nonFraction> from Kyongbo Pharm.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 16, 2021, the Company announced it signed an exclusive distribution agreement with Switzerland-based Ewopharma for Piclidenoson in the treatment of psoriasis and Namodenoson in the treatment of liver diseases namely, hepatocellular carcinoma (HCC) the most common form of liver cancer and non-alcoholic steatohepatitis (NASH). Under the terms of the distribution agreement, Ewopharma paid Can-Fite non-refundable upfront payment in an amount of $<ix:nonFraction contextRef="c74" decimals="-3" format="ixt:num-dot-decimal" name="canf:UnfrontPaymentAmount" scale="3" unitRef="usd">2,250</ix:nonFraction> and is entitled to up to an additional $<ix:nonFraction contextRef="c75" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RetentionPayable" scale="3" unitRef="usd">40,450</ix:nonFraction> payable upon the achievement of regulatory and sales milestones and <ix:nonFraction contextRef="c74" decimals="3" format="ixt:num-dot-decimal" name="canf:RoyaltyOnNetSales" scale="-2" unitRef="pure">17.5</ix:nonFraction>% royalties on net sales. In exchange, Ewopharma will have the exclusive right to market and sell Piclidenoson in Central Eastern European (CEE) countries and Namodenoson in CEE countries and Switzerland. Ewopharma has the right to extend the distribution agreement to new indications that Can-Fite may identify for its drug candidates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 28, 2021, the Company announced it signed a development and commercialization agreement with Vetbiolix, a France-based veterinary biotech company, for the development of Piclidenoson for the treatment of osteoarthritis in companion animals including dogs and cats. According to the agreement, the Company will grant Vetbiolix an exclusive option to purchase its license of Piclidenoson in the veterinary osteoarthritis market for two years from the signature date, during which time Vetbiolix will conduct proof-of-concept studies and cover all associated costs. If the studies yield positive data and Vetbiolix exercises its option to obtain the license from Can-Fite, then Vetbiolix will be obligated to pay Can-Fite a non-refundable upfront payment in an amount of Euro <ix:nonFraction contextRef="c76" decimals="-3" format="ixt:num-dot-decimal" name="canf:NonRefundableUpfrontPayment" scale="3" unitRef="eur">250</ix:nonFraction> thousand, additional milestones payment equal to <ix:nonFraction contextRef="c76" decimals="2" format="ixt:num-dot-decimal" name="canf:RoyaltyPaymentsPercentage" scale="-2" unitRef="pure">30</ix:nonFraction>% upon each upfront payment received from sublicensee and <ix:nonFraction contextRef="c77" decimals="2" format="ixt:num-dot-decimal" name="canf:RoyaltyPaymentsPercentage" scale="-2" unitRef="pure">15</ix:nonFraction>%-<ix:nonFraction contextRef="c78" decimals="2" format="ixt:num-dot-decimal" name="canf:RoyaltyPaymentsPercentage" scale="-2" unitRef="pure">40</ix:nonFraction>% royalties on net sales upon regulatory approval for veterinary use.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> </table></ix:continuation><div>
</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;<b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 149; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9:-&#160;SHAREHOLDERS&#8217; EQUITY </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 10, 2019, the Company effected a change in the ratio of the Company&#8217;s ADS to ordinary shares from one <ix:nonNumeric contextRef="c79" name="canf:StockholdersEquityChangeInRatioDescription">(1) ADS representing two (2) ordinary shares to a new ratio of one (1) ADS representing thirty (30) ordinary shares. For ADS holders, the ratio change had the same effect as a one-for-fifteen reverse ADS split. All ADS and per ADS data in the financial statements and their related notes have been retroactively adjusted for all periods presented to reflect the ratio change.</ix:nonNumeric></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">All ordinary shares have equal rights
for all intent and purposes and each ordinary share confers its holder:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_3"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to be invited and participate in all the Company&#8217;s general meetings, both annual and regular, and the right to one vote per ordinary share owned in all votes and in all Company&#8217;s general meeting participated.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to receive dividends if and when declared and the right to receive bonus shares if and when distributed.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_5"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to participate in the distribution of the Company&#8217;s assets upon liquidation.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of shares and warrants and changes in equity:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_7"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 18, 2019, the Company completed a registered direct offering with an institutional investor, pursuant to which it sold an aggregate <ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares">149,206</ix:nonFraction> ADSs representing <ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">4,476,192</ix:nonFraction> ordinary shares. In addition, in a concurrent private placement, the Company issued to the investor unregistered warrants to purchase <ix:nonFraction contextRef="c80" decimals="0" format="ixt:num-dot-decimal" name="canf:WarrantsToPurchaseAdditionalSharesIssued" scale="0" unitRef="shares">149,206</ix:nonFraction> ADSs representing <ix:nonFraction contextRef="c81" decimals="0" format="ixt:num-dot-decimal" name="canf:WarrantsToPurchaseAdditionalSharesIssued" scale="0" unitRef="shares">4,476,192</ix:nonFraction> ordinary shares for an aggregate purchase price of USD <ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="canf:AggregatePurchasePrice" scale="3" unitRef="usd">2,350</ix:nonFraction> (excluding issuance cost of USD <ix:nonFraction contextRef="c82" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" unitRef="usd">428</ix:nonFraction>). The warrants have an exercise price of USD <ix:nonFraction contextRef="c83" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">19.50</ix:nonFraction> per ADS, are immediately exercisable and expire five and one-half years from the issuance date. The Company also issued unregistered placement agent warrants to purchase an aggregate of <ix:nonFraction contextRef="c83" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">7,460</ix:nonFraction> ADSs representing <ix:nonFraction contextRef="c84" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">223,810</ix:nonFraction> ordinary shares on the same terms as the warrants except they have a term of five years.&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>
</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 150; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9:-&#160;SHAREHOLDERS&#8217; EQUITY (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_8"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 4, 2019, the Company completed a registered direct offering with certain institutional investors, pursuant to which it sold an aggregate <ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares">328,205</ix:nonFraction> ADSs representing <ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares">9,846,156</ix:nonFraction> ordinary shares. In addition, in a concurrent private placement, the Company issued to the investor unregistered warrants to purchase <ix:nonFraction contextRef="c87" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">328,205</ix:nonFraction> ADSs representing <ix:nonFraction contextRef="c86" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">9,846,156</ix:nonFraction> ordinary shares for an aggregate purchase price of USD <ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="canf:AggregatePurchasePrice" scale="3" unitRef="usd">3,200</ix:nonFraction> (excluding issuance cost of USD <ix:nonFraction contextRef="c88" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" unitRef="usd">414</ix:nonFraction>). The warrants have an exercise price of USD <ix:nonFraction contextRef="c85" decimals="2" format="ixt:num-dot-decimal" name="canf:ExercisePrices" scale="0" unitRef="usdPershares">12.90</ix:nonFraction> per ADS, are immediately exercisable and expire five years from the issuance date. The Company also issued unregistered placement agent warrants to purchase an aggregate of <ix:nonFraction contextRef="c85" decimals="0" format="ixt:num-dot-decimal" name="canf:AggregateWarrantPurchased" scale="0" unitRef="shares">16,410</ix:nonFraction> ADSs representing <ix:nonFraction contextRef="c89" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">492,308</ix:nonFraction> ordinary shares on the same terms as the warrants except they have a term of five years.&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 22, 2019, the Company completed a registered direct offering with certain institutional investors, pursuant to which it sold an aggregate <ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" unitRef="shares">1,500,000</ix:nonFraction> ADSs representing <ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">45,000,000</ix:nonFraction> ordinary shares. In addition, in a concurrent private placement, the Company issued to the investor unregistered warrants to purchase <ix:nonFraction contextRef="c92" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" unitRef="shares">1,500,000</ix:nonFraction> ADSs representing <ix:nonFraction contextRef="c93" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">45,000,000</ix:nonFraction> ordinary shares for an aggregate purchase price of USD <ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="canf:AggregatePurchasePrice" scale="3" unitRef="usd">6,000</ix:nonFraction> (excluding issuance cost of USD <ix:nonFraction contextRef="c94" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" unitRef="usd">540</ix:nonFraction>). The warrants have an exercise price of USD <ix:nonFraction contextRef="c90" decimals="2" format="ixt:num-dot-decimal" name="canf:ExercisePrices" scale="0" unitRef="usdPershares">4.00</ix:nonFraction> per ADS, are immediately exercisable and expire five and one-half years from the issuance date. The Company also issued unregistered placement agent warrants to purchase an aggregate of <ix:nonFraction contextRef="c90" decimals="0" format="ixt:num-dot-decimal" name="canf:AggregateWarrantPurchased" scale="0" unitRef="shares">75,000</ix:nonFraction> ADSs representing <ix:nonFraction contextRef="c91" decimals="0" format="ixt:num-dot-decimal" name="canf:ShareIssued" scale="0" unitRef="shares">2,250,000</ix:nonFraction> ordinary shares on the same terms as the warrants except they have a term of five years.&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_10"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2019, the Company issued <ix:nonFraction contextRef="c95" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">19,934,355</ix:nonFraction> of its ordinary shares in connection with the Univo collaboration agreement</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_11"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the Company issued <ix:nonFraction contextRef="c96" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">996,690</ix:nonFraction> of its ordinary shares to a consultant in exchange for his services in connection with the Univo collaboration agreement.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_12"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 9, 2020, the Company entered into warrant exercise agreements (the &#8220;Exercise Agreements&#8221;) with several accredited investors who are the holders of certain warrants (the &#8220;Public Warrants&#8221;) to purchase the Company&#8217;s ordinary shares, represented by ADSs, pursuant to which the Holders exercised in cash their Public Warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">22,278,540</ix:nonFraction> ordinary shares represented by <ix:nonFraction contextRef="c98" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="0" unitRef="shares">742,618</ix:nonFraction> ADSs having exercise prices ranging from USD <ix:nonFraction contextRef="c99" decimals="2" format="ixt:num-dot-decimal" name="canf:ExercisePrices" scale="0" unitRef="usdPershares">12.90</ix:nonFraction> to USD <ix:nonFraction contextRef="c100" decimals="2" format="ixt:num-dot-decimal" name="canf:ExercisePrices" scale="0" unitRef="usdPershares">78.75</ix:nonFraction> per ADS issued by the Company, at a reduced exercise price of USD <ix:nonFraction contextRef="c97" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:WarrantExercisePriceDecrease" scale="0" unitRef="usdPershares">3.25</ix:nonFraction> per ADS, for gross proceeds to the Company of approximately USD <ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">2,400</ix:nonFraction>, prior to deducting placement agent fees and estimated offering expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Exercise Agreements, the Company issued to the warrant holders new unregistered warrants to purchase up to <ix:nonFraction contextRef="c97" decimals="0" format="ixt:num-dot-decimal" name="canf:IssueOfNewUnregisteredWarrants" scale="0" unitRef="shares">22,278,540</ix:nonFraction> ordinary shares represented by <ix:nonFraction contextRef="c101" decimals="0" format="ixt:num-dot-decimal" name="canf:IssueOfNewUnregisteredWarrants" scale="0" unitRef="shares">742,618</ix:nonFraction> ADSs (the &#8220;Private Placement Warrants&#8221;). The Private Placement Warrants are immediately exercisable, expire five and one-half years from issuance date and have an exercise price of USD <ix:nonFraction contextRef="c98" decimals="2" format="ixt:num-dot-decimal" name="canf:ExercisePriceSubjectToAdjusment" scale="0" unitRef="usdPershares">3.45</ix:nonFraction> per ADS, subject to adjustment as set forth therein. The Private Placement Warrants may be exercised on a cashless basis if six months after issuance there is no effective registration statement registering the ADSs underlying the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the terms of the Exercise Agreements, the warrant holders agreed to exercise the warrants at a reduced exercise price, thereby creating a benefit to these warrant holders. As such, the Company recorded a deemed dividend in the amount of $<ix:nonFraction contextRef="c97" decimals="-3" format="ixt:num-dot-decimal" name="canf:DeemedDividend" scale="3" unitRef="usd">715</ix:nonFraction>.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_13"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 12, 2020, <ix:nonNumeric contextRef="c102" name="canf:SecuritiesPurchaseAgreementDescription">the Company completed a public offering with certain institutional investors pursuant to which the Company issued and sold (i) 1,825,000 units, each unit consisting of one ADS, and one warrant to purchase one ADS, at a price of USD 1.50 per unit, and (ii) 1,508,334 pre-funded units each pre-funded unit consisting of one pre-funded warrant to purchase one ADS and one warrant, at a price of USD 1.49 per pre-funded unit.</ix:nonNumeric></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The gross proceeds from the offering were approximately USD <ix:nonFraction contextRef="c103" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromOtherEquity" scale="3" unitRef="usd">5,000</ix:nonFraction>, prior to deducting the placement agent&#8217;s fees and estimated offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The placement agent in the offering also received compensation warrants exercisable for up to <ix:nonFraction contextRef="c104" decimals="0" format="ixt:num-dot-decimal" name="canf:CompensationWarrantsExercisable" scale="0" unitRef="shares">250,000</ix:nonFraction> ADSs at an exercise price of USD <ix:nonFraction contextRef="c104" decimals="3" format="ixt:num-dot-decimal" name="canf:ExercisePrices" scale="0" unitRef="usdPershares">1.875</ix:nonFraction> per ADS expiring on <ix:nonNumeric contextRef="c103" format="ixt:date-monthname-day-year-en" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">February 10, 2025</ix:nonNumeric>.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 151; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9:-&#160;SHAREHOLDERS&#8217; EQUITY (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_14"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 9, 2020, as a result of an exercise of warrants by the investors from the February 2020 offering, the Company issued an aggregate of <ix:nonFraction contextRef="c105" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">20,250,000</ix:nonFraction> ordinary shares represented by <ix:nonFraction contextRef="c106" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">675,000</ix:nonFraction> ADSs, at a price of $<ix:nonFraction contextRef="c107" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares">1.50</ix:nonFraction> per ADS for gross proceeds of $<ix:nonFraction contextRef="c105" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">1,012</ix:nonFraction>.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_15"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 28, 2020, a special meeting of shareholders of the Company approved to increase Company&#8217;s authorized share capital to <ix:nonFraction contextRef="c108" decimals="0" format="ixt:num-dot-decimal" name="canf:IncreaseAuthorizedShareCapital" scale="0" unitRef="shares">1,000,000,000</ix:nonFraction> ordinary shares of <ix:nonFraction contextRef="c109" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="ilsPershares">0.25</ix:nonFraction> NIS par value each.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_16"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April and May, 2020, as a result of an exercise of warrants by the investors from the February 2020 offering, the Company issued an aggregate of <ix:nonFraction contextRef="c110" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">31,000,020</ix:nonFraction> ordinary shares represented by <ix:nonFraction contextRef="c111" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" unitRef="shares">1,033,334</ix:nonFraction> ADSs, at a price of $<ix:nonFraction contextRef="c112" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharePrice" scale="0" unitRef="usdPershares">1.50</ix:nonFraction> per ADS for gross proceeds of $<ix:nonFraction contextRef="c110" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">1,550</ix:nonFraction>.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_17"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:nonNumeric contextRef="c113" name="canf:StockIssuanceAgreementDescription">On June 12, 2020, the Company completed a registered direct offering with certain institutional and accredited investors pursuant to which it sold an aggregate of 3,902,440 ADSs at a purchase price of $2.05 per ADS for aggregate gross proceeds of approximately $8,000 prior to deducting the placement agent&#8217;s fees and estimated offering expenses payable by the Company.</ix:nonNumeric></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in a concurrent private placement the investors received unregistered warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="canf:IssueOfNewUnregisteredWarrants" scale="0" unitRef="shares">1,951,220</ix:nonFraction> ADSs. The warrants were immediately exercisable and will expire four and a half years from issuance at an exercise price of $<ix:nonFraction contextRef="c114" decimals="2" format="ixt:num-dot-decimal" name="canf:ExercisePrices" scale="0" unitRef="usdPershares">2.50</ix:nonFraction> per ADS, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The placement agent in the offering also received compensation warrants on substantially the same terms as the investors in the offering in an amount equal to <ix:nonFraction contextRef="c113" decimals="3" format="ixt:num-dot-decimal" name="canf:AggregateNumberOfADS" scale="-2" unitRef="pure">7.5</ix:nonFraction>% of the aggregate number of ADSs sold in the offering (or warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c114" decimals="0" format="ixt:num-dot-decimal" name="canf:AggregateWarrantPurchased" scale="0" unitRef="shares">292,683</ix:nonFraction> ADSs), at an exercise price of $<ix:nonFraction contextRef="c113" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">2.50</ix:nonFraction> per ADSs and a term expiring four and a half years from the date of issuance.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_18"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 8, 2020, the Company completed a registered direct offering with certain institutional and accredited investors pursuant to which it sold an aggregate of <ix:nonFraction contextRef="c115" decimals="0" format="ixt:num-dot-decimal" name="canf:IssueOfNewUnregisteredWarrants" scale="0" unitRef="shares">1,705,000</ix:nonFraction> ADSs at a purchase price of $<ix:nonFraction contextRef="c115" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">2.00</ix:nonFraction> per ADS for aggregate gross proceeds of approximately $<ix:nonFraction contextRef="c116" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" unitRef="usd">3,400</ix:nonFraction> prior to deducting the placement agent&#8217;s fees and estimated offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in a concurrent private placement, the investors received unregistered warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c116" decimals="0" format="ixt:num-dot-decimal" name="canf:IssueOfNewUnregisteredWarrants" scale="0" unitRef="shares">852,750</ix:nonFraction> ADSs. The warrants were immediately exercisable and will expire four and a half years from issuance at an exercise price of $<ix:nonFraction contextRef="c116" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">2.50</ix:nonFraction> per ADS, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The placement agent in the offering also received compensation warrants on substantially the same terms as the investors in the offering in an amount equal to <ix:nonFraction contextRef="c116" decimals="3" format="ixt:num-dot-decimal" name="canf:AggregateNumberOfADS" scale="-2" unitRef="pure">7.5</ix:nonFraction>% of the aggregate number of ADSs sold in the offering (or warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c117" decimals="0" format="ixt:num-dot-decimal" name="canf:WarrantsToPurchaseAggregateShares" scale="0" unitRef="shares">127,913</ix:nonFraction> ADSs), at an exercise price of $<ix:nonFraction contextRef="c117" decimals="2" format="ixt:num-dot-decimal" name="canf:ExercisePrice" scale="0" unitRef="usdPershares">2.50</ix:nonFraction> per ADSs and a term expiring.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_19"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"><td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2020, the Company issued <ix:nonFraction contextRef="c4" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">1,350,000</ix:nonFraction> of its ordinary shares to a consultant in exchange for his services.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_21" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_20"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February and March 2021, the Company issued <ix:nonFraction contextRef="c118" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">50,926,830</ix:nonFraction> ordinary shares represented by <ix:nonFraction contextRef="c119" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">1,697,561</ix:nonFraction> ADSs in exchange for exercise of warrants. Total consideration received by the Company was $<ix:nonFraction contextRef="c120" decimals="-3" format="ixt:num-dot-decimal" name="canf:TotalConsiderationAmount" scale="3" unitRef="usd">2,744</ix:nonFraction>.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>


</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 152; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 9:-&#160;SHAREHOLDERS&#8217; EQUITY (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_22" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_21"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2021, the Company issued <ix:nonFraction contextRef="c121" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">1,050,000</ix:nonFraction> of its ordinary shares represented by <ix:nonFraction contextRef="c122" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">35,000</ix:nonFraction> ADSs to certain consultants in exchange for their services with fair value of $ <ix:nonFraction contextRef="c120" decimals="-3" format="ixt:num-dot-decimal" name="canf:FairValueAmount" scale="3" unitRef="usd">68</ix:nonFraction>.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_23" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_22"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</span></td> <td> <ix:nonNumeric contextRef="c123" continuedAt="_PurchaseAgreementDescription-c123_cont_1" name="canf:PurchaseAgreementDescription"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 16, 2021, the Company completed a registered direct offering with an institutional investor pursuant to which it sold (i) 57,000,000 ordinary shares represented by 1,900,000 ADSs, and (ii) a pre-funded warrant to purchase 93,000,000 ordinary shares represented by 3,100,000 ADSs at an offering price of $2.00 per ADS and $1.999 per pre-funded warrant, for aggregate gross proceeds of approximately $10,000 (without taking into account any proceeds from any future exercises of warrants issued in the concurrent private placement), before deducting the placement agent&#8217;s fees and other estimated offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has also sold to the investor, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of <ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="canf:AggregateWarrantPurchased" scale="0" unitRef="shares">5,000,000</ix:nonFraction> ADSs. The warrants have an exercise price of $ <ix:nonFraction contextRef="c123" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:StockOptionExercisePriceIncrease" scale="0" unitRef="usdPershares">2.00</ix:nonFraction> per ADS and are exercisable at any time upon issuance and will expire three years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the financial statements date, the Company received a total of $ <ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="canf:TotalReceivedAmount" scale="3" unitRef="usd">9,997</ix:nonFraction> and issued <ix:nonFraction contextRef="c126" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">57,000,000</ix:nonFraction> ordinary shares represented by <ix:nonFraction contextRef="c124" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" unitRef="shares">1,900,000</ix:nonFraction> ADSs and <ix:nonFraction contextRef="c125" decimals="0" format="ixt:num-dot-decimal" name="canf:OrdinaryShares" scale="0" unitRef="shares">93,000,000</ix:nonFraction> ordinary shares represented by <ix:nonFraction contextRef="c127" decimals="0" format="ixt:num-dot-decimal" name="canf:OrdinaryShares" scale="0" unitRef="shares">3,100,000</ix:nonFraction> ADSs following the exercise of the pre-funded warrants (issuance expenses were $<ix:nonFraction contextRef="c125" decimals="-3" format="ixt:num-dot-decimal" name="canf:IssuanceExpensesAmount" scale="3" unitRef="usd">1,307</ix:nonFraction>).</p></ix:nonNumeric></td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"><ix:continuation continuedAt="_PurchaseAgreementDescription-c123_cont_2" id="_PurchaseAgreementDescription-c123_cont_1">&#160;</ix:continuation></td> <td style="font-size: 10pt"><ix:continuation continuedAt="_PurchaseAgreementDescription-c123_cont_3" id="_PurchaseAgreementDescription-c123_cont_2">&#160;</ix:continuation></td> <td style="text-align: justify; font-size: 10pt"><ix:continuation continuedAt="_PurchaseAgreementDescription-c123_cont_4" id="_PurchaseAgreementDescription-c123_cont_3">&#160;</ix:continuation></td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt"><ix:continuation continuedAt="_PurchaseAgreementDescription-c123_cont_5" id="_PurchaseAgreementDescription-c123_cont_4">&#160;</ix:continuation></td> <td style="font-size: 10pt"><ix:continuation continuedAt="_PurchaseAgreementDescription-c123_cont_6" id="_PurchaseAgreementDescription-c123_cont_5"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.</span></ix:continuation></td> <td><ix:continuation continuedAt="_PurchaseAgreementDescription-c123_cont_7" id="_PurchaseAgreementDescription-c123_cont_6"> </ix:continuation><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><ix:continuation id="_PurchaseAgreementDescription-c123_cont_7">On December 20, 2021, the Company entered into a warrant exercise agreement (the &#8220;Exercise Agreement&#8221;) with an institutional investor who is the holder of certain existing warrants to purchase Company&#8217;s ordinary shares, par value NIS 0.25 per share, represented by ADSs issued by the Company in a registered direct offering consummated in August 2021.</ix:continuation> <ix:nonNumeric contextRef="c128" continuedAt="_ExerciseAgreementDescription-c128_cont_1" name="canf:ExerciseAgreementDescription">Pursuant to the Exercise Agreement, the holder agreed to exercise in cash its warrants to purchase up to an aggregate of 150,000,000 Ordinary Shares represented by 5,000,000 ADSs having an exercise price of $2.00 per ADS, at an exercise price of $2.00 per ADS, for gross proceeds to the Company of $10 million, prior to deducting placement agent fees and offering expenses (which amounted to $0.98 million).</ix:nonNumeric></p><ix:continuation id="_ExerciseAgreementDescription-c128_cont_1"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Exercise Agreement, the Company also agreed to issue to the holder new unregistered warrants to purchase up to 180,000,000 Ordinary Shares represented by 6,000,000 ADSs (the &#8220;Private Placement Warrants&#8221;). The Private Placement Warrants will be immediately exercisable, will expire five years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants, and have an exercise price of $2.00 per ADS.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Exercise Agreements, the holder agreed to exercise the warrants while receiving a-120% warrants coverage, thereby creating a benefit to this warrant holder. As such, the Company recorded a deemed dividend in the amount of $ 2,590.</p></ix:continuation></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_24" id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_23"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 72px"></td><td style="width: 24px">c.</td><td style="text-align: justify">Warrants to Purchase Common stock:</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                            <tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">The following table
summarizes information regarding outstanding warrants to purchase shares of the Company&#8217;s ADS&#8217;s issued as of December 31,
2021:</td></tr>
                                                                                                                                            </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: 0in">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_StockholdersEquityNoteDisclosureTextBlock-c0_cont_24"><ix:nonNumeric contextRef="c0" escape="true" name="canf:ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Issuance date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <br/> outstanding <br/> warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exercise<br/> price per<br/> warrant</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>($)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify"><ix:nonNumeric contextRef="c129" name="canf:IssuanceDate">January 2017</ix:nonNumeric></td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c130" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">91,667</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c130" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">33.75</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c131" name="canf:IssuanceDate">March 2018</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c132" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">11,111</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c132" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">30.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c133" name="canf:IssuanceDate">January 2019</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c134" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">7,460</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c134" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">19.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c135" name="canf:IssuanceDate">April 2019</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c136" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">16,410</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c136" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">12.90</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c137" name="canf:IssuanceDate">May 2019</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c138" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">1,575,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c138" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">4.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c139" name="canf:IssuanceDate">January 2020</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c140" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">794,601</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c140" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">3.45</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c141" name="canf:IssuanceDate">February 2020</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c142" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">375,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c142" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">1.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c143" name="canf:IssuanceDate">June 2020</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c144" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">2,046,342</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c144" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">2.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c145" name="canf:IssuanceDate">July 2020</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c146" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">980,663</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c146" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">2.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c147" name="canf:IssuanceDate">August 2021</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c148" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">350,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c148" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">2.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify"><ix:nonNumeric contextRef="c149" name="canf:IssuanceDate">December 2021</ix:nonNumeric></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c150" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">6,350,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c150" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" unitRef="usdPershares">2.00</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" unitRef="shares">12,598,254</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>


</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: 0in">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 153; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1" escape="true" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10:-&#160;SHARE-BASED PAYMENT TRANSACTIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share options:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On November 28, 2013, the board of
directors approved the adoption of the 2013 Share Option Plan (the &#8220;2013 Plan&#8221;). Under the 2013 Plan, the Company may grant
its officers, directors, employees and consultants, stock options, of the Company. Each stock option granted shall be exercisable at such
times and terms and conditions as the Board of Directors may specify in the applicable option agreement, provided that no option will
be granted with a term in excess of <ix:nonNumeric contextRef="c151" format="ixt-sec:duryear" name="canf:GrantedExcessYears">10</ix:nonNumeric> years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_4" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Upon the adoption of the 2013 Plan
the Company reserved for issuance <ix:nonFraction contextRef="c152" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharesIssued" scale="0" unitRef="shares">2,500,000</ix:nonFraction> shares of ordinary shares, NIS <ix:nonFraction contextRef="c151" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" unitRef="ilsPershares">0.25</ix:nonFraction> par value each. In May 2020, the Company&#8217;s Board
of Directors approved to increase number of ordinary shares reserved for issuance to <ix:nonFraction contextRef="c153" decimals="0" format="ixt:num-dot-decimal" name="canf:NumberOfOrdinaryShares" scale="0" unitRef="shares">25,000,000</ix:nonFraction>. As of December 31, 2021, <ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="canf:FutureShares" scale="0" unitRef="shares">6,618,500</ix:nonFraction> shares
available for future grant under the 2013 Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_5" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses recognized in the financial statements:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_6" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_5"><ix:nonNumeric contextRef="c0" escape="true" name="canf:ScheduleOfExpensesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" unitRef="usd">200</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" unitRef="usd">159</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="3" unitRef="usd">138</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd">198</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd">158</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherGeneralAndAdministrativeExpense" scale="3" unitRef="usd">132</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:SharebasedPayments" scale="3" unitRef="usd">398</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:SharebasedPayments" scale="3" unitRef="usd">317</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="canf:SharebasedPayments" scale="3" unitRef="usd">270</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"></p><div>

</div><!-- Field: Page; Sequence: 154; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10:-&#160;SHARE-BASED PAYMENT TRANSACTIONS
(Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_7" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions granted by the Company:</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_8" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The fair value of the Company&#8217;s
share options granted was estimated using the binomial option pricing model using the following range assumptions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_9" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="canf:ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Description</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Risk-free interest rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c62" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.22</ix:nonFraction>-<ix:nonFraction contextRef="c63" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">1.28</ix:nonFraction></span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c154" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">0.93</ix:nonFraction>-<ix:nonFraction contextRef="c155" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" unitRef="pure">2.40</ix:nonFraction></span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap; text-align: justify">Expected volatility</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;<ix:nonFraction contextRef="c62" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">82.40</ix:nonFraction>-<ix:nonFraction contextRef="c63" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">82.43</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left">%</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;<ix:nonFraction contextRef="c154" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">65.63</ix:nonFraction>-<ix:nonFraction contextRef="c155" decimals="4" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" unitRef="pure">78.77</ix:nonFraction> </span></td><td style="white-space: nowrap; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify">Dividend yield</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right"><ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" unitRef="pure">0</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Contractual life</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonNumeric contextRef="c154" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">9.83</ix:nonNumeric> - <ix:nonNumeric contextRef="c155" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">10</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Early Exercise Multiple (Suboptimal Factor)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares">3</ix:nonFraction></td><td style="text-align: left"></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c156" decimals="1" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares">2.5</ix:nonFraction> - <ix:nonFraction contextRef="c157" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="usdPershares">3</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap; text-align: justify">Exercise price (NIS)</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c62" decimals="2" format="ixt:num-dot-decimal" name="canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="ilsPershares">0.25</ix:nonFraction>-<ix:nonFraction contextRef="c63" decimals="3" format="ixt:num-dot-decimal" name="canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="ilsPershares">0.253</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c154" decimals="2" format="ixt:num-dot-decimal" name="canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="ilsPershares">0.25</ix:nonFraction>
- <ix:nonFraction contextRef="c155" decimals="3" format="ixt:num-dot-decimal" name="canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" unitRef="ilsPershares">2.344</ix:nonFraction></span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_10" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_9"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Movement during the year:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_11" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table lists the number
of share options, their weighted average exercise prices and modification in option plans of employees, directors and consultants for
the periods indicated:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_12" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="6">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares subject to options <br/>
outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/>
average <br/>
exercise <br/>
price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">11,923,400</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.28</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" unitRef="shares">7,100,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.08</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Forfeited/expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" scale="0" unitRef="shares">600,700</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">1.00</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Outstanding at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" unitRef="shares">18,422,700</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" unitRef="usdPershares">0.18</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Exercisable at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="0" format="ixt:num-dot-decimal" name="canf:NumberOfExercisableAtEndOfShares" scale="0" unitRef="shares">6,322,700</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="canf:WeightedAverageExercisePriceExercisableAtEndOfPerShares" scale="0" unitRef="usdPershares">0.35</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_13" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_12"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average remaining contractual life for the shares subject to options outstanding as of December&#160;31, 2021, 2020 and 2019 was <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">8.45</ix:nonNumeric> years, <ix:nonNumeric contextRef="c4" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">6.98</ix:nonNumeric> years and <ix:nonNumeric contextRef="c5" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">7.93</ix:nonNumeric> years, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_14" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_13"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average grant date fair value in 2021 was $<ix:nonFraction contextRef="c0" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">0.18</ix:nonFraction> and in 2020 was $<ix:nonFraction contextRef="c4" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" unitRef="usdPershares">0.16</ix:nonFraction> and the remaining compensation costs not yet recognized as of December 31, 2021 is $<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="0" unitRef="usd">1,139</ix:nonFraction> with a weighted average period of <ix:nonNumeric contextRef="c0" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">2.82</ix:nonNumeric> years to recognize these expenses.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_15" id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_14"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The range of exercise prices for shares subject to options outstanding as of December&#160;31, 2021 have been separated into ranges of exercise prices, as follows:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-c0_cont_15"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; border-bottom: Black 1.5pt solid">Exercise price per share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options <br/>
outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/>
average <br/>
remaining <br/>
contractual<br/>
life in <br/>
years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/>
average<br/>
exercise<br/> price per<br/> share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options <br/>
exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/>
average <br/>
exercise<br/> price per<br/> share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: left"><ix:nonFraction contextRef="c158" decimals="2" format="ixt:num-dot-decimal" name="canf:SharebasedPaymentArrangementOptionExercisePriceRange" scale="0" unitRef="usdPershares">0.08</ix:nonFraction> - $<ix:nonFraction contextRef="c159" decimals="2" format="ixt:num-dot-decimal" name="canf:SharebasedPaymentArrangementOptionExercisePriceRange" scale="0" unitRef="usdPershares">0.94</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right"><ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">17,796,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c161" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">8.32</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">0.13</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c160" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">5,696,500</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c160" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares">0.21</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c162" decimals="2" format="ixt:num-dot-decimal" name="canf:SharebasedPaymentArrangementOptionExercisePriceRange" scale="0" unitRef="usdPershares">1.09</ix:nonFraction> - $<ix:nonFraction contextRef="c163" decimals="2" format="ixt:num-dot-decimal" name="canf:SharebasedPaymentArrangementOptionExercisePriceRange" scale="0" unitRef="usdPershares">1.73</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c164" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">555,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonNumeric contextRef="c165" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">0.14</ix:nonNumeric></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c164" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">0.04</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c164" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">555,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c164" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares">0.11</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><ix:nonFraction contextRef="c166" decimals="2" format="ixt:num-dot-decimal" name="canf:SharebasedPaymentArrangementOptionExercisePriceRange" scale="0" unitRef="usdPershares">2.61</ix:nonFraction>
- $<ix:nonFraction contextRef="c167" decimals="2" format="ixt:num-dot-decimal" name="canf:SharebasedPaymentArrangementOptionExercisePriceRange" scale="0" unitRef="usdPershares">5.18</ix:nonFraction></span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">71,200</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonNumeric contextRef="c169" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">0.01</ix:nonNumeric></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c168" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="0" unitRef="shares">0.01</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c168" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">71,200</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><ix:nonFraction contextRef="c168" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" unitRef="usdPershares">0.04</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" scale="0" unitRef="shares">18,422,700</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" unitRef="usdPershares">6,322,700</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 155; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_1" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11- LEASES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_2" id="_LesseeOperatingLeasesTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company has lease contracts for
motor vehicles used in its operations. Leases of motor vehicles have lease terms of <ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm">3</ix:nonNumeric> years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_3" id="_LesseeOperatingLeasesTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following is a summary of weighted
average remaining lease terms and discount rate for all of the Company&#8217;s operating leases:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_4" id="_LesseeOperatingLeasesTextBlock-c0_cont_3"><ix:nonNumeric contextRef="c0" continuedAt="_LeaseCostTableTextBlock-c0_cont_1" escape="true" name="us-gaap:LeaseCostTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">weighted average remaining lease term (years)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c2" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">2.42</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right"><ix:nonNumeric contextRef="c3" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1">1.71</ix:nonNumeric></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">13</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" unitRef="pure">13</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_5" id="_LesseeOperatingLeasesTextBlock-c0_cont_4"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">The components
of lease expense and supplemental cash flow information related to leases for the year ended December 31, 2021 and 2020 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; ">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_6" id="_LesseeOperatingLeasesTextBlock-c0_cont_5"><ix:continuation continuedAt="_LeaseCostTableTextBlock-c0_cont_2" id="_LeaseCostTableTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Components of lease expense:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Operating lease cost</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">55</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseCost" scale="3" unitRef="usd">43</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:continuation></ix:continuation><div>


</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_7" id="_LesseeOperatingLeasesTextBlock-c0_cont_6"><ix:continuation id="_LeaseCostTableTextBlock-c0_cont_2"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/>
December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/>
December&#160;31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Supplemental cash flow information</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" scale="3" unitRef="usd">55</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" scale="3" unitRef="usd">43</ix:nonFraction></td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" scale="3" unitRef="usd">120</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" scale="3" unitRef="usd">29</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">&#160;</p></ix:continuation></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_LesseeOperatingLeasesTextBlock-c0_cont_8" id="_LesseeOperatingLeasesTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">Maturities
of lease liabilities as of December 31, 2021 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation id="_LesseeOperatingLeasesTextBlock-c0_cont_8"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" unitRef="usd">69</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" unitRef="usd">59</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" unitRef="usd">20</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating lease payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="canf:LesseeOperatingLeaseLiabilityPaymentDue" scale="3" unitRef="usd">148</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: imputed interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="canf:ImputedInterestLessImputedInterest" scale="3" unitRef="usd">24</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Present value of lease liability</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" unitRef="usd">124</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 156; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_InterestIncomeAndInterestExpenseDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 12:-&#160;FINANCE INCOME (EXPENSE), NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_InterestIncomeAndInterestExpenseDisclosureTextBlock-c0_cont_1"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Finance expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Bank commissions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:BanksCommissions" scale="3" sign="-" unitRef="usd">18</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:BanksCommissions" scale="3" sign="-" unitRef="usd">23</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="canf:BanksCommissions" scale="3" sign="-" unitRef="usd">21</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Net loss from exchange rate fluctuations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="canf:NetLossFromExchangeRateFluctuations" scale="3" sign="-" unitRef="usd">33</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other loss from short-term investment revaluation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="canf:OtherLossFromShorttermInvestmentRevaluation" scale="3" sign="-" unitRef="usd">209</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other financial expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="3" unitRef="usd">4</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="3" unitRef="usd">363</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherExpenses" scale="3" unitRef="usd">427</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:FinanceExpenses" scale="3" sign="-" unitRef="usd">22</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:FinanceExpenses" scale="3" sign="-" unitRef="usd">386</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="canf:FinanceExpenses" scale="3" sign="-" unitRef="usd">690</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Finance income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Interest income on bank deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" unitRef="usd">24</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" unitRef="usd">44</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeDepositsWithFinancialInstitutions" scale="3" unitRef="usd">72</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Exchange rate fluctuations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:ExchangeRateFluctuations" scale="3" unitRef="usd">59</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:ExchangeRateFluctuations" scale="3" unitRef="usd">27</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other gain from short-term investment remeasurement</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="3" unitRef="usd">162</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GainLossOnInvestments" scale="3" unitRef="usd">11</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="canf:FinanceIncome" scale="3" unitRef="usd">249</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="canf:FinanceIncome" scale="3" unitRef="usd">82</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="canf:FinanceIncome" scale="3" unitRef="usd">72</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total financial income (expenses), net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" unitRef="usd">227</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" sign="-" unitRef="usd">304</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestIncomeExpenseNet" scale="3" sign="-" unitRef="usd">618</ix:nonFraction></td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table></ix:nonNumeric></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13:-&#160;TAXES ON INCOME</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_2" id="_IncomeTaxDisclosureTextBlock-c0_cont_1"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate tax rates:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_3" id="_IncomeTaxDisclosureTextBlock-c0_cont_2"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Israeli taxation:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_4" id="_IncomeTaxDisclosureTextBlock-c0_cont_3"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Corporate tax rate in Israel in 2021
was <ix:nonFraction contextRef="c170" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure">23</ix:nonFraction>%, 2020 - <ix:nonFraction contextRef="c171" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure">23</ix:nonFraction>% and in 2019 was <ix:nonFraction contextRef="c172" decimals="2" format="ixt:num-dot-decimal" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" unitRef="pure">23</ix:nonFraction>%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_5" id="_IncomeTaxDisclosureTextBlock-c0_cont_4"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Final tax assessments:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_6" id="_IncomeTaxDisclosureTextBlock-c0_cont_5"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company received final tax assessments
through 2016.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_7" id="_IncomeTaxDisclosureTextBlock-c0_cont_6"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating carryforward losses for tax purposes and other temporary differences:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_8" id="_IncomeTaxDisclosureTextBlock-c0_cont_7"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of December 31, 2021, the Company
had carryforward losses amounting to approximately USD&#160;<ix:nonFraction contextRef="c2" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsCapitalLossCarryforwards" scale="0" unitRef="usd">164,680</ix:nonFraction>.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p><div>

</div><!-- Field: Page; Sequence: 157; Value: 1 --><div>
    </div><div style="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></p></div><div>
    </div><div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div><div>
    </div><!-- Field: /Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><b>CAN-FITE BIOPHARMA LTD. AND ITS SUBSIDIARY</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; border-bottom: black 1.5pt solid"><b>NOTES TO CONSOLIDATED FINANCIAL
STATEMENTS</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>(U.S. dollars in thousands except for share
and per share data)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13:-&#160;TAXES ON INCOME (Cont.)</b></p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_9" id="_IncomeTaxDisclosureTextBlock-c0_cont_8"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_10" id="_IncomeTaxDisclosureTextBlock-c0_cont_9"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Deferred income taxes reflect the net
tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts
used for income tax purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_11" id="_IncomeTaxDisclosureTextBlock-c0_cont_10"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Significant components of the Company&#8217;s
deferred tax assets and liabilities are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_12" id="_IncomeTaxDisclosureTextBlock-c0_cont_11"><ix:nonNumeric contextRef="c0" escape="true" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating loss carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd">37,875</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" unitRef="usd">32,312</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Temporary differences mainly relating to Research and Development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd">3,285</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" unitRef="usd">3,581</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred tax asset before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd">41,160</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" unitRef="usd">35,893</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c2" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd">41,160</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction contextRef="c3" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" unitRef="usd">35,893</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax asset, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p></ix:nonNumeric></ix:continuation><div>

</div><div>

</div><ix:continuation continuedAt="_IncomeTaxDisclosureTextBlock-c0_cont_13" id="_IncomeTaxDisclosureTextBlock-c0_cont_12"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reconciliation of the theoretical tax expense to the actual tax expense:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p></ix:continuation><div>
</div><div>

</div><ix:continuation id="_IncomeTaxDisclosureTextBlock-c0_cont_13"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The main reconciling item between the
statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating
to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><div>

</div><ix:nonNumeric contextRef="c0" continuedAt="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 14:- TRANSACTIONS WITH RELATED PARTIES
</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></ix:nonNumeric><div>

</div><div>

</div><ix:continuation id="_RelatedPartyTransactionsDisclosureTextBlock-c0_cont_1"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Chairman of the Company&#8217;s
board of directors is a senior partner in the patent firm which represents the Company in intellectual property and commercial matters
(the &#8220;Service Provider&#8221;). The Service Provider charges the Company for services it renders on an hourly basis. The aggregate
amount of these expenses was approximately $<ix:nonFraction contextRef="c0" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" unitRef="usd">241</ix:nonFraction>, $<ix:nonFraction contextRef="c4" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" unitRef="usd">252</ix:nonFraction> and $<ix:nonFraction contextRef="c5" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" scale="3" unitRef="usd">163</ix:nonFraction> in 2021, 2020 and 2019, respectively, which were recorded under research
and development expenses within Company&#8217;s consolidated statements of comprehensive loss.</p></ix:continuation><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&#160;</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">F-30</p><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>

</div><!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="font-size: 1pt; border-top: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page --><div>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></p><div>




</div><div style="display: none"><ix:header>
<ix:hidden>
<ix:nonFraction contextRef="c3" id="hidden-fact-0" name="us-gaap:DepositsAssetsCurrent" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-1" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-2" name="us-gaap:CommitmentsAndContingencies" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-3" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-4" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-5" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-6" name="us-gaap:RedeemablePreferredStockDividends" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-7" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-8" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-9" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-10" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-11" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-12" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c14" id="hidden-fact-13" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c11" id="hidden-fact-14" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c12" id="hidden-fact-15" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c13" id="hidden-fact-16" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-17" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-18" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-19" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-20" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-21" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-22" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-23" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-24" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-25" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c23" id="hidden-fact-26" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c20" id="hidden-fact-27" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c21" id="hidden-fact-28" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c22" id="hidden-fact-29" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-30" name="canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-31" name="canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-32" name="canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-33" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-34" name="us-gaap:StockIssuedDuringPeriodValueOther" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-35" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-36" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-37" name="us-gaap:StockIssuedDuringPeriodValueStockDividend" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-38" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c29" id="hidden-fact-39" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-40" name="us-gaap:NetIncomeLoss" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c28" id="hidden-fact-41" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c30" id="hidden-fact-42" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c31" id="hidden-fact-43" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-44" name="us-gaap:ShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-45" name="us-gaap:ShareBasedCompensation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-46" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-47" name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-48" name="us-gaap:PaymentsToAcquireOtherInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-49" name="us-gaap:PaymentsToAcquireOtherInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-50" name="us-gaap:PaymentsOfDividends" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c47" id="hidden-fact-51" name="canf:RevenueContractWithCustomer" unitRef="pure" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c56" id="hidden-fact-52" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c57" id="hidden-fact-53" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c60" id="hidden-fact-54" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c61" id="hidden-fact-55" name="us-gaap:ShortTermInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-56" name="canf:NetLossFromExchangeRateFluctuations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-57" name="canf:NetLossFromExchangeRateFluctuations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c0" id="hidden-fact-58" name="canf:OtherLossFromShorttermInvestmentRevaluation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c4" id="hidden-fact-59" name="canf:OtherLossFromShorttermInvestmentRevaluation" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-60" name="canf:ExchangeRateFluctuations" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c5" id="hidden-fact-61" name="us-gaap:GainLossOnInvestments" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c2" id="hidden-fact-62" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction contextRef="c3" id="hidden-fact-63" name="us-gaap:DeferredTaxAssetsNet" unitRef="usd" xsi:nil="true"></ix:nonFraction>
<ix:nonNumeric contextRef="c0" name="dei:AmendmentFlag">false</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="c0" name="dei:EntityCentralIndexKey">0001536196</ix:nonNumeric>
</ix:hidden>
<ix:references><link:schemaRef xlink:href="canf-20211231.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources xmlns="http://www.xbrl.org/2003/instance"><xbrli:context id="c0">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c1">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c2">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c3">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c4">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c5">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c6">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c7">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c8">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c9">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c10">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2018-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c11">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c12">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c13">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c14">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c15">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c16">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c17">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c18">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c19">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c20">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c21">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c22">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c23">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c24">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c25">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c26">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c27">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c28">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c29">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c30">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c31">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c32">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c33">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c34">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c35">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c36">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:LaboratoryEquipmentAndLeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c37">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c38">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c39">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c40">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CipherPharmaceuticalsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c41">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CipherPharmaceuticalsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c42">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:ChongKunDangPharmaceuticalsCorpMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c43">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:ChongKunDangPharmaceuticalsCorpMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c44">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:GebroHoldingGmBHMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c45">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:GebroHoldingGmBHMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c46">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaAGMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c47">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaAGMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c48">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:LaboratoryEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c49">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:LaboratoryEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c50">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c51">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c52">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c53">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c54">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c55">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c56">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c57">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c58">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c59">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c60">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c61">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c62">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c63">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c64">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:CipherMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2015-03-01</xbrli:startDate>
    <xbrli:endDate>2015-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c65">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:ChongKunDangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-01-01</xbrli:startDate>
    <xbrli:endDate>2016-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c66">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:ChongKunDangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2017-08-01</xbrli:startDate>
    <xbrli:endDate>2017-08-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c67">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2016-10-01</xbrli:startDate>
    <xbrli:endDate>2016-10-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c68">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:ChongKunDangMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2019-02-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c69">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-02-01</xbrli:startDate>
    <xbrli:endDate>2019-02-25</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c70">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c71">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:CMSMedicalMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2018-08-01</xbrli:startDate>
    <xbrli:endDate>2018-08-06</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c72">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:KyongboPharmMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-07-01</xbrli:startDate>
    <xbrli:endDate>2019-07-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c73">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:KyongboPharmMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-08-01</xbrli:startDate>
    <xbrli:endDate>2019-08-19</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c74">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:SwitzerlandBasedEwopharmaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-01</xbrli:startDate>
    <xbrli:endDate>2021-03-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c75">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:SwitzerlandBasedEwopharmaMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c76">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:VetbiolixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-06-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c77">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:VetbiolixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-06-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c78">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:VetbiolixMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-06-01</xbrli:startDate>
    <xbrli:endDate>2021-06-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c79">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-05-01</xbrli:startDate>
    <xbrli:endDate>2019-05-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c80">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-01-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c81">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-01-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c82">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-01-18</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c83">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbKPcFX/25U7tJjZ1e/QkjhiUJn9hDzDjBiHcqiPkVBCCODXCRCIM9u4S3gJiJPkfeA4IWMDZOgz1+S5KnQ1ZJmUdVT2gUh0PhPHv3pa4+fTZTkTD4DIrxKSC26B+qiQe8tCtLe+ud+bxP4dcVqp2G92WtBs6vOj1FOZTxFulqqlkvzOQstgQaJRgDCb5YCPoowr65z/mmHOEcI1jMPatk/] CSR-->
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-01-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c84">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-01-18</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c85">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-04-01</xbrli:startDate>
    <xbrli:endDate>2019-04-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c86">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-04-01</xbrli:startDate>
    <xbrli:endDate>2019-04-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c87">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-04-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c88">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-04-01</xbrli:startDate>
    <xbrli:endDate>2019-04-04</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c89">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-04-04</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c90">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-05-01</xbrli:startDate>
    <xbrli:endDate>2019-05-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c91">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-05-01</xbrli:startDate>
    <xbrli:endDate>2019-05-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c92">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-05-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c93">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2019-05-22</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c94">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-05-01</xbrli:startDate>
    <xbrli:endDate>2019-05-22</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c95">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-09-01</xbrli:startDate>
    <xbrli:endDate>2019-09-30</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c96">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-12-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c97">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-01-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c98">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-01-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c99">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-01-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c100">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-01-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c101">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-01-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c102">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2020-02-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c103">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2020-02-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c104">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-02-01</xbrli:startDate>
    <xbrli:endDate>2020-02-10</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c105">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-01</xbrli:startDate>
    <xbrli:endDate>2020-03-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c106">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-03-01</xbrli:startDate>
    <xbrli:endDate>2020-03-09</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c107">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-03-09</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c108">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-04-28</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c109">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-04-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c110">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c111">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-04-01</xbrli:startDate>
    <xbrli:endDate>2020-05-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c112">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c113">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2020-06-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c114">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-06-01</xbrli:startDate>
    <xbrli:endDate>2020-06-12</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c115">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-07-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c116">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-07-01</xbrli:startDate>
    <xbrli:endDate>2020-07-08</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c117">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-07-08</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c118">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c119">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-02-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c120">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-03-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c121">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c122">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-03-01</xbrli:startDate>
    <xbrli:endDate>2021-03-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c123">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-08-01</xbrli:startDate>
    <xbrli:endDate>2021-08-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c124">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-08-01</xbrli:startDate>
    <xbrli:endDate>2021-08-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c125">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-08-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c126">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-08-01</xbrli:startDate>
    <xbrli:endDate>2021-08-16</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c127">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-08-16</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c128">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-12-17</xbrli:startDate>
    <xbrli:endDate>2021-12-20</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c129">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2017Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c130">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2017Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c131">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:March2018Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c132">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:March2018Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c133">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2019Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c134">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2019Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c135">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:April2019Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c136">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:April2019Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c137">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:May2019Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c138">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:May2019Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c139">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c140">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c141">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:February2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c142">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:February2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c143">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:June2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c144">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:June2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c145">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:July2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c146">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:July2020Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c147">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:August2021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c148">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:August2021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c149">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:December2021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c150">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:December2021Member</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c151">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2013-11-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c152">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2013-11-28</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c153">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-05-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c154">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c155">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c156">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c157">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2020-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c158">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c159">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c160">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c161">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c162">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c163">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c164">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c165">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c166">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c167">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c168">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:instant>2021-12-31</xbrli:instant>
  </xbrli:period>
</xbrli:context><xbrli:context id="c169">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c170">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2021-01-01</xbrli:startDate>
    <xbrli:endDate>2021-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c171">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2020-01-01</xbrli:startDate>
    <xbrli:endDate>2020-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:context id="c172">
  <xbrli:entity>
    <xbrli:identifier scheme="http://www.sec.gov/CIK">0001536196</xbrli:identifier>
    <xbrli:segment>
      <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
    </xbrli:segment>
  </xbrli:entity>
  <xbrli:period>
    <xbrli:startDate>2019-01-01</xbrli:startDate>
    <xbrli:endDate>2019-12-31</xbrli:endDate>
  </xbrli:period>
</xbrli:context><xbrli:unit id="shares">
  <xbrli:measure>xbrli:shares</xbrli:measure>
</xbrli:unit><xbrli:unit id="usd">
  <xbrli:measure>iso4217:USD</xbrli:measure>
</xbrli:unit><xbrli:unit id="ilsPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:ILS</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="usdPershares">
  <xbrli:divide>
    <xbrli:unitNumerator>
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unitNumerator>
    <xbrli:unitDenominator>
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unitDenominator>
  </xbrli:divide>
</xbrli:unit><xbrli:unit id="pure">
  <xbrli:measure>xbrli:pure</xbrli:measure>
</xbrli:unit><xbrli:unit id="eur">
  <xbrli:measure>iso4217:EUR</xbrli:measure>
</xbrli:unit><xbrli:unit id="cad">
  <xbrli:measure>iso4217:CAD</xbrli:measure>
</xbrli:unit></ix:resources></ix:header>

</div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-8.1
<SEQUENCE>2
<FILENAME>f20f2021ex8-1_canfitebio.htm
<DESCRIPTION>LIST OF SUBSIDIARIES OF CAN-FITE BIOPHARMA LTD
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 8.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Subsidiary of Can-Fite BioPharma Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following table sets forth the name and jurisdiction
of incorporation of our subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%; border-bottom: black 1.5pt solid"><FONT STYLE="font-size: 10pt"><B>Name of Subsidiary</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Jurisdiction of Incorporation</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-size: 10pt">Can-Fite Biopharma Europe</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">France</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.1
<SEQUENCE>3
<FILENAME>f20f2021ex12-1_canfitebio.htm
<DESCRIPTION>CERTIFICATION EXHIBIT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
12.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CERTIFICATION
OF THE CHIEF  EXECUTIVE OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I,
Pnina Fishman, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I
    have reviewed this annual report on Form 20-F of Can-Fite BioPharma Ltd;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
    material respects the financial condition, results of operations and cash flows of the company as of, and for, the periods
    presented in this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
    company&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and
    procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined
    in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD STYLE="text-align: justify; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the company, including its consolidated subsidiaries, is made known to us
    by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such internal
    control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
    to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated the effectiveness
    of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
    of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed in this
    report any change in the company&rsquo;s internal control over financial reporting that occurred during the period covered
    by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal
    control over financial reporting;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The company&rsquo;s
    other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
    to the company&rsquo;s auditors and the audit committee of the company&rsquo;s board of directors (or persons performing the
    equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All significant
    deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
    likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any fraud, whether
    or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal control
    over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated:
    March 24, 2022</FONT></TD>
    <TD STYLE="width: 60%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Pnina Fishman </FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pnina Fishman, Ph.D.</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive
    Officer</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-12.2
<SEQUENCE>4
<FILENAME>f20f2021ex12-2_canfitebio.htm
<DESCRIPTION>CERTIFICATION EXHIBIT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
12.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CERTIFICATION
OF THE CHIEF FINANCIAL OFFICER UNDER SECTION 302 OF THE SARBANES-OXLEY ACT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I,
Motti Farbstein, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">I have reviewed
    this annual report on Form 20-F of Can-Fite BioPharma Ltd;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge,
    this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
    statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period
    covered by this report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Based on my knowledge,
    the financial statements, and other financial information included in this report, fairly present in all material respects
    the financial condition, results of operations and cash flows of the company as of, and for, the periods presented in this
    report;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The company&rsquo;s
    other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as
    defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange
    Act Rules 13a-15(f) and 15d-15(f)) for the company and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such disclosure
    controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure
    that material information relating to the company, including its consolidated subsidiaries, is made known to us by others
    within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Designed such internal
    control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision,
    to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
    for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Evaluated the effectiveness
    of the company&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness
    of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Disclosed in this
    report any change in the company&rsquo;s internal control over financial reporting that occurred during the period covered
    by the annual report that has materially affected, or is reasonably likely to materially affect, the company&rsquo;s internal
    control over financial reporting;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The company&rsquo;s
    other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
    to the company&rsquo;s auditors and the audit committee of the company&rsquo;s board of directors (or persons performing the
    equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All significant
    deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
    likely to adversely affect the company&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Any fraud, whether
    or not material, that involves management or other employees who have a significant role in the company&rsquo;s internal control
    over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated:
    March 24, 2022</FONT></TD>
    <TD STYLE="width: 60%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Mott Farbstein </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Motti Farbstein</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Operating
    and Financial Officer</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.1
<SEQUENCE>5
<FILENAME>f20f2021ex13-1_canfitebio.htm
<DESCRIPTION>CERTIFICATION EXHIBIT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
13.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CERTIFICATION
OF CHIEF EXECUTIVE OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Can-Fite BioPharma
Ltd. (the &ldquo;Company&rdquo;) hereby certifies to such officer&rsquo;s knowledge that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(i)
the accompanying Annual Report on Form 20-F of the Company for the year ended December 31, 2021 (the &ldquo;Report&rdquo;) fully
complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ii)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated:
    March 24, 2022</FONT></TD>
    <TD STYLE="width: 60%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Pnina Fishman </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pnina Fishman, Ph.D.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Executive
    Officer</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being
filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference
to any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in
such filing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13.2
<SEQUENCE>6
<FILENAME>f20f2021ex13-2_canfitebio.htm
<DESCRIPTION>CERTIFICATION EXHIBIT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
13.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">CERTIFICATION
OF CHIEF  FINANCIAL OFFICER UNDER SECTION 906 OF THE SARBANES-OXLEY ACT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Can-Fite BioPharma
Ltd. (the &ldquo;Company&rdquo;) hereby certifies to such officer&rsquo;s knowledge that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(i)
the accompanying Annual Report on Form 20-F of the Company for the year ended December 31, 2021 (the &ldquo;Report&rdquo;) fully
complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended;
and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(ii)
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated:
    March 24, 2022</FONT></TD>
    <TD STYLE="width: 60%; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Motti Farbstein </FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Motti Farbstein</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Chief Operating
    and Financial Officer</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. Section 1350, and is not being
filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference
to any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in
such filing.</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-15.1
<SEQUENCE>7
<FILENAME>f20f2021ex15-1_canfitebio.htm
<DESCRIPTION>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
15.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in the following Registration Statements: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
                                            Statement (Form F-3 No. 333-195124) of Can-Fite Biopharma Ltd.,</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
                                            Statement (Form F-3 No. 333-236064) of Can-Fite Biopharma Ltd.,</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
                                            Statement (Form F-3 No. 333-209037) of Can-Fite Biopharma Ltd.,</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
                                            Statement (Form F-3 No. 333-249063) of Can-Fite Biopharma Ltd.,</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
                                            Statement (Form F-3 No. 333-262055) of Can-Fite Biopharma Ltd., and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; background-color: white"><TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
<TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Registration
                                            Statement (Form S-8 No. 333-227753) pertaining to the 2003 Israeli Share Option Plan and
                                            2013 Global Incentive Option Scheme of Can-Fite Biopharma Ltd.;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
our report dated March 24, 2022, with respect to the consolidated financial statements of Can-Fite Biopharma Ltd. included in this Annual
Report (Form 20-F) of Can-Fite Biopharma Ltd. for the year ended December 31, 2021.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;<B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tel-Aviv,
    Israel</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; width: 20%">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 40%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/&nbsp; Kost
    Forer Gabbay &amp; Kasierer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March 24,
    2022</FONT></TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A Member of Ernst &amp; Young
    Global</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !L %T# 2(  A$! Q$!_\0
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1CC+#+%% S]:M4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" 'J GH# 2(  A$! Q$!_\0
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MF>#?!$9Y% ,D/'[WH"F6&.A/.#TJPK20.R);;(?*$HD!&3*>L)''3MZ\X[T
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M_/)]: .0_P"$"T3_ )XC\A_A3X_ ^@Q-O> $8*X/')^GMFNK^THIPQZ>W?\
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M"#D'.!CMGTXK^4#_ (-X-.T^V_:<_;SN]$G:V2?XA>(<Z.!BWMY1JTWELP!
M"[PN-H !&* /ZS%E\[R8HKQ6O82GVE<Y+*"-WZ<]3GOBM0-'([%7$C( '0'@
MD\9'ICZ'ICUK'TZ"ZMHGO-26'[=.[*=@YVDX &,=LD]>O..*V+6/:&;^_P#Y
M_P _UH ?C_IA^O\ ]:C'_3#]?_K58HH A0?-_JMG7G.?Z5(_W3\N_IQTIU%
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M98X\ K(P 96QZ$'&>N.N<UJ6DT<]QYJP>4S*V]^IDQTYZ?+SV[U\_:_H=_\
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M0<&L;_@CU\,/AYXPN?\ @J9\'M6TR)OV5+2^\7?\(]X$U/\ >>$-$827L_\
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M!'7C%16PSYX[[K37R^77K\[FN)TP6UGR2M+35*'=+>]E9N_;R_DQ;]O#_@O
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M/X]_&'[8?_!?'XD>%]:\ :!^SA9^'M<\1:?-8#7SICP+IL&HK]FN)Q(1A/\
M1Y)$7/=N.<5^GO\ P1J_X)^^+/V(/A/XI\2_&[4K+4?C_P#&/4SK7C1H2/,@
MFNKC[3-$!GJI=@Q'0*?K7[@W*SE7"RLL;+M+0HIE&>%VD+GJ>>>!G&*P8;,0
M7=K';V$DDD;2.]].<NFY&R.2<^8"4'<;O<&@#1M8FCG*6S!8T*M(2>,O['KD
MX&/K6NHD\Y\R94 ';CUZ?3UX_P#KU2BM'BO)+E#\DZMYB]@P#$$8_P!KV _'
M%78NK?5OYB@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>H'Z#/\ +OW'7FK= !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 55NV=8LKW8!N>V?\
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MV*=Y4'+!<<DD9 '6CR_K70%HT_-?F9(B@@MYM/@S=D7 >YW-G$.\&4EB2?N
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M,XKXET/]E3XI:U\2[KP-J6EY\(Z3$UU<:G;JQ@.GAB2A)R/E7'^Z>,BOTX\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG^B]^RK^W_\ LX_ME:;I%]X#\8Z79>+M2:"36O#&KS^4+6X"%I(+=,@*0RG
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M&M^#_#VN/=_\));"XFN(\6\BJ/W>X\;CC)SC![\@D'DGY%\7_!RZT'49Y]#
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MU#-L,3#&7=#E1GDCY3@5].?\%$#%>Z+X(T2ZTD7<,=\;UKY)S%Y0$@_=8#
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MUO\ ?*/7=?@F3+X9=='V[,_+^P^\"!DB&$@=><K@#O[5U5A,[2'SK<HAR(V
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M1F0A5(XSE"V1SD$9!ZUY_HUU)=Z-9W$WR>88@67@_.RC' R1S]"3[&O3(A!
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M1%2'^8G<,8);)R<D=.O>N(T:9(YFAN,JTG[O!&.7X&,<Y!&/6NXTD^9J0:8
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MH1T*3R=,@T.(C[%:*8"L;O)"%7./GY)SSG^'^/O&#&83,FN>I;G27OS2O?\
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M_:.UA/"/PRTBZUB/PO<*+J[OK*?S[>U))$L=Q%RP08YD)7;^G](7[<4O_!-
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M.XASK-,;07M(M4W=3O%KW%\32;^%K5/9[V5D>3Q'BO\ 9T[_ &79:MV:=_\
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M,;USU'*G%=)\'?@EX0\4>&?&WQ#^)/BR^\.?#OP%IVH^(([?3W*)X@,B-/\
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M_P ?ESU8@_ZY^HR,'UX'TH ^V_A;F+P1I_G'[0>Q!)]>I]AU_$UZ=@^9YO\
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M5^248_6,54J+113=DFD[7>O3[[ZGQ<</+GC>[?,KOYKR3_$BN&C$>V1PCE<
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M7IVG7VG2N2(GO9;C#O)GAQ%D?>S@<9Q@5^O,UQ9QNC2RS;!(C852,.&RI8#
M(5N2#V]>WY(_\%!/#FL>'/%FB_%(6L^LZ8J0(ENHW10QHP!(4_*JQJ-Q  !)
M!(->IPW/V>-I3>G)54DF]+Q:>S[>6VKZAJOA^)?#Z]#PS]HK0O'GBK]F+XEZ
M;\.+DV_C.SM7NX6LB&N;L0V[S&*/'S&+8 & .% !&T5^"6F?\%2/AWX0_9T\
M4?"7XBZ$;7XAZ#HNH:)<Z?>:3(UWKVLV^89?LTH7=)*7)VC)+$\Y[?T4>!?%
M.FWMMH?B:PO(I[>[AAGUC07+GS8Y8]LD<B+P4(.UR1MP?F&.!X3\0?V&?V(_
MBCXGNOB'XJ^&MOIGB)-0;44M+6W4VEU=2RB3SF*Q!8][\M@9.><D5^WY?F,'
M3]]>[;71:+9^?7Y=3BQ$L5=J::C]K=:6\M?R^ZQ\#_\ ! ]O'OB_3/C'\3M=
MT?5M"\':G+(_A32=>CEM )Y02KPPRD$*H!*   @XQG%?I[\8X)H_!GBN>YF2
M,VDTUS*H^98W:5B@5CRI(SC&.*]$FMO 7@G0=/\ !.A:=8> /".DZ;'-+?:,
M/(,<:*/*ENF@$08,!ABY))QD\UXE;RZY^T?XPA^'/@/3[V7PN;B"S\0^))$Q
M::A;V[JL<\;CAF=6)/))[D]#YF:YAA5&JXN[Y7RIM635UU;W]+'+J[;[KN^U
MC]>/V.)+RZ^ O@^[O5;%Q9QM;.Q+"6#: &&>,'OVX%?4,C"-?,P,1_,>.B]#
M_GZ5YM\)_!+?#CP7HW@D3*UKHEI#:V;_ -Z.-%#GD\@,V?8M7I;@*I)E5@,D
MIA<. #\I&3G)QV]^U?C6,JJOC*U16LYMZ;6>VVFMO-/<]*E\"_KO]Q&[6[,F
M6(:XC+J-QQM&PD\G ZXQZ]A4+W,)4R3.(K>+,1<L!EFVD#V(V<^^0/6L.:^\
MF&XO+:T:YO8Y1#;61W'YWR-X R5C &"0-O.."0:BEU:QMVFL[Z_TZ&_>!9;G
M3Y[VVW1RR@,OEP,-P8 ?)D <D^]9;[ZVVOK;T-3>>.U,D0FN$#R*9(%X&^+Y
M<$CORPYY%-O1>QB+[-'%+&90'4(I)C*/NYQ@9( )QWQDUBB^MI_)>"?2]1B@
MA(NK@7<0N[.#Y=RI A.0'"#/ !P,<BM:VO&O(P;)9&$9&R:Y4Q!XP!D*.-PS
MM(;G@'FDVXIN/Q;KU_4#YL^,_P"RW\-_C&TU_<6R:/XEDMVC_M*V"I*<@_))
MY8#+\Y#%@>J@=2:_/J\_9$_:'\"75SX:\*ZA%K?A>YED#O<_.PMV)(",Y8^8
M#C@'.,_4?LFLEY/>"'%O"R R-(@!9N=I!.,D?,#WR14\9N3-,DUQO09)2,9<
MXQPN,8)P1D$?W:]'"9WC,&DFVU'92<M.F]]M>J=NX'X]:!^Q+\5/$Y73?&.O
M/:6HE$J.BMM@@W!&@=A_LN3C.!C/4 U][?"G]FCX7_"'^S_[*TR.;Q3:VY\O
M4+HHYFN-H)E&Y2?++C.TG&1TS7O4%U=7T\XS)9Z=;,5D-Q\K,2<8+=\[MQY]
M![U))'<6P=D42RGFSE?9M*/@8DED!,<>#N!###>G%3BLVQ>-?+)ODE\2YI:+
M[^Z2T8%J.2[CL]U^T#7@B9VG3!A1#)@(5(VXP1@8.3C.#R+-C=6ZHT8A-JS+
MYI9QM69FP#(GJ&)^7G@8 K!@L[>22*.WU"/R%#0:FD%XMPAGDR?+9G)V8;YN
M/3 P:F-_#8@:>L5K=744RVT%LMVDMYY$I^:21,[XU"D@9 &[ XK@LKWLK][*
M_P!^X'1QRQ1JTKW *C@DG ![<$GK^':GEA'&68^<KDNIQDC?T(SG .0!CUQ7
M(/?^0^H9#"'376)--=5,MY&P5L(Q!9W$G0Y)"@CH>;=G?WDTT+7EJUG:RH#'
M&^1L1N!&>@RN>/0=J8&V(UA1C/)E%_>JI9MR[SMP<\D#IUP#BIU%O&_DQR8E
MF4L@8[N!SE0>A )./S[5SVH2"WU"STN6"XGL]3>14DB?YXW1/-&YR=WE ] #
M@''&*S++Q1I-OJK>'K_7] D\3-(\>G:6+R(WIM5R51XERXD"X#$C)Q@^E '9
M17=F!*(YU?R&VS;6W%7)P0W/8@_*.ASBJERFG3Q/%-+F)2MS.3(QVA&RA)SA
M5+9Z#'%9K3G=?VMM9QI?0PK-,L;H$;S"PW%F SP"<]01U[U2G?SY=,(^RPP2
M0.)I?M"/FYBPT$4H'!664E0'R&.5P: .AD>SQ&$9G^WJ&1E9LF., J1C!V\_
M7KUP:LQFV*D@[%5?+8-D=.X)Z-ZD<GCGI6!;71G2Y5X(;#4[>(BX624*D,65
M FC#?+'&ZC@K@*>3UJ[;D27UR9Q )$,26D+3JP>U,:F2ZV*2"9"20VTY &"#
MU +<4L!0H(F,89@CY)W<C."3R,;>I_GS)*+&%&EFS&F5&]\@#).,8Z#/7\*Y
MN*\N0]RES"\3VFH[-.C5P@N;:0@,5[.$P">I&<YYJ/57MH5E34M6L+*PDN[>
M2/[;>1(T=X'#10+N;#"5N'C)(Q@;2"<@'2@6\DCI]L5G55;8I&4C;.PD \!L
M'![XJ0>1#(B&X#&97V0-MS,5 ^X#R2N[M_>%8&J-?I%!<V$5H"KQ2:C<*T92
M2",96.$KR<J6(' Y!&>:L:0(I=]S!'(MK),TENMPI:6*1MOGF.1P6",=N%5@
M!MZ>@!?O1"=-OAY3(RVEW^[_ (AE.O![G:?P.*_.*_;_ $Z]Q;DC[7<X. <_
MOG[D9/XU^CFI$_V?J9R<_9)>>_1Z_/J]_P"/R[_Z^9__ $:] 'V-\*Y O@FU
MAN"%*Y!XP3NP,#CDC'&>Q'>O287G:4K(N(<'G[N2 ,=".<__ *A7F_PL D\&
MP&?"GH=PP>O7GN?Z^U>D>>DTA@\MQCD\GC&>< \?T- %CS/^FL?Y5!YDH/(;
MZ%S3/D/2)L_5C_6G0AXXI@T@8C.,GD=N_J,D>G'O0 NV&1S(LAQ@C"L0"2#U
M ..OMP/TKD<"(QH< -S(3C!SGD]1]?QJ"62$6HB638ZG.Y>O!S@D8)R/\^K8
M,,3R"?7@D#BI^K.SWZ^7Z@JZVOV5OP^\TA)%P?,_ M_D_KGUJM^ZDD8K(P.T
MM\KL">IP>?0#@=!U[4\QRJ3Y2*<<\J#^6<Y[?YS5&=KH#'E!5(()"J" P(.2
M /Q_3UIX?#[W:]+][Z:N^U]OOV%B&EKK9?EK?9[VOV%28-;3EQO')8-\P*@#
M<H)YY'Z^O?X4_:WT3Q5XG^SV%E)>6_AD62LPL5DWK*%^4?)CD_+GGDY[FON)
MXO*M .3G [\DG'/J,=??M5+4=)M+B-HK]4N8FAA40;%9HR[!-Y!!('.2>.!Q
MT%>7GN&>+PJPF$?,^97=VW:ZN[W;VN]]SU<LQ&$P;6+;333T>JOILFM;O;3;
M:Y_/YX"^#?Q7G\<)'80:['H FDD;4KIKD*KQ?,NU6?:2A4,%QC@#'8_KS\-?
M WCG2I-/U*YU=M62YTJ.R>&Z+021DQ[&D*!@"Z@[N022,9/?WJST6WM!/8BV
MM8A!(/LVQ8U\Q"V-Y 4$L1SSDYX)YK=CMK50J,^V2([XU4[.4Y"_+@@9&#^/
M%?.X/)I83%2BW*W57E:SWMJ^E_Q;VN>QC<YABL(FHQ3MORQOU[1O\[O[B+3[
M"XMK6,7&YVM0%RC%02.YP1D#J>OTYQ70!4EC61BV0=V S#)'(!.0""< ?7/>
ML]9IY;:9ECC7+$EE<Y&?;OC\CCZUDS272",O*-@9&?!(^0$'H,=5';'7M7U^
M'CA9)812?/'6[;N[+O>^K\_\CY*R5\2VU"6C2MIW[]&[&G&\Z&5X[96$DNTY
ME;G<0.<DCGN<<\#C-4M6>W1&\V)A:SHUI=*H\U&DD'EB-B=P"G>5R<  9XJV
M9Y)%0VLJ1(2" P&XJ2>F>-P!^4]S@^M8VLZQ9:3&CZA>P6:/(O-W-#$DKY P
M%;";V. #@D'!.>W3@\//ZU)*[?17>]]-M=]O/7HCIP^'EB''ZK[UW[JLVW9W
MM;6_G:Z7D?SL?\%!/V1-1^&?B^+XB^#;?^S/#FMZH+SQ;-I\2N@:^G!5+M(P
M%CCF#%9I&7[FXL<<C\M?B3\:_#O@-7CTLP7EE;K#;7EI 0TL5P^$-S$H'(5O
MF  YZ'J*_5C_ (+'_MQ^+?A-HT'PQ\.^"FU+P]\0();#6O$S*US%9S7436MK
M*D\>5B\II1(K;@%"Y&!FOY=9I;F">.\DO+G6=2N4GO&L5+7 9F5FC64N7(C#
M8 9L@#D8.*_8.&L?C:--8.;E=)*2YI76B3M>3?7N[6U?4_K7P(\,<FQ5?^V>
M(W&$YN,H1:A92336ZM\5ONON=YXD\?\ B#X@3W6LZK=/J>@)+<I9:;-N\PX#
M[(U5R<.P^1< 88\<XKZ._9*\.^-KGQ6VJZ-+>Z7X<BC26:SO(3#;H(V#NL<@
MP'.T$ \GKUZ5SWP4^ %MXM$/C#Q+JK:#!IBB]72F'^C74JD2I#(O$6)" A<J
M2 <Y) Q^@.E6\.EZ-:Z5I2BTBNS&\4ELBK'/Y)'R!H@,K(<J<$Y!YS7Z;EN7
M2Q-I\STDGN];-/5W7;U/5^D9Q-PSD^7?V)@G3YE&4+J,$W>$H[I7ZK5OH>P&
M^OKJ_CAN!:W$<\'(#@J$@ $F.,#@<GZ@YJUI;6UE>WDTD1O%ANH)$M+,  E7
M&(F<# W'Y<G@ Y/&:X7399)K^5Y%9?LZP1%%X'. X&W&-Q&#V;()SGCK=,OX
M["YD;RWB\P@;U7)#'&'*X(<KUPP/([UZF*RV33M\5FD]];/EM\[=?T/X#6:/
M+W]9PSYH2WO=^Z]^^MFV?>7P_P!+^WP:;=65WJ&C12)!)-9!@$=05)5E4C)(
MXR%W ''6OT>^'MMI.J6D%E:PF"P+VSW#7!V7#R( )I(2,.%<C+*I <$@Y!K\
M2/"GQ,;PUJUHUWJ=[>Q2S0B.VC#*$RPPN<[4'4#@ #D\5^A7A#X_Z(\FGQVS
MS0:DUM'&T$DT8"QL /,(R ,?WQ@^Y-?D_$N2X[G=HIR=TG;6[ND[V=];>GY?
M09;Q"L9;;5I?-V_'[[['V3X\TG3[72ET/PW,/[4+&6.:<B=;>0\JSJX;,8Q\
MRGY2",U\'?&&/4I$DAMW&EW1C,.HSZ?"MQ]N &'WP;2GS;2"=O /' %>U:W\
M2C=6DK6EX(IKN!XVN1-&\D.]"-ZX^<E,]%;GZU\@>-O'-ZGVI+!EN)<R^?=2
MRNFX8P67+9S@_J.!7EY1E&*H2IK&*TO:16KZN2M]SM\MM=_?6+2:=GH[O;HT
M[?@?*?Q)LO#KO?D0-;:G,5D$,5P\NGL\8^:X9BQ2"9FY,*!0IXQD5\ ^/I+#
MS9;2.&12]P3/:^<R6]^ZGA9)=P4$]1*Q) & 1S7V-XXU&RFM+R*ZU"."1I9)
MIUBP5&XG.6'()).6SGW/(KXN\<7_ )MM>6LNGP7-NZRI!<EQ%(3@E&#<8(8<
M\\=>.:_=^',O:IIMM)6=FWTL]KVV7K^!T*NL1)35DD^9VTVL]DU;;T/D/XEZ
M3/?:;K4XN;J[E-]'%I^EM(BQQS@C9'#(""V IP,_-C-?,GB&^\9Z?K%IXD^'
MS7$OCG18X8=<CU23[-IT=C!AMK.A4L50$(V=V[&" ,5])^.+O2]/71;=Q;W&
MHO%->- /M<_EZC&S"WC=H&VYVG;G&1UX[>/#X8?%CXD3/K/AC0[F 7DJV4L]
MLDZ6ZQ%@/,GB)S*"H*[6#'YOK7UT\2J494FD^9."NE)*ZLFD[\KU6QAC<5&-
M.;=N50DW;311;;^6_=GSC\;_ (B>+OBOJ.EZW\1KW4-:\&VD'V!/"NF,BQ0:
MFL31O,%SYDP>0@@C,C =>M>W_L4?\$^M9_:'\4:?XD\6V.H>'_AGX>G2>VM=
M;@\A+FU4L_EVZN-DN?E!X(VY)Z9K]&_@9_P3*T"VNM*^*OQHN+^SM[(P3:/H
M<+B72;O58QOC_M.SR3Y4C$!@B[BQ4$XS7ZC*;:*SL+6UTFTT#P[9VD=D;70X
MEMH;B:) D*RQ(L9A+J SD ,W0YR<NMG<:>#CA(J*E&-E9)7=K+5)/5Z;OMKU
M_.<]XAP="E"FI>]-J"UUO)\J6E^K_0BT33-'\%^%['P%X'6VT30-)L8M+DL[
M6"*6RU>QA"B1Y@J>7$SO&#OVABP +'<:HS7,RV\]C;LL5JRA+8!0L\$@97D(
MD4!T1@C*%4A26Z=*=*8;2)K9Y@D[C*0IA'2'<&7>!R5(['OU''&%+)$6)#D$
M\GYCSCD@\Y/^ Z\5\-F'UO%58RE\*DFU=[)J^_97V[=#\XJ5?K6)J-:VVMTT
M:\[>NY.]^L:JCAC'SNMV<AU?!_>RL?F8,3P6)Y(/I6--<A[B-A;JL:2!_,\P
MMM56W'Y6.,-TQR,$T7$\5RS"/YY -H'4MQTR.3]#QWXQQDQRNLACE7"DG=D8
M P#DG\<<#CVKGEAW"$Y0=I*,FK-ZM*Z6C6C=OUN=N&PSMKJ[K?I_5_S'7ERC
MF5>%#W1N<@8PH7ID8( )''3@\&L]I[< SNQVR9 )/\8QTYZ[AR03GI[52OY(
M@[,CY(_A!ZJ""5^F!TQ^??+:1)=TS<1R#"C^!6&<;5^Z,MCL/Q/7@C+%2E%-
M>[)I/?9M)^6AZ-*BJ=2$Y22C"2E+67PIIO\ #N79;P(3YP"QN058@<@$'@GD
MY[@'GGL<'FKR39=7,H0-#=0O&,_+M&T]"".5/.!CD8Z9!>[W"AUN580M]QGS
ME5)X*ENASP,>Q[5@:O(EE! \+-+&V3("2V![;C@#."3Z 'C!KVZ6%<Z<H+2\
M6OO3V_SO>^WG]IE2PN$<<7%ZRE&44K_%=26G;U[Z[6./\3Z/;>(?"&NZ8DUY
M?7[6<\5M-(AC-J21B.-?^6BL!LQT"G/7FOR5N=*B\!_VGHFII>3:U+J,GERV
M\1\VWWS_ "%F W+&HX<@_*N3T%?K_/JL[I;&RC*HVZ.:0<85U*G=CDGL,Y/<
M=J^)/VDO!FHZ'>VWB[PYIQOUO@MO>,R JN643$$@_-M9CGJ>Q)Z?,YI#ZE&H
MW]B+EKY)WU_/7<_OCZ./$F69I&67XZ>]J4E*5XI2]UV3;77=(]J_97MK[XX:
MQX?^%A-U:W$;V]K<75J'E@N8'&Z4W/)4,L8)8D$C';'']F/P"^#NB_ OP%X:
M\(>%],MDCBLK==2OH&4&]GV!B=PP5VN<E1D' ]<U_!_^SK\9-3_9J^,7@[XC
MZ3JQU/0]:O+:T\0Z$, Z:)Q]GED=SPGE&0OGC=MQR#7]ZGP(\;Z-\1/ /ASQ
M1X<O_MFG:OIMMJBN;A9A')=0(6CQEC\C,<+G"]<  "OQCB6N\5.3YVXZW3NU
M9WM]IK3JK/MT1\1](+A6ED^<RS'+[2PV(J2<]$UR-WU:T5D]K/5;I[^R7EMY
MC"1X%1U*LC;BQ5B1EE&<!B,@MG(Y.>QG%\8@D8^=B.,G)P.>_) '3G]#5II1
MD)(Z$$?-D#)P,XR1^>/\#6+<O'YF8B"X;   SC)!QUX(/Y<\#%? UJ#C)23T
M3YE9OSVVMW^9_+V)KK6-K-JRMIH^O>^Z5W\]#<25F7=*N(QQZ\GI[GMT&!GG
MI3Q+:,?FCQQU()_D<U5L7D<*'!VX/)Z''0_SX]SZ5L%5 .$4G_='^%0M6NNJ
M\^OS"C\"=_O\F^ICSK"+>5DM7F5B(@ ,GYR1OZ' 7@D]?IBN.\<>!O#WCSP\
MOAGQ'8Q75O>6DMLLDT<<B6\DBD)M,B,%D)SM"X)QCL,=]*9CA4'E\Y'9>F"/
M0YSGZFHKBWN) JED95*OC /S*>V<8QG(/49//6NB,I4VIT])1?-&VFJ]+&I^
M*?Q4_8H^+/P_\1R>(?A-?C4-&C63&EN96AX/ VHV!Y8&%3&"21@XQ7GMOIW[
M0SW5CX>N? [7.I2 QW+&V=+95EPNXNRX+*<&->O<=*_?+<YCQL^7.TC "].<
M@CG/!.<\U7,4 ;SI(($VX9YOL\+N O3+>66^C9R.HKU\-Q#BZ$?9M7;]V[>B
MO_7;Y@]=_P 3\=O!W[&'Q:\9Z@UCXXU"32O"^L.K:U!N>23[$"':UC:1B1N'
MR@ X'XG'Z5?"KX1> _A+I'_"/^!M$BLRD26TMW=)&D\RP*$65'VAB9/O @@^
MA]/6V5Y9!/;W,DL,Y&] 2$5!U9<=,8![9YYX-33Q0SH8[E J*RF.53ARJ@\[
MQ\V!QGD9)Y]N3%8_%8MWD[1>Z3>NNM]4WT\NHK+LON7^16MIH?DMY6<S0/AF
M8$H#UP'.>N!GGYL'TJW%,S--MC5@N2G RS @A 2.K -C'7MTS38PB?*\9&TA
M82PR9(_[[9^\W3#-S[@$U:D#I$3"@,C':@ &%)S\YZ= #^?6N(9X-\?OB8GP
M@^#WQ#^+5E;A[_P[X;U&ZLK2X!$4FK6\#_94G(^586*L78C:3@MR17X,_L>_
M ?\ :_\ VS],F_:L^(GQ2OO &IZAKVI-X,\,V&H2OH&I:?%<EH?/\IVW2+"@
M 65654+^F*_>WXW_  NL/C#\*?'_ ,(KY[A+7QGX;U2PN=3BF*BRNKBW:.%D
M8G ?>X(48R 6QQQ^#O[)GB?]OG]@XZO^S!>_!#4OBG\/K/4Y&^'OQ!9YY(M/
MCU&:2.SBN F[=&PD!<MP3'M)Y((!Y5KO[8GQ'_9D_;J\6>$X?#?B?XOZOIGA
M4R:SI.BW5[=Z/'+;P))<3_91BU5T6)BP"#)8-C*@C]1M8_X*H_"C3?V??!_Q
ML^R0V>K^(_$!\/-X N9]FJ1Z@-A>U5"0XE\^$Q !>-Q!'->6?!']G?XV>'/V
MLOBM\9OB7X,T;4].\?\ PWU""R@LH(GN+;7YM-VWEJ"Z$J8IG6(E2&R_')Q7
MYW_%#_@E_P#M ZA\(M/\7VWAR+5O$/A?XQ:EXU@\"I<NET^C-=M=1HD:L#N9
M)(E4@#ELB@#](O"'_!7_ .&NI>#OB'XB\7^#9] \5?#[3H=1NO#@F(NY;2>>
M1+<M'G?B4O" 2,$L!GI7D]E_P6Y^U:CH6G/^SYXHTK4?%]N]SX3MYTE:3Q$F
M08UM<JI/FQAI%VYX6O&-9_9@MOC;\!?BC;^#_P!F_4O _P :_&+:+IM]J>L7
M%SY>W3+JSCN(U?(<J9U201DF,!6PIKZ=\;_L@?$*?XB_L ^*(/"VB2W'P"TZ
MTT[QO##;A8)I8[1H7DN51 EPV75!YXD/S9!R* /5OA/_ ,%6_A?\0OA]\4/$
M7C+PQ?\ @3Q/\-&FAU#P7J@:*]U"ZW+''#$KX9I)9&4*#\V,GD"O,?AA_P %
M5X_B1K%UX"^)'PM\1?!K3_$^G:HWA+Q%KB/;QW\*Q.;&:P>? E:[*KY2)_"=
MPX4U\F?M!?\ !/+X]_%SXQ?M)?$+PCX<T_PK%J&MV6M>%=*+36\/B"/3)H+Z
M6.&WB*0R><(&7[A)&5(P:K^(?AO^U=^VAXM^"?P^\9? R'X7>'/@GI\4.JZ]
M&GV:^U:ZLK?R[::!V1':";9N2,,02>A#-D WOV'_ -MZT\#>(?B]\/\ 4=;U
MOXL?$7Q=\6)K>V\(/<37-_X=\-2W30R7B0M)(\");L)(VC"*"1C! KZC\8_M
M3_#;]G'XW>/O'.HZMXF\21Z+X9?5=9\*6\\UQ=Z-%(8UMH1!/(X>0N_ELJIN
M7EP?EKX \"?\$VOVA/V</VB]5_:W^'FGO<^(]:\6V*:];ZB1(DFAQ7"12PI:
MD%(]R()FE"#< 02<U]#?&W]DCXZ_$7XK?'#Q\O@9/L'COX>OINAR6JAY+B_O
M_L[W,D<0&-]N/,:)L!H\ *RC@@'NOP@_X*UP>-_BSX,\.?$7X4WGP\\+?$>$
M3^"?%VI6TTEO<Z: 96GNIF'EQ7(A4RLG\$8/1<@0_&/_ (+)^ /AGX^\4Z9H
M_AZ7QO\ #'P;J\.E>(OB+9W$+Z/I=Q+*(G^TX^8I&S%0J$-D9^F=\6_V5/BA
MK_P]_8>\#Z)X<L?[/^&T]O\ \)EK$T,*:BDE_9F!K&Z*H)BD3%F<2,05!C(V
ML5K\^_"G[!>O?L\_'+XQ>"?B1\&?$'QK\!?%KQ-9:M:7E@9_^$<TLFZ9G$]O
MS9%@DRHV^/)(!.2 : /Z/-,^,FB?&G]G^[^)GPA\2Z,]OK'@C5=5T?Q)+YD=
MEH\\^ES,EQ&T^6:6W8+G)P, @Y(S_(-^S)\>?C'\>_V@KK0_ WQ2U74?C]\,
MOB5?WGQ)O-5FGMO#4?A+2-1=#JEG*\I1X+BT0QM&!Y8QO*G.:_J(^.'[/.O^
M)?V&?%/P1^ FG-\+?$,GA#[/X:TFSD2T$<HA#M8M/#Y3@7" Q;(V!).U@5.*
M_F8\7?L6_MG>,/@WI'PD_9E^!UU\#/VB=-@NK3XK_%R/-K<>-M'A7;):7%Z1
M'-*MY,))8R)F=S)M8LO% ']B?A[QUI/B'P)?>(-'O8-9.G^&#]MU73KB&:VN
M]0CM3+</#.A8R*+D.WS-A5^7 !K^6_\ 8]_;A_:7\*_\%5/B3\,?CG?W6I_L
M\>.-4EM?!<T\DCVFE:X+B4V( 9FCABC#1%D150X)VY%?MI_P3@\"^+_ W[&U
MI\+/'ND:KIWQ&\/Z/J.F^(DO1(]W=:N;-XFGB>8L95END9UC!*E&'8BOREG_
M .">/[0VO?L__M17L4=SH?QKN_%FH^(/A-XRNX@][82"[F:UM[0 >?%^Y\L!
M8F1>< 4 <K_P4M_;&_:5B_;J^!/P]_9Y\87%G\.[#QSH6C?&!K7?]DOH9&W2
M6D,BL XN(=Z"([EW#<02*Y#XD?MI?M5_";_@JUX+NXO$,U_^Q_?V&A^'=5LI
MI7D_LW6Y[6-98KQO,*0J)9"RA@,\C!QQ[EX,_P""=O[0-Q^RS\!'\5JVM_':
M'Q_IGB?XH>+[DLFHW*6'EN(I2Y,\2IMD96,GS;B"3TKT76?^"?OQB\<:Q^UA
MK'B#0%$.N^&K*3X9R##26_B>TTH?9[ZUA;/SR2!270*ZE?O!F- 'G/\ P6V_
M;2^/^B:S\!_A!^QUXG;3/$^I:OHGBW6_%=FSRZ3'X=N;BT>_LK^YB8>5_HX<
M('/WBR$97 Y?]H?QSXZ^,_[1?P4\!:]^T4/A#X<7X%VOB[6IK:_$%IKWBW3=
M.65W+&9 [W%W&1 %R[M(0Q( I?@1^P!^U%;_ +#GCZQ^,4$?BKXVW_B2#_A%
M-2NUD?4(O"2W)CM;>&X<O=P"-XY0RK(B'C"XZ^NQ_P#!-CQ3\8/VD/@1XE^,
MWA.-O ?@[X8Z+H.OFREEM98+ZR7<1*ZE2?/;*DDDL5.[.: /I[_@CO\ 'SXP
M_&3X2^.+'XMVNIZY9>$OB%K6A>'_ !AJT<T%WK&D6=Q-;VUV4<D36K0P1O"_
M(=78YQU_8G3K&Y_M6:_:_:XM)OW=O: ;8[5(MV?E&$S(67) 'W!QDXKGO 7P
M_P#!GPH\.6WA+P9X;LM"\-:;;QK%';)"&ECC!"R3M&B-(QY.^3+-\Q)YQ766
M<21^>BEH[6Y9;B&0,>DF[*J<Y P%( P"#ZT 7;\+]AOV( 4VEUGIV3\N.2,^
MYXK\Z[^:S%]>@R."+NYX#<#]\_3GIZ5^B=]Y2:==Q*VY/L-URQW9(CQR3U//
M?VK\X=0M[3[??989^V7.?F'7SGS0!]M_"S"^"; Q?O"<\L=Q]LYYXZ<]<\UZ
M/+-'"86,;><V!CD'G@[O7O\ @:\X^$IEE\$:=Y2>1R3\W/H>/7G\N/Q]/(#3
M#(!QTR,X^;MGI^% $)W@?/*LHP?N<'\Q^7'XXXJFT0FM)X5CD#C^(,P)'H3G
M/3/&>?7BK\<*H?,BPZG/RG& /;_:[>G'3FF^:XDQYD:Y^GIWXYP>?7/'3B@#
M*CAMVC5Y48&VZ\G.1S\P'+9/7.3_ "JO)J@95?S([:(X(8HH9L^Y&!QZXZ@4
MZ^>YM[:>:1UE#$_<  /KG'!(Z8/?U(KX!_:Z^+/B/PM'HW@GP5?&U\2:^#-;
M3."JVR+@[&VX)SCTR3@#J*^<SG-/[)3O)V2O9MZW3MN_)WW^5CZ')LK_ +6E
M&*2O-M+W=%9QO:T;7O)6[W[Z'W#<^)+*WD(GU5T'(QYL8Z8'3D?0?4>])'XK
MT:)T#:J7RC##RHP+#OR>V.@^@K^=OQOXK_:6\.[-;\3>-3;V$I11;KYJ.-S+
MC@,!R.AP>3CI7T+\.?'OB#Q#I]O<7&M:I/=6UM#YLGF;D?D9SECAFZ9^]R><
MU^;+Q!Q6(Q;PF#7-9W>KT2>J;5EHM?D?I,O"ZEA\(L9C*LH)J^C3_P#2KK]-
M3]J[3Q7H]Z3";N"1P!CRPGWL\9 YY.,^E7OM7FGS-\? &X[1]U<DJ>AZ9ZG
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MKFR\$M+Y=F(X\!HMQ4;G& 0%&2<<"O.H=>1;6U%LX&DPA8[=0</%<9&Q0PY
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MT^/D:8M)D@*>E?//PGU*73OBAX7U'SDM[7R(K=9D<N)[@,4++)]X1$DE5SM
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M*Y*&^M9&)N;FYAD'1@6!5AD#Y>!UXXYYJS#?7;QS+"JS*$?RY9Y"O&,Y(/?
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MBT3PM<6>E74P1;R:WFCD2)R2')( Y)"C)XSP<@5^QW[,O_!,7P?X#CBU?XD
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M'P_;>*]1LM&U#Q!XJUS6!Y]OX7:^A$W]DV_G"06QA=BJQQ^6J$90!B37UO\
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M*C.,]\&OOL!XIUJ-.5.=/2491NXQE\2<=&G)_<MMCFH86-'&2Q;M:3O^*?\
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M\\X'I70OTC_ST7BJLS*OE1(AV$]3G"XY QT'I^(!YJ]@$)D _7_=-,"';O\
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M=Q.Q1?,!7+$^6<87K]1V]^W8U').ENI8R([#C'&22,YS_P#7]O:F)<[HUD#
M$N@W-Z$\C/7GZX-3+X7Z?Y&@Y=1@<2$"8A P(\LYR,9Q@#\#R#^'*)?0RR1Q
MHLR-(I 8Q$*#Q]XXQGT[ U1OW:WD2<NWEKR\5OG=(.!MPO#%N.?PS3&D10EW
M=2W+)-@VUO"I62!3V?;@D\_,3WQ64?B7J!>CU*%WG15E0VTACD#1',C-R'CR
M>4&#D]/F&*D-_%E1MG;+  ",C!Z@Y!SV_6HK:5G8-%;80@?O'),IZ<$') (Y
M)]B,U;F9(F5L@,Q52F<\'OC\/Q_&MP+*DMAN@*]#U!]_I3J08.".XZ^QYI:
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M&#]1VJX0#GIGUQS]?PIGE\AB<D="1SUSC.:Z1$/DD<GD#KTZ?G0Z"12AX!&
M?[N>X]"/45:/0Y]*S)(W:YDVL0HB8A=Q"[ATX& .G6E9=E]R_P @N2P+(N]9
M"Q5?]622<D=^>AQCT]O:V"=F<\X//YUS5S=L(A=:E,FEPP/MCE:4@3$'C"9
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M>))0)=*F+111?*C6_)*E.%)V]-V0,9 K],PW",?J]*52*:]WF<DF[)=VG?\
M7\3P\9F^*Y)<_-R)-M.3=O-7O9V[)=7U../C;]I2.&XL9/'<A&H%?LCF0DD
MYX9GW#!8%<'@CC' K;T.X_:1D@_LR7XB3#5;IMEJ\UQ)((WD^[(V)2P5.,D8
M /X5KZ,ND:W+:ZE:12K;02$!96+!<'&8@QPJ]SMQZ'I7KND6VD2ZC#J<9*RP
M,L!;(&P2\,S'LJXYSST^E:U^&<+2HU9PC!.$)22Y8[I?X?O-,NK/$\M2[=K/
M5MO\_E?HM[GK?['OQZ\5^*O$>N?!SXBW4<WBGP/)NEU&61@-8(0M&T3.Q+XW
M9QGGGKTKS#]L*+5;K]HCX:6/FRMITELD5[9( Q1+ABK31;\HN%ZE!EAC)(%<
MO\3O 7B?1+T_'/X.O /%/A-8IKJQE9HHM;W!B_GK#M^UJ@3A9O- !_/G?B3\
M6;+XL+\"/&,-]8#XJ_:S;^,=$L&9GLIED5%@\G)VQ*"201\O! !//YY]1>'Q
M_M8I*,)<S2TNXRNM%I9^?DCVCXH?_@CKX>E_:-\7_'.V^)NLVEMXSU-KA=#C
MFDCMAO*R26TT<3A"7V%064[?FK]*_#_PM\,^&_#T/A;X:Z*OAE='^3Q5J21Q
MQG5Y(05>9[B)8WEDD))4R,S8R!WS]/SZ#)I]E92PPF5;RV@NC/N):&\>/,Y(
M_A2-B=_3&1GJ36%-I-P%#6[K%9R-G4(T1=EZ^.I &"#_ !N<D$C)R17U5#._
MK,%1YG^Y?>7*[*VU[-);)I*Z[[\E?XDM;7VOYKH?.NI:);JL27MNUS;I"\%G
MJ4*@PP.Y4A9648WNRG#,=QVMUKQ7QEX%T76#+I^O:$))GC,EMK>GI%]IDBCP
M!"S[?,.[=G)<D;1BOKG6=,CMIA9J_D:==2+)/IS(\EL-JM_I2RQXVR19(50=
MI,ASR*\SUO0)K^&YA@>XLUM)%:UG0PJCVJ%C)\SD2<MLZ'/MS7JTJ$<7"\W[
MKTEHK)=_P[:==CS*TG"HI;6=]'IL_P#/MW/C5OAOK5F(M-\)_$#Q-X;L)Y%@
MN+>.ZN80$8DL9!%,@900,E@>OITGE^$NI[=1M]6\?:]J,<#P%9;:]G627Y23
MPL^2Q!Y/4^N<U[9JFFW=O)J=U<7&FN\L"QZ=%*)(Y)708)!C^0NW? Y8Y->:
M^,+[7-'\ :S>66A:M-K"PM<%]/\ *8D1!FVJSYD&XJOS YQ\O0D5Z%#*,$X-
MOE?RCW7E\[&,\54<)*$FY-6BKO?0Y^[^$6F7$5E>>'O%OB'1-6M551>W4TI'
MF=3O+29Y?#!SSQU]>V\)?M ?'S]GOQOX?'C76W\;?#1@L-]-$?M$Z02L@63<
M7=E*1HZ[@< D?C^3OAG]NJ^T_P +^(9/B?<S6>N6WBRXT31]$16%[)IZW!7?
M+&I 9E\M4WG+ R8!PV#^FXU"T\=_!NY\4Z7;"S@U'0(94.I,%DM9GM_,66$2
M9.05.$3K][' QCG.3X185J$8\SINUH12;LMTEK^9K0K8I0;FGRKXG=O3:]W\
MO+U/W;^'7BG0_&'AC3?%/AP*-*UBU^UQF0AKQ7F*2>7,[?O-H!. S=0 !TKM
MC)OA?GIR/S S^'K[FOB7]@1-5/[/N@_VS>M?W:W$\<5TRE2;96.V/!.2JD#:
M3G P!CI7VNT,K*1$P![Y'!&>1CG/K[5^*XNE]7Q=6G?[37W=OSTU[GJ8>OSI
M1WOI??\ K[R] 28X\DG]WGGUS4]5K82A<2[>,@%0 >Q / Z<_B:LUD=84444
M %%%% !1110 4444 %%%% !1110 5%*I93@D8].,]JEI&Z'Z'^5 &;>AET^\
MR3S977<\8BQ_+_/-?F_J)/\ :%]R?^/RZ[G_ )[O7Z-ZB VG:D"Q4_8[@ @D
M$#RVZ>G(4?C7YNZA:$W]Z?-?F[N3]X_\]G]J /MCX2PD^#]/-SRW<M\Q.!QE
MCDG]?6O1[L1^=;$H_P I.SC[F1@;<_=/&.,>G3%<#\)RESX(T\RI(I(.<[L^
MW<'C\N1WKTQB3)M:,%@,[C@X[9''3IWS]:YE1DMI/_P+Y]PQ5L5MIL]%V=WV
MML5)N7\D@$C'7!S^/(R?\^TFX>:/]'; Y'' &>W&!_/M5DP$G<0"W]X@$_GG
M-6ZZKON_O?\ F))+9)>B2_(J;8O._P!6V?7;QGU]<YXSZ]^U6^M%!Z'M2&9T
M@\J3G@'IR,GGCKGJ ./ZUGWEW%%!<SW&U$ _>%L &-!N;+>BJ"3@G &:OW<9
M$MO,21'$"'7)(.1@%AT.,=3G'X\>:?%.:_'@KQ)/I">9?+H=Z(HDST?=&TJ@
M<EPA(!49ZC/(%<>98F.%P?-]KE:OUT3UTZ_,>#CSXV,)ZQ<DFF]+.45I?16O
M;8_./]I;]NS0_!4^L>%O!*37WB2QNA9Q262?;$9)'$0.],L%^8'<#Q[XKX:\
M)?M:_%3Q/J=QH_C74WTOQ1:7KS6T,3RQQ7NA*^ZUCMT5U!N  /,<*6./F)S@
M]I\(/A3X?\37GCG5+U_M?B6&?48I([D*983YCJK*) S#RN"HX(( 7 Q7B?Q8
M^'<L'BWP;INBE8O$ZS31)K5JHEG2,?*L5PJCS,;MO#'@GIBOY9XSS'.L1F"^
MIN;7.DK2FGK*/][73M<_L+@?(>&J62.>.]E[3DD^:<(2DGR/EO*46]7M9^9^
MA?@SXO>-_%BV=CI6L3C4 \?FPNLFYCO4!?O9YZ=!CZXK]&_AG9^)K;1DU#Q1
MJ)>20?+;A270]MV<MTQQ^'6ODK]E#X%-X/T73M?UUFUOQ+>0I+</=':D(SEW
MC23<,H SK@#G ["OOR* OA85#IG@<%>O4 \<]_UZ<?KW F$QT\#&6-YN9)/W
MG)M)6>\F^J=U>]M[7U_!/$3&X)8Z>#P2AI=.48Q3O=IK1)Z=[J_3J:$$X56D
M#O*A4]4SR!GKV[=\>W2N,UR22[L[V*..1&FAFA5P3A7EC9%<=P58J>,$$?0U
MW4(DB0QE %'8  <=L#]>HXZ^F3?6Y?=Y:C.&(4  ,PZ @8R2?RSZG-?>YMA7
MB\(DK\KTY4]+/3X=MMM+]#X3*Y?591<E>SB]==%)/K?3371]?G^'6D:,_@3X
MM>/H?%ZRVJ7EY=26][/"#]HAN=RA@[@LWW]R$\@XVXXK&^-]UX8MM%N%T^[B
MO3K=MY<BZ=B>ZMIHHRML&CC)>V,TH19&7!PQ.00!7ZR_$;X'>%/B,HGU2W1-
M3"DF2*-%E8JIV))(%\PKD#&X[0,\=Z\[\+?L@?#O0M5O-7N=.^W7-^ML@BE"
M311-$ZDL$D5U&".<#CMCM^/YAP,L9C;N$&KK>$797OUB]5\M;:/I^PY5QX\O
MIM0G.FDFU"%2<8W2NO=C**W6_+9K7:YX'^P[^SYIOA+0;3XB:I;0+XD\003F
MX@G1D%OIY1BKB-A@7)C&5?&XOM.X<BOTF$Y6!)TLY-J 00 @E64X6.4CD,0<
M,&/X$5+IVA:?I>G6UAI%C''%:*D&#M 5%(4@J!@@8R5P 0,8QD#I%@VQJ)R@
M3;@X "XXX4 <'' QWQ@9K]!X8X;PN41LK*5ELDM>B;23U_/R/RSBO/<;GV8O
M&.4Y1E-W4IMZ<VNCFULW;K9ZKHLZSCEM7$17*3Q>>7(R1(!N" \G ;MP#TK5
MMWD9R&3CCD\X_P /Z4VW*%R@C8QKC8[9/3IC// XSGM5U0 S8 '3H/4<_G7V
MVZL]5YZK]3PTDMDON7^0^D/ )SC /)Z#W/TJ.9BD99>J\@>N.<?CTJJY,:"7
M)D,G#1L<KAN2,$X QZ]N:!EEI$ ),J$ '(RHR/3(/&?7M6/K$SFWNHH)FBG1
M4?/EG:RCDH\@'"-_$3T''0U<:%"Q@>)0KJ68AQN"Y^;'? R<8';VYIW$0NVN
MK=)#&[VS0M$QY>(KMWX_O8Q@\GTX(P ?DA_P5I^.OC_X*^ ?A)?> ]4DL[C5
M_&>C6=[Y!=5F2:[@C8,T9 96#$;&^7';K6K^T?\ \%&-)_97;X._#6'PKXB^
M)?QC^)W@W0_$EOH&EVHFA#W%G#(JG:#Y)D9F#.O3 8-N-4O^"J?[.'Q5_:#\
M*_!OP[\+8(;H:'XQTK4-8+@LD=I;WL,LLLK("541H>3R,9KG_%G[.7Q!U;]L
MW]GGXIVFCZ7KWACX??#NP\-^*M3NK82G3KBQMH8I_L\LR/YKPL#Y<9/&, #F
M@#PO]H__ (*2>*?B5_P3Y^.?Q2^"_@O7-!^,7@>XE\-^+/AW.%&O0VMU</%-
M) QQ-;JZ.0I!"X'I7PC\'I_B!X8^'W[&VNW+^+? &L_%77K;Q'XGBN;R]O-4
MNTED2:ZC+K,QV,Q90LC%!NSCC%?>GB3]B[XXV^F?MCZKH/ARSMY/B[XA6?PY
M#"$?[=IBWH$C?9E&U,#H HVY.*N_&7]D']HWQ;X)_913P7-;Z5J/PKT&2'4T
MV"*5KR-@ZPC&#DL%4#. !MQB@#W#XN?\%+]0^!OQ@\'?#KQK\/CI7@3Q9K6G
M>'M$\9R7:^9)-*L$:Q7Z[AY,LDA)4G# OCI6=^T#_P %:/"GPB^*M]\/?"?P
MMUSXAW&BZ4=<\6WFF0F[72K-[9;D-), PBB5"&P2J=P.Q_'GXH?LI_MO?%SQ
MUH6G?$;PCK?B-=*^*^E:_?ZC-#(+&PTS2[V!F:S9]RJWDQAV,6W<"22<U^L/
M@G]DCXJ:#\2OVAM2E\!Z1JVE^./AY<V&B:G<QV[SW9U#28X$M//DC:21XG7;
M&A8[/X0 #0#UWU]=?SN97A?_ (++^$?&%S\-M2E^%'B;1?ASX_UZ#PS'XJE@
MS#HNJS2M"\\DB* JP2C8<,#E\9KLOC]_P5B\,?"3XMZM\*?!/PSUKXK0^$M"
MM]>\5>*+"%I[>QTRX@6=DFD DP8=RY#-P03QC)^7KG]BSX[7G[%/PM^$ND^
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M"?V@/A3IUTWQ_L=;\.^"O"D.AB4W[:=K<@CGAF^S;)IK57=K<1NQB$9W;>,
M _6[]E3]K+2/VJ]1^)T6AZ+>:+:?#KQ5/H4=U(4,6IK S0JR.O+)P) ,XXS@
M# K[; '!/4=^_3!YZ_Y%?G[_ ,$[/@Y+\'/V6OA>^MZ/;Z=\0?&6AZ5XB\>S
M+''%=2ZQJ-FMS=+<%561I8K@^6XE)?G!8=*_0 N VTD#C.3QCZD\>E #Z8Y&
MUN1]UN_L:HL'DN54,WE$DD@G'"DC/..7QVZGCJ*<B1^?-'O.2!@;N1C!XQP.
M,Y&.1F@" 6[20H03C)XSV)^O?H?THNRT$!(ZH 1QP.06QZ9 Y]NM7(3."5=
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ME0:B_:Q=-72?Q:*S:;3T[ZW/IGPW'"K&1+6VM=,MK827.<! ZKD.$3H,[BQ
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M:6Q1=SK&I0J!PL>[:H&[G$_9;U:#X=?M*:S%:7IM?"GBO0Q<V&FSKB4:UJ$
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M1PPY)-?N'9ZMHVJV6D3P))<V/B>TM-7M+RUP$=9ECN8H]\>,A>,J3QR",Y-
M'7,\VT%RH5BI4J<$_,,>G4<XZ8J.Y;;+"3R,'@\C)4<X/&<_KSD5$K![MX"<
MBU4% #D!7&T;QT)QC!()SW%6Y$#J00">,$@$C!'3/MQUI-<RY>^GWBD[)MJ]
MD]#!\2:):^(-'O\ 2;J(/#J%G/:_=4E))HV5)!G@%&(.[@^A S7X!ZGHNM_
M#XQ^)=$^(_VJW\%7>HW-QHFJ0PLMNJ7/F*AWX55=BX <8;/.>F/Z%<,G+R%5
MX7)/ +$ =2<<G@]CCM7C_P 6?A'\/OB[H]QHOCS1(;JU'E)#J,:PF>,^8K(2
M^PN-KX[Y![]!7L\/\0+)L4F[VA.+=WMRO31]'LUZ/75'%4PGMHRJ+2T7*]K;
M>B7E<_(/PQ/HVJ3[XDT?7?#^GV,]E93:A-#<79N;FX:XCG3[1O99(L@[U(91
MCYEP*LQJ;"6[\4>+Y]-M-.ACFMDTP/%N%G"I6&: R?(&?@OM&9,@?,*]B\;?
M\$[=5CU"Z?X9^*Y](A.H1HMO+*S)#8>6N9 A<1I(R<;L;B1U) )J#_@GSXHU
M>]UU/'_CF^U#24T:)K""WF*PNUG&99"BAPBN2HW' W9Y[9_3L1QU3Q=*DN9)
M2LFE+OILFN_;J<4<-:<9.SLT^[T]5W\SQ;]G<Z?XM^*FL_'7XH:WINC_  Y^
M&A_LOPF+YX-\LEOE\)9<B228$(TRH6  +'&*3P==^$_%7[9'BSQ3I6AW'CK0
M_%&E?VC823H\VE:89MJB55N!);PS'"F,JJR-R,D# \*^''P^TC5O$WC/1]=;
M7=1LO ^LMIX\*6TLD5M=:9O,,NH74,3"*698PK-)(C,XR&)&!7>>(/VGO!_P
M]\=VOP9^$^AV_AG4+9+.Y\2:O?B%9[VT7]Y;V]A.RJX6U!/FK&P4>@KBCEDL
M=56*;<E5DDDW=*[;O%/KJE>^FRZG;3^.'^)'Z@:;)JEE97&G&Z%M<V=_-)::
M7DE9+1F!:#.0#Y:!1&@R.N%QFO8[#4D?1UFF(ANM4LY;&(1(B_82Z>7(S@A5
M7)(+' 88'-?GYI'[47@S5/ /B/QS:SKK.J>$PME>06C1R-/=1DI(JA-SB9W
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M#[G^$R1KX TXHYD/)RQW'.5QR>><GC/:O2(80D^Y7.\VJDQ!B$!)P&*\ '\
M?YUY3\)28?AYITEK^]!)_<$[I!RO4YSDY)'T)[5ZR##N^U!AYA4+MSR1G 7&
M<X_2@"]1110 4$ ]0#]>:** *3+F0DPH2H.TE 2"!P <9&< \?2H8EEE!$R
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M3S!>/(_[R.XXW$%@6"G^(@@L..C9 ['M5^65MP1.B_><>W(.1[XZXZCBGKY
M=?*BV,P)+!0N?E.=Q'7(SR>M2[ <@  GV'..>>E %"0>8K!OFX)PW()49 (/
M7D 54C2>96BN+:,0]0#&I! Y!VD8.>,9[@X&36T(67E0N<'&X#'X]:%%Q@[P
MC#(PN <C//J!CT_+O4M15Y<JNM;V5_O:_,.ENCW71^JV9SE]'/Y$\=N9%EN8
MS;[HC\X\T% P/^QG*MU4<<5!;VUC:6=AIU[J<$DEHDB7D=S/&TTL4Z['AD4G
M>0V[:<G"]>*=XUU"WT+PWK?B&5F5='TJ\O@B.8]TD$+O&#C&?G X/49XXK\
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M3U6RF,8EQZ=ORS5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFB!$C*V54 L!NS7]=&IQ7$]O&MO.(;C>KKNYC<1MN9'CZ.I P0V<X]:_"?\
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M4[UWCB#)_>"D@X(#$#@CGGH?PH YW5[R&RT^^U!F^SQVUNT4.1M!EE! 5,8
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MOD@C!QSQTSCICGU!YF5@KJN/[S=!GWX'/]:?@)A2(MLAP0% R,$]!P<_C[4
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MWQS1 B/<-R@D$%MN,9SR#@XZBF_8Y95=;F=)3)C(CC W*O.&/<_W<Y&1D#-
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MDU_HNC:A*TD6B-Y1V%4E)2UEE16+21A"_.3ELU]\);)#.]U*S2W0 '[K*J4
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MU6W_ $$X_P#OX/\ &C[5;?\ 03C_ ._@_P :\7HH ]H^U6W_ $$X_P#OX/\
M&C[5;?\ 03C_ ._@_P :\7HH ]H^U6W_ $$X_P#OX/\ &C[5;?\ 03C_ ._@
M_P :\7HH ]H^U6W_ $$X_P#OX/\ &C[5;?\ 03C_ ._@_P :\7HH ]H^U6W_
M $$X_P#OX/\ &C[5;?\ 03C_ ._@_P :\7HH ]H^U6W_ $$X_P#OX/\ &C[5
M;?\ 03C_ ._@_P :\7HH ]H^U6W_ $$X_P#OX/\ &C[5;?\ 03C_ ._@_P :
M\7HH ]H^U6W_ $$X_P#OX/\ &C[5;?\ 03C_ ._@_P :\7HH ]H^U6W_ $$X
M_P#OX/\ &C[5;?\ 03C_ ._@_P :\7HH ]H^U6W_ $$X_P#OX/\ &C[5;?\
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M>3+(3GJ7;/?OG- 'NAN;0'?)>0=,;E90WL-V2<>U(+W3%.[[3$QZ<E3U_P"
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M9RV2./?UKQD?-)&#R"W(/([=C7.:E)(NI7<2R.L0TVX81J[! PC)#! 0H8$
MYQG/>@#W2XU_0].0'4]5MY2MNC,!('4DN1N1-VTMV]>/?%<]+\0O#%M)+%;2
M7-U(8@YC,#%63G:L9*X."<8';I7Q)+>WDWV'S;NYES)< ^9/*_"_='S.?N_P
M^G;%?8VA65F_A_0YWM+9YVTEW:9H(FE9QC#&0H7+#LQ;/O0!@7VK>-_$L3S>
M'M-%A9AVCAD<E"2PV[L KL('.[@\@[JO:%\+_-C2]\87$M]JV[S5)D:922>5
M._?D# PN< GW(KU30D1#=Q(JI$I@*Q*H6-2T>6(0 *"Q )('/>NAVKD' R.
M<#('H#VH P;6![&""UT^%4C7(==JKM0 ;2 H'/7TZ>M78I!(;B$QM'*$WL6!
M!8G(5@>N0>_4^HK1P,YP,],X&<>F>M&U<[MJ[L8W8&<>F>N/:@"FD(55W@,Q
MC3<S ,6(W=2<DGD<GG\N)XT09PJC'3"@8SG...*EP#U /X4N .@ H **** /
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>img_003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $X G # 2(  A$! Q$!_\0
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MPZY_X)Y?]&@?!+_PC++_ !K[YHH ^!O^'7/_  3R_P"C0/@E_P"$99?XT?\
M#KG_ ()Y?]&@?!+_ ,(RR_QK[YHH ^!O^'7/_!/+_HT#X)?^$99?XT?\.N?^
M">7_ $:!\$O_  C++_&OOFB@#X&_X=<_\$\O^C0/@E_X1EE_C1_PZY_X)Y?]
M&@?!+_PC++_&OOFB@#X&_P"'7/\ P3R_Z- ^"7_A&67^-'_#KG_@GE_T:!\$
MO_",LO\ &OOFB@#X&_X=<_\ !/+_ *- ^"7_ (1EE_C1_P .N?\ @GE_T:!\
M$O\ PC++_&OOFB@#X&_X=<_\$\O^C0/@E_X1EE_C1_PZY_X)Y?\ 1H'P2_\
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M+ <=QNQGOR1GMZ4 7<X./8G\NM,\V/.-PSSQSGCJ/3CZUD_:I#'MVL2)%$#
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M* ):**3<,XSSG'0]: %HHJ'S@."KY'HAQ^% $U%1"4M]U'XZY7'TQDCWI/.
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M]<>GK7U.1D$'N"/SKY:_;/)7]DOX^+YJH1\+_$7[RYP$YM6^\S#&<#"CZ?4
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M2<$"K9O[PKE=,O?, PH>5>>"I+-@ /C))XRW3!KI2H/<@8P0#@'\N<^X(I2
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M^;:V*2_O!:6YCME<Y$8[S6L<B:K>2NS);BSD6="[A-V,,0@)4'J00"1D=>*
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MP"T;P%\+_'7ASQEXH\/^*+C[9HFJ^.K#3M*>]TRPTK0)HI;BQN!! %WSJK3
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MEJ<%K:M-=-&YQ%9)=0H6M7G*95&=5&X-0!]*?;(V(C\R R%]H4H^2.PPPSN
MQD8X SVJ^2P!^7=QV.,\= #S[=:^5/@A^UE\!/VAK_QW:?!_X@:;XQ;X7Z_?
M^&_',UIN73?#VO:=+)97ME=:Y,OV2ZFBE!#+!,Q5U^8@'%>]WWB/0M)1FO\
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MBO%+[$8QK,P5SDDDF@";X9_ +X=?"?3]"T?PII][(=(MB+34=7O[C499+V8
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M %[]B7XBWOA?P1X-\=^)_"-UI?B#3Y/&=CH]\FAJ]^JWVL^&CKJ_V8FNV<(
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MC&+-P3]DG#.S,;8L5,>593G/RY.1@<<C'7.>@!6TM"+, 'EIU9VR,3MP2$/
MQT(/ ['I705S.E-:R6@=5&Q[A3#N\U2I&U3T# '(;N,^G&3TU $<O^J?_=-?
M+?[:!(_9,_:!PRJ?^%:>(AEQD<VOIZ^G7I^(^I)?]4_^Z:^7/VTOD_9,_:"/
MR\?#/Q%]]0R\VG<' [\?XT <#_P3=&/V"/V2U*&8_P#"D_!R[DX (L0,G';/
MY8XK[C7A5^7;P/E]/;\*^'/^";I)_8(_9+9&**?@GX-8A< $M8J<'(/'+<?K
MQ7W(I)52>I4$_4B@"K*J!L"/+'&X')!!/?GCZGI]1BN>U9MEQ8R.L++";YO.
M4R"YL@;3A;*WC.VZ<GY6$HV@XVC-=#+GS5QW*YY"Y'7&3ZXKG=4R+S1RF;>=
MS>;;D)YL-OB/<Q<_=7>,K\P/4  '!H ^ ?B-\-?V7?!W[5MS\;;[X2S>*_VA
M]3^&&OZGJ>NZ<]KJ-Q'X(T2P$=SI5QX>N;M8+J_UB)3IM@TEFS-<L<.@0[_J
M3X&?$6Q^*'PW\->,=+\#:_X(TG5E%IIW@W7]-ATS6='L8BR>9=VZ/%"H!C,G
ME6JNB!S$"2":_F__ ."C>C?L=V/[87[1VA>._C[^U/X-_:3^*?PH\*/X!M/A
M'X<\6:G/\.M*(6TU;Q/X8U/3 VCW?A;5TV6FK0S6[3:9?,Z[S+EE_HM_97\+
MCPI^SM\$_"\GBC5O%Z>'O >B6*^*?$5JT7B+79K*!3->:A')F6*YF )N7;]^
M[9,C;NH!^,?Q:_X) _&#XV_%WXW?%KQ3\4?A)INL>+_B7:ZA\.&TCP=Y5AH_
MPX06\&K:)XHT^(06FH^))0I;3M3N8YKJUE9I8IE92#^Z?A3P7#X%\*_#GP?:
MZA?7W_",Z'I?AI+N>=GFNH]+@CBDGFDD^=G?9C<QWM&%5LD5ZH;>Q)8^1&-[
M^9(%0()),YWR!<;V!Y#-D@]^3G)U55>\TYHP2RS-(./XL@$GCC('//?.* -V
M&$(.0<@\<^W7Z=/RY]^1\0:?-JLEK;)!97-O.EY::K9:A&7MKO3YEVL&((QM
M(*'@Y)X[5U<0#-*NUDR<YW$G@C@9^GUZBEFB3 ..0I3/<HQ!93[$\GOGO0!\
ML0_LR?"[2;_4=>\'>#]%\#:E<6+:/->^'4EM9-0M9[IFN8+TQ%#+;S)(PE@8
MLC@#Y"0"*TW[*WP/'ACQ9X0@^%'AR#1O%6@ZEX7\47UA"+:^U33M:P]^0XC$
MC;)P)%CZ*0.2!FOJC[B!5P%4D[<#!+$$ELCD@]#U%6< M$2H)(.3C'7.>!@?
MI4N26CUVZ7_,#\LO#_\ P3*^&5IK'PEO_B5XX^(WQU_X4AKJ>)/A'I?C[6((
MO#7@);: Q6.C:+H^GJHN19P>6EK=W1D>%+90P(; I_''_@FA\$/V@?%'C3Q3
MK>L>,OAWXD^)/B3P_P")]3NO!\T%A<I>>%[%=)U9K:X$$<$6B:[H0CLKF"8"
MYEE#S!G=@3^K;1(L9557C)4;5&"26&, $!3R.?J36>?L5PDHFVE9V^SR+*Q(
MGD7Y\!,[05(!^51TQZ50'Q5X8_8S^'_P_M?C3:?#N75/A^WQM\%:?X0UOQ'X
M;OXH]2\.:;H^@?V!I]WX<LA$L:ZS-;-)>W.HW(,QNV\R,Y !\(TS_@EE\'+G
M]G#X4?LV^/?%7B?XF>$?A#XAO_%7ASQCXJCL9_%M_JVLFX,K:_(T;1ZM*4N@
MKS7H>1W56887%?JFJKF&;:@D=661@JY=4(558X)(4$X&:GFC0J$959'8!E*K
M@X(*_P (.5Q\ISQ[T ?SH_&C_@B!I]S\3O@_K7[.OCBT^'_@G0O$OAKQ'\56
M\86T6HZMJ,'A_5/M-I#X5$,2V6F7MVBNEW-##%(ZB*)7VD@_T-6ENT,,5O$[
M-#8V<%I"S)M>39''&&8=-QV@L1W.:T6AB,@0HA0!<*8XV P05QN0XVGE>X/-
M6PH'0=3D_4]_K_D4 -0$=?11^0P:?110 4444 %%%% !44R%P /?K[BI:* /
M/_%EC_;/AW6]"L]HGUG1M=T&ROYHS):65SJ.E75NDM\ .;0RRA94*OO&!U''
MX%?LT_\ !"CX=> _@YXQT?XH_%'XCZ9^T!XWM_&6CZ5\3?!&N)H^H_#G1M=U
MR;5H[;P/<6$=ND6GR@J]Q%>2!I$+QDJ6!/\ 19]DAV21A2L<H(=!C:=Q!8X(
M(R<8.<\$X%1O;@Y4%]AXV+'%L(( P05PWR@+EE) &!TH _F9^+G_  1M^/.N
MZA\$-!\!^._@YK'@OPUI7A;P7\0M=U70KNT\5:3I7A#Q)%XEMO'OA*\NOM=S
M:>/M=DLTMO$VI>8J7_VB5H3@[1ZG\>O^"</[3OQW_:LTGXSWNI?"/POX6\;0
M>$=,\>ZK<R7%]X]^'EK\,FG7PRGPYU% 9+2/QW (H_$K)=Q[HY&C,3$BOZ$#
M:6Y=I! JM)&D4C87,B1MN17(&653G"'Y!N/R\TV.& RS#R8P"V[(0 @A,#![
M8!.,?=/W2* /PA_83_X)F_%?X&:#^V+X"^(6I>%?AW\*_CT^I:=X.^'OPZOY
M[B/3M;G:ZG7XI7&MW#?VM'J]S.\$MUIZW+1N[R!0!7Q=\1_^"/G[>?BW]F#P
M)X>U/]HEO&?[56F?'&[\5ZUX\O?%VJ^&/!9^''AV\:/P;I$WAN&=A+Y>E%9M
M8A-PQNKK$A^]MK^J.Y+1P$P6T4TY8?9E,2%X9LJ-TKE&4.%^;>V!@?-D"OAO
MXN?M,>)-4\9/\#?V;]$T[XE_&2\66/Q'XG(,GPZ^%=EM.Z?Q)J2M):7.L;%=
MX=,&'9P-ZL,( #\PO^"AG[)^@_%'XC?L37GQ\\:OJ-O\,_AU>?#+X@_#CX1V
M_G_%GXD:WK-C8+)/X;$GGR:5X%FN4D.HW=W''*Z.2LF6!KQK]H?_ (([?M7Z
MYINL^$/V6_%/@;X0_";5OBQX9^)GAWP\=9U.S\8^$M.T#0M,TVUT&74+:>W6
M[E86\K72R22(TRLW*28K]VO@+^S3H7PIO-6^(/BS5KWX@_&SQ./-\9?%7Q)&
MEQJJW&(F;0/#%M,KQZ9HT(!MH?L"1+)$N<!C\OUBB6[B-O(#L8@0V%8LQ&<Y
M=6.\Y.223G/TH _F(\7?\$HOVXO$?ASX]^%K;XJ^&W\9_$?3K74M,_:%C\9:
MNWC'Q7IUM! LGP;UK2=Q@\.^'8YH2B:QIOF/\I='!8Y\PU#_ ((K_M<"]^!?
MB$^+_".KZYX/^&=IX(U/Q?KWC7Q OBWX-7EQXBM=7&L^"/$-G()O$B^%8H9T
M@T_45D34%F5)LJI _K+$40*LJ1AT4QJP5?-2(\F+S -PC?CA2/N\-V#A:0R!
M?,3E&9H=C&-5W]0JIA5)[G;D>N: /P8_8L_X)Y_M6? ?]K6#XP?$KXM:9KWA
M+PWX>\5Z+XH\;:=JNIW?BG]IJ;7XD/AZZ\6:!>3OIVB7O@]H?]%:QC1;M2PR
M7)Q^Y-K*6UB6*)I99+JWM[H--$!]BM\D26V\_.KN,##?,"#V&:V)+.UBC1#;
MQ?N!FW0/F4D$Y.\_/E=^2P(;)&".]2P&->U-0,9M+)CR2=V.?F)).>_KB@#?
M/&,]UVC_ 'NN*Y^Q)&HZAC&0PR&. 0.HR>#QD_A71MV]CD^V >?SKFK!8YKJ
M_<$M"Y",9#M*%CM.UL8)YX.,9YZF@#\P/^"PX\ W7[ GQLC^)(\41Z&7T6VM
M9O!U^MAJ.F^(KO5%31KMY7(M[G3C<?9A=P2*R-N93@AC7$_\$1_A]_PK[]CJ
MR6^OM9U76M>\6WE_K&KZAKMAKNEZG=M%&(#H5MITCVVC6L$)026_R*K[A@;2
M:[3_ (+%VGA&_P#V!/B__P );'XMNM/TZ?1-1T6/PCIT6HW\7B+1=2CDL7U.
M"93;7&E9 FNEN$*$0E2K!N.._P""(WCS0?'G['WVW0]3EU[[#XJO].U+7HO"
M5EX0TB^OTBCWPZ-I]E'':7=M;KD27:1Y9F)=FR* /L9?V.?@"/VFW_:_7P[J
MDWQLDT\Z1;:NNJRFS-@4^PLHL1F,1MA^#P H('S"OJZP2(ZOJ\RG$CI9@KTP
M2A) [9!X.._J:V$MX4$#)%&A4"--J(/+3.\JGR_*"R@^O)YK-L8U75;Y@BAF
M"DG<,\'@[0.PZ#M0!L^6&^\#QTY_/^E2  # '&,?TYI:* # ]!SU]Z8(U#;L
M'.XMUXW'J<>O-/HH , = !1@>@HHH 3 R#@9'0XY&>N#[TWRUW;B,GGKSUSG
M^=/HH **** "BBB@ HHHH ***"<?F!^9Q0 C=#]#5,QY,+*%8Q."_P K9PW!
M(R>3R3^O-*[.#()681@$J54DXYYR"0/0#&>.>N*8#N9=Z2D':5^9L%0002N>
MHX)QC% 'C?@GY_BM\3YY#'B*+0+4;<C+MY[X"GJ2<YQD?=)]:]C158LRQC>H
M)W.">2#USR0>_.!G->->")$/Q5^)JNT;*#I)0, A5PI&-ISDC&0W7KSTKU:6
MX5#+(SN1%NDGG$D=O9VJKD*'FG*(63AFR0HQAN.: -,.R1AY=@&"TKH?E3;]
MPYZX)P3P,8]L57<S3"01R>3-B$A@/,4?*2P*@X.\$  <D8(Z5\F_$K]K[X3>
M M4;PEI%W=_%+XDW.Z&W\#_#RWDU_4IIL;5&H268DT^R =D0AIPS+N< !&)\
MH?0_VS?CV4C\2ZMI'[+WPWNT\V70?#+)K?Q6U" 'YHIKWYK73&D 5<P,DD63
MEMR@4 ?1'Q9_:$^%7P8M!<_$3QS8Z-+,P6RT73PNL^*]1O\ )*6VD:'8K=7\
M$C!=KK/;J&8% 1S7S^OQ4_:I^/$##X-?#RQ^#'@S4-R#XK_%7S&\0-9.IC>\
MT#P0-LUI<3(3,K7.U/,*F09&![9\)_V4?@Y\*9'URP\/3>)_&,K!KSQ]XTF3
MQ-XJEGR7\V.^OFNS;OO;<1;LI20E00<BOI1L3[HYI!-'+"I5%0B(;2,GSA@.
MW/(&,$$=\4 ?%?@/]CGX<Z?K<7BKXJZQXJ_: \>QH!<^)O'DWVW2(9"3,8].
M\/*W]G0)%)^[B'DOB(KN8X./L2RLK.WMK>VATR/3H+%?+T[384CM[.WB0854
M@MEBB0$?PM$<<8/)SMVRJJ*J@*-@ "@# &  , ?F<GWQQ3Q;H,X+9/WF+99N
M<\D@]/;'% #4B<* "JCJ% X&0"?U_3%>.?&H;?A_=R1J7(UK30,CD*=016)'
M.!\C<^WO7M?0<=A_(5XE\9KGR_ 5S+,! 3K&AQE7/R-YFI$8/4_O,G.#SP/J
M >MV1C%C9*IS#]DA*MUW;8D+8/7O@#/52.<5/)]RX [QL!^1-9UN<:?9#F.$
MVMDRR*#)U3)4*N" <]R>!TR*TL!TG)_N'IP/NMV.?2@#)\/C%C$3V=U_$N0/
M_P!==#7/:%QIL1[FY93]!(?UYKH: (Y?]4_^Z:^6_P!L]MO[)G[0)^3_ ))I
MXB'S\KS:]QWX[?CVKZDE_P!4_P#NFOES]M+Y?V3/V@\;>/AGXB/SJ&7_ (].
MX.!W_#ZT <!_P3<X_8'_ &3,_,1\$_!P+ 8^[9 $8_#.?;C.:^Y$^XO;Y5X_
M 5\.?\$VPZ_L#?LFG>.?@GX-)*C!^>Q#'J6&.2.GIS7W&F=JY.25!)/?B@"L
M[ <?,">F%)'XGL/?M_+G-6;;>:;%&&2:2._*2 -)"F(LAI$ PS_W5SD$5U$O
M?''RG..XYX/L<#\JY+5W5+O294=EE@-[<>2&(CG18L,K*.2!U."/>@#\=?V^
M/^"G'['/[ WQ-\&M\0_AY8?$3XOZ_HT?@NPO_".AVFN>,?!\GBF[1]*TWQQ<
M&VGO=&\)^(;N1;J>>":2"!TG+QA9$:OU8^&WC"?Q?X*\&>*;BSBTBY\2^&=/
M\01:-I5TM_9Z=;ZM''+"CRF**-K= X&]0 @(7)*U_/Q_P7;3Q/X"UG]GGQ5\
M(;3X-VGC3Q[XE&@:WI_B/0]-D\3ZA%;R0MIGBF^U.[@_Y%K05,C70ED6!=BJ
M67<M?O!\"5U,_ WX3S>)-9T+Q5JJ>"_"W]L^)/#?EQ^']=N%TZ ,^A_V</LZ
MZ?'+N$<,(-N2G!;):@#VY'G=H@5$JRL8;UP!&T?E ,CJ&8?N\X0MQEN!GBJ.
MIG][:L\B2(\BJAE<?9QN*[64PYF!X)+$;,\YQ7\Y?[8OPA_X*&SS_M*GX;>/
M?BGJFF:Q^T1X$\3?"6+PS$EL^I>$["2SN+SX>3$2++IVERS//'-J("QSQKA@
M=P-?T!>#Y=>?PI\/+CQ/I<6E>*8_#6D#Q-I"W/VEM+U>ZTJW_M"U6YW%;N2V
MN?-4-E@CJQY!H ]9C.2WL$4GU*@YQZCWJ7K35&%7D\#^>#^G;ZFG4 0^2O\
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M9URY=F!=M/MBV.YQS_GC\:V9O]5=?[O^-8MG@:W=ML3*V%E@[^</D$D8Z\'
MXY&* .D;[I'<@@?4@XKG+!O,O=05G(12L(BV<>9G_6#H"0<8]?7O72'MZYR/
MP]?;UKFM/+&^OAN21QM^:$83?GAB&+9Y.#GOW] #\^O^"H6O:;HW[#WQIOKZ
M:^BABL[>"VFT:]LK<KK*7\:6<D]K>1RC4[!KAE.IZ3;JU[=QA4MT;<^.5_X)
M*>+O''B7]C#P3>?$'X@_";XC^*M*O[VREC^#'A%_!>D:'IDOE_V=X7UOPY)'
M:O:^)[.#;+JES-"99&WL25XIW_!6?2=;N?V)?B5KOA/PC!XJUCPSJ6A>)K+3
M8?$&G^'KO2O[)U6.;4_%&AW.H(VGW/B'3UW-:6U[M@/0LASOS/\ @D;:?#O_
M (90A\<_#_PWXZL)O'WBF^\5>*?$/C[6M'UGQ;XY\6SQI'J6K7<VBE-+A5"7
MABABAMHV4Y*'!H _0G_A:/@27QE+\-(?'/AEOB7;V2ZPO@[[?#-KNFZ9D!IK
MNPB8S+&JN4WR*IY)P0 :[6TD1-4O&E0;O*C420[FA.1U&,[03_"QS[\$5^56
MD?\ !/GQ5IG_  4YU+]O;1_B=;6GACQ%X0'AW7? ]U:7 U::1;=;;^S8T9S:
MI;LX$C78!R<[3SD?J9HMO:?VEJ%Y$\L:WY(C@DF9DRCDR%(RS(&!R %) &=H
MQ0!V(.0#ZC-%&/\ ]788]** "BBB@ HHHH *0D@9 R>.!]1G]*6HY<^6VUBK
M8X(&XYR, #ONZ?C0!"Q8)N,GEJ)L[EPX*$D!3CH.QZ^E1!BSH!(K#?*N I!)
M#!@-WH%(Y. 3G%><?$GQM>>!/#4GB+2_#UUXI:WO["S^QV%PD;8N[E8;J1]Q
M(5K96W#(.6&T\G%=IIM]/J6GV=Y/;7%E+>6]I+);S*BR0M(2[ @$E3SM( )!
M !H Z ?>;_@/\J=35Z'V^7/<@=,^_-.H *:_W3],_ES2D@ D] "3]!_^JJY#
M2C<LH\EP#P#OP2#P22.G;:>.V: (1<1\,9D$1!#1E27+9^F1D#^1JTTJH@;^
M'* 'H#NP0!GGD>V<\=:R6NC%'-)%,TQ6W,Z1/ ,85MF Z@97.>.3G^+M7DWQ
M(^.?PL^$UNMU\0O&FA:-+M^TV>A+=K<^)+^Y(#+;VVCV\DUS,S@@1QK%N<\\
M $  ]<NI)!)NB6-IE"M$DDQB#QY/F?P[3A<XSD[CC&.G*>(O$EAX=TJYUOQ)
MK%GHFBV\%[>7.MZAJ5G86%L+8;[90MQ)&S"0 IE02Q&0,D5\6)^T%^T+\<A-
M%^SE\*%\)>&EG,4_Q1^,L4FD11++)L>3P[X?>);R^=<DHMPBHKA0ZL) 1O:/
M^QQHGB?4#XH_:(^('BOX\>(@R7$^G:C++H7@C3XX#YT$%MX1LYHDEBA?Y$5R
MPE'^M7J* .$E^/WQ*L=:B\3?#WX6:+\5I_C*EU;^"/\ A%/$$8T[1[30SM:\
M\://F:%1M$GF6VT+&RXRP:M=_P!G[X[_ !QO1?\ [2WQ8.A^$[F.)G^"_P )
M;RXTW3[)F;*PZMXHCE@N-70( K"'<6,F#G!%>X?"7P5X2\-_&#XFV?A_0+#1
MK:PT_1X["QLE$=C8V]V@:5+*TCVV]FLRA?.C@2,DY63<W-?3,6FVT;%1!$(%
M.Z"(1Q>7$YY=HTV_*S'))P?7CN >9_##X*_"_P"$VE1Z=\._!&B^&(\#SKVW
MMXI]8N9  &:\U2X22^N7=0NYY;C=DGY>A/I-Q% 5="CE7.9Y5;;(%!R%4G)V
ML?E;#=#DYYK4557.T8SU[9P,=!P/P 'M5<0$LV[[K]<$9]NQ_K0 RVMXDA6.
M-0D:\*@SP" W)S@DDY)_/D&K8  "J !STZ#OT[\TH ' ]OT '\@*6@"JS-"C
M;G5FSN7=A<C &T9X)R">.>1UY-51/)'"IFD,<A.?])CW#:3EL-#G&!]T''.,
M^RWYZEH]_EQ[[=0X5II\G,2CUP%^N<>F/P>_X*:?\%(_VB?V5OVD_A%\"O@1
MX.\-^+M9\;_#V[^(4?A75=(U/6/$/C%]/U0:=-X6T*;3H;D65\[ NUU=!+-(
M06\W<N  ?O"+F1?-;+!(QYDDDP$2J"..7&,87<,'H0<#(KB_&7@C1/B%X?;P
M]XL2YGL+J03+]BN9K"=I$<2Q.?)96=D=4:,Y"G))X//X=>//^"W&F>&(O'O@
M/_AG[Q[HOQR\)>#=+FU#1_$K,O@SP_XQUNVM8[?3-4U0Q/#!I45_/)<->2!5
M-E$^&7((F\+_ /!57XRK^PC\5?C9XS\%?#F/]H3P!\4-/^#&EIHVO0W?P?U3
MQ?XC_LPZ'JZ:K&QNVT&Q&I(FIW656-P6!5$((!^\>F0V^E6-A8137#PV5G'9
M6\=R':YE:%!&K,TA+2,%"J6!8=^AS5V1FFBE=@T3-;D$.ZB$LH.2)0=H7G!.
M>">:_G1B_P""M/[1\/AC]E_QWJG@?X+6NA>)?C>GP!_:&B?Q;)=WNCZ^;U=.
MF\:^"H8%W?\ "(W-\?(L=2G00RN(HM[%P3_14JVDUNJ0LK6+1GR AWQSJ\9=
MLEMQ9>01@@]\YS0!3T4A;-&\G:)[C!^<')! +<,1@D9'(R 21Z]-7.Z#'G3[
M=6Z'>RX"C 25PN !CI@'(S@ =JZ*@".7_5/_ +IKY;_;/Q_PR9^T#DJ/^+:>
M(OOC*Y^R]Q7U)+_JG_W37RW^V@=O[)G[0)^3_DFGB+[ZAEYM<=#WYX]Z ."_
MX)PN#^P-^R;NDC+M\$O!@\Q4)0XL5R, # XQ]0:^XU.5!R"" 00,#&.U?#?_
M  3?"2?L#?LF$*H3_A2?@PA5R #]A7!'/?D_7FON1  B@<#:./P]Z *LYQ)@
M]UR/<#@_SZ5S>K O=V40A:X4K(SJ5\J.- .K77 4G_GFQY'7BNDE(;$BD%XL
M;@?N]1D$=>^<9]*P=9C!N]*=99E234/+EB$A\F1,#AX^00"2>,$]#0!_,]_P
M<2:K\+O"WA_]F'Q5X]\*7_BV4^+K31Y-(MM8_P"$.@U_P_>W,,-YHMWXX93H
MNCK*S%I8#<(;F$93(QC]^_V=M/\ "NC_  '^#MEX+\.6?@SPO9_#SPRN@^&+
M74WUBQT?1)]-ADCTJTUF*5H+]K9G99+\;A*Y#[R"*_++_@IA\7?V/;;XM?#;
MX)?M5_LM?'']H]-/T*Z\?>$[3PWX5GUSX9:IK5I.B:=I&H01WMII<^IRL1$J
MW&TP%2S!@&5OUN^#\MKJ'PQ\ :GX?\'-\/\ 1+KP]I@T[P-<VH2Y\(Z(81]G
MT5;>WD>UC:VA"(8H0R0C"CD$T >KK:R$1- OV<!2KL9&FE&%& <Y5ONX#CYP
M2,$ 9K)O8EBFT@)%]F!N,D,V]@6.2&')/)SN.<Y]*WEN(7(@1GR0S J0&.WY
MB"<< @<]ST'8G&U+]]=:7([[!)<YCC7Y90%[L_5E.W..!VXS0!T,.=\HY^5L
M<YX^GY=JL5!#*)=Q&!@]AUY/)]>G7C.?RGH **** "BBB@ HHHH **** "BB
MB@ HHH/0]Z $R/7OC\::S #D'+< ="3Z>V:K2SK&A,F^,-*$X0ONWG&, $@>
M_;KS@BD+0X$.\ J2"H8NV&.0#C#*2#G)^[GTH =(PV,'W6X)&'^\<@] !GKT
M^E,<RE)&&<(%:%HN&9=H!9LG!)(;"=QC'NAMX) 4 F(/)*N1C'(SDCKT_P .
MM>7>/_BU\-OA;8M??$/QMHWA>!E\B&PN[Z-M0O<[MI@TN)YM1G<Y"AHHF4G;
MR 1D ]$GNP\9N$E_<P9650L=PK2="I4$D2 GD#@-G/3!^;/CQ^TQX5^"D6EZ
M#]FE\:?%?Q@)+;X<?"+2-MWXL\4:L<F*[O%MS,FA:!"N#/J=_';VJKD!C("H
M\3A^/NN?&;Q//_PKGP7\8O#GP^\+Z1J/VKQ>-"AL--\1W6I+C3WTVVG,5U=Q
MVER8K@2;2?W>3PS ^G?LX_LVZ/\ "N&Y^).NW5[\0?C5XUC>[\5_$?Q>!)XC
MBT^1MT&C:4)C)_9&F1QE%^QVK0Q[MS>6V2" <!\-/V:?&'C_ ,3Z)\</VI]1
MM?&'Q,TL#6/ _P *_,_M+X=_!YM3\I\6MDP2T\1>(-.*,(]3NE9K>7=]F &U
MA]ZPKN>2;<I9!(J[9'VLNWY"$*A 05R$&%0C:O !+[2/SXB9_G!<LJD%'C.[
M)3@@LF>=Q)R2>U:6T#@<#&, #&/3IG'XT (JKPQ4!BH!Z'I3Z** "BBB@ HH
MHH @N,"-L]\#IUZ]:P+,!M<N<D9BL+4ML(!QDX#]S@=0/;'&*Z"<!HR"=O<$
M] 0#R?4>HR/K7/V1C.N78"Y8V-JK31XV.5)P#D'DC'(..* .D/0$8Z$\^F#U
M[XSC-<U8#9?7B?+EE8CR@?*P 20N3PA[ G)&<5TI X'U7\".1^.!FN7TY0]S
MJJLNU)&4 )P552V44Y) 9<YSSD\8P, 'YH_\%:;+P5_PPY\6+OQ+XFU?P?8:
M1K/A>_TO4] TQ]?N_P#A(SJUG]GT/4M!FF@M[S1-3G$2:AIUW(;6>!B9 Q9:
M^>?^",/PB^,/@SP%\0_'WB/Q]>:GX ^)?BJXU>U^%^J>'-.T"+0/$06TC;4?
M#T6FRFQT?1+JP43C2+*-0;D$RHK*#7N?_!6?P;XE^,'[,7B3X*^$OA[XY\:Z
MEXJOM&UQ-0\(:(NM6,-]X9O4U&UT?Q!:I)%((+Z&!+9YT8.#C."0*O\ _!)#
M2/B%H?[*=O;?$OX9ZC\)?$"^+-4=/#.J:/=:3=K8PHL*3K:W;NX$D<9\N4!>
M#\P/ H _4-K96$QF@CF6(A;<QMC,;$8W$?Q(<8!)XSGK6?I]O)#K.I>882LB
MQ/!&"Q:)2"-N -BL >1QGGWK2MI$GVSQ.P@"&2(@JL<FXXYCDVS Y!!)103C
M:3Q5>QE']JWUN9&:0*DOS1_\LV/ W8!XS@'J?2@#?HHHH **** "BBB@ JO(
MI*2;V,>3PX8 @%N#GL2,#\<<FK%-8!E(*A@<?*>AP<]_3K0!X[\: D7@)RF%
M#:YH 9D!7?\ \3&(_-M R3W)X)ZUZK;JC1VDC+EEM8\'J<[5&,=SR<'&>>U>
M1_'.11X#?S<PK_;N@!<#>&;^T8\*,  ,1VZGK7JT,JI:VJE]KBRB<Q ;IBH5
M"<*">HXZ9 R<\< &CYJ;@F</@DJ>H &<G&<9'3UJE+=IG8PFA=CF/(RKXR03
M@G"L!R"!D'!Y-<+XT\<>$/AYHU]K_CCQCHW@S1;*,74]WJ%_;VDT4*_,?,^U
M2-+<=@T=O"\A!VJO45\C7W[7'BWXDS7&C_LM?"+7?B3=A2)?'_BJ*X\+?#FT
M:7Y1+97M\L=SKRKG<PM4B101D8XH ^\9KA+:">XO+E+>."U:2XFE=(+&W3#-
MYTDLK*BA%&78N54#DBOD3QW^V5\&/".KOX7\-:EJ/Q5\=.GV8>$OAQ9W&NR/
M,P(#7%_;B73; @@B203^9M1CMW *>&LOV7OBW\4IDU3]J+XSZIK]A<7#30_"
MWX:O)X8\&V28'^BW>HP/#?ZF%7,<Z29CD0#!Y-?5OP\^$WP\^%&E1:/\.O!G
MASPGI^W9&=/T^W&H7DQPQFO+_:]S<R$@N3/,6)+,1N- 'R5)H_[97QR@BFUS
M7=%_9D\%3S"7^R-"FB\0^/+ZRE "Q7>I.@@L&FA+,Z*OF+(_^R /8?AO^R/\
M$_AM>Q^(8/#?_";>-9"LL_C#QQ-)XDUZ:Y4LQN;&75'N(M+9MQ.;5(U"Y4@+
MT^ES$TT;F.,)*"$:1PI<HH^958C=M5CA226 _BJ0#,84[]B##Q ?O0P  ?</
MFQNP1@C('/<4 *T R%=5*",HL8";8W8%@0BJJ C@$@'D;@0. ^ &-(%<"255
M9"Y/S9#'=SU88X_#(%()855(_.Y'*@H=PZ?>YY_,'U-%Q+%%)!))( I;Y0,J
MI8C)9LEA@ Y[$"@#QGP2JI\6_B:1]Y[327)Q@_*\F<]\@#(]1C'85[@6!DCP
M>V?S!Q_.O O!EW OQ9^)\GVFU9WMM-,(CG64LH.T?(N&&&+ X)R>GI7N) #Q
M1^:OFP 3,I& T9&!D9SDL<#!QZB@#1W#ZX.#[>Y]N.M+64;B)UDD4-(MNPD_
MUFPB4L<Q'@;C@!@&R,$9%7(CN42@DY )#'.">HXQR#D>GIQ0!9HHHH JW4!G
M4* G'(8C+*<@Y!R,>V"*\*'P8^'MU\6M'^--]X9TS4?B9H'A_4/!^@>)41YY
MM$\*SR/.UG UP-RRW%RS22/%@Q[B/F&17O\ @#H,51,$<N697B(/+(Q4'GTY
M'/?@]<^N #Q+QQ\"/A3\0]&\:Z1XN^&_@K6M,^(.B_V-XTA.B:5;ZMJMI+!)
M;SR7NOI:QWT\ME%)_HKF<.C#*GD5\VZ%_P $Y_V-=%^%:_ _1OA%IUO\)+O0
M=2M;W1VU*ZEL=2?4Y2EQJ-_)/(9KC6[=U!M-1;$MHP22$_(*_0.2.+8?E5A@
MQE64%61AAU92 "'& W&3ZUX%^T!8RW_P\%K:W^H:0YU_01]LT_;:RP6DVH+'
M+")(2&6)D7YEZ-GYPPP  ?/4/_!,K]B^-?@K);?!C38?^%!B-_AM!_:NJ/8I
M-#*MW!-XBB\_R]?DBO!]L26]$A$^YE?&!7WDD<[16GFI%#Y=O()HXAMBC9%.
MWRUZHN>Q_AZ=*@TJU%CIUE;1F2ZBM[.S@CFE??YR^4K-,2.K,2?F)SQT/!K6
M*';*3YH+QON9@G]TXZ$XQVX]C0!C>'W+:6N3RKRJ/QDR,?7G_P"L*Z2N=T,@
MZ;",XQ<L.$)SAR%R1@?E714 1R_ZI_\ =-?+?[9^/^&3/V@<E1_Q;3Q%@O\
M=S]EXS7U)+_JG_W37RW^VEA?V3/V@ON\?#3Q$1YFW:3]D[[ACZ>^* .!_P""
M;HDD_8&_9+^:.-S\$_!N?+4B/ L5^5<Y(R.Y/7)K[C0%5 /4#!Z<GUKX<_X)
MN;8_V!OV2A(X'_%DO!G,0)0M]@4C .YL<X^]USCU'W(GW0<DY ()&.,#MVH
MJS$*Y/ &!GM[_P!*Y[5Y%6YT@^2L[O=.(4$VQG8)N8*O0L%Z9R3T'.!70S*)
M&<,$ QC)D  [ D8SUZC/ZX-<]>*B7]@Y%MYEO#?F%)E >*[CBR+E 3GR50]>
MO)(.0!0!^/\ _P %2_\ @G9XT_;VT?P%)X._:8UGX WGP[AFNM+TBUU1](CU
MF[NYQ)%)K4JR0WL!C"L(SPKJQ*C)X_37X&>!]3^'/P>^&'P[\2^('\1ZSX,\
M*:7X<U?Q+Y[R#6M3M=.C1]42XE=I9O.QD.S$ECD@&ORZ_:<_8)_8]^,_[8FC
M_$?XZ?M$?$/P?XL^(G@&6RT?X+Q_%N^\%>'O$!T6_M+A/$OAZ)+ZTM9[J.-?
M(DMT#E(G*L,[L_KKX+\-:7X7\-^%_"VBW,DOASPYHUEI.CO?WG]M7>H:980H
MEG=R:LSN;B6:%5W3LTAD R&R<D _!O\ :5_X*:?M8_ _QE\<O"MU\._!?AB3
MP'\8_#'ASP%X@O\ 3-7U;2M7^'&I6$=S=Q74MM%)YWB74[]O)L'R!(TDFT<8
MK]NO!WBW4/%_@_X6>+K_ $2[TJ\\3>'M!\17^E3;E73-0UVQAEN+-LCSXQ%+
M*[+&ZA8T* X.0.]O_!7@KQ!#<#6/"?A_55N[FQOKI=9T2POC=7FF.'TZZG-S
M#();BR8*;:5\RQXX;!;-[43!%=:='$;>.16C'RQ$810%A10BE4C4<(JX"XY
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MC'- ' _\$W01^P1^R<,["/@KX1[9X^QXQQ]1]*^XTSM7)R<#G&,\=<5\._\
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M!8H;2*?S+-%\UV5'Q7Z4:9<D>(+^WE-YCRUN4FNXTAQNR1 FQR)(U!PNY02
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M=7>*-V56^9@<\C!"@84 ]^.1@'I7C?@K_DK'Q*;N+;2\>G#/7M ^:(,>K>G
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M/IS639 C4Y528%8["S)B*$?>9LL2>03Q@9_#B@#HF[>QR?H.I_6N<TX@:I?
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M2ZHOC-;&%O!QUR*$7%WX12XY=-3@TY!<2')5=P8E2.<CXQ_MJ>$_@HEG?3^
MO'&OW_C;5;SP[X%L=#T\ZEI.NZY;N4:35;^ EK6!'P_G2(=D08YX)KN[/]B_
MX%Q?M0G]KAM)UL?%Z?2KFV:Q&MRMX8W7-FFG77B(: P^Q_VU<V:I"]V&+; =
MJ!\FO3_"G@3X0:7XHU"'1KS1[OQ#X?>XU*_\/3ZQ:ZK-H3:DI$4]QH<IFN-$
MD923$Z0QB0D_.W2FK)IO:ZOZ7&M&GV:?W-'YTS:UXG^.]_-J'[1WC3Q:?!P*
M3Z=\!?AAHNH:=HVH0AL+%XF\21#SM102 ++;-\KD.JR!7%?77@KQS>^%=#@\
M-?";]G'6/"WAG3H(Q!I4=M::#%,Z*J0O)L0RR$*%R9V8E002.WUK;:9;121B
M*UM8UN,,GEV]NHM0<M^Z/E*=KGE=X(^\<9YK6_L\$Y69LXP%60A2![DG/'<Y
MR/PKJ=2@OAYOG%M?TMCLA6H1=Y0YU;1.-DG??MM='RQ/XI_:3U%0--\ ^$_#
M:X,@&HZS%>L&?[SLN/DVKEF&0%/R@#.#@ZIX1^/VK6K?VS\4O">GRPPOJ%YI
M&FZ6\27=B@,TUH\Z[BT4B*T08D;LY. :^RELD1&3[-;LK AEW9=P>#R2>?RP
M3P!6'J4,%O97:QVUL;B.QO'CM+E5%O+:QHW[JXN6 \N$8"D%U$8 )Z5/UN,&
MTEMUY5?\#3Z[2CI"A%):\UE==6[>6I\@>$? WB?Q5HIUW2_BKJO@+2KJ>2U7
MP]H45L=-AF1RDDJVY\P[YBK;OGR2Y+ $"NOE^!MY<8%S\:?&P*_*#NAM5([E
M552'#>K'.#GJ:]&^$^L:-J^@7AM!X1>&#5Y+>2W\):Q:ZY'I]\TA3R[\VCOY
M4BOPR'#*=P/0U[05M]O^JC=\#YFB0L3ZY()&>>AS^-*682AK%-W;32@M//5$
M3S%JW)9WW3BE;3TU['R6GP T$OG4?BEXVOHAUB;63:X&?F"O&RDJS $D X(Z
M@U:'[.OPVD8M<^(_'%Z)R%B:3Q9?L5+$;=@4D$<@(2N,=\5]7_9K9U&ZW@/U
MAC.,'H,J>/:D:U@"_);PAU!\O$48VL00" % [_A6+S.LY:0TZ75G]UM.R$LP
MK-)I1M]WZ'P]XS^&7A'X=:'+XK\+>(=5T_7[ V7A^:ZUW4IM0AO=-O+Q;6YM
MI3)Y@:YDMI'10N)-H^8=*])TSX!_!.TABN9/#=O-)/%%>S7<L]](C.P7#F!Y
M"H1RY*C9M7<,8QBO6_$>B>&;O2)HM=BTJ;P]!/'=ZH;ZYAL[+3;B"19/[1NK
MJY8(KPN!Q(X##Y57)S756CZ;+#;S6CVDUI)9A[:\A*3PW5FJA4>%XR5*@F/)
M!*GC!]$\RK/3D\^OX: \?7?1+KH]?RV_IGD5E\-_A%H:S?9/"_A]MQ5Q)<60
MN'S*0>#)'(R@9QCJ.@XKL=*T/P782XTS0])M'8!E:VTJW&[Y<DAC$" 5)XR#
MC/X=L(8)'Y6*176+&(E 4 9Q\P)Y[\U96RA1_-6.#=UQY8!]>N>OK]/<UF\=
MB)2^'232VUMHM]+>NAE+&8AMZ*ST?O.]K6>EK'+&\T!#N62TC9&,>P62J5?D
M$86([?0G[O&>F#5R/6=)3]T;V""1L!(T!4\]"$51U[G QDY&:V=L*K,2"2\F
M, */+WCDH-G"J>><GKR>E<O?:]X8TC5M+TW7-4\/VM_JY>VT"&]O;:WU;6[B
M%P;M;.S<I+,;0E%=HXV^\"2!C-^TJ2^.ZMM[U_R9/MIOJ:ZZKIHS#)>;B0"P
M,+\9XP=P&1@^A&*>FJ:"KC_3K<D9^4JXP<$=""H(ZCC@CCG%:47V><!7C4L1
MD$H Q7)"[@1P5 P<@<@$"I#%:D;1%&3TYBCYQZG9GM09N3DVV]_N_KY&5_:^
MA][VW/[P#.UCT'0?(>?\\TW^V-&60*;^W&YP%4QNH))PH)VCC.!GIQS6HL<4
M@.;>+Y6XVA(_Q(QR??I5:>!$^S@VB.TT^UY-J-Y W$H3A"2K':I Y))Y!P:"
M3PGP?=Z=_P +A^*\37%NIDL=)>9<.#\H B)P!P#ELC[^<#(&*]L34])V%&O+
M923ED59"K$'.YMR\,",@<8(&!G%<CH=UX N?%FO1:3K'AVX\8RH+7Q-96>H6
MLVO1-"?]'-S91NUU:Q1E24$T:I@ [B=U>@9@<!-CYX!<VZDG'<MM(.<9) Y[
M46 RSJ>B/MWW,),;Y4E901CL..%[^]-_MO2 SL+@-@$@"W?G Z@X&,?AN[YK
M7\N+>$^SP.-N=Q\L'J>.G&/3'XTXP1 $I"A8*Q"@*I<@$A Q&!N.%R<@9H R
M8M8TZ4+)%=HB?\MP8RJQ_P"T^00"<@=03CUS4J:K8$_+?0NN.N&9<'I]T8R1
MTQ_+FL?4[O0=,LKR?5KVRTFS/D1W\U]<PV%O;->KY5O"UU<O';R71GQ]FC5U
M+EL;2<&L[1?$'A&\O=0T;0M>T#6+_P /Q6TNK:;IM]:7>KV$1MG$1U&U@D>2
M![IB-FY%!."H- '4MJFCY)$\)XR=QF!)YZ#!]!Q[U&-;TU'59;JT)\O(9%F)
MP#C! 7L, ]\_3%7;>.VN8HYX=H\T^<JO&O\ $ -A!&0 5(P#G<#@^EG[/&&R
MUM#T(+;4/?/3 /)]_KZT 9G]M:.>MU"3_N3#_P!EKR/XR:OIL_P_$D=W%(O_
M  D6E*#YC0X*:BI*[F (*@J ,<D@#DU[AY$7:*,>PC3K^*GFO'/B9JVAVOAV
M.VU#1--\4R/>"6+1KBZM+74;\12*TVJZ=:RO')<0Z;*%>>95*+Y!.!BE9;V5
M^]E?[[ >I:<ZMIUA'MVO_9T;8E#[HSL5?WC'&SD_Q$'.3ZUHAF,,VY< 1N0>
MW"$'I[?XCVXKPQXC\.^+-#L]7T'7-+\0V4J#3+J^T?4(+ZT^VP "XMII;9G2
M-H)(GCD&Y2IR& &2>TE8I;2XRX%L6 X[J1@' X Z=?QI@8^B1J=/A"N^R.Z/
MED'&[,A)R#R"22/F[ $>@Z6N:T.,-IL)^=?]*(QD?W^O3W/T_6NEH CE_P!4
M_P#NFOES]M##?LF_M!!EWC_A6OB,XD(P?]%ZY&",=<YS[U]1R_ZI_P#=-?+7
M[:'_ ":9^T#PC?\ %M/$7#X"G_1?4\>] 'GW_!-]?,_8!_9,"@$'X)^"L=AQ
M9H3UX['ZU]TK]U?H/Y5\.?\ !-U6/[ _[)B($1O^%)>#2%&?*_X\5Z$DMGN!
MGNW'3'W$@(502"0 #CID#GUH @D^^W^Y_2L:;/VW2B>ANIAGW,)_&M>8XD!Z
MXV\'H>W/Y_G6->,4U328NTM[=LI.<YCM2^!VQD<^PP.>@!KP?*)=W'^DN/7N
M3VSV-6V164JRAE/!! (Y]OQK.\]5&"\.#<,.7VY/.>3G)![8_$=:E:XGR=HM
MBO8F5N?_ !V@!'M+>*&.*.",1H=D<84#&00!DDL22<G).<$GGFOQF_X*?^.?
MVQ/!OQ%_9=M_V<F\9V/A34?&:Q:Z_@C2I-3?5?&"W]A%H^B>/\!Q9^ +VUF?
M^T[XK''M Q.-I%?LRTT[J53[.6YZ2DD#!!;&T?=!R,'KCM5".!&FADAN#-)#
MN.\R!9Y8&SOC;=@M")-K;?E7<JMG(Y=VMF_O*4FE9>?XD6F"\FM=/.I0P0ZL
MUA8SZT(/]0FHM:Q+=Q1;BW[H3JX@Y)")N).03L-;KR4RG??G=GKG@YQCMCU[
M566.6!3Q$^2!F23+$ ' +9!8@< L2<9JPKW&W[D('.0&/3//>B[[O[V*[[O[
MV0!8%0Q@$ XW2X(#<C '0Y+8  YXS1<QL4%O^]CWX'FPXW,!P58D%1D<')''
M)X.:D<2LI$,:A1C"[U()!!],X[@@@\D9IFUA\H,V"?-R)NDO3R@<Y$0&6(QG
M..>]%WW?WL+ON_O/Q_\ '_Q*^-US_P %6/A9\-O!'BCXNZ/\'XOAQJNH>.HK
MGPJ]Y\&M1U&,%M/TFSUG:$M]=GSEG+J0\;!6 (%?L.BH01&@QR0   <DG(SD
M$$GU/O65)I,5S<"X27:WF12.4P"9K<[H.5!P(_FYX\S)#YS5Z-YX\CR[8<D<
M3@# /7;@D$]2,_@.E3*\E;FDO1_YW"[[O[V6%7Y< E3GJV"/_'1_/TI0JD@-
MAN1DXQ_@1@=ZKF27^%K4^QE;D>@^7KT]:<&G92=D6,'@29Z9&,G Y]2,#W%"
M5E:[?F]PN^[^\I74P"&8+)*\4C+!;(=C74BC*)S_  [@,E@5/'X_DA^PU\5/
MVYOB'^V#^VMHG[4GPL\1?#;X,:1J?AVU_9X%PEO/X<U#1HX6CO[VSO8R"FH7
M;$22I'DN=S2?-S7ZYFW$K1/-;Q-);[S#(\RDHSC:2%1@I(!X+ @8R.>:>UN2
M49G9S"WF1!KC<%DP5W8)PV%)"J<A03BJN^[^]A=]W]Y:V;<+UQ&J@_W@!R3G
MGKZ^M5O*?NN1W&1R.XZT\2RE@'$(.-JX<=??+>W:D,LQ&T-;J^6!S*05&3M;
M&#T&&(S^50XMN_-);:)JVGR;"[[O[P*@A4CB8,#D,"/DXQN/(/MGH/KC/B7Q
M]U3X@:9\&_BK=?"#35NOBG!X+\0W'@5+RW_M"PN/$]G8'^S8IH=ZY\RX91&N
M5!D"EFP>>G^*GB_5? WPW\?>-M%\.R^+-9\&>&M8\0V/ANUE"7>M+IEG)=_9
M@VX*KS1Q2R1XV[RH &<U^!OA_P#X.%O@[XP^(&I^ _#OPEU^XN)/#O@B7P?X
MA2[6#3?%OC_5;SR/'W@FUF7:DFH?#Z")I-;M$9KB:-9"A&P@-JZM=KS1$80B
M[J*?36_^9]Z?\$D/B!^TG\0OV7CK/[5ND>,-)^*5MXU\1:9J,_C>W:PU*_N+
M*=DN7TK3Y(T:S\,QLJKHJN"SP[G+MD$_J(@(0OY+-,6QAB S(<9? ."H'&?^
M ]17Y2S_ /!9'_@G]:^%O'/BG4/C-:&[^'FM:3X3\4Z+I^G7\VI:AKVHQP^;
M#X5L=L8\00V$TLJ7DUK_ *LP.K$E<'0^"O\ P52^ /QG_:DUK]E[0-2>3Q>W
MAOPYXS^&2V"^???$?PAJU@;C6-9EL9%CFT.'PG+M2_M9099?OIG:<N-XJW,W
MZO\ RL7>VWNKLKV_-_F?J=\YXV)@]2"IQGKWZ^U)Y*#K&&]R3S^&>?3&>:S(
MKIII"5>)\R"W*6[,R[BQ/GL3C!4$K(AY!SG;VT_WZHR>26P'&XN #U&['7'<
M#.<47:VT"[[O[W_F?E'_ ,%?/&/[3OP\_9+?7?V3)O&$'Q1'C708Q<>"],?4
MM673+F^VW1_L\*Q\F5"8G)!94+'HN1]\_L\:CXWU;X%_"75/B4+R#Q]J'@7P
M]-XLBO(5@N/[=.GQO?M=1$?N9Y)LF9201(6]J]9@M\21-+(KE;5(IQ(RD^;$
MV8I65MR[U'*G'WLD5/&DB&0B,2F1BS$S@[=S$$X/"C:1]T#&.,$4[ON_O87?
M=_>,-MM9CNERQ)RAZ'N 3P![+Q08L @S3JN#E1C..^ .Y[8!^AJ=WN% VK$@
MST:7CZ#:,_GQ^.<M$UQC[EN3_>\\9SZX*YX[4@N^[^]C94!*2RQH5BP48[C<
M*25&<9V@,A=6S@C((/!-?S_?MM>./^"@?@#QC^UW/\/_ !%XTU7X:VFA?#2]
M^%K^ _#4FH:[X.L+NXC/B ^'I424:CK%S-$$O=Z2F*) 8U ))_H#DA6Y1C.H
M4,N,Q2Y/H?X1GMZUFV^EQ6K.;2XDCADA*,A7.9 6*.Q8'+ GY=V53J%!S0%W
MW?WG@W[-&K?%+7O@!\)-5^,MBT7Q%U/PEI=]XGMI/,M[L7$L"S64U_$H^35;
MB+RI-7CX$5X\J;4&!7T,49F_?+N7A@H8G86 + '.6 )(Y/(QZ542P2W58XII
M'D\MK@F6X8_O'(WE%)PBRGE@F!V7 P#?62X0!1%:\ =9<<GGH<GO[TFK]6O3
M_AF%WW?WCU0.'41A0HZY!!ZX!'![9Z\?G6?,'<R6EN_DS/'(C23VS20G>I50
M&!"X#$<9Y QFKQFO "!!;<\'%P!C_P =Y_2F/#-,4:5VCC"X>..<A"I!!)QS
MG!/(P"#T'6FKI6YF_5[^MK":3O=)M]7>_P"9_,WXM^)__!0'PNWPK\"^._&'
MQNG^*US^VIX@T&#Q%X4\)01^!(OV?[C6S)I=SXKBA1A=V%IIQCMHG:5-UN$D
ME<2<G^D2TF:/6V\V2W9([.PM;B[$.V2\O_+4CR?F.V$@>8"N5RVP,2!G96RV
M0[)&21,F-5<JX\DAE"CS%9E.QMI965F"+N)QFJ$4$7]MQH%41P60@C10"J%2
M&5UR"#(H.%<DG:3WQAW;W;9,81CK%6N=.Q!QCL0WX>O_ -;K7/Z<RB_OHMLN
M\A2<$&'.2<D@DB3ID'Y1TZYQT! X]QM_#!/Y\5S5D[+J%U(9%B3Y2\:?/O#G
M9$Y RRL\L=R&&X<1K@#YLHHZ8< ?04C(CJR,H*L"&'8@]0<4SS4&.3R ?NL/
MYX_+MWJ3.Y<CG(XS_6@#"NU2W>*5X8)DC3R]@C#3H,JVQ>=P#[<9(VC )K\?
M_@5^PK\=O '_  42^*O[3_B/QIH]_P#"_P :65U>VMSIEWJ*^(/$0O%86'A_
MQ#IT[&SBL] W#[*L<:G"XWDBOV+FL?M&R20&.=2?WL+['VG@#//!Y[ Y Q[I
M#8QB2 D3?Z(&*EW)$SN3\[C@.1U#8SQR2: $B2,.#$LF3,)9&?G.<_=]%7D!
M1Z\"I6P<Y. 3G)],Y]C_ %J\%53D#'THVC&,#\A_A0!6(5R?*:/[I!W*3SU!
MR.G?H/6N)\2V\M_H6MV=G86^LW=SI>K1VMAJ%T]IIE[J8@FM5L+YD*N+%Y2C
M7#JZGR=[H=X%=]L&<\]".PZ_051FLH"50* &,C\XP))#N>3&.68\G.0>01CB
MI<$VWKJ!^7'_  3#_9<^*7[,/@3XQ_\ "Y_"_A#PQ\0/B+\5]9\8/8>!?$VK
M>(O"$6A7\TIT2VT:352\ECLC8?;(T8IYS%F*@#/ZG1Q+LW%07(&YLY!8X+$=
MO?(Z]O2HHK&-4:-G:2,@@(2-J[LEMO'RC=AE PJD?*!5U5"C Z#H/3C&/TH4
M$O/ULR.1>?\ 7R(]C>GZC_&G.=L9)XPHSTSVSC/!;^Z.[8'-24U@",'U7\PP
M(_(T[+LON125E9'YP_\ !23]F7XS_M8_LL>.?@7\"_BI!\(/&?C*2)CXG:*6
M)-9TV%GEDT5I()5DM;R1TB\R<M$H&2&'('U1^SOX!\4_#?X&_"/X>>.=7M=;
M\;^"/ /A_P -^(];M [6^HZGI^GVMM>7&926>6Z>'S'<L=["23D-FO77L[6'
M=LS");QI)$1<K(V3R<ABK9_B0JV.!QQ6G'%&'.%!.5D+D89G"E S=!PIP!@8
M^M%EV7W(9 T2H1N4,?[V2/;H.GKVZXJ.YV-;EDE>W\H@EMI'W2,D$]C]?FSC
M'-:6 3R >!V]<_X5GWF?*?RV;S)T,$<9V>4)&^7<=P[<GDD<<"BR[+[@,6ZE
M1HV$33>4NR6ZU&/,F=OW4C5=WRR'Y9 !DJ" ,\U^3'[7_P"Q3\??C9^VS^R7
M^TE\,/B!I&E^!OA ;NT\:^&M5O=3TZVALKZ2*XN[_1+.(B/4-2N84\J19D?
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MC(484!0N!T RN"0!P.: ,7S-9'W;32&.<X-P#C/4]!S[^]/\_P 0?\^>E?\
M@0:V/LR_\\83]5!_G2^1$.##%D=<+@?I@4 8OFZ]WL=*^JS D'UPQ' [XY]C
M1LUH,CK%I8:,$*0<$AN2NX'( /.!P>N*V&M\ %8(#SSD'ISGHW_UJ8$@S@I
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M&3V#=:J>&TFX93C*M=Q],]\<Y'7CN*Z#REX^9^/]HDGZYS^F*3R?^FLP]@_
M^G% &%)<ZFR@+I,@(&.;H#\<@$\9[>^,YJ$7FI'&=&U-<@D 7MOM4P?ZM1ER
M<7&2/FS@8W_-C'0FW5CDRS^G^M(_EBC[,F<EI"206)898CE2WR\E3@K].<T
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M3PLHNXX8F?E][,0: /N=?B#:R2F-;:<,#.(\8/F>6$ *\8/WV+'/R[>2*?\
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M $J2VN?#OA+1[('5M2MM)FA^U?9HEEBD\]B4C4DD@D, #].8O'T$L)41237
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MMXE^-'BZRFN)H]/\&^!]#BDG2\\02IM6!+V40PZ;;O(9[F>8A$95Y^ O#/\
MP5)\3Z-HO@CQ)\7OA-:>)-(^)?PZ3QCX;U'P'!/]ATGQ;KOB$Z'X'^'&IR&,
M+)K>J0/;W]R1EO()8$ -0!^ZH\?1$EC;OD,%-IAA-NYQM? 0JPP02QY/7&*:
MOQ!MG#G[-)B/89%.=R;B=JD,0"_RG('(Z]QGXG\&^./C6/B/X;\(_$S5/A7;
M6&K>#&\3^,O#>AWB0_$3X8Q7WV>73X=2TURYOK*-2(7U=$\E2'/(C).%\#_V
MG=.^.?QB_:5^'?AW1WTGPQ^S[?Z3X?/C::>/4-/\>ZOK4*W27&G>4!C[%&I4
M^6<;LY! S0!]YCX@0$AUL[M8VG%N^^U9?G&%XR1G). 1][L2*DF\?11O(QL[
MI+>'&YC$SL<@CCRPW .,AN1]:^7_ !;\9_AKX,\?:-\,O'?B=-,\>>*M!_X2
M/PSX:F+)9OI\23M=>)+NYRL?V;3X[?=)")%8,%1N>O+6O[47P%@U"[LSXWNY
MK^QN!:0Q2VD]JGCV>YM7O;@>%DD#?:K73D@<330[T^5E) P: /L[_A.845]U
MO*2([=LAE?'F*2"=I)&X*V<C)8;>O6$>/;=D,RH_E@6Q)>2W0X<,&&TR%\DX
MXVYSUP*^'9_VNOV8;+7_  KX=;XGFUU7Q/ NM:5!::?+=V]]833/:*VJW*[H
M["QL;K]S+<SM BRMM:3 Q7?>"OC/\+_B?KGB3POX,U:/Q)XJ\!MI=WXM\.6]
MD$T][?408[*72M<&+2[5F82;4D=O,^0DGJ ?49^(,!$P-O<VYMH@\JRQ!VY)
M(<X.=K*5(P, >QX1_'\'DM<?8KT1AT$**8(VEA= R3C=(2(RW!)'HN<G-?F3
M\<OVQE^$OC_QUX'\.:%8^)K#X+:-X;U+XQ^*M=N#;S75YXVU&.TT;P/X8._9
M)KEI%*"8T4,4C<AC7OW[0OQ9B^$_P$\6?&GPO;:7XFU?PYH&AKHVAS:E:E[C
M4]=NK1;?0U2S:7.I0K=*?)?,BF/=(#S0!]>2>-[=VC1$E61XOM#(&&X&URUQ
M;..=KE2F[(^4=>^*\WQ%L4B\PQ75ON( O&6&2S9L@>7@29,H&!M7!'WB,"OE
M3PI\5[.;XBZ%\)O$FGVMMX_N?A-I?Q8N;.*Z</IAU*VM(=2L6&U3=M)<W;-*
M3&K%HG50JH,T?BY\:-*^#^I> HM272[!/%VJ7=]KMO*@NHM!^'^A6$CZGXC2
M!^2[2([$C<ZE.5/- 'V'_P )]:'*BTN'9Y-J #YL$*HQP  SAF4Y(P1]:9_P
ML"S81 0RB>6%B57B(,N><L 6(Z  \]*^(?#7[7O[-WBE?$;>&/B8-;E\*1:;
M>W*RV<WF^(K+6(FO-)G\)VOE+-/=26^1=^0C+'L!7 .!1TW]LS]EW4O$:>#[
M;XF7RZK=Z<UY>37^BRZ5:>%[*#]]$NN7EQ'_ *#/J<G^AQK,8&\QEPN30!]V
M1_$&S>-W$<A6 ?OG8@"4CJ+8\!G'1NJ@\=C3#X_AWLBV^HM(NTF,VL!X90ZY
M*RYP5/)&<<@C(X^.+?\ :?\ @'=:/=26WCD/;Z#>:I;W^FK9O)JNA?8"][<7
M^H1 ;=3T--/)F2]0B+SCY.0S#+=%_:8^ /B'4CH^D?$A;G4+?1X/%<5\;9K.
MS_X1K54+1W>M1SI&NE^20$LL[V;<P^=L4 ?9(^(-N6;;!(9$#!D&?(PG+-OQ
MPW.'P2 <#.>:^;/VN_%R:Y^R5^T-):66I2QQ?"[7I6CDM84E9G&UP '!("\@
M '<C!AD&O*M:_;!_9ZT_P3XW\5Z-XWGOI_"&DZD9/#4-E+/>:CK.F1->6-Y;
M.45XM'NYU$$ES(%B<.=I'!KA_&WC'QO\3?\ @GG\5?B7\0K33M \5>-_V?/%
M'B.;PWHL8DCLM/666;2-7=$**%GLE2,P@ABO0%@2 #7_ &!#>2?L!?L?R>'[
MZ_BU+4/V?/#,6G:M#;+=PVOVG2[JW-PUA*(YHWA^TQ7$;[ _F0J &YQM_!']
ME'PK\,/@)XL^ >K74?Q#;QY;^.(/B5XUBL[:P\9^(H_B/<7$$TK:A<J)89+=
M;AH)(%;;*$3[YSBC^P*]E_PP7^R-K6J7WD6>F?L]Z/KM[YUP8Y'T?1=*>ZDA
M+Q[6CB4P9=DQB-2#QFOS)\7_ +:GQJ\;-\$_'FJZ3I7VS1_%'Q*^,&CZ)X1U
M:;2=+O?@KX1UJ30/"Z^,]2C @EU'5]=\L6VGS,KO'^]5=N30!]MZ7^PK?^'[
M#X)Z!?\ QOMO$7A+]E.+7W^!&GWV@[KK0]:U&RDTO2+SQ3$CHNLW/AY+R6.R
MD7B!;=)642(17=>$OV-=)\#?M'^"/VASXUGN_%'A_P"%NN^#]:R)[ZR^(>J^
M*;B)Y?&\P5U6*6WO]]K(JK&!9@97*Y/@6E_\%(O%=[:ZYXVO_@3HMG\(=)\5
M^&/A]:>+].U,7K^*/B?\0(([G3/#6A0E/DMM'NYV;Q+<2(8%5&\IXAMJ>_\
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M-Y=X;9<%9IT96*;F.3S^./B?]LSQK:_M,CXO75AH=Y\+O@GX:\)_#OQGX?\
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MBS3OAK9?"OP)I7AYH_MR+?QPZ0WC"ZNH6"Z=I36[7-V%1<RDM,<YX_+/Q_\
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M/>I9YB+219([@--:0)*87B,3P0/B%&@5 I\M3M!P&Z,V2,T ?(7C?]D#X?\
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M_92\9ZG8VUG-XZTF:[U&P82/X8N9)5NK[3)=:LH[NW$!%@&T:+[9.!A5:2-
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M>(VS:@$;='!;S1G=L:0G*R]"P)&X[AS7RM=?M>_"*UO(M,DLOB%<ZAK$_E>
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MKXQ_8L^/'BO1($L-*USX)ZYJ.E+?B6TNY+:*T?9+=PJ$:&X;H8F"D*22,GD
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MJ#67PU3X;:/XN19K;QEX;\)V-N+737L)H&5(F2$;I9!'YLK%BS8D*GVI3,)
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MRQ1^)](\,:!(AT?Q+X6OU7RXM0M)XK>Y6)=N\F4,!Q7,? ;]FJ[\(1:;XO\
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M",/EV@$4 ?+VA?L7_"#PCXK\!^,- U'Q"GB#X<^.M0\=2C>C_P#"676KZ?\
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MG@BXAOK30M0CD#?:;.;4RD0#DH\"!PI7%>[,\\IC83_O2 AMY5417P9\/M*
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53C-%%&*I*+M&4DHQ4NFK??3[@/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>img_004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %+ G # 2(  A$! Q$!_\0
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M$GF(5#*2RD#!"M_AGM[T$33:5E?7]"6+Y1@\$_XGT^M0WMS#:PB2<D(TL,0
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ME9D,>N3WD7F%FN<D.Q<MGI!1^4GBG_@NC^V+\0/V/?A5\5?AC\,=(T#7]?\
M&VL_#_XF>/HX(=1B\*7GA:;R[F[33H&:=;?5)$!RT2K!'*6D,;J%;T3XS_\
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M-]Y,9+C*^HR.M.CO()) WFA0VZ- 5?=O5B"00F#Q@XSTYI1G6DKQI2:[J/\
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M\Q<25O\ G[?SYW^2?];;']3<7_!W+^WHA*R_";P(RE0 3"3M=2WFON*<8!C
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M:F>TJ,G"\6[W=[:>EVV^ODFG:^[]Z&62G%2LE>SLUKT?\KZ?TCZTB_X+I_\
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M3[U*%L!V))SE3_>Y(ZT\_P#!?'_@JQ$=LW[05P3(T2H/L<)&Z-$C4CY2 FT
MR9'/8CI7Y(P6L4L0VQJH4C:$GG# #KPV%]CGD=!S4C;(!M*E P96)E\W*\'
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M*0,#CG)],'G%5[O4I%DECM;FZ9$7:"N%MP<@#:WWF8].O.<\TG3@]XJ7KO\
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M@C&P9_ESP,_AFN5OF@A"(J<LJX (Y!'!)[9&.#@CT'?M-3M&=90CJ%CYWNP
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M%I)96(9F*J<L=N 0>1D9'I7K1K\L=;*UDDTU)W_!VZZI^1RQC+F2DK)Z:?\
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M5. ,G.0<=<8/(R,?7UK0MFS[ G!YX/W?I4UPJB/+*LA).P-@J,\*N,\#D#C
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M;)<H/+GW*VUW.1DQ[FX' KWBPT*WU34IYKR4RR:;(ZPVY4F&Y!)"([8*%T&
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M^S(;P.UU;I("1( S!>I!;:N$8'&..."1W@N=-28C^R[4P/*KB0%3$A&TD#!
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MX?$?PX^-'Q"FNM UF[MK'0=4:."_M4E>%;BV1@_[TJP#JI4'#;ESQP>GTEX
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M[W/8JXZG5I)KE2C'E7+HG^.YV,_A'5+.QFN?#[E]0".Z_90DBLZ$_,=_S$X
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MSD)C@9(KU)S;IQA96I[=_G]_0XXR<(N*V=[OK\ON-R:SBVQ3*^4>;S48#);
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M,1!!\/+Z17MAYK!%\H(9-P(.6(W>W(K]2F<RQ!8+4/O94:,CR!&"3F3+!L@
M#H/FZ9Q@'\KO^"V'FM_P2[_:WBE5;6,_#K4HI0KART$<L10AL+RQ5,\=%P,9
M 'P6"7)C\+-;ITTKO2W,OGL]-NB/>Q\$\.XN_OIM[:?Y:K=[>>Y_CVVTTDD
M8_NQ-M8A3P/WDY&"/0X'KVZYK!UF^%NNU/D:3*L_<@#C P.A)/7/' ZFMFQD
M22RA977:=J[BP49\RX+=3QM&3WR/KQSNJ1V]PMS+)O9+4;E90=K G&0P]>,
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M:>(IPE*+4?=T>W;U\_4\GT^Z?6H=5.E1SVL:7R231W BBD94E1F4HP4D8!R
M0,=^#7L]KK5EKT%CIYMX$-G&2TS<)E(\>6<_*RE@<*#UP>U?/.K6.J:?>7EU
M+,M[#+*96LK2)H9B5&^W4RQ@%@R ^>3D%AASN//8?#C6M3N1-)JM@EI93.R6
M\$JX$+9(1PK@ 9P-S@#C.>M6Y/K*WJTCAE%58RJP2BHJ_+'2][+:[[W/5/ML
M++(EVAB"E1'&HR2DAV;58 ]0GR\97D]#45IJ]Q/$MHD++#,-V2N"F#P'SP6
MQD^U9,]R5CN87'F7:.Y1Q\T1 !,;1N,KQG@J>#C!YHT6XN[>PFN)@+JY9L"
M'E58\AAR3]2#GG)R*7M*,-:LK1>B::>N^MGM;Y7..K?W4K_%KZ6.AOK6=V2
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M *N>ASD>P_K5^\MUC.3,BXP%5MC#'/()S@ #@#W]1G):XVW/W@1]G49R%SD
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M&U[+F:Z[6O;?6[MH4_%7CRSTC2KE9G:TMG0I"MVZM<3S;MN^%B=XB<DX49
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M7"OYH 8.DD:H5! )VAE..<#)K^6W_@Y%O)E_9U^%^GZ==O%;77B]8FA\B:+
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M.QP=K,S'OTQD9["N:>\OG^1[F%I4^9\SM+JM=_DO3KOW,".^&I7 L[R=E",
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M]_+2]_N^>/>1SB4).Y!&-V2#U[]#_AZU6:T+3!ED) 0YX [ ].G\_K4TPDN
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M35^^ZT27Z]CZZ\#Z>=.T^.W5VGDG8-CY(V0N0(Y-^#M:-@'QC/RXY)K\Y/\
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M>OF6^C%]% T4P1X,(J<@;#U4KT)SW/3KFOIW]OIX[K]N']IB]AS'#+\2=1*
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MM/&8DN RL'Y W+G/4Y(//],&LK2YHR;0OL<[$^8$,<LH8;NX^7O@@'CZ</\
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MM([@3R,X.4()4)\Q4JW?*H$SQQD>E<[XFU18=#US5)F=+?2/"FH-+<2 X"+
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M_422;=3])7^^Q^<^(LU/"PIP^*,&H=>J;OOLM;V1\M)YHC#!H\#:/D/&6.0
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M?*KKYV3[KT-ZU":J1;?,KZIMV>^ZW^X]UM/%MOI^H6NF(N\-*K-(RR>6@9B
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MEV,5 X+E&8 9XZCFOZY_A1<W%K96LO[MAY7D#YAYD"2[&DCA1\D(&X$GWMO
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M>:_!G_@HYHMQX/\ &/PL^+VCH4_L35H;77+BY0+ L,K+N9I%Z1NQ)"/Q@X(
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M93-)YV9-GF%<,IV$@,"3C!Z8P#GD?V>_ 34KW[=()3';"[*_9[1(8_-D9@K
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MF?89?AJGL9\\;1Y?>=[VU7;SLCW[QAX5N[B<ZEIP+0^8CSZ?9N=DL9?YV<C
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M\S4;:Z:+\+O;U/S;,+.<+-->U7R][_(Y[Q9(\D1:9B<'_4PXR-HP-B#@#('
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MCW_#V^7]VH<MO>,8(/ W#//4?>!QU_,\'_O$_P#KY'\#Z-.ZO:U[NVGW7/\
M&>M;?S+&1UD;Y3N"J,'+,ZM[G(1,CH ,C&2:A>!%5%42AFC!;*_*"2 2V3@#
MJ.,?X7K%-ML<),09A%NCSNVH\[<'[O;#>P([\0W8#.P5[A<JW#D,K8!PIQ@
M#OG\.]?:37LL*F_>]I&]M5:R?WW"G44:D;QNDWUWT:_7\#ZP_8NL))/C7X=N
M/,:.'3V6YDU&!AFV3(!B:,?>9CM^\#@-Q[?U]? R^F^RZ*)GEDE!EN!?MF-Y
M8?E\L.G"D,F,JP)'!Q7\EG["82T^(MY?N JP:8CW!^\$CWCRY@#\I<.3O'^[
M["OZJO@E=R:II>E3O>LT\4<#W$\Z^23;;$=$CC& V1T8#![YK\@X@G>O4C;X
MI-7OM;5GZ%P_'EIJ._/?Y+6Q^LWP_NS.L6&(41JV 2N-J@]@"!GZCC)KZ5TB
MT6ZLT1;N17WQ>:%ZB:-C(68]1F-E 4';QD#K7R#\.M5=;>$P1H\,D&T2&)DE
M8R*44+D\DDX^O08Z_67A+>EG-("F2)GQ(^TDM$B+MR?F8NI4=#E<#'2L<IE%
MN$6[<ONM][:II+U>GWG'FF%4:U3FDI.3;O9JRVMJW?:_SL=8ED[RSNEW<,"S
MA3CU501_A^@%<%XNT4)I$MNJ"9;J^:656)_>%X"KEB>A*J 3G&<G&>:]2LKA
MW1+<QA;AT&P ?? 49P.I(();^[QSG&.&\7^8+>0*&>>"1ML2GYY'8E3A>IQG
MG(..I[U]UAJ=*IK-QFNBMTLM-_+<\AT(PPE27M$KRYDN5Z;66^NJ1_'%_P %
MWC=:5>?#VXAMV@%AJ2R07$4H,D)MI5D@*%3NR';;NS_%W KW/]C;XEQ^-OA+
MX5UZ-HXV&G6FCWEJ).7U1X$6Y:9<\S6FW8TF [G&YB17DW_!?VR?3M(\"QS*
MBSW-XMUL9BUR,RRD?.I^ZK %AT(7 '&:^0/^"8?Q&NHO"NN>%+J9I[FSUY;N
MQAF.U ^H1BTE7)))(1C(N.0R%N",UX>>X2"BIT4H<\6TK7:NM=5:^WEOV/3R
M;'5'/EE=J#BWKOK9+6]OS_ _H\\*W]L#&D]PURT&R>&V4[DDV(0<\_-N(*LI
M)'3(KZC\%WMO?6<$MJ-A=6)MI3M6VD\P/'$I!X$41\L#.".2,\CX9\!Z]I\:
MV-X[DK:(=,W18D8WL.Z&2-1_&<*KC/+9)ZYKZA\(ZI=W]G')8-;JZK)<QM"C
M1SRV\&8=\X)PTK*<N0.6/&#7R& <X<T92LN;1]W=Z+Y>>Y];C'[7E>UH>NZ2
M/LCP[-$IAC$4!D,NY,MC$A.<NWWECP?G88VJ.,=1]%>&K]GBC>1"[?.L4D@!
MD1!M!$O'RL6R(UQAH0CG)8FODCP5K$:36JW4+2H]NIR@SN*_>//7YL!CTZ@G
MM7T_X<U 74;.'00L6#0@XE^5<9"^N.,]<8&<  ?9Y=4C)I.:;;W^2W7]:'R6
M80Y5-WZ>G?\ R/H/2/LD5FDDMPXEFV#( 8\'"_>)X&>,' YYY-=[:!!&N)LK
MO7[P7)4XY/J6'7\NIKS;PM9?:;:-UD5H@5PCMND7:1NX))& >?SKUZSMX(H6
M81^8<G!VY0X&1QSE<XX';OWKZ3V=X_%T?3RMW/FJM3VFEK65M7?R['R'^T5H
M\^J:048JJ)(S%PH7S+<,& RO0+UW @G&,D5^>^CWGV'49TBD-U:QR%2<@A&!
MVGD>NW&">,'IUK]5?CY#$/#LDS1VY$EE(CK&&5AOX;&2-I4$DXZ<\5^5$%B?
MMM[-;IY-LM]Y2#IN*<D\8SUR#WY^M?*YE#V;:O>UM4K=NYZF 5H<GKKZ7?Y>
M9]?^$[FV;^S)R[HMQ$&EACX1F ^\0I W-QN^G/K7O%A%8R[3&9DWQAF"%@<L
MNYL8)/T ^F*^9/!SRPQ6CEE#; $9LX&"O !)QGG..M?2&A-*]O;3M)$6W%7'
M &> <X/3D\ 9(S3P7;NK?BNGS.7'1Y9)WO>3_);_ ''H>CRSI'!!; [&A<A[
MDE>58@%@QQR,J!ZD=373NCR2_O?+,ZS>0SE1Y8CV*0N,8 R3\_WNV<<#&L[C
MS(_*8VN8HR,(,.3("$QGNS$ #G/;GIM0'<96&QPLVT[FX'R $?4'KZ?K7?4H
MV:O%2O%.^JWOIYG %Q9R,& 2VF56*HT;?+A1]SC )'<')]>:XW5H+L7")O/D
M@',*<*4/WX\CDIL) SG&>,<5WQC\GYD>)TE 8VL)'VAY"?E*,."!CY@,$=\D
M5C:WI\DR09N"EU=(I>V./.2-0!O*J =N25+C:#C/<&N6K^[L[;O9=-;6U]?T
M.[!5I4YM;I].UUYW_IGDEWI\6JZF)56.%[9QL$:>6RJJA=H*8.W;P5YSRS#<
M2:U]<D!AE5D'F06)*R$ L?ER"#CAAMR& R.N:OR6DFCSXF4S^:08VC7=LR,?
M.>?49SR.W!Q7*ZW=2RV-W?1*6FE9K*=3G:+48WRKQQ+&NYDQRV6[#%>7BYZM
M6Z/KV3/4ISC4G&*BTV][WVUV_P""?S0?\%?_ !.;OX@?L]V$,D<5S#XI@GDG
MCBS=L([Z-1YDB89@%SM+'W/2O?/# U)+F&]MDECADM(9OD!%U)&"D7F#^+#,
M=Y8\GN?7YN_X*CVL6H_M:_ 7PZ/GM+<PW5LN,R2R-?+)F1.GF. #M(!V@5]8
MZ#E+K3K0W5S#.(8?]((3]W&57$13J8DZ$=2.>M?->QOBE+FTE-:6?1W[_P!=
M#] RZ?\ L<H6_P"72U]/^'/MSP)<(H8173B&*6-/*G)W(\*1/L9C\[$L2"&)
MSGH:^K_"%],\37151+)(D5O''@;F&<L0H"M@ 8SD9)-?'W@X1AK:=3'/-=R1
M2R%XVCW&*,(S+GCG;GU8=>0:^K/!?E;#<QM(ERMP%C60$1Q.21D 8&'4NF?4
M@=Q7V&!E[-1CO>SOMNEZ_P#!/E\='DJS=T];V6G?\K'ML_[^1)S#*SB**40C
M<44$ XQG:<X).1U//!S7G7C)[:X0HL06W>#=/,Q+2B_23>(E5B1&FT&%@FT$
M<D$UZ ]Z8WD6%V3-N%8'YC''&N;9&)R0]G.6ENQU6)UWY4UYKXOO8X)HV^1E
MG98&M1&S,_FV^QK@$?\ +4EBX(S\Q!SWK'&T>:NJW,ET<6K];7O_ , K+'><
MWM=-KRNCY^_LZ"XE#M \T]]/>P-;I(^]%$4HC?EL,3G:NX$X^4<<5_"=^V+X
M%O/ W[5/QGT6_P!.N-)AN]?O[VPL[ACN87%P[&8+G*B0N#C@-GUK^^B/3[K^
MSQJ2V[17&FW96&0 QW$PE8K"L:D?O'QG(P2>O'&?Y5?^"X'P5A\,?%_PO\;M
M%=K?1O%EG;6D<]QC)G$3+?+='C:\<TF5W\_-["OV[P/QL(9I5P\*J4HU&N6Z
MM+W6W;72RN_Z1^<>(^7^WH\Z7.U!M2MYOST['X>,TL0A@194%G(IVJ6*B1<?
M-DY.3TP>,8R,YI'8N[OCYI'+$'@DDYP2.1SUQC)ZUJ6L<;G79IKV.*#3DM_D
ME0E[KSXU,4L'=T)Q@KG/!] <>/D29. 0V3@\=.<=?PZU_>.$]C7HTTFG.-.+
MEI?LEJM-[G\NUZ4J56I&:<4JDK;J[;OM]QH6IL#.T=Y<R6MHT,AD981-=AO+
M_A@(("%CA'P..<UTWAZUDN-;\**8WL;26-3;WL,LK3SQAY )I&5LV\C  &/A
M.3M& <U])N--@N9Y[$R/="S:.%KF(27RW(B.];2Z(,%O$1G<;A7*QGY??.TY
M7&IZ:);;;*K%IO+-T-TSN699HDGA!E'4R1CRI,_(HP=VLJ5.+L[=^NWW,3C#
MV+]^WQ:/ORK;5/JK/KJK;'QWXUN1;^*-?B\TNIE+(% QVX9LC&>   >2.@YK
M O7BE:SD5\M]B=Y%3EXP <+(. &/89/;D<UJ>();:X\1ZW.\4NT,2=P   (.
M[J>%ZGU _"L5EB,UI.$:..6;8\W\%U%A@WE#KM! # GK7^?6+Q<)O&58M<D:
M4G+J[76VO=K_ (?0_J&A!>VI\M[\R2ZZNZV^?X'Z7_\ !+7P==ZK\9-2\2_9
MI9;30-$N9HYGC8PB>Y0^6!(1Y8.$.X,RD<'D<C^ISX,W5U>/;-<M)!&]I'/%
M'$B['<L1DO"S("O\6\J>>W6OPE_X)3>&%TSX<>-?$=VK6R:O>16&GW$K#R?L
MZ"1@6AZNS%BK$G&T =017[:?!K6/+CL8/M$)B@GFM&FM4^SV;+*/E:96_P!8
M8R>.Q.03Q7\7^)^8^TS&M3IR3M6=[QOI:2OOOJ?T;P1@X4L)1;C\23>O6Z>B
MMM_G;;?]@_A3.[:=:('C N%C5&F8H6(D5B.%8#A2.,\_I]:6+F8S,T6V5"J(
MS# ;"CYE/)V'GG'?M7Q3\(Y;M+.QGGFMKRV0<+;R;C$X!P!\NXY./?\ #D_:
M>C7HN5L'"\/ XEQQLDV$(O(YR=OOGH#BOC,MG#V=+VE[N*2L[*WIKU9ZN:4Y
M3J5'%))-K1>;96UVW>XLI(7""6X*VX56)!+$G?\ =XCQU;!((/%?FO\ M5>"
MI7TB:ZMH9&8JUN^U'( 4].%_B()0#J2.F:_4PVLUS;0S_8A+);AK:X42J'B$
MKN5GVOC)56!YZDGKC(^4OCWX3N]=T>:2&"WMHXW\V<MYLJRI9Y^=1$?^6X'[
MP@ *0=N>17=.IRX^A4A;W;*+:OH[?YG%AZD:.%K+535[W=U=I].GI_D?YT7[
M4A@\&?M5Z^7CE$-MK<]TZ*DV$DNK@&+S#M4+L)!E/\/\.['/]!?P@U70_%_@
MOPEJ$4?G++I$!2X65HT2ZD@@0L[<MA'0DKAB5 XYK\"_^"@6F77AS]K?QS9(
M\=O.^K7&H)(_G2J+>=_W<>R;,95%RR@\@#/4"OU@_9"\=2:E\,/!^F,\>VT
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M0T8^78&R23QG /<BOU6\IO(82!9\2%E65,J,XQQ_LYXR/Q.37Y5_\%Q,Q_\
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M#."<DD=./NKX$>,8-#\9OX7USS[A(]2#K#_$L;.2 _F HQ"D<XSTYZU\J?\
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MG+J=_;R2K>HYEA^Q@-(D8<*!$ <D#OD\YXO^/?$D0T#5[- \-KIEI?WDEU<
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MK-UI5G;E'D$<I+IM5O+(;*YX#<=L9 [BOT?^.%T)KN!HYXIGL \:(A#-*I7
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M)VLWMMI9]O0\J68JE)T^5RY-+]_ZN?B_^T?X+M_$-V;Z>V>/5HY2VV#Y/FW
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ME@CQ?)L=VVC[P+5\Y6$GV2T:!8-N\+O2=SM90 2H/"8(."0,,/O*03G]&_\
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M7]K4O( Q^']T3M'1<QY4$@8Y[D<>U?JU<23VS;O(CFC!7!5\2Q*QP2P;C8,
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M\C@;B3C]4+ZWTC[,[7)B^Q1QG+;WR)D0LTGIM5B@4'D@D$GO^,'[;VLV^O\
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M,0)'!R<Y[# KUI/AM<:DDFKW:R0?91Y*V@C($Z@<70S_  9Z$G=D<@=\[4O
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MI8B-/EOS;RO:V[VL[V7FC^E;P BV\,T5[$UJ"C0B\;/$9&<'!Q\^ !P#D@Y
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MT?SR9#>DQ;R;:!7&, C;&?XL%FP 2>XSQDUW]F!8O;QM-'(Z@!F!XS_=Z8R
M><9QWKMPJJ1FDD[7;>]NG]?<<U6O"I%Q7NW\[_G8]FTG3OLT:/#<()R2?+;
M)S@J3_O<\^GN*[>Q6XP#=(,@#8QZ8"C&#G[F>ASZX]O*M(U>1;F)TPV"%X&<
M;<\#GC&<>F.F>:]2BU WD:O,0BJ%&20HZ#/&<\$D8Q[<Y%?44JLU3IITT[12
MO>WSM8\:I\<^OO/4V+<RF8+-()$D;9&JG+*7R!C!YP3R3G@'FJNHQM*LPWW
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M]+]U7G&"3G-W2BG:^CTLF^EWHGM\SC4:-.I'$3C-*FU)M3LETU2;T=S\D/\
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M'O=<$N!\VS&22".Q/7%<1XTN#;VL-K;M\\MM,L?G"2$".1&P"0K;I%<,2!M
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MWWZ'WC_P3FUF'0OC[86D\TMF-0:W6*>!HUFFC$APD/F-]X,"S'!4J2,\'/\
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M%&27+%\SLE9/X5LM.O9'RK^TIX3/B_5M ^'VCS^;-XMNI[?58\\M$$)D<KR
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M.?\ P5'_ &KOV=GT?0[?Q'-XNTFRDC(74[F6>7[,FP-!$+B0GSO)C52>5R<
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M!.,'@\=N<XXZ?$WPVUZ'Q'X7T77--GF\R^TZSGF3?$0EWGRIH9-J@AD8,O)
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M^BDFE;ND]+>BL[7/A#]N7Q5%/\3?AGX1NIE&D17BW=Q8LC22:AY94A;<9PP
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M5C6NHK:0++<I>/:G]U%*OSF;C[^.JE<@Y(QR<=Z_L:_;L_8"TC]KOPM/XY\
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M]@,G"Y&:_,[XH?\ !Q5^U+K]K+I7PX\,>&_!>GW2R&YFDBB-]&[# :W9#E4
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MJ J]^ >E;>E"9K^QNM/CC>X"E"EXJO9LZ@!_,C/#Y/L>>1QBN,TR_N-MS:2
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M55(RC,NQ?)1L#:1W))[G)]:ZL?6EAIX:</B<8Z^O_#'G9I0AR/TOMY?(S/\
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MS"ZA.F7@,?E^:Y8#RL@'?LV]5((:N5U9;N]<M'8:M^[+%5_LRZ)8YQR&BQC
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M3>%+*6U5<#Y1!(&CP.PVX%+^V,1W?W_\$YZF7TN;5)Z7T;6BNVM%;T9_C/\
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M%+OV?;<K&8B<N9>J?W'\^.@7]Q!/)#J$$RP3W#2M/''<QE04PB$(O#,W&0,
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I@U],O'=^S]E+)ZO+J],0GJ[7WDO\SS99#A:E-MI73MU[7[/_ ()__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>img_005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %C D # 2(  A$! Q$!_\0
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MK6K7RQPZ7<KM9QDA7!+$$,"",+@#&<@T >CQ?L6_L]PDQ6WA46Y))/H<G/'
M('IG%+/^QG^S[=#[/<>%_M(''MZ=<>G%>B_"[XX>"OBT]_-X.N=\5JJDWG#"
M[/7RQVX/''<9Z<5ZW9>=&MS>S7 N JG"@'"@<;1@=N^/RH ^71^PS^SG@?\
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MD^#H5*2^=@M\P+'<0>.#V]J^MCYA)QTR<?>Z=OTJNMO-YLLWG8\Q"@7!^7'
M//<8^O>@#Y0;]B7]GH--+_PA\ -P[*,-_>)'I^1^G<U2'[#_ .SK /(/@\9.
M1QT_#(Z"OKV.S98T5KB;<J@'##&0.<?+T]*26$A<>?<<#'!ST_ ?C@<_R /D
MH?L-?LYNJH?!4)P,$LW)V]SQW_KCCFGK^P_^SO$CQ0^#;>!FR"V?O'/!S^1_
M^M7U@L,V!B<XP,;C@X[9YZ^M.6([7S/SDYZ=<GW]>GZ\5/UG%K1-V6BTZ+1
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M_8E_9RB$BGP#;X?/\7X<]?\ ./6OK!HCD_Z1,OLN !]!M/'XFFM!YFP^?/\
M)QQ_%R#S\H^F>XH^LXO^D@^L/O\ C_P6?)S?L2?LZ+$%_P"$"MSA@,9P<'D=
MCZ^Y[8-/D_8B_9S9)/\ B@[<993C=V"@?W?;!/'3D=Z^L?(RSMYK_,3QCD<
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M#KGV_P *E$)!9_./WCSCISG'4=/:@#Y'_P"&(/V=)8''_"$1<J%_>-\W&2.
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M==U]Z_S [VBO.M4\<>$-&U%/#FH>*M)TW5;F54M;"XO5_M"\=U&U%4_,"2&
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M5R#RN%(P,\=#].M?'OB7_@A+^PO8:Y-J7A;P-!I+WL"PFSD:64G:,#Y\KN/
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M?V9/AQ\4O#NE^)SXQ\6>.]+GL[6;4SE;:65& GE)RKY8[CN!P"<$#%?E^O\
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M.=P[\Y&"._K@8TH%*PQJS;RJ %O7 _PXJD\32+-;R(3OMP1(O!P  5!Y(()
MZY.,U>A0)%$@! 6-% )R>% Y/<^I[FNA;+T7Y")****8!1110 4444 %%%%
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MQ)%?F7X8_P""A]IK/P_^+'C.7P;+J4_P[NY[>QM]-7SK6YNA&ZJLDV#C+KP
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M>_ TD>GP?:L21^<),2&,/,02.XW,3QT/;BOJ(ILE/.=Q9^@&,YXX] .O4FJ
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M,^\@!@'/W\\,.N,Y_(5$(HM76>&[CN$;2YHI/M,,CI'=F/JB[6 8%E( QP"
M*P-SX_\ V+OV<?$'[./P@70?%URFH^+-4N%NM5DM\!#>3JLEX?DX<?:&E*%L
M\8QUK[=CM]EO!*20RA"1@=P!@]<]QU'TJK-=V\!CO'>?RG14%J4+," !\H/.
M1]T\YXR#DU-:2&X/GPW,JP<G[+<1A."<A06&<+T]^.: -:.59.%XQ].GM^&,
MCMTJ6JEN4)?;"\1W-RW0G)&1Z ]ABK0Z#G/ Y]??CUH 6BBB@ HHHH ****
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MQ!XC\96OB(Z4OAK0@+8)"MP8FO[B&;$\L=H5(G,8*.RDKP!GIOV+/V0/C/\
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M^W&>>F*@DD=G8K<^6">$V?=X Q_7\: -.BLG$QY%ZW/HN*F"W#JJK=(3R"2
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M!R/F;=NQP.N> *DM+>2)"LK!B2Q('W>6)Z<@\'D]SS0VI:O6^NNOYC+,:(J
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M6U8DBW'G%SY.TX\L8C(^\N,U^AB@,RI!B(0##AN%*XY! R",^OZ4PV91_,C
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M3@Y) SCTXQ1[:,=---/ZU'2]YN[W;VOIOW_K0NF5(UW.Q 8X')/8=.>_J/\
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MYENDF@,<"/'.,7>7SL&!]W/7'3N#C J668Q,(8N6QG&<D>WMQV]*S4U&*"&
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M>:TZI&T$BB2-98B3YBQLI4'+G# =A@G&1(FE6EK:V\Q5DN8U@7> %D #'@.
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MI* W++@*&SPI&#T((S7R]XW_ ."I6J>!=0;PCK_PXNM0\51-]IM[VU@+VT<
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M65K?A;0/UW\_7O\ ,[-@ 20 "W#8 &X +@'U R>#QR:MHJJJJJJ% &   !]
M!BO%-3^.WPSTCQ0G@O5_$VE:?XIN;:&[L-&O[V"SN+K>TB2V\.74RR0^22R8
M8\\BO5=/U5-1MOM=J$GMI(P\4D4H(Y'^KW#[Q!Y++U#"MH*$8I0MRI:6[?\
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MX-_ WX:?!/P_:Z/\-?#4%C::>BVMQ<7=I"=2N)(RP-T;HQ^;(\C%FW%CA2
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MRY4VWKI?3=KN;86CBL14Y>5W<FDDKW?1+E6JZ]/P/Y+?@3XTUCXB?MQ?M/\
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M\A0^2 ,9([#=CGIC'?%16RR*K&0[B"Q')('/\\=_\:J0W%VY+"T#9RI8N 2
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M*SM%<JVMNDCQ)-MMO=[E<H0/+90R'YCD C/3'?I@>_/I2JJK( @##;TR..O
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M0,(JI@8[$XXSUXKH8;**%0 YWX =V(+OCNQ.<^OIZ4];6)':1&VR. &=2 6
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MM1_9@O/CEK/A[QYHFEZK9R>&_#5UX;NK:1IU3[?*SJ)"A&PR!LX<KO&,YXH
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M]=?DU;_A[9GA#PGX?\":-9>%?">DV>EZ5:6ZC9;QQ1L!'PK-)$J^:Y49W'.
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M,FDU]K?5;WU>G7<]BB^RH@^S'<6W?,V2"<G/).3SD?ACFN;\1ZUHV@6<VO\
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M6&#G  R.,5^/,_QE_;Y^/5S-#\/O"@\!:3<.ZQ2ZQ!);L(9"6B,@9.'",N\
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M-M4@BDO=>OEBN+Y#+&OF(B3;_*  P0%W$KD8%?84&G;'22&X:V*A"0OR!CM
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M FQ#U4&JTA7SEA"X!4/GMNRV/KC /;M5MB0"1_GFLTM*9U_?*B[<?-U[G_\
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M!^55+H2">H4@XK6C0EB=(<WG;=)Z=^G7MO?<TI4L16=L-355Z75KKK;H_/\
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M!SG\^E9TC)'?0K>7%^]Q,H98UB=X(W.,*'08VC@Y'&3SR*NVB3UMIKKY:?\
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MK(BHXSLVH %P& . #V/:OTVM[>&Y93-;P+Y2")HO+0K\@"$1@J=BC;A2F.
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MWO AA)9C&A.X\E1FGF*,[LQH=V-WRCG'2M8ZQ5]=.H'A$GQ$\<&%)4\)3$L
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MB !HE&-Z@[1T!)?.0.=QY/<YZ@%K=<'G8HSVW#CVJ4;\#.W.!GKU[U5%Q;@
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MB'\5)OV@/A=XV\&:G!?>"O!ELUO96:WLR)I<H41QW%P!/N+QG/RN6C&"2.]
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M/W/6JEK\:?BMYFI'_A._$&1'+@_:QQU''R<<<444<J[+[D%EV7W(J6WQL^+
MM=%4>/?$.#/.A'VP'*A> 24SQD]\UD^)_CI\7K>+2T@^('B*)?M!)"7:@D[C
MRQ\O+?B31119=E]R%22<M4G[Z6J]3(N?C_\ &?\ M73O^+C^)B%@MIE!O58"
M1<A6P8R.!VQM/<5V6N_'SXRQ+ 8OB+XEC+V5P[[+Q5#LGW6D58@KD9Y+@Y'!
MR***FFDY.Z3UZKU%623T26L=E;N>::Y^T?\ '.PU+339_$WQ/!YNBW+N$NHB
MI:+_ %9"- RKMR<;0!S6+#^U/^T.=*GS\6_%_P LD17_ $V(8W-SC%OW].@[
M8HHJ\0DJE))))I7222>G6VXTE9:+9=#M;_\ :"^-+:=971^)'B8W,MA(\L_V
MM/-D9&PK22"+<Y XRQ.1P<UJZ5\?_C/_ ,)-9(?B/XF*MH<4K*;Q2#(4!+D&
M(\Y/^%%%8/=^K_-G')OF>KW[C]/^/?QDFUC4_-^(GB.7"C DND< QX9"H:(A
M2I)(9<'MG %,\%_M$?&X>*M3@_X67XG:(65T0CWB2 9C9N"\+$<DD $ =L"B
MBM$E;9;+IY(U6R]%^1!X?^.WQ@;1=:F/Q"\2&7^U7&_[8-V/.;DGR^2.@8_,
M!P#CBN@O?V@/C.;+Q 3\1?$9(ET@ FYBRHVQ$A3Y.5R>3C&>^:**UY8V7NKI
MT7F,6_\ C]\9O[1LA_PL7Q)@6CIC[4FTJT>X[E\K#$DD[F!8=CP,<_X1^-_Q
M:ETG4#)X^\1.1K<@!:[!P"YX_P!7T]J**EQ5WHMWT7=G51C%M72>D=TGU]#<
M'QJ^*[3V:'QYXA*RW5VD@^V8W*D>Y1P@QAN<C![$D5-_PNCXJLISX[\0G]\J
M?\?G\+("1]SN?QHHK&KI'33TTZHQQ*492LK:O;3JNPZ#XU_%<:<<>/?$/RZL
M@'^F= "H ^YZ<4MO\:/BK_:%^W_"=^("3&TA)O,_.-JAL;,=.,8Q[9HHJJ:3
MA!M)MQ5VUKL."3A%M)NRZ#_^%V?%@7.GN/'GB ,()B"+I1R68DD>7@\D]0:R
MH/C=\6MR'_A/O$1WW4BMF\SE3(>/N445?*NR^Y%679?<C6@^,_Q4EC+2>.O$
M#L9)5)-WR0LC*HX0=% &>O%3#XQ_%$<#QQK_ /X%_P#V%%%8O=^K_,Q>[]7^
M8#XR?%(9QXY\0#/_ $^'_P")K$G^-GQ9BU"1(_'OB)4$ 8*+S@-L!SRAYS11
M6E))R5TGK'=7Z@MUZK\QM[\<OBZLFD,/'_B+)F12?M:G*L5W#F,]<GW]*T+_
M .-7Q6-U&I\=^("I%PQ'VL<E&^4YV9XS_0T45NXQ][W5]R_R-4E9:+9="*X^
M-?Q7$5DP\>>(0SS1HQ%X.5).1C9CMU S[UI/\:?BL-4@4>._$.UK2X8C[9P6
MA!$9^YP4'3'7OFBBLW%7>BW?1=QV79?<B)/C-\5)K2*27QWXA=Q<,-QO2.&(
M+<!0.3[>W2GZ-\:/BJ7OE/COQ!@2S*/]+&<!"0-VS=P>G/'3I112LNR^Y!9=
ME]R(M/\ C/\ %4Z;;L?'?B$M*UU*Y-Z26?>PW<J<< 8 P!V%/A^,GQ2,:D^.
M?$!)!))O,]S_ +%%%954E'33TTZHQ>[]7^8]OC)\4@"1XZ\0#'I>D=_0+BJD
MWQG^*CMH\;>._$)1[Z96'VPC(,8;&0H/W@#U_2BBL:+;DDVVK==?M2$6(?C+
M\4RK,?'/B EGDW$WF<X=E'!3'W0!P*<WQB^*"QS.OCC7U8*""+PCG(&<!<$X
MXY%%%:1_BR72[TZ?<:4TF]4GMOZHR_\ A>'Q;\V-?^$^\18(7(^UCG).?^6=
M,E^-OQ9,A!\>^(<"2)1_I8^Z2<C[G?\ .BBNOECI[JZ=%Y>1K522T26G1(N7
M7QF^*B)L7QWXA"B[B0 7IX5U)89VYY(!SG/H:+#XW_%J34=-#^/O$3 VUV#N
MNP>$E(7_ )9]@,>XZYHHIJ,;?#';LNS\B*23C5ND[7M=7M[KV/:_V1_''B[Q
M3^U+;P>(?$&IZM$A,J)=W!<+(80,@J%.,*N%SL!&0H))/[U!%\V;K]UI/O-]
>_>XSU]%''3CIDFBBN67Q2]?\CCBWSR5W;G?7R/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>img_006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %: BT# 2(  A$! Q$!_\0
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MC/5?_B:,_P#3?]/_ *] 'YA_\.C?V(_^B8K_ ./?X4G_  Z/_8E_Z)F?S_\
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ME^!Y]<<E4TQ/$6D7NI':0NU8Q*6)!!&6&3CGD8H ^'3_ ,$E/V*S()SX#'&
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MGG^+O^%?IV#D ^=C(!QCIGMU[5 \\4<BQ&?E^OUSSW_'_&@#\R_^'1O[$?\
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MXYQ\N3VX!';\>>>E6L#_ )XG]*JPS22RC"J!CG ' SZGT_/ZU9_Y:X[?_94
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M/XCBOP5_X*-_\$POC1\7_B):_M._L5?$YOA3\=;M%TG7-1@!BCN]+;B1B9"
MY!X.<]SZ4 >8>%?V-_C7_P $Y_V ?VN/ <O[1,WQB\.1:)JT_@74M2OYKSQ'
MX*L'MV,EBY$C2!^0%4ON'4@ FOYJ?^"-_@(_%_\ :?\ !_B+Q7??&JZU*'QS
M=:G/XAU.36QX3U2"VF<FV$K$QJ@P5V#Y0 !CN?ZJOV=_^"7'[2?A7]E/X_\
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MV\$\DS@8W[(^6)R"2!CI7[*?'_XX3?&G_@F5XT^-W@B[>QU.3X1S>*&AL_\
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MF&_<IR01@?H5:_\ !-*TG_8#C_92&F>'+#Q1I=^NN6WB4:;:KJ9G%UO,XE2
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M#/ !Q^1S^ ]11&L3">:W D!! 1OF&\9/ )P!^IYSSF@ :-W9'68!"-P'(P&
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M)7 ?\,5?"EL#<=*+$X&2PSAB>I/N>:_0.U=&M,.JL/1E##\B"._4]>:^ O\
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MD6R>:>21$650L7(RHQU7/0]<XQG]:=!YN")G0#!P#C&/7G Z>HZ=/6HG6&Y
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M\@[2,\]?7TI[0NS[6A+(1]TRDI]=I..OMC''M0L,J1L5:-&;[Q'!.!@ D#G
MX]>] $TFV,PCL"!TSDG\._KB@0PX80A1G.\*% .>3N  SSU^M1;I9<>;;E2/
MNGS,9(X!'/![Y'K^-3!!%+O ")C[JC R0.PX)R>3S^% #L87RN_;/4?3\>G/
M Z>M0_O83E760D8^8DG / ZY''_Z\U.GE2-YJ.'P,<'=^6>GU^M58Y,H285)
M#-R5&3\QQGC/Y_AF@ -PC##0[O4$9'ZDTP,LB&Z2!ED3("@;<@' SC!/3IS[
M5,/-*F4,FT9R.P ZG!X&.F#SBH/.D#<7,8/:+9Q@GTX^N: %C:XE>"1U**6(
M8 [<C/&0,9Y]>_TJ5B2QD!.T$C )V\>JC /O\O)JQ"2<[CG'KT'3H.WMZ55B
M$T9=77<C,Q*D9&"21Q[\'^G4D D,V6\T%@H[9[#J, XYYZ]/PI/M#YR$ ';C
MM^5)*\:)Y*HH+ \!1C!.3P!P3ZGT^AJ8/$K+%M7=A0,@<Y YY'/]: "7@)CC
M&",<8)SR/2H&X7RY\2,?NE!EAN)(R2-PZ\<_IC*SHZQ-(C.\BYVQEBPX)&,9
M].1_2F2\"WE V3';E%^7?]0.>>F3]* $3Y(F^RQ $$\2@9SGG/\ /\!P<TY(
MTB7[1<-F7&[!Y )Z!0<D@9XP<=O:I@=BS%Y5(QE5)SLR"<8/H3@#\ZKQQY<S
MRGS(G 5$<[@O3!4,,#..HZ],4 /"7'FK/Y@\ME!*9(&",CCU[=.Q/':=(XV8
MRJY8'.X$[@<]01[=AV[<4;0%\I@"3P,]1_/'' Y&.WI2(H1(@H"Y<A@H S\Q
M'..OXYH 3;#_ ,\W'T Q^'/2HT.%8C(P>.Q W$ ?EQ3V9@\P#, JG R<#CL.
M@J,'"^6>K<YZMSS][D_3GKF@!(6;=U/YGT-3;T[PN3W.WK[_ (U"^RW7=+N(
MQUBR#]25Y_7U[4[[; &C =@,<@H?0=3U^OOF@!!'%$'F#%W.YOF.6&<DKDG.
M!T]!TI[DF(MWVY'MGD 'MZ5$)($B5F1B'D8DE>H+,<GU&,8!_3I2DF216.Z.
M(<;<D+CME1@'CKGIV(Q0!7BN+9@8C/)YA[[#D'H<$ G /^?2P(W7EF=AVW$G
MCH#S[8SQUQ5ATC4!D15..&50K8R/X@,U#"9<,)9$F?)V1D;#@G*@DCGC!SWP
M?:@">*4=#].N>G7_ .N/Q&:Y'7)]NLZ6%8J#($.TXR">AZ'![COR#72I+(TF
MU[01]>0X7H>^, _CUYKG=;,8U;3,QID2#DJI.<C/."3CU_&@#9NDF$TDL=[#
M#"$Q)'*@)^7/ ##D8X&..@'2J(ELDM9KV^-C##$A ?<44 # =A@8)^]\O4]*
MNW(62[=9[-ITV87#9! Z'&1@XZCL35>^LX;VSGLY+.*YM&B^:U^5'X PF"/F
M8=,\YQG/- 'SX_[3?PMM]=F\.2ZS:6NJ+*]I,&E=3LAD:(.&X)4E,JV<$8X)
M(-?@!_P5G_X.(? '_!/CQMX6^%WPG\&6OCWQ7>:Q9R>/?.REO9>'+E\W5]:W
M)'[Z<1LS[ 258XX.:_H!OOV>_@9J&JMKNH^$[:/7"6+W!C3=*Q.YH=X3+L#E
M2N1AA7Y%?\%&O^"%/[)_[=FI^%M?.G6_@_Q)X<UNPN?$FI6TD=I=:OI;LLDU
MA+<QHLLJ.I(,$KE"<KC/%=N4X;"RF^><I<S;;E>44[W2;;=GK9:6Z:6-*-+$
MXAV44E?1V^7;?9?TC[6_8S_X*8?L[_M>? #0/C#X*UF73TU31X7O-+U))4":
MB$C:ZBBWX#JDQ>-6QDA>N"!7UOX0^._PS\=W\FA^$M5MM9U:% [V;2O&L-P
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M=#FRPNMH;_24^8*"-H/7';.*_8Z0R-# UN8XX!M\Q"N-P[A?;T Z]>E?C?\
MM^JI^*.AE;>,J=#F(RB]#<I@].I'6N=[OU?YL#Z*_P"":>FVS?L7?"^VT3R-
M+2XTMC+):R+<PQD8R1N.,XP3R./0<#Z2\3_'CX%^!]1@\/>-?B1X-T;7F3[.
MT.I7\-M*\P&-P"N3O/K[^YKY&_X)OZ3!??L*> =.T^ZN/#FFSZ"6M]3DN/\
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M)XACCO?!>B"^4WLQTX7'VA)UMR\"YC1VV% "N*\!\5_M:?M5^/OB3\/OA?\
MLO?%6'1?A9X>^$+^++G5;R_MSJM[J>A:/#.]DD<K"3R'N$=D@;.W?ZCG] /V
MJO\ @G-X"\8?&^^^*?B7]I6[\%>&/B]JVGVGC_X):OKB6FDZM(+EG@?2[5[E
M0AD9MTBI#A=Z %B"%TO'O["7[('[-OQ"\.^/?%WQ*TKX>^&-0\%7WA'P_'>:
MT@N#/?6?D03QH"I:WF4JZO@AE;GH<?)^NY\!9)6LM--NVA^7'A3]O#]OWPA\
M)O"W[4_Q)\6&U\%V'Q$M_"OB/1I+<O=:OIUM??9'N@L+MN@NXXS,B$;-LB@
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MZ#.,CRV'"\<X!QQGTZ9''/,TAE!WK:X;GY@RYS^9SZ8[].U,5X1,9%M KO\
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M9L)#'/Q,YX$8RA^8##>O;OUSBD_<PD6HWOOZM]XJ3VST')(]OKT?&4CC??\
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MOOV)?B5XV^$'P\_:$^-&E>$O%NF^)=+U[P]H%C,)+EK^UU%)+<WC1MLMHI'
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M":9I5P9I6$ULEM,J@LL(/E,QY=F;')W9(/0]>@IS&(/?R6P$DPA</DD@'!)
M.02!S@]<<YS3-$%T;("=4VR,1O4Y8*W;K_"#M/7G\: -226-'"8WS2 X*#*C
M)X#'. /K@XQZBFF18L02/)YD@XV*3&N1P"?0=#ZC IB);VS26D>Y7E4L'&6*
ME@0#DYP0>11 5A46\DDDK,,&5@"0< 'G'7.>?;CF@!'FC@D2"0.9G^ZR#Y.>
M 6/8GJ>^#BKBLH7YP"Z97/7)'!Y^HQSCT%11F4HX*J/++(CG!8JI(!.<X.!D
M_7\HX(9_F:60'<247C# DD$X]>H_PH L [L'KD9SUZCUIBRAC("NP@LF_H2
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M*L5Z<MU';)(Y.!TSQW[%&GFT^!]@\R1I/<RMYT\9&Y^QR5^7(W$$KC/?D9H
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M@,.!QW&<X_#I5=89XY@S3L\9))3CY>>G&#@=N_ ZD5:9E8%1WZX./QX.?SH
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MP,<8INE/<RB>2[(1DDD! P,X8Y/'49SC'\S0!?;'G;1+$LRKN9B/G*#'WN0
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MH#-*,$^4=P//'- %O]BGXK:]X_\ A?:^'?&GA3Q%X:UFQC^T1G4[*>(21@
MC<J@@@$]\C-?=;R);16TMP%F &%)51@?@!SG@9S_ (^'?!3XN>$OC/\ #O3/
M&WA)'TG3K@'3+9IH5AOG5<)YB1*JJRG!/W2,ECD C/MJP&2UM;>XEAE5 /-F
M+%7.,XPBE0,]">!^9R 6YII8;>>XB@0D6_F0HJKE6&1G@#CD-CGH.@-*ES/]
MBCN1"-\D!D= <'S, 9XZ9QG X[?1ZLJ.%$9VJGE@%F*[?3DGOSGTI?(^4+]H
MPJKL"[5P%]/N_J<GWH \,_X41\+8O%DWQ&7PE:MXU@CDCO\ 4U2,7E]%.,O%
M(^[:8V! P%X[>E>1_#W]AG]FGX5?%SQ'\:O"G@:UL?''C*XDNM3UB*W11#/,
M,R2R2ECO)Z%6#(.<* :^MX-/M;>>9+B2[FDG!\R4@@..FT[> ,8Y &>G/6K:
M*\<_V1+<>7C'S%G3/^ZY9/QZT ?+_A?]C?\ 9R^'?Q0UOXU^'OA]HNG?$36/
MGO?$<MG )6<G.]I2"J')SN0(W/)QBOIRT%Z!8EDC5&V_:-A5E=5/[L@'(0+P
M05V].<]YTTV)!.7Q(MQ@3+>DO&V/[L;$HO;[@' QQ2:;I1TY?*6=[I>H:5V^
M3.<  ,0!Z =NU 'YZ^#TNF_;>\;B!MJG302P*EF&.KN1O<@'^(D>W&*_0R_4
M$EY@+>VMB':Y7A@0O.%'&,G'(/YXK\Z_ LL0_;A\>>7,P*Z:0O)8#CG[Q.1C
M/7/I7Z*R1R73W5I,^8KBV)5&5<!C_$#C)'T('MQ0!FW,S2P?:=+C@!CG4-?-
MY:12(/O 9.[G< 2,$'D<4KP0V"F<"*>ZN9U20OC8Z'^$X&T8)ZC!]>:_(?XX
M^$_VHK7X]>'_  CX&^(QTOPQJ5WY\-K?2F.UEC)^8;70EAS@\\ =?7]/_AUH
M7BCPAX0CLO&$LVN:RA$DMW:!+EV<*.54@QJ-PX 0C'44 =#/XB\*:(]Q;:AX
METVV"#,T>I7" 6P[B(SMEL'IDL#@<<4:%XBT?6HYUTJ^TS5)0_FPIIKHZB$<
M8!0D#(Y/.<DX-? G[=_P<3Q9X.L/$T6O:EX:OI]06":&SFE@,T)'*/Y3J,D'
M+$#/IP*]]_96^#MC\,/ .DZG:^(-0UZ?4-*W227[MN9BHR 221@\97![Y)H
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ME*M R;@C,PP YRR]><XK]*EEM'N(@;6;]X<-\A[_ (\8[GT&.F:_*3_@I_\
M'+X=^!O 'A#0O%,&JQSR>-M&U.WOM-A:>ZM;."X_>@Q1@LS-CY2W0 $8[@'W
MQ\$?"%SX2\!:-#J^J27FMZWHUE=7UE=N7$DTZ1A]K,3L') V=_FZDFO==.(7
MY#!-'M^0!P2HVG 4$GH /E;I@9S7B_P1^(?@_P")OPR\(^+O!4D^IV#Z/IEO
M!<ZJ0MS"!'&KB3S=K%MP)Q_#TQQS[5'=/(3\^[!(PA Y!(/W0>A_/Z4 69)&
M0Y7 )Z_*.^>>G7WIAF$2QLR!]Y(8XR><<@=/8#^=!EAE=HL,'5,@YXR!GK^?
M)X/7BIHU01Q%RI()P3CKST)Z]./Y4 598C#&77<=V6*Y) R=V-N>OX=:L*9,
M>:L>%*KN3 WD ?X'].G>E19'C8EE(W-C*9P 3G^@QZ<Y[4RXE=&B,3??(!'5
M<?0]/YT "N9(S&N$<YQGGJ3CCCH" 1CJ*!.0TJ; ?+4 $*.H&#GCU'2GR(&8
M.,AQCE3C)'4GH,_X>]13N4*&+&9B%D.,Y& IZ]#_ %^M #(O]($<P)0%BK(3
M\K8..%Z<\\]Z;&C/,RH6106R22>A(X].W Z4LC*&B6/(,;?O .@!()..F-W?
MH3TZ5;EVQJ9<9;/487K_ #..OK0!!^ZBE#/,7/4!F)QGC@9P"N.GIVYJ0O(%
M,I3Y!R4)PS ]"#GN2,"H"B0[995#Y&[D>H^Z/<#G/] *=.DMRH-O)Y9 !&X
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M<;B>N2?S)/TH07D<:K&D);=ELG!*$DKGWP>3U)!QUI'MB)DG\PL@(P > O)
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M\UJVW;J_\_Z9YG,^[+H29056.0C/!W]<<;NG4COZ<4$3'9^X;Y#D?-W]^/\
M"I8I6D 96(CP,$]<8[_0=>OK[%Q\Y&&Z0%"3T'./U]0?Z53W^;_,V'PDE"[J
M8CD_>Y R>N/?IP>]0GRBBL91E&8@]>YSGU_D,8]Z="9,,KJ&0DD;G!8C(QV
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M5BH5P<D?>XZX_+.?PIKB*/\ U0,DH<JR(2!M!.=P[G'.><G)H :IB,#0--M
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M%<D*-I/8=1_#UYJ%8XU9V2;;O8LRN1MRQ)/ "\<D<GZ^X ^-I9 ^&VG)* C
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M0,L<#' &,#]:(U=W4J<VQAWF$1E3)*G#8W<;6;/'!SCK51R+ZTE33YVT^7+
MO(FT@@G."0!C(P/8<^X9G$>-_&_A3P#I-W>^/M<AT;2X 98[N1PC!22VUF;<
MG X 51CC)[5S'@'X[?#7QV8_^$2\0?VW98"PL@#E9 ,$KL4CJ#C.1SG.>*\"
M_;\LY(OV<_$K?\(;J'CZ]LK1WVV;[)3(4)VL8P&VL=H&"".Q/?P3_@G1=?\
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MR4FU#]C3X3VMQ.]E>6D/G)/:6NV,\*1&S%<,AQ\W.1U]:_"+]MSQ!X4\+_\
M!1#7/%'Q%M_#UKIR6OV&*\\4VDDEK-(>%E@D"X:3) P3CJ<'L ?T:_LC>#O"
M/PT^ '@RR^&D]]JV@/96K6M[=/OBVS[0^8R%;"!AR!U//:OKUX[67$#R+%+U
M_=8&>G0D9[D8/8XZBOE[]F/4;/4?@1X.O=*O;&73I[/3WM8;)#!;)$Q!S&A
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M((]J_F:_X)\^*?VZ=-_:ZU?7])TS5[G1/$VKQZ5XPM=3@NC;6&F)<N6E3=R
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MY4GVYKQ+PW\?_A9XDVO;>)XK2Y)),$I8*0W/)ZI@'! X!SC( KUNQU+^T?\
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MMM)$,9,UU&AW=>!N.1G/7KZ=0?!QN$=*O&$8\L=;Q6JZ=7KTZ=[6/D<PRB.
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MD^3-#8:U>6,T.XVP6YE=8?[A + <<$\XX SCIK[*=MW]W_ "U?\ F=_1=/\
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ML-+2]C(C()5W6U+!9)#SG*X+9YYS7[+:Y^SUK5PEG?V7Q"\30M"GRV'VI#:
M. 53##.U.%4$'( SSFOYI?\ @M/_ ,$\_CE\1=3\*^._AI)<^)],TVYABUG2
M-\NSS@1YDQ\MBSRLX9RNP*2>RULJ\5;2/W*^GS/N>$,-DV(J\V)ITH3C?5MI
MZ=7>:Z_?^7Z4_P#!,;]LWP)XO^%^N:=X9AU"Z\/>'FW?8URX#!%#G;&#LSM(
M*1_*#P,C%?HY'^UYX&N)HX;OPWK4,<1&UOLT_(7Y5(+* 0>.<YP.N.OXU_\
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MQ\]-RX4D[-BA0"I! &<9'4<\0> \'@_YTG_BV_'>_<_2R[\4^&4G@*ZY8C,
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M=,8 Y'H::'FNFN(TPGE86*?'SL>C'GCCJ/<\U\?V'[:OPFU-]\M^+>VY/G3
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M\'@]&N!DC@$Y!)R1[<=!^QO_ ,%%=$O9;O1OCK9".4L6MWG8C#,3][[1UYY
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MX^(/CK6H?BYK#WR6T=A$PN7<[C\P0L^U5;.V-4"D# PO%11RS"S=I2B[M_\
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MW]BTGQ1%-_R'XU7:L\K,KD X1B'EE#[F;<M?IO87T-T;AE20W+*//A9MT48
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MCD=3SCG.>*V%%KJ%L;FXM]S6Y8)O^;:Z9!=< =2-V#TZ9JS93JT3;E"L.A5
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MF0$&T I][!Y'R<\\C.,^F.*L722-%&4&UF8,R@D$$^^1]WV')Z<5.!@<CG:
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M!!9I8R^\KN^3)R2I)QQ@D"I =+;+<^3-%+T=2T:#Y<GDJ"&X S@8!XK\?_\
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MN <Y'7OM/N2,5"]W]E:SCF8L]SL4 *<("!\S$YS]!@]>XJ5[Y8@[3K]FMTW
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M,9_^O35C:)?)09CP%8D_-P,''7T[D<>AYJ1HG90H7Y0H P5!P,8SSUX[?G0
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MJ.;Q5X5D?9'XLT4-TYU2TQV[B4]./RXK^1)O%'B;[4?^*BUWJ?\ F+ZAZ_\
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M?Q/XE\NW/_"0ZYDV<))_M:_R3Y2<D_:.34\7BCQ+]D@_XJ+7?X?^8OJ'L/\
MGX].*.2/G]X>QAY_?_P#^M__ (2?0 WECQGHZD+N"_VG:<+V'^NZX[=?6IAX
ML\-A%)\5:*W\)8ZG:99AP21YO<C)^M?R(R^*/$WVR3_BHM=Z?]!?4/\ :_Z>
M*Q;GQ7XI!4#Q+KX'GMP-9U$#[Q[?::.2/G]X>QAY_?\ \ _L,/BKPR" _BS1
M0Y *#^T+,Y!&0!F;+$<>E?D]^V]J&D:G\2-(:U\5Z0_DZ,ZRXGMF"M),CA=P
MEY*@X)XYSCUK\:;OQ3XG_M#1_P#BH]>Y,&?^)OJ'/$?7_2.?QKX6_:E\4^)Q
@\1"!XCUX 6K  :OJ& /,''_'Q63W#V,/[WW_ / /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>14
<FILENAME>canf-20211231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 24 13:02:57 UTC 2022 -->
<xs:schema elementFormDefault="qualified" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" targetNamespace="http://www.confite.com/20211231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:canf="http://www.confite.com/20211231" xmlns:dtr="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="canf-20211231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="canf-20211231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="canf-20211231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="canf-20211231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://www.confite.com/role/ConsolidatedBalanceSheet" id="canf_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals" id="canf_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ConsolidatedComprehensiveIncome" id="canf_r_ConsolidatedComprehensiveIncome">
        <link:definition>003 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShareholdersEquityType2or3" id="canf_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Consolidated Statements of Changes in Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals" id="canf_r_ShareholdersEquityType2or3_Parentheticals">
        <link:definition>005 - Statement - Consolidated Statements of Changes in Equity (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ConsolidatedCashFlow" id="canf_r_ConsolidatedCashFlow">
        <link:definition>006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/General" id="canf_r_General">
        <link:definition>007 - Disclosure - General</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/SignificantAccountingPolicies" id="canf_r_SignificantAccountingPolicies">
        <link:definition>008 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpenses" id="canf_r_OtherAccountsReceivableandPrepaidExpenses">
        <link:definition>009 - Disclosure - Other Accounts Receivable and Prepaid Expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShortTermInvestment" id="canf_r_ShortTermInvestment">
        <link:definition>010 - Disclosure - Short-Term Investment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNet" id="canf_r_PropertyPlantandEquipmentNet">
        <link:definition>011 - Disclosure - Property, Plant and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/OtherAccountsPayable" id="canf_r_OtherAccountsPayable">
        <link:definition>012 - Disclosure - Other Accounts Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/FairValueMeasurements" id="canf_r_FairValueMeasurements">
        <link:definition>013 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ContingentLiabilitiesandCommitments" id="canf_r_ContingentLiabilitiesandCommitments">
        <link:definition>014 - Disclosure - Contingent Liabilities and Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShareholdersEquity" id="canf_r_ShareholdersEquity">
        <link:definition>015 - Disclosure - Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShareBasedPaymentTransactions" id="canf_r_ShareBasedPaymentTransactions">
        <link:definition>016 - Disclosure - Share-Based Payment Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/Leases" id="canf_r_Leases">
        <link:definition>017 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/FinanceIncomeExpense" id="canf_r_FinanceIncomeExpense">
        <link:definition>018 - Disclosure - Finance Income (Expense)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/TaxesonIncome" id="canf_r_TaxesonIncome">
        <link:definition>019 - Disclosure - Taxes on Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/TransactionswithRelatedParties" id="canf_r_TransactionswithRelatedParties">
        <link:definition>020 - Disclosure - Transactions with Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/AccountingPoliciesByPolicy" id="canf_r_AccountingPoliciesByPolicy">
        <link:definition>021 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/SignificantAccountingPoliciesTables" id="canf_r_SignificantAccountingPoliciesTables">
        <link:definition>022 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpensesTables" id="canf_r_OtherAccountsReceivableandPrepaidExpensesTables">
        <link:definition>023 - Disclosure - Other Accounts Receivable and Prepaid Expenses (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNetTables" id="canf_r_PropertyPlantandEquipmentNetTables">
        <link:definition>024 - Disclosure - Property, Plant and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/OtherAccountsPayableTables" id="canf_r_OtherAccountsPayableTables">
        <link:definition>025 - Disclosure - Other Accounts Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/FairValueMeasurementsTables" id="canf_r_FairValueMeasurementsTables">
        <link:definition>026 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShareholdersEquityTables" id="canf_r_ShareholdersEquityTables">
        <link:definition>027 - Disclosure - Shareholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShareBasedPaymentTransactionsTables" id="canf_r_ShareBasedPaymentTransactionsTables">
        <link:definition>028 - Disclosure - Share-Based Payment Transactions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/LeasesTables" id="canf_r_LeasesTables">
        <link:definition>029 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/FinanceIncomeExpenseTables" id="canf_r_FinanceIncomeExpenseTables">
        <link:definition>030 - Disclosure - Finance Income (Expense) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/TaxesonIncomeTables" id="canf_r_TaxesonIncomeTables">
        <link:definition>031 - Disclosure - Taxes on Income (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/GeneralDetails" id="canf_r_GeneralDetails">
        <link:definition>032 - Disclosure - General (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/SignificantAccountingPoliciesDetails" id="canf_r_SignificantAccountingPoliciesDetails">
        <link:definition>033 - Disclosure - Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable" id="canf_r_ScheduleofpropertyplantandequipmentTable">
        <link:definition>034 - Disclosure - Significant Accounting Policies (Details) - Schedule of property, plant and equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" id="canf_r_ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable">
        <link:definition>035 - Disclosure - Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable" id="canf_r_ScheduleofotheraccountsreceivableandprepaidexpensesTable">
        <link:definition>036 - Disclosure - Other Accounts Receivable and Prepaid Expenses (Details) - Schedule of other accounts receivable and prepaid expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShortTermInvestmentDetails" id="canf_r_ShortTermInvestmentDetails">
        <link:definition>037 - Disclosure - Short-Term Investment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNetDetails" id="canf_r_PropertyPlantandEquipmentNetDetails">
        <link:definition>038 - Disclosure - Property, Plant and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable" id="canf_r_ScheduleofpropertyplantandequipmentnetTable">
        <link:definition>039 - Disclosure - Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofotheraccountspayableTable" id="canf_r_ScheduleofotheraccountspayableTable">
        <link:definition>040 - Disclosure - Other Accounts Payable (Details) - Schedule of other accounts payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" id="canf_r_ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable">
        <link:definition>041 - Disclosure - Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbKPcFX/25U7tJjZ1e/QkjhiUJn9hDzDjBiHcqiPkVBCCODXCRCIM9u4S3gJiJPkfeA4IWMDZOgz1+S5KnQ1ZJmUdVT2gUh0PhPHv3pa4+fTZTkTD4DIrxKSC26B+qiQe8tCtLe+ud+bxP4dcVqp2G92WtBs6vOj1FOZTxFulqqlkvzOQstgQaJRgDCb5YCPorZquLT7Lip1DRas17WZuBa] CSR-->
      <link:roleType roleURI="http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails" id="canf_r_ContingentLiabilitiesandCommitmentsDetails">
        <link:definition>042 - Disclosure - Contingent Liabilities and Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShareholdersEquityDetails" id="canf_r_ShareholdersEquityDetails">
        <link:definition>043 - Disclosure - Shareholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" id="canf_r_ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable">
        <link:definition>044 - Disclosure - Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ShareBasedPaymentTransactionsDetails" id="canf_r_ShareBasedPaymentTransactionsDetails">
        <link:definition>045 - Disclosure - Share-Based Payment Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofexpensesTable" id="canf_r_ScheduleofexpensesTable">
        <link:definition>046 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of expenses</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable" id="canf_r_ScheduleofestimatedusingthebinomialoptionpricingmodelTable">
        <link:definition>047 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable" id="canf_r_ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable">
        <link:definition>048 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of weighted average exercise prices and modification in option plans of employees</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable" id="canf_r_ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable">
        <link:definition>049 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of options outstanding classified by exercise price</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/LeasesDetails" id="canf_r_LeasesDetails">
        <link:definition>050 - Disclosure - Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable" id="canf_r_ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable">
        <link:definition>051 - Disclosure - Leases (Details) - Schedule of lease expense and supplemental cash flow information related to leases and weighted average remaining lease terms and discount rate</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable" id="canf_r_ScheduleofmaturitiesofleaseliabilitiesTable">
        <link:definition>052 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable" id="canf_r_ScheduleofcomponentsoffinanceincomeTable">
        <link:definition>053 - Disclosure - Finance Income (Expense) (Details) - Schedule of components of finance (income)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/TaxesonIncomeDetails" id="canf_r_TaxesonIncomeDetails">
        <link:definition>054 - Disclosure - Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable" id="canf_r_ScheduleofdeferredtaxassetsandliabilitiesTable">
        <link:definition>055 - Disclosure - Taxes on Income (Details) - Schedule of deferred tax assets and liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/TransactionswithRelatedPartiesDetails" id="canf_r_TransactionswithRelatedPartiesDetails">
        <link:definition>056 - Disclosure - Transactions with Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.confite.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
  <xs:element name="ScheduleOfPropertyPlantAndEquipmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
  <xs:element name="ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract"/>
  <xs:element name="OtherAccountsReceivableAndPrepaidExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_OtherAccountsReceivableAndPrepaidExpensesAbstract"/>
  <xs:element name="ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract"/>
  <xs:element name="ScheduleOfPropertyPlantAndEquipmentNetAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract"/>
  <xs:element name="ScheduleOfOtherAccountsPayableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfOtherAccountsPayableAbstract"/>
  <xs:element name="ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract"/>
  <xs:element name="ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract"/>
  <xs:element name="ScheduleOfExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfExpensesAbstract"/>
  <xs:element name="ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract"/>
  <xs:element name="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract"/>
  <xs:element name="ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract"/>
  <xs:element name="ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract"/>
  <xs:element name="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
  <xs:element name="ScheduleOfComponentsOfFinanceIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfComponentsOfFinanceIncomeAbstract"/>
  <xs:element name="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
  <xs:element name="CostAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_CostAbstract"/>
  <xs:element name="AccumulatedDepreciationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_AccumulatedDepreciationAbstract"/>
  <xs:element name="ComponentsOfLeaseExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ComponentsOfLeaseExpenseAbstract"/>
  <xs:element name="FinanceExpensesAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_FinanceExpensesAbstract"/>
  <xs:element name="FinanceIncomeAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_FinanceIncomeAbstract"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_DeferredTaxAssetsAbstract"/>
  <xs:element name="StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants"/>
  <xs:element name="StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants"/>
  <xs:element name="IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses"/>
  <xs:element name="IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares"/>
  <xs:element name="WarrantsNetOfIssueExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_WarrantsNetOfIssueExpenses"/>
  <xs:element name="StockIssuedDuringPeriodValueNetOfIssueExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_StockIssuedDuringPeriodValueNetOfIssueExpenses"/>
  <xs:element name="IncreaseDecreaseInSharebasedPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_IncreaseDecreaseInSharebasedPayment"/>
  <xs:element name="IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment"/>
  <xs:element name="OtherAccountsReceivableAndPrepaidExpensesTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock"/>
  <xs:element name="ShortTermInvestmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_ShortTermInvestmentTable"/>
  <xs:element name="OtherAccountsPayableTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_OtherAccountsPayableTable"/>
  <xs:element name="OtherAccountsPayableLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_OtherAccountsPayableLineItems"/>
  <xs:element name="SeverancePayPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_SeverancePayPolicyTextBlock"/>
  <xs:element name="OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock"/>
  <xs:element name="AccountingPronouncementsNotYetAdoptedPolicyTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
  <xs:element name="ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock"/>
  <xs:element name="ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock"/>
  <xs:element name="ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock"/>
  <xs:element name="ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock"/>
  <xs:element name="ScheduleOfExpensesTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfExpensesTableTextBlock"/>
  <xs:element name="ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" type="dtr:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems"/>
  <xs:element name="UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"/>
  <xs:element name="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems"/>
  <xs:element name="RevenueContractWithCustomer" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_RevenueContractWithCustomer"/>
  <xs:element name="GovernmentAuthorities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_GovernmentAuthorities"/>
  <xs:element name="EmployeesAndPayrollAccruals" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_EmployeesAndPayrollAccruals"/>
  <xs:element name="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
  <xs:element name="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"/>
  <xs:element name="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems"/>
  <xs:element name="IssuanceDate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_IssuanceDate"/>
  <xs:element name="SharebasedPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_SharebasedPayments"/>
  <xs:element name="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable"/>
  <xs:element name="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems"/>
  <xs:element name="ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
  <xs:element name="NumberOfExercisableAtEndOfShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_NumberOfExercisableAtEndOfShares"/>
  <xs:element name="WeightedAverageExercisePriceExercisableAtEndOfPerShares" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares"/>
  <xs:element name="SharebasedPaymentArrangementOptionExercisePriceRange" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_SharebasedPaymentArrangementOptionExercisePriceRange"/>
  <xs:element name="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities"/>
  <xs:element name="SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets"/>
  <xs:element name="LesseeOperatingLeaseLiabilityPaymentDue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_LesseeOperatingLeaseLiabilityPaymentDue"/>
  <xs:element name="ImputedInterestLessImputedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_ImputedInterestLessImputedInterest"/>
  <xs:element name="BanksCommissions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_BanksCommissions"/>
  <xs:element name="NetLossFromExchangeRateFluctuations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_NetLossFromExchangeRateFluctuations"/>
  <xs:element name="OtherLossFromShorttermInvestmentRevaluation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_OtherLossFromShorttermInvestmentRevaluation"/>
  <xs:element name="FinanceExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_FinanceExpenses"/>
  <xs:element name="ExchangeRateFluctuations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_ExchangeRateFluctuations"/>
  <xs:element name="FinanceIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_FinanceIncome"/>
  <xs:element name="CashFlowsFromOperatingActivities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_CashFlowsFromOperatingActivities"/>
  <xs:element name="ContractLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_ContractLiabilities"/>
  <xs:element name="Revenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_Revenue"/>
  <xs:element name="RevenuesIncludedInContractLiabilities" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_RevenuesIncludedInContractLiabilities"/>
  <xs:element name="PercentageOfDepositsOnMonthlySalary" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_PercentageOfDepositsOnMonthlySalary"/>
  <xs:element name="PercentageOfRealizationOnUltimateSettlement" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_PercentageOfRealizationOnUltimateSettlement"/>
  <xs:element name="PercentageOfOutstandingShares" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_PercentageOfOutstandingShares"/>
  <xs:element name="ContingentLiabilitiesandCommitmentsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_ContingentLiabilitiesandCommitmentsDetailsTable"/>
  <xs:element name="ContingentLiabilitiesandCommitmentsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems"/>
  <xs:element name="PercentageOfNetSales" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_PercentageOfNetSales"/>
  <xs:element name="PatentAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_PatentAgreementDescription"/>
  <xs:element name="RoyaltyPaymentsPercentage" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_RoyaltyPaymentsPercentage"/>
  <xs:element name="UnfrontPaymentAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_UnfrontPaymentAmount"/>
  <xs:element name="AdditionalPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_AdditionalPayments"/>
  <xs:element name="RoyaltyOnNetSales" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_RoyaltyOnNetSales"/>
  <xs:element name="NonRefundableUpfrontPayment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_NonRefundableUpfrontPayment"/>
  <xs:element name="ShareholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_ShareholdersEquityDetailsTable"/>
  <xs:element name="ShareholdersEquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ShareholdersEquityDetailsLineItems"/>
  <xs:element name="StockholdersEquityChangeInRatioDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_StockholdersEquityChangeInRatioDescription"/>
  <xs:element name="WarrantsToPurchaseAdditionalSharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_WarrantsToPurchaseAdditionalSharesIssued"/>
  <xs:element name="AggregatePurchasePrice" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_AggregatePurchasePrice"/>
  <xs:element name="ExercisePrices" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ExercisePrices"/>
  <xs:element name="AggregateWarrantPurchased" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_AggregateWarrantPurchased"/>
  <xs:element name="ShareIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ShareIssued"/>
  <xs:element name="IssueOfNewUnregisteredWarrants" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_IssueOfNewUnregisteredWarrants"/>
  <xs:element name="ExercisePriceSubjectToAdjusment" type="dtr:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ExercisePriceSubjectToAdjusment"/>
  <xs:element name="DeemedDividend" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_DeemedDividend"/>
  <xs:element name="SecuritiesPurchaseAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_SecuritiesPurchaseAgreementDescription"/>
  <xs:element name="CompensationWarrantsExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_CompensationWarrantsExercisable"/>
  <xs:element name="IncreaseAuthorizedShareCapital" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_IncreaseAuthorizedShareCapital"/>
  <xs:element name="StockIssuanceAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_StockIssuanceAgreementDescription"/>
  <xs:element name="AggregateNumberOfADS" type="dtr:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_AggregateNumberOfADS"/>
  <xs:element name="WarrantsToPurchaseAggregateShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="canf_WarrantsToPurchaseAggregateShares"/>
  <xs:element name="ExercisePrice" type="dtr:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="canf_ExercisePrice"/>
  <xs:element name="TotalConsiderationAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="canf_TotalConsiderationAmount"/>
  <xs:element name="FairValueAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_FairValueAmount"/>
  <xs:element name="PurchaseAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_PurchaseAgreementDescription"/>
  <xs:element name="TotalReceivedAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_TotalReceivedAmount"/>
  <xs:element name="OrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="canf_OrdinaryShares"/>
  <xs:element name="IssuanceExpensesAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="canf_IssuanceExpensesAmount"/>
  <xs:element name="ExerciseAgreementDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ExerciseAgreementDescription"/>
  <xs:element name="ShareBasedPaymentTransactionsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_ShareBasedPaymentTransactionsDetailsTable"/>
  <xs:element name="ShareBasedPaymentTransactionsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ShareBasedPaymentTransactionsDetailsLineItems"/>
  <xs:element name="GrantedExcessYears" type="xbrli:durationItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="canf_GrantedExcessYears"/>
  <xs:element name="NumberOfOrdinaryShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="canf_NumberOfOrdinaryShares"/>
  <xs:element name="FutureShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="canf_FutureShares"/>
  <xs:element name="TaxesonIncomeDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="canf_TaxesonIncomeDetailsTable"/>
  <xs:element name="TaxesonIncomeDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_TaxesonIncomeDetailsLineItems"/>
  <xs:element name="ADSMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ADSMember"/>
  <xs:element name="April2019Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_April2019Member"/>
  <xs:element name="August2021Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_August2021Member"/>
  <xs:element name="CMSMedicalMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_CMSMedicalMember"/>
  <xs:element name="ChongKunDangMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ChongKunDangMember"/>
  <xs:element name="ChongKunDangPharmaceuticalsCorpMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ChongKunDangPharmaceuticalsCorpMember"/>
  <xs:element name="CipherMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_CipherMember"/>
  <xs:element name="CipherPharmaceuticalsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_CipherPharmaceuticalsMember"/>
  <xs:element name="ComputersOfficeFurnitureAndEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ComputersOfficeFurnitureAndEquipmentMember"/>
  <xs:element name="December2021Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_December2021Member"/>
  <xs:element name="EwopharmaAGMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_EwopharmaAGMember"/>
  <xs:element name="ExercisePriceRangeOneMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ExercisePriceRangeOneMember"/>
  <xs:element name="ExercisePriceRangeThreeMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ExercisePriceRangeThreeMember"/>
  <xs:element name="ExercisePriceRangeTwoMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_ExercisePriceRangeTwoMember"/>
  <xs:element name="February2020Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_February2020Member"/>
  <xs:element name="GebroHoldingGmBHMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_GebroHoldingGmBHMember"/>
  <xs:element name="January2017Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_January2017Member"/>
  <xs:element name="January2019Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_January2019Member"/>
  <xs:element name="January2020Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_January2020Member"/>
  <xs:element name="July2020Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_July2020Member"/>
  <xs:element name="June2020Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_June2020Member"/>
  <xs:element name="KyongboPharmMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_KyongboPharmMember"/>
  <xs:element name="LaboratoryEquipmentAndLeaseholdImprovementsMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember"/>
  <xs:element name="LaboratoryEquipmentMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_LaboratoryEquipmentMember"/>
  <xs:element name="March2018Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_March2018Member"/>
  <xs:element name="May2019Member" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_May2019Member"/>
  <xs:element name="SwitzerlandBasedEwopharmaMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_SwitzerlandBasedEwopharmaMember"/>
  <xs:element name="VetbiolixMember" type="dtr:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_VetbiolixMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="canf_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>15
<FILENAME>canf-20211231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 24 13:02:57 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ConsolidatedBalanceSheet" roleURI="http://www.confite.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ConsolidatedComprehensiveIncome" roleURI="http://www.confite.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ConsolidatedCashFlow" roleURI="http://www.confite.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofotheraccountsreceivableandprepaidexpensesTable" roleURI="http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofotheraccountspayableTable" roleURI="http://www.confite.com/role/ScheduleofotheraccountspayableTable"/>
  <calculationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedComprehensiveIncome">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbKPcFX/25U7tJjZ1e/QkjhiUJn9hDzDjBiHcqiPkVBCCODXCRCIM9u4S3gJiJPkfeA4IWMDZOgz1+S5KnQ1ZJmUdVT2gUh0PhPHv3pa4+fTZTkTD4DIrxKSC26B+qiQe8tCtLe+ud+bxP4dcVqp2G92WtBs6vOj1FOZTxFulqqlkvzOQstgQaJRgDCb5YCPorW2i462h5ePiH92uuceiYr] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedeemablePreferredStockDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemablePreferredStockDividends"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_RedeemablePreferredStockDividends" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="canf_IncreaseDecreaseInSharebasedPayment" xlink:href="canf-20211231.xsd#canf_IncreaseDecreaseInSharebasedPayment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="canf_IncreaseDecreaseInSharebasedPayment" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="5" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="6" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="7" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="8" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="9" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10" weight="-1"/>
    <loc xlink:type="locator" xlink:label="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" xlink:href="canf-20211231.xsd#canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" order="11" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="12" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="13" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireOtherInvestments" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="4" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <loc xlink:type="locator" xlink:label="canf_GovernmentAuthorities" xlink:href="canf-20211231.xsd#canf_GovernmentAuthorities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="canf_GovernmentAuthorities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="2" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofotheraccountspayableTable">
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <loc xlink:type="locator" xlink:label="canf_EmployeesAndPayrollAccruals" xlink:href="canf-20211231.xsd#canf_EmployeesAndPayrollAccruals"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="canf_EmployeesAndPayrollAccruals" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="2" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>16
<FILENAME>canf-20211231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 24 13:02:57 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ConsolidatedBalanceSheet" roleURI="http://www.confite.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ConsolidatedComprehensiveIncome" roleURI="http://www.confite.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ShareholdersEquityType2or3" roleURI="http://www.confite.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ConsolidatedCashFlow" roleURI="http://www.confite.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_General" roleURI="http://www.confite.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_SignificantAccountingPolicies" roleURI="http://www.confite.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_OtherAccountsReceivableandPrepaidExpenses" roleURI="http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpenses"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ShortTermInvestment" roleURI="http://www.confite.com/role/ShortTermInvestment"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_PropertyPlantandEquipmentNet" roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_OtherAccountsPayable" roleURI="http://www.confite.com/role/OtherAccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_FairValueMeasurements" roleURI="http://www.confite.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ContingentLiabilitiesandCommitments" roleURI="http://www.confite.com/role/ContingentLiabilitiesandCommitments"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ShareholdersEquity" roleURI="http://www.confite.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ShareBasedPaymentTransactions" roleURI="http://www.confite.com/role/ShareBasedPaymentTransactions"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_Leases" roleURI="http://www.confite.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_FinanceIncomeExpense" roleURI="http://www.confite.com/role/FinanceIncomeExpense"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_TaxesonIncome" roleURI="http://www.confite.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_TransactionswithRelatedParties" roleURI="http://www.confite.com/role/TransactionswithRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_AccountingPoliciesByPolicy" roleURI="http://www.confite.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_SignificantAccountingPoliciesTables" roleURI="http://www.confite.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_OtherAccountsReceivableandPrepaidExpensesTables" roleURI="http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_PropertyPlantandEquipmentNetTables" roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_OtherAccountsPayableTables" roleURI="http://www.confite.com/role/OtherAccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_FairValueMeasurementsTables" roleURI="http://www.confite.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ShareholdersEquityTables" roleURI="http://www.confite.com/role/ShareholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ShareBasedPaymentTransactionsTables" roleURI="http://www.confite.com/role/ShareBasedPaymentTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_LeasesTables" roleURI="http://www.confite.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_FinanceIncomeExpenseTables" roleURI="http://www.confite.com/role/FinanceIncomeExpenseTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_TaxesonIncomeTables" roleURI="http://www.confite.com/role/TaxesonIncomeTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofpropertyplantandequipmentTable" roleURI="http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" roleURI="http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofotheraccountsreceivableandprepaidexpensesTable" roleURI="http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofpropertyplantandequipmentnetTable" roleURI="http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofotheraccountspayableTable" roleURI="http://www.confite.com/role/ScheduleofotheraccountspayableTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" roleURI="http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" roleURI="http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofexpensesTable" roleURI="http://www.confite.com/role/ScheduleofexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofestimatedusingthebinomialoptionpricingmodelTable" roleURI="http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable" roleURI="http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable" roleURI="http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable" roleURI="http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofmaturitiesofleaseliabilitiesTable" roleURI="http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofcomponentsoffinanceincomeTable" roleURI="http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofdeferredtaxassetsandliabilitiesTable" roleURI="http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_GeneralDetails" roleURI="http://www.confite.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_SignificantAccountingPoliciesDetails" roleURI="http://www.confite.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ShortTermInvestmentDetails" roleURI="http://www.confite.com/role/ShortTermInvestmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_PropertyPlantandEquipmentNetDetails" roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ContingentLiabilitiesandCommitmentsDetails" roleURI="http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ShareholdersEquityDetails" roleURI="http://www.confite.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ShareBasedPaymentTransactionsDetails" roleURI="http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_LeasesDetails" roleURI="http://www.confite.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_TaxesonIncomeDetails" roleURI="http://www.confite.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_TransactionswithRelatedPartiesDetails" roleURI="http://www.confite.com/role/TransactionswithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#DocumentAndEntityInformation" roleURI="http://www.confite.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedComprehensiveIncome">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_Revenues" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedeemablePreferredStockDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemablePreferredStockDividends"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RedeemablePreferredStockDividends" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" xlink:href="canf-20211231.xsd#canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" xlink:href="canf-20211231.xsd#canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockDividend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockDividend" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" xlink:href="canf-20211231.xsd#canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" xlink:href="canf-20211231.xsd#canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_WarrantsNetOfIssueExpenses" xlink:href="canf-20211231.xsd#canf_WarrantsNetOfIssueExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="canf_WarrantsNetOfIssueExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_StockIssuedDuringPeriodValueNetOfIssueExpenses" xlink:href="canf-20211231.xsd#canf_StockIssuedDuringPeriodValueNetOfIssueExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="canf_StockIssuedDuringPeriodValueNetOfIssueExpenses" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IncreaseDecreaseInSharebasedPayment" xlink:href="canf-20211231.xsd#canf_IncreaseDecreaseInSharebasedPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="canf_IncreaseDecreaseInSharebasedPayment" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" xlink:href="canf-20211231.xsd#canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireOtherInvestments" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_PaymentsOfDividends" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/General">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpenses">
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:href="canf-20211231.xsd#canf_OtherAccountsReceivableAndPrepaidExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:href="canf-20211231.xsd#canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_OtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:to="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShortTermInvestment">
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_ShortTermInvestmentTable" xlink:href="canf-20211231.xsd#canf_ShortTermInvestmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="canf_ShortTermInvestmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_InvestmentTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/PropertyPlantandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/OtherAccountsPayable">
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsPayableLineItems" xlink:href="canf-20211231.xsd#canf_OtherAccountsPayableLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsPayableTable" xlink:href="canf-20211231.xsd#canf_OtherAccountsPayableTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_OtherAccountsPayableLineItems" xlink:to="canf_OtherAccountsPayableTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_OtherAccountsPayableLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/FairValueMeasurements">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ContingentLiabilitiesandCommitments">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareBasedPaymentTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/FinanceIncomeExpense">
    <loc xlink:type="locator" xlink:label="us-gaap_BankingAndThriftInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankingAndThriftInterestAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BankingAndThriftInterestAbstract" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/TaxesonIncome">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/TransactionswithRelatedParties">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_SeverancePayPolicyTextBlock" xlink:href="canf-20211231.xsd#canf_SeverancePayPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_SeverancePayPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" xlink:href="canf-20211231.xsd#canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:href="canf-20211231.xsd#canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" order="20" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" xlink:href="canf-20211231.xsd#canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" xlink:href="canf-20211231.xsd#canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpensesTables">
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:href="canf-20211231.xsd#canf_OtherAccountsReceivableAndPrepaidExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:href="canf-20211231.xsd#canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_OtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:to="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/PropertyPlantandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/OtherAccountsPayableTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/FairValueMeasurementsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" xlink:href="canf-20211231.xsd#canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareBasedPaymentTransactionsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfExpensesTableTextBlock" xlink:href="canf-20211231.xsd#canf_ScheduleOfExpensesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="canf_ScheduleOfExpensesTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" xlink:href="canf-20211231.xsd#canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/FinanceIncomeExpenseTables">
    <loc xlink:type="locator" xlink:label="us-gaap_BankingAndThriftInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankingAndThriftInterestAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BankingAndThriftInterestAbstract" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/TaxesonIncomeTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable">
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:href="canf-20211231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:href="canf-20211231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:to="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember" xlink:href="canf-20211231.xsd#canf_LaboratoryEquipmentAndLeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ComputersOfficeFurnitureAndEquipmentMember" xlink:href="canf-20211231.xsd#canf_ComputersOfficeFurnitureAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="canf_ComputersOfficeFurnitureAndEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" xlink:href="canf-20211231.xsd#canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:to="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable">
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" xlink:href="canf-20211231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" xlink:href="canf-20211231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" xlink:to="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" xlink:to="srt_MajorCustomersAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_CipherPharmaceuticalsMember" xlink:href="canf-20211231.xsd#canf_CipherPharmaceuticalsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="canf_CipherPharmaceuticalsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ChongKunDangPharmaceuticalsCorpMember" xlink:href="canf-20211231.xsd#canf_ChongKunDangPharmaceuticalsCorpMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="canf_ChongKunDangPharmaceuticalsCorpMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_GebroHoldingGmBHMember" xlink:href="canf-20211231.xsd#canf_GebroHoldingGmBHMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="canf_GebroHoldingGmBHMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_EwopharmaAGMember" xlink:href="canf-20211231.xsd#canf_EwopharmaAGMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="canf_EwopharmaAGMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_RevenueContractWithCustomer" xlink:href="canf-20211231.xsd#canf_RevenueContractWithCustomer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" xlink:to="canf_RevenueContractWithCustomer" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_GovernmentAuthorities" xlink:href="canf-20211231.xsd#canf_GovernmentAuthorities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:to="canf_GovernmentAuthorities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_LaboratoryEquipmentMember" xlink:href="canf-20211231.xsd#canf_LaboratoryEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="canf_LaboratoryEquipmentMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ComputersOfficeFurnitureAndEquipmentMember" xlink:href="canf-20211231.xsd#canf_ComputersOfficeFurnitureAndEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="canf_ComputersOfficeFurnitureAndEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_CostAbstract" xlink:href="canf-20211231.xsd#canf_CostAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="canf_CostAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_CostAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_AccumulatedDepreciationAbstract" xlink:href="canf-20211231.xsd#canf_AccumulatedDepreciationAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="canf_AccumulatedDepreciationAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_AccumulatedDepreciationAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_AccumulatedDepreciationAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofotheraccountspayableTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfOtherAccountsPayableAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_EmployeesAndPayrollAccruals" xlink:href="canf-20211231.xsd#canf_EmployeesAndPayrollAccruals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfOtherAccountsPayableAbstract" xlink:to="canf_EmployeesAndPayrollAccruals" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfOtherAccountsPayableAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfOtherAccountsPayableAbstract" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable">
    <loc xlink:type="locator" xlink:label="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:href="canf-20211231.xsd#canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:href="canf-20211231.xsd#canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:to="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbKPcFX/25U7tJjZ1e/QkjhiUJn9hDzDjBiHcqiPkVBCCODXCRCIM9u4S3gJiJPkfeA4IWMDZOgz1+S5KnQ1ZJmUdVT2gUh0PhPHv3pa4+fTZTkTD4DIrxKSC26B+qiQe8tCtLe+ud+bxP4dcVqp2G92WtBs6vOj1FOZTxFulqqlkvzOQstgQaJRgDCb5YCPorNryMQ3aJRX7pwrfRwnyAq] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:to="us-gaap_ShortTermInvestments" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable">
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:href="canf-20211231.xsd#canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" xlink:href="canf-20211231.xsd#canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" xlink:to="us-gaap_AwardDateAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_January2017Member" xlink:href="canf-20211231.xsd#canf_January2017Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_January2017Member" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_March2018Member" xlink:href="canf-20211231.xsd#canf_March2018Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_March2018Member" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_January2019Member" xlink:href="canf-20211231.xsd#canf_January2019Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_January2019Member" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_April2019Member" xlink:href="canf-20211231.xsd#canf_April2019Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_April2019Member" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_May2019Member" xlink:href="canf-20211231.xsd#canf_May2019Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_May2019Member" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_January2020Member" xlink:href="canf-20211231.xsd#canf_January2020Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_January2020Member" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_February2020Member" xlink:href="canf-20211231.xsd#canf_February2020Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_February2020Member" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_June2020Member" xlink:href="canf-20211231.xsd#canf_June2020Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_June2020Member" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_July2020Member" xlink:href="canf-20211231.xsd#canf_July2020Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_July2020Member" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_August2021Member" xlink:href="canf-20211231.xsd#canf_August2021Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_August2021Member" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_December2021Member" xlink:href="canf-20211231.xsd#canf_December2021Member"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AwardDateDomain" xlink:to="canf_December2021Member" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceDate" xlink:href="canf-20211231.xsd#canf_IssuanceDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="canf_IssuanceDate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofexpensesTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfExpensesAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfExpensesAbstract" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_SharebasedPayments" xlink:href="canf-20211231.xsd#canf_SharebasedPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfExpensesAbstract" xlink:to="canf_SharebasedPayments" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable">
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:href="canf-20211231.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" xlink:href="canf-20211231.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="canf-20211231.xsd#canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_NumberOfExercisableAtEndOfShares" xlink:href="canf-20211231.xsd#canf_NumberOfExercisableAtEndOfShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="canf_NumberOfExercisableAtEndOfShares" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares" xlink:href="canf-20211231.xsd#canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable">
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePriceRangeOneMember" xlink:href="canf-20211231.xsd#canf_ExercisePriceRangeOneMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="canf_ExercisePriceRangeOneMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePriceRangeTwoMember" xlink:href="canf-20211231.xsd#canf_ExercisePriceRangeTwoMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="canf_ExercisePriceRangeTwoMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePriceRangeThreeMember" xlink:href="canf-20211231.xsd#canf_ExercisePriceRangeThreeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="canf_ExercisePriceRangeThreeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_SharebasedPaymentArrangementOptionExercisePriceRange" xlink:href="canf-20211231.xsd#canf_SharebasedPaymentArrangementOptionExercisePriceRange"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="canf_SharebasedPaymentArrangementOptionExercisePriceRange" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ComponentsOfLeaseExpenseAbstract" xlink:href="canf-20211231.xsd#canf_ComponentsOfLeaseExpenseAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="canf_ComponentsOfLeaseExpenseAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ComponentsOfLeaseExpenseAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:href="canf-20211231.xsd#canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" xlink:href="canf-20211231.xsd#canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_LesseeOperatingLeaseLiabilityPaymentDue" xlink:href="canf-20211231.xsd#canf_LesseeOperatingLeaseLiabilityPaymentDue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="canf_LesseeOperatingLeaseLiabilityPaymentDue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ImputedInterestLessImputedInterest" xlink:href="canf-20211231.xsd#canf_ImputedInterestLessImputedInterest"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="canf_ImputedInterestLessImputedInterest" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_OperatingLeaseLiability" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfComponentsOfFinanceIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceExpensesAbstract" xlink:href="canf-20211231.xsd#canf_FinanceExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="canf_FinanceExpensesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_BanksCommissions" xlink:href="canf-20211231.xsd#canf_BanksCommissions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FinanceExpensesAbstract" xlink:to="canf_BanksCommissions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_NetLossFromExchangeRateFluctuations" xlink:href="canf-20211231.xsd#canf_NetLossFromExchangeRateFluctuations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FinanceExpensesAbstract" xlink:to="canf_NetLossFromExchangeRateFluctuations" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_OtherLossFromShorttermInvestmentRevaluation" xlink:href="canf-20211231.xsd#canf_OtherLossFromShorttermInvestmentRevaluation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FinanceExpensesAbstract" xlink:to="canf_OtherLossFromShorttermInvestmentRevaluation" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FinanceExpensesAbstract" xlink:to="us-gaap_OtherExpenses" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceExpenses" xlink:href="canf-20211231.xsd#canf_FinanceExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FinanceExpensesAbstract" xlink:to="canf_FinanceExpenses" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceIncomeAbstract" xlink:href="canf-20211231.xsd#canf_FinanceIncomeAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="canf_FinanceIncomeAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FinanceIncomeAbstract" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ExchangeRateFluctuations" xlink:href="canf-20211231.xsd#canf_ExchangeRateFluctuations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FinanceIncomeAbstract" xlink:to="canf_ExchangeRateFluctuations" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FinanceIncomeAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceIncome" xlink:href="canf-20211231.xsd#canf_FinanceIncome"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FinanceIncomeAbstract" xlink:to="canf_FinanceIncome" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_FinanceIncomeAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="canf_DeferredTaxAssetsAbstract" xlink:href="canf-20211231.xsd#canf_DeferredTaxAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="canf_DeferredTaxAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SharesIssued" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_CashFlowsFromOperatingActivities" xlink:href="canf-20211231.xsd#canf_CashFlowsFromOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_CashFlowsFromOperatingActivities" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtWeightedAverageInterestRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ContractLiabilities" xlink:href="canf-20211231.xsd#canf_ContractLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_ContractLiabilities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_Revenue" xlink:href="canf-20211231.xsd#canf_Revenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_Revenue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_RevenuesIncludedInContractLiabilities" xlink:href="canf-20211231.xsd#canf_RevenuesIncludedInContractLiabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_RevenuesIncludedInContractLiabilities" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfDepositsOnMonthlySalary" xlink:href="canf-20211231.xsd#canf_PercentageOfDepositsOnMonthlySalary"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_PercentageOfDepositsOnMonthlySalary" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SeveranceCosts1" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfRealizationOnUltimateSettlement" xlink:href="canf-20211231.xsd#canf_PercentageOfRealizationOnUltimateSettlement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="canf_PercentageOfRealizationOnUltimateSettlement" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShortTermInvestmentDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfOutstandingShares" xlink:href="canf-20211231.xsd#canf_PercentageOfOutstandingShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="canf_PercentageOfOutstandingShares" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/PropertyPlantandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationExpenseOnReclassifiedAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationExpenseOnReclassifiedAssets" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails">
    <loc xlink:type="locator" xlink:label="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:href="canf-20211231.xsd#canf_ContingentLiabilitiesandCommitmentsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:href="canf-20211231.xsd#canf_ContingentLiabilitiesandCommitmentsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="canf_ContingentLiabilitiesandCommitmentsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_CipherMember" xlink:href="canf-20211231.xsd#canf_CipherMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="canf_CipherMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ChongKunDangMember" xlink:href="canf-20211231.xsd#canf_ChongKunDangMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="canf_ChongKunDangMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_CMSMedicalMember" xlink:href="canf-20211231.xsd#canf_CMSMedicalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="canf_CMSMedicalMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_KyongboPharmMember" xlink:href="canf-20211231.xsd#canf_KyongboPharmMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="canf_KyongboPharmMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_SwitzerlandBasedEwopharmaMember" xlink:href="canf-20211231.xsd#canf_SwitzerlandBasedEwopharmaMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="canf_SwitzerlandBasedEwopharmaMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_VetbiolixMember" xlink:href="canf-20211231.xsd#canf_VetbiolixMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="canf_VetbiolixMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseCommissionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoninterestExpenseCommissionExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_NoninterestExpenseCommissionExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfNetSales" xlink:href="canf-20211231.xsd#canf_PercentageOfNetSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="canf_PercentageOfNetSales" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_PatentAgreementDescription" xlink:href="canf-20211231.xsd#canf_PatentAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="canf_PatentAgreementDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvanceRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvanceRoyalties"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_AdvanceRoyalties" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_RoyaltyPaymentsPercentage" xlink:href="canf-20211231.xsd#canf_RoyaltyPaymentsPercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="canf_RoyaltyPaymentsPercentage" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_UnfrontPaymentAmount" xlink:href="canf-20211231.xsd#canf_UnfrontPaymentAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="canf_UnfrontPaymentAmount" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_AdditionalPayments" xlink:href="canf-20211231.xsd#canf_AdditionalPayments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="canf_AdditionalPayments" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetentionPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetentionPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_RetentionPayable" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_RoyaltyOnNetSales" xlink:href="canf-20211231.xsd#canf_RoyaltyOnNetSales"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="canf_RoyaltyOnNetSales" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_NonRefundableUpfrontPayment" xlink:href="canf-20211231.xsd#canf_NonRefundableUpfrontPayment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="canf_NonRefundableUpfrontPayment" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsLineItems" xlink:href="canf-20211231.xsd#canf_ShareholdersEquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsTable" xlink:href="canf-20211231.xsd#canf_ShareholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_ShareholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ADSMember" xlink:href="canf-20211231.xsd#canf_ADSMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="canf_ADSMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_StockholdersEquityChangeInRatioDescription" xlink:href="canf-20211231.xsd#canf_StockholdersEquityChangeInRatioDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_StockholdersEquityChangeInRatioDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_WarrantsToPurchaseAdditionalSharesIssued" xlink:href="canf-20211231.xsd#canf_WarrantsToPurchaseAdditionalSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_WarrantsToPurchaseAdditionalSharesIssued" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_AggregatePurchasePrice" xlink:href="canf-20211231.xsd#canf_AggregatePurchasePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_AggregatePurchasePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePrices" xlink:href="canf-20211231.xsd#canf_ExercisePrices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_ExercisePrices" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_AggregateWarrantPurchased" xlink:href="canf-20211231.xsd#canf_AggregateWarrantPurchased"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_AggregateWarrantPurchased" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ShareIssued" xlink:href="canf-20211231.xsd#canf_ShareIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_ShareIssued" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IssueOfNewUnregisteredWarrants" xlink:href="canf-20211231.xsd#canf_IssueOfNewUnregisteredWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_IssueOfNewUnregisteredWarrants" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePriceSubjectToAdjusment" xlink:href="canf-20211231.xsd#canf_ExercisePriceSubjectToAdjusment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_ExercisePriceSubjectToAdjusment" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_DeemedDividend" xlink:href="canf-20211231.xsd#canf_DeemedDividend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_DeemedDividend" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_SecuritiesPurchaseAgreementDescription" xlink:href="canf-20211231.xsd#canf_SecuritiesPurchaseAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_SecuritiesPurchaseAgreementDescription" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromOtherEquity" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_CompensationWarrantsExercisable" xlink:href="canf-20211231.xsd#canf_CompensationWarrantsExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_CompensationWarrantsExercisable" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharePrice" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IncreaseAuthorizedShareCapital" xlink:href="canf-20211231.xsd#canf_IncreaseAuthorizedShareCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_IncreaseAuthorizedShareCapital" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_StockIssuanceAgreementDescription" xlink:href="canf-20211231.xsd#canf_StockIssuanceAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_StockIssuanceAgreementDescription" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_AggregateNumberOfADS" xlink:href="canf-20211231.xsd#canf_AggregateNumberOfADS"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_AggregateNumberOfADS" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_WarrantsToPurchaseAggregateShares" xlink:href="canf-20211231.xsd#canf_WarrantsToPurchaseAggregateShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_WarrantsToPurchaseAggregateShares" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePrice" xlink:href="canf-20211231.xsd#canf_ExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_ExercisePrice" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_TotalConsiderationAmount" xlink:href="canf-20211231.xsd#canf_TotalConsiderationAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_TotalConsiderationAmount" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_FairValueAmount" xlink:href="canf-20211231.xsd#canf_FairValueAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_FairValueAmount" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_PurchaseAgreementDescription" xlink:href="canf-20211231.xsd#canf_PurchaseAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_PurchaseAgreementDescription" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_TotalReceivedAmount" xlink:href="canf-20211231.xsd#canf_TotalReceivedAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_TotalReceivedAmount" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_OrdinaryShares" xlink:href="canf-20211231.xsd#canf_OrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_OrdinaryShares" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceExpensesAmount" xlink:href="canf-20211231.xsd#canf_IssuanceExpensesAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_IssuanceExpensesAmount" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_ExerciseAgreementDescription" xlink:href="canf-20211231.xsd#canf_ExerciseAgreementDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_ExerciseAgreementDescription" order="38" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareBasedPaymentTransactionsDetails">
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:href="canf-20211231.xsd#canf_ShareBasedPaymentTransactionsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsTable" xlink:href="canf-20211231.xsd#canf_ShareBasedPaymentTransactionsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="canf_ShareBasedPaymentTransactionsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_ShareBasedPaymentTransactionsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_GrantedExcessYears" xlink:href="canf-20211231.xsd#canf_GrantedExcessYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="canf_GrantedExcessYears" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_NumberOfOrdinaryShares" xlink:href="canf-20211231.xsd#canf_NumberOfOrdinaryShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="canf_NumberOfOrdinaryShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="canf_FutureShares" xlink:href="canf-20211231.xsd#canf_FutureShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="canf_FutureShares" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="9" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/TaxesonIncomeDetails">
    <loc xlink:type="locator" xlink:label="canf_TaxesonIncomeDetailsLineItems" xlink:href="canf-20211231.xsd#canf_TaxesonIncomeDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="canf_TaxesonIncomeDetailsTable" xlink:href="canf-20211231.xsd#canf_TaxesonIncomeDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="canf_TaxesonIncomeDetailsLineItems" xlink:to="canf_TaxesonIncomeDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="canf_TaxesonIncomeDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IsraelTaxAuthorityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IsraelTaxAuthorityMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IsraelTaxAuthorityMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_TaxesonIncomeDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="canf_TaxesonIncomeDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/TransactionswithRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://www.confite.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain_0" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_AddressTypeDomain" xlink:to="dei_BusinessContactMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="21" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="22" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="23" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="24" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="25" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine3" order="26" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="27" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="28" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="29" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="30" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="31" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="32" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelFaxNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelFaxNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelFaxNumber" order="33" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelEmailAddress" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelEmailAddress"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelEmailAddress" order="34" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="35" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="36" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="37" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="38" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="39" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="40" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="41" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>17
<FILENAME>canf-20211231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 24 13:02:57 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressesAddressTypeAxis_lbl" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_EntityAddressesAddressTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsNoncurrent_lbl" xml:lang="en-US">Total long-term assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl" xml:lang="en-US">Total Long-term liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US">Loss before taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl1" xml:lang="en-US">Net losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Total comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash and cash equivalents at the beginning of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl0" xml:lang="en-US">Cash and cash equivalents at the end of the year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfPropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Schedule of property, plant and equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:to="canf_ScheduleOfPropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xml:lang="en-US">Asset Class [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract_lbl" xml:lang="en-US">Schedule of major customer data as a percentage of total revenues [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract" xlink:to="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MajorCustomersAxis_lbl" xml:lang="en-US">Customer [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:href="canf-20211231.xsd#canf_OtherAccountsReceivableAndPrepaidExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OtherAccountsReceivableAndPrepaidExpensesAbstract_lbl" xml:lang="en-US">Other Accounts Receivable And Prepaid Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:to="canf_OtherAccountsReceivableAndPrepaidExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract_lbl" xml:lang="en-US">Schedule of other accounts receivable and prepaid expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:to="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract_lbl" xml:lang="en-US">Disclosure Text Block Supplement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_DisclosureTextBlockSupplementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US">Schedule of property, plant and equipment, net [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract" xlink:to="canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfOtherAccountsPayableAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfOtherAccountsPayableAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfOtherAccountsPayableAbstract_lbl" xml:lang="en-US">Schedule of other accounts payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfOtherAccountsPayableAbstract" xlink:to="canf_ScheduleOfOtherAccountsPayableAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US">Other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract_lbl" xml:lang="en-US">Schedule of financial assets and liabilities measured at fair value on a recurring basis [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:to="canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xml:lang="en-US">Measurement Frequency [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract_lbl" xml:lang="en-US">Schedule of information regarding outstanding warrants to purchase shares [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract" xlink:to="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfExpensesAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfExpensesAbstract_lbl" xml:lang="en-US">Schedule of expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfExpensesAbstract" xlink:to="canf_ScheduleOfExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract_lbl" xml:lang="en-US">Schedule of estimated using the binomial option pricing model [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract" xlink:to="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract_lbl" xml:lang="en-US">Schedule of weighted average exercise prices and modification in option plans of employees [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Outstanding at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of Outstanding at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Outstanding at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted average exercise price, Outstanding at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract_lbl" xml:lang="en-US">Schedule of options outstanding classified by exercise price [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract" xlink:to="canf_ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xml:lang="en-US">Exercise Price Range [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US">Leases [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract_lbl" xml:lang="en-US">Schedule of lease expense and supplemental cash flow information related to leases and weighted average remaining lease terms and discount rate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of maturities of lease liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BankingAndThriftInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankingAndThriftInterestAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BankingAndThriftInterestAbstract_lbl" xml:lang="en-US">Banking and Thrift, Interest [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BankingAndThriftInterestAbstract" xlink:to="us-gaap_BankingAndThriftInterestAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfComponentsOfFinanceIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfComponentsOfFinanceIncomeAbstract_lbl" xml:lang="en-US">Schedule of components of finance (income) [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="canf_ScheduleOfComponentsOfFinanceIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelName_lbl" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelFaxNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelFaxNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelFaxNumber_lbl" xml:lang="en-US">Contact Personnel Fax Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelFaxNumber" xlink:to="dei_ContactPersonnelFaxNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelEmailAddress" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelEmailAddress"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_ContactPersonnelEmailAddress_lbl" xml:lang="en-US">Contact Personnel Email Address</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelEmailAddress" xlink:to="dei_ContactPersonnelEmailAddress_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorName_lbl" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepositsAssetsCurrent_lbl" xml:lang="en-US">Short-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses, and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShortTermInvestments_lbl" xml:lang="en-US">Short-term investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT ASSETS:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease right of use assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl" xml:lang="en-US">Trade payables</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US">Current maturity of operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xml:lang="en-US">Deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl" xml:lang="en-US">NON-CURRENT LIABILITIES:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US">Long-term operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xml:lang="en-US">Deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">CONTIGENT LIABILITIES AND COMMITMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Ordinary shares of NIS 0.25 par value - Authorized: 5,000,000,000 and 1,000,000,000 shares at December 31, 2021 and December 31, 2020, respectively; Issued and outstanding: 815,746,293 shares as of December 31, 2021; 463,769,463 shares as of December 31, 2020</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Ordinary shares, par value (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Par value (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Ordinary shares, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Ordinary shares, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Ordinary shares, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total financial income (expense), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl" xml:lang="en-US">Taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Basic and diluted net loss per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of ordinary shares used in computing basic and diluted net loss per share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" xlink:href="canf-20211231.xsd#canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_lbl" xml:lang="en-US">Issuance of share capital and warrants, net of issuance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" xlink:to="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" xlink:href="canf-20211231.xsd#canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_lbl" xml:lang="en-US">Issuance of share capital and warrants, net of issuance expenses (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" xlink:to="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_WarrantsNetOfIssueExpenses" xlink:href="canf-20211231.xsd#canf_WarrantsNetOfIssueExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_WarrantsNetOfIssueExpenses_lbl" xml:lang="en-US">Warrants, net of issue expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsNetOfIssueExpenses" xlink:to="canf_WarrantsNetOfIssueExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of share capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of share capital (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xml:lang="en-US">Share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockDividend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend_lbl" xml:lang="en-US">Deemed dividends related to the warrants exercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockDividend_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" xlink:href="canf-20211231.xsd#canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses_lbl" xml:lang="en-US">Issuance of share capital due to warrants exercise, net of issuance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" xlink:href="canf-20211231.xsd#canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares_lbl" xml:lang="en-US">Issuance of share capital due to warrants exercise, net of issuance expenses (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_StockIssuedDuringPeriodValueNetOfIssueExpenses" xlink:href="canf-20211231.xsd#canf_StockIssuedDuringPeriodValueNetOfIssueExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_StockIssuedDuringPeriodValueNetOfIssueExpenses_lbl" xml:lang="en-US">Warrants exercise, net of issue expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodValueNetOfIssueExpenses" xlink:to="canf_StockIssuedDuringPeriodValueNetOfIssueExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of share capital in exchange for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of share capital in exchange for services (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments required to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US">Depreciation of property, plant and equipment and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IncreaseDecreaseInSharebasedPayment" xlink:href="canf-20211231.xsd#canf_IncreaseDecreaseInSharebasedPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_IncreaseDecreaseInSharebasedPayment_lbl" xml:lang="en-US">Share-based payment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IncreaseDecreaseInSharebasedPayment" xlink:to="canf_IncreaseDecreaseInSharebasedPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Share-based payment in exchange for services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl" xml:lang="en-US">Decrease in operating lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl" xml:lang="en-US">Increase (decrease) in trade payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xml:lang="en-US">Increase (decrease) in deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl" xml:lang="en-US">Increase (decrease) in other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl" xml:lang="en-US">Issuance of share capital and warrants, net of issuance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl" xml:lang="en-US">Exchange differences on balances of cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Non-cash activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US">Lease liabilities arising from obtaining right-of-use-assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfDividends_lbl" xml:lang="en-US">Deemed Dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividends" xlink:to="us-gaap_PaymentsOfDividends_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl0" xml:lang="en-US">Supplemental cash flow information</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid during the year for interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedeemablePreferredStockDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemablePreferredStockDividends"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RedeemablePreferredStockDividends_lbl" xml:lang="en-US">Deemed dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemablePreferredStockDividends" xlink:to="us-gaap_RedeemablePreferredStockDividends_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xml:lang="en-US">Decrease in operating lease right of use asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Change in prepaid expenses, and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" xlink:href="canf-20211231.xsd#canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment_lbl" xml:lang="en-US">Changes in fair value of short-term investment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" xlink:to="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US">Interest on bank deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xml:lang="en-US">non-cash financial expenses (income), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchase of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireOtherInvestments_lbl" xml:lang="en-US">Investment in short-term deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="us-gaap_PaymentsToAcquireOtherInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_BusinessContactMember_lbl" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Ordinary Shares [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated other comprehensive Income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US">GENERAL</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" xlink:href="canf-20211231.xsd#canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock_lbl" xml:lang="en-US">Schedule of property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" xlink:to="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" xlink:href="canf-20211231.xsd#canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments_lbl" xml:lang="en-US">Depreciation rates property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" xlink:to="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" xlink:href="canf-20211231.xsd#canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock_lbl" xml:lang="en-US">Schedule of major customer data as a percentage of total revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" xlink:to="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_RevenueContractWithCustomer" xlink:href="canf-20211231.xsd#canf_RevenueContractWithCustomer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_RevenueContractWithCustomer_lbl" xml:lang="en-US">Total revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RevenueContractWithCustomer" xlink:to="canf_RevenueContractWithCustomer_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:href="canf-20211231.xsd#canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock_lbl" xml:lang="en-US">OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:to="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:href="canf-20211231.xsd#canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of other accounts receivable and prepaid expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:to="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_GovernmentAuthorities" xlink:href="canf-20211231.xsd#canf_GovernmentAuthorities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_GovernmentAuthorities_lbl" xml:lang="en-US">Government authorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GovernmentAuthorities" xlink:to="canf_GovernmentAuthorities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid expenses and others</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InvestmentTextBlock_lbl" xml:lang="en-US">SHORT-TERM INVESTMENT</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTextBlock" xlink:to="us-gaap_InvestmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT, NET</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Schedule of property, plant and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_CostAbstract" xlink:href="canf-20211231.xsd#canf_CostAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CostAbstract_lbl" xml:lang="en-US">Cost:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CostAbstract" xlink:to="canf_CostAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Property and equipment, gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_AccumulatedDepreciationAbstract" xlink:href="canf-20211231.xsd#canf_AccumulatedDepreciationAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_AccumulatedDepreciationAbstract_lbl" xml:lang="en-US">Accumulated depreciation:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AccumulatedDepreciationAbstract" xlink:to="canf_AccumulatedDepreciationAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Accumulated depreciation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">OTHER ACCOUNTS PAYABLE</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of other accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_EmployeesAndPayrollAccruals" xlink:href="canf-20211231.xsd#canf_EmployeesAndPayrollAccruals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_EmployeesAndPayrollAccruals_lbl" xml:lang="en-US">Employees and payroll accruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_EmployeesAndPayrollAccruals" xlink:to="canf_EmployeesAndPayrollAccruals_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Accrued expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xml:lang="en-US">Schedule of financial assets and liabilities measured at fair value on a recurring basis</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">CONTINGENT LIABILITIES AND COMMITMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">SHAREHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" xlink:href="canf-20211231.xsd#canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock_lbl" xml:lang="en-US">Schedule of information regarding outstanding warrants to purchase shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" xlink:to="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceDate" xlink:href="canf-20211231.xsd#canf_IssuanceDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_IssuanceDate_lbl" xml:lang="en-US">Issuance date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceDate" xlink:to="canf_IssuanceDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xml:lang="en-US">Number of outstanding warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Exercise price per warrant (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Warrant exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">SHARE-BASED PAYMENT TRANSACTIONS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfExpensesTableTextBlock" xlink:href="canf-20211231.xsd#canf_ScheduleOfExpensesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ScheduleOfExpensesTableTextBlock_lbl" xml:lang="en-US">Schedule of expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfExpensesTableTextBlock" xlink:to="canf_ScheduleOfExpensesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SharebasedPayments" xlink:href="canf-20211231.xsd#canf_SharebasedPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_SharebasedPayments_lbl" xml:lang="en-US">Share-based payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SharebasedPayments" xlink:to="canf_SharebasedPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" xlink:href="canf-20211231.xsd#canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock_lbl" xml:lang="en-US">Schedule of estimated using the binomial option pricing model</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" xlink:to="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Early Exercise Multiple (Suboptimal Factor) (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="canf-20211231.xsd#canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Exercise price (NIS) (in New Shekels per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of weighted average exercise prices and modification in option plans of employees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Forfeited/expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_NumberOfExercisableAtEndOfShares" xlink:href="canf-20211231.xsd#canf_NumberOfExercisableAtEndOfShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_NumberOfExercisableAtEndOfShares_lbl" xml:lang="en-US">Number of Exercisable at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NumberOfExercisableAtEndOfShares" xlink:to="canf_NumberOfExercisableAtEndOfShares_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares" xlink:href="canf-20211231.xsd#canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares_lbl" xml:lang="en-US">Weighted average exercise price, Exercisable at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares" xlink:to="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xml:lang="en-US">Schedule of options outstanding classified by exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SharebasedPaymentArrangementOptionExercisePriceRange" xlink:href="canf-20211231.xsd#canf_SharebasedPaymentArrangementOptionExercisePriceRange"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_SharebasedPaymentArrangementOptionExercisePriceRange_lbl" xml:lang="en-US">Exercise price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SharebasedPaymentArrangementOptionExercisePriceRange" xlink:to="canf_SharebasedPaymentArrangementOptionExercisePriceRange_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xml:lang="en-US">Options outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life in years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl" xml:lang="en-US">Weighted average exercise price per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xml:lang="en-US">Exercisable, Options exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xml:lang="en-US">Exercisable, Weighted average exercise price per share (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">LEASES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xml:lang="en-US">Schedule of weighted average remaining lease terms and discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US">weighted average remaining lease term (years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US">weighted average discount rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ComponentsOfLeaseExpenseAbstract" xlink:href="canf-20211231.xsd#canf_ComponentsOfLeaseExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ComponentsOfLeaseExpenseAbstract_lbl" xml:lang="en-US">Components of lease expense:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ComponentsOfLeaseExpenseAbstract" xlink:to="canf_ComponentsOfLeaseExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Operating lease cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:href="canf-20211231.xsd#canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:to="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" xlink:href="canf-20211231.xsd#canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets_lbl" xml:lang="en-US">Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" xlink:to="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of maturities of lease liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US">2023</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US">2024</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_LesseeOperatingLeaseLiabilityPaymentDue" xlink:href="canf-20211231.xsd#canf_LesseeOperatingLeaseLiabilityPaymentDue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_LesseeOperatingLeaseLiabilityPaymentDue_lbl" xml:lang="en-US">Total operating lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LesseeOperatingLeaseLiabilityPaymentDue" xlink:to="canf_LesseeOperatingLeaseLiabilityPaymentDue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Present value of lease liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock_lbl" xml:lang="en-US">FINANCE INCOME (EXPENSE)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl" xml:lang="en-US">Schedule of components of finance (income)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceExpensesAbstract" xlink:href="canf-20211231.xsd#canf_FinanceExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_FinanceExpensesAbstract_lbl" xml:lang="en-US">Finance expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceExpensesAbstract" xlink:to="canf_FinanceExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_BanksCommissions" xlink:href="canf-20211231.xsd#canf_BanksCommissions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_BanksCommissions_lbl" xml:lang="en-US">Bank commissions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_BanksCommissions" xlink:to="canf_BanksCommissions_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_NetLossFromExchangeRateFluctuations" xlink:href="canf-20211231.xsd#canf_NetLossFromExchangeRateFluctuations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_NetLossFromExchangeRateFluctuations_lbl" xml:lang="en-US">Net loss from exchange rate fluctuations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NetLossFromExchangeRateFluctuations" xlink:to="canf_NetLossFromExchangeRateFluctuations_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_OtherLossFromShorttermInvestmentRevaluation" xlink:href="canf-20211231.xsd#canf_OtherLossFromShorttermInvestmentRevaluation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_OtherLossFromShorttermInvestmentRevaluation_lbl" xml:lang="en-US">Other loss from short-term investment revaluation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherLossFromShorttermInvestmentRevaluation" xlink:to="canf_OtherLossFromShorttermInvestmentRevaluation_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceExpenses" xlink:href="canf-20211231.xsd#canf_FinanceExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_FinanceExpenses_lbl" xml:lang="en-US">Finance expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceExpenses" xlink:to="canf_FinanceExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceIncomeAbstract" xlink:href="canf-20211231.xsd#canf_FinanceIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_FinanceIncomeAbstract_lbl" xml:lang="en-US">Finance income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceIncomeAbstract" xlink:to="canf_FinanceIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl" xml:lang="en-US">Interest income on bank deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ExchangeRateFluctuations" xlink:href="canf-20211231.xsd#canf_ExchangeRateFluctuations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ExchangeRateFluctuations_lbl" xml:lang="en-US">Exchange rate fluctuations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExchangeRateFluctuations" xlink:to="canf_ExchangeRateFluctuations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GainLossOnInvestments_lbl" xml:lang="en-US">Other gain from short-term investment remeasurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FinanceIncome" xlink:href="canf-20211231.xsd#canf_FinanceIncome"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_FinanceIncome_lbl" xml:lang="en-US">Finance income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceIncome" xlink:to="canf_FinanceIncome_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Total financial income (expenses), net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">TAXES ON INCOME</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets and liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_DeferredTaxAssetsAbstract" xlink:href="canf-20211231.xsd#canf_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_DeferredTaxAssetsAbstract" xlink:to="canf_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carry forward</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Temporary differences mainly relating to Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Deferred tax asset before valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Deferred tax asset, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">TRANSACTIONS WITH RELATED PARTIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl" xml:lang="en-US">Number of Forfeited/expired</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ImputedInterestLessImputedInterest" xlink:href="canf-20211231.xsd#canf_ImputedInterestLessImputedInterest"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="canf_ImputedInterestLessImputedInterest_lbl" xml:lang="en-US">Less: imputed interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ImputedInterestLessImputedInterest" xlink:to="canf_ImputedInterestLessImputedInterest_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherExpenses_lbl" xml:lang="en-US">Other financial expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember" xlink:href="canf-20211231.xsd#canf_LaboratoryEquipmentAndLeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember_lbl" xml:lang="en-US">Laboratory equipment and Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember" xlink:to="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ComputersOfficeFurnitureAndEquipmentMember" xlink:href="canf-20211231.xsd#canf_ComputersOfficeFurnitureAndEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ComputersOfficeFurnitureAndEquipmentMember_lbl" xml:lang="en-US">Computers, office furniture and equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ComputersOfficeFurnitureAndEquipmentMember" xlink:to="canf_ComputersOfficeFurnitureAndEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_CipherPharmaceuticalsMember" xlink:href="canf-20211231.xsd#canf_CipherPharmaceuticalsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CipherPharmaceuticalsMember_lbl" xml:lang="en-US">Cipher Pharmaceuticals [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CipherPharmaceuticalsMember" xlink:to="canf_CipherPharmaceuticalsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ChongKunDangPharmaceuticalsCorpMember" xlink:href="canf-20211231.xsd#canf_ChongKunDangPharmaceuticalsCorpMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ChongKunDangPharmaceuticalsCorpMember_lbl" xml:lang="en-US">Chong Kun Dang Pharmaceuticals Corp [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ChongKunDangPharmaceuticalsCorpMember" xlink:to="canf_ChongKunDangPharmaceuticalsCorpMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_GebroHoldingGmBHMember" xlink:href="canf-20211231.xsd#canf_GebroHoldingGmBHMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_GebroHoldingGmBHMember_lbl" xml:lang="en-US">Gebro Holding GmBH [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GebroHoldingGmBHMember" xlink:to="canf_GebroHoldingGmBHMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_EwopharmaAGMember" xlink:href="canf-20211231.xsd#canf_EwopharmaAGMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_EwopharmaAGMember_lbl" xml:lang="en-US">Ewopharma AG [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_EwopharmaAGMember" xlink:to="canf_EwopharmaAGMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_LaboratoryEquipmentMember" xlink:href="canf-20211231.xsd#canf_LaboratoryEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_LaboratoryEquipmentMember_lbl" xml:lang="en-US">Laboratory equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LaboratoryEquipmentMember" xlink:to="canf_LaboratoryEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Level 1 [Member]]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_January2017Member" xlink:href="canf-20211231.xsd#canf_January2017Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_January2017Member_lbl" xml:lang="en-US">January 2017 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_January2017Member" xlink:to="canf_January2017Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_March2018Member" xlink:href="canf-20211231.xsd#canf_March2018Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_March2018Member_lbl" xml:lang="en-US">March 2018 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_March2018Member" xlink:to="canf_March2018Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_January2019Member" xlink:href="canf-20211231.xsd#canf_January2019Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_January2019Member_lbl" xml:lang="en-US">January 2019 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_January2019Member" xlink:to="canf_January2019Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_April2019Member" xlink:href="canf-20211231.xsd#canf_April2019Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_April2019Member_lbl" xml:lang="en-US">April 2019 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_April2019Member" xlink:to="canf_April2019Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_May2019Member" xlink:href="canf-20211231.xsd#canf_May2019Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_May2019Member_lbl" xml:lang="en-US">May 2019 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_May2019Member" xlink:to="canf_May2019Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_January2020Member" xlink:href="canf-20211231.xsd#canf_January2020Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_January2020Member_lbl" xml:lang="en-US">January 2020 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_January2020Member" xlink:to="canf_January2020Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_February2020Member" xlink:href="canf-20211231.xsd#canf_February2020Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_February2020Member_lbl" xml:lang="en-US">February 2020 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_February2020Member" xlink:to="canf_February2020Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_June2020Member" xlink:href="canf-20211231.xsd#canf_June2020Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_June2020Member_lbl" xml:lang="en-US">June 2020 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_June2020Member" xlink:to="canf_June2020Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_July2020Member" xlink:href="canf-20211231.xsd#canf_July2020Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_July2020Member_lbl" xml:lang="en-US">July 2020 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_July2020Member" xlink:to="canf_July2020Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_August2021Member" xlink:href="canf-20211231.xsd#canf_August2021Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_August2021Member_lbl" xml:lang="en-US">August 2021 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_August2021Member" xlink:to="canf_August2021Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_December2021Member" xlink:href="canf-20211231.xsd#canf_December2021Member"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_December2021Member_lbl" xml:lang="en-US">December 2021 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_December2021Member" xlink:to="canf_December2021Member_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePriceRangeOneMember" xlink:href="canf-20211231.xsd#canf_ExercisePriceRangeOneMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ExercisePriceRangeOneMember_lbl" xml:lang="en-US">Exercise price $0.08 - $0.94 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePriceRangeOneMember" xlink:to="canf_ExercisePriceRangeOneMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePriceRangeTwoMember" xlink:href="canf-20211231.xsd#canf_ExercisePriceRangeTwoMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ExercisePriceRangeTwoMember_lbl" xml:lang="en-US">Exercise price $1.09 - $1.73 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePriceRangeTwoMember" xlink:to="canf_ExercisePriceRangeTwoMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePriceRangeThreeMember" xlink:href="canf-20211231.xsd#canf_ExercisePriceRangeThreeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ExercisePriceRangeThreeMember_lbl" xml:lang="en-US">Exercise price $2.61 - $5.18 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePriceRangeThreeMember" xlink:to="canf_ExercisePriceRangeThreeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xml:lang="en-US">Business Acquisition [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis_lbl" xml:lang="en-US">Income Tax Authority, Name [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Number of ordinary shares represent by each ADS (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:label="us-gaap_SharesIssued_lbl1" xml:lang="en-US">Shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl1"/>
    <loc xlink:type="locator" xlink:label="canf_CashFlowsFromOperatingActivities" xlink:href="canf-20211231.xsd#canf_CashFlowsFromOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CashFlowsFromOperatingActivities_lbl" xml:lang="en-US">Cash flows from operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CashFlowsFromOperatingActivities" xlink:to="canf_CashFlowsFromOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtWeightedAverageInterestRate_lbl" xml:lang="en-US">Weighted average interest rates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtWeightedAverageInterestRate" xlink:to="us-gaap_DebtWeightedAverageInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ContractLiabilities" xlink:href="canf-20211231.xsd#canf_ContractLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ContractLiabilities_lbl" xml:lang="en-US">Contract liabilities under deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ContractLiabilities" xlink:to="canf_ContractLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_Revenue" xlink:href="canf-20211231.xsd#canf_Revenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_Revenue_lbl" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_Revenue" xlink:to="canf_Revenue_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_RevenuesIncludedInContractLiabilities" xlink:href="canf-20211231.xsd#canf_RevenuesIncludedInContractLiabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_RevenuesIncludedInContractLiabilities_lbl" xml:lang="en-US">Revenues included in contract liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RevenuesIncludedInContractLiabilities" xlink:to="canf_RevenuesIncludedInContractLiabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfDepositsOnMonthlySalary" xlink:href="canf-20211231.xsd#canf_PercentageOfDepositsOnMonthlySalary"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_PercentageOfDepositsOnMonthlySalary_lbl" xml:lang="en-US">Percentage of deposits on monthly salary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfDepositsOnMonthlySalary" xlink:to="canf_PercentageOfDepositsOnMonthlySalary_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeveranceCosts1_lbl" xml:lang="en-US">Severance pay expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfRealizationOnUltimateSettlement" xlink:href="canf-20211231.xsd#canf_PercentageOfRealizationOnUltimateSettlement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_PercentageOfRealizationOnUltimateSettlement_lbl" xml:lang="en-US">Maximum percentage of realization on ultimate settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfRealizationOnUltimateSettlement" xlink:to="canf_PercentageOfRealizationOnUltimateSettlement_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Total number of shares subject to outstanding unlisted options (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of shares hold by company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0" xml:lang="en-US">Sold an aggregate shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl0"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfOutstandingShares" xlink:href="canf-20211231.xsd#canf_PercentageOfOutstandingShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_PercentageOfOutstandingShares_lbl" xml:lang="en-US">Percentage of outstanding shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfOutstandingShares" xlink:to="canf_PercentageOfOutstandingShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationExpenseOnReclassifiedAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationExpenseOnReclassifiedAssets_lbl" xml:lang="en-US">Depreciation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:to="us-gaap_DepreciationExpenseOnReclassifiedAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseCommissionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoninterestExpenseCommissionExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoninterestExpenseCommissionExpense_lbl" xml:lang="en-US">Commission Income Expense (in Euro)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseCommissionExpense" xlink:to="us-gaap_NoninterestExpenseCommissionExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Annual royalties (in Euro)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_PercentageOfNetSales" xlink:href="canf-20211231.xsd#canf_PercentageOfNetSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_PercentageOfNetSales_lbl" xml:lang="en-US">Percentage of net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfNetSales" xlink:to="canf_PercentageOfNetSales_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_PatentAgreementDescription" xlink:href="canf-20211231.xsd#canf_PatentAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_PatentAgreementDescription_lbl" xml:lang="en-US">Patent agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PatentAgreementDescription" xlink:to="canf_PatentAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvanceRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvanceRoyalties"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdvanceRoyalties_lbl" xml:lang="en-US">Royalties in a total amount (in Euro)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvanceRoyalties" xlink:to="us-gaap_AdvanceRoyalties_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_RoyaltyPaymentsPercentage" xlink:href="canf-20211231.xsd#canf_RoyaltyPaymentsPercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_RoyaltyPaymentsPercentage_lbl" xml:lang="en-US">Royalty payments, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RoyaltyPaymentsPercentage" xlink:to="canf_RoyaltyPaymentsPercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_UnfrontPaymentAmount" xlink:href="canf-20211231.xsd#canf_UnfrontPaymentAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_UnfrontPaymentAmount_lbl" xml:lang="en-US">Upfront payment amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnfrontPaymentAmount" xlink:to="canf_UnfrontPaymentAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_AdditionalPayments" xlink:href="canf-20211231.xsd#canf_AdditionalPayments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_AdditionalPayments_lbl" xml:lang="en-US">Additional payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AdditionalPayments" xlink:to="canf_AdditionalPayments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl" xml:lang="en-US">Distribution and supply agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetentionPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetentionPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetentionPayable_lbl" xml:lang="en-US">Additional payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetentionPayable" xlink:to="us-gaap_RetentionPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_RoyaltyOnNetSales" xlink:href="canf-20211231.xsd#canf_RoyaltyOnNetSales"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_RoyaltyOnNetSales_lbl" xml:lang="en-US">Percentage of royalties on net sales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RoyaltyOnNetSales" xlink:to="canf_RoyaltyOnNetSales_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_NonRefundableUpfrontPayment" xlink:href="canf-20211231.xsd#canf_NonRefundableUpfrontPayment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_NonRefundableUpfrontPayment_lbl" xml:lang="en-US">Non-refundable upfront payment (in Euro)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NonRefundableUpfrontPayment" xlink:to="canf_NonRefundableUpfrontPayment_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_StockholdersEquityChangeInRatioDescription" xlink:href="canf-20211231.xsd#canf_StockholdersEquityChangeInRatioDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_StockholdersEquityChangeInRatioDescription_lbl" xml:lang="en-US">Stockholders equity change In ratio description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockholdersEquityChangeInRatioDescription" xlink:to="canf_StockholdersEquityChangeInRatioDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_WarrantsToPurchaseAdditionalSharesIssued" xlink:href="canf-20211231.xsd#canf_WarrantsToPurchaseAdditionalSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_WarrantsToPurchaseAdditionalSharesIssued_lbl" xml:lang="en-US">Warrants to purchase additional shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsToPurchaseAdditionalSharesIssued" xlink:to="canf_WarrantsToPurchaseAdditionalSharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_AggregatePurchasePrice" xlink:href="canf-20211231.xsd#canf_AggregatePurchasePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_AggregatePurchasePrice_lbl" xml:lang="en-US">Aggregate purchase price (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregatePurchasePrice" xlink:to="canf_AggregatePurchasePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Issuance cost (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Purchase aggregate warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePrices" xlink:href="canf-20211231.xsd#canf_ExercisePrices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ExercisePrices_lbl" xml:lang="en-US">Exercise prices (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePrices" xlink:to="canf_ExercisePrices_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_AggregateWarrantPurchased" xlink:href="canf-20211231.xsd#canf_AggregateWarrantPurchased"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_AggregateWarrantPurchased_lbl" xml:lang="en-US">Aggregate warrant purchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateWarrantPurchased" xlink:to="canf_AggregateWarrantPurchased_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareIssued" xlink:href="canf-20211231.xsd#canf_ShareIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ShareIssued_lbl" xml:lang="en-US">Ordinary shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareIssued" xlink:to="canf_ShareIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl" xml:lang="en-US">Reduced exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IssueOfNewUnregisteredWarrants" xlink:href="canf-20211231.xsd#canf_IssueOfNewUnregisteredWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_IssueOfNewUnregisteredWarrants_lbl" xml:lang="en-US">Issue of new unregistered warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssueOfNewUnregisteredWarrants" xlink:to="canf_IssueOfNewUnregisteredWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePriceSubjectToAdjusment" xlink:href="canf-20211231.xsd#canf_ExercisePriceSubjectToAdjusment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ExercisePriceSubjectToAdjusment_lbl" xml:lang="en-US">Exercise price subject to adjustment (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePriceSubjectToAdjusment" xlink:to="canf_ExercisePriceSubjectToAdjusment_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_DeemedDividend" xlink:href="canf-20211231.xsd#canf_DeemedDividend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_DeemedDividend_lbl" xml:lang="en-US">Deemed dividend (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_DeemedDividend" xlink:to="canf_DeemedDividend_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SecuritiesPurchaseAgreementDescription" xlink:href="canf-20211231.xsd#canf_SecuritiesPurchaseAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_SecuritiesPurchaseAgreementDescription_lbl" xml:lang="en-US">Securities purchase agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SecuritiesPurchaseAgreementDescription" xlink:to="canf_SecuritiesPurchaseAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl" xml:lang="en-US">Gross proceeds from offering (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Expiring date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_CompensationWarrantsExercisable" xlink:href="canf-20211231.xsd#canf_CompensationWarrantsExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CompensationWarrantsExercisable_lbl" xml:lang="en-US">Compensation warrant exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CompensationWarrantsExercisable" xlink:to="canf_CompensationWarrantsExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IncreaseAuthorizedShareCapital" xlink:href="canf-20211231.xsd#canf_IncreaseAuthorizedShareCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_IncreaseAuthorizedShareCapital_lbl" xml:lang="en-US">Increase authorized capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IncreaseAuthorizedShareCapital" xlink:to="canf_IncreaseAuthorizedShareCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_StockIssuanceAgreementDescription" xlink:href="canf-20211231.xsd#canf_StockIssuanceAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_StockIssuanceAgreementDescription_lbl" xml:lang="en-US">Stock issuance agreement, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuanceAgreementDescription" xlink:to="canf_StockIssuanceAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_AggregateNumberOfADS" xlink:href="canf-20211231.xsd#canf_AggregateNumberOfADS"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_AggregateNumberOfADS_lbl" xml:lang="en-US">Aggregate number of ADS percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateNumberOfADS" xlink:to="canf_AggregateNumberOfADS_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl" xml:lang="en-US">Exercise price per ADS (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_WarrantsToPurchaseAggregateShares" xlink:href="canf-20211231.xsd#canf_WarrantsToPurchaseAggregateShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_WarrantsToPurchaseAggregateShares_lbl" xml:lang="en-US">Warrants to purchase aggregate ADS shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsToPurchaseAggregateShares" xlink:to="canf_WarrantsToPurchaseAggregateShares_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ExercisePrice" xlink:href="canf-20211231.xsd#canf_ExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ExercisePrice_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePrice" xlink:to="canf_ExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_TotalConsiderationAmount" xlink:href="canf-20211231.xsd#canf_TotalConsiderationAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_TotalConsiderationAmount_lbl" xml:lang="en-US">Total consideration amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TotalConsiderationAmount" xlink:to="canf_TotalConsiderationAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FairValueAmount" xlink:href="canf-20211231.xsd#canf_FairValueAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_FairValueAmount_lbl" xml:lang="en-US">Fair value amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FairValueAmount" xlink:to="canf_FairValueAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_PurchaseAgreementDescription" xlink:href="canf-20211231.xsd#canf_PurchaseAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_PurchaseAgreementDescription_lbl" xml:lang="en-US">Purchase agreement description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PurchaseAgreementDescription" xlink:to="canf_PurchaseAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_TotalReceivedAmount" xlink:href="canf-20211231.xsd#canf_TotalReceivedAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_TotalReceivedAmount_lbl" xml:lang="en-US">Total received amount (in Dollars)</label>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbKPcFX/25U7tJjZ1e/QkjhiUJn9hDzDjBiHcqiPkVBCCODXCRCIM9u4S3gJiJPkfeA4IWMDZOgz1+S5KnQ1ZJmUdVT2gUh0PhPHv3pa4+fTZTkTD4DIrxKSC26B+qiQe8tCtLe+ud+bxP4dcVqp2G92WtBs6vOj1FOZTxFulqqlkvzOQstgQaJRgDCb5YCPopT4T5cLPiSro8uctJwwYYf] CSR-->
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TotalReceivedAmount" xlink:to="canf_TotalReceivedAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_OrdinaryShares" xlink:href="canf-20211231.xsd#canf_OrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_OrdinaryShares_lbl" xml:lang="en-US">Ordinary shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OrdinaryShares" xlink:to="canf_OrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_IssuanceExpensesAmount" xlink:href="canf-20211231.xsd#canf_IssuanceExpensesAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_IssuanceExpensesAmount_lbl" xml:lang="en-US">Issuance expenses amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceExpensesAmount" xlink:to="canf_IssuanceExpensesAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ExerciseAgreementDescription" xlink:href="canf-20211231.xsd#canf_ExerciseAgreementDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ExerciseAgreementDescription_lbl" xml:lang="en-US">Exercise agreement description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExerciseAgreementDescription" xlink:to="canf_ExerciseAgreementDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_GrantedExcessYears" xlink:href="canf-20211231.xsd#canf_GrantedExcessYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_GrantedExcessYears_lbl" xml:lang="en-US">Granted excess years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GrantedExcessYears" xlink:to="canf_GrantedExcessYears_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_NumberOfOrdinaryShares" xlink:href="canf-20211231.xsd#canf_NumberOfOrdinaryShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_NumberOfOrdinaryShares_lbl" xml:lang="en-US">Number of ordinary shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NumberOfOrdinaryShares" xlink:to="canf_NumberOfOrdinaryShares_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FutureShares" xlink:href="canf-20211231.xsd#canf_FutureShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_FutureShares_lbl" xml:lang="en-US">Future shares (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FutureShares" xlink:to="canf_FutureShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted average remaining contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Compensation costs not yet recognized (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl" xml:lang="en-US">Lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Corporate tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl" xml:lang="en-US">Carryforward losses amount (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl" xml:lang="en-US">Aggregate amount of research and development expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl" xml:lang="en-US">Functional currency, reporting currency and foreign currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtPolicyTextBlock_lbl" xml:lang="en-US">Short-term bank deposits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock_lbl" xml:lang="en-US">Prepaid expenses, and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock" xlink:to="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl" xml:lang="en-US">Operating lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property, plant and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of long-lived assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and development expenditures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair value measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentration of Credit Risk</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xml:lang="en-US">Legal and other contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SeverancePayPolicyTextBlock" xlink:href="canf-20211231.xsd#canf_SeverancePayPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_SeverancePayPolicyTextBlock_lbl" xml:lang="en-US">Severance pay</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SeverancePayPolicyTextBlock" xlink:to="canf_SeverancePayPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Share-based payment transactions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Taxes on income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" xlink:href="canf-20211231.xsd#canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_lbl" xml:lang="en-US">Ordinary share warrants classification and measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" xlink:to="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recently adopted and recently issued accounting pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:href="canf-20211231.xsd#canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl" xml:lang="en-US">Accounting pronouncements not yet adopted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_CipherMember" xlink:href="canf-20211231.xsd#canf_CipherMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CipherMember_lbl" xml:lang="en-US">Cipher [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CipherMember" xlink:to="canf_CipherMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ChongKunDangMember" xlink:href="canf-20211231.xsd#canf_ChongKunDangMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ChongKunDangMember_lbl" xml:lang="en-US">Chong kun dang [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ChongKunDangMember" xlink:to="canf_ChongKunDangMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl" xml:lang="en-US">Business Combination [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_CMSMedicalMember" xlink:href="canf-20211231.xsd#canf_CMSMedicalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_CMSMedicalMember_lbl" xml:lang="en-US">CMS Medical [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CMSMedicalMember" xlink:to="canf_CMSMedicalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_KyongboPharmMember" xlink:href="canf-20211231.xsd#canf_KyongboPharmMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_KyongboPharmMember_lbl" xml:lang="en-US">Kyongbo Pharm [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_KyongboPharmMember" xlink:to="canf_KyongboPharmMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SwitzerlandBasedEwopharmaMember" xlink:href="canf-20211231.xsd#canf_SwitzerlandBasedEwopharmaMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_SwitzerlandBasedEwopharmaMember_lbl" xml:lang="en-US">Switzerland Based Ewopharma [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SwitzerlandBasedEwopharmaMember" xlink:to="canf_SwitzerlandBasedEwopharmaMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_VetbiolixMember" xlink:href="canf-20211231.xsd#canf_VetbiolixMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_VetbiolixMember_lbl" xml:lang="en-US">Vetbiolix [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_VetbiolixMember" xlink:to="canf_VetbiolixMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ADSMember" xlink:href="canf-20211231.xsd#canf_ADSMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="canf_ADSMember_lbl" xml:lang="en-US">ADS [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ADSMember" xlink:to="canf_ADSMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">Private Placement Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IsraelTaxAuthorityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IsraelTaxAuthorityMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IsraelTaxAuthorityMember_lbl" xml:lang="en-US">Israel [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IsraelTaxAuthorityMember" xlink:to="us-gaap_IsraelTaxAuthorityMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShortTermInvestmentTable" xlink:href="canf-20211231.xsd#canf_ShortTermInvestmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShortTermInvestmentTable_lbl" xml:lang="en-US">Short-Term Investment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShortTermInvestmentTable" xlink:to="canf_ShortTermInvestmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-Term Investment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsPayableTable" xlink:href="canf-20211231.xsd#canf_OtherAccountsPayableTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OtherAccountsPayableTable_lbl" xml:lang="en-US">Other Accounts Payable [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherAccountsPayableTable" xlink:to="canf_OtherAccountsPayableTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_OtherAccountsPayableLineItems" xlink:href="canf-20211231.xsd#canf_OtherAccountsPayableLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OtherAccountsPayableLineItems_lbl" xml:lang="en-US">Other Accounts Payable [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherAccountsPayableLineItems" xlink:to="canf_OtherAccountsPayableLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xml:lang="en-US">Asset Class [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:href="canf-20211231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:href="canf-20211231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:to="canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_NameOfMajorCustomerDomain_lbl" xml:lang="en-US">Customer [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" xlink:href="canf-20211231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" xlink:to="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" xlink:href="canf-20211231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" xlink:to="canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xml:lang="en-US">Measurement Frequency [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:href="canf-20211231.xsd#canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable_lbl" xml:lang="en-US">Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:href="canf-20211231.xsd#canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems_lbl" xml:lang="en-US">Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:to="canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateDomain_lbl" xml:lang="en-US">Award Date [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateDomain" xlink:to="us-gaap_AwardDateDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" xlink:href="canf-20211231.xsd#canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" xlink:to="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:href="canf-20211231.xsd#canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" xlink:href="canf-20211231.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable_lbl" xml:lang="en-US">Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" xlink:to="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:href="canf-20211231.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems_lbl" xml:lang="en-US">Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xml:lang="en-US">Exercise Price Range [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xml:lang="en-US">Related Party Transaction [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:href="canf-20211231.xsd#canf_ContingentLiabilitiesandCommitmentsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ContingentLiabilitiesandCommitmentsDetailsTable_lbl" xml:lang="en-US">Contingent Liabilities and Commitments (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="canf_ContingentLiabilitiesandCommitmentsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:href="canf-20211231.xsd#canf_ContingentLiabilitiesandCommitmentsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems_lbl" xml:lang="en-US">Contingent Liabilities and Commitments (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="canf_ContingentLiabilitiesandCommitmentsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsTable" xlink:href="canf-20211231.xsd#canf_ShareholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareholdersEquityDetailsTable_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareholdersEquityDetailsTable" xlink:to="canf_ShareholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareholdersEquityDetailsLineItems" xlink:href="canf-20211231.xsd#canf_ShareholdersEquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareholdersEquityDetailsLineItems_lbl" xml:lang="en-US">Shareholders&apos; Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareholdersEquityDetailsLineItems" xlink:to="canf_ShareholdersEquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsTable" xlink:href="canf-20211231.xsd#canf_ShareBasedPaymentTransactionsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareBasedPaymentTransactionsDetailsTable_lbl" xml:lang="en-US">Share-Based Payment Transactions (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentTransactionsDetailsTable" xlink:to="canf_ShareBasedPaymentTransactionsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:href="canf-20211231.xsd#canf_ShareBasedPaymentTransactionsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareBasedPaymentTransactionsDetailsLineItems_lbl" xml:lang="en-US">Share-Based Payment Transactions (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="canf_ShareBasedPaymentTransactionsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain_lbl" xml:lang="en-US">Income Tax Authority, Name [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_TaxesonIncomeDetailsTable" xlink:href="canf-20211231.xsd#canf_TaxesonIncomeDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_TaxesonIncomeDetailsTable_lbl" xml:lang="en-US">Taxes on Income (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TaxesonIncomeDetailsTable" xlink:to="canf_TaxesonIncomeDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="canf_TaxesonIncomeDetailsLineItems" xlink:href="canf-20211231.xsd#canf_TaxesonIncomeDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_TaxesonIncomeDetailsLineItems_lbl" xml:lang="en-US">Taxes on Income (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TaxesonIncomeDetailsLineItems" xlink:to="canf_TaxesonIncomeDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for accounting pronouncements not yet adopted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_AdditionalPayments_lbl0" xml:lang="en-US">Additional payments maximum charges.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AdditionalPayments" xlink:to="canf_AdditionalPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_AggregateNumberOfADS_lbl0" xml:lang="en-US">aggregate number of ADS.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateNumberOfADS" xlink:to="canf_AggregateNumberOfADS_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_AggregatePurchasePrice_lbl0" xml:lang="en-US">Aggregate purchase price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregatePurchasePrice" xlink:to="canf_AggregatePurchasePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_AggregateWarrantPurchased_lbl0" xml:lang="en-US">Aggregate warrant purchased.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateWarrantPurchased" xlink:to="canf_AggregateWarrantPurchased_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_BanksCommissions_lbl0" xml:lang="en-US">Bank commissions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_BanksCommissions" xlink:to="canf_BanksCommissions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_CashFlowsFromOperatingActivities_lbl0" xml:lang="en-US">Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CashFlowsFromOperatingActivities" xlink:to="canf_CashFlowsFromOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl0" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:to="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_CompensationWarrantsExercisable_lbl0" xml:lang="en-US">compensation warrants exercisable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CompensationWarrantsExercisable" xlink:to="canf_CompensationWarrantsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ContractLiabilities_lbl0" xml:lang="en-US">Amouunt of contract liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ContractLiabilities" xlink:to="canf_ContractLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_DeemedDividend_lbl0" xml:lang="en-US">Deemed dividend.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_DeemedDividend" xlink:to="canf_DeemedDividend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_EmployeesAndPayrollAccruals_lbl0" xml:lang="en-US">Amount of employees and payroll accruals.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_EmployeesAndPayrollAccruals" xlink:to="canf_EmployeesAndPayrollAccruals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ExchangeRateFluctuations_lbl0" xml:lang="en-US">Exchange rate fluctuations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExchangeRateFluctuations" xlink:to="canf_ExchangeRateFluctuations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ExercisePrice_lbl0" xml:lang="en-US">Exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePrice" xlink:to="canf_ExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ExercisePriceSubjectToAdjusment_lbl0" xml:lang="en-US">Exercise price Subject to adjustment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePriceSubjectToAdjusment" xlink:to="canf_ExercisePriceSubjectToAdjusment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ExercisePrices_lbl0" xml:lang="en-US">Warrant, Exercise Price, Decrease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePrices" xlink:to="canf_ExercisePrices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_FairValueAmount_lbl0" xml:lang="en-US">Fair value amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FairValueAmount" xlink:to="canf_FairValueAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_FinanceExpenses_lbl0" xml:lang="en-US">The aggregate expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceExpenses" xlink:to="canf_FinanceExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_FinanceIncome_lbl0" xml:lang="en-US">The aggregate amount of income from finance income.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceIncome" xlink:to="canf_FinanceIncome_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_FutureShares_lbl0" xml:lang="en-US">Future shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FutureShares" xlink:to="canf_FutureShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_GovernmentAuthorities_lbl0" xml:lang="en-US">Amount of government authorities for the period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GovernmentAuthorities" xlink:to="canf_GovernmentAuthorities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ImputedInterestLessImputedInterest_lbl0" xml:lang="en-US">imputed interest.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ImputedInterestLessImputedInterest" xlink:to="canf_ImputedInterestLessImputedInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_IncreaseAuthorizedShareCapital_lbl0" xml:lang="en-US">Increase authorized Share Capital.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IncreaseAuthorizedShareCapital" xlink:to="canf_IncreaseAuthorizedShareCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment_lbl0" xml:lang="en-US">Amount of changes in fair value of short-term investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" xlink:to="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_IncreaseDecreaseInSharebasedPayment_lbl0" xml:lang="en-US">Amount of changes in share based payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IncreaseDecreaseInSharebasedPayment" xlink:to="canf_IncreaseDecreaseInSharebasedPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_IssuanceExpensesAmount_lbl0" xml:lang="en-US">Issuance expenses amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceExpensesAmount" xlink:to="canf_IssuanceExpensesAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses_lbl0" xml:lang="en-US">Issuance of share capital due to warrants exercise, net of issuance expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares_lbl0" xml:lang="en-US">Issuance of share capital due to warrants exercise, net of issuance expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_IssueOfNewUnregisteredWarrants_lbl0" xml:lang="en-US">Issue of New Unregistered Warrants.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssueOfNewUnregisteredWarrants" xlink:to="canf_IssueOfNewUnregisteredWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_LesseeOperatingLeaseLiabilityPaymentDue_lbl0" xml:lang="en-US">Amount of lessee&apos;s undiscounted obligation for lease payment for operating lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LesseeOperatingLeaseLiabilityPaymentDue" xlink:to="canf_LesseeOperatingLeaseLiabilityPaymentDue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_NetLossFromExchangeRateFluctuations_lbl0" xml:lang="en-US">Net loss from exchange rate fluctuations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NetLossFromExchangeRateFluctuations" xlink:to="canf_NetLossFromExchangeRateFluctuations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_NonRefundableUpfrontPayment_lbl0" xml:lang="en-US">The amount of non refundable upfront payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NonRefundableUpfrontPayment" xlink:to="canf_NonRefundableUpfrontPayment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_NumberOfExercisableAtEndOfShares_lbl0" xml:lang="en-US">The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NumberOfExercisableAtEndOfShares" xlink:to="canf_NumberOfExercisableAtEndOfShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for ordinary share warrants classification and measurement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" xlink:to="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_OrdinaryShares_lbl0" xml:lang="en-US">Ordinary shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OrdinaryShares" xlink:to="canf_OrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock_lbl0" xml:lang="en-US">Disclosure of other accounts receivable and prepaid expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:to="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_OtherLossFromShorttermInvestmentRevaluation_lbl0" xml:lang="en-US">Other loss from short-term investment revaluation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherLossFromShorttermInvestmentRevaluation" xlink:to="canf_OtherLossFromShorttermInvestmentRevaluation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_PatentAgreementDescription_lbl0" xml:lang="en-US">The description of patent agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PatentAgreementDescription" xlink:to="canf_PatentAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_PercentageOfDepositsOnMonthlySalary_lbl0" xml:lang="en-US">Percentage of deposits on monthly salary.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfDepositsOnMonthlySalary" xlink:to="canf_PercentageOfDepositsOnMonthlySalary_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_PercentageOfNetSales_lbl0" xml:lang="en-US">The percentage of net sales.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfNetSales" xlink:to="canf_PercentageOfNetSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_PercentageOfOutstandingShares_lbl0" xml:lang="en-US">Percentage of outstanding shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfOutstandingShares" xlink:to="canf_PercentageOfOutstandingShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_PercentageOfRealizationOnUltimateSettlement_lbl0" xml:lang="en-US">Percentage of realization on ultimate settlement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfRealizationOnUltimateSettlement" xlink:to="canf_PercentageOfRealizationOnUltimateSettlement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_Revenue_lbl0" xml:lang="en-US">Revenues.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_Revenue" xlink:to="canf_Revenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_RevenueContractWithCustomer_lbl0" xml:lang="en-US">Revenue contract with customer.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RevenueContractWithCustomer" xlink:to="canf_RevenueContractWithCustomer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_RevenuesIncludedInContractLiabilities_lbl0" xml:lang="en-US">Revenues included in contract liabilities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RevenuesIncludedInContractLiabilities" xlink:to="canf_RevenuesIncludedInContractLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_RoyaltyPaymentsPercentage_lbl0" xml:lang="en-US">The royalty payment in percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RoyaltyPaymentsPercentage" xlink:to="canf_RoyaltyPaymentsPercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock_lbl0" xml:lang="en-US">Tabular disclosure of major customer data as a percentage of total revenues.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" xlink:to="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Other Accounts Receivable and Prepaid Expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:to="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock_lbl0" xml:lang="en-US">Useful lives of the assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" xlink:to="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_SecuritiesPurchaseAgreementDescription_lbl0" xml:lang="en-US">Securities Purchase Agreement, Description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SecuritiesPurchaseAgreementDescription" xlink:to="canf_SecuritiesPurchaseAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_SeverancePayPolicyTextBlock_lbl0" xml:lang="en-US">Disclosure of accounting policy for severance pay.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SeverancePayPolicyTextBlock" xlink:to="canf_SeverancePayPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ShareIssued_lbl0" xml:lang="en-US">Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareIssued" xlink:to="canf_ShareIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_SharebasedPaymentArrangementOptionExercisePriceRange_lbl0" xml:lang="en-US">The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SharebasedPaymentArrangementOptionExercisePriceRange" xlink:to="canf_SharebasedPaymentArrangementOptionExercisePriceRange_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_SharebasedPayments_lbl0" xml:lang="en-US">Share-based payments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SharebasedPayments" xlink:to="canf_SharebasedPayments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_StockIssuanceAgreementDescription_lbl0" xml:lang="en-US">Stock issuance agreement description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuanceAgreementDescription" xlink:to="canf_StockIssuanceAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_lbl0" xml:lang="en-US">Number of issuance of share capital and warrants, net of issuance expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" xlink:to="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_lbl0" xml:lang="en-US">Issuance of share capital and warrants, net of issuance expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" xlink:to="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_StockIssuedDuringPeriodValueNetOfIssueExpenses_lbl0" xml:lang="en-US">Amount of net of issue expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodValueNetOfIssueExpenses" xlink:to="canf_StockIssuedDuringPeriodValueNetOfIssueExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_StockholdersEquityChangeInRatioDescription_lbl0" xml:lang="en-US">Stockholders Equity Change In Ratio Description.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockholdersEquityChangeInRatioDescription" xlink:to="canf_StockholdersEquityChangeInRatioDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets_lbl0" xml:lang="en-US">Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" xlink:to="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_TotalConsiderationAmount_lbl0" xml:lang="en-US">Total consideration amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TotalConsiderationAmount" xlink:to="canf_TotalConsiderationAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_TotalReceivedAmount_lbl0" xml:lang="en-US">Total received amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TotalReceivedAmount" xlink:to="canf_TotalReceivedAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_UnfrontPaymentAmount_lbl0" xml:lang="en-US">Unfront payment amount.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnfrontPaymentAmount" xlink:to="canf_UnfrontPaymentAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments_lbl0" xml:lang="en-US">Depreciation rates property, plant and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" xlink:to="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_WarrantsNetOfIssueExpenses_lbl0" xml:lang="en-US">Warrants, net of issue expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsNetOfIssueExpenses" xlink:to="canf_WarrantsNetOfIssueExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_WarrantsToPurchaseAdditionalSharesIssued_lbl0" xml:lang="en-US">Warrants to purchase additional shares issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsToPurchaseAdditionalSharesIssued" xlink:to="canf_WarrantsToPurchaseAdditionalSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_WarrantsToPurchaseAggregateShares_lbl0" xml:lang="en-US">Warrants to purchase aggregate shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsToPurchaseAggregateShares" xlink:to="canf_WarrantsToPurchaseAggregateShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares_lbl0" xml:lang="en-US">Weighted average exercise price, Exercisable at end of per shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares" xlink:to="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="canf_ADSMember_lbl0" xml:lang="en-US">American Depository Receipt (or American Depository Share, ADS).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ADSMember" xlink:to="canf_ADSMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AddressTypeDomain_lbl" xml:lang="en-US">Address Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AddressTypeDomain" xlink:to="dei_AddressTypeDomain_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_RoyaltyPaymentsPercentage_lbl1" xml:lang="en-US">RoyaltyPaymentsPercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RoyaltyPaymentsPercentage" xlink:to="canf_RoyaltyPaymentsPercentage_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_June2020Member_lbl0" xml:lang="en-US">June2020Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_June2020Member" xlink:to="canf_June2020Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments_lbl1" xml:lang="en-US">UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" xlink:to="canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_lbl1" xml:lang="en-US">StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" xlink:to="canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_VetbiolixMember_lbl0" xml:lang="en-US">VetbiolixMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_VetbiolixMember" xlink:to="canf_VetbiolixMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SharebasedPaymentArrangementOptionExercisePriceRange_lbl1" xml:lang="en-US">SharebasedPaymentArrangementOptionExercisePriceRange</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SharebasedPaymentArrangementOptionExercisePriceRange" xlink:to="canf_SharebasedPaymentArrangementOptionExercisePriceRange_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_GrantedExcessYears_lbl0" xml:lang="en-US">GrantedExcessYears</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GrantedExcessYears" xlink:to="canf_GrantedExcessYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">DeferredTaxAssetsAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_DeferredTaxAssetsAbstract" xlink:to="canf_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_March2018Member_lbl0" xml:lang="en-US">March2018Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_March2018Member" xlink:to="canf_March2018Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ExercisePrice_lbl1" xml:lang="en-US">ExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePrice" xlink:to="canf_ExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CipherPharmaceuticalsMember_lbl0" xml:lang="en-US">CipherPharmaceuticalsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CipherPharmaceuticalsMember" xlink:to="canf_CipherPharmaceuticalsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_NumberOfOrdinaryShares_lbl0" xml:lang="en-US">NumberOfOrdinaryShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NumberOfOrdinaryShares" xlink:to="canf_NumberOfOrdinaryShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ADSMember_lbl1" xml:lang="en-US">ADSMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ADSMember" xlink:to="canf_ADSMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_StockholdersEquityChangeInRatioDescription_lbl1" xml:lang="en-US">StockholdersEquityChangeInRatioDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockholdersEquityChangeInRatioDescription" xlink:to="canf_StockholdersEquityChangeInRatioDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_AggregateNumberOfADS_lbl1" xml:lang="en-US">AggregateNumberOfADS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateNumberOfADS" xlink:to="canf_AggregateNumberOfADS_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ExercisePriceRangeOneMember_lbl0" xml:lang="en-US">ExercisePriceRangeOneMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePriceRangeOneMember" xlink:to="canf_ExercisePriceRangeOneMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_StockIssuanceAgreementDescription_lbl1" xml:lang="en-US">StockIssuanceAgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuanceAgreementDescription" xlink:to="canf_StockIssuanceAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_EmployeesAndPayrollAccruals_lbl1" xml:lang="en-US">EmployeesAndPayrollAccruals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_EmployeesAndPayrollAccruals" xlink:to="canf_EmployeesAndPayrollAccruals_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_May2019Member_lbl0" xml:lang="en-US">May2019Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_May2019Member" xlink:to="canf_May2019Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_January2017Member_lbl0" xml:lang="en-US">January2017Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_January2017Member" xlink:to="canf_January2017Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_RevenueContractWithCustomer_lbl1" xml:lang="en-US">RevenueContractWithCustomer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RevenueContractWithCustomer" xlink:to="canf_RevenueContractWithCustomer_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ComponentsOfLeaseExpenseAbstract_lbl0" xml:lang="en-US">ComponentsOfLeaseExpenseAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ComponentsOfLeaseExpenseAbstract" xlink:to="canf_ComponentsOfLeaseExpenseAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IssuanceExpensesAmount_lbl1" xml:lang="en-US">IssuanceExpensesAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceExpensesAmount" xlink:to="canf_IssuanceExpensesAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ExerciseAgreementDescription_lbl0" xml:lang="en-US">ExerciseAgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExerciseAgreementDescription" xlink:to="canf_ExerciseAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ExercisePriceRangeTwoMember_lbl0" xml:lang="en-US">ExercisePriceRangeTwoMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePriceRangeTwoMember" xlink:to="canf_ExercisePriceRangeTwoMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares_lbl1" xml:lang="en-US">WeightedAverageExercisePriceExercisableAtEndOfPerShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares" xlink:to="canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_January2020Member_lbl0" xml:lang="en-US">January2020Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_January2020Member" xlink:to="canf_January2020Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IncreaseDecreaseInSharebasedPayment_lbl1" xml:lang="en-US">IncreaseDecreaseInSharebasedPayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IncreaseDecreaseInSharebasedPayment" xlink:to="canf_IncreaseDecreaseInSharebasedPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock_lbl1" xml:lang="en-US">ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" xlink:to="canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ExercisePriceSubjectToAdjusment_lbl1" xml:lang="en-US">ExercisePriceSubjectToAdjusment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePriceSubjectToAdjusment" xlink:to="canf_ExercisePriceSubjectToAdjusment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FinanceExpensesAbstract_lbl0" xml:lang="en-US">FinanceExpensesAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceExpensesAbstract" xlink:to="canf_FinanceExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CompensationWarrantsExercisable_lbl1" xml:lang="en-US">CompensationWarrantsExercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CompensationWarrantsExercisable" xlink:to="canf_CompensationWarrantsExercisable_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_February2020Member_lbl0" xml:lang="en-US">February2020Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_February2020Member" xlink:to="canf_February2020Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_TotalConsiderationAmount_lbl1" xml:lang="en-US">TotalConsiderationAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TotalConsiderationAmount" xlink:to="canf_TotalConsiderationAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock_lbl1" xml:lang="en-US">OtherAccountsReceivableAndPrepaidExpensesTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:to="canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ImputedInterestLessImputedInterest_lbl1" xml:lang="en-US">ImputedInterestLessImputedInterest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ImputedInterestLessImputedInterest" xlink:to="canf_ImputedInterestLessImputedInterest_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CashFlowsFromOperatingActivities_lbl1" xml:lang="en-US">CashFlowsFromOperatingActivities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CashFlowsFromOperatingActivities" xlink:to="canf_CashFlowsFromOperatingActivities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_RevenuesIncludedInContractLiabilities_lbl1" xml:lang="en-US">RevenuesIncludedInContractLiabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RevenuesIncludedInContractLiabilities" xlink:to="canf_RevenuesIncludedInContractLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_LaboratoryEquipmentMember_lbl0" xml:lang="en-US">LaboratoryEquipmentMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LaboratoryEquipmentMember" xlink:to="canf_LaboratoryEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_WarrantsToPurchaseAggregateShares_lbl1" xml:lang="en-US">WarrantsToPurchaseAggregateShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsToPurchaseAggregateShares" xlink:to="canf_WarrantsToPurchaseAggregateShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ExercisePrices_lbl1" xml:lang="en-US">ExercisePrices</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePrices" xlink:to="canf_ExercisePrices_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets_lbl1" xml:lang="en-US">SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" xlink:to="canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" xlink:to="canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_PercentageOfNetSales_lbl1" xml:lang="en-US">PercentageOfNetSales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfNetSales" xlink:to="canf_PercentageOfNetSales_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_lbl1" xml:lang="en-US">OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" xlink:to="canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_lbl1" xml:lang="en-US">StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" xlink:to="canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CMSMedicalMember_lbl0" xml:lang="en-US">CMSMedicalMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CMSMedicalMember" xlink:to="canf_CMSMedicalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SecuritiesPurchaseAgreementDescription_lbl1" xml:lang="en-US">SecuritiesPurchaseAgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SecuritiesPurchaseAgreementDescription" xlink:to="canf_SecuritiesPurchaseAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_PatentAgreementDescription_lbl1" xml:lang="en-US">PatentAgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PatentAgreementDescription" xlink:to="canf_PatentAgreementDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock_lbl1" xml:lang="en-US">ScheduleOfUsefulLivesOfTheAssetsTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" xlink:to="canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CostAbstract_lbl0" xml:lang="en-US">CostAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CostAbstract" xlink:to="canf_CostAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FinanceIncome_lbl1" xml:lang="en-US">FinanceIncome</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceIncome" xlink:to="canf_FinanceIncome_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ComputersOfficeFurnitureAndEquipmentMember_lbl0" xml:lang="en-US">ComputersOfficeFurnitureAndEquipmentMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ComputersOfficeFurnitureAndEquipmentMember" xlink:to="canf_ComputersOfficeFurnitureAndEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_StockIssuedDuringPeriodValueNetOfIssueExpenses_lbl1" xml:lang="en-US">StockIssuedDuringPeriodValueNetOfIssueExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_StockIssuedDuringPeriodValueNetOfIssueExpenses" xlink:to="canf_StockIssuedDuringPeriodValueNetOfIssueExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_TotalReceivedAmount_lbl1" xml:lang="en-US">TotalReceivedAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_TotalReceivedAmount" xlink:to="canf_TotalReceivedAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl1" xml:lang="en-US">AccountingPronouncementsNotYetAdoptedPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:to="canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CipherMember_lbl0" xml:lang="en-US">CipherMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CipherMember" xlink:to="canf_CipherMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_WarrantsNetOfIssueExpenses_lbl1" xml:lang="en-US">WarrantsNetOfIssueExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsNetOfIssueExpenses" xlink:to="canf_WarrantsNetOfIssueExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_AggregatePurchasePrice_lbl1" xml:lang="en-US">AggregatePurchasePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregatePurchasePrice" xlink:to="canf_AggregatePurchasePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_KyongboPharmMember_lbl0" xml:lang="en-US">KyongboPharmMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_KyongboPharmMember" xlink:to="canf_KyongboPharmMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FairValueAmount_lbl1" xml:lang="en-US">FairValueAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FairValueAmount" xlink:to="canf_FairValueAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OtherLossFromShorttermInvestmentRevaluation_lbl1" xml:lang="en-US">OtherLossFromShorttermInvestmentRevaluation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OtherLossFromShorttermInvestmentRevaluation" xlink:to="canf_OtherLossFromShorttermInvestmentRevaluation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_lbl1" xml:lang="en-US">ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:to="canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_OrdinaryShares_lbl1" xml:lang="en-US">OrdinaryShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_OrdinaryShares" xlink:to="canf_OrdinaryShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SwitzerlandBasedEwopharmaMember_lbl0" xml:lang="en-US">SwitzerlandBasedEwopharmaMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SwitzerlandBasedEwopharmaMember" xlink:to="canf_SwitzerlandBasedEwopharmaMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_Revenue_lbl1" xml:lang="en-US">Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_Revenue" xlink:to="canf_Revenue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_NumberOfExercisableAtEndOfShares_lbl1" xml:lang="en-US">NumberOfExercisableAtEndOfShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NumberOfExercisableAtEndOfShares" xlink:to="canf_NumberOfExercisableAtEndOfShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FinanceIncomeAbstract_lbl0" xml:lang="en-US">FinanceIncomeAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceIncomeAbstract" xlink:to="canf_FinanceIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IncreaseAuthorizedShareCapital_lbl1" xml:lang="en-US">IncreaseAuthorizedShareCapital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IncreaseAuthorizedShareCapital" xlink:to="canf_IncreaseAuthorizedShareCapital_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_DeemedDividend_lbl1" xml:lang="en-US">DeemedDividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_DeemedDividend" xlink:to="canf_DeemedDividend_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_April2019Member_lbl0" xml:lang="en-US">April2019Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_April2019Member" xlink:to="canf_April2019Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_PercentageOfDepositsOnMonthlySalary_lbl1" xml:lang="en-US">PercentageOfDepositsOnMonthlySalary</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfDepositsOnMonthlySalary" xlink:to="canf_PercentageOfDepositsOnMonthlySalary_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_PercentageOfOutstandingShares_lbl1" xml:lang="en-US">PercentageOfOutstandingShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfOutstandingShares" xlink:to="canf_PercentageOfOutstandingShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_BanksCommissions_lbl1" xml:lang="en-US">BanksCommissions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_BanksCommissions" xlink:to="canf_BanksCommissions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ExchangeRateFluctuations_lbl1" xml:lang="en-US">ExchangeRateFluctuations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExchangeRateFluctuations" xlink:to="canf_ExchangeRateFluctuations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_NonRefundableUpfrontPayment_lbl1" xml:lang="en-US">NonRefundableUpfrontPayment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NonRefundableUpfrontPayment" xlink:to="canf_NonRefundableUpfrontPayment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SharebasedPayments_lbl1" xml:lang="en-US">SharebasedPayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SharebasedPayments" xlink:to="canf_SharebasedPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ChongKunDangMember_lbl0" xml:lang="en-US">ChongKunDangMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ChongKunDangMember" xlink:to="canf_ChongKunDangMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ExercisePriceRangeThreeMember_lbl0" xml:lang="en-US">ExercisePriceRangeThreeMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ExercisePriceRangeThreeMember" xlink:to="canf_ExercisePriceRangeThreeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares_lbl1" xml:lang="en-US">IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_December2021Member_lbl0" xml:lang="en-US">December2021Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_December2021Member" xlink:to="canf_December2021Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_PercentageOfRealizationOnUltimateSettlement_lbl1" xml:lang="en-US">PercentageOfRealizationOnUltimateSettlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PercentageOfRealizationOnUltimateSettlement" xlink:to="canf_PercentageOfRealizationOnUltimateSettlement_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_RoyaltyOnNetSales_lbl0" xml:lang="en-US">RoyaltyOnNetSales</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_RoyaltyOnNetSales" xlink:to="canf_RoyaltyOnNetSales_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember_lbl0" xml:lang="en-US">LaboratoryEquipmentAndLeaseholdImprovementsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember" xlink:to="canf_LaboratoryEquipmentAndLeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_UnfrontPaymentAmount_lbl1" xml:lang="en-US">UnfrontPaymentAmount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_UnfrontPaymentAmount" xlink:to="canf_UnfrontPaymentAmount_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_AggregateWarrantPurchased_lbl1" xml:lang="en-US">AggregateWarrantPurchased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AggregateWarrantPurchased" xlink:to="canf_AggregateWarrantPurchased_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment_lbl1" xml:lang="en-US">IncreaseDecreaseInChangesInFairValueOfShorttermInvestment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" xlink:to="canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_AdditionalPayments_lbl1" xml:lang="en-US">AdditionalPayments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AdditionalPayments" xlink:to="canf_AdditionalPayments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FinanceExpenses_lbl1" xml:lang="en-US">FinanceExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FinanceExpenses" xlink:to="canf_FinanceExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IssuanceDate_lbl0" xml:lang="en-US">IssuanceDate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceDate" xlink:to="canf_IssuanceDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IssueOfNewUnregisteredWarrants_lbl1" xml:lang="en-US">IssueOfNewUnregisteredWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssueOfNewUnregisteredWarrants" xlink:to="canf_IssueOfNewUnregisteredWarrants_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl1" xml:lang="en-US">ShareBasedPaymentAwardFairValueAssumptionsExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ChongKunDangPharmaceuticalsCorpMember_lbl0" xml:lang="en-US">ChongKunDangPharmaceuticalsCorpMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ChongKunDangPharmaceuticalsCorpMember" xlink:to="canf_ChongKunDangPharmaceuticalsCorpMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_NetLossFromExchangeRateFluctuations_lbl1" xml:lang="en-US">NetLossFromExchangeRateFluctuations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_NetLossFromExchangeRateFluctuations" xlink:to="canf_NetLossFromExchangeRateFluctuations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses_lbl1" xml:lang="en-US">IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" xlink:to="canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfExpensesTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfExpensesTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfExpensesTableTextBlock" xlink:to="canf_ScheduleOfExpensesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" xlink:to="canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_EwopharmaAGMember_lbl0" xml:lang="en-US">EwopharmaAGMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_EwopharmaAGMember" xlink:to="canf_EwopharmaAGMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_FutureShares_lbl1" xml:lang="en-US">FutureShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_FutureShares" xlink:to="canf_FutureShares_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_SeverancePayPolicyTextBlock_lbl1" xml:lang="en-US">SeverancePayPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_SeverancePayPolicyTextBlock" xlink:to="canf_SeverancePayPolicyTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_GovernmentAuthorities_lbl1" xml:lang="en-US">GovernmentAuthorities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GovernmentAuthorities" xlink:to="canf_GovernmentAuthorities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_LesseeOperatingLeaseLiabilityPaymentDue_lbl1" xml:lang="en-US">LesseeOperatingLeaseLiabilityPaymentDue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_LesseeOperatingLeaseLiabilityPaymentDue" xlink:to="canf_LesseeOperatingLeaseLiabilityPaymentDue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_GebroHoldingGmBHMember_lbl0" xml:lang="en-US">GebroHoldingGmBHMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_GebroHoldingGmBHMember" xlink:to="canf_GebroHoldingGmBHMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_PurchaseAgreementDescription_lbl0" xml:lang="en-US">PurchaseAgreementDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_PurchaseAgreementDescription" xlink:to="canf_PurchaseAgreementDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_August2021Member_lbl0" xml:lang="en-US">August2021Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_August2021Member" xlink:to="canf_August2021Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_January2019Member_lbl0" xml:lang="en-US">January2019Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_January2019Member" xlink:to="canf_January2019Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_AccumulatedDepreciationAbstract_lbl0" xml:lang="en-US">AccumulatedDepreciationAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_AccumulatedDepreciationAbstract" xlink:to="canf_AccumulatedDepreciationAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ShareIssued_lbl1" xml:lang="en-US">ShareIssued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ShareIssued" xlink:to="canf_ShareIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_WarrantsToPurchaseAdditionalSharesIssued_lbl1" xml:lang="en-US">WarrantsToPurchaseAdditionalSharesIssued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_WarrantsToPurchaseAdditionalSharesIssued" xlink:to="canf_WarrantsToPurchaseAdditionalSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl1" xml:lang="en-US">CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:to="canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_July2020Member_lbl0" xml:lang="en-US">July2020Member</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_July2020Member" xlink:to="canf_July2020Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="canf_ContractLiabilities_lbl1" xml:lang="en-US">ContractLiabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="canf_ContractLiabilities" xlink:to="canf_ContractLiabilities_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl0" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl0" xml:lang="en-US">ICFR Auditor Attestation Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl0" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_BusinessContactMember_lbl0" xml:lang="en-US">Business Contact [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_BusinessContactMember" xlink:to="dei_BusinessContactMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IsraelTaxAuthorityMember_lbl0" xml:lang="en-US">Israel Tax Authority [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IsraelTaxAuthorityMember" xlink:to="us-gaap_IsraelTaxAuthorityMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0" xml:lang="en-US">Schedule of Stockholders&apos; Equity Note, Warrants or Rights [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl0" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentTextBlock_lbl0" xml:lang="en-US">Investment [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTextBlock" xlink:to="us-gaap_InvestmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl0" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl1" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl1" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl0" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoninterestExpenseCommissionExpense_lbl0" xml:lang="en-US">Noninterest Expense Commission Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoninterestExpenseCommissionExpense" xlink:to="us-gaap_NoninterestExpenseCommissionExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelEmailAddress_lbl0" xml:lang="en-US">Contact Personnel Email Address</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelEmailAddress" xlink:to="dei_ContactPersonnelEmailAddress_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionExercisePriceIncrease_lbl0" xml:lang="en-US">Stock Option, Exercise Price, Increase</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionExercisePriceIncrease" xlink:to="us-gaap_StockOptionExercisePriceIncrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl0" xml:lang="en-US">Operating Lease, Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl0" xml:lang="en-US">Leasehold Improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetentionPayable_lbl0" xml:lang="en-US">Retention Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetentionPayable" xlink:to="us-gaap_RetentionPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">Other General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl2" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtWeightedAverageInterestRate_lbl0" xml:lang="en-US">Debt, Weighted Average Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtWeightedAverageInterestRate" xlink:to="us-gaap_DebtWeightedAverageInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Receivables and Portions of Securitizations that can be Prepaid at Potential Loss, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock" xlink:to="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Capital Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl1" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl0" xml:lang="en-US">Fair Value, Recurring [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelFaxNumber_lbl0" xml:lang="en-US">Contact Personnel Fax Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelFaxNumber" xlink:to="dei_ContactPersonnelFaxNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl0" xml:lang="en-US">Interest Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantExercisePriceDecrease_lbl0" xml:lang="en-US">Warrant, Exercise Price, Decrease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantExercisePriceDecrease" xlink:to="us-gaap_WarrantExercisePriceDecrease_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl0" xml:lang="en-US">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl0" xml:lang="en-US">Other Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl0" xml:lang="en-US">Interest Income, Deposits with Financial Institutions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl0" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationExpenseOnReclassifiedAssets_lbl0" xml:lang="en-US">Depreciation Expense on Reclassified Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:to="us-gaap_DepreciationExpenseOnReclassifiedAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl1" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl0" xml:lang="en-US">Other Noncash Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl0" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtPolicyTextBlock_lbl0" xml:lang="en-US">Debt, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtPolicyTextBlock" xlink:to="us-gaap_DebtPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl0" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueCurrent_lbl0" xml:lang="en-US">Deferred Revenue, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl0" xml:lang="en-US">Auditor Firm ID</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireOtherInvestments_lbl0" xml:lang="en-US">Payments to Acquire Other Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireOtherInvestments" xlink:to="us-gaap_PaymentsToAcquireOtherInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableTradeCurrent_lbl0" xml:lang="en-US">Accounts Payable, Trade, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableTradeCurrent" xlink:to="us-gaap_AccountsPayableTradeCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl0" xml:lang="en-US">Entity Address, Postal Zip Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl0" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl0" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesNoncurrent_lbl0" xml:lang="en-US">Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesNoncurrent" xlink:to="us-gaap_LiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl0" xml:lang="en-US">Series of Individually Immaterial Business Acquisitions [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl0" xml:lang="en-US">Local Phone Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl0" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrent_lbl0" xml:lang="en-US">Assets, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrent" xlink:to="us-gaap_AssetsNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0" xml:lang="en-US">Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl0" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl0" xml:lang="en-US">Document Transition Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock_lbl0" xml:lang="en-US">Interest Income and Interest Expense Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepositsAssetsCurrent_lbl0" xml:lang="en-US">Deposits Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepositsAssetsCurrent" xlink:to="us-gaap_DepositsAssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsNoncurrentAbstract_lbl0" xml:lang="en-US">Assets, Noncurrent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl0" xml:lang="en-US">Document Registration Statement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl0" xml:lang="en-US">Royalty Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermInvestments_lbl0" xml:lang="en-US">Short-term Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl0" xml:lang="en-US">Document Annual Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl0" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl0" xml:lang="en-US">Operating Lease, Liability, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdvanceRoyalties_lbl0" xml:lang="en-US">Advance Royalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdvanceRoyalties" xlink:to="us-gaap_AdvanceRoyalties_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl0" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeveranceCosts1_lbl0" xml:lang="en-US">Severance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeveranceCosts1" xlink:to="us-gaap_SeveranceCosts1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RedeemablePreferredStockDividends_lbl0" xml:lang="en-US">Redeemable Preferred Stock Dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemablePreferredStockDividends" xlink:to="us-gaap_RedeemablePreferredStockDividends_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl2" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl0" xml:lang="en-US">Entity Address, City or Town</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl0" xml:lang="en-US">Auditor Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl0" xml:lang="en-US">Document Accounting Standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl1" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl0" xml:lang="en-US">Deferred Revenue, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl0" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_ContactPersonnelName_lbl0" xml:lang="en-US">Contact Personnel Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_ContactPersonnelName" xlink:to="dei_ContactPersonnelName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl0" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl0" xml:lang="en-US">Auditor Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl0" xml:lang="en-US">Payments of Stock Issuance Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl0" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl0" xml:lang="en-US">Entity Address, Country</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromOtherEquity_lbl0" xml:lang="en-US">Proceeds from Other Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromOtherEquity" xlink:to="us-gaap_ProceedsFromOtherEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl0" xml:lang="en-US">Operating Lease, Lease Income [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl0" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl0" xml:lang="en-US">Document Shell Company Report</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherReceivablesNetCurrent_lbl0" xml:lang="en-US">Other Receivables, Net, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherReceivablesNetCurrent" xlink:to="us-gaap_OtherReceivablesNetCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfDividends_lbl0" xml:lang="en-US">Payments of Dividends</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDividends" xlink:to="us-gaap_PaymentsOfDividends_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl0" xml:lang="en-US">City Area Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl0" xml:lang="en-US">Entity Address, Address Line Three</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl0" xml:lang="en-US">Entity Address, Address Line Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl0" xml:lang="en-US">Revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherExpenses_lbl0" xml:lang="en-US">Other Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenses" xlink:to="us-gaap_OtherExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl0" xml:lang="en-US">Entity Address, Address Line One</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl0" xml:lang="en-US">Security Exchange Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Stock Dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockDividend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl0" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnInvestments_lbl0" xml:lang="en-US">Gain (Loss) on Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnInvestments" xlink:to="us-gaap_GainLossOnInvestments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0" xml:lang="en-US">Class of Warrant or Right, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl0" xml:lang="en-US">Title of 12(b) Security</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl0" xml:lang="en-US">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>18
<FILENAME>canf-20211231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Thu Mar 24 13:02:57 UTC 2022 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ConsolidatedBalanceSheet" roleURI="http://www.confite.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ConsolidatedComprehensiveIncome" roleURI="http://www.confite.com/role/ConsolidatedComprehensiveIncome"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ShareholdersEquityType2or3" roleURI="http://www.confite.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ShareholdersEquityType2or3_Parentheticals" roleURI="http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ConsolidatedCashFlow" roleURI="http://www.confite.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_General" roleURI="http://www.confite.com/role/General"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_SignificantAccountingPolicies" roleURI="http://www.confite.com/role/SignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_OtherAccountsReceivableandPrepaidExpenses" roleURI="http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpenses"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ShortTermInvestment" roleURI="http://www.confite.com/role/ShortTermInvestment"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_PropertyPlantandEquipmentNet" roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNet"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_OtherAccountsPayable" roleURI="http://www.confite.com/role/OtherAccountsPayable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_FairValueMeasurements" roleURI="http://www.confite.com/role/FairValueMeasurements"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ContingentLiabilitiesandCommitments" roleURI="http://www.confite.com/role/ContingentLiabilitiesandCommitments"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ShareholdersEquity" roleURI="http://www.confite.com/role/ShareholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ShareBasedPaymentTransactions" roleURI="http://www.confite.com/role/ShareBasedPaymentTransactions"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_Leases" roleURI="http://www.confite.com/role/Leases"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_FinanceIncomeExpense" roleURI="http://www.confite.com/role/FinanceIncomeExpense"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_TaxesonIncome" roleURI="http://www.confite.com/role/TaxesonIncome"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_TransactionswithRelatedParties" roleURI="http://www.confite.com/role/TransactionswithRelatedParties"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_AccountingPoliciesByPolicy" roleURI="http://www.confite.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_SignificantAccountingPoliciesTables" roleURI="http://www.confite.com/role/SignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_OtherAccountsReceivableandPrepaidExpensesTables" roleURI="http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpensesTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_PropertyPlantandEquipmentNetTables" roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNetTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_OtherAccountsPayableTables" roleURI="http://www.confite.com/role/OtherAccountsPayableTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_FairValueMeasurementsTables" roleURI="http://www.confite.com/role/FairValueMeasurementsTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ShareholdersEquityTables" roleURI="http://www.confite.com/role/ShareholdersEquityTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ShareBasedPaymentTransactionsTables" roleURI="http://www.confite.com/role/ShareBasedPaymentTransactionsTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_LeasesTables" roleURI="http://www.confite.com/role/LeasesTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_FinanceIncomeExpenseTables" roleURI="http://www.confite.com/role/FinanceIncomeExpenseTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_TaxesonIncomeTables" roleURI="http://www.confite.com/role/TaxesonIncomeTables"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofpropertyplantandequipmentTable" roleURI="http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" roleURI="http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofotheraccountsreceivableandprepaidexpensesTable" roleURI="http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofpropertyplantandequipmentnetTable" roleURI="http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofotheraccountspayableTable" roleURI="http://www.confite.com/role/ScheduleofotheraccountspayableTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" roleURI="http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" roleURI="http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofexpensesTable" roleURI="http://www.confite.com/role/ScheduleofexpensesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofestimatedusingthebinomialoptionpricingmodelTable" roleURI="http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable" roleURI="http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable" roleURI="http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable" roleURI="http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofmaturitiesofleaseliabilitiesTable" roleURI="http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofcomponentsoffinanceincomeTable" roleURI="http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ScheduleofdeferredtaxassetsandliabilitiesTable" roleURI="http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_GeneralDetails" roleURI="http://www.confite.com/role/GeneralDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_SignificantAccountingPoliciesDetails" roleURI="http://www.confite.com/role/SignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ShortTermInvestmentDetails" roleURI="http://www.confite.com/role/ShortTermInvestmentDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_PropertyPlantandEquipmentNetDetails" roleURI="http://www.confite.com/role/PropertyPlantandEquipmentNetDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ContingentLiabilitiesandCommitmentsDetails" roleURI="http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ShareholdersEquityDetails" roleURI="http://www.confite.com/role/ShareholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_ShareBasedPaymentTransactionsDetails" roleURI="http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_LeasesDetails" roleURI="http://www.confite.com/role/LeasesDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_TaxesonIncomeDetails" roleURI="http://www.confite.com/role/TaxesonIncomeDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#canf_r_TransactionswithRelatedPartiesDetails" roleURI="http://www.confite.com/role/TransactionswithRelatedPartiesDetails"/>
  <roleRef xlink:type="simple" xlink:href="canf-20211231.xsd#DocumentAndEntityInformation" roleURI="http://www.confite.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepositsAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_DepositsAssetsCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_AssetsNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsNoncurrentAbstract" xlink:to="us-gaap_Assets" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableTradeCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableTradeCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableTradeCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesNoncurrentAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenueNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="us-gaap_LiabilitiesNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedComprehensiveIncome">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_Revenues" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RedeemablePreferredStockDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemablePreferredStockDividends"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_RedeemablePreferredStockDividends" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" xlink:href="canf-20211231.xsd#canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" xlink:href="canf-20211231.xsd#canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockDividend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockDividend" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" xlink:href="canf-20211231.xsd#canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" xlink:href="canf-20211231.xsd#canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="WarrantsNetOfIssueExpenses" xlink:href="canf-20211231.xsd#canf_WarrantsNetOfIssueExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="WarrantsNetOfIssueExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuedDuringPeriodValueNetOfIssueExpenses" xlink:href="canf-20211231.xsd#canf_StockIssuedDuringPeriodValueNetOfIssueExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="StockIssuedDuringPeriodValueNetOfIssueExpenses" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInSharebasedPayment" xlink:href="canf-20211231.xsd#canf_IncreaseDecreaseInSharebasedPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInSharebasedPayment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" xlink:href="canf-20211231.xsd#canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInChangesInFairValueOfShorttermInvestment" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOtherAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccountsPayable" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireOtherInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireOtherInvestments" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDividends"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_PaymentsOfDividends" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/General">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/SignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpenses">
    <loc xlink:type="locator" xlink:label="OtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:href="canf-20211231.xsd#canf_OtherAccountsReceivableAndPrepaidExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherAccountsReceivableAndPrepaidExpensesTextBlock" xlink:href="canf-20211231.xsd#canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:to="OtherAccountsReceivableAndPrepaidExpensesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShortTermInvestment">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="ShortTermInvestmentTable" xlink:href="canf-20211231.xsd#canf_ShortTermInvestmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="ShortTermInvestmentTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShortTermInvestmentTable" xlink:to="us-gaap_ShortTermDebtLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InvestmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_InvestmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/PropertyPlantandEquipmentNet">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/OtherAccountsPayable">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="OtherAccountsPayableTable" xlink:href="canf-20211231.xsd#canf_OtherAccountsPayableTable"/>
    <loc xlink:type="locator" xlink:label="OtherAccountsPayableLineItems" xlink:href="canf-20211231.xsd#canf_OtherAccountsPayableLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="OtherAccountsPayableTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsPayableTable" xlink:to="OtherAccountsPayableLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsPayableLineItems" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/FairValueMeasurements">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ContingentLiabilitiesandCommitments">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareBasedPaymentTransactions">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/Leases">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/FinanceIncomeExpense">
    <loc xlink:type="locator" xlink:label="us-gaap_BankingAndThriftInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankingAndThriftInterestAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BankingAndThriftInterestAbstract" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/TaxesonIncome">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/TransactionswithRelatedParties">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLeaseIncomeTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OperatingLeaseLeaseIncomeTableTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SeverancePayPolicyTextBlock" xlink:href="canf-20211231.xsd#canf_SeverancePayPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SeverancePayPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" xlink:href="canf-20211231.xsd#canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccountingPronouncementsNotYetAdoptedPolicyTextBlock" xlink:href="canf-20211231.xsd#canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="AccountingPronouncementsNotYetAdoptedPolicyTextBlock" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/SignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" xlink:href="canf-20211231.xsd#canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfUsefulLivesOfTheAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" xlink:href="canf-20211231.xsd#canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpensesTables">
    <loc xlink:type="locator" xlink:label="OtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:href="canf-20211231.xsd#canf_OtherAccountsReceivableAndPrepaidExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" xlink:href="canf-20211231.xsd#canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:to="ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/PropertyPlantandEquipmentNetTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/OtherAccountsPayableTables">
    <loc xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/FairValueMeasurementsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityTables">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" xlink:href="canf-20211231.xsd#canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareBasedPaymentTransactionsTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfExpensesTableTextBlock" xlink:href="canf-20211231.xsd#canf_ScheduleOfExpensesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfExpensesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" xlink:href="canf-20211231.xsd#canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/LeasesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/FinanceIncomeExpenseTables">
    <loc xlink:type="locator" xlink:label="us-gaap_BankingAndThriftInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BankingAndThriftInterestAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BankingAndThriftInterestAbstract" xlink:to="us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/TaxesonIncomeTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfPropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:href="canf-20211231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:href="canf-20211231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentAbstract" xlink:to="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="LaboratoryEquipmentAndLeaseholdImprovementsMember" xlink:href="canf-20211231.xsd#canf_LaboratoryEquipmentAndLeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="LaboratoryEquipmentAndLeaseholdImprovementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComputersOfficeFurnitureAndEquipmentMember" xlink:href="canf-20211231.xsd#canf_ComputersOfficeFurnitureAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="ComputersOfficeFurnitureAndEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable" xlink:to="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" xlink:href="canf-20211231.xsd#canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems" xlink:to="UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" xlink:href="canf-20211231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"/>
    <loc xlink:type="locator" xlink:label="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" xlink:href="canf-20211231.xsd#canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract" xlink:to="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" xlink:to="srt_MajorCustomersAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CipherPharmaceuticalsMember" xlink:href="canf-20211231.xsd#canf_CipherPharmaceuticalsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="CipherPharmaceuticalsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChongKunDangPharmaceuticalsCorpMember" xlink:href="canf-20211231.xsd#canf_ChongKunDangPharmaceuticalsCorpMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="ChongKunDangPharmaceuticalsCorpMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GebroHoldingGmBHMember" xlink:href="canf-20211231.xsd#canf_GebroHoldingGmBHMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="GebroHoldingGmBHMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EwopharmaAGMember" xlink:href="canf-20211231.xsd#canf_EwopharmaAGMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="EwopharmaAGMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable" xlink:to="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="RevenueContractWithCustomer" xlink:href="canf-20211231.xsd#canf_RevenueContractWithCustomer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems" xlink:to="RevenueContractWithCustomer" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="GovernmentAuthorities" xlink:href="canf-20211231.xsd#canf_GovernmentAuthorities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:to="GovernmentAuthorities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract" xlink:to="us-gaap_OtherReceivablesNetCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfPropertyPlantAndEquipmentNetAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="LaboratoryEquipmentMember" xlink:href="canf-20211231.xsd#canf_LaboratoryEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="LaboratoryEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComputersOfficeFurnitureAndEquipmentMember" xlink:href="canf-20211231.xsd#canf_ComputersOfficeFurnitureAndEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="ComputersOfficeFurnitureAndEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="CostAbstract" xlink:href="canf-20211231.xsd#canf_CostAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="CostAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccumulatedDepreciationAbstract" xlink:href="canf-20211231.xsd#canf_AccumulatedDepreciationAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="AccumulatedDepreciationAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccumulatedDepreciationAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofotheraccountspayableTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOtherAccountsPayableAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfOtherAccountsPayableAbstract"/>
    <loc xlink:type="locator" xlink:label="EmployeesAndPayrollAccruals" xlink:href="canf-20211231.xsd#canf_EmployeesAndPayrollAccruals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="EmployeesAndPayrollAccruals" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOtherAccountsPayableAbstract" xlink:to="us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:href="canf-20211231.xsd#canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"/>
    <loc xlink:type="locator" xlink:label="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:href="canf-20211231.xsd#canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract" xlink:to="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrbKPcFX/25U7tJjZ1e/QkjhiUJn9hDzDjBiHcqiPkVBCCODXCRCIM9u4S3gJiJPkfeA4IWMDZOgz1+S5KnQ1ZJmUdVT2gUh0PhPHv3pa4+fTZTkTD4DIrxKSC26B+qiQe8tCtLe+ud+bxP4dcVqp2G92WtBs6vOj1FOZTxFulqqlkvzOQstgQaJRgDCb5YCPoq9ZtlzpPbiJe/2t4x9IIzQ] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable" xlink:to="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems" xlink:to="us-gaap_ShortTermInvestments" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" xlink:href="canf-20211231.xsd#canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:href="canf-20211231.xsd#canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract" xlink:to="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" xlink:to="us-gaap_AwardDateAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardDateDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="January2017Member" xlink:href="canf-20211231.xsd#canf_January2017Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="January2017Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="March2018Member" xlink:href="canf-20211231.xsd#canf_March2018Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="March2018Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="January2019Member" xlink:href="canf-20211231.xsd#canf_January2019Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="January2019Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="April2019Member" xlink:href="canf-20211231.xsd#canf_April2019Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="April2019Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="May2019Member" xlink:href="canf-20211231.xsd#canf_May2019Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="May2019Member" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="January2020Member" xlink:href="canf-20211231.xsd#canf_January2020Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="January2020Member" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="February2020Member" xlink:href="canf-20211231.xsd#canf_February2020Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="February2020Member" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="June2020Member" xlink:href="canf-20211231.xsd#canf_June2020Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="June2020Member" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="July2020Member" xlink:href="canf-20211231.xsd#canf_July2020Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="July2020Member" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="August2021Member" xlink:href="canf-20211231.xsd#canf_August2021Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="August2021Member" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="December2021Member" xlink:href="canf-20211231.xsd#canf_December2021Member"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardDateAxis" xlink:to="December2021Member" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable" xlink:to="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="IssuanceDate" xlink:href="canf-20211231.xsd#canf_IssuanceDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="IssuanceDate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofexpensesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfExpensesAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfExpensesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherGeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesAbstract" xlink:to="us-gaap_OtherGeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedPayments" xlink:href="canf-20211231.xsd#canf_SharebasedPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfExpensesAbstract" xlink:to="SharebasedPayments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" xlink:href="canf-20211231.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:href="canf-20211231.xsd#canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract" xlink:to="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable" xlink:to="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="canf-20211231.xsd#canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems" xlink:to="ShareBasedPaymentAwardFairValueAssumptionsExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfExercisableAtEndOfShares" xlink:href="canf-20211231.xsd#canf_NumberOfExercisableAtEndOfShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="NumberOfExercisableAtEndOfShares" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedAverageExercisePriceExercisableAtEndOfPerShares" xlink:href="canf-20211231.xsd#canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract" xlink:to="WeightedAverageExercisePriceExercisableAtEndOfPerShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeOneMember" xlink:href="canf-20211231.xsd#canf_ExercisePriceRangeOneMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeOneMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeTwoMember" xlink:href="canf-20211231.xsd#canf_ExercisePriceRangeTwoMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeTwoMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceRangeThreeMember" xlink:href="canf-20211231.xsd#canf_ExercisePriceRangeThreeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ExercisePriceRangeThreeMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="SharebasedPaymentArrangementOptionExercisePriceRange" xlink:href="canf-20211231.xsd#canf_SharebasedPaymentArrangementOptionExercisePriceRange"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="SharebasedPaymentArrangementOptionExercisePriceRange" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ComponentsOfLeaseExpenseAbstract" xlink:href="canf-20211231.xsd#canf_ComponentsOfLeaseExpenseAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="ComponentsOfLeaseExpenseAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfLeaseExpenseAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" xlink:href="canf-20211231.xsd#canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" xlink:href="canf-20211231.xsd#canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract" xlink:to="SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="LesseeOperatingLeaseLiabilityPaymentDue" xlink:href="canf-20211231.xsd#canf_LesseeOperatingLeaseLiabilityPaymentDue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="LesseeOperatingLeaseLiabilityPaymentDue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ImputedInterestLessImputedInterest" xlink:href="canf-20211231.xsd#canf_ImputedInterestLessImputedInterest"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="ImputedInterestLessImputedInterest" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_OperatingLeaseLiability" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfComponentsOfFinanceIncomeAbstract"/>
    <loc xlink:type="locator" xlink:label="FinanceExpensesAbstract" xlink:href="canf-20211231.xsd#canf_FinanceExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="FinanceExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BanksCommissions" xlink:href="canf-20211231.xsd#canf_BanksCommissions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpensesAbstract" xlink:to="BanksCommissions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetLossFromExchangeRateFluctuations" xlink:href="canf-20211231.xsd#canf_NetLossFromExchangeRateFluctuations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpensesAbstract" xlink:to="NetLossFromExchangeRateFluctuations" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OtherLossFromShorttermInvestmentRevaluation" xlink:href="canf-20211231.xsd#canf_OtherLossFromShorttermInvestmentRevaluation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpensesAbstract" xlink:to="OtherLossFromShorttermInvestmentRevaluation" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpensesAbstract" xlink:to="us-gaap_OtherExpenses" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceExpenses" xlink:href="canf-20211231.xsd#canf_FinanceExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceExpensesAbstract" xlink:to="FinanceExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceIncomeAbstract" xlink:href="canf-20211231.xsd#canf_FinanceIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfComponentsOfFinanceIncomeAbstract" xlink:to="FinanceIncomeAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeDepositsWithFinancialInstitutions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="us-gaap_InterestIncomeDepositsWithFinancialInstitutions" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExchangeRateFluctuations" xlink:href="canf-20211231.xsd#canf_ExchangeRateFluctuations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="ExchangeRateFluctuations" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="us-gaap_GainLossOnInvestments" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FinanceIncome" xlink:href="canf-20211231.xsd#canf_FinanceIncome"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="FinanceIncome" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FinanceIncomeAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="canf-20211231.xsd#canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAbstract" xlink:href="canf-20211231.xsd#canf_DeferredTaxAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="DeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/GeneralDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NetIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="CashFlowsFromOperatingActivities" xlink:href="canf-20211231.xsd#canf_CashFlowsFromOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="CashFlowsFromOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/SignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtWeightedAverageInterestRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ContractLiabilities" xlink:href="canf-20211231.xsd#canf_ContractLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ContractLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="Revenue" xlink:href="canf-20211231.xsd#canf_Revenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="Revenue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RevenuesIncludedInContractLiabilities" xlink:href="canf-20211231.xsd#canf_RevenuesIncludedInContractLiabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="RevenuesIncludedInContractLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfDepositsOnMonthlySalary" xlink:href="canf-20211231.xsd#canf_PercentageOfDepositsOnMonthlySalary"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PercentageOfDepositsOnMonthlySalary" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SeveranceCosts1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfRealizationOnUltimateSettlement" xlink:href="canf-20211231.xsd#canf_PercentageOfRealizationOnUltimateSettlement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="PercentageOfRealizationOnUltimateSettlement" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShortTermInvestmentDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockSupplementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfOutstandingShares" xlink:href="canf-20211231.xsd#canf_PercentageOfOutstandingShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockSupplementAbstract" xlink:to="PercentageOfOutstandingShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/PropertyPlantandEquipmentNetDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationExpenseOnReclassifiedAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationExpenseOnReclassifiedAssets" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:href="canf-20211231.xsd#canf_ContingentLiabilitiesandCommitmentsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:href="canf-20211231.xsd#canf_ContingentLiabilitiesandCommitmentsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ContingentLiabilitiesandCommitmentsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="CipherMember" xlink:href="canf-20211231.xsd#canf_CipherMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="CipherMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ChongKunDangMember" xlink:href="canf-20211231.xsd#canf_ChongKunDangMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="ChongKunDangMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CMSMedicalMember" xlink:href="canf-20211231.xsd#canf_CMSMedicalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="CMSMedicalMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="KyongboPharmMember" xlink:href="canf-20211231.xsd#canf_KyongboPharmMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="KyongboPharmMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SwitzerlandBasedEwopharmaMember" xlink:href="canf-20211231.xsd#canf_SwitzerlandBasedEwopharmaMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="SwitzerlandBasedEwopharmaMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="VetbiolixMember" xlink:href="canf-20211231.xsd#canf_VetbiolixMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="VetbiolixMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsTable" xlink:to="ContingentLiabilitiesandCommitmentsDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NoninterestExpenseCommissionExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoninterestExpenseCommissionExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_NoninterestExpenseCommissionExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_RoyaltyExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PercentageOfNetSales" xlink:href="canf-20211231.xsd#canf_PercentageOfNetSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="PercentageOfNetSales" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PatentAgreementDescription" xlink:href="canf-20211231.xsd#canf_PatentAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="PatentAgreementDescription" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdvanceRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvanceRoyalties"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_AdvanceRoyalties" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyPaymentsPercentage" xlink:href="canf-20211231.xsd#canf_RoyaltyPaymentsPercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="RoyaltyPaymentsPercentage" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UnfrontPaymentAmount" xlink:href="canf-20211231.xsd#canf_UnfrontPaymentAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="UnfrontPaymentAmount" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionalPayments" xlink:href="canf-20211231.xsd#canf_AdditionalPayments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="AdditionalPayments" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetentionPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetentionPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="us-gaap_RetentionPayable" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="RoyaltyOnNetSales" xlink:href="canf-20211231.xsd#canf_RoyaltyOnNetSales"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="RoyaltyOnNetSales" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NonRefundableUpfrontPayment" xlink:href="canf-20211231.xsd#canf_NonRefundableUpfrontPayment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ContingentLiabilitiesandCommitmentsDetailsLineItems" xlink:to="NonRefundableUpfrontPayment" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsTable" xlink:href="canf-20211231.xsd#canf_ShareholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareholdersEquityDetailsLineItems" xlink:href="canf-20211231.xsd#canf_ShareholdersEquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="ShareholdersEquityDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="ADSMember" xlink:href="canf-20211231.xsd#canf_ADSMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="ADSMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="srt_RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsTable" xlink:to="ShareholdersEquityDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityChangeInRatioDescription" xlink:href="canf-20211231.xsd#canf_StockholdersEquityChangeInRatioDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="StockholdersEquityChangeInRatioDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchaseAdditionalSharesIssued" xlink:href="canf-20211231.xsd#canf_WarrantsToPurchaseAdditionalSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="WarrantsToPurchaseAdditionalSharesIssued" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregatePurchasePrice" xlink:href="canf-20211231.xsd#canf_AggregatePurchasePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="AggregatePurchasePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrices" xlink:href="canf-20211231.xsd#canf_ExercisePrices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ExercisePrices" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateWarrantPurchased" xlink:href="canf-20211231.xsd#canf_AggregateWarrantPurchased"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="AggregateWarrantPurchased" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareIssued" xlink:href="canf-20211231.xsd#canf_ShareIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ShareIssued" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantExercisePriceDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantExercisePriceDecrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_WarrantExercisePriceDecrease" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="IssueOfNewUnregisteredWarrants" xlink:href="canf-20211231.xsd#canf_IssueOfNewUnregisteredWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="IssueOfNewUnregisteredWarrants" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePriceSubjectToAdjusment" xlink:href="canf-20211231.xsd#canf_ExercisePriceSubjectToAdjusment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ExercisePriceSubjectToAdjusment" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeemedDividend" xlink:href="canf-20211231.xsd#canf_DeemedDividend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="DeemedDividend" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="SecuritiesPurchaseAgreementDescription" xlink:href="canf-20211231.xsd#canf_SecuritiesPurchaseAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="SecuritiesPurchaseAgreementDescription" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromOtherEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromOtherEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromOtherEquity" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CompensationWarrantsExercisable" xlink:href="canf-20211231.xsd#canf_CompensationWarrantsExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="CompensationWarrantsExercisable" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_SharePrice" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseAuthorizedShareCapital" xlink:href="canf-20211231.xsd#canf_IncreaseAuthorizedShareCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="IncreaseAuthorizedShareCapital" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="StockIssuanceAgreementDescription" xlink:href="canf-20211231.xsd#canf_StockIssuanceAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="StockIssuanceAgreementDescription" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateNumberOfADS" xlink:href="canf-20211231.xsd#canf_AggregateNumberOfADS"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="AggregateNumberOfADS" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionExercisePriceIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionExercisePriceIncrease"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockOptionExercisePriceIncrease" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantsToPurchaseAggregateShares" xlink:href="canf-20211231.xsd#canf_WarrantsToPurchaseAggregateShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="WarrantsToPurchaseAggregateShares" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExercisePrice" xlink:href="canf-20211231.xsd#canf_ExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ExercisePrice" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalConsiderationAmount" xlink:href="canf-20211231.xsd#canf_TotalConsiderationAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="TotalConsiderationAmount" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueAmount" xlink:href="canf-20211231.xsd#canf_FairValueAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="FairValueAmount" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PurchaseAgreementDescription" xlink:href="canf-20211231.xsd#canf_PurchaseAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="PurchaseAgreementDescription" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TotalReceivedAmount" xlink:href="canf-20211231.xsd#canf_TotalReceivedAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="TotalReceivedAmount" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrdinaryShares" xlink:href="canf-20211231.xsd#canf_OrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="OrdinaryShares" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceExpensesAmount" xlink:href="canf-20211231.xsd#canf_IssuanceExpensesAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="IssuanceExpensesAmount" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ExerciseAgreementDescription" xlink:href="canf-20211231.xsd#canf_ExerciseAgreementDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareholdersEquityDetailsLineItems" xlink:to="ExerciseAgreementDescription" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/ShareBasedPaymentTransactionsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsDetailsTable" xlink:href="canf-20211231.xsd#canf_ShareBasedPaymentTransactionsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="ShareBasedPaymentTransactionsDetailsLineItems" xlink:href="canf-20211231.xsd#canf_ShareBasedPaymentTransactionsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedPaymentTransactionsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsTable" xlink:to="ShareBasedPaymentTransactionsDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="GrantedExcessYears" xlink:href="canf-20211231.xsd#canf_GrantedExcessYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="GrantedExcessYears" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="NumberOfOrdinaryShares" xlink:href="canf-20211231.xsd#canf_NumberOfOrdinaryShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="NumberOfOrdinaryShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FutureShares" xlink:href="canf-20211231.xsd#canf_FutureShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="FutureShares" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedPaymentTransactionsDetailsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/LeasesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/TaxesonIncomeDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="TaxesonIncomeDetailsTable" xlink:href="canf-20211231.xsd#canf_TaxesonIncomeDetailsTable"/>
    <loc xlink:type="locator" xlink:label="TaxesonIncomeDetailsLineItems" xlink:href="canf-20211231.xsd#canf_TaxesonIncomeDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="TaxesonIncomeDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsTable" xlink:to="us-gaap_IncomeTaxAuthorityNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IncomeTaxAuthorityNameDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IsraelTaxAuthorityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IsraelTaxAuthorityMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="us-gaap_IsraelTaxAuthorityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsTable" xlink:to="TaxesonIncomeDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsCapitalLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxesonIncomeDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsCapitalLossCarryforwards" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/TransactionswithRelatedPartiesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://www.confite.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="canf-20211231.xsd#canf_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_EntityAddressesAddressTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AddressTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_AddressTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="dei_BusinessContactMember" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_BusinessContactMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityAddressesAddressTypeAxis" xlink:to="dei_BusinessContactMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentRegistrationStatement" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentRegistrationStatement" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentShellCompanyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentShellCompanyReport" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine2" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine3" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCountry" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelName" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelFaxNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelFaxNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelFaxNumber" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_ContactPersonnelEmailAddress" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_ContactPersonnelEmailAddress"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_ContactPersonnelEmailAddress" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentAccountingStandard" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAccountingStandard" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" order="39.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819061531704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Can-Fite BioPharma Ltd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CANF<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">20-F<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">815,746,293<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001536196<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentRegistrationStatement', window );">Document Registration Statement</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentShellCompanyReport', window );">Document Shell Company Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10 Bareket Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Kiryat Matalon<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">P.O. Box 7537<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Petah-Tikva<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">4951778<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">American Depositary Shares, each representing 30 Ordinary Shares, par value NIS 0.25 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAccountingStandard', window );">Document Accounting Standard</a></td>
<td class="text">U.S. GAAP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">1281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Kost Forer Gabbay & Kasierer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Tel-Aviv, Israel<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10 Bareket Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Kiryat Matalon<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">P.O. Box 7537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Petah-Tikva<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">4951778<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Motti Farbstein<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">(3) 924-1114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelFaxNumber', window );">Contact Personnel Fax Number</a></td>
<td class="text">972 (3) 924-9378<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_ContactPersonnelEmailAddress', window );">Contact Personnel Email Address</a></td>
<td class="text">motti@canfite.co.il<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelEmailAddress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Email address of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelEmailAddress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelFaxNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fax Number of contact personnel.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelFaxNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:accountingStandardItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentRegistrationStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a registration statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentRegistrationStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentShellCompanyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentShellCompanyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819053786584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,390<span></span>
</td>
<td class="nump">$ 8,268<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Short-term deposits</a></td>
<td class="nump">14,512<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses, and other current assets</a></td>
<td class="nump">929<span></span>
</td>
<td class="nump">1,057<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investment</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">20,068<span></span>
</td>
<td class="nump">9,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total long-term assets</a></td>
<td class="nump">185<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">20,253<span></span>
</td>
<td class="nump">9,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Trade payables</a></td>
<td class="nump">954<span></span>
</td>
<td class="nump">561<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current maturity of operating lease liability</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenues</a></td>
<td class="nump">818<span></span>
</td>
<td class="nump">334<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Other accounts payable</a></td>
<td class="nump">905<span></span>
</td>
<td class="nump">331<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,730<span></span>
</td>
<td class="nump">1,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenues</a></td>
<td class="nump">3,070<span></span>
</td>
<td class="nump">2,156<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total Long-term liabilities</a></td>
<td class="nump">3,141<span></span>
</td>
<td class="nump">2,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">CONTIGENT LIABILITIES AND COMMITMENTS</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>SHAREHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares of NIS 0.25 par value - Authorized: 5,000,000,000 and 1,000,000,000 shares at December 31, 2021 and December 31, 2020, respectively; Issued and outstanding: 815,746,293 shares as of December 31, 2021; 463,769,463 shares as of December 31, 2020</a></td>
<td class="nump">60,654<span></span>
</td>
<td class="nump">33,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">93,275<span></span>
</td>
<td class="nump">97,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">1,127<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(140,674)<span></span>
</td>
<td class="num">(125,469)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">14,382<span></span>
</td>
<td class="nump">6,074<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 20,253<span></span>
</td>
<td class="nump">$ 9,523<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819053786536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - &#8362; / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, par value (in New Shekels per share)</a></td>
<td class="nump">&#8362; 0.25<span></span>
</td>
<td class="nump">&#8362; 0.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized</a></td>
<td class="nump">5,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued</a></td>
<td class="nump">815,746,293<span></span>
</td>
<td class="nump">463,769,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding</a></td>
<td class="nump">815,746,293<span></span>
</td>
<td class="nump">463,769,463<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819061543400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 853<span></span>
</td>
<td class="nump">$ 763<span></span>
</td>
<td class="nump">$ 2,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="num">(9,850)<span></span>
</td>
<td class="num">(11,951)<span></span>
</td>
<td class="num">(10,976)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="num">(3,845)<span></span>
</td>
<td class="num">(2,951)<span></span>
</td>
<td class="num">(3,063)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(12,842)<span></span>
</td>
<td class="num">(14,139)<span></span>
</td>
<td class="num">(12,007)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total financial income (expense), net</a></td>
<td class="nump">227<span></span>
</td>
<td class="num">(304)<span></span>
</td>
<td class="num">(618)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before taxes on income</a></td>
<td class="num">(12,615)<span></span>
</td>
<td class="num">(14,443)<span></span>
</td>
<td class="num">(12,625)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Taxes on income</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(12,615)<span></span>
</td>
<td class="num">(14,443)<span></span>
</td>
<td class="num">(12,625)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RedeemablePreferredStockDividends', window );">Deemed dividend</a></td>
<td class="num">(2,590)<span></span>
</td>
<td class="num">(715)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Total comprehensive loss</a></td>
<td class="num">$ (15,205)<span></span>
</td>
<td class="num">$ (15,158)<span></span>
</td>
<td class="num">$ (12,625)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share (in Dollars per share)</a></td>
<td class="num">$ (0.03)<span></span>
</td>
<td class="num">$ (0.04)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of ordinary shares used in computing basic and diluted net loss per share (in Shares)</a></td>
<td class="nump">553,079,638<span></span>
</td>
<td class="nump">358,411,297<span></span>
</td>
<td class="nump">85,909,859<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RedeemablePreferredStockDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RedeemablePreferredStockDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139818982182072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Ordinary shares</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive Income</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 2,635<span></span>
</td>
<td class="nump">$ 96,939<span></span>
</td>
<td class="nump">$ 1,127<span></span>
</td>
<td class="num">$ (97,686)<span></span>
</td>
<td class="nump">$ 3,015<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2018</a></td>
<td class="nump">40,399,290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants', window );">Issuance of share capital and warrants, net of issuance expenses</a></td>
<td class="nump">$ 5,518<span></span>
</td>
<td class="nump">6,149<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants', window );">Issuance of share capital and warrants, net of issuance expenses (in Shares)</a></td>
<td class="nump">79,256,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of share capital</a></td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of share capital (in Shares)</a></td>
<td class="nump">996,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based payment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">270<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,625)<span></span>
</td>
<td class="num">(12,625)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 8,225<span></span>
</td>
<td class="nump">103,401<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
<td class="num">(110,311)<span></span>
</td>
<td class="nump">2,442<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2019</a></td>
<td class="nump">120,652,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockDividend', window );">Deemed dividends related to the warrants exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">715<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(715)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants', window );">Issuance of share capital and warrants, net of issuance expenses</a></td>
<td class="nump">$ 24,711<span></span>
</td>
<td class="num">(7,028)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">17,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants', window );">Issuance of share capital and warrants, net of issuance expenses (in Shares)</a></td>
<td class="nump">341,766,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of share capital</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of share capital (in Shares)</a></td>
<td class="nump">1,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based payment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">317<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(14,443)<span></span>
</td>
<td class="num">(14,443)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 33,036<span></span>
</td>
<td class="nump">97,380<span></span>
</td>
<td class="nump">1,127<span></span>
</td>
<td class="num">(125,469)<span></span>
</td>
<td class="nump">6,074<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="nump">463,769,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses', window );">Issuance of share capital due to warrants exercise, net of issuance expenses</a></td>
<td class="nump">$ 23,106<span></span>
</td>
<td class="num">(11,339)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,767<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares', window );">Issuance of share capital due to warrants exercise, net of issuance expenses (in Shares)</a></td>
<td class="nump">293,926,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of share capital in exchange for services</a></td>
<td class="nump">$ 80<span></span>
</td>
<td class="num">(12)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of share capital in exchange for services (in Shares)</a></td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockDividend', window );">Deemed dividends related to the warrants exercise</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,590<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2,590)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants', window );">Issuance of share capital and warrants, net of issuance expenses</a></td>
<td class="nump">$ 4,432<span></span>
</td>
<td class="nump">4,258<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants', window );">Issuance of share capital and warrants, net of issuance expenses (in Shares)</a></td>
<td class="nump">57,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based payment</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">398<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,615)<span></span>
</td>
<td class="num">(12,615)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 60,654<span></span>
</td>
<td class="nump">$ 93,275<span></span>
</td>
<td class="nump">$ 1,127<span></span>
</td>
<td class="num">$ (140,674)<span></span>
</td>
<td class="nump">$ 14,382<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2021</a></td>
<td class="nump">815,746,293<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of share capital due to warrants exercise, net of issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of share capital due to warrants exercise, net of issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of issuance of share capital and warrants, net of issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of share capital and warrants, net of issuance expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued to shareholders as a dividend during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819058127384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Equity (Parentheticals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_WarrantsNetOfIssueExpenses', window );">Warrants, net of issue expenses</a></td>
<td class="nump">$ 1,307<span></span>
</td>
<td class="nump">$ 3,703<span></span>
</td>
<td class="nump">$ 1,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_StockIssuedDuringPeriodValueNetOfIssueExpenses', window );">Warrants exercise, net of issue expenses</a></td>
<td class="nump">$ 980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_StockIssuedDuringPeriodValueNetOfIssueExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net of issue expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_StockIssuedDuringPeriodValueNetOfIssueExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_WarrantsNetOfIssueExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants, net of issue expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_WarrantsNetOfIssueExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819061358600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (12,615)<span></span>
</td>
<td class="num">$ (14,443)<span></span>
</td>
<td class="num">$ (12,625)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments required to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation of property, plant and equipment and amortization</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Decrease in operating lease right of use asset</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Change in prepaid expenses, and other current assets</a></td>
<td class="nump">128<span></span>
</td>
<td class="nump">4,275<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_IncreaseDecreaseInSharebasedPayment', window );">Share-based payment</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="nump">385<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based payment in exchange for services</a></td>
<td class="nump">68<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment', window );">Changes in fair value of short-term investment</a></td>
<td class="num">(162)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Decrease in operating lease liability</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Interest on bank deposits</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">non-cash financial expenses (income), net</a></td>
<td class="num">(34)<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Increase (decrease) in trade payable</a></td>
<td class="nump">393<span></span>
</td>
<td class="num">(1,595)<span></span>
</td>
<td class="nump">1,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Increase (decrease) in deferred revenues</a></td>
<td class="nump">1,398<span></span>
</td>
<td class="num">(401)<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable', window );">Increase (decrease) in other accounts payable</a></td>
<td class="nump">574<span></span>
</td>
<td class="num">(279)<span></span>
</td>
<td class="num">(512)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(9,858)<span></span>
</td>
<td class="num">(12,063)<span></span>
</td>
<td class="num">(11,084)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant and equipment</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireOtherInvestments', window );">Investment in short-term deposits</a></td>
<td class="num">(14,500)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(14,511)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Issuance of share capital and warrants, net of issuance expenses</a></td>
<td class="nump">20,457<span></span>
</td>
<td class="nump">17,683<span></span>
</td>
<td class="nump">10,167<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">20,457<span></span>
</td>
<td class="nump">17,683<span></span>
</td>
<td class="nump">10,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents', window );">Exchange differences on balances of cash and cash equivalents</a></td>
<td class="nump">34<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(3,878)<span></span>
</td>
<td class="nump">5,571<span></span>
</td>
<td class="num">(918)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at the beginning of the year</a></td>
<td class="nump">8,268<span></span>
</td>
<td class="nump">2,697<span></span>
</td>
<td class="nump">3,615<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash and cash equivalents at the end of the year</a></td>
<td class="nump">4,390<span></span>
</td>
<td class="nump">8,268<span></span>
</td>
<td class="nump">2,697<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Lease liabilities arising from obtaining right-of-use-assets</a></td>
<td class="nump">120<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="nump">76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividends', window );">Deemed Dividend</a></td>
<td class="nump">2,590<span></span>
</td>
<td class="nump">715<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the year for interest</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of changes in fair value of short-term investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IncreaseDecreaseInSharebasedPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of changes in share based payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IncreaseDecreaseInSharebasedPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819058004104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">GENERAL</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1:-&#160;GENERAL</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Company description:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Can-Fite Biopharma Ltd. (the &#8220;Company&#8221;)
was incorporated and started to operate in September 1994 as a private Israeli company. Can-Fite is a clinical-stage biopharmaceutical
company focused on developing orally bioavailable small molecule therapeutic products for the treatment of psoriasis, liver cancer, NASH
and erectile dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is highly expressed
in patholological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting that the receptor
could be a specific target for pharmacological intervention. The Company&#8217;s pipeline of drug candidates are synthetic, highly specific
agonists and allosteric modulators at the A3AR.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s ordinary shares
have been publicly traded on the Tel-Aviv Stock Exchange since October 2005 under the symbol &#8220;CFBI&#8221; and the Company&#8217;s
American Depositary Shares (&#8220;ADSs&#8221;) began public trading on the over the counter market in the U.S. in October 2012 and since
November 2013 the Company&#8217;s ADSs have been publicly traded on the NYSE American under the symbol &#8220;CANF&#8221;. Each ADS represents
30 ordinary shares of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the year ended December 31, 2021, the Company incurred net losses of USD&#160;12,615 and it had negative cash flows from operating activities in the amount of USD&#160;9,858.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Furthermore, the Company intends to
continue to finance its operating activities by raising capital and seeking collaborations with multinational companies in the industry.
There are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research
and development activities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">If the Company will not have sufficient
liquidity resources, the Company may not be able to continue the development of all of its products or may be required to implement a
cost reduction and may be required to delay part of its development programs. The Company&#8217;s management and board of directors are
of the opinion that its current financial resources will be sufficient to continue the development of the Company&#8217;s products for
at least the next twelve months beyond the date of the filing date of the consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819057982248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; ">The consolidated financial
statements have been prepared in conformity with accounting principles generally accepted in the United States (&#8220;U.S. GAAP&#8221;).</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of estimates:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#8217;s
management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they
are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting
period. Actual results could differ from those estimates.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principles of consolidation:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The consolidated financial statements
include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency, reporting currency and foreign currency:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency and reporting currency:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">From the Company&#8217;s inception through
January 1, 2018, the Company&#8217;s functional and presentation currency was the New Israeli Shekel (&#8220;NIS&#8221;). In 2018, management
conducted a review of the functional currency of the Company and concluded that the Company&#8217;s functional currency has changed to the U.S
dollar (&#8220;dollar&#8221;, &#8220;USD&#8221; or &#8220;$&#8221;) effective January 1, 2018.These changes were based on an assessment
made by the Company&#8217;s management that the USD is the primary currency of the economic environment in which the Company operates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions, assets and liabilities in foreign currency:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Transactions and balances denominated
in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured
into dollars in accordance with ASC No.&#160;830, &#8220;Foreign Currency Matters&#8221;. All transaction gains and losses from the re-measurement
of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as
appropriate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Cash equivalents are short-term, highly
liquid investments that are readily convertible to cash with a maturity of three months or less at the date of acquisition, to be cash
equivalents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Short-term bank deposits:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Short-term bank deposits are deposits with maturities of more than three months and less than one year. As of December 31, 2021 and 2020, the Company&#8217;s bank deposits are denominated mainly in U.S. dollars and bears yearly interest at weighted average rates of 0.53% and none. Short-term bank deposits are presented at their cost, including accrued interest.</p></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 8pt">&#160;</span></td> <td><span style="font-size: 8pt">&#160;</span></td> <td><span style="font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: top"> <td style="padding-right: -6.55pt">&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses, and other current assets:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Prepaid expenses are composed mainly from prepayments to suppliers
and from active pharmaceutical ingredients and clinical trial drug-capsules which are expensed when designate to a clinical trial and
no longer have an alternative future use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In accordance with ASU No. 2016-02,
"Leases (Topic 842)", the Company determines if an arrangement is a lease and the classification of that lease at inception
based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially
all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of
the asset. The Company elected to not recognize a lease liability and a right-of-use ("ROU") asset for leases with a term of
twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases.
ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum
lease payments arising from the lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ROU assets are initially measured at amounts, which represents the
discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially
measured at lease commencement date based on the discounted present value of minimum lease payments over the lease term. The implicit
rate within the operating leases is generally not determinable, therefore the Company uses its Incremental Borrowing Rate ("IBR")
based on the information available at commencement date in determining the present value of lease payments. The Company's IBR is estimated
to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased
asset is located. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection
with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option
to terminate is considered unless it is reasonably certain that the Company will not exercise the option.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Property and equipment are stated at
cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the
assets at the following annual rates:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mainly<br/> %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Laboratory equipment and Leasehold improvements</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 49.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6 - 33</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including extension option held by the Company and intended to be exercised)
and the expected life of the improvement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of long-lived assets:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Property and equipment are reviewed
for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment,&#8221; whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair
value of the assets. As of December 31, 2021, and 2020, no impairment indicators have been identified.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td><td style="text-align: justify">Revenue recognition:</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue in
accordance with ASC Topic&#160;606, Revenue from contracts with customers (&#8220;ASC 606&#8221;) and determines revenue recognition
through the following steps:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
of the contract, or contracts, with a customer;</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
of the performance obligations in the contract;</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determination
of the transaction price;</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation
of the transaction price to the performance obligations in the contract; and</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition
of revenue when, or as, the performance obligations are satisfied.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates rev</span>enues from supply and distribution agreements. The consideration under these agreements comprise of upfront
license fees, milestone payments and potential royalty payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and
distribution agreements with customers is recognized when the control over the goods or services is transferred to the customer. The
transaction price is the amount of the consideration that is expected to be received based on the contract terms, excluding amounts
collected on behalf of third parties (such as taxes).<b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and distribution
agreements with customers are recognized over time as the Company satisfies the performance obligations. The Company usually accepts long-term
upfront payment from its customers. Contract liabilities for those upfront payments are recognized as revenue over time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts generally
include three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of
an exclusive licensing to distribute the product, once available; and, (iii) participation in joint steering committee.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company has concluded that the
abovementioned contracts contain a single performance obligation satisfied over time. Consequently, revenue from these contracts is recorded
based on the term of the research and development services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts also
include development milestones payments and future sales-based royalties. Development milestones payments are recognized only to the extent
that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated
with those milestones is subsequently resolved. As such sales based royalties are recognized only when the subsequent sale occurs. As
of December 31, 2021, the Company has not yet received the required regulatory approvals for its products and has not yet recognized any
sales-based royalties .</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The prepayments terms from the Company&#8217;s
contracts with customers do not include a significant financing component as the primary purpose of these payments is not to receive financing
from the customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="text-decoration:underline">Revenue Recognition &#8211; Contract
Balances </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Contract liabilities, due to the upfront
payments, include amounts received from customers for which revenue has not yet been recognized. As of December 31, 2021 and December
31, 2020 contract liabilities amounted to $3,888&#160;and $2,490, respectively and are presented under deferred revenues. During the year
ended December 31, 2021, the Company recognized revenues in the amount of $853&#160;out of which $507 have been included in the contract
liabilities at December&#160;31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Deferred revenue that is anticipated
to be recognized during the succeeding 12-months period is recorded as current deferred revenue and the remaining portion is recorded
as non-current deferred revenue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Research and development costs are
expensed as incurred. Research and development costs include payroll and personnel expenses, consulting costs, external contract research
and development expenses, raw materials, drug product manufacturing costs, and allocated overhead including depreciation and amortization,
rent, and utilities. Research and development are generally expensed as incurred. Research and development costs that are paid in advance
of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company applies ASC 820, &#8220;Fair
Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;). Under this standard, fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market
participants at the measurement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In determining fair value, the Company
uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable
inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs
are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent
from the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken
down into three levels based on the inputs as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 1 - Valuations based on quoted
prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are
not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active
market, valuation of these products does not entail a significant degree of judgment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 2 - Valuations based on one or
more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 3 - Valuations based on inputs
that are unobservable and significant to the overall fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The carrying amounts of cash and cash
equivalents, other accounts receivable and prepaid expenses, trade payables and other accounts payable and accrued expenses approximate
their fair value due to the short-term maturity of such instruments. The Company has an investment measured using Level 1 inputs. See
Note 4.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Concentration of Credit Risk:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents and short-term deposits. For cash and cash equivalents, the Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.</p></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 8pt">&#160;</span></td> <td><span style="font-size: 8pt">&#160;</span></td> <td><span style="font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal and other contingencies</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for its contingent
liabilities in accordance with ASC 450, Contingencies (&#8220;ASC 450&#8221;). A provision is recorded when it is both probable that a liability
has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, the Company reviews the status
of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable
and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. As of December 31, 2021, and 2020,
the Company is not a party to any litigation that could have a material adverse effect on the Company&#8217;s business, financial position,
results of operations or cash flows. Legal costs incurred in connection with loss contingencies are expensed as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Major customer data as a percentage
of total revenues:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cipher Pharmaceuticals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">12</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Chong Kun Dang Pharmaceuticals Corp.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Gebro Holding GmBH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Ewopharma AG</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severance pay<span style="text-transform: uppercase">:</span></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s liability for severance
pay is pursuant to Section 14 of the Severance Compensation Act, 1963 (&#8220;Section 14&#8221;), pursuant to which all the Company&#8217;s
employees are included under Section 14, and are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in
the employee&#8217;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release the Company
from any future severance payments in respect of those employees. The fund is made available to the employee at the time the employer-employee
relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected
in the consolidated balance sheets as the severance pay risks have been irrevocably transferred to the severance funds.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Severance pay expense for the year
ended December 31, 2021, 2020 and 2019 amounted to $53, $46 and $42, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions<span style="text-transform: uppercase">:</span></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for share-based
compensation in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221; (&#8220;ASC 718&#8221;), which requires companies
to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion
of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#8217;s
consolidated statement of comprehensive loss, based on acceleration method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company recognizes compensation
expenses for the value of its awards granted based on the vesting attribution approach over the requisite service period of each of the
awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in
subsequent periods if actual forfeitures differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company estimates the fair value
of share options granted using the Binomial option pricing model. The option-pricing model requires a number of assumptions, of which
the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated based upon
historical volatility of the Company. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term.
The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for income taxes
in accordance with ASC No. 740, &#8220;Income Taxes&#8221;, (&#8220;ASC 740&#8221;) which prescribes the use of the liability method whereby
deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company provides a valuation allowance,
if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2021, and 2020, a full valuation allowance
was provided by the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ASC 740 contains a two-step approach
to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected
to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation
of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes.
The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
As of December 31, 2021, and 2020, no liability for unrecognized tax benefits was recorded.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ordinary share warrants classification and measurement:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#8217;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net loss per share<span style="text-transform: uppercase">:</span></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Basic and diluted net loss per share
is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated
based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260,
&#8220;Earnings per Share&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">All outstanding share options and warrants
for the years ended December 31, 2021, 2020 and 2019 have been excluded from the calculation of the diluted net loss per share, because
all such securities are anti-dilutive for all periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">To compute diluted loss per share for the years ended December 31,
2021, December 31, 2020 and December 31, 2019, the total number of 18,422,700, 11,923,400 and 2,673,400 shares, respectively subject to
outstanding unlisted options have not been considered since they have anti-dilutive effect.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 47px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recently adopted and recently issued accounting pronouncements</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#8211;
Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which replaces the existing incurred loss impairment
model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected
to be collected. The adoption of the standard did not have material effect on Company&#8217;s results.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 47px">&#160;</td> <td style="width: 24px">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic
740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing a variety of exceptions
within the framework of ASC 740. These exceptions include the exception to the incremental approach for intra period tax allocation in
the event of a loss from continuing operations and income or a gain from other items (such as other comprehensive income), and the exception
to using general methodology for the interim period tax accounting for year-to-date losses that exceed anticipated losses. The adoption
of the standard did not have material effect on Company&#8217;s results.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting pronouncements not yet adopted:</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provides guidance to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. As a result, the Company will not be required to adopt ASU 2021-04 until January 1, 2022. The Company is currently evaluating the impact of the adoption of this principle on the Company&#8217;s unaudited consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/></td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819057792312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Receivable and Prepaid Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_OtherAccountsReceivableAndPrepaidExpensesAbstract', window );"><strong>Other Accounts Receivable And Prepaid Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock', window );">OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 3:-&#160;OTHER ACCOUNTS RECEIVABLE AND
PREPAID EXPENSES</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Government authorities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Prepaid expenses and others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">881</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">1,039</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">929</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,057</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_OtherAccountsReceivableAndPrepaidExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_OtherAccountsReceivableAndPrepaidExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of other accounts receivable and prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819058021688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-Term Investment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTextBlock', window );">SHORT-TERM INVESTMENT</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 4:-&#160;SHORT-TERM INVESTMENT</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company holds 356,803 shares of
Mawson Infrastructure Group Inc. (formerly Wize Pharma Inc.) as of December 31, 2021 and December 31, 2020, which as of such dates represents
less than 5 percent of Mawson Infrastructure Group Inc.&#8217;s outstanding shares, respectively. The investments in marketable equity
securities are measured at fair value with the related gains and losses, including unrealized, recognized in finance income (expenses),
net.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -URI http://asc.fasb.org/topic&amp;trid=75115024<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -URI http://asc.fasb.org/topic&amp;trid=2197064<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -URI http://asc.fasb.org/topic&amp;trid=2196965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819057789304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT, NET</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 5:-&#160;PROPERTY, PLANT AND EQUIPMENT,
NET </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Composition of assets, grouped by major classification,
is as follows:&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">62</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">57</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">281</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">270</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">184</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">234</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">220</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">47</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">50</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">Depreciation expenses for the year ended December 31, 2021, 2020 and
2019 amounted to $14, $12 and $14, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819057927864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_OtherAccountsPayableLineItems', window );"><strong>Other Accounts Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">OTHER ACCOUNTS PAYABLE</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 6:-</b>&#160;<b>OTHER ACCOUNTS PAYABLE</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Employees and payroll accruals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">603</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">96</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">302</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">235</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">905</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">331</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_OtherAccountsPayableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_OtherAccountsPayableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819077050328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 7:- FAIR VALUE MEASUREMENTS </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">In accordance with ASC 820 &#8220;Fair
Value Measurements and Disclosures&#8221;, the Company measures its short-term investment at fair value. Short-term investments are classified
within Level 1 as the valuation inputs are valuations based on quoted prices in active markets for identical assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company&#8217;s financial assets
and liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of the following dates:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measurements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Description</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair value</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; width: 52%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">237</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">237</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value measurements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Description</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair value</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 52%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">75</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">75</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819057978920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities and Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">CONTINGENT LIABILITIES AND COMMITMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 8:-&#160;CONTINGENT LIABILITIES AND COMMITMENTS
</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px; padding-right: 0.9pt">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a. </span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities to pay royalties:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px">&#160;</td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">According to the patent license agreement that the Company entered into with Leiden University in the Netherlands on November 2, 2009, which is affiliated with the National Institutes of Health (NIH), the Company was granted an exclusive license for the use of the patents of several compounds, including CF602 in certain territories.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company is committed to pay royalties
as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">A one-time concession commission of &#8364;25 thousand;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Annual royalties of &#8364;10 thousand until the clinical trials commence;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2%-3% of net sales (as defined in the agreement) received by the Company;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4)</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Royalties in a total amount of up to &#8364;850 thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) &#8364;50 thousand upon initiation of Phase I studies; (ii) &#8364;100 thousand upon initiation of Phase II studies; (iii) &#8364;200 thousand upon initiation of Phase III studies; and (iv) &#8364;500 thousand upon marketing approval by any regulatory authority.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5)</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">If the agreement is sublicensed to another company, the Company will provide Leiden University royalties at a rate of 10%. A merger, consolidation or any other change in ownership will not be viewed as an assignment of the agreement as discussed in this paragraph.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.25in">As of December
31 2021, no accrual has been recorded with respect to Leiden University.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: top">
    <td style="width: 48px; padding-right: 0.9pt">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Commitments and license agreements:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2015, the Company signed a distribution agreement with Cipher Pharmaceuticals (&#8220;Cipher&#8221;). As part of the distribution agreement, Cipher will distribute Can-Fite&#8217;s lead drug candidate, Piclidenoson for the treatment of psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under the terms of the agreement, Cipher
made an upfront payment of USD 1,292 (CAD 1,650 thousand) to the Company in March 2015. In addition, the agreement provides that additional
payments of up to CAD 2,000 thousand will be received by the Company upon the achievement of certain milestones plus royalty payments
of 16.5% of net sales of Piclidenoson in Canada.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities. In addition, the Company agreed to form
a joint steering committee with Cipher which will oversee the progress of the clinical studies.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In October 2016, the Company signed a distribution agreement with Chong Kun Dang Pharmaceuticals Corp. (&#8220;CKD&#8221;) for future sales in South Korea. As part of the distribution agreement, CKD will distribute Namodenoson for the treatment of liver cancer in the South Korean market upon receipt of regulatory approvals.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under the terms of the agreement, CKD
made an upfront payment of USD 500 to the Company in December 2016 and in August 2017, the Company received a second milestone payment
in the amount of USD 500 from CKD, which has licensed the exclusive right to distribute Namodenoson for the treatment of liver cancer
in Korea upon receipt of regulatory approvals.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">In addition, the agreement provides that
additional payments of up to USD 2,500 will be received by the Company upon the achievement of certain milestones.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">On February 25, 2019, the Company&#8217;s
Distribution Agreement with CKD was amended to expand the exclusive right to distribute Namodenoson for the treatment of NASH in addition
to liver cancer in South Korea. CKD has agreed to pay the Company up to an additional USD 6,000 in upfront and milestone payments payable
with respect to the NASH indication. The Company will also be entitled to a transfer price for delivering finished product to CKD following
commercial launch. In April 2019, the Company received an upfront payment of USD 1,000.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 22, 2008, the Company signed an agreement
    regarding the provision of a license for Piclodenoson with a South Korean pharmaceutical company, Kwang Dong Pharmaceutical Co. Ltd. (&#8220;KD&#8221;).
    According to the license agreement, the Company granted the KD a license to use, develop and market its Piclodenoson for treating only
    rheumatoid arthritis only in the Republic of Korea.</p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">As of December 31, 2021, the Company estimates
that such contingent payments are remote.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 8, 2018, the Company entered into a Distribution and Supply Agreement with Gebro Holding GmBH (&#8220;Gebro&#8221;), granting Gebro the exclusive right to distribute Piclidenoson in Spain, Switzerland, Liechtenstein and Austria for the treatment of psoriasis and rheumatoid arthritis.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>&#160;</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Under the Distribution and Supply Agreement,
the Company is entitled to &#8364;1,500 thousand upon execution of the agreement plus milestone payments upon achieving certain clinical,
launch and sales milestones, as follows: (i) &#8364;300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment
of rheumatoid arthritis and &#8364;300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis,
(ii) between &#8364;750 thousand and &#8364;1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either
the treatment of rheumatoid arthritis or psoriasis, and (iii) between &#8364;300 thousand and up to &#8364;4,025 thousand upon meeting certain
net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson
in the territories and payment for the manufacturing Piclidenoson.&#160;On January 25, 2018 the Company received a first payment of approximately
USD 2,200 from Gebro and in August 2018 received approximately USD 350 upon reaching the first milestone.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">The Company estimates these services will
spread over a period ending December 2026. Component (iv) was not accounted as part of the research and development services and will
be recognized entirely upon the Company reaching sales stage.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 6, 2018, the Company entered into a License, Collaboration and Distribution Agreement with CMS Medical Venture Investment Limited (&#8220;CMS Medical&#8221;) for the commercialization of Piclidenoson for the treatment of rheumatoid arthritis and psoriasis and Namodenoson for the treatment of advanced liver cancer and NAFLD/NASH in China (including Hong Kong, Macao and Taiwan). Under the License, Collaboration and Distribution Agreement, the Company received USD 2,000 upon execution of the agreement and is entitled to additional milestone payments upon achieving certain regulatory and sales milestones. In addition, following regulatory approval, the Company shall be entitled to future double digit royalties on net sales in the territories and payment for the manufacturing of Piclidenoson and Namodenoson.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/></td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 31, 2019, the Company signed a distribution agreement with Kyongbo Pharm Co., Ltd. (&#8220;Kyongbo Pharm&#8221;), to distribute Piclidenoson, for the treatment of psoriasis in South Korea, upon receipt of regulatory approvals. Under the terms of the distribution agreement, Kyongbo Pharm, in exchange for exclusive distribution rights to sell Piclidenoson in the treatment of psoriasis in South Korea, is required to make a total upfront payment of USD 750 to the Company, with additional payments of up to USD 3,250 upon achievement of certain milestones. The Company will also be entitled to a transfer price for delivering finished product to Kyongbo Pharm upon commercial launch. In August 2019, the Company received the upfront payment of USD 750 from Kyongbo Pharm.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 16, 2021, the Company announced it signed an exclusive distribution agreement with Switzerland-based Ewopharma for Piclidenoson in the treatment of psoriasis and Namodenoson in the treatment of liver diseases namely, hepatocellular carcinoma (HCC) the most common form of liver cancer and non-alcoholic steatohepatitis (NASH). Under the terms of the distribution agreement, Ewopharma paid Can-Fite non-refundable upfront payment in an amount of $2,250 and is entitled to up to an additional $40,450 payable upon the achievement of regulatory and sales milestones and 17.5% royalties on net sales. In exchange, Ewopharma will have the exclusive right to market and sell Piclidenoson in Central Eastern European (CEE) countries and Namodenoson in CEE countries and Switzerland. Ewopharma has the right to extend the distribution agreement to new indications that Can-Fite may identify for its drug candidates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On June 28, 2021, the Company announced it signed a development and commercialization agreement with Vetbiolix, a France-based veterinary biotech company, for the development of Piclidenoson for the treatment of osteoarthritis in companion animals including dogs and cats. According to the agreement, the Company will grant Vetbiolix an exclusive option to purchase its license of Piclidenoson in the veterinary osteoarthritis market for two years from the signature date, during which time Vetbiolix will conduct proof-of-concept studies and cover all associated costs. If the studies yield positive data and Vetbiolix exercises its option to obtain the license from Can-Fite, then Vetbiolix will be obligated to pay Can-Fite a non-refundable upfront payment in an amount of Euro 250 thousand, additional milestones payment equal to 30% upon each upfront payment received from sublicensee and 15%-40% royalties on net sales upon regulatory approval for veterinary use.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819058891688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">SHAREHOLDERS&#8217; EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 9:-&#160;SHAREHOLDERS&#8217; EQUITY </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 10, 2019, the Company effected a change in the ratio of the Company&#8217;s ADS to ordinary shares from one (1) ADS representing two (2) ordinary shares to a new ratio of one (1) ADS representing thirty (30) ordinary shares. For ADS holders, the ratio change had the same effect as a one-for-fifteen reverse ADS split. All ADS and per ADS data in the financial statements and their related notes have been retroactively adjusted for all periods presented to reflect the ratio change.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">All ordinary shares have equal rights
for all intent and purposes and each ordinary share confers its holder:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to be invited and participate in all the Company&#8217;s general meetings, both annual and regular, and the right to one vote per ordinary share owned in all votes and in all Company&#8217;s general meeting participated.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to receive dividends if and when declared and the right to receive bonus shares if and when distributed.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The right to participate in the distribution of the Company&#8217;s assets upon liquidation.</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issue of shares and warrants and changes in equity:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 18, 2019, the Company completed a registered direct offering with an institutional investor, pursuant to which it sold an aggregate 149,206 ADSs representing 4,476,192 ordinary shares. In addition, in a concurrent private placement, the Company issued to the investor unregistered warrants to purchase 149,206 ADSs representing 4,476,192 ordinary shares for an aggregate purchase price of USD 2,350 (excluding issuance cost of USD 428). The warrants have an exercise price of USD 19.50 per ADS, are immediately exercisable and expire five and one-half years from the issuance date. The Company also issued unregistered placement agent warrants to purchase an aggregate of 7,460 ADSs representing 223,810 ordinary shares on the same terms as the warrants except they have a term of five years.&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 4, 2019, the Company completed a registered direct offering with certain institutional investors, pursuant to which it sold an aggregate 328,205 ADSs representing 9,846,156 ordinary shares. In addition, in a concurrent private placement, the Company issued to the investor unregistered warrants to purchase 328,205 ADSs representing 9,846,156 ordinary shares for an aggregate purchase price of USD 3,200 (excluding issuance cost of USD 414). The warrants have an exercise price of USD 12.90 per ADS, are immediately exercisable and expire five years from the issuance date. The Company also issued unregistered placement agent warrants to purchase an aggregate of 16,410 ADSs representing 492,308 ordinary shares on the same terms as the warrants except they have a term of five years.&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td> <td style="text-align: justify; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On May 22, 2019, the Company completed a registered direct offering with certain institutional investors, pursuant to which it sold an aggregate 1,500,000 ADSs representing 45,000,000 ordinary shares. In addition, in a concurrent private placement, the Company issued to the investor unregistered warrants to purchase 1,500,000 ADSs representing 45,000,000 ordinary shares for an aggregate purchase price of USD 6,000 (excluding issuance cost of USD 540). The warrants have an exercise price of USD 4.00 per ADS, are immediately exercisable and expire five and one-half years from the issuance date. The Company also issued unregistered placement agent warrants to purchase an aggregate of 75,000 ADSs representing 2,250,000 ordinary shares on the same terms as the warrants except they have a term of five years.&#160;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In September 2019, the Company issued 19,934,355 of its ordinary shares in connection with the Univo collaboration agreement</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the Company issued 996,690 of its ordinary shares to a consultant in exchange for his services in connection with the Univo collaboration agreement.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On January 9, 2020, the Company entered into warrant exercise agreements (the &#8220;Exercise Agreements&#8221;) with several accredited investors who are the holders of certain warrants (the &#8220;Public Warrants&#8221;) to purchase the Company&#8217;s ordinary shares, represented by ADSs, pursuant to which the Holders exercised in cash their Public Warrants to purchase up to an aggregate of 22,278,540 ordinary shares represented by 742,618 ADSs having exercise prices ranging from USD 12.90 to USD 78.75 per ADS issued by the Company, at a reduced exercise price of USD 3.25 per ADS, for gross proceeds to the Company of approximately USD 2,400, prior to deducting placement agent fees and estimated offering expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Exercise Agreements, the Company issued to the warrant holders new unregistered warrants to purchase up to 22,278,540 ordinary shares represented by 742,618 ADSs (the &#8220;Private Placement Warrants&#8221;). The Private Placement Warrants are immediately exercisable, expire five and one-half years from issuance date and have an exercise price of USD 3.45 per ADS, subject to adjustment as set forth therein. The Private Placement Warrants may be exercised on a cashless basis if six months after issuance there is no effective registration statement registering the ADSs underlying the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the terms of the Exercise Agreements, the warrant holders agreed to exercise the warrants at a reduced exercise price, thereby creating a benefit to these warrant holders. As such, the Company recorded a deemed dividend in the amount of $715.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On February 12, 2020, the Company completed a public offering with certain institutional investors pursuant to which the Company issued and sold (i) 1,825,000 units, each unit consisting of one ADS, and one warrant to purchase one ADS, at a price of USD 1.50 per unit, and (ii) 1,508,334 pre-funded units each pre-funded unit consisting of one pre-funded warrant to purchase one ADS and one warrant, at a price of USD 1.49 per pre-funded unit.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The gross proceeds from the offering were approximately USD 5,000, prior to deducting the placement agent&#8217;s fees and estimated offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The placement agent in the offering also received compensation warrants exercisable for up to 250,000 ADSs at an exercise price of USD 1.875 per ADS expiring on February 10, 2025.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 9, 2020, as a result of an exercise of warrants by the investors from the February 2020 offering, the Company issued an aggregate of 20,250,000 ordinary shares represented by 675,000 ADSs, at a price of $1.50 per ADS for gross proceeds of $1,012.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 28, 2020, a special meeting of shareholders of the Company approved to increase Company&#8217;s authorized share capital to 1,000,000,000 ordinary shares of 0.25 NIS par value each.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In April and May, 2020, as a result of an exercise of warrants by the investors from the February 2020 offering, the Company issued an aggregate of 31,000,020 ordinary shares represented by 1,033,334 ADSs, at a price of $1.50 per ADS for gross proceeds of $1,550.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 12, 2020, the Company completed a registered direct offering with certain institutional and accredited investors pursuant to which it sold an aggregate of 3,902,440 ADSs at a purchase price of $2.05 per ADS for aggregate gross proceeds of approximately $8,000 prior to deducting the placement agent&#8217;s fees and estimated offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in a concurrent private placement the investors received unregistered warrants to purchase up to an aggregate of 1,951,220 ADSs. The warrants were immediately exercisable and will expire four and a half years from issuance at an exercise price of $2.50 per ADS, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The placement agent in the offering also received compensation warrants on substantially the same terms as the investors in the offering in an amount equal to 7.5% of the aggregate number of ADSs sold in the offering (or warrants to purchase up to an aggregate of 292,683 ADSs), at an exercise price of $2.50 per ADSs and a term expiring four and a half years from the date of issuance.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On July 8, 2020, the Company completed a registered direct offering with certain institutional and accredited investors pursuant to which it sold an aggregate of 1,705,000 ADSs at a purchase price of $2.00 per ADS for aggregate gross proceeds of approximately $3,400 prior to deducting the placement agent&#8217;s fees and estimated offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, in a concurrent private placement, the investors received unregistered warrants to purchase up to an aggregate of 852,750 ADSs. The warrants were immediately exercisable and will expire four and a half years from issuance at an exercise price of $2.50 per ADS, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The placement agent in the offering also received compensation warrants on substantially the same terms as the investors in the offering in an amount equal to 7.5% of the aggregate number of ADSs sold in the offering (or warrants to purchase up to an aggregate of 127,913 ADSs), at an exercise price of $2.50 per ADSs and a term expiring.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top"><td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2020, the Company issued 1,350,000 of its ordinary shares to a consultant in exchange for his services.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February and March 2021, the Company issued 50,926,830 ordinary shares represented by 1,697,561 ADSs in exchange for exercise of warrants. Total consideration received by the Company was $2,744.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In March 2021, the Company issued 1,050,000 of its ordinary shares represented by 35,000 ADSs to certain consultants in exchange for their services with fair value of $ 68.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 72px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 16, 2021, the Company completed a registered direct offering with an institutional investor pursuant to which it sold (i) 57,000,000 ordinary shares represented by 1,900,000 ADSs, and (ii) a pre-funded warrant to purchase 93,000,000 ordinary shares represented by 3,100,000 ADSs at an offering price of $2.00 per ADS and $1.999 per pre-funded warrant, for aggregate gross proceeds of approximately $10,000 (without taking into account any proceeds from any future exercises of warrants issued in the concurrent private placement), before deducting the placement agent&#8217;s fees and other estimated offering expenses payable by the Company.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has also sold to the investor, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 5,000,000 ADSs. The warrants have an exercise price of $ 2.00 per ADS and are exercisable at any time upon issuance and will expire three years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of the financial statements date, the Company received a total of $ 9,997 and issued 57,000,000 ordinary shares represented by 1,900,000 ADSs and 93,000,000 ordinary shares represented by 3,100,000 ADSs following the exercise of the pre-funded warrants (issuance expenses were $1,307).</p></td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt">&#160;</td> <td style="text-align: justify; font-size: 10pt">&#160;</td></tr> <tr style="vertical-align: top"> <td style="font-size: 10pt">&#160;</td> <td style="font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">17.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 20, 2021, the Company entered into a warrant exercise agreement (the &#8220;Exercise Agreement&#8221;) with an institutional investor who is the holder of certain existing warrants to purchase Company&#8217;s ordinary shares, par value NIS 0.25 per share, represented by ADSs issued by the Company in a registered direct offering consummated in August 2021. Pursuant to the Exercise Agreement, the holder agreed to exercise in cash its warrants to purchase up to an aggregate of 150,000,000 Ordinary Shares represented by 5,000,000 ADSs having an exercise price of $2.00 per ADS, at an exercise price of $2.00 per ADS, for gross proceeds to the Company of $10 million, prior to deducting placement agent fees and offering expenses (which amounted to $0.98 million).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Under the Exercise Agreement, the Company also agreed to issue to the holder new unregistered warrants to purchase up to 180,000,000 Ordinary Shares represented by 6,000,000 ADSs (the &#8220;Private Placement Warrants&#8221;). The Private Placement Warrants will be immediately exercisable, will expire five years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants, and have an exercise price of $2.00 per ADS.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the terms of the Exercise Agreements, the holder agreed to exercise the warrants while receiving a-120% warrants coverage, thereby creating a benefit to this warrant holder. As such, the Company recorded a deemed dividend in the amount of $ 2,590.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top">
<td style="width: 72px"/><td style="width: 24px">c.</td><td style="text-align: justify">Warrants to Purchase Common stock:</td></tr><tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">&#160;</td></tr>
                                                                                                                                            <tr style="vertical-align: top">
<td>&#160;</td><td>&#160;</td><td style="text-align: justify">The following table
summarizes information regarding outstanding warrants to purchase shares of the Company&#8217;s ADS&#8217;s issued as of December 31,
2021:</td></tr>
                                                                                                                                            </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: 0in">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Issuance date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <br/> outstanding <br/> warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exercise<br/> price per<br/> warrant</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>($)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify">January 2017</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">91,667</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">33.75</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">March 2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">January 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,460</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">April 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,410</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.90</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">May 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,575,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">January 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">794,601</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.45</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">February 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">375,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">June 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,046,342</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">July 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">980,663</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">August 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">350,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">December 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,350,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,598,254</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819058016136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED PAYMENT TRANSACTIONS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 10:-&#160;SHARE-BASED PAYMENT TRANSACTIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share options:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">On November 28, 2013, the board of
directors approved the adoption of the 2013 Share Option Plan (the &#8220;2013 Plan&#8221;). Under the 2013 Plan, the Company may grant
its officers, directors, employees and consultants, stock options, of the Company. Each stock option granted shall be exercisable at such
times and terms and conditions as the Board of Directors may specify in the applicable option agreement, provided that no option will
be granted with a term in excess of 10 years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Upon the adoption of the 2013 Plan
the Company reserved for issuance 2,500,000 shares of ordinary shares, NIS 0.25 par value each. In May 2020, the Company&#8217;s Board
of Directors approved to increase number of ordinary shares reserved for issuance to 25,000,000. As of December 31, 2021, 6,618,500 shares
available for future grant under the 2013 Plan.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenses recognized in the financial statements:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">200</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">159</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">138</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">198</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">158</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">132</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">398</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">317</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">270</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions granted by the Company:</span></td></tr>
</table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The fair value of the Company&#8217;s
share options granted was estimated using the binomial option pricing model using the following range assumptions:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Description</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Risk-free interest rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.22-1.28</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.93-2.40</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap; text-align: justify">Expected volatility</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;82.40-82.43</span></td><td style="white-space: nowrap; text-align: left">%</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;65.63-78.77 </span></td><td style="white-space: nowrap; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify">Dividend yield</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Contractual life</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.83 - 10</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Early Exercise Multiple (Suboptimal Factor)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5 - 3</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap; text-align: justify">Exercise price (NIS)</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25-0.253</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25
- 2.344</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Movement during the year:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The following table lists the number
of share options, their weighted average exercise prices and modification in option plans of employees, directors and consultants for
the periods indicated:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="6">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares subject to options <br/>
outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/>
average <br/>
exercise <br/>
price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,923,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.28</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.08</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Forfeited/expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(600,700</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Outstanding at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">18,422,700</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.18</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Exercisable at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,322,700</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.35</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average remaining contractual life for the shares subject to options outstanding as of December&#160;31, 2021, 2020 and 2019 was 8.45 years, 6.98 years and 7.93 years, respectively.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The weighted average grant date fair value in 2021 was $0.18 and in 2020 was $0.16 and the remaining compensation costs not yet recognized as of December 31, 2021 is $1,139 with a weighted average period of 2.82 years to recognize these expenses.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The range of exercise prices for shares subject to options outstanding as of December&#160;31, 2021 have been separated into ranges of exercise prices, as follows:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>&#160;</b></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; border-bottom: Black 1.5pt solid">Exercise price per share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options <br/>
outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/>
average <br/>
remaining <br/>
contractual<br/>
life in <br/>
years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/>
average<br/>
exercise<br/> price per<br/> share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options <br/>
exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/>
average <br/>
exercise<br/> price per<br/> share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: left">0.08 - $0.94</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">17,796,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8.32</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.13</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5,696,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.21</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.09 - $1.73</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">555,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">555,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.11</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.61
- $5.18</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">71,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.01</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.01</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">71,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.04</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">18,422,700</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,322,700</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819057982808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 11- LEASES:</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The Company has lease contracts for
motor vehicles used in its operations. Leases of motor vehicles have lease terms of 3 years.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">The following is a summary of weighted
average remaining lease terms and discount rate for all of the Company&#8217;s operating leases:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">weighted average remaining lease term (years)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.42</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.71</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">The components
of lease expense and supplemental cash flow information related to leases for the year ended December 31, 2021 and 2020 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; ">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Components of lease expense:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Operating lease cost</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;55</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;43</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/>
December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/>
December&#160;31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Supplemental cash flow information</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;55</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;43</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">120</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">29</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">Maturities
of lease liabilities as of December 31, 2021 were as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">69</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating lease payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">148</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: imputed interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(24</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Present value of lease liability</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">124</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819058918744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income (Expense)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BankingAndThriftInterestAbstract', window );"><strong>Banking and Thrift, Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock', window );">FINANCE INCOME (EXPENSE)</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 12:-&#160;FINANCE INCOME (EXPENSE), NET</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Finance expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Bank commissions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(18</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(23</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(21</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Net loss from exchange rate fluctuations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(33</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other loss from short-term investment revaluation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(209</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other financial expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(363</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(427</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(22</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(386</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(690</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Finance income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Interest income on bank deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Exchange rate fluctuations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other gain from short-term investment remeasurement</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">162</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">249</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">82</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">72</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total financial income (expenses), net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">227</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(304</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(618</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BankingAndThriftInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BankingAndThriftInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for interest income and interest expense for enterprises that derive a significant portion of their revenue from interest collected on investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.1-12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819057948008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">TAXES ON INCOME</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 13:-&#160;TAXES ON INCOME</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate tax rates:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Israeli taxation:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Corporate tax rate in Israel in 2021
was 23%, 2020 - 23% and in 2019 was 23%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Final tax assessments:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company received final tax assessments
through 2016.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net operating carryforward losses for tax purposes and other temporary differences:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">As of December 31, 2021, the Company
had carryforward losses amounting to approximately USD&#160;164,680.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Deferred income taxes:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Deferred income taxes reflect the net
tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts
used for income tax purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Significant components of the Company&#8217;s
deferred tax assets and liabilities are as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating loss carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">37,875</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">32,312</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Temporary differences mainly relating to Research and Development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,285</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,581</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred tax asset before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,160</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,893</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(41,160</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(35,893</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax asset, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 48px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reconciliation of the theoretical tax expense to the actual tax expense:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The main reconciling item between the
statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating
to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819057923848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with Related Parties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">TRANSACTIONS WITH RELATED PARTIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 14:- TRANSACTIONS WITH RELATED PARTIES
</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Chairman of the Company&#8217;s
board of directors is a senior partner in the patent firm which represents the Company in intellectual property and commercial matters
(the &#8220;Service Provider&#8221;). The Service Provider charges the Company for services it renders on an hourly basis. The aggregate
amount of these expenses was approximately $241, $252 and $163 in 2021, 2020 and 2019, respectively, which were recorded under research
and development expenses within Company&#8217;s consolidated statements of comprehensive loss.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819054543128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Use of estimates:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#8217;s
management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they
are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting
period. Actual results could differ from those estimates.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of consolidation</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Principles of consolidation:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The consolidated financial statements
include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Functional currency, reporting currency and foreign currency</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency, reporting currency and foreign currency:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Functional currency and reporting currency:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">From the Company&#8217;s inception through
January 1, 2018, the Company&#8217;s functional and presentation currency was the New Israeli Shekel (&#8220;NIS&#8221;). In 2018, management
conducted a review of the functional currency of the Company and concluded that the Company&#8217;s functional currency has changed to the U.S
dollar (&#8220;dollar&#8221;, &#8220;USD&#8221; or &#8220;$&#8221;) effective January 1, 2018.These changes were based on an assessment
made by the Company&#8217;s management that the USD is the primary currency of the economic environment in which the Company operates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 72px">&#160;</td>
    <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td>
    <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Transactions, assets and liabilities in foreign currency:</span></td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt"><b>&#160;</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify">Transactions and balances denominated
in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured
into dollars in accordance with ASC No.&#160;830, &#8220;Foreign Currency Matters&#8221;. All transaction gains and losses from the re-measurement
of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as
appropriate.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and cash equivalents</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Cash equivalents are short-term, highly
liquid investments that are readily convertible to cash with a maturity of three months or less at the date of acquisition, to be cash
equivalents.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtPolicyTextBlock', window );">Short-term bank deposits</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Short-term bank deposits:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Short-term bank deposits are deposits with maturities of more than three months and less than one year. As of December 31, 2021 and 2020, the Company&#8217;s bank deposits are denominated mainly in U.S. dollars and bears yearly interest at weighted average rates of 0.53% and none. Short-term bank deposits are presented at their cost, including accrued interest.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock', window );">Prepaid expenses, and other current assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">e.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Short-term bank deposits:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Short-term bank deposits are deposits with maturities of more than three months and less than one year. As of December 31, 2021 and 2020, the Company&#8217;s bank deposits are denominated mainly in U.S. dollars and bears yearly interest at weighted average rates of 0.53% and none. Short-term bank deposits are presented at their cost, including accrued interest.</p></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 8pt">&#160;</span></td> <td><span style="font-size: 8pt">&#160;</span></td> <td><span style="font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: top"> <td style="padding-right: -6.55pt">&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">f.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid expenses, and other current assets:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Prepaid expenses are composed mainly from prepayments to suppliers
and from active pharmaceutical ingredients and clinical trial drug-capsules which are expensed when designate to a clinical trial and
no longer have an alternative future use.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock', window );">Operating lease</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">g.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating lease:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In accordance with ASU No. 2016-02,
"Leases (Topic 842)", the Company determines if an arrangement is a lease and the classification of that lease at inception
based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially
all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of
the asset. The Company elected to not recognize a lease liability and a right-of-use ("ROU") asset for leases with a term of
twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases.
ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum
lease payments arising from the lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ROU assets are initially measured at amounts, which represents the
discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially
measured at lease commencement date based on the discounted present value of minimum lease payments over the lease term. The implicit
rate within the operating leases is generally not determinable, therefore the Company uses its Incremental Borrowing Rate ("IBR")
based on the information available at commencement date in determining the present value of lease payments. The Company's IBR is estimated
to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased
asset is located. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection
with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option
to terminate is considered unless it is reasonably certain that the Company will not exercise the option.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, plant and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">h.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property, plant and equipment:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Property and equipment are stated at
cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the
assets at the following annual rates:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mainly<br/> %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Laboratory equipment and Leasehold improvements</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 49.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6 - 33</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including extension option held by the Company and intended to be exercised)
and the expected life of the improvement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of long-lived assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">i.</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impairment of long-lived assets:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Property and equipment are reviewed
for impairment in accordance with ASC 360, &#8220;Property, Plant and Equipment,&#8221; whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair
value of the assets. As of December 31, 2021, and 2020, no impairment indicators have been identified.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue recognition</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 48px"/><td style="width: 24px; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">j.</span></td><td style="text-align: justify">Revenue recognition:</td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company recognizes revenue in
accordance with ASC Topic&#160;606, Revenue from contracts with customers (&#8220;ASC 606&#8221;) and determines revenue recognition
through the following steps:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
of the contract, or contracts, with a customer;</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
of the performance obligations in the contract;</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Determination
of the transaction price;</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Allocation
of the transaction price to the performance obligations in the contract; and</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"><tr style="vertical-align: top; text-align: justify">
<td style="width: 0.75in"/><td style="width: 0.25in; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</span></td><td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Recognition
of revenue when, or as, the performance obligations are satisfied.</span></td>
</tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company generates rev</span>enues from supply and distribution agreements. The consideration under these agreements comprise of upfront
license fees, milestone payments and potential royalty payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and
distribution agreements with customers is recognized when the control over the goods or services is transferred to the customer. The
transaction price is the amount of the consideration that is expected to be received based on the contract terms, excluding amounts
collected on behalf of third parties (such as taxes).<b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><b>&#160;</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Revenue from supply and distribution
agreements with customers are recognized over time as the Company satisfies the performance obligations. The Company usually accepts long-term
upfront payment from its customers. Contract liabilities for those upfront payments are recognized as revenue over time.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts generally
include three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of
an exclusive licensing to distribute the product, once available; and, (iii) participation in joint steering committee.&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company has concluded that the
abovementioned contracts contain a single performance obligation satisfied over time. Consequently, revenue from these contracts is recorded
based on the term of the research and development services.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s contracts also
include development milestones payments and future sales-based royalties. Development milestones payments are recognized only to the extent
that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated
with those milestones is subsequently resolved. As such sales based royalties are recognized only when the subsequent sale occurs. As
of December 31, 2021, the Company has not yet received the required regulatory approvals for its products and has not yet recognized any
sales-based royalties .</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The prepayments terms from the Company&#8217;s
contracts with customers do not include a significant financing component as the primary purpose of these payments is not to receive financing
from the customers.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="text-decoration:underline">Revenue Recognition &#8211; Contract
Balances </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Contract liabilities, due to the upfront
payments, include amounts received from customers for which revenue has not yet been recognized. As of December 31, 2021 and December
31, 2020 contract liabilities amounted to $3,888&#160;and $2,490, respectively and are presented under deferred revenues. During the year
ended December 31, 2021, the Company recognized revenues in the amount of $853&#160;out of which $507 have been included in the contract
liabilities at December&#160;31, 2020.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Deferred revenue that is anticipated
to be recognized during the succeeding 12-months period is recorded as current deferred revenue and the remaining portion is recorded
as non-current deferred revenue.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and development expenditures</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">k.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research and development expenditures:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Research and development costs are
expensed as incurred. Research and development costs include payroll and personnel expenses, consulting costs, external contract research
and development expenses, raw materials, drug product manufacturing costs, and allocated overhead including depreciation and amortization,
rent, and utilities. Research and development are generally expensed as incurred. Research and development costs that are paid in advance
of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurement</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">l.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fair value measurement:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company applies ASC 820, &#8220;Fair
Value Measurements and Disclosures&#8221; (&#8220;ASC 820&#8221;). Under this standard, fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability (i.e., the &#8220;exit price&#8221;) in an orderly transaction between market
participants at the measurement date.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">In determining fair value, the Company
uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable
inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs
are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent
from the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken
down into three levels based on the inputs as follows:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 1 - Valuations based on quoted
prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are
not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active
market, valuation of these products does not entail a significant degree of judgment.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 2 - Valuations based on one or
more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Level 3 - Valuations based on inputs
that are unobservable and significant to the overall fair value measurement.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The carrying amounts of cash and cash
equivalents, other accounts receivable and prepaid expenses, trade payables and other accounts payable and accrued expenses approximate
their fair value due to the short-term maturity of such instruments. The Company has an investment measured using Level 1 inputs. See
Note 4.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Concentration of Credit Risk:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents and short-term deposits. For cash and cash equivalents, the Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Legal and other contingencies</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">m.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Concentration of Credit Risk:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents and short-term deposits. For cash and cash equivalents, the Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.</p></td></tr> <tr style="vertical-align: top"> <td><span style="font-size: 8pt">&#160;</span></td> <td><span style="font-size: 8pt">&#160;</span></td> <td><span style="font-size: 8pt">&#160;</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">n.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal and other contingencies</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for its contingent
liabilities in accordance with ASC 450, Contingencies (&#8220;ASC 450&#8221;). A provision is recorded when it is both probable that a liability
has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, the Company reviews the status
of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable
and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. As of December 31, 2021, and 2020,
the Company is not a party to any litigation that could have a material adverse effect on the Company&#8217;s business, financial position,
results of operations or cash flows. Legal costs incurred in connection with loss contingencies are expensed as incurred.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Major customer data as a percentage
of total revenues:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cipher Pharmaceuticals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">12</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Chong Kun Dang Pharmaceuticals Corp.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Gebro Holding GmBH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Ewopharma AG</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_SeverancePayPolicyTextBlock', window );">Severance pay</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">o.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Severance pay<span style="text-transform: uppercase">:</span></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company&#8217;s liability for severance
pay is pursuant to Section 14 of the Severance Compensation Act, 1963 (&#8220;Section 14&#8221;), pursuant to which all the Company&#8217;s
employees are included under Section 14, and are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in
the employee&#8217;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release the Company
from any future severance payments in respect of those employees. The fund is made available to the employee at the time the employer-employee
relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected
in the consolidated balance sheets as the severance pay risks have been irrevocably transferred to the severance funds.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Severance pay expense for the year
ended December 31, 2021, 2020 and 2019 amounted to $53, $46 and $42, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based payment transactions</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">p.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Share-based payment transactions<span style="text-transform: uppercase">:</span></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for share-based
compensation in accordance with ASC 718, &#8220;Compensation - Stock Compensation&#8221; (&#8220;ASC 718&#8221;), which requires companies
to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion
of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#8217;s
consolidated statement of comprehensive loss, based on acceleration method.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company recognizes compensation
expenses for the value of its awards granted based on the vesting attribution approach over the requisite service period of each of the
awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in
subsequent periods if actual forfeitures differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-size: 8pt">&#160;</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company estimates the fair value
of share options granted using the Binomial option pricing model. The option-pricing model requires a number of assumptions, of which
the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated based upon
historical volatility of the Company. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term.
The Company has historically not paid dividends and has no foreseeable plans to pay dividends.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-size: 8pt">&#160;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Taxes on income</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">q.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Taxes on income:</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company accounts for income taxes
in accordance with ASC No. 740, &#8220;Income Taxes&#8221;, (&#8220;ASC 740&#8221;) which prescribes the use of the liability method whereby
deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">The Company provides a valuation allowance,
if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2021, and 2020, a full valuation allowance
was provided by the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; ">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">ASC 740 contains a two-step approach
to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected
to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation
of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes.
The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
As of December 31, 2021, and 2020, no liability for unrecognized tax benefits was recorded.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock', window );">Ordinary share warrants classification and measurement</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ordinary share warrants classification and measurement:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p>&#160;&#160; <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#8217;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and diluted net loss per share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px">&#160;</td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">r.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ordinary share warrants classification and measurement:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#8217;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#8217;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.</p></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">s.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic and diluted net loss per share<span style="text-transform: uppercase">:</span></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">Basic and diluted net loss per share
is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated
based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260,
&#8220;Earnings per Share&#8221;.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">All outstanding share options and warrants
for the years ended December 31, 2021, 2020 and 2019 have been excluded from the calculation of the diluted net loss per share, because
all such securities are anti-dilutive for all periods presented.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">To compute diluted loss per share for the years ended December 31,
2021, December 31, 2020 and December 31, 2019, the total number of 18,422,700, 11,923,400 and 2,673,400 shares, respectively subject to
outstanding unlisted options have not been considered since they have anti-dilutive effect.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently adopted and recently issued accounting pronouncements</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 47px; font-size: 10pt">&#160;</td> <td style="width: 24px; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t.</span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Recently adopted and recently issued accounting pronouncements</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#8211;
Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which replaces the existing incurred loss impairment
model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected
to be collected. The adoption of the standard did not have material effect on Company&#8217;s results.</p></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 47px">&#160;</td> <td style="width: 24px">&#160;</td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic
740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing a variety of exceptions
within the framework of ASC 740. These exceptions include the exception to the incremental approach for intra period tax allocation in
the event of a loss from continuing operations and income or a gain from other items (such as other comprehensive income), and the exception
to using general methodology for the interim period tax accounting for year-to-date losses that exceed anticipated losses. The adoption
of the standard did not have material effect on Company&#8217;s results.</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting pronouncements not yet adopted:</span></td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td style="text-align: justify">&#160;</td></tr> <tr style="vertical-align: top"> <td>&#160;</td> <td>&#160;</td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provides guidance to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. As a result, the Company will not be required to adopt ASU 2021-04 until January 1, 2022. The Company is currently evaluating the impact of the adoption of this principle on the Company&#8217;s unaudited consolidated financial statements.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/></td></tr> </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock', window );">Accounting pronouncements not yet adopted</a></td>
<td class="text"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">u.</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounting pronouncements not yet adopted:</span>&#160;&#160;&#160;&#160;&#160; <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provides guidance to clarify and reduce diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. As a result, the Company will not be required to adopt ASU 2021-04 until January 1, 2022. The Company is currently evaluating the impact of the adoption of this principle on the Company&#8217;s unaudited consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for accounting pronouncements not yet adopted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for ordinary share warrants classification and measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SeverancePayPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for severance pay.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SeverancePayPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI http://asc.fasb.org/extlink&amp;oid=124502072&amp;loc=SL77927221-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for classification and method of accounting for interest-only strips, loans, other receivables, or retained interests in securitizations that can be contractually prepaid or otherwise settled in a way that the holder would not recover substantially all of its recorded investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819061442248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock', window );">Schedule of property, plant and equipment</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Mainly<br/> %</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Laboratory equipment and Leasehold improvements</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: center">&#160;</td><td style="width: 9%; text-align: center">10</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">10</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-left: 49.65pt">&#160;</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td><td style="text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6 - 33</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">33</td><td style="text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock', window );">Schedule of major customer data as a percentage of total revenues</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Cipher Pharmaceuticals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">12</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">20</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Chong Kun Dang Pharmaceuticals Corp.</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">45</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Gebro Holding GmBH</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">23</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Ewopharma AG</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">41</td><td style="padding-bottom: 1.5pt; text-align: left">%</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-51">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 4pt; text-align: left">%</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">100</td><td style="padding-bottom: 4pt; text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of major customer data as a percentage of total revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful lives of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819057980584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Receivable and Prepaid Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_OtherAccountsReceivableAndPrepaidExpensesAbstract', window );"><strong>Other Accounts Receivable And Prepaid Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock', window );">Schedule of other accounts receivable and prepaid expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Government authorities</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">48</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">18</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Prepaid expenses and others</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">881</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">1,039</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">929</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">1,057</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_OtherAccountsReceivableAndPrepaidExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_OtherAccountsReceivableAndPrepaidExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Other Accounts Receivable and Prepaid Expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819057986584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property, plant and equipment, net</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Cost:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Laboratory equipment</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">62</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">57</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">206</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">13</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">281</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">270</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Accumulated depreciation:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Laboratory equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Computers, office furniture and equipment</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">190</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">184</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Leasehold improvements</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">9</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">8</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">234</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">220</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Property and equipment, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">47</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">50</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819058918744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Accounts Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of other accounts payable</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Employees and payroll accruals</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">603</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">96</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Accrued expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">302</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">235</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: right">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">905</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">331</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819057967368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of financial assets and liabilities measured at fair value on a recurring basis</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Fair value measurements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Description</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair value</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; width: 52%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">237</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">237</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-52">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-53">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Fair value measurements</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Description</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Fair value</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 1</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 2</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Level 3</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="width: 52%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="text-align: left; width: 1%">&#160;</td><td style="text-align: right; width: 9%">&#160;</td><td style="text-align: left; width: 1%">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Short-term investment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">75</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">75</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-54">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-55">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819058918744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock', window );">Schedule of information regarding outstanding warrants to purchase shares</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid">Issuance date</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of <br/> outstanding <br/> warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Exercise<br/> price per<br/> warrant</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>($)</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify">January 2017</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">91,667</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">33.75</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">March 2018</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,111</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">30.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">January 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,460</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">19.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">April 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">16,410</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">12.90</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">May 2019</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,575,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">January 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">794,601</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3.45</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">February 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">375,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">June 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,046,342</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">July 2020</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">980,663</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">August 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">350,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">December 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">6,350,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.00</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,598,254</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">&#160;</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819059441640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ScheduleOfExpensesTableTextBlock', window );">Schedule of expenses</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Research and development expenses</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">200</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">159</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">138</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">General and administrative expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">198</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">158</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">132</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">398</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">317</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">270</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock', window );">Schedule of estimated using the binomial option pricing model</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify">Description</td>
    <td>&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td>
    <td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Risk-free interest rate</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.22-1.28</span></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.93-2.40</span></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap; text-align: justify">Expected volatility</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;&#160;82.40-82.43</span></td><td style="white-space: nowrap; text-align: left">%</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#160;65.63-78.77 </span></td><td style="white-space: nowrap; text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%; text-align: justify">Dividend yield</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 8%; text-align: right">0</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Contractual life</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.83 - 10</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Early Exercise Multiple (Suboptimal Factor)</td>
    <td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3</td><td style="text-align: left"/><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.5 - 3</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="white-space: nowrap; text-align: justify">Exercise price (NIS)</td>
    <td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25-0.253</span></td><td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap">&#160;</td>
    <td style="white-space: nowrap; text-align: left">&#160;</td><td style="white-space: nowrap; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.25
- 2.344</span></td><td style="white-space: nowrap; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of weighted average exercise prices and modification in option plans of employees</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td colspan="6">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares subject to options <br/>
outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Number</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Weighted <br/>
average <br/>
exercise <br/>
price</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: justify">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: justify">Outstanding at beginning of year</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">11,923,400</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">0.28</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Grants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">7,100,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.08</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 1.5pt">Forfeited/expired</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(600,700</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1.00</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Outstanding at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">18,422,700</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.18</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify; padding-bottom: 4pt">Exercisable at end of year</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,322,700</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">0.35</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Schedule of options outstanding classified by exercise price</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td colspan="2" style="font-weight: bold; border-bottom: Black 1.5pt solid">Exercise price per share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options <br/>
outstanding</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/>
average <br/>
remaining <br/>
contractual<br/>
life in <br/>
years</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted <br/>
average<br/>
exercise<br/> price per<br/> share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Options <br/>
exercisable</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted<br/>
average <br/>
exercise<br/> price per<br/> share</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: left">0.08 - $0.94</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">17,796,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8.32</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.13</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5,696,500</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 13%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.21</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">$</td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.09 - $1.73</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">555,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.14</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.04</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">555,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">0.11</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.61
- $5.18</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">71,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; text-align: right">0.01</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.01</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">71,200</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.04</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">18,422,700</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">6,322,700</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt; text-align: right">&#160;</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfExpensesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfExpensesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819058904824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of weighted average remaining lease terms and discount rate</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#160;31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">weighted average remaining lease term (years)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">2.42</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">1.71</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td>weighted average discount rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">13</td><td style="text-align: left">%</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/> December&#160;31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Components of lease expense:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt">Operating lease cost</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;55</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">&#160;&#160;&#160;&#160;&#160;43</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  </table><p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/>
December&#160;31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended <br/>
December&#160;31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in">Supplemental cash flow information</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Cash paid for amounts included in the measurement of lease liabilities</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;55</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="width: 1%; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;43</td><td style="width: 1%; padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">120</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">29</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; ">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of maturities of lease liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 88%; text-align: left">2022</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">69</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">2023</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">2024</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">20</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Total operating lease payments</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">148</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Less: imputed interest</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(24</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 4pt">Present value of lease liability</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">124</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819057982248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income (Expense) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BankingAndThriftInterestAbstract', window );"><strong>Banking and Thrift, Interest [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock', window );">Schedule of components of finance (income)</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Year ended December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">USD</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: justify">Finance expenses:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: justify">Bank commissions</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(18</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(23</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(21</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Net loss from exchange rate fluctuations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-56">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-57">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(33</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other loss from short-term investment revaluation</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-58">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-59">-</div></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(209</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 1.5pt">Other financial expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(4</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(363</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(427</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(22</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(386</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#160;</td><td style="border-bottom: Black 4pt double; text-align: right">(690</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Finance income:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify">Interest income on bank deposits</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">24</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">44</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">72</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">Exchange rate fluctuations</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">59</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">27</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-60">-</div></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">Other gain from short-term investment remeasurement</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">162</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">11</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-61">-</div></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">249</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">82</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">72</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: justify">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: justify; padding-bottom: 4pt">Total financial income (expenses), net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">227</td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(304</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(618</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr>
  </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BankingAndThriftInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BankingAndThriftInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819058906696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets and liabilities</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>Deferred tax assets:</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: right">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left">Net operating loss carry forward</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">37,875</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">32,312</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 1.5pt">Temporary differences mainly relating to Research and Development</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,285</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">3,581</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left">Deferred tax asset before valuation allowance</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">41,160</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">35,893</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Valuation allowance</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(41,160</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(35,893</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-bottom: 4pt">Deferred tax asset, net</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-62">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td><td style="padding-bottom: 4pt">&#160;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-63">-</div></td><td style="padding-bottom: 4pt; text-align: left">&#160;</td></tr>
  </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify">&#160;</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819061434200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>General (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Number of ordinary shares represent by each ADS (in Shares)</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net losses</a></td>
<td class="num">$ (12,615)<span></span>
</td>
<td class="num">$ (14,443)<span></span>
</td>
<td class="num">$ (12,625)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_CashFlowsFromOperatingActivities', window );">Cash flows from operating activities</a></td>
<td class="num">$ (9,858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_CashFlowsFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_CashFlowsFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819061498520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rates</a></td>
<td class="nump">0.53%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ContractLiabilities', window );">Contract liabilities under deferred revenues</a></td>
<td class="nump">$ 3,888<span></span>
</td>
<td class="nump">$ 2,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_Revenue', window );">Revenues</a></td>
<td class="nump">853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_RevenuesIncludedInContractLiabilities', window );">Revenues included in contract liabilities</a></td>
<td class="nump">$ 507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_PercentageOfDepositsOnMonthlySalary', window );">Percentage of deposits on monthly salary</a></td>
<td class="nump">8.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance pay expense</a></td>
<td class="nump">$ 53<span></span>
</td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_PercentageOfRealizationOnUltimateSettlement', window );">Maximum percentage of realization on ultimate settlement</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total number of shares subject to outstanding unlisted options (in Shares)</a></td>
<td class="nump">18,422,700<span></span>
</td>
<td class="nump">11,923,400<span></span>
</td>
<td class="nump">2,673,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amouunt of contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_PercentageOfDepositsOnMonthlySalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of deposits on monthly salary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_PercentageOfDepositsOnMonthlySalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_PercentageOfRealizationOnUltimateSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of realization on ultimate settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_PercentageOfRealizationOnUltimateSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_RevenuesIncludedInContractLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenues included in contract liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_RevenuesIncludedInContractLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139818982230056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - Schedule of property, plant and equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=canf_LaboratoryEquipmentAndLeaseholdImprovementsMember', window );">Laboratory equipment and Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments', window );">Depreciation rates property, plant and equipment</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=canf_ComputersOfficeFurnitureAndEquipmentMember', window );">Computers, office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments', window );">Depreciation rates property, plant and equipment</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Computers, office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments', window );">Depreciation rates property, plant and equipment</a></td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Computers, office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments', window );">Depreciation rates property, plant and equipment</a></td>
<td class="nump">33.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Depreciation rates property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=canf_LaboratoryEquipmentAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=canf_LaboratoryEquipmentAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=canf_ComputersOfficeFurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=canf_ComputersOfficeFurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139818982143256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_RevenueContractWithCustomer', window );">Total revenues</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=canf_CipherPharmaceuticalsMember', window );">Cipher Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_RevenueContractWithCustomer', window );">Total revenues</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=canf_ChongKunDangPharmaceuticalsCorpMember', window );">Chong Kun Dang Pharmaceuticals Corp [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_RevenueContractWithCustomer', window );">Total revenues</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=canf_GebroHoldingGmBHMember', window );">Gebro Holding GmBH [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_RevenueContractWithCustomer', window );">Total revenues</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=canf_EwopharmaAGMember', window );">Ewopharma AG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems', window );"><strong>Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_RevenueContractWithCustomer', window );">Total revenues</a></td>
<td class="nump">41.00%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_RevenueContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_RevenueContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_CipherPharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_CipherPharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_ChongKunDangPharmaceuticalsCorpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_ChongKunDangPharmaceuticalsCorpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_GebroHoldingGmBHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_GebroHoldingGmBHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=canf_EwopharmaAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=canf_EwopharmaAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819053669832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accounts Receivable and Prepaid Expenses (Details) - Schedule of other accounts receivable and prepaid expenses - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract', window );"><strong>Schedule of other accounts receivable and prepaid expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_GovernmentAuthorities', window );">Government authorities</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid expenses and others</a></td>
<td class="nump">881<span></span>
</td>
<td class="nump">1,039<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Total</a></td>
<td class="nump">$ 929<span></span>
</td>
<td class="nump">$ 1,057<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_GovernmentAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of government authorities for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_GovernmentAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819062488424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Short-Term Investment (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockSupplementAbstract', window );"><strong>Disclosure Text Block Supplement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares hold by company</a></td>
<td class="nump">356,803<span></span>
</td>
<td class="nump">356,803<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_PercentageOfOutstandingShares', window );">Percentage of outstanding shares</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_PercentageOfOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of outstanding shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_PercentageOfOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockSupplementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockSupplementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819062401640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationExpenseOnReclassifiedAssets', window );">Depreciation expenses</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationExpenseOnReclassifiedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the asset that is reclassified back to held and use from held-for-sale, the depreciation expense recognized when the asset is reclassified. This represents the difference between the carrying value at the time the decision to reclassify is made and the carrying amount that the asset would have had if it had never been classified as held for sale (including consideration of depreciation expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 44<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=29634951&amp;loc=d3e1756-110224<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2459-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationExpenseOnReclassifiedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139818981888296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 281<span></span>
</td>
<td class="nump">$ 270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">234<span></span>
</td>
<td class="nump">220<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_LaboratoryEquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">35<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_ComputersOfficeFurnitureAndEquipmentMember', window );">Computers, office furniture and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_CostAbstract', window );"><strong>Cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_AccumulatedDepreciationAbstract', window );"><strong>Accumulated depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_AccumulatedDepreciationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_AccumulatedDepreciationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_CostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_CostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_ComputersOfficeFurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=canf_ComputersOfficeFurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819061420984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Accounts Payable (Details) - Schedule of other accounts payable - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ScheduleOfOtherAccountsPayableAbstract', window );"><strong>Schedule of other accounts payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_EmployeesAndPayrollAccruals', window );">Employees and payroll accruals</a></td>
<td class="nump">$ 603<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued expenses</a></td>
<td class="nump">302<span></span>
</td>
<td class="nump">235<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Other accounts payable</a></td>
<td class="nump">$ 905<span></span>
</td>
<td class="nump">$ 331<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_EmployeesAndPayrollAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of employees and payroll accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_EmployeesAndPayrollAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfOtherAccountsPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfOtherAccountsPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139818982151256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis - Fair Value, Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investment</a></td>
<td class="nump">$ 237<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 [Member]]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investment</a></td>
<td class="nump">237<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems', window );"><strong>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139818980680648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities and Commitments (Details)<br> &#8364; in Thousands, $ in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="9">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 06, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 28, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 16, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 19, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 25, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoninterestExpenseCommissionExpense', window );">Commission Income Expense (in Euro) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Annual royalties (in Euro) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_PatentAgreementDescription', window );">Patent agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4)Royalties in a total amount of up to &#8364;850 thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) &#8364;50 thousand upon initiation of Phase I studies; (ii) &#8364;100 thousand upon initiation of Phase II studies; (iii) &#8364;200 thousand upon initiation of Phase III studies; and (iv) &#8364;500 thousand upon marketing approval by any regulatory authority.  &#160; 5) If the agreement is sublicensed to another company, the Company will provide Leiden University royalties at a rate of 10%. A merger, consolidation or any other change in ownership will not be viewed as an assignment of the agreement as discussed in this paragraph. &#160;As of December
31 2021, no accrual has been recorded with respect to Leiden University.&#160;

    &#160;
    b.
    Commitments and license agreements:
  &#160;

    &#160;
    1.
    In March 2015, the Company signed a distribution agreement with Cipher Pharmaceuticals (&#8220;Cipher&#8221;). As part of the distribution agreement, Cipher will distribute Can-Fite&#8217;s lead drug candidate, Piclidenoson for the treatment of psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.
  &#160;Under the terms of the agreement, Cipher
made an upfront payment of USD 1,292 (CAD 1,650 thousand) to the Company in March 2015. In addition, the agreement provides that additional
payments of up to CAD 2,000 thousand will be received by the Company upon the achievement of certain milestones plus royalty payments
of 16.5% of net sales of Piclidenoson in Canada.&#160;Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities. In addition, the Company agreed to form
a joint steering committee with Cipher which will oversee the progress of the clinical studies.&#160;

    &#160;
    2.
    In October 2016, the Company signed a distribution agreement with Chong Kun Dang Pharmaceuticals Corp. (&#8220;CKD&#8221;) for future sales in South Korea. As part of the distribution agreement, CKD will distribute Namodenoson for the treatment of liver cancer in the South Korean market upon receipt of regulatory approvals.
  &#160;Under the terms of the agreement, CKD
made an upfront payment of USD 500 to the Company in December 2016 and in August 2017, the Company received a second milestone payment
in the amount of USD 500 from CKD, which has licensed the exclusive right to distribute Namodenoson for the treatment of liver cancer
in Korea upon receipt of regulatory approvals.&#160;In addition, the agreement provides that
additional payments of up to USD 2,500 will be received by the Company upon the achievement of certain milestones.&#160;Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities.&#160;On February 25, 2019, the Company&#8217;s
Distribution Agreement with CKD was amended to expand the exclusive right to distribute Namodenoson for the treatment of NASH in addition
to liver cancer in South Korea. CKD has agreed to pay the Company up to an additional USD 6,000 in upfront and milestone payments payable
with respect to the NASH indication. The Company will also be entitled to a transfer price for delivering finished product to CKD following
commercial launch. In April 2019, the Company received an upfront payment of USD 1,000.&#160;

    &#160;
    3.

    On December 22, 2008, the Company signed an agreement
    regarding the provision of a license for Piclodenoson with a South Korean pharmaceutical company, Kwang Dong Pharmaceutical Co. Ltd. (&#8220;KD&#8221;).
    According to the license agreement, the Company granted the KD a license to use, develop and market its Piclodenoson for treating only
    rheumatoid arthritis only in the Republic of Korea.
    &#160;
  &#160;As of December 31, 2021, the Company estimates
that such contingent payments are remote.&#160;&#160;4.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvanceRoyalties', window );">Royalties in a total amount (in Euro) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_RoyaltyPaymentsPercentage', window );">Royalty payments, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_UnfrontPaymentAmount', window );">Upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_AdditionalPayments', window );">Additional payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember', window );">Business Combination [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription', window );">Distribution and supply agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company is entitled to &#8364;1,500 thousand upon execution of the agreement plus milestone payments upon achieving certain clinical,
launch and sales milestones, as follows: (i) &#8364;300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment
of rheumatoid arthritis and &#8364;300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis,
(ii) between &#8364;750 thousand and &#8364;1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either
the treatment of rheumatoid arthritis or psoriasis, and (iii) between &#8364;300 thousand and up to &#8364;4,025 thousand upon meeting certain
net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson
in the territories and payment for the manufacturing Piclidenoson.&#160;On January 25, 2018 the Company received a first payment of approximately
USD 2,200 from Gebro and in August 2018 received approximately USD 350 upon reaching the first milestone.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=canf_CipherMember', window );">Cipher [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_RoyaltyPaymentsPercentage', window );">Royalty payments, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
<td class="nump">16.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_UnfrontPaymentAmount', window );">Upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,292<span></span>
</td>
<td class="nump">$ 1,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_AdditionalPayments', window );">Additional payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=canf_ChongKunDangMember', window );">Chong kun dang [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_UnfrontPaymentAmount', window );">Upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=canf_CMSMedicalMember', window );">CMS Medical [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_UnfrontPaymentAmount', window );">Upfront payment amount</a></td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=canf_KyongboPharmMember', window );">Kyongbo Pharm [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_UnfrontPaymentAmount', window );">Upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_AdditionalPayments', window );">Additional payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=canf_SwitzerlandBasedEwopharmaMember', window );">Switzerland Based Ewopharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_UnfrontPaymentAmount', window );">Upfront payment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetentionPayable', window );">Additional payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_RoyaltyOnNetSales', window );">Percentage of royalties on net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionAxis=canf_VetbiolixMember', window );">Vetbiolix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_RoyaltyPaymentsPercentage', window );">Royalty payments, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_NonRefundableUpfrontPayment', window );">Non-refundable upfront payment (in Euro) | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_PercentageOfNetSales', window );">Percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Vetbiolix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_RoyaltyPaymentsPercentage', window );">Royalty payments, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_PercentageOfNetSales', window );">Percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Vetbiolix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems', window );"><strong>Contingent Liabilities and Commitments (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_RoyaltyPaymentsPercentage', window );">Royalty payments, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_AdditionalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional payments maximum charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_AdditionalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ContingentLiabilitiesandCommitmentsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ContingentLiabilitiesandCommitmentsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_NonRefundableUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non refundable upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_NonRefundableUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_PatentAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The description of patent agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_PatentAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_PercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_PercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_RoyaltyOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_RoyaltyOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_RoyaltyPaymentsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The royalty payment in percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_RoyaltyPaymentsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_UnfrontPaymentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unfront payment amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_UnfrontPaymentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvanceRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount paid to music publishers, record producers, songwriters, or other artists in advance of their earning royalties from record or music sales. Such an amount is based on contractual terms and is generally nonrefundable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473541&amp;loc=d3e61799-108003<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvanceRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents a description of such arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoninterestExpenseCommissionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of fees incurred for commissions on mutual funds and insurance products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoninterestExpenseCommissionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetentionPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts owed to vendors and subcontractors that have been withheld because of retainage provisions in a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetentionPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=canf_CipherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=canf_CipherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=canf_ChongKunDangMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=canf_ChongKunDangMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=canf_CMSMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=canf_CMSMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=canf_KyongboPharmMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=canf_KyongboPharmMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=canf_SwitzerlandBasedEwopharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=canf_SwitzerlandBasedEwopharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=canf_VetbiolixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=canf_VetbiolixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139818976506040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="7">1 Months Ended</th>
<th class="th" colspan="2">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 20, 2021</div></th>
<th class="th">
<div>Jul. 08, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 12, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 09, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Feb. 12, 2020</div></th>
<th class="th">
<div>Feb. 10, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 09, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>May 10, 2019</div></th>
<th class="th">
<div>Apr. 04, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 16, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 28, 2020 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 22, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 18, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>Nov. 28, 2013 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_StockholdersEquityChangeInRatioDescription', window );">Stockholders equity change In ratio description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(1) ADS representing two (2) ordinary shares to a new ratio of one (1) ADS representing thirty (30) ordinary shares. For ADS holders, the ratio change had the same effect as a one-for-fifteen reverse ADS split. All ADS and per ADS data in the financial statements and their related notes have been retroactively adjusted for all periods presented to reflect the ratio change.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sold an aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">356,803<span></span>
</td>
<td class="nump">356,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">996,690<span></span>
</td>
<td class="nump">19,934,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,000,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_AggregatePurchasePrice', window );">Aggregate purchase price (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="nump">$ 2,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Issuance cost (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
<td class="nump">$ 428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,278,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantExercisePriceDecrease', window );">Reduced exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_IssueOfNewUnregisteredWarrants', window );">Issue of new unregistered warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,278,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_DeemedDividend', window );">Deemed dividend (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_SecuritiesPurchaseAgreementDescription', window );">Securities purchase agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company completed a public offering with certain institutional investors pursuant to which the Company issued and sold (i) 1,825,000 units, each unit consisting of one ADS, and one warrant to purchase one ADS, at a price of USD 1.50 per unit, and (ii) 1,508,334 pre-funded units each pre-funded unit consisting of one pre-funded warrant to purchase one ADS and one warrant, at a price of USD 1.49 per pre-funded unit.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromOtherEquity', window );">Gross proceeds from offering (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Expiring date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Feb. 10,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_IncreaseAuthorizedShareCapital', window );">Increase authorized capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in New Shekels per share) | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.25<span></span>
</td>
<td class="nump">&#8362; 0.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_StockIssuanceAgreementDescription', window );">Stock issuance agreement, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On June 12, 2020, the Company completed a registered direct offering with certain institutional and accredited investors pursuant to which it sold an aggregate of 3,902,440 ADSs at a purchase price of $2.05 per ADS for aggregate gross proceeds of approximately $8,000 prior to deducting the placement agent&#8217;s fees and estimated offering expenses payable by the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_AggregateNumberOfADS', window );">Aggregate number of ADS percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price per ADS (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_WarrantsToPurchaseAggregateShares', window );">Warrants to purchase aggregate ADS shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ExercisePrice', window );">Exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_TotalConsiderationAmount', window );">Total consideration amount (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_FairValueAmount', window );">Fair value amount (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_PurchaseAgreementDescription', window );">Purchase agreement description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On August 16, 2021, the Company completed a registered direct offering with an institutional investor pursuant to which it sold (i) 57,000,000 ordinary shares represented by 1,900,000 ADSs, and (ii) a pre-funded warrant to purchase 93,000,000 ordinary shares represented by 3,100,000 ADSs at an offering price of $2.00 per ADS and $1.999 per pre-funded warrant, for aggregate gross proceeds of approximately $10,000 (without taking into account any proceeds from any future exercises of warrants issued in the concurrent private placement), before deducting the placement agent&#8217;s fees and other estimated offering expenses payable by the Company. &#160; The Company has also sold to the investor, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 5,000,000 ADSs. The warrants have an exercise price of $ 2.00 per ADS and are exercisable at any time upon issuance and will expire three years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants. &#160; As of the financial statements date, the Company received a total of $ 9,997 and issued 57,000,000 ordinary shares represented by 1,900,000 ADSs and 93,000,000 ordinary shares represented by 3,100,000 ADSs following the exercise of the pre-funded warrants (issuance expenses were $1,307).&#160;&#160;&#160;&#160;17. On December 20, 2021, the Company entered into a warrant exercise agreement (the &#8220;Exercise Agreement&#8221;) with an institutional investor who is the holder of certain existing warrants to purchase Company&#8217;s ordinary shares, par value NIS 0.25 per share, represented by ADSs issued by the Company in a registered direct offering consummated in August 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_TotalReceivedAmount', window );">Total received amount (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_OrdinaryShares', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_IssuanceExpensesAmount', window );">Issuance expenses amount (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ExerciseAgreementDescription', window );">Exercise agreement description</a></td>
<td class="text">Pursuant to the Exercise Agreement, the holder agreed to exercise in cash its warrants to purchase up to an aggregate of 150,000,000 Ordinary Shares represented by 5,000,000 ADSs having an exercise price of $2.00 per ADS, at an exercise price of $2.00 per ADS, for gross proceeds to the Company of $10 million, prior to deducting placement agent fees and offering expenses (which amounted to $0.98 million). &#160; Under the Exercise Agreement, the Company also agreed to issue to the holder new unregistered warrants to purchase up to 180,000,000 Ordinary Shares represented by 6,000,000 ADSs (the &#8220;Private Placement Warrants&#8221;). The Private Placement Warrants will be immediately exercisable, will expire five years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants, and have an exercise price of $2.00 per ADS. &#160; Pursuant to the terms of the Exercise Agreements, the holder agreed to exercise the warrants while receiving a-120% warrants coverage, thereby creating a benefit to this warrant holder. As such, the Company recorded a deemed dividend in the amount of $ 2,590.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=canf_ADSMember', window );">ADS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sold an aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">149,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,033,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_WarrantsToPurchaseAdditionalSharesIssued', window );">Warrants to purchase additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Purchase aggregate warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">7,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ExercisePrices', window );">Exercise prices (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_AggregateWarrantPurchased', window );">Aggregate warrant purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,410<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">742,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_IssueOfNewUnregisteredWarrants', window );">Issue of new unregistered warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,705,000<span></span>
</td>
<td class="nump">1,951,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ExercisePriceSubjectToAdjusment', window );">Exercise price subject to adjustment (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_CompensationWarrantsExercisable', window );">Compensation warrant exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockOptionExercisePriceIncrease', window );">Exercise price per ADS (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,697,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_OrdinaryShares', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=canf_ADSMember', window );">ADS [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ExercisePrices', window );">Exercise prices (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=canf_ADSMember', window );">ADS [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ExercisePrices', window );">Exercise prices (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sold an aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,846,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,846,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="nump">4,476,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,350,000<span></span>
</td>
<td class="nump">996,690<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_WarrantsToPurchaseAdditionalSharesIssued', window );">Warrants to purchase additional shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,476,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">492,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="nump">223,810<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareIssued', window );">Ordinary shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Aggregate shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds (in Dollars) | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,000,000<span></span>
</td>
<td class="nump">1,050,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,926,830<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement Warrants [Member] | ADS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsLineItems', window );"><strong>Shareholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_IssueOfNewUnregisteredWarrants', window );">Issue of new unregistered warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">742,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_AggregateNumberOfADS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>aggregate number of ADS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_AggregateNumberOfADS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_AggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate purchase price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_AggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_AggregateWarrantPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate warrant purchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_AggregateWarrantPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_CompensationWarrantsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>compensation warrants exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_CompensationWarrantsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_DeemedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deemed dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_DeemedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ExerciseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ExerciseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ExercisePriceSubjectToAdjusment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price Subject to adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ExercisePriceSubjectToAdjusment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ExercisePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrant, Exercise Price, Decrease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ExercisePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_FairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_FairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IncreaseAuthorizedShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase authorized Share Capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IncreaseAuthorizedShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IssuanceExpensesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance expenses amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IssuanceExpensesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IssueOfNewUnregisteredWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issue of New Unregistered Warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IssueOfNewUnregisteredWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_OrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ordinary shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_OrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_PurchaseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_PurchaseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SecuritiesPurchaseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities Purchase Agreement, Description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SecuritiesPurchaseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ShareIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ShareIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ShareholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ShareholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_StockIssuanceAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issuance agreement description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_StockIssuanceAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_StockholdersEquityChangeInRatioDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stockholders Equity Change In Ratio Description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_StockholdersEquityChangeInRatioDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_TotalConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total consideration amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_TotalConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_TotalReceivedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total received amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_TotalReceivedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_WarrantsToPurchaseAdditionalSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants to purchase additional shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_WarrantsToPurchaseAdditionalSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_WarrantsToPurchaseAggregateShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants to purchase aggregate shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_WarrantsToPurchaseAggregateShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromOtherEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the issuance of equity classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromOtherEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockOptionExercisePriceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockOptionExercisePriceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantExercisePriceDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantExercisePriceDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=canf_ADSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=canf_ADSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819056880184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="nump">12,598,254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_January2017Member', window );">January 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">January 2017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="nump">91,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 33.75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_March2018Member', window );">March 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">March 2018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="nump">11,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_January2019Member', window );">January 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">January 2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="nump">7,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 19.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_April2019Member', window );">April 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">April 2019<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="nump">16,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 12.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_May2019Member', window );">May 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">May 2019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="nump">1,575,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_January2020Member', window );">January 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">January 2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="nump">794,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_February2020Member', window );">February 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">February 2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="nump">375,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_June2020Member', window );">June 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">June 2020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="nump">2,046,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_July2020Member', window );">July 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">July 2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="nump">980,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_August2021Member', window );">August 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">August 2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="nump">350,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardDateAxis=canf_December2021Member', window );">December 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems', window );"><strong>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_IssuanceDate', window );">Issuance date</a></td>
<td class="text">December 2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of outstanding warrants</a></td>
<td class="nump">6,350,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_IssuanceDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_IssuanceDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_January2017Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_January2017Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_March2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_March2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_January2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_January2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_April2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_April2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_May2019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_May2019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_January2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_January2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_February2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_February2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_June2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_June2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_July2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_July2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_August2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_August2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=canf_December2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=canf_December2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819058869400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#8362; / shares </div>
<div>$ / shares</div>
</th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 28, 2020 </div>
<div>&#8362; / shares</div>
</th>
<th class="th">
<div>May 22, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Apr. 04, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 18, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 28, 2013 </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareBasedPaymentTransactionsDetailsLineItems', window );"><strong>Share-Based Payment Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_GrantedExcessYears', window );">Granted excess years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in Shares)</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in New Shekels per share) | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_NumberOfOrdinaryShares', window );">Number of ordinary shares (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_FutureShares', window );">Future shares (in Shares)</a></td>
<td class="nump">6,618,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life</a></td>
<td class="text">8 years 5 months 12 days<span></span>
</td>
<td class="text">6 years 11 months 23 days<span></span>
</td>
<td class="text">7 years 11 months 4 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in Dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.18<span></span>
</td>
<td class="nump">&#8362; 0.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation costs not yet recognized (in Dollars) | $</a></td>
<td class="nump">$ 1,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average period</a></td>
<td class="text">2 years 9 months 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareBasedPaymentTransactionsDetailsLineItems', window );"><strong>Share-Based Payment Transactions (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="nump">492,308<span></span>
</td>
<td class="nump">223,810<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_FutureShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_FutureShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_GrantedExcessYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_GrantedExcessYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_NumberOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_NumberOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ShareBasedPaymentTransactionsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ShareBasedPaymentTransactionsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819059484072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details) - Schedule of expenses - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ScheduleOfExpensesAbstract', window );"><strong>Schedule of expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 159<span></span>
</td>
<td class="nump">$ 138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherGeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_SharebasedPayments', window );">Share-based payments</a></td>
<td class="nump">$ 398<span></span>
</td>
<td class="nump">$ 317<span></span>
</td>
<td class="nump">$ 270<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of general and administrative expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819061359496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>&#8362; / shares </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>&#8362; / shares </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems', window );"><strong>Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Early Exercise Multiple (Suboptimal Factor) (in Dollars per share)</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems', window );"><strong>Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.22%<span></span>
</td>
<td class="nump">0.93%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">82.40%<span></span>
</td>
<td class="nump">65.63%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 9 months 29 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Early Exercise Multiple (Suboptimal Factor) (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (NIS) (in New Shekels per share) | &#8362; / shares</a></td>
<td class="nump">$ 0.25<span></span>
</td>
<td class="nump">$ 0.25<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems', window );"><strong>Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.28%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">82.43%<span></span>
</td>
<td class="nump">78.77%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Early Exercise Multiple (Suboptimal Factor) (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (NIS) (in New Shekels per share) | &#8362; / shares</a></td>
<td class="nump">$ 0.253<span></span>
</td>
<td class="nump">$ 2.344<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819059085992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details) - Schedule of weighted average exercise prices and modification in option plans of employees<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract', window );"><strong>Schedule of weighted average exercise prices and modification in option plans of employees [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding at beginning of year | shares</a></td>
<td class="nump">11,923,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at beginning of year | $ / shares</a></td>
<td class="nump">$ 0.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Grants | shares</a></td>
<td class="nump">7,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Grants | $ / shares</a></td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations', window );">Number of Forfeited/expired | shares</a></td>
<td class="num">(600,700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Forfeited/expired | $ / shares</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Outstanding at end of year | shares</a></td>
<td class="nump">18,422,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Outstanding at end of year | $ / shares</a></td>
<td class="nump">$ 0.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_NumberOfExercisableAtEndOfShares', window );">Number of Exercisable at end of year | shares</a></td>
<td class="nump">6,322,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares', window );">Weighted average exercise price, Exercisable at end of year | $ / shares</a></td>
<td class="nump">$ 0.35<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_NumberOfExercisableAtEndOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_NumberOfExercisableAtEndOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price, Exercisable at end of per shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were either cancelled or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139818980568632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payment Transactions (Details) - Schedule of options outstanding classified by exercise price<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in Shares) | shares</a></td>
<td class="nump">18,422,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price per share</a></td>
<td class="nump">$ 6,322,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeOneMember', window );">Exercise price $0.08 - $0.94 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in Shares) | shares</a></td>
<td class="nump">17,796,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life in years</a></td>
<td class="text">8 years 3 months 25 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price per share</a></td>
<td class="nump">$ 5,696,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Options exercisable</a></td>
<td class="nump">$ 0.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, Weighted average exercise price per share (in Shares) | shares</a></td>
<td class="nump">0.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeOneMember', window );">Exercise price $0.08 - $0.94 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_SharebasedPaymentArrangementOptionExercisePriceRange', window );">Exercise price</a></td>
<td class="nump">$ 0.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeOneMember', window );">Exercise price $0.08 - $0.94 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_SharebasedPaymentArrangementOptionExercisePriceRange', window );">Exercise price</a></td>
<td class="nump">$ 0.94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeTwoMember', window );">Exercise price $1.09 - $1.73 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in Shares) | shares</a></td>
<td class="nump">555,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life in years</a></td>
<td class="text">1 month 20 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price per share</a></td>
<td class="nump">$ 555,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Options exercisable</a></td>
<td class="nump">$ 0.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, Weighted average exercise price per share (in Shares) | shares</a></td>
<td class="nump">0.04<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeTwoMember', window );">Exercise price $1.09 - $1.73 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_SharebasedPaymentArrangementOptionExercisePriceRange', window );">Exercise price</a></td>
<td class="nump">$ 1.09<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeTwoMember', window );">Exercise price $1.09 - $1.73 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_SharebasedPaymentArrangementOptionExercisePriceRange', window );">Exercise price</a></td>
<td class="nump">$ 1.73<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeThreeMember', window );">Exercise price $2.61 - $5.18 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options outstanding (in Shares) | shares</a></td>
<td class="nump">71,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life in years</a></td>
<td class="text">3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Weighted average exercise price per share</a></td>
<td class="nump">$ 71,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Options exercisable</a></td>
<td class="nump">$ 0.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable, Weighted average exercise price per share (in Shares) | shares</a></td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeThreeMember', window );">Exercise price $2.61 - $5.18 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_SharebasedPaymentArrangementOptionExercisePriceRange', window );">Exercise price</a></td>
<td class="nump">$ 2.61<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeThreeMember', window );">Exercise price $2.61 - $5.18 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_SharebasedPaymentArrangementOptionExercisePriceRange', window );">Exercise price</a></td>
<td class="nump">$ 5.18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SharebasedPaymentArrangementOptionExercisePriceRange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SharebasedPaymentArrangementOptionExercisePriceRange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=canf_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819057930664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lease term</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819059081448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details) - Schedule of lease expense and supplemental cash flow information related to leases and weighted average remaining lease terms and discount rate - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract', window );"><strong>Schedule of lease expense and supplemental cash flow information related to leases and weighted average remaining lease terms and discount rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">weighted average remaining lease term (years)</a></td>
<td class="text">2 years 5 months 1 day<span></span>
</td>
<td class="text">1 year 8 months 15 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">weighted average discount rate</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ComponentsOfLeaseExpenseAbstract', window );"><strong>Components of lease expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 55<span></span>
</td>
<td class="nump">$ 43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets', window );">Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ComponentsOfLeaseExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ComponentsOfLeaseExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819053724680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases (Details) - Schedule of maturities of lease liabilities<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract', window );"><strong>Schedule of maturities of lease liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2022</a></td>
<td class="nump">$ 69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2023</a></td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2024</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_LesseeOperatingLeaseLiabilityPaymentDue', window );">Total operating lease payments</a></td>
<td class="nump">148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ImputedInterestLessImputedInterest', window );">Less: imputed interest</a></td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liability</a></td>
<td class="nump">$ 124<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ImputedInterestLessImputedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>imputed interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ImputedInterestLessImputedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_LesseeOperatingLeaseLiabilityPaymentDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_LesseeOperatingLeaseLiabilityPaymentDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139818982669960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Finance Income (Expense) (Details) - Schedule of components of finance (income) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_FinanceExpensesAbstract', window );"><strong>Finance expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_BanksCommissions', window );">Bank commissions</a></td>
<td class="num">$ (18)<span></span>
</td>
<td class="num">$ (23)<span></span>
</td>
<td class="num">$ (21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_NetLossFromExchangeRateFluctuations', window );">Net loss from exchange rate fluctuations</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_OtherLossFromShorttermInvestmentRevaluation', window );">Other loss from short-term investment revaluation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(209)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Other financial expense</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(363)<span></span>
</td>
<td class="num">(427)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_FinanceExpenses', window );">Finance expenses</a></td>
<td class="num">(22)<span></span>
</td>
<td class="num">(386)<span></span>
</td>
<td class="num">(690)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_FinanceIncomeAbstract', window );"><strong>Finance income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeDepositsWithFinancialInstitutions', window );">Interest income on bank deposits</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_ExchangeRateFluctuations', window );">Exchange rate fluctuations</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Other gain from short-term investment remeasurement</a></td>
<td class="nump">162<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_FinanceIncome', window );">Finance income</a></td>
<td class="nump">249<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Total financial income (expenses), net</a></td>
<td class="nump">$ 227<span></span>
</td>
<td class="num">$ (304)<span></span>
</td>
<td class="num">$ (618)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_BanksCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Bank commissions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_BanksCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_ExchangeRateFluctuations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exchange rate fluctuations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_ExchangeRateFluctuations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_FinanceExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_FinanceExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_FinanceExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_FinanceExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income from finance income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_FinanceIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_FinanceIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_NetLossFromExchangeRateFluctuations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net loss from exchange rate fluctuations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_NetLossFromExchangeRateFluctuations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_OtherLossFromShorttermInvestmentRevaluation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other loss from short-term investment revaluation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_OtherLossFromShorttermInvestmentRevaluation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27405-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeDepositsWithFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (a)<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1402<br> -Paragraph (b)<br> -Subparagraph (1)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeDepositsWithFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139818976393048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes on Income (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_TaxesonIncomeDetailsLineItems', window );"><strong>Taxes on Income (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards', window );">Carryforward losses amount (in Dollars)</a></td>
<td class="nump">$ 164,680<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember', window );">Israel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_TaxesonIncomeDetailsLineItems', window );"><strong>Taxes on Income (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Corporate tax rate</a></td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_TaxesonIncomeDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_TaxesonIncomeDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsCapitalLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsCapitalLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_IsraelTaxAuthorityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819061529448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Taxes on Income (Details) - Schedule of deferred tax assets and liabilities - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_canf_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carry forward</a></td>
<td class="nump">$ 37,875<span></span>
</td>
<td class="nump">$ 32,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Temporary differences mainly relating to Research and Development</a></td>
<td class="nump">3,285<span></span>
</td>
<td class="nump">3,581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax asset before valuation allowance</a></td>
<td class="nump">41,160<span></span>
</td>
<td class="nump">35,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(41,160)<span></span>
</td>
<td class="num">(35,893)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax asset, net</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_canf_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">canf_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>canf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139819058006648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Transactions with Related Parties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Aggregate amount of research and development expenses</a></td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 252<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>f20f2021_canfitebio_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:canf="http://www.confite.com/20211231"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="canf-20211231.xsd" xlink:type="simple"/>
    <context id="c0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="c11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="c20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:LaboratoryEquipmentAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CipherPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:CipherPharmaceuticalsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:ChongKunDangPharmaceuticalsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:ChongKunDangPharmaceuticalsCorpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:GebroHoldingGmBHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:GebroHoldingGmBHMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">canf:EwopharmaAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">canf:ComputersOfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:CipherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="c65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:ChongKunDangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="c66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:ChongKunDangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="c67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2016-10-01</startDate>
            <endDate>2016-10-31</endDate>
        </period>
    </context>
    <context id="c68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:ChongKunDangMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-25</endDate>
        </period>
    </context>
    <context id="c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2019-02-01</startDate>
            <endDate>2019-02-25</endDate>
        </period>
    </context>
    <context id="c70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:CMSMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-08-01</startDate>
            <endDate>2018-08-06</endDate>
        </period>
    </context>
    <context id="c72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:KyongboPharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="c73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:KyongboPharmMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-19</endDate>
        </period>
    </context>
    <context id="c74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:SwitzerlandBasedEwopharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-16</endDate>
        </period>
    </context>
    <context id="c75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:SwitzerlandBasedEwopharmaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-16</instant>
        </period>
    </context>
    <context id="c76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:VetbiolixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-28</endDate>
        </period>
    </context>
    <context id="c77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:VetbiolixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-28</endDate>
        </period>
    </context>
    <context id="c78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">canf:VetbiolixMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-28</endDate>
        </period>
    </context>
    <context id="c79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-10</endDate>
        </period>
    </context>
    <context id="c80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-18</endDate>
        </period>
    </context>
    <context id="c81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-18</endDate>
        </period>
    </context>
    <context id="c82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-18</endDate>
        </period>
    </context>
    <context id="c83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-18</instant>
        </period>
    </context>
    <context id="c84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-18</instant>
        </period>
    </context>
    <context id="c85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-04</endDate>
        </period>
    </context>
    <context id="c86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-04</endDate>
        </period>
    </context>
    <context id="c87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-04</instant>
        </period>
    </context>
    <context id="c88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-04</endDate>
        </period>
    </context>
    <context id="c89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-04</instant>
        </period>
    </context>
    <context id="c90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-22</endDate>
        </period>
    </context>
    <context id="c91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-22</endDate>
        </period>
    </context>
    <context id="c92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-22</instant>
        </period>
    </context>
    <context id="c93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-22</instant>
        </period>
    </context>
    <context id="c94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-22</endDate>
        </period>
    </context>
    <context id="c95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="c96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-09</endDate>
        </period>
    </context>
    <context id="c98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-09</endDate>
        </period>
    </context>
    <context id="c99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-09</endDate>
        </period>
    </context>
    <context id="c100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-09</endDate>
        </period>
    </context>
    <context id="c101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-09</endDate>
        </period>
    </context>
    <context id="c102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-12</endDate>
        </period>
    </context>
    <context id="c103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-10</endDate>
        </period>
    </context>
    <context id="c104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-01</startDate>
            <endDate>2020-02-10</endDate>
        </period>
    </context>
    <context id="c105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-09</endDate>
        </period>
    </context>
    <context id="c106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-09</endDate>
        </period>
    </context>
    <context id="c107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-09</instant>
        </period>
    </context>
    <context id="c108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-04-28</endDate>
        </period>
    </context>
    <context id="c109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2020-04-28</instant>
        </period>
    </context>
    <context id="c110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="c111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="c112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="c113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-12</endDate>
        </period>
    </context>
    <context id="c114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-12</endDate>
        </period>
    </context>
    <context id="c115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-08</endDate>
        </period>
    </context>
    <context id="c116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-08</endDate>
        </period>
    </context>
    <context id="c117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2020-07-08</instant>
        </period>
    </context>
    <context id="c118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="c121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="c123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-16</endDate>
        </period>
    </context>
    <context id="c124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-16</endDate>
        </period>
    </context>
    <context id="c125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2021-08-16</instant>
        </period>
    </context>
    <context id="c126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-16</endDate>
        </period>
    </context>
    <context id="c127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">canf:ADSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-16</instant>
        </period>
    </context>
    <context id="c128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <startDate>2021-12-17</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="c129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2017Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:March2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:March2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:April2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:April2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:May2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:May2019Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:January2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:February2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:February2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:June2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:June2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:July2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:July2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:August2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:August2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:December2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">canf:December2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2013-11-28</instant>
        </period>
    </context>
    <context id="c152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-11-28</instant>
        </period>
    </context>
    <context id="c153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="c154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">canf:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="c172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001536196</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:IsraelTaxAuthorityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="ilsPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="usdPershares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="pure">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <dei:DocumentType contextRef="c0">20-F</dei:DocumentType>
    <dei:DocumentRegistrationStatement contextRef="c0">false</dei:DocumentRegistrationStatement>
    <dei:DocumentAnnualReport contextRef="c0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c0">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c0">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c0">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="c0">false</dei:DocumentTransitionReport>
    <dei:DocumentShellCompanyReport contextRef="c0">false</dei:DocumentShellCompanyReport>
    <dei:EntityFileNumber contextRef="c0">001-36203</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c0">Can-Fite BioPharma Ltd.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c0">L3</dei:EntityIncorporationStateCountryCode>
    <dei:EntityAddressAddressLine1 contextRef="c0">10 Bareket Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c0">Kiryat Matalon</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="c0">P.O. Box 7537</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="c0">Petah-Tikva</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c0">4951778</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c0">IL</dei:EntityAddressCountry>
    <dei:ContactPersonnelName contextRef="c1">Motti Farbstein</dei:ContactPersonnelName>
    <dei:CityAreaCode contextRef="c1">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c1">(3) 924-1114</dei:LocalPhoneNumber>
    <dei:ContactPersonnelFaxNumber contextRef="c1">972 (3) 924-9378</dei:ContactPersonnelFaxNumber>
    <dei:ContactPersonnelEmailAddress contextRef="c1">motti@canfite.co.il</dei:ContactPersonnelEmailAddress>
    <dei:EntityAddressAddressLine1 contextRef="c1">10 Bareket Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c1">Kiryat Matalon</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="c1">P.O. Box 7537</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="c1">Petah-Tikva</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="c1">4951778</dei:EntityAddressPostalZipCode>
    <dei:EntityAddressCountry contextRef="c1">IL</dei:EntityAddressCountry>
    <dei:Security12bTitle contextRef="c0">American Depositary Shares, each representing 30 Ordinary Shares, par value NIS 0.25 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c0">CANF</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c0">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityCommonStockSharesOutstanding contextRef="c2" decimals="INF" unitRef="shares">815746293</dei:EntityCommonStockSharesOutstanding>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c0">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c0">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c0">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c0">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c0">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntityEmergingGrowthCompany contextRef="c0">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c0">false</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentAccountingStandard contextRef="c0">U.S. GAAP</dei:DocumentAccountingStandard>
    <dei:EntityShellCompany contextRef="c0">false</dei:EntityShellCompany>
    <dei:AuditorFirmId contextRef="c0">1281</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c0">Kost Forer Gabbay &amp; Kasierer</dei:AuditorName>
    <dei:AuditorLocation contextRef="c0">Tel-Aviv, Israel</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c2" decimals="-3" unitRef="usd">4390000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c3" decimals="-3" unitRef="usd">8268000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DepositsAssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">14512000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">929000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">1057000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ShortTermInvestments contextRef="c2" decimals="-3" unitRef="usd">237000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c3" decimals="-3" unitRef="usd">75000</us-gaap:ShortTermInvestments>
    <us-gaap:AssetsCurrent contextRef="c2" decimals="-3" unitRef="usd">20068000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c3" decimals="-3" unitRef="usd">9400000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c2" decimals="-3" unitRef="usd">138000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c3" decimals="-3" unitRef="usd">73000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" unitRef="usd">47000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">50000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsNoncurrent contextRef="c2" decimals="-3" unitRef="usd">185000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent contextRef="c3" decimals="-3" unitRef="usd">123000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets contextRef="c2" decimals="-3" unitRef="usd">20253000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c3" decimals="-3" unitRef="usd">9523000</us-gaap:Assets>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c2" decimals="-3" unitRef="usd">954000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:AccountsPayableTradeCurrent contextRef="c3" decimals="-3" unitRef="usd">561000</us-gaap:AccountsPayableTradeCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c2" decimals="-3" unitRef="usd">53000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c3" decimals="-3" unitRef="usd">43000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c2" decimals="-3" unitRef="usd">818000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent contextRef="c3" decimals="-3" unitRef="usd">334000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">905000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">331000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c2" decimals="-3" unitRef="usd">2730000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c3" decimals="-3" unitRef="usd">1269000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c2" decimals="-3" unitRef="usd">71000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c3" decimals="-3" unitRef="usd">24000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c2" decimals="-3" unitRef="usd">3070000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent contextRef="c3" decimals="-3" unitRef="usd">2156000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c2" decimals="-3" unitRef="usd">3141000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c3" decimals="-3" unitRef="usd">2180000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c2" decimals="2" unitRef="ilsPershares">0.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c3" decimals="2" unitRef="ilsPershares">0.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c2" decimals="0" unitRef="shares">5000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c3" decimals="0" unitRef="shares">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c2" decimals="0" unitRef="shares">815746293</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c2" decimals="0" unitRef="shares">815746293</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c3" decimals="0" unitRef="shares">463769463</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c3" decimals="0" unitRef="shares">463769463</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c2" decimals="-3" unitRef="usd">60654000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c3" decimals="-3" unitRef="usd">33036000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c2" decimals="-3" unitRef="usd">93275000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c3" decimals="-3" unitRef="usd">97380000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c2" decimals="-3" unitRef="usd">1127000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c3" decimals="-3" unitRef="usd">1127000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c2" decimals="-3" unitRef="usd">-140674000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c3" decimals="-3" unitRef="usd">-125469000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">14382000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">6074000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">20253000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">9523000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c0" decimals="-3" unitRef="usd">853000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c4" decimals="-3" unitRef="usd">763000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c5" decimals="-3" unitRef="usd">2032000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c0" decimals="-3" unitRef="usd">9850000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c4" decimals="-3" unitRef="usd">11951000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c5" decimals="-3" unitRef="usd">10976000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c0" decimals="-3" unitRef="usd">3845000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c4" decimals="-3" unitRef="usd">2951000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c5" decimals="-3" unitRef="usd">3063000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-12842000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-14139000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-12007000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense contextRef="c0" decimals="-3" unitRef="usd">227000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c4" decimals="-3" unitRef="usd">-304000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c5" decimals="-3" unitRef="usd">-618000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c0" decimals="-3" unitRef="usd">-12615000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c4" decimals="-3" unitRef="usd">-14443000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c5" decimals="-3" unitRef="usd">-12625000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-12615000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-14443000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-12625000</us-gaap:NetIncomeLoss>
    <us-gaap:RedeemablePreferredStockDividends contextRef="c0" decimals="-3" unitRef="usd">2590000</us-gaap:RedeemablePreferredStockDividends>
    <us-gaap:RedeemablePreferredStockDividends contextRef="c4" decimals="-3" unitRef="usd">715000</us-gaap:RedeemablePreferredStockDividends>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c0" decimals="-3" unitRef="usd">-15205000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c4" decimals="-3" unitRef="usd">-15158000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c5" decimals="-3" unitRef="usd">-12625000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c0" decimals="2" unitRef="usdPershares">-0.03</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c4" decimals="2" unitRef="usdPershares">-0.04</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="c5" decimals="2" unitRef="usdPershares">-0.14</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c0" decimals="0" unitRef="shares">553079638</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c4" decimals="0" unitRef="shares">358411297</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="c5" decimals="0" unitRef="shares">85909859</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding contextRef="c6" decimals="0" unitRef="shares">40399290</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c6" decimals="-3" unitRef="usd">2635000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c7" decimals="-3" unitRef="usd">96939000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c8" decimals="-3" unitRef="usd">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c9" decimals="-3" unitRef="usd">-97686000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c10" decimals="-3" unitRef="usd">3015000</us-gaap:StockholdersEquity>
    <canf:WarrantsNetOfIssueExpenses contextRef="c5" decimals="-3" unitRef="usd">1382000</canf:WarrantsNetOfIssueExpenses>
    <canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants contextRef="c11" decimals="0" unitRef="shares">79256703</canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants contextRef="c11" decimals="-3" unitRef="usd">5518000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants contextRef="c12" decimals="-3" unitRef="usd">6149000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants contextRef="c5" decimals="-3" unitRef="usd">11667000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c11" decimals="0" unitRef="shares">996690</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c11" decimals="-3" unitRef="usd">72000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c12" decimals="-3" unitRef="usd">43000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c5" decimals="-3" unitRef="usd">115000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c12" decimals="-3" unitRef="usd">270000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c5" decimals="-3" unitRef="usd">270000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss contextRef="c14" decimals="-3" unitRef="usd">-12625000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-12625000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c15" decimals="0" unitRef="shares">120652683</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="-3" unitRef="usd">8225000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" unitRef="usd">103401000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="-3" unitRef="usd">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="-3" unitRef="usd">-110311000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="-3" unitRef="usd">2442000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c15" decimals="0" unitRef="shares">120652683</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c15" decimals="-3" unitRef="usd">8225000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c16" decimals="-3" unitRef="usd">103401000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c17" decimals="-3" unitRef="usd">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c18" decimals="-3" unitRef="usd">-110311000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c19" decimals="-3" unitRef="usd">2442000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend contextRef="c21" decimals="-3" unitRef="usd">715000</us-gaap:StockIssuedDuringPeriodValueStockDividend>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend contextRef="c23" decimals="-3" unitRef="usd">-715000</us-gaap:StockIssuedDuringPeriodValueStockDividend>
    <canf:WarrantsNetOfIssueExpenses contextRef="c4" decimals="-3" unitRef="usd">3703000</canf:WarrantsNetOfIssueExpenses>
    <canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants contextRef="c20" decimals="0" unitRef="shares">341766780</canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants contextRef="c20" decimals="-3" unitRef="usd">24711000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants contextRef="c21" decimals="-3" unitRef="usd">-7028000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants contextRef="c4" decimals="-3" unitRef="usd">17683000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c20" decimals="0" unitRef="shares">1350000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c20" decimals="-3" unitRef="usd">100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c21" decimals="-3" unitRef="usd">-25000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c4" decimals="-3" unitRef="usd">75000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c21" decimals="-3" unitRef="usd">317000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c4" decimals="-3" unitRef="usd">317000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss contextRef="c23" decimals="-3" unitRef="usd">-14443000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-14443000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding contextRef="c24" decimals="0" unitRef="shares">463769463</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c24" decimals="-3" unitRef="usd">33036000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c25" decimals="-3" unitRef="usd">97380000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c26" decimals="-3" unitRef="usd">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c27" decimals="-3" unitRef="usd">-125469000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c3" decimals="-3" unitRef="usd">6074000</us-gaap:StockholdersEquity>
    <canf:StockIssuedDuringPeriodValueNetOfIssueExpenses contextRef="c0" decimals="-3" unitRef="usd">980000</canf:StockIssuedDuringPeriodValueNetOfIssueExpenses>
    <canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares contextRef="c28" decimals="0" unitRef="shares">293926830</canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares>
    <canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses contextRef="c28" decimals="-3" unitRef="usd">23106000</canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses>
    <canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses contextRef="c29" decimals="-3" unitRef="usd">-11339000</canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses>
    <canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses contextRef="c0" decimals="-3" unitRef="usd">11767000</canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses>
    <canf:WarrantsNetOfIssueExpenses contextRef="c0" decimals="-3" unitRef="usd">1307000</canf:WarrantsNetOfIssueExpenses>
    <canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants contextRef="c28" decimals="0" unitRef="shares">57000000</canf:StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants contextRef="c28" decimals="-3" unitRef="usd">4432000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants contextRef="c29" decimals="-3" unitRef="usd">4258000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants contextRef="c0" decimals="-3" unitRef="usd">8690000</canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c28" decimals="0" unitRef="shares">1050000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c28" decimals="-3" unitRef="usd">80000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c29" decimals="-3" unitRef="usd">-12000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c0" decimals="-3" unitRef="usd">68000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend contextRef="c29" decimals="-3" unitRef="usd">2590000</us-gaap:StockIssuedDuringPeriodValueStockDividend>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend contextRef="c31" decimals="-3" unitRef="usd">-2590000</us-gaap:StockIssuedDuringPeriodValueStockDividend>
    <us-gaap:NetIncomeLoss contextRef="c31" decimals="-3" unitRef="usd">-12615000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-12615000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c29" decimals="-3" unitRef="usd">398000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c0" decimals="-3" unitRef="usd">398000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding contextRef="c32" decimals="0" unitRef="shares">815746293</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c32" decimals="-3" unitRef="usd">60654000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c33" decimals="-3" unitRef="usd">93275000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c34" decimals="-3" unitRef="usd">1127000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c35" decimals="-3" unitRef="usd">-140674000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c2" decimals="-3" unitRef="usd">14382000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-12615000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c4" decimals="-3" unitRef="usd">-14443000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c5" decimals="-3" unitRef="usd">-12625000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c0" decimals="-3" unitRef="usd">14000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c4" decimals="-3" unitRef="usd">12000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c5" decimals="-3" unitRef="usd">14000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c0" decimals="-3" unitRef="usd">-55000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c4" decimals="-3" unitRef="usd">-9000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="c5" decimals="-3" unitRef="usd">-28000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c0" decimals="-3" unitRef="usd">-128000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c4" decimals="-3" unitRef="usd">-4275000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c5" decimals="-3" unitRef="usd">-221000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <canf:IncreaseDecreaseInSharebasedPayment contextRef="c0" decimals="-3" unitRef="usd">398000</canf:IncreaseDecreaseInSharebasedPayment>
    <canf:IncreaseDecreaseInSharebasedPayment contextRef="c4" decimals="-3" unitRef="usd">355000</canf:IncreaseDecreaseInSharebasedPayment>
    <canf:IncreaseDecreaseInSharebasedPayment contextRef="c5" decimals="-3" unitRef="usd">385000</canf:IncreaseDecreaseInSharebasedPayment>
    <us-gaap:ShareBasedCompensation contextRef="c0" decimals="-3" unitRef="usd">68000</us-gaap:ShareBasedCompensation>
    <canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment contextRef="c0" decimals="-3" unitRef="usd">162000</canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment>
    <canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment contextRef="c4" decimals="-3" unitRef="usd">11000</canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment>
    <canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment contextRef="c5" decimals="-3" unitRef="usd">-209000</canf:IncreaseDecreaseInChangesInFairValueOfShorttermInvestment>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c0" decimals="-3" unitRef="usd">-63000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c4" decimals="-3" unitRef="usd">-8000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c5" decimals="-3" unitRef="usd">-33000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet contextRef="c0" decimals="-3" unitRef="usd">12000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c0" decimals="-3" unitRef="usd">34000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c4" decimals="-3" unitRef="usd">-23000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c5" decimals="-3" unitRef="usd">2000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c0" decimals="-3" unitRef="usd">393000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c4" decimals="-3" unitRef="usd">-1595000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="c5" decimals="-3" unitRef="usd">1085000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c0" decimals="-3" unitRef="usd">1398000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c4" decimals="-3" unitRef="usd">-401000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="c5" decimals="-3" unitRef="usd">146000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c0" decimals="-3" unitRef="usd">574000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c4" decimals="-3" unitRef="usd">-279000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable contextRef="c5" decimals="-3" unitRef="usd">-512000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c0" decimals="-3" unitRef="usd">-9858000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c4" decimals="-3" unitRef="usd">-12063000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c5" decimals="-3" unitRef="usd">-11084000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c0" decimals="-3" unitRef="usd">11000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c4" decimals="-3" unitRef="usd">26000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c5" decimals="-3" unitRef="usd">3000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireOtherInvestments contextRef="c0" decimals="-3" unitRef="usd">14500000</us-gaap:PaymentsToAcquireOtherInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c0" decimals="-3" unitRef="usd">-14511000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c4" decimals="-3" unitRef="usd">-26000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c5" decimals="-3" unitRef="usd">-3000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c0" decimals="-3" unitRef="usd">20457000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c4" decimals="-3" unitRef="usd">17683000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c5" decimals="-3" unitRef="usd">10167000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c0" decimals="-3" unitRef="usd">20457000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c4" decimals="-3" unitRef="usd">17683000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c5" decimals="-3" unitRef="usd">10167000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c0" decimals="-3" unitRef="usd">34000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c4" decimals="-3" unitRef="usd">-23000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents contextRef="c5" decimals="-3" unitRef="usd">2000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c0" decimals="-3" unitRef="usd">-3878000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c4" decimals="-3" unitRef="usd">5571000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c5" decimals="-3" unitRef="usd">-918000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c3" decimals="-3" unitRef="usd">8268000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c19" decimals="-3" unitRef="usd">2697000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c10" decimals="-3" unitRef="usd">3615000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c2" decimals="-3" unitRef="usd">4390000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c3" decimals="-3" unitRef="usd">8268000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="c19" decimals="-3" unitRef="usd">2697000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c0" decimals="-3" unitRef="usd">120000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c4" decimals="-3" unitRef="usd">29000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c5" decimals="-3" unitRef="usd">76000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:PaymentsOfDividends contextRef="c0" decimals="-3" unitRef="usd">2590000</us-gaap:PaymentsOfDividends>
    <us-gaap:PaymentsOfDividends contextRef="c4" decimals="-3" unitRef="usd">715000</us-gaap:PaymentsOfDividends>
    <us-gaap:InterestPaidNet contextRef="c0" decimals="-3" unitRef="usd">18000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c4" decimals="-3" unitRef="usd">23000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c5" decimals="-3" unitRef="usd">29000</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 1:-&#160;GENERAL&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Company description:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Can-Fite Biopharma Ltd. (the &#x201c;Company&#x201d;)
was incorporated and started to operate in September 1994 as a private Israeli company. Can-Fite is a clinical-stage biopharmaceutical
company focused on developing orally bioavailable small molecule therapeutic products for the treatment of psoriasis, liver cancer, NASH
and erectile dysfunction. Its platform technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is highly expressed
in patholological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting that the receptor
could be a specific target for pharmacological intervention. The Company&#x2019;s pipeline of drug candidates are synthetic, highly specific
agonists and allosteric modulators at the A3AR.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s ordinary shares
have been publicly traded on the Tel-Aviv Stock Exchange since October 2005 under the symbol &#x201c;CFBI&#x201d; and the Company&#x2019;s
American Depositary Shares (&#x201c;ADSs&#x201d;) began public trading on the over the counter market in the U.S. in October 2012 and since
November 2013 the Company&#x2019;s ADSs have been publicly traded on the NYSE American under the symbol &#x201c;CANF&#x201d;. Each ADS represents
30 ordinary shares of the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;During the year ended December 31, 2021, the Company incurred net losses of USD&#160;12,615 and it had negative cash flows from operating activities in the amount of USD&#160;9,858.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Furthermore, the Company intends to
continue to finance its operating activities by raising capital and seeking collaborations with multinational companies in the industry.
There are no assurances that the Company will be successful in obtaining an adequate level of financing needed for its long-term research
and development activities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;If the Company will not have sufficient
liquidity resources, the Company may not be able to continue the development of all of its products or may be required to implement a
cost reduction and may be required to delay part of its development programs. The Company&#x2019;s management and board of directors are
of the opinion that its current financial resources will be sufficient to continue the development of the Company&#x2019;s products for
at least the next twelve months beyond the date of the filing date of the consolidated financial statements.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:SharesIssued contextRef="c2" decimals="0" unitRef="shares">30</us-gaap:SharesIssued>
    <us-gaap:NetIncomeLoss contextRef="c0" decimals="-3" unitRef="usd">-12615000</us-gaap:NetIncomeLoss>
    <canf:CashFlowsFromOperatingActivities contextRef="c0" decimals="-3" unitRef="usd">-9858000</canf:CashFlowsFromOperatingActivities>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 2:-&#160;SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; "&gt;The consolidated financial
statements have been prepared in conformity with accounting principles generally accepted in the United States (&#x201c;U.S. GAAP&#x201d;).&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Use of estimates:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#x2019;s
management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they
are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting
period. Actual results could differ from those estimates.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Principles of consolidation:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The consolidated financial statements
include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Functional currency, reporting currency and foreign currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Functional currency and reporting currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;From the Company&#x2019;s inception through
January 1, 2018, the Company&#x2019;s functional and presentation currency was the New Israeli Shekel (&#x201c;NIS&#x201d;). In 2018, management
conducted a review of the functional currency of the Company and concluded that the Company&#x2019;s functional currency has changed to the U.S
dollar (&#x201c;dollar&#x201d;, &#x201c;USD&#x201d; or &#x201c;$&#x201d;) effective January 1, 2018.These changes were based on an assessment
made by the Company&#x2019;s management that the USD is the primary currency of the economic environment in which the Company operates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions, assets and liabilities in foreign currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Transactions and balances denominated
in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured
into dollars in accordance with ASC No.&#160;830, &#x201c;Foreign Currency Matters&#x201d;. All transaction gains and losses from the re-measurement
of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as
appropriate.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Cash equivalents are short-term, highly
liquid investments that are readily convertible to cash with a maturity of three months or less at the date of acquisition, to be cash
equivalents.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Short-term bank deposits:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Short-term bank deposits are deposits with maturities of more than three months and less than one year. As of December 31, 2021 and 2020, the Company&#x2019;s bank deposits are denominated mainly in U.S. dollars and bears yearly interest at weighted average rates of 0.53% and none. Short-term bank deposits are presented at their cost, including accrued interest.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="padding-right: -6.55pt"&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid expenses, and other current assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Prepaid expenses are composed mainly from prepayments to suppliers
and from active pharmaceutical ingredients and clinical trial drug-capsules which are expensed when designate to a clinical trial and
no longer have an alternative future use.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating lease:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In accordance with ASU No. 2016-02,
"Leases (Topic 842)", the Company determines if an arrangement is a lease and the classification of that lease at inception
based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially
all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of
the asset. The Company elected to not recognize a lease liability and a right-of-use ("ROU") asset for leases with a term of
twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases.
ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum
lease payments arising from the lease.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;ROU assets are initially measured at amounts, which represents the
discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially
measured at lease commencement date based on the discounted present value of minimum lease payments over the lease term. The implicit
rate within the operating leases is generally not determinable, therefore the Company uses its Incremental Borrowing Rate ("IBR")
based on the information available at commencement date in determining the present value of lease payments. The Company's IBR is estimated
to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased
asset is located. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection
with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option
to terminate is considered unless it is reasonably certain that the Company will not exercise the option.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property, plant and equipment:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Property and equipment are stated at
cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the
assets at the following annual rates:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Mainly&lt;br/&gt; %&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Laboratory equipment and Leasehold improvements&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 49.65pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6 - 33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including extension option held by the Company and intended to be exercised)
and the expected life of the improvement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;i.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairment of long-lived assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Property and equipment are reviewed
for impairment in accordance with ASC 360, &#x201c;Property, Plant and Equipment,&#x201d; whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair
value of the assets. As of December 31, 2021, and 2020, no impairment indicators have been identified.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 48px"/&gt;&lt;td style="width: 24px; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;j.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Revenue recognition:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company recognizes revenue in
accordance with ASC Topic&#160;606, Revenue from contracts with customers (&#x201c;ASC 606&#x201d;) and determines revenue recognition
through the following steps:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identification
of the contract, or contracts, with a customer;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identification
of the performance obligations in the contract;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determination
of the transaction price;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Allocation
of the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recognition
of revenue when, or as, the performance obligations are satisfied.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company generates rev&lt;/span&gt;enues from supply and distribution agreements. The consideration under these agreements comprise of upfront
license fees, milestone payments and potential royalty payments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Revenue from supply and
distribution agreements with customers is recognized when the control over the goods or services is transferred to the customer. The
transaction price is the amount of the consideration that is expected to be received based on the contract terms, excluding amounts
collected on behalf of third parties (such as taxes).&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Revenue from supply and distribution
agreements with customers are recognized over time as the Company satisfies the performance obligations. The Company usually accepts long-term
upfront payment from its customers. Contract liabilities for those upfront payments are recognized as revenue over time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s contracts generally
include three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of
an exclusive licensing to distribute the product, once available; and, (iii) participation in joint steering committee.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company has concluded that the
abovementioned contracts contain a single performance obligation satisfied over time. Consequently, revenue from these contracts is recorded
based on the term of the research and development services.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s contracts also
include development milestones payments and future sales-based royalties. Development milestones payments are recognized only to the extent
that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated
with those milestones is subsequently resolved. As such sales based royalties are recognized only when the subsequent sale occurs. As
of December 31, 2021, the Company has not yet received the required regulatory approvals for its products and has not yet recognized any
sales-based royalties .&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The prepayments terms from the Company&#x2019;s
contracts with customers do not include a significant financing component as the primary purpose of these payments is not to receive financing
from the customers.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Revenue Recognition &#x2013; Contract
Balances &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Contract liabilities, due to the upfront
payments, include amounts received from customers for which revenue has not yet been recognized. As of December 31, 2021 and December
31, 2020 contract liabilities amounted to $3,888&#160;and $2,490, respectively and are presented under deferred revenues. During the year
ended December 31, 2021, the Company recognized revenues in the amount of $853&#160;out of which $507 have been included in the contract
liabilities at December&#160;31, 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Deferred revenue that is anticipated
to be recognized during the succeeding 12-months period is recorded as current deferred revenue and the remaining portion is recorded
as non-current deferred revenue.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;k.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development expenditures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Research and development costs are
expensed as incurred. Research and development costs include payroll and personnel expenses, consulting costs, external contract research
and development expenses, raw materials, drug product manufacturing costs, and allocated overhead including depreciation and amortization,
rent, and utilities. Research and development are generally expensed as incurred. Research and development costs that are paid in advance
of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;l.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value measurement:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company applies ASC 820, &#x201c;Fair
Value Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;). Under this standard, fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability (i.e., the &#x201c;exit price&#x201d;) in an orderly transaction between market
participants at the measurement date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In determining fair value, the Company
uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable
inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs
are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent
from the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken
down into three levels based on the inputs as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 1 - Valuations based on quoted
prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are
not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active
market, valuation of these products does not entail a significant degree of judgment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 2 - Valuations based on one or
more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 3 - Valuations based on inputs
that are unobservable and significant to the overall fair value measurement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The carrying amounts of cash and cash
equivalents, other accounts receivable and prepaid expenses, trade payables and other accounts payable and accrued expenses approximate
their fair value due to the short-term maturity of such instruments. The Company has an investment measured using Level 1 inputs. See
Note 4.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;m.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Concentration of Credit Risk:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents and short-term deposits. For cash and cash equivalents, the Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Legal and other contingencies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for its contingent
liabilities in accordance with ASC 450, Contingencies (&#x201c;ASC 450&#x201d;). A provision is recorded when it is both probable that a liability
has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, the Company reviews the status
of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable
and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. As of December 31, 2021, and 2020,
the Company is not a party to any litigation that could have a material adverse effect on the Company&#x2019;s business, financial position,
results of operations or cash flows. Legal costs incurred in connection with loss contingencies are expensed as incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Major customer data as a percentage
of total revenues:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cipher Pharmaceuticals&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Chong Kun Dang Pharmaceuticals Corp.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Gebro Holding GmBH&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Ewopharma AG&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;41&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-51"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;o.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Severance pay&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s liability for severance
pay is pursuant to Section 14 of the Severance Compensation Act, 1963 (&#x201c;Section 14&#x201d;), pursuant to which all the Company&#x2019;s
employees are included under Section 14, and are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in
the employee&#x2019;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release the Company
from any future severance payments in respect of those employees. The fund is made available to the employee at the time the employer-employee
relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected
in the consolidated balance sheets as the severance pay risks have been irrevocably transferred to the severance funds.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Severance pay expense for the year
ended December 31, 2021, 2020 and 2019 amounted to $53, $46 and $42, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;p.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment transactions&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for share-based
compensation in accordance with ASC 718, &#x201c;Compensation - Stock Compensation&#x201d; (&#x201c;ASC 718&#x201d;), which requires companies
to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion
of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#x2019;s
consolidated statement of comprehensive loss, based on acceleration method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company recognizes compensation
expenses for the value of its awards granted based on the vesting attribution approach over the requisite service period of each of the
awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in
subsequent periods if actual forfeitures differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company estimates the fair value
of share options granted using the Binomial option pricing model. The option-pricing model requires a number of assumptions, of which
the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated based upon
historical volatility of the Company. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term.
The Company has historically not paid dividends and has no foreseeable plans to pay dividends.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;q.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for income taxes
in accordance with ASC No. 740, &#x201c;Income Taxes&#x201d;, (&#x201c;ASC 740&#x201d;) which prescribes the use of the liability method whereby
deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company provides a valuation allowance,
if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2021, and 2020, a full valuation allowance
was provided by the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;ASC 740 contains a two-step approach
to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected
to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation
of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes.
The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
As of December 31, 2021, and 2020, no liability for unrecognized tax benefits was recorded.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;r.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Ordinary share warrants classification and measurement:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#x2019;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;s.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted net loss per share&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Basic and diluted net loss per share
is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated
based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260,
&#x201c;Earnings per Share&#x201d;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;All outstanding share options and warrants
for the years ended December 31, 2021, 2020 and 2019 have been excluded from the calculation of the diluted net loss per share, because
all such securities are anti-dilutive for all periods presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;To compute diluted loss per share for the years ended December 31,
2021, December 31, 2020 and December 31, 2019, the total number of 18,422,700, 11,923,400 and 2,673,400 shares, respectively subject to
outstanding unlisted options have not been considered since they have anti-dilutive effect.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 47px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;t.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Recently adopted and recently issued accounting pronouncements&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#x2013;
Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which replaces the existing incurred loss impairment
model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected
to be collected. The adoption of the standard did not have material effect on Company&#x2019;s results.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 47px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic
740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing a variety of exceptions
within the framework of ASC 740. These exceptions include the exception to the incremental approach for intra period tax allocation in
the event of a loss from continuing operations and income or a gain from other items (such as other comprehensive income), and the exception
to using general methodology for the interim period tax accounting for year-to-date losses that exceed anticipated losses. The adoption
of the standard did not have material effect on Company&#x2019;s results.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;u.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounting pronouncements not yet adopted:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provides guidance to clarify and reduce diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. As a result, the Company will not be required to adopt ASU 2021-04 until January 1, 2022. The Company is currently evaluating the impact of the adoption of this principle on the Company&#x2019;s unaudited consolidated financial statements.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Use of estimates:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The preparation of the consolidated
financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions. The Company&#x2019;s
management believes that the estimates, judgments and assumptions used are reasonable based upon information available at the time they
are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent
assets and liabilities at the dates of the financial statements, and the reported amounts of revenue and expenses during the reporting
period. Actual results could differ from those estimates.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Principles of consolidation:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The consolidated financial statements
include the accounts of the Company and its subsidiary. Intercompany accounts and transactions have been eliminated.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Functional currency, reporting currency and foreign currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Functional currency and reporting currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;From the Company&#x2019;s inception through
January 1, 2018, the Company&#x2019;s functional and presentation currency was the New Israeli Shekel (&#x201c;NIS&#x201d;). In 2018, management
conducted a review of the functional currency of the Company and concluded that the Company&#x2019;s functional currency has changed to the U.S
dollar (&#x201c;dollar&#x201d;, &#x201c;USD&#x201d; or &#x201c;$&#x201d;) effective January 1, 2018.These changes were based on an assessment
made by the Company&#x2019;s management that the USD is the primary currency of the economic environment in which the Company operates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Transactions, assets and liabilities in foreign currency:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Transactions and balances denominated
in U.S. dollars are presented at their original amounts. Monetary accounts denominated in currencies other than the dollar are re-measured
into dollars in accordance with ASC No.&#160;830, &#x201c;Foreign Currency Matters&#x201d;. All transaction gains and losses from the re-measurement
of monetary balance sheet items are reflected in the consolidated statement of comprehensive loss as financial income or expenses, as
appropriate.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Cash equivalents are short-term, highly
liquid investments that are readily convertible to cash with a maturity of three months or less at the date of acquisition, to be cash
equivalents.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Short-term bank deposits:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Short-term bank deposits are deposits with maturities of more than three months and less than one year. As of December 31, 2021 and 2020, the Company&#x2019;s bank deposits are denominated mainly in U.S. dollars and bears yearly interest at weighted average rates of 0.53% and none. Short-term bank deposits are presented at their cost, including accrued interest.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="padding-right: -6.55pt"&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Prepaid expenses, and other current assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Prepaid expenses are composed mainly from prepayments to suppliers
and from active pharmaceutical ingredients and clinical trial drug-capsules which are expensed when designate to a clinical trial and
no longer have an alternative future use.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock>
    <us-gaap:DebtPolicyTextBlock contextRef="c0">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Short-term bank deposits:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Short-term bank deposits are deposits with maturities of more than three months and less than one year. As of December 31, 2021 and 2020, the Company&#x2019;s bank deposits are denominated mainly in U.S. dollars and bears yearly interest at weighted average rates of 0.53% and none. Short-term bank deposits are presented at their cost, including accrued interest.&lt;/p&gt;</us-gaap:DebtPolicyTextBlock>
    <us-gaap:DebtWeightedAverageInterestRate contextRef="c2" decimals="4" unitRef="pure">0.0053</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:OperatingLeaseLeaseIncomeTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;g.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Operating lease:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In accordance with ASU No. 2016-02,
"Leases (Topic 842)", the Company determines if an arrangement is a lease and the classification of that lease at inception
based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether the Company obtains the right to substantially
all the economic benefits from the use of the asset throughout the period, and (3) whether the Company has a right to direct the use of
the asset. The Company elected to not recognize a lease liability and a right-of-use ("ROU") asset for leases with a term of
twelve months or less. The Company also elected the practical expedient to not separate lease and non-lease components for its leases.
ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make minimum
lease payments arising from the lease.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;ROU assets are initially measured at amounts, which represents the
discounted present value of the lease payments over the lease, plus any initial direct costs incurred. The lease liability is initially
measured at lease commencement date based on the discounted present value of minimum lease payments over the lease term. The implicit
rate within the operating leases is generally not determinable, therefore the Company uses its Incremental Borrowing Rate ("IBR")
based on the information available at commencement date in determining the present value of lease payments. The Company's IBR is estimated
to approximate the interest rate for collateralized borrowing with similar terms and payments and in economic environments where the leased
asset is located. Certain leases include options to extend or terminate the lease. An option to extend the lease is considered in connection
with determining the ROU asset and lease liability when it is reasonably certain that the Company will exercise that option. An option
to terminate is considered unless it is reasonably certain that the Company will not exercise the option.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;</us-gaap:OperatingLeaseLeaseIncomeTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;h.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Property, plant and equipment:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Property and equipment are stated at
cost, net of accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the
assets at the following annual rates:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Mainly&lt;br/&gt; %&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Laboratory equipment and Leasehold improvements&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 49.65pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6 - 33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Leasehold improvements are depreciated
on a straight-line basis over the shorter of the lease term (including extension option held by the Company and intended to be exercised)
and the expected life of the improvement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <canf:ScheduleOfUsefulLivesOfTheAssetsTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Mainly&lt;br/&gt; %&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Laboratory equipment and Leasehold improvements&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: center"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;10&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-left: 49.65pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6 - 33&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;33&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&#160;&lt;/p&gt;</canf:ScheduleOfUsefulLivesOfTheAssetsTableTextBlock>
    <canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments contextRef="c36" decimals="2" unitRef="pure">0.10</canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments>
    <canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments contextRef="c36" decimals="2" unitRef="pure">0.10</canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments>
    <canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments contextRef="c37" decimals="2" unitRef="pure">0.06</canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments>
    <canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments contextRef="c38" decimals="2" unitRef="pure">0.33</canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments>
    <canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments contextRef="c39" decimals="2" unitRef="pure">0.33</canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;i.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Impairment of long-lived assets:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Property and equipment are reviewed
for impairment in accordance with ASC 360, &#x201c;Property, Plant and Equipment,&#x201d; whenever events or changes in circumstances indicate
that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison
of the carrying amount of an asset to the future undiscounted cash flows expected to be generated by the assets. If such assets are considered
to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair
value of the assets. As of December 31, 2021, and 2020, no impairment indicators have been identified.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 48px"/&gt;&lt;td style="width: 24px; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;j.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;Revenue recognition:&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The Company recognizes revenue in
accordance with ASC Topic&#160;606, Revenue from contracts with customers (&#x201c;ASC 606&#x201d;) and determines revenue recognition
through the following steps:&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identification
of the contract, or contracts, with a customer;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Identification
of the performance obligations in the contract;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Determination
of the transaction price;&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Allocation
of the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0.75in"/&gt;&lt;td style="width: 0.25in; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Recognition
of revenue when, or as, the performance obligations are satisfied.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The
Company generates rev&lt;/span&gt;enues from supply and distribution agreements. The consideration under these agreements comprise of upfront
license fees, milestone payments and potential royalty payments.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Revenue from supply and
distribution agreements with customers is recognized when the control over the goods or services is transferred to the customer. The
transaction price is the amount of the consideration that is expected to be received based on the contract terms, excluding amounts
collected on behalf of third parties (such as taxes).&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Revenue from supply and distribution
agreements with customers are recognized over time as the Company satisfies the performance obligations. The Company usually accepts long-term
upfront payment from its customers. Contract liabilities for those upfront payments are recognized as revenue over time.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s contracts generally
include three contract obligations: (i) performing the research and development services through regulatory approval; (ii) delivery of
an exclusive licensing to distribute the product, once available; and, (iii) participation in joint steering committee.&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company has concluded that the
abovementioned contracts contain a single performance obligation satisfied over time. Consequently, revenue from these contracts is recorded
based on the term of the research and development services.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s contracts also
include development milestones payments and future sales-based royalties. Development milestones payments are recognized only to the extent
that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated
with those milestones is subsequently resolved. As such sales based royalties are recognized only when the subsequent sale occurs. As
of December 31, 2021, the Company has not yet received the required regulatory approvals for its products and has not yet recognized any
sales-based royalties .&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The prepayments terms from the Company&#x2019;s
contracts with customers do not include a significant financing component as the primary purpose of these payments is not to receive financing
from the customers.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="text-decoration:underline"&gt;Revenue Recognition &#x2013; Contract
Balances &lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Contract liabilities, due to the upfront
payments, include amounts received from customers for which revenue has not yet been recognized. As of December 31, 2021 and December
31, 2020 contract liabilities amounted to $3,888&#160;and $2,490, respectively and are presented under deferred revenues. During the year
ended December 31, 2021, the Company recognized revenues in the amount of $853&#160;out of which $507 have been included in the contract
liabilities at December&#160;31, 2020.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Deferred revenue that is anticipated
to be recognized during the succeeding 12-months period is recorded as current deferred revenue and the remaining portion is recorded
as non-current deferred revenue.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <canf:ContractLiabilities contextRef="c2" decimals="-3" unitRef="usd">3888000</canf:ContractLiabilities>
    <canf:ContractLiabilities contextRef="c3" decimals="-3" unitRef="usd">2490000</canf:ContractLiabilities>
    <canf:Revenue contextRef="c0" decimals="-3" unitRef="usd">853000</canf:Revenue>
    <canf:RevenuesIncludedInContractLiabilities contextRef="c0" decimals="-3" unitRef="usd">507000</canf:RevenuesIncludedInContractLiabilities>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;k.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Research and development expenditures:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Research and development costs are
expensed as incurred. Research and development costs include payroll and personnel expenses, consulting costs, external contract research
and development expenses, raw materials, drug product manufacturing costs, and allocated overhead including depreciation and amortization,
rent, and utilities. Research and development are generally expensed as incurred. Research and development costs that are paid in advance
of performance are capitalized as a prepaid expense and amortized over the service period as the services are provided.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;l.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Fair value measurement:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company applies ASC 820, &#x201c;Fair
Value Measurements and Disclosures&#x201d; (&#x201c;ASC 820&#x201d;). Under this standard, fair value is defined as the price that would
be received to sell an asset or paid to transfer a liability (i.e., the &#x201c;exit price&#x201d;) in an orderly transaction between market
participants at the measurement date.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 85.05pt; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;In determining fair value, the Company
uses various valuation approaches. ASC 820 establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable
inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs
are inputs that market participants would use in pricing the asset or liability developed based on market data obtained from sources independent
from the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the assumptions market participants
would use in pricing the asset or liability developed based on the best information available in the circumstances. The hierarchy is broken
down into three levels based on the inputs as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 1 - Valuations based on quoted
prices in active markets for identical assets that the Company has the ability to access. Valuation adjustments and block discounts are
not applied to Level 1 instruments. Since valuations are based on quoted prices that are readily and regularly available in an active
market, valuation of these products does not entail a significant degree of judgment.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 2 - Valuations based on one or
more quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Level 3 - Valuations based on inputs
that are unobservable and significant to the overall fair value measurement.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The carrying amounts of cash and cash
equivalents, other accounts receivable and prepaid expenses, trade payables and other accounts payable and accrued expenses approximate
their fair value due to the short-term maturity of such instruments. The Company has an investment measured using Level 1 inputs. See
Note 4.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;m.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Concentration of Credit Risk:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents and short-term deposits. For cash and cash equivalents, the Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;n.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Legal and other contingencies&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for its contingent
liabilities in accordance with ASC 450, Contingencies (&#x201c;ASC 450&#x201d;). A provision is recorded when it is both probable that a liability
has been incurred and the amount of the loss can be reasonably estimated. With respect to legal matters, the Company reviews the status
of each matter and assesses its potential financial exposure. If the potential loss from any claim or legal proceeding is considered probable
and the amount can be reasonably estimated, the Company accrues a liability for the estimated loss. As of December 31, 2021, and 2020,
the Company is not a party to any litigation that could have a material adverse effect on the Company&#x2019;s business, financial position,
results of operations or cash flows. Legal costs incurred in connection with loss contingencies are expensed as incurred.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Major customer data as a percentage
of total revenues:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cipher Pharmaceuticals&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Chong Kun Dang Pharmaceuticals Corp.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Gebro Holding GmBH&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Ewopharma AG&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;41&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-51"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c0">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;m.&lt;/span&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Concentration of Credit Risk:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents and short-term deposits. For cash and cash equivalents, the Company is exposed to credit risk in the event of default by the financial institutions to the extent of the amounts recorded on the accompanying consolidated balance sheets exceed federally insured limits. The Company places its cash and cash equivalents and short-term deposits with financial institutions with high-quality credit ratings and has not experienced any losses in such accounts.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <canf:ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Cipher Pharmaceuticals&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;12&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;20&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Chong Kun Dang Pharmaceuticals Corp.&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;45&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Gebro Holding GmBH&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;23&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Ewopharma AG&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;41&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-51"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;100&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;</canf:ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock>
    <canf:RevenueContractWithCustomer contextRef="c40" decimals="2" unitRef="pure">0.12</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c41" decimals="2" unitRef="pure">0.20</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c42" decimals="2" unitRef="pure">0.24</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c43" decimals="2" unitRef="pure">0.45</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c44" decimals="2" unitRef="pure">0.23</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c45" decimals="2" unitRef="pure">0.35</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c46" decimals="2" unitRef="pure">0.41</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c0" decimals="2" unitRef="pure">1</canf:RevenueContractWithCustomer>
    <canf:RevenueContractWithCustomer contextRef="c4" decimals="2" unitRef="pure">1</canf:RevenueContractWithCustomer>
    <canf:SeverancePayPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;o.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Severance pay&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company&#x2019;s liability for severance
pay is pursuant to Section 14 of the Severance Compensation Act, 1963 (&#x201c;Section 14&#x201d;), pursuant to which all the Company&#x2019;s
employees are included under Section 14, and are entitled only to monthly deposits, at a rate of 8.33% of their monthly salary, made in
the employee&#x2019;s name with insurance companies. Under Israeli employment law, payments in accordance with Section 14 release the Company
from any future severance payments in respect of those employees. The fund is made available to the employee at the time the employer-employee
relationship is terminated, regardless of cause of termination. The severance pay liabilities and deposits under Section 14 are not reflected
in the consolidated balance sheets as the severance pay risks have been irrevocably transferred to the severance funds.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Severance pay expense for the year
ended December 31, 2021, 2020 and 2019 amounted to $53, $46 and $42, respectively.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</canf:SeverancePayPolicyTextBlock>
    <canf:PercentageOfDepositsOnMonthlySalary contextRef="c0" decimals="4" unitRef="pure">0.0833</canf:PercentageOfDepositsOnMonthlySalary>
    <us-gaap:SeveranceCosts1 contextRef="c0" decimals="-3" unitRef="usd">53000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c4" decimals="-3" unitRef="usd">46000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c5" decimals="-3" unitRef="usd">42000</us-gaap:SeveranceCosts1>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;p.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment transactions&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for share-based
compensation in accordance with ASC 718, &#x201c;Compensation - Stock Compensation&#x201d; (&#x201c;ASC 718&#x201d;), which requires companies
to estimate the fair value of equity-based payment awards on the date of grant using an option-pricing model. The value of the portion
of the award that is ultimately expected to vest is recognized as an expense over the requisite service periods in the Company&#x2019;s
consolidated statement of comprehensive loss, based on acceleration method.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company recognizes compensation
expenses for the value of its awards granted based on the vesting attribution approach over the requisite service period of each of the
awards, net of estimated forfeitures. ASC 718 requires forfeitures to be estimated at the time of grant and revised, if necessary, in
subsequent periods if actual forfeitures differ from those estimates.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company estimates the fair value
of share options granted using the Binomial option pricing model. The option-pricing model requires a number of assumptions, of which
the most significant are the expected stock price volatility and the expected option term. Expected volatility was calculated based upon
historical volatility of the Company. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term.
The Company has historically not paid dividends and has no foreseeable plans to pay dividends.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;span style="font-size: 8pt"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;q.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company accounts for income taxes
in accordance with ASC No. 740, &#x201c;Income Taxes&#x201d;, (&#x201c;ASC 740&#x201d;) which prescribes the use of the liability method whereby
deferred tax asset and liability account balances are determined based on differences between financial reporting and tax bases of assets
and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company provides a valuation allowance,
if necessary, to reduce deferred tax assets to their estimated realizable value. As of December 31, 2021, and 2020, a full valuation allowance
was provided by the Company.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;ASC 740 contains a two-step approach
to recognizing and measuring a liability for uncertain tax positions. The first step is to evaluate the tax position taken or expected
to be taken in a tax return by determining if the weight of available evidence indicates that it is more likely than not that, on an evaluation
of the technical merits, the tax position will be sustained on audit, including resolution of any related appeals or litigation processes.
The second step is to measure the tax benefit as the largest amount that is more than 50% likely to be realized upon ultimate settlement.
As of December 31, 2021, and 2020, no liability for unrecognized tax benefits was recorded.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <canf:PercentageOfRealizationOnUltimateSettlement contextRef="c0" decimals="2" unitRef="pure">0.50</canf:PercentageOfRealizationOnUltimateSettlement>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;r.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Ordinary share warrants classification and measurement:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#x2019;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;s.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Basic and diluted net loss per share&lt;span style="text-transform: uppercase"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Basic and diluted net loss per share
is calculated based on the weighted average number of ordinary shares outstanding during each year. Diluted net loss per share is calculated
based on the weighted average number of ordinary shares outstanding during each year, plus dilutive potential in accordance with ASC 260,
&#x201c;Earnings per Share&#x201d;.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;All outstanding share options and warrants
for the years ended December 31, 2021, 2020 and 2019 have been excluded from the calculation of the diluted net loss per share, because
all such securities are anti-dilutive for all periods presented.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;To compute diluted loss per share for the years ended December 31,
2021, December 31, 2020 and December 31, 2019, the total number of 18,422,700, 11,923,400 and 2,673,400 shares, respectively subject to
outstanding unlisted options have not been considered since they have anti-dilutive effect.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <canf:OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock contextRef="c0">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;r.&lt;/span&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Ordinary share warrants classification and measurement:&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&#160;&#160; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant&#x2019;s specific terms and applicable authoritative guidance. The assessment considers whether the warrants are freestanding financial instruments, meet the definition of a liability under ASC 480, are indexed to the Company&#x2019;s own stock and whether the warrants are eligible for equity classification under ASC 815-40. This assessment is conducted at the time of warrant issuance and as of each subsequent reporting period end date while the warrants are outstanding.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt; &lt;p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Warrants that meet all the criteria for equity classification, are required to be recorded as a component of additional paid-in capital. Warrants that do not meet all the criteria for equity classification, are required to be recorded as liabilities at their initial fair value on the date of issuance and remeasured to fair value through earnings at each balance sheet date thereafter.&lt;/p&gt;</canf:OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c0" decimals="0" unitRef="shares">18422700</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c4" decimals="0" unitRef="shares">11923400</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c5" decimals="0" unitRef="shares">2673400</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 47px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;t.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Recently adopted and recently issued accounting pronouncements&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments &#x2013;
Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which replaces the existing incurred loss impairment
model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected
to be collected. The adoption of the standard did not have material effect on Company&#x2019;s results.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 47px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic
740): Simplifying the Accounting for Income Taxes, which simplifies the accounting for income taxes by removing a variety of exceptions
within the framework of ASC 740. These exceptions include the exception to the incremental approach for intra period tax allocation in
the event of a loss from continuing operations and income or a gain from other items (such as other comprehensive income), and the exception
to using general methodology for the interim period tax accounting for year-to-date losses that exceed anticipated losses. The adoption
of the standard did not have material effect on Company&#x2019;s results.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;u.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounting pronouncements not yet adopted:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provides guidance to clarify and reduce diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. As a result, the Company will not be required to adopt ASU 2021-04 until January 1, 2022. The Company is currently evaluating the impact of the adoption of this principle on the Company&#x2019;s unaudited consolidated financial statements.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <canf:AccountingPronouncementsNotYetAdoptedPolicyTextBlock contextRef="c0">&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;u.&lt;/span&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Accounting pronouncements not yet adopted:&lt;/span&gt;&#160;&#160;&#160;&#160;&#160; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. The amendments in ASU No. 2021-04 provides guidance to clarify and reduce diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. The amendments in this ASU No. 2021-04 are effective for all entities for fiscal years beginning after December 15, 2021, and interim periods within those fiscal years, with early adoption permitted, including interim periods within those fiscal years. As a result, the Company will not be required to adopt ASU 2021-04 until January 1, 2022. The Company is currently evaluating the impact of the adoption of this principle on the Company&#x2019;s unaudited consolidated financial statements.&lt;/p&gt;</canf:AccountingPronouncementsNotYetAdoptedPolicyTextBlock>
    <canf:OtherAccountsReceivableAndPrepaidExpensesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 3:-&#160;OTHER ACCOUNTS RECEIVABLE AND
PREPAID EXPENSES&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Government authorities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Prepaid expenses and others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;881&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;1,039&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;929&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,057&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</canf:OtherAccountsReceivableAndPrepaidExpensesTextBlock>
    <canf:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Government authorities&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;48&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Prepaid expenses and others&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;881&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;1,039&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;929&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;1,057&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</canf:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock>
    <canf:GovernmentAuthorities contextRef="c2" decimals="-3" unitRef="usd">48000</canf:GovernmentAuthorities>
    <canf:GovernmentAuthorities contextRef="c3" decimals="-3" unitRef="usd">18000</canf:GovernmentAuthorities>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c2" decimals="-3" unitRef="usd">881000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:PrepaidExpenseAndOtherAssets contextRef="c3" decimals="-3" unitRef="usd">1039000</us-gaap:PrepaidExpenseAndOtherAssets>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c2" decimals="-3" unitRef="usd">929000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c3" decimals="-3" unitRef="usd">1057000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:InvestmentTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 4:-&#160;SHORT-TERM INVESTMENT&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company holds 356,803 shares of
Mawson Infrastructure Group Inc. (formerly Wize Pharma Inc.) as of December 31, 2021 and December 31, 2020, which as of such dates represents
less than 5 percent of Mawson Infrastructure Group Inc.&#x2019;s outstanding shares, respectively. The investments in marketable equity
securities are measured at fair value with the related gains and losses, including unrealized, recognized in finance income (expenses),
net.&lt;/p&gt;</us-gaap:InvestmentTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c0" decimals="0" unitRef="shares">356803</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c4" decimals="0" unitRef="shares">356803</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <canf:PercentageOfOutstandingShares contextRef="c0" decimals="2" unitRef="pure">0.05</canf:PercentageOfOutstandingShares>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 5:-&#160;PROPERTY, PLANT AND EQUIPMENT,
NET &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"&gt;Composition of assets, grouped by major classification,
is as follows:&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;62&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;57&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;281&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;270&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;190&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;234&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;50&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;Depreciation expenses for the year ended December 31, 2021, 2020 and
2019 amounted to $14, $12 and $14, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Cost:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;62&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;57&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;206&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;200&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;13&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;281&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;270&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Accumulated depreciation:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Laboratory equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;28&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Computers, office furniture and equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;190&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;184&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;9&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;8&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;234&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;220&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Property and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;47&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;50&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c48" decimals="-3" unitRef="usd">62000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c49" decimals="-3" unitRef="usd">57000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c50" decimals="-3" unitRef="usd">206000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c51" decimals="-3" unitRef="usd">200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c52" decimals="-3" unitRef="usd">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c53" decimals="-3" unitRef="usd">13000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c2" decimals="-3" unitRef="usd">281000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c3" decimals="-3" unitRef="usd">270000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c48" decimals="-3" unitRef="usd">35000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c49" decimals="-3" unitRef="usd">28000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c50" decimals="-3" unitRef="usd">190000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c51" decimals="-3" unitRef="usd">184000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c52" decimals="-3" unitRef="usd">9000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c53" decimals="-3" unitRef="usd">8000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c2" decimals="-3" unitRef="usd">234000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c3" decimals="-3" unitRef="usd">220000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c2" decimals="-3" unitRef="usd">47000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c3" decimals="-3" unitRef="usd">50000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationExpenseOnReclassifiedAssets contextRef="c5" decimals="0" unitRef="usd">14</us-gaap:DepreciationExpenseOnReclassifiedAssets>
    <us-gaap:DepreciationExpenseOnReclassifiedAssets contextRef="c4" decimals="0" unitRef="usd">12</us-gaap:DepreciationExpenseOnReclassifiedAssets>
    <us-gaap:DepreciationExpenseOnReclassifiedAssets contextRef="c0" decimals="0" unitRef="usd">14</us-gaap:DepreciationExpenseOnReclassifiedAssets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 6:-&lt;/b&gt;&#160;&lt;b&gt;OTHER ACCOUNTS PAYABLE&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Employees and payroll accruals&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;603&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;302&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;235&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;905&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;331&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Employees and payroll accruals&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;603&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;96&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Accrued expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;302&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;235&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;905&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;331&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <canf:EmployeesAndPayrollAccruals contextRef="c2" decimals="0" unitRef="usd">603</canf:EmployeesAndPayrollAccruals>
    <canf:EmployeesAndPayrollAccruals contextRef="c3" decimals="0" unitRef="usd">96</canf:EmployeesAndPayrollAccruals>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c2" decimals="0" unitRef="usd">302</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent contextRef="c3" decimals="0" unitRef="usd">235</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="c2" decimals="0" unitRef="usd">905</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="c3" decimals="0" unitRef="usd">331</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 7:- FAIR VALUE MEASUREMENTS &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;In accordance with ASC 820 &#x201c;Fair
Value Measurements and Disclosures&#x201d;, the Company measures its short-term investment at fair value. Short-term investments are classified
within Level 1 as the valuation inputs are valuations based on quoted prices in active markets for identical assets.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company&#x2019;s financial assets
and liabilities measured at fair value on a recurring basis, consisted of the following types of instruments as of the following dates:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value measurements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; width: 52%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short-term investment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;237&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;237&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-52"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Fair value measurements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 52%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short-term investment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Fair value measurements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; width: 52%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short-term investment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;237&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;237&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-52"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-53"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Fair value measurements&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Description&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Fair value&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 1&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 2&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Level 3&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="width: 52%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; width: 9%"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left; width: 1%"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Short-term investment&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;75&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-54"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-55"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:ShortTermInvestments contextRef="c54" decimals="-3" unitRef="usd">237000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c55" decimals="-3" unitRef="usd">237000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c58" decimals="-3" unitRef="usd">75000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments contextRef="c59" decimals="-3" unitRef="usd">75000</us-gaap:ShortTermInvestments>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 8:-&#160;CONTINGENT LIABILITIES AND COMMITMENTS
&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px; padding-right: 0.9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a. &lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Liabilities to pay royalties:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;According to the patent license agreement that the Company entered into with Leiden University in the Netherlands on November 2, 2009, which is affiliated with the National Institutes of Health (NIH), the Company was granted an exclusive license for the use of the patents of several compounds, including CF602 in certain territories.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company is committed to pay royalties
as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;A one-time concession commission of &#x20ac;25 thousand;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Annual royalties of &#x20ac;10 thousand until the clinical trials commence;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2%-3% of net sales (as defined in the agreement) received by the Company;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Royalties in a total amount of up to &#x20ac;850 thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) &#x20ac;50 thousand upon initiation of Phase I studies; (ii) &#x20ac;100 thousand upon initiation of Phase II studies; (iii) &#x20ac;200 thousand upon initiation of Phase III studies; and (iv) &#x20ac;500 thousand upon marketing approval by any regulatory authority.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5)&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;If the agreement is sublicensed to another company, the Company will provide Leiden University royalties at a rate of 10%. A merger, consolidation or any other change in ownership will not be viewed as an assignment of the agreement as discussed in this paragraph.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.25in"&gt;As of December
31 2021, no accrual has been recorded with respect to Leiden University.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px; padding-right: 0.9pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Commitments and license agreements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In March 2015, the Company signed a distribution agreement with Cipher Pharmaceuticals (&#x201c;Cipher&#x201d;). As part of the distribution agreement, Cipher will distribute Can-Fite&#x2019;s lead drug candidate, Piclidenoson for the treatment of psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Under the terms of the agreement, Cipher
made an upfront payment of USD 1,292 (CAD 1,650 thousand) to the Company in March 2015. In addition, the agreement provides that additional
payments of up to CAD 2,000 thousand will be received by the Company upon the achievement of certain milestones plus royalty payments
of 16.5% of net sales of Piclidenoson in Canada.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities. In addition, the Company agreed to form
a joint steering committee with Cipher which will oversee the progress of the clinical studies.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In October 2016, the Company signed a distribution agreement with Chong Kun Dang Pharmaceuticals Corp. (&#x201c;CKD&#x201d;) for future sales in South Korea. As part of the distribution agreement, CKD will distribute Namodenoson for the treatment of liver cancer in the South Korean market upon receipt of regulatory approvals.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Under the terms of the agreement, CKD
made an upfront payment of USD 500 to the Company in December 2016 and in August 2017, the Company received a second milestone payment
in the amount of USD 500 from CKD, which has licensed the exclusive right to distribute Namodenoson for the treatment of liver cancer
in Korea upon receipt of regulatory approvals.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;In addition, the agreement provides that
additional payments of up to USD 2,500 will be received by the Company upon the achievement of certain milestones.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;On February 25, 2019, the Company&#x2019;s
Distribution Agreement with CKD was amended to expand the exclusive right to distribute Namodenoson for the treatment of NASH in addition
to liver cancer in South Korea. CKD has agreed to pay the Company up to an additional USD 6,000 in upfront and milestone payments payable
with respect to the NASH indication. The Company will also be entitled to a transfer price for delivering finished product to CKD following
commercial launch. In April 2019, the Company received an upfront payment of USD 1,000.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 22, 2008, the Company signed an agreement
    regarding the provision of a license for Piclodenoson with a South Korean pharmaceutical company, Kwang Dong Pharmaceutical Co. Ltd. (&#x201c;KD&#x201d;).
    According to the license agreement, the Company granted the KD a license to use, develop and market its Piclodenoson for treating only
    rheumatoid arthritis only in the Republic of Korea.&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;As of December 31, 2021, the Company estimates
that such contingent payments are remote.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On January 8, 2018, the Company entered into a Distribution and Supply Agreement with Gebro Holding GmBH (&#x201c;Gebro&#x201d;), granting Gebro the exclusive right to distribute Piclidenoson in Spain, Switzerland, Liechtenstein and Austria for the treatment of psoriasis and rheumatoid arthritis.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;Under the Distribution and Supply Agreement,
the Company is entitled to &#x20ac;1,500 thousand upon execution of the agreement plus milestone payments upon achieving certain clinical,
launch and sales milestones, as follows: (i) &#x20ac;300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment
of rheumatoid arthritis and &#x20ac;300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis,
(ii) between &#x20ac;750 thousand and &#x20ac;1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either
the treatment of rheumatoid arthritis or psoriasis, and (iii) between &#x20ac;300 thousand and up to &#x20ac;4,025 thousand upon meeting certain
net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson
in the territories and payment for the manufacturing Piclidenoson.&#160;On January 25, 2018 the Company received a first payment of approximately
USD 2,200 from Gebro and in August 2018 received approximately USD 350 upon reaching the first milestone.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify"&gt;The Company estimates these services will
spread over a period ending December 2026. Component (iv) was not accounted as part of the research and development services and will
be recognized entirely upon the Company reaching sales stage.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On August 6, 2018, the Company entered into a License, Collaboration and Distribution Agreement with CMS Medical Venture Investment Limited (&#x201c;CMS Medical&#x201d;) for the commercialization of Piclidenoson for the treatment of rheumatoid arthritis and psoriasis and Namodenoson for the treatment of advanced liver cancer and NAFLD/NASH in China (including Hong Kong, Macao and Taiwan). Under the License, Collaboration and Distribution Agreement, the Company received USD 2,000 upon execution of the agreement and is entitled to additional milestone payments upon achieving certain regulatory and sales milestones. In addition, following regulatory approval, the Company shall be entitled to future double digit royalties on net sales in the territories and payment for the manufacturing of Piclidenoson and Namodenoson.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/&gt;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On July 31, 2019, the Company signed a distribution agreement with Kyongbo Pharm Co., Ltd. (&#x201c;Kyongbo Pharm&#x201d;), to distribute Piclidenoson, for the treatment of psoriasis in South Korea, upon receipt of regulatory approvals. Under the terms of the distribution agreement, Kyongbo Pharm, in exchange for exclusive distribution rights to sell Piclidenoson in the treatment of psoriasis in South Korea, is required to make a total upfront payment of USD 750 to the Company, with additional payments of up to USD 3,250 upon achievement of certain milestones. The Company will also be entitled to a transfer price for delivering finished product to Kyongbo Pharm upon commercial launch. In August 2019, the Company received the upfront payment of USD 750 from Kyongbo Pharm.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On March 16, 2021, the Company announced it signed an exclusive distribution agreement with Switzerland-based Ewopharma for Piclidenoson in the treatment of psoriasis and Namodenoson in the treatment of liver diseases namely, hepatocellular carcinoma (HCC) the most common form of liver cancer and non-alcoholic steatohepatitis (NASH). Under the terms of the distribution agreement, Ewopharma paid Can-Fite non-refundable upfront payment in an amount of $2,250 and is entitled to up to an additional $40,450 payable upon the achievement of regulatory and sales milestones and 17.5% royalties on net sales. In exchange, Ewopharma will have the exclusive right to market and sell Piclidenoson in Central Eastern European (CEE) countries and Namodenoson in CEE countries and Switzerland. Ewopharma has the right to extend the distribution agreement to new indications that Can-Fite may identify for its drug candidates.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On June 28, 2021, the Company announced it signed a development and commercialization agreement with Vetbiolix, a France-based veterinary biotech company, for the development of Piclidenoson for the treatment of osteoarthritis in companion animals including dogs and cats. According to the agreement, the Company will grant Vetbiolix an exclusive option to purchase its license of Piclidenoson in the veterinary osteoarthritis market for two years from the signature date, during which time Vetbiolix will conduct proof-of-concept studies and cover all associated costs. If the studies yield positive data and Vetbiolix exercises its option to obtain the license from Can-Fite, then Vetbiolix will be obligated to pay Can-Fite a non-refundable upfront payment in an amount of Euro 250 thousand, additional milestones payment equal to 30% upon each upfront payment received from sublicensee and 15%-40% royalties on net sales upon regulatory approval for veterinary use.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:NoninterestExpenseCommissionExpense contextRef="c0" decimals="-3" unitRef="eur">25000</us-gaap:NoninterestExpenseCommissionExpense>
    <us-gaap:RoyaltyExpense contextRef="c0" decimals="-3" unitRef="eur">10000</us-gaap:RoyaltyExpense>
    <canf:PercentageOfNetSales contextRef="c62" decimals="2" unitRef="pure">0.02</canf:PercentageOfNetSales>
    <canf:PercentageOfNetSales contextRef="c63" decimals="2" unitRef="pure">0.03</canf:PercentageOfNetSales>
    <canf:PatentAgreementDescription contextRef="c0">4)Royalties in a total amount of up to &#x20ac;850 thousand based on certain progress milestones in the license stages of the products, which are the subject of the patent under the agreement, as follows: (i) &#x20ac;50 thousand upon initiation of Phase I studies; (ii) &#x20ac;100 thousand upon initiation of Phase II studies; (iii) &#x20ac;200 thousand upon initiation of Phase III studies; and (iv) &#x20ac;500 thousand upon marketing approval by any regulatory authority.  &#160; 5) If the agreement is sublicensed to another company, the Company will provide Leiden University royalties at a rate of 10%. A merger, consolidation or any other change in ownership will not be viewed as an assignment of the agreement as discussed in this paragraph. &#160;As of December
31 2021, no accrual has been recorded with respect to Leiden University.&#160;

    &#160;
    b.
    Commitments and license agreements:
  &#160;

    &#160;
    1.
    In March 2015, the Company signed a distribution agreement with Cipher Pharmaceuticals (&#x201c;Cipher&#x201d;). As part of the distribution agreement, Cipher will distribute Can-Fite&#x2019;s lead drug candidate, Piclidenoson for the treatment of psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.
  &#160;Under the terms of the agreement, Cipher
made an upfront payment of USD 1,292 (CAD 1,650 thousand) to the Company in March 2015. In addition, the agreement provides that additional
payments of up to CAD 2,000 thousand will be received by the Company upon the achievement of certain milestones plus royalty payments
of 16.5% of net sales of Piclidenoson in Canada.&#160;Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities. In addition, the Company agreed to form
a joint steering committee with Cipher which will oversee the progress of the clinical studies.&#160;

    &#160;
    2.
    In October 2016, the Company signed a distribution agreement with Chong Kun Dang Pharmaceuticals Corp. (&#x201c;CKD&#x201d;) for future sales in South Korea. As part of the distribution agreement, CKD will distribute Namodenoson for the treatment of liver cancer in the South Korean market upon receipt of regulatory approvals.
  &#160;Under the terms of the agreement, CKD
made an upfront payment of USD 500 to the Company in December 2016 and in August 2017, the Company received a second milestone payment
in the amount of USD 500 from CKD, which has licensed the exclusive right to distribute Namodenoson for the treatment of liver cancer
in Korea upon receipt of regulatory approvals.&#160;In addition, the agreement provides that
additional payments of up to USD 2,500 will be received by the Company upon the achievement of certain milestones.&#160;Under the agreement, the Company shall
be responsible for conducting product development activities including management of the clinical studies required in order to secure
regulatory approvals and shall use commercially reasonable efforts in conducting such activities.&#160;On February 25, 2019, the Company&#x2019;s
Distribution Agreement with CKD was amended to expand the exclusive right to distribute Namodenoson for the treatment of NASH in addition
to liver cancer in South Korea. CKD has agreed to pay the Company up to an additional USD 6,000 in upfront and milestone payments payable
with respect to the NASH indication. The Company will also be entitled to a transfer price for delivering finished product to CKD following
commercial launch. In April 2019, the Company received an upfront payment of USD 1,000.&#160;

    &#160;
    3.

    On December 22, 2008, the Company signed an agreement
    regarding the provision of a license for Piclodenoson with a South Korean pharmaceutical company, Kwang Dong Pharmaceutical Co. Ltd. (&#x201c;KD&#x201d;).
    According to the license agreement, the Company granted the KD a license to use, develop and market its Piclodenoson for treating only
    rheumatoid arthritis only in the Republic of Korea.
    &#160;
  &#160;As of December 31, 2021, the Company estimates
that such contingent payments are remote.&#160;&#160;4.</canf:PatentAgreementDescription>
    <us-gaap:AdvanceRoyalties contextRef="c2" decimals="-3" unitRef="eur">850000</us-gaap:AdvanceRoyalties>
    <canf:RoyaltyPaymentsPercentage contextRef="c0" decimals="2" unitRef="pure">0.10</canf:RoyaltyPaymentsPercentage>
    <canf:UnfrontPaymentAmount contextRef="c64" decimals="-3" unitRef="usd">1292000</canf:UnfrontPaymentAmount>
    <canf:UnfrontPaymentAmount contextRef="c64" decimals="-3" unitRef="cad">1650000</canf:UnfrontPaymentAmount>
    <canf:AdditionalPayments contextRef="c64" decimals="-3" unitRef="usd">2000000</canf:AdditionalPayments>
    <canf:RoyaltyPaymentsPercentage contextRef="c64" decimals="3" unitRef="pure">0.165</canf:RoyaltyPaymentsPercentage>
    <canf:UnfrontPaymentAmount contextRef="c65" decimals="-3" unitRef="usd">500000</canf:UnfrontPaymentAmount>
    <canf:UnfrontPaymentAmount contextRef="c66" decimals="-3" unitRef="usd">500000</canf:UnfrontPaymentAmount>
    <canf:AdditionalPayments contextRef="c67" decimals="-3" unitRef="usd">2500000</canf:AdditionalPayments>
    <canf:UnfrontPaymentAmount contextRef="c68" decimals="-3" unitRef="usd">6000000</canf:UnfrontPaymentAmount>
    <canf:UnfrontPaymentAmount contextRef="c69" decimals="-3" unitRef="usd">1000000</canf:UnfrontPaymentAmount>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription contextRef="c70">the Company is entitled to &#x20ac;1,500 thousand upon execution of the agreement plus milestone payments upon achieving certain clinical,
launch and sales milestones, as follows: (i) &#x20ac;300 thousand upon initiation of the ACRobat Phase III clinical trial for the treatment
of rheumatoid arthritis and &#x20ac;300 thousand upon the initiation of the COMFORT Phase III clinical trial for the treatment of psoriasis,
(ii) between &#x20ac;750 thousand and &#x20ac;1,600 thousand following first delivery of commercial launch quantities of Piclidenson for either
the treatment of rheumatoid arthritis or psoriasis, and (iii) between &#x20ac;300 thousand and up to &#x20ac;4,025 thousand upon meeting certain
net sales. In addition, following regulatory approval, the Company shall be entitled to future royalties on net sales of Piclidenoson
in the territories and payment for the manufacturing Piclidenoson.&#160;On January 25, 2018 the Company received a first payment of approximately
USD 2,200 from Gebro and in August 2018 received approximately USD 350 upon reaching the first milestone.</us-gaap:BusinessCombinationContingentConsiderationArrangementsDescription>
    <canf:UnfrontPaymentAmount contextRef="c71" decimals="-3" unitRef="usd">2000000</canf:UnfrontPaymentAmount>
    <canf:UnfrontPaymentAmount contextRef="c72" decimals="-3" unitRef="usd">750000</canf:UnfrontPaymentAmount>
    <canf:AdditionalPayments contextRef="c72" decimals="-3" unitRef="usd">3250000</canf:AdditionalPayments>
    <canf:UnfrontPaymentAmount contextRef="c73" decimals="-3" unitRef="usd">750000</canf:UnfrontPaymentAmount>
    <canf:UnfrontPaymentAmount contextRef="c74" decimals="-3" unitRef="usd">2250000</canf:UnfrontPaymentAmount>
    <us-gaap:RetentionPayable contextRef="c75" decimals="-3" unitRef="usd">40450000</us-gaap:RetentionPayable>
    <canf:RoyaltyOnNetSales contextRef="c74" decimals="3" unitRef="pure">0.175</canf:RoyaltyOnNetSales>
    <canf:NonRefundableUpfrontPayment contextRef="c76" decimals="-3" unitRef="eur">250000</canf:NonRefundableUpfrontPayment>
    <canf:RoyaltyPaymentsPercentage contextRef="c76" decimals="2" unitRef="pure">0.30</canf:RoyaltyPaymentsPercentage>
    <canf:RoyaltyPaymentsPercentage contextRef="c77" decimals="2" unitRef="pure">0.15</canf:RoyaltyPaymentsPercentage>
    <canf:RoyaltyPaymentsPercentage contextRef="c78" decimals="2" unitRef="pure">0.40</canf:RoyaltyPaymentsPercentage>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 9:-&#160;SHAREHOLDERS&#x2019; EQUITY &lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On May 10, 2019, the Company effected a change in the ratio of the Company&#x2019;s ADS to ordinary shares from one (1) ADS representing two (2) ordinary shares to a new ratio of one (1) ADS representing thirty (30) ordinary shares. For ADS holders, the ratio change had the same effect as a one-for-fifteen reverse ADS split. All ADS and per ADS data in the financial statements and their related notes have been retroactively adjusted for all periods presented to reflect the ratio change.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;All ordinary shares have equal rights
for all intent and purposes and each ordinary share confers its holder:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The right to be invited and participate in all the Company&#x2019;s general meetings, both annual and regular, and the right to one vote per ordinary share owned in all votes and in all Company&#x2019;s general meeting participated.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The right to receive dividends if and when declared and the right to receive bonus shares if and when distributed.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The right to participate in the distribution of the Company&#x2019;s assets upon liquidation.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Issue of shares and warrants and changes in equity:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On January 18, 2019, the Company completed a registered direct offering with an institutional investor, pursuant to which it sold an aggregate 149,206 ADSs representing 4,476,192 ordinary shares. In addition, in a concurrent private placement, the Company issued to the investor unregistered warrants to purchase 149,206 ADSs representing 4,476,192 ordinary shares for an aggregate purchase price of USD 2,350 (excluding issuance cost of USD 428). The warrants have an exercise price of USD 19.50 per ADS, are immediately exercisable and expire five and one-half years from the issuance date. The Company also issued unregistered placement agent warrants to purchase an aggregate of 7,460 ADSs representing 223,810 ordinary shares on the same terms as the warrants except they have a term of five years.&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On April 4, 2019, the Company completed a registered direct offering with certain institutional investors, pursuant to which it sold an aggregate 328,205 ADSs representing 9,846,156 ordinary shares. In addition, in a concurrent private placement, the Company issued to the investor unregistered warrants to purchase 328,205 ADSs representing 9,846,156 ordinary shares for an aggregate purchase price of USD 3,200 (excluding issuance cost of USD 414). The warrants have an exercise price of USD 12.90 per ADS, are immediately exercisable and expire five years from the issuance date. The Company also issued unregistered placement agent warrants to purchase an aggregate of 16,410 ADSs representing 492,308 ordinary shares on the same terms as the warrants except they have a term of five years.&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;3.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On May 22, 2019, the Company completed a registered direct offering with certain institutional investors, pursuant to which it sold an aggregate 1,500,000 ADSs representing 45,000,000 ordinary shares. In addition, in a concurrent private placement, the Company issued to the investor unregistered warrants to purchase 1,500,000 ADSs representing 45,000,000 ordinary shares for an aggregate purchase price of USD 6,000 (excluding issuance cost of USD 540). The warrants have an exercise price of USD 4.00 per ADS, are immediately exercisable and expire five and one-half years from the issuance date. The Company also issued unregistered placement agent warrants to purchase an aggregate of 75,000 ADSs representing 2,250,000 ordinary shares on the same terms as the warrants except they have a term of five years.&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In September 2019, the Company issued 19,934,355 of its ordinary shares in connection with the Univo collaboration agreement&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;5.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In December 2019, the Company issued 996,690 of its ordinary shares to a consultant in exchange for his services in connection with the Univo collaboration agreement.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;6.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On January 9, 2020, the Company entered into warrant exercise agreements (the &#x201c;Exercise Agreements&#x201d;) with several accredited investors who are the holders of certain warrants (the &#x201c;Public Warrants&#x201d;) to purchase the Company&#x2019;s ordinary shares, represented by ADSs, pursuant to which the Holders exercised in cash their Public Warrants to purchase up to an aggregate of 22,278,540 ordinary shares represented by 742,618 ADSs having exercise prices ranging from USD 12.90 to USD 78.75 per ADS issued by the Company, at a reduced exercise price of USD 3.25 per ADS, for gross proceeds to the Company of approximately USD 2,400, prior to deducting placement agent fees and estimated offering expenses.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under the Exercise Agreements, the Company issued to the warrant holders new unregistered warrants to purchase up to 22,278,540 ordinary shares represented by 742,618 ADSs (the &#x201c;Private Placement Warrants&#x201d;). The Private Placement Warrants are immediately exercisable, expire five and one-half years from issuance date and have an exercise price of USD 3.45 per ADS, subject to adjustment as set forth therein. The Private Placement Warrants may be exercised on a cashless basis if six months after issuance there is no effective registration statement registering the ADSs underlying the warrants.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;Pursuant to the terms of the Exercise Agreements, the warrant holders agreed to exercise the warrants at a reduced exercise price, thereby creating a benefit to these warrant holders. As such, the Company recorded a deemed dividend in the amount of $715.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;7.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On February 12, 2020, the Company completed a public offering with certain institutional investors pursuant to which the Company issued and sold (i) 1,825,000 units, each unit consisting of one ADS, and one warrant to purchase one ADS, at a price of USD 1.50 per unit, and (ii) 1,508,334 pre-funded units each pre-funded unit consisting of one pre-funded warrant to purchase one ADS and one warrant, at a price of USD 1.49 per pre-funded unit.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The gross proceeds from the offering were approximately USD 5,000, prior to deducting the placement agent&#x2019;s fees and estimated offering expenses payable by the Company.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;The placement agent in the offering also received compensation warrants exercisable for up to 250,000 ADSs at an exercise price of USD 1.875 per ADS expiring on February 10, 2025.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;8.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On March 9, 2020, as a result of an exercise of warrants by the investors from the February 2020 offering, the Company issued an aggregate of 20,250,000 ordinary shares represented by 675,000 ADSs, at a price of $1.50 per ADS for gross proceeds of $1,012.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;On April 28, 2020, a special meeting of shareholders of the Company approved to increase Company&#x2019;s authorized share capital to 1,000,000,000 ordinary shares of 0.25 NIS par value each.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;10.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In April and May, 2020, as a result of an exercise of warrants by the investors from the February 2020 offering, the Company issued an aggregate of 31,000,020 ordinary shares represented by 1,033,334 ADSs, at a price of $1.50 per ADS for gross proceeds of $1,550.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;11.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On June 12, 2020, the Company completed a registered direct offering with certain institutional and accredited investors pursuant to which it sold an aggregate of 3,902,440 ADSs at a purchase price of $2.05 per ADS for aggregate gross proceeds of approximately $8,000 prior to deducting the placement agent&#x2019;s fees and estimated offering expenses payable by the Company.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In addition, in a concurrent private placement the investors received unregistered warrants to purchase up to an aggregate of 1,951,220 ADSs. The warrants were immediately exercisable and will expire four and a half years from issuance at an exercise price of $2.50 per ADS, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying the warrants.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The placement agent in the offering also received compensation warrants on substantially the same terms as the investors in the offering in an amount equal to 7.5% of the aggregate number of ADSs sold in the offering (or warrants to purchase up to an aggregate of 292,683 ADSs), at an exercise price of $2.50 per ADSs and a term expiring four and a half years from the date of issuance.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;12.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On July 8, 2020, the Company completed a registered direct offering with certain institutional and accredited investors pursuant to which it sold an aggregate of 1,705,000 ADSs at a purchase price of $2.00 per ADS for aggregate gross proceeds of approximately $3,400 prior to deducting the placement agent&#x2019;s fees and estimated offering expenses payable by the Company.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;In addition, in a concurrent private placement, the investors received unregistered warrants to purchase up to an aggregate of 852,750 ADSs. The warrants were immediately exercisable and will expire four and a half years from issuance at an exercise price of $2.50 per ADS, subject to adjustment as set forth therein. The warrants may be exercised on a cashless basis if there is no effective registration statement registering the ADSs underlying the warrants.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The placement agent in the offering also received compensation warrants on substantially the same terms as the investors in the offering in an amount equal to 7.5% of the aggregate number of ADSs sold in the offering (or warrants to purchase up to an aggregate of 127,913 ADSs), at an exercise price of $2.50 per ADSs and a term expiring.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;&lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In December 2020, the Company issued 1,350,000 of its ordinary shares to a consultant in exchange for his services.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;14.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In February and March 2021, the Company issued 50,926,830 ordinary shares represented by 1,697,561 ADSs in exchange for exercise of warrants. Total consideration received by the Company was $2,744.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;15.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;In March 2021, the Company issued 1,050,000 of its ordinary shares represented by 35,000 ADSs to certain consultants in exchange for their services with fair value of $ 68.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 72px; font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px; font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;16.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On August 16, 2021, the Company completed a registered direct offering with an institutional investor pursuant to which it sold (i) 57,000,000 ordinary shares represented by 1,900,000 ADSs, and (ii) a pre-funded warrant to purchase 93,000,000 ordinary shares represented by 3,100,000 ADSs at an offering price of $2.00 per ADS and $1.999 per pre-funded warrant, for aggregate gross proceeds of approximately $10,000 (without taking into account any proceeds from any future exercises of warrants issued in the concurrent private placement), before deducting the placement agent&#x2019;s fees and other estimated offering expenses payable by the Company.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;The Company has also sold to the investor, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 5,000,000 ADSs. The warrants have an exercise price of $ 2.00 per ADS and are exercisable at any time upon issuance and will expire three years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;As of the financial statements date, the Company received a total of $ 9,997 and issued 57,000,000 ordinary shares represented by 1,900,000 ADSs and 93,000,000 ordinary shares represented by 3,100,000 ADSs following the exercise of the pre-funded warrants (issuance expenses were $1,307).&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: justify; font-size: 10pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="font-size: 10pt"&gt;&#160;&lt;/td&gt; &lt;td style="font-size: 10pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;17.&lt;/span&gt;&lt;/td&gt; &lt;td&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;On December 20, 2021, the Company entered into a warrant exercise agreement (the &#x201c;Exercise Agreement&#x201d;) with an institutional investor who is the holder of certain existing warrants to purchase Company&#x2019;s ordinary shares, par value NIS 0.25 per share, represented by ADSs issued by the Company in a registered direct offering consummated in August 2021. Pursuant to the Exercise Agreement, the holder agreed to exercise in cash its warrants to purchase up to an aggregate of 150,000,000 Ordinary Shares represented by 5,000,000 ADSs having an exercise price of $2.00 per ADS, at an exercise price of $2.00 per ADS, for gross proceeds to the Company of $10 million, prior to deducting placement agent fees and offering expenses (which amounted to $0.98 million).&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Under the Exercise Agreement, the Company also agreed to issue to the holder new unregistered warrants to purchase up to 180,000,000 Ordinary Shares represented by 6,000,000 ADSs (the &#x201c;Private Placement Warrants&#x201d;). The Private Placement Warrants will be immediately exercisable, will expire five years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants, and have an exercise price of $2.00 per ADS.&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;Pursuant to the terms of the Exercise Agreements, the holder agreed to exercise the warrants while receiving a-120% warrants coverage, thereby creating a benefit to this warrant holder. As such, the Company recorded a deemed dividend in the amount of $ 2,590.&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 72px"/&gt;&lt;td style="width: 24px"&gt;c.&lt;/td&gt;&lt;td style="text-align: justify"&gt;Warrants to Purchase Common stock:&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
                                                                                                                                            &lt;tr style="vertical-align: top"&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="text-align: justify"&gt;The following table
summarizes information regarding outstanding warrants to purchase shares of the Company&#x2019;s ADS&#x2019;s issued as of December 31,
2021:&lt;/td&gt;&lt;/tr&gt;
                                                                                                                                            &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 78pt; text-align: justify; text-indent: 0in"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;Issuance date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of &lt;br/&gt; outstanding &lt;br/&gt; warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Exercise&lt;br/&gt; price per&lt;br/&gt; warrant&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;($)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;January 2017&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;91,667&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;33.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;March 2018&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,111&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;January 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,460&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;April 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,410&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;May 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,575,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;January 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;794,601&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;February 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;375,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;June 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,046,342&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;July 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;980,663&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;August 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;350,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;December 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,350,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,598,254&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <canf:StockholdersEquityChangeInRatioDescription contextRef="c79">(1) ADS representing two (2) ordinary shares to a new ratio of one (1) ADS representing thirty (30) ordinary shares. For ADS holders, the ratio change had the same effect as a one-for-fifteen reverse ADS split. All ADS and per ADS data in the financial statements and their related notes have been retroactively adjusted for all periods presented to reflect the ratio change.</canf:StockholdersEquityChangeInRatioDescription>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c80" decimals="0" unitRef="shares">149206</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c81" decimals="0" unitRef="shares">4476192</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <canf:WarrantsToPurchaseAdditionalSharesIssued contextRef="c80" decimals="0" unitRef="shares">149206</canf:WarrantsToPurchaseAdditionalSharesIssued>
    <canf:WarrantsToPurchaseAdditionalSharesIssued contextRef="c81" decimals="0" unitRef="shares">4476192</canf:WarrantsToPurchaseAdditionalSharesIssued>
    <canf:AggregatePurchasePrice contextRef="c82" decimals="-3" unitRef="usd">2350000</canf:AggregatePurchasePrice>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c82" decimals="-3" unitRef="usd">428000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c83" decimals="2" unitRef="usdPershares">19.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c83" decimals="0" unitRef="shares">7460</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssued contextRef="c84" decimals="0" unitRef="shares">223810</us-gaap:SharesIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c85" decimals="0" unitRef="shares">328205</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c86" decimals="0" unitRef="shares">9846156</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c87" decimals="0" unitRef="shares">328205</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c86" decimals="0" unitRef="shares">9846156</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <canf:AggregatePurchasePrice contextRef="c88" decimals="-3" unitRef="usd">3200000</canf:AggregatePurchasePrice>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c88" decimals="-3" unitRef="usd">414000</us-gaap:PaymentsOfStockIssuanceCosts>
    <canf:ExercisePrices contextRef="c85" decimals="2" unitRef="usdPershares">12.9</canf:ExercisePrices>
    <canf:AggregateWarrantPurchased contextRef="c85" decimals="0" unitRef="shares">16410</canf:AggregateWarrantPurchased>
    <us-gaap:SharesIssued contextRef="c89" decimals="0" unitRef="shares">492308</us-gaap:SharesIssued>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="c90" decimals="0" unitRef="shares">1500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c91" decimals="0" unitRef="shares">45000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="c92" decimals="0" unitRef="shares">1500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SharesIssued contextRef="c93" decimals="0" unitRef="shares">45000000</us-gaap:SharesIssued>
    <canf:AggregatePurchasePrice contextRef="c94" decimals="-3" unitRef="usd">6000000</canf:AggregatePurchasePrice>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c94" decimals="-3" unitRef="usd">540000</us-gaap:PaymentsOfStockIssuanceCosts>
    <canf:ExercisePrices contextRef="c90" decimals="2" unitRef="usdPershares">4</canf:ExercisePrices>
    <canf:AggregateWarrantPurchased contextRef="c90" decimals="0" unitRef="shares">75000</canf:AggregateWarrantPurchased>
    <canf:ShareIssued contextRef="c91" decimals="0" unitRef="shares">2250000</canf:ShareIssued>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c95" decimals="0" unitRef="shares">19934355</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c96" decimals="0" unitRef="shares">996690</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c97" decimals="0" unitRef="shares">22278540</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c98" decimals="0" unitRef="shares">742618</us-gaap:StockIssuedDuringPeriodSharesOther>
    <canf:ExercisePrices contextRef="c99" decimals="2" unitRef="usdPershares">12.9</canf:ExercisePrices>
    <canf:ExercisePrices contextRef="c100" decimals="2" unitRef="usdPershares">78.75</canf:ExercisePrices>
    <us-gaap:WarrantExercisePriceDecrease contextRef="c97" decimals="2" unitRef="usdPershares">3.25</us-gaap:WarrantExercisePriceDecrease>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c97" decimals="-3" unitRef="usd">2400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <canf:IssueOfNewUnregisteredWarrants contextRef="c97" decimals="0" unitRef="shares">22278540</canf:IssueOfNewUnregisteredWarrants>
    <canf:IssueOfNewUnregisteredWarrants contextRef="c101" decimals="0" unitRef="shares">742618</canf:IssueOfNewUnregisteredWarrants>
    <canf:ExercisePriceSubjectToAdjusment contextRef="c98" decimals="2" unitRef="usdPershares">3.45</canf:ExercisePriceSubjectToAdjusment>
    <canf:DeemedDividend contextRef="c97" decimals="-3" unitRef="usd">715000</canf:DeemedDividend>
    <canf:SecuritiesPurchaseAgreementDescription contextRef="c102">the Company completed a public offering with certain institutional investors pursuant to which the Company issued and sold (i) 1,825,000 units, each unit consisting of one ADS, and one warrant to purchase one ADS, at a price of USD 1.50 per unit, and (ii) 1,508,334 pre-funded units each pre-funded unit consisting of one pre-funded warrant to purchase one ADS and one warrant, at a price of USD 1.49 per pre-funded unit.</canf:SecuritiesPurchaseAgreementDescription>
    <us-gaap:ProceedsFromOtherEquity contextRef="c103" decimals="-3" unitRef="usd">5000000</us-gaap:ProceedsFromOtherEquity>
    <canf:CompensationWarrantsExercisable contextRef="c104" decimals="0" unitRef="shares">250000</canf:CompensationWarrantsExercisable>
    <canf:ExercisePrices contextRef="c104" decimals="3" unitRef="usdPershares">1.875</canf:ExercisePrices>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="c103">2025-02-10</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c105" decimals="0" unitRef="shares">20250000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c106" decimals="0" unitRef="shares">675000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice contextRef="c107" decimals="2" unitRef="usdPershares">1.5</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c105" decimals="-3" unitRef="usd">1012000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <canf:IncreaseAuthorizedShareCapital contextRef="c108" decimals="0" unitRef="shares">1000000000</canf:IncreaseAuthorizedShareCapital>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c109" decimals="2" unitRef="ilsPershares">0.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c110" decimals="0" unitRef="shares">31000020</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c111" decimals="0" unitRef="shares">1033334</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice contextRef="c112" decimals="2" unitRef="usdPershares">1.5</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c110" decimals="-3" unitRef="usd">1550000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <canf:StockIssuanceAgreementDescription contextRef="c113">On June 12, 2020, the Company completed a registered direct offering with certain institutional and accredited investors pursuant to which it sold an aggregate of 3,902,440 ADSs at a purchase price of $2.05 per ADS for aggregate gross proceeds of approximately $8,000 prior to deducting the placement agent&#x2019;s fees and estimated offering expenses payable by the Company.</canf:StockIssuanceAgreementDescription>
    <canf:IssueOfNewUnregisteredWarrants contextRef="c114" decimals="0" unitRef="shares">1951220</canf:IssueOfNewUnregisteredWarrants>
    <canf:ExercisePrices contextRef="c114" decimals="2" unitRef="usdPershares">2.5</canf:ExercisePrices>
    <canf:AggregateNumberOfADS contextRef="c113" decimals="3" unitRef="pure">0.075</canf:AggregateNumberOfADS>
    <canf:AggregateWarrantPurchased contextRef="c114" decimals="0" unitRef="shares">292683</canf:AggregateWarrantPurchased>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c113" decimals="2" unitRef="usdPershares">2.5</us-gaap:StockOptionExercisePriceIncrease>
    <canf:IssueOfNewUnregisteredWarrants contextRef="c115" decimals="0" unitRef="shares">1705000</canf:IssueOfNewUnregisteredWarrants>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c115" decimals="2" unitRef="usdPershares">2</us-gaap:StockOptionExercisePriceIncrease>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c116" decimals="-3" unitRef="usd">3400000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <canf:IssueOfNewUnregisteredWarrants contextRef="c116" decimals="0" unitRef="shares">852750</canf:IssueOfNewUnregisteredWarrants>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c116" decimals="2" unitRef="usdPershares">2.5</us-gaap:StockOptionExercisePriceIncrease>
    <canf:AggregateNumberOfADS contextRef="c116" decimals="3" unitRef="pure">0.075</canf:AggregateNumberOfADS>
    <canf:WarrantsToPurchaseAggregateShares contextRef="c117" decimals="0" unitRef="shares">127913</canf:WarrantsToPurchaseAggregateShares>
    <canf:ExercisePrice contextRef="c117" decimals="2" unitRef="usdPershares">2.5</canf:ExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c4" decimals="0" unitRef="shares">1350000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c118" decimals="0" unitRef="shares">50926830</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c119" decimals="0" unitRef="shares">1697561</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <canf:TotalConsiderationAmount contextRef="c120" decimals="-3" unitRef="usd">2744000</canf:TotalConsiderationAmount>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c121" decimals="0" unitRef="shares">1050000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c122" decimals="0" unitRef="shares">35000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <canf:FairValueAmount contextRef="c120" decimals="-3" unitRef="usd">68000</canf:FairValueAmount>
    <canf:PurchaseAgreementDescription contextRef="c123">On August 16, 2021, the Company completed a registered direct offering with an institutional investor pursuant to which it sold (i) 57,000,000 ordinary shares represented by 1,900,000 ADSs, and (ii) a pre-funded warrant to purchase 93,000,000 ordinary shares represented by 3,100,000 ADSs at an offering price of $2.00 per ADS and $1.999 per pre-funded warrant, for aggregate gross proceeds of approximately $10,000 (without taking into account any proceeds from any future exercises of warrants issued in the concurrent private placement), before deducting the placement agent&#x2019;s fees and other estimated offering expenses payable by the Company. &#160; The Company has also sold to the investor, in a concurrent private placement, unregistered warrants to purchase up to an aggregate of 5,000,000 ADSs. The warrants have an exercise price of $ 2.00 per ADS and are exercisable at any time upon issuance and will expire three years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants. &#160; As of the financial statements date, the Company received a total of $ 9,997 and issued 57,000,000 ordinary shares represented by 1,900,000 ADSs and 93,000,000 ordinary shares represented by 3,100,000 ADSs following the exercise of the pre-funded warrants (issuance expenses were $1,307).&#160;&#160;&#160;&#160;17. On December 20, 2021, the Company entered into a warrant exercise agreement (the &#x201c;Exercise Agreement&#x201d;) with an institutional investor who is the holder of certain existing warrants to purchase Company&#x2019;s ordinary shares, par value NIS 0.25 per share, represented by ADSs issued by the Company in a registered direct offering consummated in August 2021.</canf:PurchaseAgreementDescription>
    <canf:AggregateWarrantPurchased contextRef="c124" decimals="0" unitRef="shares">5000000</canf:AggregateWarrantPurchased>
    <us-gaap:StockOptionExercisePriceIncrease contextRef="c123" decimals="2" unitRef="usdPershares">2</us-gaap:StockOptionExercisePriceIncrease>
    <canf:TotalReceivedAmount contextRef="c125" decimals="-3" unitRef="usd">9997000</canf:TotalReceivedAmount>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c126" decimals="0" unitRef="shares">57000000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="c124" decimals="0" unitRef="shares">1900000</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <canf:OrdinaryShares contextRef="c125" decimals="0" unitRef="shares">93000000</canf:OrdinaryShares>
    <canf:OrdinaryShares contextRef="c127" decimals="0" unitRef="shares">3100000</canf:OrdinaryShares>
    <canf:IssuanceExpensesAmount contextRef="c125" decimals="-3" unitRef="usd">1307000</canf:IssuanceExpensesAmount>
    <canf:ExerciseAgreementDescription contextRef="c128">Pursuant to the Exercise Agreement, the holder agreed to exercise in cash its warrants to purchase up to an aggregate of 150,000,000 Ordinary Shares represented by 5,000,000 ADSs having an exercise price of $2.00 per ADS, at an exercise price of $2.00 per ADS, for gross proceeds to the Company of $10 million, prior to deducting placement agent fees and offering expenses (which amounted to $0.98 million). &#160; Under the Exercise Agreement, the Company also agreed to issue to the holder new unregistered warrants to purchase up to 180,000,000 Ordinary Shares represented by 6,000,000 ADSs (the &#x201c;Private Placement Warrants&#x201d;). The Private Placement Warrants will be immediately exercisable, will expire five years following the effectiveness of an initial resale registration statement registering the ADSs issuable upon the exercise of the warrants, and have an exercise price of $2.00 per ADS. &#160; Pursuant to the terms of the Exercise Agreements, the holder agreed to exercise the warrants while receiving a-120% warrants coverage, thereby creating a benefit to this warrant holder. As such, the Company recorded a deemed dividend in the amount of $ 2,590.</canf:ExerciseAgreementDescription>
    <canf:ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-weight: bold; text-align: justify; border-bottom: Black 1.5pt solid"&gt;Issuance date&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Number of &lt;br/&gt; outstanding &lt;br/&gt; warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; border-bottom: Black 1.5pt solid"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;Exercise&lt;br/&gt; price per&lt;br/&gt; warrant&lt;/b&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"&gt;&lt;b&gt;($)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;January 2017&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;91,667&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;33.75&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;March 2018&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;11,111&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;30.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;January 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,460&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;19.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;April 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;16,410&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;12.90&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;May 2019&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,575,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;4.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;January 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;794,601&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3.45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;February 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;375,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;June 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2,046,342&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;July 2020&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;980,663&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;August 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;350,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;December 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;6,350,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;2.00&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;12,598,254&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</canf:ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock>
    <canf:IssuanceDate contextRef="c129">January 2017</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c130" decimals="INF" unitRef="shares">91667</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c130" decimals="2" unitRef="usdPershares">33.75</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c131">March 2018</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c132" decimals="INF" unitRef="shares">11111</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c132" decimals="2" unitRef="usdPershares">30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c133">January 2019</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c134" decimals="INF" unitRef="shares">7460</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c134" decimals="2" unitRef="usdPershares">19.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c135">April 2019</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c136" decimals="INF" unitRef="shares">16410</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c136" decimals="2" unitRef="usdPershares">12.9</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c137">May 2019</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c138" decimals="INF" unitRef="shares">1575000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c138" decimals="2" unitRef="usdPershares">4</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c139">January 2020</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c140" decimals="INF" unitRef="shares">794601</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c140" decimals="2" unitRef="usdPershares">3.45</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c141">February 2020</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c142" decimals="INF" unitRef="shares">375000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c142" decimals="2" unitRef="usdPershares">1.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c143">June 2020</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c144" decimals="INF" unitRef="shares">2046342</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c144" decimals="2" unitRef="usdPershares">2.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c145">July 2020</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c146" decimals="INF" unitRef="shares">980663</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c146" decimals="2" unitRef="usdPershares">2.5</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c147">August 2021</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c148" decimals="INF" unitRef="shares">350000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c148" decimals="2" unitRef="usdPershares">2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <canf:IssuanceDate contextRef="c149">December 2021</canf:IssuanceDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c150" decimals="INF" unitRef="shares">6350000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="c150" decimals="2" unitRef="usdPershares">2</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding contextRef="c2" decimals="INF" unitRef="shares">12598254</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;NOTE 10:-&#160;SHARE-BASED PAYMENT TRANSACTIONS&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share options:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;On November 28, 2013, the board of
directors approved the adoption of the 2013 Share Option Plan (the &#x201c;2013 Plan&#x201d;). Under the 2013 Plan, the Company may grant
its officers, directors, employees and consultants, stock options, of the Company. Each stock option granted shall be exercisable at such
times and terms and conditions as the Board of Directors may specify in the applicable option agreement, provided that no option will
be granted with a term in excess of 10 years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Upon the adoption of the 2013 Plan
the Company reserved for issuance 2,500,000 shares of ordinary shares, NIS 0.25 par value each. In May 2020, the Company&#x2019;s Board
of Directors approved to increase number of ordinary shares reserved for issuance to 25,000,000. As of December 31, 2021, 6,618,500 shares
available for future grant under the 2013 Plan.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Expenses recognized in the financial statements:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;200&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;159&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;138&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;198&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;158&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;132&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;398&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;317&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;270&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
&lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Share-based payment transactions granted by the Company:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The fair value of the Company&#x2019;s
share options granted was estimated using the binomial option pricing model using the following range assumptions:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;Description&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.22-1.28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.93-2.40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;Expected volatility&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;82.40-82.43&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;65.63-78.77 &lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;Dividend yield&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Contractual life&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.83 - 10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Early Exercise Multiple (Suboptimal Factor)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"/&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.5 - 3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;Exercise price (NIS)&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.25-0.253&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.25
- 2.344&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Movement during the year:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The following table lists the number
of share options, their weighted average exercise prices and modification in option plans of employees, directors and consultants for
the periods indicated:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares subject to options &lt;br/&gt;
outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt;
average &lt;br/&gt;
exercise &lt;br/&gt;
price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,923,400&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.28&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Forfeited/expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(600,700&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Outstanding at end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,422,700&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.18&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Exercisable at end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,322,700&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.35&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The weighted average remaining contractual life for the shares subject to options outstanding as of December&#160;31, 2021, 2020 and 2019 was 8.45 years, 6.98 years and 7.93 years, respectively.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt; &lt;tr style="vertical-align: top"&gt; &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt; &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The weighted average grant date fair value in 2021 was $0.18 and in 2020 was $0.16 and the remaining compensation costs not yet recognized as of December 31, 2021 is $1,139 with a weighted average period of 2.82 years to recognize these expenses.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt; &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;f.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;The range of exercise prices for shares subject to options outstanding as of December&#160;31, 2021 have been separated into ranges of exercise prices, as follows:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Exercise price per share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Options &lt;br/&gt;
outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt;
average &lt;br/&gt;
remaining &lt;br/&gt;
contractual&lt;br/&gt;
life in &lt;br/&gt;
years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt;
average&lt;br/&gt;
exercise&lt;br/&gt; price per&lt;br/&gt; share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Options &lt;br/&gt;
exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt;
average &lt;br/&gt;
exercise&lt;br/&gt; price per&lt;br/&gt; share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: left"&gt;0.08 - $0.94&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;17,796,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8.32&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5,696,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.09 - $1.73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;555,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;555,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.61
- $5.18&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;71,200&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;71,200&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.04&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,422,700&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,322,700&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <canf:GrantedExcessYears contextRef="c151">P10Y</canf:GrantedExcessYears>
    <us-gaap:SharesIssued contextRef="c152" decimals="0" unitRef="shares">2500000</us-gaap:SharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="c151" decimals="2" unitRef="ilsPershares">0.25</us-gaap:CommonStockParOrStatedValuePerShare>
    <canf:NumberOfOrdinaryShares contextRef="c153" decimals="0" unitRef="shares">25000000</canf:NumberOfOrdinaryShares>
    <canf:FutureShares contextRef="c2" decimals="0" unitRef="shares">6618500</canf:FutureShares>
    <canf:ScheduleOfExpensesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Research and development expenses&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;200&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;159&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;138&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;General and administrative expenses&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;198&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;158&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;132&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;398&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;317&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;270&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</canf:ScheduleOfExpensesTableTextBlock>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c0" decimals="-3" unitRef="usd">200000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c4" decimals="-3" unitRef="usd">159000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c5" decimals="-3" unitRef="usd">138000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c0" decimals="-3" unitRef="usd">198000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c4" decimals="-3" unitRef="usd">158000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <us-gaap:OtherGeneralAndAdministrativeExpense contextRef="c5" decimals="-3" unitRef="usd">132000</us-gaap:OtherGeneralAndAdministrativeExpense>
    <canf:SharebasedPayments contextRef="c0" decimals="-3" unitRef="usd">398000</canf:SharebasedPayments>
    <canf:SharebasedPayments contextRef="c4" decimals="-3" unitRef="usd">317000</canf:SharebasedPayments>
    <canf:SharebasedPayments contextRef="c5" decimals="-3" unitRef="usd">270000</canf:SharebasedPayments>
    <canf:ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: justify"&gt;Description&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Risk-free interest rate&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.22-1.28&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.93-2.40&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;Expected volatility&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;82.40-82.43&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;65.63-78.77 &lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%; text-align: justify"&gt;Dividend yield&lt;/td&gt;
    &lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; text-align: right"&gt;0&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Contractual life&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;10&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;9.83 - 10&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Early Exercise Multiple (Suboptimal Factor)&lt;/td&gt;
    &lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;3&lt;/td&gt;&lt;td style="text-align: left"/&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.5 - 3&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="white-space: nowrap; text-align: justify"&gt;Exercise price (NIS)&lt;/td&gt;
    &lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.25-0.253&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap"&gt;&#160;&lt;/td&gt;
    &lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;0.25
- 2.344&lt;/span&gt;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;</canf:ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c62" decimals="4" unitRef="pure">0.0122</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c63" decimals="4" unitRef="pure">0.0128</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c154" decimals="4" unitRef="pure">0.0093</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c155" decimals="4" unitRef="pure">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c62" decimals="4" unitRef="pure">0.824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c63" decimals="4" unitRef="pure">0.8243</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c154" decimals="4" unitRef="pure">0.6563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c155" decimals="4" unitRef="pure">0.7877</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c0" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c4" decimals="2" unitRef="pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c0">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c154">P9Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c155">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c2" decimals="0" unitRef="usdPershares">3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c156" decimals="1" unitRef="usdPershares">2.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c157" decimals="0" unitRef="usdPershares">3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c62" decimals="2" unitRef="ilsPershares">0.25</canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c63" decimals="3" unitRef="ilsPershares">0.253</canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c154" decimals="2" unitRef="ilsPershares">0.25</canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice contextRef="c155" decimals="3" unitRef="ilsPershares">2.344</canf:ShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Shares subject to options &lt;br/&gt;
outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Number&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Weighted &lt;br/&gt;
average &lt;br/&gt;
exercise &lt;br/&gt;
price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: justify"&gt;Outstanding at beginning of year&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;11,923,400&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;0.28&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Grants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;7,100,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.08&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Forfeited/expired&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(600,700&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1.00&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Outstanding at end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,422,700&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.18&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Exercisable at end of year&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,322,700&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;0.35&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c3" decimals="0" unitRef="shares">11923400</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c3" decimals="2" unitRef="usdPershares">0.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c0" decimals="0" unitRef="shares">7100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">0.08</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations contextRef="c0" decimals="0" unitRef="shares">600700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="c0" decimals="2" unitRef="usdPershares">1</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c2" decimals="0" unitRef="shares">18422700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="c2" decimals="2" unitRef="usdPershares">0.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <canf:NumberOfExercisableAtEndOfShares contextRef="c0" decimals="0" unitRef="shares">6322700</canf:NumberOfExercisableAtEndOfShares>
    <canf:WeightedAverageExercisePriceExercisableAtEndOfPerShares contextRef="c0" decimals="2" unitRef="usdPershares">0.35</canf:WeightedAverageExercisePriceExercisableAtEndOfPerShares>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c0">P8Y5M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c4">P6Y11M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 contextRef="c5">P7Y11M4D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="c0" decimals="2" unitRef="usdPershares">0.18</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="c4" decimals="2" unitRef="usdPershares">0.16</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c2" decimals="0" unitRef="usd">1139</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="c0">P2Y9M25D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="2" style="font-weight: bold; border-bottom: Black 1.5pt solid"&gt;Exercise price per share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Options &lt;br/&gt;
outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt;
average &lt;br/&gt;
remaining &lt;br/&gt;
contractual&lt;br/&gt;
life in &lt;br/&gt;
years&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted &lt;br/&gt;
average&lt;br/&gt;
exercise&lt;br/&gt; price per&lt;br/&gt; share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Options &lt;br/&gt;
exercisable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Weighted&lt;br/&gt;
average &lt;br/&gt;
exercise&lt;br/&gt; price per&lt;br/&gt; share&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: left"&gt;0.08 - $0.94&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;17,796,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;8.32&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.13&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5,696,500&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 13%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;0.21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;1.09 - $1.73&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;555,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;0.14&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.04&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;555,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;0.11&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2.61
- $5.18&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;71,200&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.01&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;71,200&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;$&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;0.04&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;18,422,700&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;6,322,700&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <canf:SharebasedPaymentArrangementOptionExercisePriceRange contextRef="c158" decimals="2" unitRef="usdPershares">0.08</canf:SharebasedPaymentArrangementOptionExercisePriceRange>
    <canf:SharebasedPaymentArrangementOptionExercisePriceRange contextRef="c159" decimals="2" unitRef="usdPershares">0.94</canf:SharebasedPaymentArrangementOptionExercisePriceRange>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c160" decimals="0" unitRef="shares">17796500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c161">P8Y3M25D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c160" decimals="2" unitRef="shares">0.13</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c160" decimals="0" unitRef="usdPershares">5696500</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="c160" decimals="2" unitRef="usdPershares">0.21</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <canf:SharebasedPaymentArrangementOptionExercisePriceRange contextRef="c162" decimals="2" unitRef="usdPershares">1.09</canf:SharebasedPaymentArrangementOptionExercisePriceRange>
    <canf:SharebasedPaymentArrangementOptionExercisePriceRange contextRef="c163" decimals="2" unitRef="usdPershares">1.73</canf:SharebasedPaymentArrangementOptionExercisePriceRange>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c164" decimals="0" unitRef="shares">555000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c165">P0Y1M20D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c164" decimals="2" unitRef="shares">0.04</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c164" decimals="0" unitRef="usdPershares">555000</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="c164" decimals="2" unitRef="usdPershares">0.11</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <canf:SharebasedPaymentArrangementOptionExercisePriceRange contextRef="c166" decimals="2" unitRef="usdPershares">2.61</canf:SharebasedPaymentArrangementOptionExercisePriceRange>
    <canf:SharebasedPaymentArrangementOptionExercisePriceRange contextRef="c167" decimals="2" unitRef="usdPershares">5.18</canf:SharebasedPaymentArrangementOptionExercisePriceRange>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c168" decimals="0" unitRef="shares">71200</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 contextRef="c169">P0Y3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions contextRef="c168" decimals="2" unitRef="shares">0.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c168" decimals="0" unitRef="usdPershares">71200</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 contextRef="c168" decimals="2" unitRef="usdPershares">0.04</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions contextRef="c2" decimals="0" unitRef="shares">18422700</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 contextRef="c2" decimals="0" unitRef="usdPershares">6322700</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 11- LEASES:&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The Company has lease contracts for
motor vehicles used in its operations. Leases of motor vehicles have lease terms of 3 years.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;The following is a summary of weighted
average remaining lease terms and discount rate for all of the Company&#x2019;s operating leases:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;weighted average remaining lease term (years)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.42&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.71&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "&gt;The components
of lease expense and supplemental cash flow information related to leases for the year ended December 31, 2021 and 2020 were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; "&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Components of lease expense:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;55&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;43&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt;
December&#160;31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt;
December&#160;31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Supplemental cash flow information&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;55&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;43&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;120&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;29&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "&gt;Maturities
of lease liabilities as of December 31, 2021 were as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; "&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;69&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total operating lease payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;148&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: imputed interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(24&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Present value of lease liability&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;124&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="c2">P3Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LeaseCostTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;December&#160;31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;weighted average remaining lease term (years)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;2.42&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;1.71&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td&gt;weighted average discount rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;13&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt; December&#160;31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Components of lease expense:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left; padding-bottom: 1.5pt; padding-left: 9pt"&gt;Operating lease cost&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;55&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; border-bottom: Black 1.5pt solid; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;43&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt;
December&#160;31, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"&gt;Year ended &lt;br/&gt;
December&#160;31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;Supplemental cash flow information&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left"&gt;Cash paid for amounts included in the measurement of lease liabilities&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;55&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; width: 9%; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;43&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt"&gt;Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;120&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;29&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; "&gt;&#160;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c2">P2Y5M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c3">P1Y8M15D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c2" decimals="2" unitRef="pure">0.13</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c3" decimals="2" unitRef="pure">0.13</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseCost contextRef="c0" decimals="-3" unitRef="usd">55000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c4" decimals="-3" unitRef="usd">43000</us-gaap:OperatingLeaseCost>
    <canf:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities contextRef="c0" decimals="-3" unitRef="usd">55000</canf:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities>
    <canf:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities contextRef="c4" decimals="-3" unitRef="usd">43000</canf:CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities>
    <canf:SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets contextRef="c0" decimals="-3" unitRef="usd">120000</canf:SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets>
    <canf:SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets contextRef="c4" decimals="-3" unitRef="usd">29000</canf:SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 88%; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;69&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;2024&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;20&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Total operating lease payments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;148&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Less: imputed interest&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;(24&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 4pt"&gt;Present value of lease liability&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;124&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c2" decimals="-3" unitRef="usd">69000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c2" decimals="-3" unitRef="usd">59000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c2" decimals="-3" unitRef="usd">20000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <canf:LesseeOperatingLeaseLiabilityPaymentDue contextRef="c2" decimals="-3" unitRef="usd">148000</canf:LesseeOperatingLeaseLiabilityPaymentDue>
    <canf:ImputedInterestLessImputedInterest contextRef="c2" decimals="-3" unitRef="usd">24000</canf:ImputedInterestLessImputedInterest>
    <us-gaap:OperatingLeaseLiability contextRef="c2" decimals="-3" unitRef="usd">124000</us-gaap:OperatingLeaseLiability>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 12:-&#160;FINANCE INCOME (EXPENSE), NET&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Finance expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Bank commissions&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(23&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Net loss from exchange rate fluctuations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(33&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other loss from short-term investment revaluation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(209&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other financial expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(363&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(427&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(22&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(386&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(690&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Finance income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Interest income on bank deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Exchange rate fluctuations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Other gain from short-term investment remeasurement&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;162&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;249&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;82&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;72&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total financial income (expenses), net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;227&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(304&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(618&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock>
    <us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Year ended December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;USD&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;Finance expenses:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: justify"&gt;Bank commissions&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(18&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(23&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;(21&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Net loss from exchange rate fluctuations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-56"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-57"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(33&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Other loss from short-term investment revaluation&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-58"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-59"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(209&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;Other financial expense&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(4&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(363&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(427&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(22&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(386&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(690&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Finance income:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify"&gt;Interest income on bank deposits&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;44&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;72&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Exchange rate fluctuations&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;59&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;27&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-60"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;Other gain from short-term investment remeasurement&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;162&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;11&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-61"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;249&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;82&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;72&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: justify; padding-bottom: 4pt"&gt;Total financial income (expenses), net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;227&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(304&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;(618&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;</us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock>
    <canf:BanksCommissions contextRef="c0" decimals="-3" unitRef="usd">-18000</canf:BanksCommissions>
    <canf:BanksCommissions contextRef="c4" decimals="-3" unitRef="usd">-23000</canf:BanksCommissions>
    <canf:BanksCommissions contextRef="c5" decimals="-3" unitRef="usd">-21000</canf:BanksCommissions>
    <canf:NetLossFromExchangeRateFluctuations contextRef="c5" decimals="-3" unitRef="usd">-33000</canf:NetLossFromExchangeRateFluctuations>
    <canf:OtherLossFromShorttermInvestmentRevaluation contextRef="c5" decimals="-3" unitRef="usd">-209000</canf:OtherLossFromShorttermInvestmentRevaluation>
    <us-gaap:OtherExpenses contextRef="c0" decimals="-3" unitRef="usd">4000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="c4" decimals="-3" unitRef="usd">363000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses contextRef="c5" decimals="-3" unitRef="usd">427000</us-gaap:OtherExpenses>
    <canf:FinanceExpenses contextRef="c0" decimals="-3" unitRef="usd">-22000</canf:FinanceExpenses>
    <canf:FinanceExpenses contextRef="c4" decimals="-3" unitRef="usd">-386000</canf:FinanceExpenses>
    <canf:FinanceExpenses contextRef="c5" decimals="-3" unitRef="usd">-690000</canf:FinanceExpenses>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions contextRef="c0" decimals="-3" unitRef="usd">24000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions contextRef="c4" decimals="-3" unitRef="usd">44000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <us-gaap:InterestIncomeDepositsWithFinancialInstitutions contextRef="c5" decimals="-3" unitRef="usd">72000</us-gaap:InterestIncomeDepositsWithFinancialInstitutions>
    <canf:ExchangeRateFluctuations contextRef="c0" decimals="-3" unitRef="usd">59000</canf:ExchangeRateFluctuations>
    <canf:ExchangeRateFluctuations contextRef="c4" decimals="-3" unitRef="usd">27000</canf:ExchangeRateFluctuations>
    <us-gaap:GainLossOnInvestments contextRef="c0" decimals="-3" unitRef="usd">162000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c4" decimals="-3" unitRef="usd">11000</us-gaap:GainLossOnInvestments>
    <canf:FinanceIncome contextRef="c0" decimals="-3" unitRef="usd">249000</canf:FinanceIncome>
    <canf:FinanceIncome contextRef="c4" decimals="-3" unitRef="usd">82000</canf:FinanceIncome>
    <canf:FinanceIncome contextRef="c5" decimals="-3" unitRef="usd">72000</canf:FinanceIncome>
    <us-gaap:InterestIncomeExpenseNet contextRef="c0" decimals="-3" unitRef="usd">227000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c4" decimals="-3" unitRef="usd">-304000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet contextRef="c5" decimals="-3" unitRef="usd">-618000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 13:-&#160;TAXES ON INCOME&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;a.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Corporate tax rates:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Israeli taxation:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Corporate tax rate in Israel in 2021
was 23%, 2020 - 23% and in 2019 was 23%.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;b.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Final tax assessments:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Company received final tax assessments
through 2016.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;c.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Net operating carryforward losses for tax purposes and other temporary differences:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;As of December 31, 2021, the Company
had carryforward losses amounting to approximately USD&#160;164,680.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;d.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred income taxes:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Deferred income taxes reflect the net
tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts
used for income tax purposes.&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;Significant components of the Company&#x2019;s
deferred tax assets and liabilities are as follows:&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net operating loss carry forward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;37,875&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;32,312&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Temporary differences mainly relating to Research and Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,285&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,581&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred tax asset before valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41,160&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,893&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(41,160&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(35,893&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Deferred tax asset, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="width: 48px"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 24px"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;e.&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Reconciliation of the theoretical tax expense to the actual tax expense:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The main reconciling item between the
statutory tax rate of the Company and the effective tax rate is the recognition of valuation allowance in respect of deferred taxes relating
to accumulated net operating losses carried forward due to the uncertainty of the realization of such deferred taxes.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c170" decimals="2" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c171" decimals="2" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c172" decimals="2" unitRef="pure">0.23</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredTaxAssetsCapitalLossCarryforwards contextRef="c2" decimals="0" unitRef="usd">164680</us-gaap:DeferredTaxAssetsCapitalLossCarryforwards>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 76%; text-align: left"&gt;Net operating loss carry forward&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;37,875&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;32,312&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Temporary differences mainly relating to Research and Development&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,285&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;3,581&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left"&gt;Deferred tax asset before valuation allowance&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;41,160&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;35,893&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 1.5pt"&gt;Valuation allowance&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(41,160&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(35,893&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; "&gt;
    &lt;td style="text-align: left; padding-bottom: 4pt"&gt;Deferred tax asset, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-62"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 4pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 4pt double; text-align: right"&gt;&lt;div style="-sec-ix-hidden: hidden-fact-63"&gt;-&lt;/div&gt;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"&gt;&#160;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c2" decimals="-3" unitRef="usd">37875000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c3" decimals="-3" unitRef="usd">32312000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c2" decimals="-3" unitRef="usd">3285000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c3" decimals="-3" unitRef="usd">3581000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross contextRef="c2" decimals="-3" unitRef="usd">41160000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c3" decimals="-3" unitRef="usd">35893000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c2" decimals="-3" unitRef="usd">41160000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c3" decimals="-3" unitRef="usd">35893000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="c0">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&lt;b&gt;NOTE 14:- TRANSACTIONS WITH RELATED PARTIES
&lt;/b&gt;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"&gt;&#160;&lt;/p&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify"&gt;The Chairman of the Company&#x2019;s
board of directors is a senior partner in the patent firm which represents the Company in intellectual property and commercial matters
(the &#x201c;Service Provider&#x201d;). The Service Provider charges the Company for services it renders on an hourly basis. The aggregate
amount of these expenses was approximately $241, $252 and $163 in 2021, 2020 and 2019, respectively, which were recorded under research
and development expenses within Company&#x2019;s consolidated statements of comprehensive loss.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="c0" decimals="-3" unitRef="usd">241000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="c4" decimals="-3" unitRef="usd">252000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="c5" decimals="-3" unitRef="usd">163000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <us-gaap:DepositsAssetsCurrent
      contextRef="c3"
      id="hidden-fact-0"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c2"
      id="hidden-fact-1"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c3"
      id="hidden-fact-2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c0"
      id="hidden-fact-3"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c4"
      id="hidden-fact-4"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="c5"
      id="hidden-fact-5"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RedeemablePreferredStockDividends
      contextRef="c5"
      id="hidden-fact-6"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="c13"
      id="hidden-fact-7"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="c14"
      id="hidden-fact-8"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c13"
      id="hidden-fact-9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c14"
      id="hidden-fact-10"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c11"
      id="hidden-fact-11"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c13"
      id="hidden-fact-12"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c14"
      id="hidden-fact-13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c11"
      id="hidden-fact-14"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c12"
      id="hidden-fact-15"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c13"
      id="hidden-fact-16"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend
      contextRef="c20"
      id="hidden-fact-17"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend
      contextRef="c22"
      id="hidden-fact-18"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend
      contextRef="c4"
      id="hidden-fact-19"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="c22"
      id="hidden-fact-20"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="c23"
      id="hidden-fact-21"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c22"
      id="hidden-fact-22"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c23"
      id="hidden-fact-23"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c20"
      id="hidden-fact-24"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c22"
      id="hidden-fact-25"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c23"
      id="hidden-fact-26"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c20"
      id="hidden-fact-27"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c21"
      id="hidden-fact-28"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c22"
      id="hidden-fact-29"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses
      contextRef="c30"
      id="hidden-fact-30"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses
      contextRef="c31"
      id="hidden-fact-31"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants
      contextRef="c30"
      id="hidden-fact-32"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c30"
      id="hidden-fact-33"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="c31"
      id="hidden-fact-34"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend
      contextRef="c28"
      id="hidden-fact-35"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend
      contextRef="c30"
      id="hidden-fact-36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockDividend
      contextRef="c0"
      id="hidden-fact-37"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c28"
      id="hidden-fact-38"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c29"
      id="hidden-fact-39"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="c30"
      id="hidden-fact-40"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c28"
      id="hidden-fact-41"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c30"
      id="hidden-fact-42"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="c31"
      id="hidden-fact-43"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="c4"
      id="hidden-fact-44"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensation
      contextRef="c5"
      id="hidden-fact-45"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="c4"
      id="hidden-fact-46"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="c5"
      id="hidden-fact-47"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="c4"
      id="hidden-fact-48"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireOtherInvestments
      contextRef="c5"
      id="hidden-fact-49"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PaymentsOfDividends
      contextRef="c5"
      id="hidden-fact-50"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:RevenueContractWithCustomer
      contextRef="c47"
      id="hidden-fact-51"
      unitRef="pure"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c56"
      id="hidden-fact-52"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c57"
      id="hidden-fact-53"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c60"
      id="hidden-fact-54"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:ShortTermInvestments
      contextRef="c61"
      id="hidden-fact-55"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:NetLossFromExchangeRateFluctuations
      contextRef="c0"
      id="hidden-fact-56"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:NetLossFromExchangeRateFluctuations
      contextRef="c4"
      id="hidden-fact-57"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:OtherLossFromShorttermInvestmentRevaluation
      contextRef="c0"
      id="hidden-fact-58"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:OtherLossFromShorttermInvestmentRevaluation
      contextRef="c4"
      id="hidden-fact-59"
      unitRef="usd"
      xsi:nil="true"/>
    <canf:ExchangeRateFluctuations
      contextRef="c5"
      id="hidden-fact-60"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:GainLossOnInvestments
      contextRef="c5"
      id="hidden-fact-61"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c2"
      id="hidden-fact-62"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c3"
      id="hidden-fact-63"
      unitRef="usd"
      xsi:nil="true"/>
    <dei:AmendmentFlag contextRef="c0">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c0">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c0">0001536196</dei:EntityCentralIndexKey>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>77
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M(';'G+L;Q?/RI/"9*\73\G)#]9P@C(!^O^9<[6_,X6-]V#S]#U!+ P04
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M4#8 SY=2FNW"MK+^RY7] 5!+ P04    " #.3'A4%U6Y0%D$  "I#P  &
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M/8>:V>ADIAEB/Q.Q+9A$)=V 2>\J!K=$,Q<V#XKOS:2TY@KF+G.[@UF:"BT
M_V\X5\\/>H%N.E_^!U!+ P04    " #.3'A4)L7*V84&  "/)@  &    'AL
M+W=O<FMS:&5E=',O<VAE970U+GAM;+5:WW.;.!#^5S2>/K0S=:T?(*"3>*:Q
MS5P?>M=IVKMG%928*48NR$GZWY_ Q!A)R+%+7VS N]^N=E?2IS57CZ+\4:TY
ME^!IDQ?5]60MY?;];%8E:[YAU3NQY87ZY4Z4&R;5;7D_J[8E9VFCM,EG&$(Z
MV["LF,ROFF>?R_F5V,D\*_CG$E2[S8:5OVYX+AZO)VCR_.!+=K^6]8/9_&K+
M[ODME]^VGTMU-SN@I-F&%U4F"E#RN^O)!_0^)HU"(_%OQA^KHVM0#^6[$#_J
MFX_I]036'O&<)[*&8.KK@2]XGM=(RH^?+>CD8+-6/+Y^1H^;P:O!?&<57XC\
MORR5Z^M). $IOV.[7'X1CW_Q=D!^C9>(O&H^P6,K"R<@V552;%IEY<$F*_;?
M[*D-Q)$"H@,*N%7 F@(.!A1(JT T!1(-*'BM@J=;&!J#WRKX^AC(@ )M%6@3
M^WVPFD@OF63SJU(\@K*65FCU19.N1EL%."OJRKJ5I?HU4WIROA!%)?(L99*G
MX%:J+U4VL@+B#BS6K+CG%<@*L/JYR^0O, 7?;I?@]:LWX%7]].M:["I6I-75
M3"I7:L!9TIJ]V9O% V;_*=.L4)4,JC4KN0U@X0;XD*9979HL!UN6I5/E3L*V
MF62Y!6MY BM)=IM=WH1 R#4O02(V:IZNZPGTP,''0MUS"^[JY;BJV+,DDQ:0
MV WR51ACFJD<'Q*-#XG&#8XW@'/#<E8D'# )ECQY!PAZ"S!$H2UW>R3:(-5+
MT\,<4^)?S1Z.\V,*130B45]J:4HAA(.^T,H4FD8!#6E?+#;%"$2=6[VPD$-8
MR(O"\EH5T&U3BV]>%*(]JG_DBP=)%.$(VOWQ#OYX3G\^5M6N<4A-P&9N/)<U
M4!,-/+*R9&IZO@6%VG242/8LSI_47E-99]*-9\3-]^M1]=+I&0.BR-.SZ?2]
MW@3?5UN6\.N)FCT5+Q_X9 YL\V8DG-AT&B%* WL*_$,*_#^:@N-:LJ7#-YP.
M(NS3 !*[W_3@-[W,;YL3U*B) &L50<T2)UH].!TZHQY&PHE-E]'0 A$<HAI<
M6 TGTAP8OD01I4/K0WAP)W2ZTQB<UEPJ51O?KWJSMAEW@KP\H(O0& 0.H%8$
M(]E:C803NWWN13TZ1#UR1OUO-=5S45E75Z?F&:$>"6<Y$LXJ,L(X19ABC0;$
M)\5Z 4>PXZ7P$KX26;DF-%:S$.N>+EJIWNH B0>15L\V.9.S6*2F2.$A#2ZV
M"&+/PP/Q.>+MZ'>)BSU6R!P=AM3'-!S8?U!',9&;8RZY.CTHKIL]9"E7YP)U
M]-RS7RF XM6'O5-ME;Q,LLK&J6_<-LZ84"U0;Z-%OI[LD:RM+-:FAKEX!'/]
MW'0\%[F)[I\@EJW)WD'!"_09L$ F69X&$(=Z*IP#."<5(P'%%L=1,#Q/.HZ/
M_BS)/T4]D,F+B:<\IT$XL!&BCARC"]FQU1'?//Y!J)>'28BG^N*]='MU3G&,
M!!1;W Z&=KV.PJ,+.?S)E%NH+_$AA$,)[_@O<A/@%S).-\HYR[9)G D*]'(8
MR=IJ+*#XA-O]X'=L'[GIOHMXNE7/B?A(0,NQ@%;(Y/!3Y'GZ^3,^+=>/>\?W
MD9OPV]DGAM8\1&9?BD!"]67.9,I10$+]-&41L[%/*^WV/1KI$3(%*0P\>WQP
MQ\[QR]CY,/NTQPJ;9-BC)*"1^ASPJ6/$V,V(A]?.=,=K"FK0S_/83FN^QW8(
M@GJ>L4FPU<& F)U1YVC.F"QC <46SY%B#0.+&#[J/+N/!6,FYM0^B$T:CB,2
MU:>;@9T0=Q0:7TJAE4_\*6G^+P%WH@1UE+-DH(Q,TJPO @ML8<P(ZP4T%E\>
M"RBVN$W#@:AW9!E?2I:'HGZR1BQM8^C@2K@CQ]A-CD<Y +MMG+&O8Y.A8C_2
M-YRQS*TLYJ:FO7@$>_WL=.0:7TJN+S\"8[.1KNB'WDK'EEXZ]O4#L-O]<^:A
M:2X<[#SC[B2 +VV%CW-LQ2:%]@,('1.SX]%XE+:Y&^6<J6<24Q(9^1Z++H\%
M%)]PNQ_\CDSCR[OG;M5S(CY6_WPLH!6VM\:-GN!IN?X_VQU))Y>TT#&R_I]M
MMM II+ZG+606L8C@0._66,0LAQB+E#J]01IH5F,;G$?"@1XZZ4X,Y'=[Z /!
M,HERB/S HXIJ:C[-CE[-J5_5^L3*^ZRH0,[OE"Y\%RB0<O_VT_Y&BFWSMLYW
M(:78-)=KSE)>U@+J]SLAY/--_0+0X1VT^?]02P,$%     @ SDQX5(\K'/"'
M @  9P8  !@   !X;"]W;W)K<VAE971S+W-H965T-BYX;6R555UOVC 4_2M6
M5&FMU#5?T"^%2 4Z;0^54%G7AVD/)KD0"\>FMM/0?[]K)V300L5>$G_<<^XY
MOO%-4DNUU 6 (>N2"SWP"F-6M[ZOLP)*JB_D"@3NS*4JJ<&I6OAZI8#F#E1R
M/PJ"2[^D3'AIXM8F*DUD93@3,%%$5V5)U=L0N*P'7NAM%A[9HC!VP4^3%5W
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M5O3V;'J;:M/S*Z;]M_X%W5?\7NKP.+_=^VW1K;"F6.LE+#V=/G]ZPB]=<A_
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M9ZJ0D+ <\[\)/)ULFW%XS'@<7F2<8G8#G> :0C\,+O!U6@4ZEJ_SWPK$9Q2
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M\/)ZX(-J&V%K&%F[YK.6AEJ9&Q;T[4!E'6@]E](<#$O0?8VFOP%02P,$%
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M#(8?X'R4#C4,Q8IJI*9U7--<YZ+.<G'3F8F:JSVB 28+J-E>*\YI(W*]9=S
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MW>%1 +INZ?7"JM*WT96RU)3]-*=7$+53H/U,T35L%LY!^ZY._P)02P,$%
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M$#.Q>75^MA5T.+N75DQSF1(5F0KU$"6%!4^U5( ^WE#@,R@U<C-AJ\ ^CHM
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M(LA(ME2!^*R!4-"(L2!:0;5#@>HJ(V46OBBM]IK)9ZI -6<T9,W=#%ZJ:W#
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M%+!E@O3GUD'9K1MJ2*>E-%I5^1V2D.6"HN=?%G(_"0$R5 PFAKX9<5LM27C
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M=2[1W<9DH,DCQP"-/[IO$:&VPS)-(8&'AR\.R^Z0%8PNEUT+ ?J;<F,-=WY
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M?_8I]2 M#,=+M>:A>'4"\:9$MA$GKS]\_/&:!9<OV# GQDWV,6$_\#MF6ZA
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MV89 E=04&$$PT2_[E7C^R/@G&H\.[(Y:.[O>CV %2%.9J_9D*MY.(25:DW,
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M*YH2M3(&2JT:(L@K+C<(FEN$LM[E=L>M)[B@:S D:/!H*Y+R 3*5TO:"BMZ
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MWI[UPMY^X4%N,L<+P\6\%!M\1/>UO#<T&[8HJ2Q06:D5&%R?]<[#V<68Y;W
M-XE;>S &]F2E]7>>7*=GO1$3PAP3QPB"_I[Q$O.<@8C&/PUFKS7)BH?C/?H7
M[SOYLA(6+W7^ATQ==M:;]B#%M:AR]Z"WOV/CSX3Q$IU;_X5M+1O'/4@JZW31
M*!.#0JKZ7[PT<3A0F([>4(@:A<CSK@UYEDOAQ&)N]!8,2Q,:#[RK7IO(2<5)
M>72&=B7IN<63>$$+%)YKE>@"YT-'H+PU3!J BQH@>@,@C.!&*Y=9N%(IIL<
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MSR*O1'VWL&,4?X1QV ]/1A!/^M//<?"M0^)#(_(1/M12\+'#1I^KAESZQ+\
M!\0UT91@"JO':[)!/V+B*%EU\^$+W=86V3F?\,15QSMU^W(LN'=K1 J&I((\
M++_ .N$JIRF&[6%R7 !M4=5538? P;%C_0X;H%+:\^T*EZ=A2^X4DCBL)=]#
M=:H";LTDJ8J*YK2K?B@)K(M"UF7MRR*MVBA49,DX<MGM]D[0^R67_[:AM!45
MP;'U0=>U,#RX: LT&_^<(-O<5O6=VZZV+Y;S^J)^%:^?.S?";*2RD..:5$>#
MTTD/3/V$J"=.E_[:7FE'CP _S.C5A88%:'^MM=M/V$#[CEO\!U!+ P04
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M@&BU5D2.+/"G:'C)!C?J14PT+2E\A@3AJV$2C=BJ6-'P*;-JG6Q!NX*J0E"
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ME9CCV12%LG<_HODWP< N5R;V ;$%[/]J> [ON57:W]41N\Q=G[AS"LB;UNR
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MTZ^0TD_J50W_5*=_*MPOG;[@W_<,K_//I+[+]!K+ 4JY@J&SZ=/S$[X!WGT
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MN5KY1[EUAJPUQ;GU;24-5KHIT=B7</FSK]TO>/59;ANTKY>)(PKOF!0CW,4
M)YZ XP(^:>4J"Y>JQ/)O@(1R.R8H'A.\$,\BOL5B BF/03#!G\%+CP6G 2]]
MJF"GB[M_"[[2#N'[9FN=H3;Y\0Q-=J3) DWV% U-3]DW"'H'M1J&9^CCO31E
MK?9 $V*=5.%\D,9(Y2PX#5UOBHKZ#*Q_&ON_-WB6VH_QN>UD@:N(YM2BN<=H
M_<':7JH"H914ZE7?;M'XW"X?T!0UL;UZ\?KLHU0]329=-9_!@L?3Z0S2=#++
MSSY)2LKKY\!YS#F'E$T8.XU8P"S.I@SX8I*SLTUGZF90\VF<<=*+R8(1T.C,
MXWR6QXPQR/X&$@QFBRR>,N*89/G9.]R:/Z9T#.*>Y&.O<%"+F&73.,T$B,'0
MC/Z+.:,RTD&]Z?<T4:&3(,U9 !*>G9H,PXT$$P&=&KF(\\4\%GD&_VN,Y&3X
M6C3[L&(L%+I7;IC#H_:XQ3;#\/YQ'U8@W?*^5A8:W%$HHXN/P QK91"<[L(H
M;[6CQ1".%6UB--Z![#M-C3P*GN"XV]>_ 5!+ P04    " #.3'A4H1C Q7\$
M  "5"@  &0   'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6R-5EN/VC@4?L^O
M.(JFTHP$N1("(T":6W?[,.UH:+=:K?;!20[@;1*GMH'AW^^Q"1DZHF@>,+Z<
MZ_>=XWBR%?*'6B%J>*G*6DW=E=;-M>^K?(454YYHL*:3A9 5T[242U\U$EEA
ME:K2CX)@Z%>,U^YL8O>>Y&PBUKKD-3Y)4.NJ8G)WBZ783MW0/6P\\^5*FPU_
M-FG8$N>HOS5/DE9^9Z7@%=:*BQHD+J;N37A]FQIY*_ 7QZTZFH/))!/BAUE\
M*J9N8 +"$G-M+##ZV^ =EJ4Q1&'\;&VZG4NC>#P_6/]H<Z=<,J;P3I3?>:%7
M4W?D0H$+MB[UL]C^B6T^B;&7BU+9$;:M;.!"OE9:5*TR15#Q>O_/7EH<WJ,0
MM0J1C7OOR$9YSS2;3:38@C329,U,;*I6FX+CM2%EKB6=<M+3L_F*2>S?4EX%
M/+$=P:WAJV2U8A8U!9=?65:BNIKXFMP9)3]O3=_N34>_,1U&\"AJO5+P4!=8
M_&K ISB[8*-#L+?168OWF'L0ASV(@B@\8R_NDH^MO?AL\MDOR=](RGZ)=O[/
M3::T)"3^/>-LT#D;6&>#WSFC?BK6)8)8 +Y04RE4IT ]:\7TZ+5J6(Y3EYI0
MH=R@._L;F00T( -!A%6&TL#D&)@,5@$-X=CY-K]WGDF'R7P%K"ZH>C?4E8W-
M]1 27)!P0&.8C,T8CYP_L$;)2JO""BI";E QW?2J%8Y'I$&_.'(N(*85C6%J
MK*4!G($OZ>!+W@^?TIP:DM)=*UXO0:\0,EZ+BE.4HK'MWDB>F[-*%%B>POFL
MN],XWZ/*)=_;[[!UGKGZT5](1."U1A+60.@@A%X4]6D8P0<(O''<C[Q! !^<
M!\(L-\%O1$DHEESO8&3.^F:,27J8>,.XGXZ\-"7Y>[[A!;$+.XYE 0$$SAWU
ME:G+->5;\@7Y"F#LC6+HT\QY8++<P<,+RIPKA$>ZH'A#R%W.UYE!IR*MCZ0M
MY!7$$'D)J<5.)V^0(^'/G^97%'>4],T0VZG3)_%X,#A'Z+ C=/AN0K?V\B1(
MV(8J;6GJZC@894N/F.0+GC,+/Z\[HDNZK6Q55$TI=GBZJ\[&<IIM>SLH^EQE
M_Q%?H$7K4=F^<CZO;9]];T.WW?5EK96F6$WA,0T9+GE=FP6%MS--&H:]<13W
M!M1AA">U%ETV6D':"X.@%]C=8.30]V:!G(SZU%]<$BZ70SI/Z?R*RBH(WCHR
MU=&Y&/4&462% R\<'7@UM_A;T6$O[B3CY!RI:4=J^FY26[1 ',6:ETPI8I%2
MRG9O6#Y%VUEOIVD[AN8H][?UW1!WRC ,7]HX#TR^3MZ>T,UF^*%VN:"&'D"8
M]M+QL)<0@",OCL <AS$DO6&[:S:H5"X,:6.C%GHIG2=)RW4XL"+!H-NS)HQ&
MY U#:K>+A#B$-.Q%^^((]PKA86NO[AR1_DKJ*3[]HZ="A7)I'T0*<K&N]?[5
MT.UV;ZZ;_5/C57S_8'MDDLI;08D+4@V\E&Y4N7\$[1=:-/;AD0E-SQ@[7=&[
M$:41H/.%$/JP, ZZE^CL?U!+ P04    " #.3'A4<6W):BX#  "&!P  &0
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M:G1Y/0Y M^.AW5A5>TMFRI+!_;*DB8K:!=#[M5)VOW$$_8Q>_ %02P,$%
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M;_+4]>$ $"1' &$'"%\#XB. J -$;P7$'2!VG6E+<7W(B";I1(H=2!MMV.S
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M_T!9 _R^E=*\#:R#KJ%<_ ]02P,$%     @ SDQX5/O(DOC# @  ZPH  !D
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MC;)LS8:@9*)YTM>V#UN&L'?"$+6&Z+V&N#7$KM"&S)4UH4C31,DU459MTNS
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MJV A5@IOS?H;]/F<>;[2*!>^;-W9GIU%K%PY-$T/I@@:J;N_>.[KL 6(S_<
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MTRQW]$F+B&9^-('BE;V":Z[TA;;+7(]<$ :@SS/.U3$PM[H;XO%_4$L#!!0
M   ( ,Y,>%1GO5@AR0(  "0+   9    >&PO=V]R:W-H965T<R]S:&5E=#0R
M+GAM;-5634_C,!#]*Z.( TC0?/4#4!MI:846"21$%_: .+C)I+%PXJ[MM.R_
M7]L)I@A:=;4]+)?$CN>]S)LW2F:XXN)9%H@*7DI6R9%7*+4X]WV9%E@2V>$+
MK/1)SD5)E-Z*N2\7 DEF027SHR#H^R6AE9<,[;-;D0QYK1BM\%: K,N2B-\7
MR/AJY(7>ZX,[.B^4>> GPP69XQ35_>)6Z)WO6#):8B4IKT!@/O*^A>?C,#(
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M<ABR<;RWEC=PZ0;BOTG)\E.P';["WJV#E^+<!B=,,!_,SB&B@.0BPG J2!?
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MBBC_G-R<4+$AA_$+DBCC7XV;DM:S]HR@R/)D(Q:#!ILP+K^36V&(QH*%.;
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M"G=XLZ .->-:S?C$3AGO.642A.&HW2:36L;$*>/#BU#SR-9\HR);FHV55&E
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M _ ,P*L 4)VDC@%TJH Z"[X!^!4 [-4  @,(CK70-8#NL19" PBK%MP:0,\
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M>S\T,X;!YNP._FZG(IT>^^S1*O^C33KH1-%.?^'6_TKX3[?I8^1VE=74C]_
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M+H&%P'4#]7R>97)[H0>H]KPF_P-02P,$%     @ SDQX5$%E?PRT 0  IP,
M !D   !X;"]W;W)K<VAE971S+W-H965T-3$N>&UL?9/=:MPP$(5?1>BJA;+R
M3]*68!NR64H#"2P);2]*+[3V>"TB6:XT&R=OWY'L-5M(]L;22',^G=%8Q6C=
MD^\ D+T8W?N2=XC#E1"^[L!(O[(#]+336F<D4NCVP@\.9!-%1HLL23X+(U7/
MJR*N;5U5V -JU</6,7\P1KK7-6@[ECSEQX4'M>\P+(BJ&.0>'@%_#%M'D5@H
MC3+0>V5[YJ M^75ZM<Y#?DSXJ6#T)W,6*ME9^Q2"VZ;D23 $&FH,!$G#,]R
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M)8$+";3?6HO'('1W>9O5/U!+ P04    " #.3'A4H7E%7$@#  #Q"0  &0
M 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6S-5FUOTS 0_BNG"*1-@N6MW=:I
MK;1U()! 3"N##X@/;G)M+!P[V,ZZ_7O.3I:U:QO!-[XD?KE[?,]SYY?Q6NE?
MID"T\% *:29!86UU$88F*[!DYD15*&EFJ73)+'7U*C251I9[IU*$212=AB7C
M,IB._=B-GHY5;067>*/!U&7)].,5"K6>!''P-'#+5X5U ^%T7+$5SM'>53>:
M>F&'DO,2I>%*@L;E)+B,+V8C9^\-OG%<FXTV."8+I7ZYSL=\$D0N(!2868?
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M>L U0/T?,R:/ _V"]NRX^0]02P,$%     @ SDQX5'7Q$"]W @  %P<  !D
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M,"S?@SOOHV#SG@J:?T#'?P!02P,$%     @ SDQX5)>*NQS     $P(   L
M  !?<F5L<R\N<F5L<YV2N6[#, Q ?\70GC 'T"&(,V7Q%@3Y 5:B#]@2!8I%
MG;^OVJ5QD L9>3T\$MP>:4#M.*2VBZD8_1!2:5K5N %(MB6/:<Z10J[4+!XU
MA]) 1-MC0[!:+#Y +AEFM[UD%J=SI%>(7->=I3W;+T]!;X"O.DQQ0FE(2S,.
M\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B':5_'<?VD-/IKV,B
MM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    " #.3'A4*=,V2X4$
M   %)@  #P   'AL+W=O<FMB;V]K+GAM;,6:VV[;.!! ?X70RV:!9&W=G#:H
M"VQSZ0;(;HW:R.N"ENB(*$5Z23J)^_6EI @=I?)@7R9^DG4Q=32BY@Q%?7@R
M]MO:F&_LN5;:S:/*^^W%9.**2M3<_6&V0H<]&V-K[L.J?9BXK16\=)40OE:3
M9#J=36HN=?3Q0]_6PD[@BO&B\-+HL+'9<"_%D_NYOUEEC]+)M532[^=1^UN)
MB-52RUI^%^4\FD;,5>;I+V/E=Z,]5\O"&J7F4=SMN!?6R^*7S<L&<L77KMWB
M^?HK#R#S:#8-#6ZD=;X]HFV?!\9'$0[NUG;>W$CEA;WB7GRV9K>5^J%I)ES%
M!%Q&&X=^V07QPOZ?,)K-1A;BRA2[6FC?Q=$*U0!J5\FMBYCFM9A'_2'L3UVR
M:^U#D-BM[IH*QS97&DY]6W97[0,NB*&]D&&'O2U;<#K(R[!NE"S#V4OVB2NN
M"\':X#H F"" R=$ V<F" \@4@4S?$'+90#1_<,QLV*6IMP R0R"SXT%6'/;'
M'(',CPCY;P(@9PCD['B0W%4 \AR!/*>%_"RTL%P!F'<(S#M:F*5\T#(<RYMT
M6!1F%]*A?F"+$,5""IAJWB.0[VDAO_A*V![/L:^B$/*1!P3&0P9?P(0]Q3+V
ME#B6E;'^;"5L'73R*)QOCH=PJ$Z(?1*JAFUP^OZ4+51SLYO(7?^WD]OF?Z<,
M8F)2B8FM\NI6+_B>MP _Z3";Q,0ZN>'2LGNN=H+]+;C;V2Z_0#S,(S&]2)JG
MMREM[B1OR[_P#+>W.MBNAIB826)BE2PK;D5E5"FL^ZWMA'X/V3"!Q,0&:=G.
M/G$7!!(Z7ULFKBS7CA>O:T-,(3&Q0^Y"[QMDYQAS2$PLD1NIV^KO5A>F%NSD
M^CDTYL3OD _31TSLCQ5_#H^!T2^ L'[&?)$0^P+T*\>>I*^"V51;NBQX&'U!
M3,P<";$Y1LJ"4[;>=RM[:(X$'8X0FP.M9 8%:H(I)"%6"%K+##$QE23$*D'+
MA2$FII*$6"7CY0([634+!Q-0@EDE(;;*@;JAYX28F%428JN,B7DTEIAL$NH1
M"V;H8<_$G),0.Z<S]%CT4LPY*;%S#JGZ!11B8LY)B9WSRMBC8<1DDQ++YF4,
MSTZNA.=2#<'0]UW$>L$MF$),3"\IL5YPS QB8GI)J4<J*&8.,3&]I,1ZP6N*
MP4W'])*2ZV7D_<CX(X0))B46#%[Z#**)"28E%@R."1^A#!-.1BR<0Q7:RUV'
MF)AP,F+A'*S0.DZ(B7DGHY]T.?R&9U#\9)B%,FH+C1:2(P]ZADZ[4$L(I80#
MVPR34/86K\L.%KPP'V68A+)COCD;YB-,0ME;C'$.8D*E9YB$LJ..<F80$Y-0
M1BPA'/,<3EUB$LJ))=0/QD8R4(Y9)R>VSFLN=L:6H=ER%PQI-C #Y9AU<F+K
MH)@#Z^28=7+JV9F#8]L6'&)BVLF)M?/+V':L5Z(S_<3".0C8W7>(B0DG)Q8.
M^OI\V"LQX>2M<";]9T>EV$@MRG_"*5S87G!5+"QK%MW<:)8W4QF;G5*78=L7
M?6=XV7_%U'^!]?$'4$L#!!0    ( ,Y,>%3S((MYZ0$  !(B   :    >&PO
M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-VCM.PT 4A>&M1%X D_N8\%!"14.+
MV( 5)@^1Q)9G$,GNB4(1CD5!@^94UMCR]5]]LL:>OZ1=6[;=(6^V?9X<][M#
M7C2;4OJ'$/)RD_9MONGZ=#A?677#OBWGY; .?;M\;]<IZ'0Z"\//&<WC_.?,
MR>NI3W^9V*U6VV5ZZI8?^W0HOPP.G]WPGC<IE6;RV@[K5!9-..ZNIW.X'.3F
M/+F9/+\MFN'Y39I0.T@A2.L'&019_2"'(*\?%"$HU@^:0="L?M M!-W6#[J#
MH+OZ0?<0=%\_2*8HXY0@:80U@=:"7 N!UX)@"X'8@F0+@=F": N!VH)L"X';
M@G +@=R"= N!W8)X"X'>BGHK@=Z*>BN!WCIZV2;06U%O)=!;46\ET%M1;R70
M6U%O)=!;46\ET%M1;R706U%O)=#;4&\CT-M0;R/0VU!O(]#;1ILE!'H;ZFT$
M>AOJ;01Z&^IM!'H;ZFT$>AOJ;01Z&^IM!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$
M>OMHLYM ;T>]G4!O1[V=0&]'O9U ;T>]G4!O1[V=0.^(>D<"O2/J'0GTCJAW
M)- [HMZ10.^(>D<"O>/H8R6!WA'UC@1Z1]0[_J?>N9QV*5][OM?X_/^DNISO
M3=?'7Y;?)T?L7' .\ O(XQ=02P,$%     @ SDQX5+)H2=C5 0  OR$  !,
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M<F]P<R]A<' N>&UL4$L! A0#%     @ SDQX5',)6R_O    *P(  !$
M         ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ SDQX
M5)E<G",0!@  G"<  !,              ( !S0$  'AL+W1H96UE+W1H96UE
M,2YX;6Q02P$"% ,4    " #.3'A4^T/_4!D'   T(0  &
M@($."   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ SDQX
M5"G?.G'7!0  >!8  !@              ("!70\  'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;%!+ 0(4 Q0    ( ,Y,>%0[Y$,XA0(  ,4&   8
M      " @6H5  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4
M" #.3'A4%U6Y0%D$  "I#P  &               @($E&   >&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L! A0#%     @ SDQX5";%RMF%!@  CR8  !@
M             ("!M!P  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4
M Q0    ( ,Y,>%2/*QSPAP(  &<&   8              " @6\C  !X;"]W
M;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #.3'A4:AL:(!<'  "F
M'@  &               @($L)@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL
M4$L! A0#%     @ SDQX5#YG6XU-!@  @0T  !@              ("!>2T
M 'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ,Y,>%3+ /=5
MFA\  ,)<   8              " @?PS  !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6Q02P$"% ,4    " #.3'A4'?L<_'\"  !8!0  &0
M@(',4P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ,Y,
M>%3;=FP=^P(  # &   9              " @8)6  !X;"]W;W)K<VAE971S
M+W-H965T,3$N>&UL4$L! A0#%     @ SDQX5)^Z0R\+ P  F08  !D
M         ("!M%D  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
M    " #.3'A46'6'NE0"  #N!   &0              @('V7   >&PO=V]R
M:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,Y,>%228V^A. ,  &,'
M   9              " @8%?  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M4$L! A0#%     @ SDQX5+JH+]$+#@  CRL  !D              ("!\&(
M 'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #.3'A4[B*Q
MU0X.  !I.   &0              @($R<0  >&PO=V]R:W-H965T<R]S:&5E
M=#$V+GAM;%!+ 0(4 Q0    ( ,Y,>%3)3\X4)0<  /</   9
M  " @7=_  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @
MSDQX5)4=#F>K P  A0@  !D              ("!TX8  'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6Q02P$"% ,4    " #.3'A4O'5&51,#  !X!@  &0
M            @(&UB@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4
M Q0    ( ,Y,>%3N 1K07 0  -,)   9              " @?^-  !X;"]W
M;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ SDQX5)]5Q1$] P
MKP8  !D              ("!DI(  'AL+W=O<FMS:&5E=',O<VAE970R,2YX
M;6Q02P$"% ,4    " #.3'A4=$:M6CDA   +=@  &0              @($&
ME@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ,Y,>%3@
M[I3IZ0(  %(&   9              " @7:W  !X;"]W;W)K<VAE971S+W-H
M965T,C,N>&UL4$L! A0#%     @ SDQX5.5?3Y!B @  -04  !D
M     ("!EKH  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4
M" #.3'A4/C/N.* "  #;!0  &0              @($OO0  >&PO=V]R:W-H
M965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ,Y,>%0(+*:!3P(  .($   9
M              " @0;   !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L!
M A0#%     @ SDQX5%NN(<]W @  M 4  !D              ("!C,(  'AL
M+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #.3'A4I)U8#=\"
M  #G!0  &0              @($ZQ0  >&PO=V]R:W-H965T<R]S:&5E=#(X
M+GAM;%!+ 0(4 Q0    ( ,Y,>%2A&,#%?P0  )4*   9              "
M@5#(  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ SDQX
M5'%MR6HN P  A@<  !D              ("!!LT  'AL+W=O<FMS:&5E=',O
M<VAE970S,"YX;6Q02P$"% ,4    " #.3'A4IH. (0P#  !K!@  &0
M        @(%KT   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0
M   ( ,Y,>%10] "DM0(  *\%   9              " @:[3  !X;"]W;W)K
M<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ SDQX5#E;E*BB @  O08
M !D              ("!FM8  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q0
M2P$"% ,4    " #.3'A4VPH$>HD#  !<"@  &0              @(%SV0
M>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ,Y,>%3[R)+X
MPP(  .L*   9              " @3/=  !X;"]W;W)K<VAE971S+W-H965T
M,S4N>&UL4$L! A0#%     @ SDQX5.' NQP6 P  8PT  !D
M ("!+>   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    " #.
M3'A4J4EL360"   :!@  &0              @(%ZXP  >&PO=V]R:W-H965T
M<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ,Y,>%0;=R,S8 (  +,%   9
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M970T,BYX;6Q02P$"% ,4    " #.3'A4D*3WOY$,  "Z-0  &0
M    @($F]   >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (
M ,Y,>%07XFQ<( \  .A(   9              " @>X  0!X;"]W;W)K<VAE
M971S+W-H965T-#0N>&UL4$L! A0#%     @ SDQX5%V%NLX8!0  020  !D
M             ("!11 ! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"
M% ,4    " #.3'A4JDB1<W$$  #U$   &0              @(&4%0$ >&PO
M=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( ,Y,>%3G'FDMM (
M &,'   9              " @3P: 0!X;"]W;W)K<VAE971S+W-H965T-#<N
M>&UL4$L! A0#%     @ SDQX5(-^,)H%!   E1   !D              ("!
M)QT! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " #.3'A4
MG._@I#$#  #/"@  &0              @(%C(0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0Y+GAM;%!+ 0(4 Q0    ( ,Y,>%1G&HNRV 0  /\:   9
M      " @<LD 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%
M  @ SDQX5$%E?PRT 0  IP,  !D              ("!VBD! 'AL+W=O<FMS
M:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " #.3'A4H7E%7$@#  #Q"0
M&0              @('%*P$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+
M 0(4 Q0    ( ,Y,>%3\UTU!: (  %$&   9              " @40O 0!X
M;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ SDQX5+,UMA+>
M P  1PX  !D              ("!XS$! 'AL+W=O<FMS:&5E=',O<VAE970U
M-"YX;6Q02P$"% ,4    " #.3'A4=?$0+W<"   7!P  &0
M@('X-0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( ,Y,
M>%3.XR7IQ0(  *\'   9              " @:8X 0!X;"]W;W)K<VAE971S
M+W-H965T-38N>&UL4$L! A0#%     @ SDQX5(@$8,5G @  T@4  !D
M         ("!HCL! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
M    " #.3'A4NP,];U0#   .%0  #0              @ % /@$ >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( ,Y,>%27BKL<P    !,"   +
M  "  ;]! 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ,Y,>%0ITS9+A00   4F
M   /              "  :A" 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" #.3'A4\R"+>>D!   2(@  &@              @ %:1P$ >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #.3'A4LFA)V-4!  "_(0
M$P              @ %[20$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..00!! +X1  "!2P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>173</ContextCount>
  <ElementCount>297</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>44</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ConsolidatedComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Changes in Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Changes in Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Changes in Equity (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals</Role>
      <ShortName>Consolidated Statements of Changes in Equity (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - General</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/General</Role>
      <ShortName>General</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Other Accounts Receivable and Prepaid Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpenses</Role>
      <ShortName>Other Accounts Receivable and Prepaid Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Short-Term Investment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShortTermInvestment</Role>
      <ShortName>Short-Term Investment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Property, Plant and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/PropertyPlantandEquipmentNet</Role>
      <ShortName>Property, Plant and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Other Accounts Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/OtherAccountsPayable</Role>
      <ShortName>Other Accounts Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Contingent Liabilities and Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ContingentLiabilitiesandCommitments</Role>
      <ShortName>Contingent Liabilities and Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareholdersEquity</Role>
      <ShortName>Shareholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Share-Based Payment Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareBasedPaymentTransactions</Role>
      <ShortName>Share-Based Payment Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Finance Income (Expense)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/FinanceIncomeExpense</Role>
      <ShortName>Finance Income (Expense)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Taxes on Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/TaxesonIncome</Role>
      <ShortName>Taxes on Income</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Transactions with Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/TransactionswithRelatedParties</Role>
      <ShortName>Transactions with Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.confite.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Other Accounts Receivable and Prepaid Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpensesTables</Role>
      <ShortName>Other Accounts Receivable and Prepaid Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpenses</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Property, Plant and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/PropertyPlantandEquipmentNetTables</Role>
      <ShortName>Property, Plant and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/PropertyPlantandEquipmentNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Other Accounts Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/OtherAccountsPayableTables</Role>
      <ShortName>Other Accounts Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/OtherAccountsPayable</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/FairValueMeasurements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Shareholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareholdersEquityTables</Role>
      <ShortName>Shareholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareholdersEquity</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Share-Based Payment Transactions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareBasedPaymentTransactionsTables</Role>
      <ShortName>Share-Based Payment Transactions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareBasedPaymentTransactions</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/Leases</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Finance Income (Expense) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/FinanceIncomeExpenseTables</Role>
      <ShortName>Finance Income (Expense) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/FinanceIncomeExpense</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Taxes on Income (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/TaxesonIncomeTables</Role>
      <ShortName>Taxes on Income (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.confite.com/role/TaxesonIncome</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - General (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/GeneralDetails</Role>
      <ShortName>General (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/General</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/SignificantAccountingPoliciesDetails</Role>
      <ShortName>Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Significant Accounting Policies (Details) - Schedule of property, plant and equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable</Role>
      <ShortName>Significant Accounting Policies (Details) - Schedule of property, plant and equipment</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable</Role>
      <ShortName>Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Other Accounts Receivable and Prepaid Expenses (Details) - Schedule of other accounts receivable and prepaid expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable</Role>
      <ShortName>Other Accounts Receivable and Prepaid Expenses (Details) - Schedule of other accounts receivable and prepaid expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpensesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Short-Term Investment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShortTermInvestmentDetails</Role>
      <ShortName>Short-Term Investment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShortTermInvestment</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Property, Plant and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/PropertyPlantandEquipmentNetDetails</Role>
      <ShortName>Property, Plant and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/PropertyPlantandEquipmentNetTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable</Role>
      <ShortName>Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/PropertyPlantandEquipmentNetTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Other Accounts Payable (Details) - Schedule of other accounts payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofotheraccountspayableTable</Role>
      <ShortName>Other Accounts Payable (Details) - Schedule of other accounts payable</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/OtherAccountsPayableTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable</Role>
      <ShortName>Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Contingent Liabilities and Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails</Role>
      <ShortName>Contingent Liabilities and Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ContingentLiabilitiesandCommitments</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Shareholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareholdersEquityDetails</Role>
      <ShortName>Shareholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareholdersEquityTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable</Role>
      <ShortName>Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareholdersEquityTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Share-Based Payment Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ShareBasedPaymentTransactionsDetails</Role>
      <ShortName>Share-Based Payment Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofexpensesTable</Role>
      <ShortName>Share-Based Payment Transactions (Details) - Schedule of expenses</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable</Role>
      <ShortName>Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of weighted average exercise prices and modification in option plans of employees</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable</Role>
      <ShortName>Share-Based Payment Transactions (Details) - Schedule of weighted average exercise prices and modification in option plans of employees</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of options outstanding classified by exercise price</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable</Role>
      <ShortName>Share-Based Payment Transactions (Details) - Schedule of options outstanding classified by exercise price</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/ShareBasedPaymentTransactionsTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/LeasesTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Leases (Details) - Schedule of lease expense and supplemental cash flow information related to leases and weighted average remaining lease terms and discount rate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable</Role>
      <ShortName>Leases (Details) - Schedule of lease expense and supplemental cash flow information related to leases and weighted average remaining lease terms and discount rate</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/LeasesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable</Role>
      <ShortName>Leases (Details) - Schedule of maturities of lease liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/LeasesTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Finance Income (Expense) (Details) - Schedule of components of finance (income)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable</Role>
      <ShortName>Finance Income (Expense) (Details) - Schedule of components of finance (income)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/FinanceIncomeExpenseTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/TaxesonIncomeDetails</Role>
      <ShortName>Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/TaxesonIncomeTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Taxes on Income (Details) - Schedule of deferred tax assets and liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable</Role>
      <ShortName>Taxes on Income (Details) - Schedule of deferred tax assets and liabilities</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/TaxesonIncomeTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="f20f2021_canfitebio.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Transactions with Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.confite.com/role/TransactionswithRelatedPartiesDetails</Role>
      <ShortName>Transactions with Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.confite.com/role/TransactionswithRelatedParties</ParentRole>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="20-F" original="f20f2021_canfitebio.htm">f20f2021_canfitebio.htm</File>
    <File>canf-20211231.xsd</File>
    <File>canf-20211231_cal.xml</File>
    <File>canf-20211231_def.xml</File>
    <File>canf-20211231_lab.xml</File>
    <File>canf-20211231_pre.xml</File>
    <File>f20f2021ex12-1_canfitebio.htm</File>
    <File>f20f2021ex12-2_canfitebio.htm</File>
    <File>f20f2021ex13-1_canfitebio.htm</File>
    <File>f20f2021ex13-2_canfitebio.htm</File>
    <File>f20f2021ex15-1_canfitebio.htm</File>
    <File>f20f2021ex8-1_canfitebio.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img_001.jpg</File>
    <File>img_002.jpg</File>
    <File>img_003.jpg</File>
    <File>img_004.jpg</File>
    <File>img_005.jpg</File>
    <File>img_006.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="510">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="47">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>83
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "f20f2021_canfitebio.htm": {
   "axisCustom": 0,
   "axisStandard": 14,
   "contextCount": 173,
   "dts": {
    "calculationLink": {
     "local": [
      "canf-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "canf-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "f20f2021_canfitebio.htm"
     ]
    },
    "labelLink": {
     "local": [
      "canf-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "canf-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "canf-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd"
     ]
    }
   },
   "elementCount": 448,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 51,
    "http://www.confite.com/20211231": 13,
    "http://xbrl.sec.gov/dei/2021q4": 3,
    "total": 67
   },
   "keyCustom": 78,
   "keyStandard": 219,
   "memberCustom": 28,
   "memberStandard": 15,
   "nsprefix": "canf",
   "nsuri": "http://www.confite.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.confite.com/role/DocumentAndEntityInformation",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Other Accounts Receivable and Prepaid Expenses",
     "role": "http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpenses",
     "shortName": "Other Accounts Receivable and Prepaid Expenses",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:OtherAccountsReceivableAndPrepaidExpensesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Short-Term Investment",
     "role": "http://www.confite.com/role/ShortTermInvestment",
     "shortName": "Short-Term Investment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Property, Plant and Equipment, Net",
     "role": "http://www.confite.com/role/PropertyPlantandEquipmentNet",
     "shortName": "Property, Plant and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Other Accounts Payable",
     "role": "http://www.confite.com/role/OtherAccountsPayable",
     "shortName": "Other Accounts Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Fair Value Measurements",
     "role": "http://www.confite.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Contingent Liabilities and Commitments",
     "role": "http://www.confite.com/role/ContingentLiabilitiesandCommitments",
     "shortName": "Contingent Liabilities and Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Shareholders' Equity",
     "role": "http://www.confite.com/role/ShareholdersEquity",
     "shortName": "Shareholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Share-Based Payment Transactions",
     "role": "http://www.confite.com/role/ShareBasedPaymentTransactions",
     "shortName": "Share-Based Payment Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Leases",
     "role": "http://www.confite.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Finance Income (Expense)",
     "role": "http://www.confite.com/role/FinanceIncomeExpense",
     "shortName": "Finance Income (Expense)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "role": "http://www.confite.com/role/ConsolidatedBalanceSheet",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Taxes on Income",
     "role": "http://www.confite.com/role/TaxesonIncome",
     "shortName": "Taxes on Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Transactions with Related Parties",
     "role": "http://www.confite.com/role/TransactionswithRelatedParties",
     "shortName": "Transactions with Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Accounting Policies, by Policy (Policies)",
     "role": "http://www.confite.com/role/AccountingPoliciesByPolicy",
     "shortName": "Accounting Policies, by Policy (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:ScheduleOfUsefulLivesOfTheAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Significant Accounting Policies (Tables)",
     "role": "http://www.confite.com/role/SignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:ScheduleOfUsefulLivesOfTheAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Other Accounts Receivable and Prepaid Expenses (Tables)",
     "role": "http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpensesTables",
     "shortName": "Other Accounts Receivable and Prepaid Expenses (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Property, Plant and Equipment, Net (Tables)",
     "role": "http://www.confite.com/role/PropertyPlantandEquipmentNetTables",
     "shortName": "Property, Plant and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Other Accounts Payable (Tables)",
     "role": "http://www.confite.com/role/OtherAccountsPayableTables",
     "shortName": "Other Accounts Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.confite.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Shareholders' Equity (Tables)",
     "role": "http://www.confite.com/role/ShareholdersEquityTables",
     "shortName": "Shareholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:ScheduleOfExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Share-Based Payment Transactions (Tables)",
     "role": "http://www.confite.com/role/ShareBasedPaymentTransactionsTables",
     "shortName": "Share-Based Payment Transactions (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:ScheduleOfExpensesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "ilsPershares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "role": "http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Leases (Tables)",
     "role": "http://www.confite.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Finance Income (Expense) (Tables)",
     "role": "http://www.confite.com/role/FinanceIncomeExpenseTables",
     "shortName": "Finance Income (Expense) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Taxes on Income (Tables)",
     "role": "http://www.confite.com/role/TaxesonIncomeTables",
     "shortName": "Taxes on Income (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - General (Details)",
     "role": "http://www.confite.com/role/GeneralDetails",
     "shortName": "General (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "lang": null,
      "name": "canf:CashFlowsFromOperatingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "td",
       "tr",
       "table",
       "us-gaap:ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Significant Accounting Policies (Details)",
     "role": "http://www.confite.com/role/SignificantAccountingPoliciesDetails",
     "shortName": "Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "td",
       "tr",
       "table",
       "us-gaap:ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtWeightedAverageInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "canf:ScheduleOfUsefulLivesOfTheAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c36",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Significant Accounting Policies (Details) - Schedule of property, plant and equipment",
     "role": "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable",
     "shortName": "Significant Accounting Policies (Details) - Schedule of property, plant and equipment",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "canf:ScheduleOfUsefulLivesOfTheAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c36",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "canf:UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "canf:ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "canf:RevenueContractWithCustomer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues",
     "role": "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable",
     "shortName": "Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "canf:ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "canf:RevenueContractWithCustomer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "canf:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "canf:GovernmentAuthorities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Other Accounts Receivable and Prepaid Expenses (Details) - Schedule of other accounts receivable and prepaid expenses",
     "role": "http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable",
     "shortName": "Other Accounts Receivable and Prepaid Expenses (Details) - Schedule of other accounts receivable and prepaid expenses",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "canf:ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "canf:GovernmentAuthorities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Short-Term Investment (Details)",
     "role": "http://www.confite.com/role/ShortTermInvestmentDetails",
     "shortName": "Short-Term Investment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "2",
      "lang": null,
      "name": "canf:PercentageOfOutstandingShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationExpenseOnReclassifiedAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Property, Plant and Equipment, Net (Details)",
     "role": "http://www.confite.com/role/PropertyPlantandEquipmentNetDetails",
     "shortName": "Property, Plant and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationExpenseOnReclassifiedAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.confite.com/role/ConsolidatedComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net",
     "role": "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable",
     "shortName": "Property, Plant and Equipment, Net (Details) - Schedule of property, plant and equipment, net",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "canf:EmployeesAndPayrollAccruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Other Accounts Payable (Details) - Schedule of other accounts payable",
     "role": "http://www.confite.com/role/ScheduleofotheraccountspayableTable",
     "shortName": "Other Accounts Payable (Details) - Schedule of other accounts payable",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "canf:EmployeesAndPayrollAccruals",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c54",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis",
     "role": "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable",
     "shortName": "Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c54",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NoninterestExpenseCommissionExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Contingent Liabilities and Commitments (Details)",
     "role": "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails",
     "shortName": "Contingent Liabilities and Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NoninterestExpenseCommissionExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "eur",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c79",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:StockholdersEquityChangeInRatioDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Shareholders' Equity (Details)",
     "role": "http://www.confite.com/role/ShareholdersEquityDetails",
     "shortName": "Shareholders' Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c79",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:StockholdersEquityChangeInRatioDescription",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "canf:ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares",
     "role": "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable",
     "shortName": "Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "canf:ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c151",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:GrantedExcessYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Share-Based Payment Transactions (Details)",
     "role": "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails",
     "shortName": "Share-Based Payment Transactions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c151",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "canf:GrantedExcessYears",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "canf:ScheduleOfExpensesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of expenses",
     "role": "http://www.confite.com/role/ScheduleofexpensesTable",
     "shortName": "Share-Based Payment Transactions (Details) - Schedule of expenses",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "canf:ScheduleOfExpensesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "canf:ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model",
     "role": "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable",
     "shortName": "Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "canf:ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pure",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of weighted average exercise prices and modification in option plans of employees",
     "role": "http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable",
     "shortName": "Share-Based Payment Transactions (Details) - Schedule of weighted average exercise prices and modification in option plans of employees",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c3",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statements of Changes in Equity",
     "role": "http://www.confite.com/role/ShareholdersEquityType2or3",
     "shortName": "Consolidated Statements of Changes in Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c6",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Share-Based Payment Transactions (Details) - Schedule of options outstanding classified by exercise price",
     "role": "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable",
     "shortName": "Share-Based Payment Transactions (Details) - Schedule of options outstanding classified by exercise price",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Leases (Details)",
     "role": "http://www.confite.com/role/LeasesDetails",
     "shortName": "Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Leases (Details) - Schedule of lease expense and supplemental cash flow information related to leases and weighted average remaining lease terms and discount rate",
     "role": "http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable",
     "shortName": "Leases (Details) - Schedule of lease expense and supplemental cash flow information related to leases and weighted average remaining lease terms and discount rate",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Leases (Details) - Schedule of maturities of lease liabilities",
     "role": "http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable",
     "shortName": "Leases (Details) - Schedule of maturities of lease liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "canf:BanksCommissions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "053 - Disclosure - Finance Income (Expense) (Details) - Schedule of components of finance (income)",
     "role": "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable",
     "shortName": "Finance Income (Expense) (Details) - Schedule of components of finance (income)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "canf:BanksCommissions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsCapitalLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "054 - Disclosure - Taxes on Income (Details)",
     "role": "http://www.confite.com/role/TaxesonIncomeDetails",
     "shortName": "Taxes on Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsCapitalLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "055 - Disclosure - Taxes on Income (Details) - Schedule of deferred tax assets and liabilities",
     "role": "http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable",
     "shortName": "Taxes on Income (Details) - Schedule of deferred tax assets and liabilities",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "056 - Disclosure - Transactions with Related Parties (Details)",
     "role": "http://www.confite.com/role/TransactionswithRelatedPartiesDetails",
     "shortName": "Transactions with Related Parties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "canf:WarrantsNetOfIssueExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Consolidated Statements of Changes in Equity (Parentheticals)",
     "role": "http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals",
     "shortName": "Consolidated Statements of Changes in Equity (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "canf:WarrantsNetOfIssueExpenses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "006 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.confite.com/role/ConsolidatedCashFlow",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - General",
     "role": "http://www.confite.com/role/General",
     "shortName": "General",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Significant Accounting Policies",
     "role": "http://www.confite.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "f20f2021_canfitebio.htm",
      "contextRef": "c0",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 44,
   "tag": {
    "canf_ADSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "American Depository Receipt (or American Depository Share, ADS).",
        "label": "ADSMember",
        "terseLabel": "ADS [Member]"
       }
      }
     },
     "localname": "ADSMember",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_AccountingPronouncementsNotYetAdoptedPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for accounting pronouncements not yet adopted.",
        "label": "AccountingPronouncementsNotYetAdoptedPolicyTextBlock",
        "terseLabel": "Accounting pronouncements not yet adopted"
       }
      }
     },
     "localname": "AccountingPronouncementsNotYetAdoptedPolicyTextBlock",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_AccumulatedDepreciationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "AccumulatedDepreciationAbstract",
        "terseLabel": "Accumulated depreciation:"
       }
      }
     },
     "localname": "AccumulatedDepreciationAbstract",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_AdditionalPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional payments maximum charges.",
        "label": "AdditionalPayments",
        "terseLabel": "Additional payments"
       }
      }
     },
     "localname": "AdditionalPayments",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_AggregateNumberOfADS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "aggregate number of ADS.",
        "label": "AggregateNumberOfADS",
        "terseLabel": "Aggregate number of ADS percentage"
       }
      }
     },
     "localname": "AggregateNumberOfADS",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_AggregatePurchasePrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate purchase price.",
        "label": "AggregatePurchasePrice",
        "terseLabel": "Aggregate purchase price (in Dollars)"
       }
      }
     },
     "localname": "AggregatePurchasePrice",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_AggregateWarrantPurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate warrant purchased.",
        "label": "AggregateWarrantPurchased",
        "terseLabel": "Aggregate warrant purchased"
       }
      }
     },
     "localname": "AggregateWarrantPurchased",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_April2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "April2019Member",
        "terseLabel": "April 2019 [Member]"
       }
      }
     },
     "localname": "April2019Member",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_August2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "August2021Member",
        "terseLabel": "August 2021 [Member]"
       }
      }
     },
     "localname": "August2021Member",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_BanksCommissions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bank commissions.",
        "label": "BanksCommissions",
        "terseLabel": "Bank commissions"
       }
      }
     },
     "localname": "BanksCommissions",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_CMSMedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CMSMedicalMember",
        "terseLabel": "CMS Medical [Member]"
       }
      }
     },
     "localname": "CMSMedicalMember",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_CashFlowsFromOperatingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "CashFlowsFromOperatingActivities",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "CashFlowsFromOperatingActivities",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/GeneralDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities.",
        "label": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "CashPaidForAmountsIncludedInTheMeasurementOfLeaseLiabilities",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_ChongKunDangMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ChongKunDangMember",
        "terseLabel": "Chong kun dang [Member]"
       }
      }
     },
     "localname": "ChongKunDangMember",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_ChongKunDangPharmaceuticalsCorpMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ChongKunDangPharmaceuticalsCorpMember",
        "terseLabel": "Chong Kun Dang Pharmaceuticals Corp [Member]"
       }
      }
     },
     "localname": "ChongKunDangPharmaceuticalsCorpMember",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_CipherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CipherMember",
        "terseLabel": "Cipher [Member]"
       }
      }
     },
     "localname": "CipherMember",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_CipherPharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CipherPharmaceuticalsMember",
        "terseLabel": "Cipher Pharmaceuticals [Member]"
       }
      }
     },
     "localname": "CipherPharmaceuticalsMember",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_CompensationWarrantsExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "compensation warrants exercisable.",
        "label": "CompensationWarrantsExercisable",
        "terseLabel": "Compensation warrant exercisable"
       }
      }
     },
     "localname": "CompensationWarrantsExercisable",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_ComponentsOfLeaseExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ComponentsOfLeaseExpenseAbstract",
        "terseLabel": "Components of lease expense:"
       }
      }
     },
     "localname": "ComponentsOfLeaseExpenseAbstract",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ComputersOfficeFurnitureAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ComputersOfficeFurnitureAndEquipmentMember",
        "terseLabel": "Computers, office furniture and equipment [Member]"
       }
      }
     },
     "localname": "ComputersOfficeFurnitureAndEquipmentMember",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable",
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_ContingentLiabilitiesandCommitmentsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities and Commitments (Details) [Line Items]"
       }
      }
     },
     "localname": "ContingentLiabilitiesandCommitmentsDetailsLineItems",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ContingentLiabilitiesandCommitmentsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingent Liabilities and Commitments (Details) [Table]"
       }
      }
     },
     "localname": "ContingentLiabilitiesandCommitmentsDetailsTable",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ContractLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amouunt of contract liabilities.",
        "label": "ContractLiabilities",
        "terseLabel": "Contract liabilities under deferred revenues"
       }
      }
     },
     "localname": "ContractLiabilities",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_CostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CostAbstract",
        "terseLabel": "Cost:"
       }
      }
     },
     "localname": "CostAbstract",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_December2021Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "December2021Member",
        "terseLabel": "December 2021 [Member]"
       }
      }
     },
     "localname": "December2021Member",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_DeemedDividend": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deemed dividend.",
        "label": "DeemedDividend",
        "terseLabel": "Deemed dividend (in Dollars)"
       }
      }
     },
     "localname": "DeemedDividend",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_DeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "DeferredTaxAssetsAbstract",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsAbstract",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.confite.com/20211231",
     "xbrltype": "stringItemType"
    },
    "canf_EmployeesAndPayrollAccruals": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ScheduleofotheraccountspayableTable": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAccountsPayableAndAccruedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of employees and payroll accruals.",
        "label": "EmployeesAndPayrollAccruals",
        "terseLabel": "Employees and payroll accruals"
       }
      }
     },
     "localname": "EmployeesAndPayrollAccruals",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofotheraccountspayableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_EwopharmaAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "EwopharmaAGMember",
        "terseLabel": "Ewopharma AG [Member]"
       }
      }
     },
     "localname": "EwopharmaAGMember",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_ExchangeRateFluctuations": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange rate fluctuations.",
        "label": "ExchangeRateFluctuations",
        "terseLabel": "Exchange rate fluctuations"
       }
      }
     },
     "localname": "ExchangeRateFluctuations",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_ExerciseAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExerciseAgreementDescription",
        "terseLabel": "Exercise agreement description"
       }
      }
     },
     "localname": "ExerciseAgreementDescription",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price.",
        "label": "ExercisePrice",
        "terseLabel": "Exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "ExercisePrice",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "canf_ExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExercisePriceRangeOneMember",
        "terseLabel": "Exercise price $0.08 - $0.94 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeOneMember",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_ExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExercisePriceRangeThreeMember",
        "terseLabel": "Exercise price $2.61 - $5.18 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeThreeMember",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_ExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ExercisePriceRangeTwoMember",
        "terseLabel": "Exercise price $1.09 - $1.73 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRangeTwoMember",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_ExercisePriceSubjectToAdjusment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price Subject to adjustment.",
        "label": "ExercisePriceSubjectToAdjusment",
        "terseLabel": "Exercise price subject to adjustment (in Dollars per share)"
       }
      }
     },
     "localname": "ExercisePriceSubjectToAdjusment",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "canf_ExercisePrices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant, Exercise Price, Decrease.",
        "label": "ExercisePrices",
        "terseLabel": "Exercise prices (in Dollars per share)"
       }
      }
     },
     "localname": "ExercisePrices",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "canf_FairValueAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value amount.",
        "label": "FairValueAmount",
        "terseLabel": "Fair value amount (in Dollars)"
       }
      }
     },
     "localname": "FairValueAmount",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Line Items]"
       }
      }
     },
     "localname": "FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisLineItems",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements (Details) - Schedule of financial assets and liabilities measured at fair value on a recurring basis [Table]"
       }
      }
     },
     "localname": "FairValueMeasurementsDetailsScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_February2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "February2020Member",
        "terseLabel": "February 2020 [Member]"
       }
      }
     },
     "localname": "February2020Member",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_FinanceExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "FinanceExpenses",
        "terseLabel": "Finance expenses"
       }
      }
     },
     "localname": "FinanceExpenses",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_FinanceExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FinanceExpensesAbstract",
        "terseLabel": "Finance expenses:"
       }
      }
     },
     "localname": "FinanceExpensesAbstract",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_FinanceIncome": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income from finance income.",
        "label": "FinanceIncome",
        "terseLabel": "Finance income"
       }
      }
     },
     "localname": "FinanceIncome",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_FinanceIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "FinanceIncomeAbstract",
        "terseLabel": "Finance income:"
       }
      }
     },
     "localname": "FinanceIncomeAbstract",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_FutureShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future shares.",
        "label": "FutureShares",
        "terseLabel": "Future shares (in Shares)"
       }
      }
     },
     "localname": "FutureShares",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_GebroHoldingGmBHMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GebroHoldingGmBHMember",
        "terseLabel": "Gebro Holding GmBH [Member]"
       }
      }
     },
     "localname": "GebroHoldingGmBHMember",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_GovernmentAuthorities": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherReceivablesNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of government authorities for the period.",
        "label": "GovernmentAuthorities",
        "terseLabel": "Government authorities"
       }
      }
     },
     "localname": "GovernmentAuthorities",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_GrantedExcessYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GrantedExcessYears",
        "terseLabel": "Granted excess years"
       }
      }
     },
     "localname": "GrantedExcessYears",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "canf_ImputedInterestLessImputedInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "imputed interest.",
        "label": "ImputedInterestLessImputedInterest",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "ImputedInterestLessImputedInterest",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_IncreaseAuthorizedShareCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase authorized Share Capital.",
        "label": "IncreaseAuthorizedShareCapital",
        "terseLabel": "Increase authorized capital"
       }
      }
     },
     "localname": "IncreaseAuthorizedShareCapital",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_IncreaseDecreaseInChangesInFairValueOfShorttermInvestment": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of changes in fair value of short-term investment.",
        "label": "IncreaseDecreaseInChangesInFairValueOfShorttermInvestment",
        "negatedLabel": "Changes in fair value of short-term investment"
       }
      }
     },
     "localname": "IncreaseDecreaseInChangesInFairValueOfShorttermInvestment",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_IncreaseDecreaseInSharebasedPayment": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of changes in share based payment.",
        "label": "IncreaseDecreaseInSharebasedPayment",
        "terseLabel": "Share-based payment"
       }
      }
     },
     "localname": "IncreaseDecreaseInSharebasedPayment",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_IssuanceDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IssuanceDate",
        "terseLabel": "Issuance date"
       }
      }
     },
     "localname": "IssuanceDate",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_IssuanceExpensesAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance expenses amount.",
        "label": "IssuanceExpensesAmount",
        "terseLabel": "Issuance expenses amount (in Dollars)"
       }
      }
     },
     "localname": "IssuanceExpensesAmount",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of share capital due to warrants exercise, net of issuance expenses.",
        "label": "IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses",
        "terseLabel": "Issuance of share capital due to warrants exercise, net of issuance expenses"
       }
      }
     },
     "localname": "IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpenses",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of share capital due to warrants exercise, net of issuance expenses.",
        "label": "IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares",
        "terseLabel": "Issuance of share capital due to warrants exercise, net of issuance expenses (in Shares)"
       }
      }
     },
     "localname": "IssuanceOfShareCapitalDueToWarrantsExerciseNetOfIssuanceExpensesinShares",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_IssueOfNewUnregisteredWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issue of New Unregistered Warrants.",
        "label": "IssueOfNewUnregisteredWarrants",
        "terseLabel": "Issue of new unregistered warrants"
       }
      }
     },
     "localname": "IssueOfNewUnregisteredWarrants",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_January2017Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "January2017Member",
        "terseLabel": "January 2017 [Member]"
       }
      }
     },
     "localname": "January2017Member",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_January2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "January2019Member",
        "terseLabel": "January 2019 [Member]"
       }
      }
     },
     "localname": "January2019Member",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_January2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "January2020Member",
        "terseLabel": "January 2020 [Member]"
       }
      }
     },
     "localname": "January2020Member",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_July2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "July2020Member",
        "terseLabel": "July 2020 [Member]"
       }
      }
     },
     "localname": "July2020Member",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_June2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "June2020Member",
        "terseLabel": "June 2020 [Member]"
       }
      }
     },
     "localname": "June2020Member",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_KyongboPharmMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "KyongboPharmMember",
        "terseLabel": "Kyongbo Pharm [Member]"
       }
      }
     },
     "localname": "KyongboPharmMember",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_LaboratoryEquipmentAndLeaseholdImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LaboratoryEquipmentAndLeaseholdImprovementsMember",
        "terseLabel": "Laboratory equipment and Leasehold improvements [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentAndLeaseholdImprovementsMember",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "LaboratoryEquipmentMember",
        "terseLabel": "Laboratory equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_LesseeOperatingLeaseLiabilityPaymentDue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "LesseeOperatingLeaseLiabilityPaymentDue",
        "terseLabel": "Total operating lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentDue",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_March2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "March2018Member",
        "terseLabel": "March 2018 [Member]"
       }
      }
     },
     "localname": "March2018Member",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_May2019Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "May2019Member",
        "terseLabel": "May 2019 [Member]"
       }
      }
     },
     "localname": "May2019Member",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_NetLossFromExchangeRateFluctuations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net loss from exchange rate fluctuations.",
        "label": "NetLossFromExchangeRateFluctuations",
        "terseLabel": "Net loss from exchange rate fluctuations"
       }
      }
     },
     "localname": "NetLossFromExchangeRateFluctuations",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_NonRefundableUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of non refundable upfront payment.",
        "label": "NonRefundableUpfrontPayment",
        "terseLabel": "Non-refundable upfront payment (in Euro)"
       }
      }
     },
     "localname": "NonRefundableUpfrontPayment",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_NumberOfExercisableAtEndOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "NumberOfExercisableAtEndOfShares",
        "terseLabel": "Number of Exercisable at end of year"
       }
      }
     },
     "localname": "NumberOfExercisableAtEndOfShares",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_NumberOfOrdinaryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NumberOfOrdinaryShares",
        "terseLabel": "Number of ordinary shares (in Shares)"
       }
      }
     },
     "localname": "NumberOfOrdinaryShares",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for ordinary share warrants classification and measurement.",
        "label": "OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock",
        "terseLabel": "Ordinary share warrants classification and measurement"
       }
      }
     },
     "localname": "OrdinaryShareWarrantsClassificationAndMeasurementPolicyTextBlock",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_OrdinaryShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ordinary shares.",
        "label": "OrdinaryShares",
        "terseLabel": "Ordinary shares"
       }
      }
     },
     "localname": "OrdinaryShares",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_OtherAccountsPayableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Payable [Abstract]"
       }
      }
     },
     "localname": "OtherAccountsPayableLineItems",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/OtherAccountsPayable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_OtherAccountsPayableTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Payable [Table]"
       }
      }
     },
     "localname": "OtherAccountsPayableTable",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/OtherAccountsPayable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_OtherAccountsReceivableAndPrepaidExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accounts Receivable And Prepaid Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherAccountsReceivableAndPrepaidExpensesAbstract",
     "nsuri": "http://www.confite.com/20211231",
     "xbrltype": "stringItemType"
    },
    "canf_OtherAccountsReceivableAndPrepaidExpensesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of other accounts receivable and prepaid expenses.",
        "label": "OtherAccountsReceivableAndPrepaidExpensesTextBlock",
        "terseLabel": "OTHER ACCOUNTS RECEIVABLE AND PREPAID EXPENSES"
       }
      }
     },
     "localname": "OtherAccountsReceivableAndPrepaidExpensesTextBlock",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpenses"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_OtherLossFromShorttermInvestmentRevaluation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other loss from short-term investment revaluation.",
        "label": "OtherLossFromShorttermInvestmentRevaluation",
        "terseLabel": "Other loss from short-term investment revaluation"
       }
      }
     },
     "localname": "OtherLossFromShorttermInvestmentRevaluation",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_PatentAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of patent agreement.",
        "label": "PatentAgreementDescription",
        "terseLabel": "Patent agreement, description"
       }
      }
     },
     "localname": "PatentAgreementDescription",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_PercentageOfDepositsOnMonthlySalary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of deposits on monthly salary.",
        "label": "PercentageOfDepositsOnMonthlySalary",
        "terseLabel": "Percentage of deposits on monthly salary"
       }
      }
     },
     "localname": "PercentageOfDepositsOnMonthlySalary",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_PercentageOfNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of net sales.",
        "label": "PercentageOfNetSales",
        "terseLabel": "Percentage of net sales"
       }
      }
     },
     "localname": "PercentageOfNetSales",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_PercentageOfOutstandingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of outstanding shares.",
        "label": "PercentageOfOutstandingShares",
        "terseLabel": "Percentage of outstanding shares"
       }
      }
     },
     "localname": "PercentageOfOutstandingShares",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShortTermInvestmentDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_PercentageOfRealizationOnUltimateSettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of realization on ultimate settlement.",
        "label": "PercentageOfRealizationOnUltimateSettlement",
        "terseLabel": "Maximum percentage of realization on ultimate settlement"
       }
      }
     },
     "localname": "PercentageOfRealizationOnUltimateSettlement",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_PurchaseAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PurchaseAgreementDescription",
        "terseLabel": "Purchase agreement description"
       }
      }
     },
     "localname": "PurchaseAgreementDescription",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_Revenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues.",
        "label": "Revenue",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenue",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_RevenueContractWithCustomer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue contract with customer.",
        "label": "RevenueContractWithCustomer",
        "terseLabel": "Total revenues"
       }
      }
     },
     "localname": "RevenueContractWithCustomer",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_RevenuesIncludedInContractLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues included in contract liabilities.",
        "label": "RevenuesIncludedInContractLiabilities",
        "terseLabel": "Revenues included in contract liabilities"
       }
      }
     },
     "localname": "RevenuesIncludedInContractLiabilities",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_RoyaltyOnNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "RoyaltyOnNetSales",
        "terseLabel": "Percentage of royalties on net sales"
       }
      }
     },
     "localname": "RoyaltyOnNetSales",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_RoyaltyPaymentsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The royalty payment in percentage.",
        "label": "RoyaltyPaymentsPercentage",
        "terseLabel": "Royalty payments, percentage"
       }
      }
     },
     "localname": "RoyaltyPaymentsPercentage",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_ScheduleOfComponentsOfFinanceIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of components of finance (income) [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfFinanceIncomeAbstract",
     "nsuri": "http://www.confite.com/20211231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of deferred tax assets and liabilities [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://www.confite.com/20211231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of estimated using the binomial option pricing model [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsingTheBinomialOptionPricingModelAbstract",
     "nsuri": "http://www.confite.com/20211231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock",
        "terseLabel": "Schedule of estimated using the binomial option pricing model"
       }
      }
     },
     "localname": "ScheduleOfEstimatedUsingTheBinomialOptionPricingModelTableTextBlock",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_ScheduleOfExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of expenses [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfExpensesAbstract",
     "nsuri": "http://www.confite.com/20211231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfExpensesTableTextBlock",
        "terseLabel": "Schedule of expenses"
       }
      }
     },
     "localname": "ScheduleOfExpensesTableTextBlock",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of financial assets and liabilities measured at fair value on a recurring basis [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnARecurringBasisAbstract",
     "nsuri": "http://www.confite.com/20211231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of information regarding outstanding warrants to purchase shares [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesAbstract",
     "nsuri": "http://www.confite.com/20211231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock",
        "terseLabel": "Schedule of information regarding outstanding warrants to purchase shares"
       }
      }
     },
     "localname": "ScheduleOfInformationRegardingOutstandingWarrantsToPurchaseSharesTableTextBlock",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of lease expense and supplemental cash flow information related to leases and weighted average remaining lease terms and discount rate [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfLeaseExpenseAndSupplementalCashFlowInformationRelatedToLeasesAndWeightedAverageRemainingLeaseTermsAndDiscountRateAbstract",
     "nsuri": "http://www.confite.com/20211231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of major customer data as a percentage of total revenues [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesAbstract",
     "nsuri": "http://www.confite.com/20211231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of major customer data as a percentage of total revenues.",
        "label": "ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock",
        "terseLabel": "Schedule of major customer data as a percentage of total revenues"
       }
      }
     },
     "localname": "ScheduleOfMajorCustomerDataAsAPercentageOfTotalRevenuesTableTextBlock",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of maturities of lease liabilities [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLeaseLiabilitiesAbstract",
     "nsuri": "http://www.confite.com/20211231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of options outstanding classified by exercise price [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfOptionsOutstandingClassifiedByExercisePriceAbstract",
     "nsuri": "http://www.confite.com/20211231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfOtherAccountsPayableAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of other accounts payable [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfOtherAccountsPayableAbstract",
     "nsuri": "http://www.confite.com/20211231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of other accounts receivable and prepaid expenses [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfOtherAccountsReceivableAndPrepaidExpensesAbstract",
     "nsuri": "http://www.confite.com/20211231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Other Accounts Receivable and Prepaid Expenses.",
        "label": "ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
        "terseLabel": "Schedule of other accounts receivable and prepaid expenses"
       }
      }
     },
     "localname": "ScheduleOfOtherAccountsReceivableAndPrepaidExpensesTableTextBlock",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/OtherAccountsReceivableandPrepaidExpensesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_ScheduleOfPropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of property, plant and equipment [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentAbstract",
     "nsuri": "http://www.confite.com/20211231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfPropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of property, plant and equipment, net [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://www.confite.com/20211231",
     "xbrltype": "stringItemType"
    },
    "canf_ScheduleOfUsefulLivesOfTheAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful lives of the assets.",
        "label": "ScheduleOfUsefulLivesOfTheAssetsTableTextBlock",
        "terseLabel": "Schedule of property, plant and equipment"
       }
      }
     },
     "localname": "ScheduleOfUsefulLivesOfTheAssetsTableTextBlock",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of weighted average exercise prices and modification in option plans of employees [Abstract]"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageExercisePricesAndModificationInOptionPlansOfEmployeesAbstract",
     "nsuri": "http://www.confite.com/20211231",
     "xbrltype": "stringItemType"
    },
    "canf_SecuritiesPurchaseAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement, Description.",
        "label": "SecuritiesPurchaseAgreementDescription",
        "terseLabel": "Securities purchase agreement, description"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementDescription",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_SeverancePayPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for severance pay.",
        "label": "SeverancePayPolicyTextBlock",
        "terseLabel": "Severance pay"
       }
      }
     },
     "localname": "SeverancePayPolicyTextBlock",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "canf_ShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price.",
        "label": "ShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
        "terseLabel": "Exercise price (NIS) (in New Shekels per share)"
       }
      }
     },
     "localname": "ShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "canf_ShareBasedPaymentTransactionsDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions (Details) [Line Items]"
       }
      }
     },
     "localname": "ShareBasedPaymentTransactionsDetailsLineItems",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model [Line Items]"
       }
      }
     },
     "localname": "ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelLineItems",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions (Details) - Schedule of estimated using the binomial option pricing model [Table]"
       }
      }
     },
     "localname": "ShareBasedPaymentTransactionsDetailsScheduleofestimatedusingthebinomialoptionpricingmodelTable",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShareBasedPaymentTransactionsDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Transactions (Details) [Table]"
       }
      }
     },
     "localname": "ShareBasedPaymentTransactionsDetailsTable",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShareIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "ShareIssued",
        "terseLabel": "Ordinary shares issued"
       }
      }
     },
     "localname": "ShareIssued",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_SharebasedPaymentArrangementOptionExercisePriceRange": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "SharebasedPaymentArrangementOptionExercisePriceRange",
        "terseLabel": "Exercise price"
       }
      }
     },
     "localname": "SharebasedPaymentArrangementOptionExercisePriceRange",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "canf_SharebasedPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payments.",
        "label": "SharebasedPayments",
        "terseLabel": "Share-based payments"
       }
      }
     },
     "localname": "SharebasedPayments",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_ShareholdersEquityDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Line Items]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsLineItems",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Line Items]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesLineItems",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) - Schedule of information regarding outstanding warrants to purchase shares [Table]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShareholdersEquityDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shareholders' Equity (Details) [Table]"
       }
      }
     },
     "localname": "ShareholdersEquityDetailsTable",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_ShortTermInvestmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Investment [Table]"
       }
      }
     },
     "localname": "ShortTermInvestmentTable",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShortTermInvestment"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesLineItems",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) - Schedule of major customer data as a percentage of total revenues [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesDetailsScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Line Items]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentLineItems",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies (Details) - Schedule of property, plant and equipment [Table]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesDetailsScheduleofpropertyplantandequipmentTable",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_StockIssuanceAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issuance agreement description.",
        "label": "StockIssuanceAgreementDescription",
        "terseLabel": "Stock issuance agreement, description"
       }
      }
     },
     "localname": "StockIssuanceAgreementDescription",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of issuance of share capital and warrants, net of issuance expenses.",
        "label": "StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants",
        "terseLabel": "Issuance of share capital and warrants, net of issuance expenses (in Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodShareIssuanceOfShareCapitalAndWarrants",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of share capital and warrants, net of issuance expenses.",
        "label": "StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants",
        "terseLabel": "Issuance of share capital and warrants, net of issuance expenses"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuanceOfShareCapitalAndWarrants",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_StockIssuedDuringPeriodValueNetOfIssueExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net of issue expenses.",
        "label": "StockIssuedDuringPeriodValueNetOfIssueExpenses",
        "terseLabel": "Warrants exercise, net of issue expenses"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNetOfIssueExpenses",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_StockholdersEquityChangeInRatioDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stockholders Equity Change In Ratio Description.",
        "label": "StockholdersEquityChangeInRatioDescription",
        "terseLabel": "Stockholders equity change In ratio description"
       }
      }
     },
     "localname": "StockholdersEquityChangeInRatioDescription",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets.",
        "label": "SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets",
        "terseLabel": "Supplemental non-cash information related to lease liabilities arising from obtaining ROU assets"
       }
      }
     },
     "localname": "SupplementalNoncashInformationRelatedToLeaseLiabilitiesArisingFromObtainingROUAssets",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_SwitzerlandBasedEwopharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SwitzerlandBasedEwopharmaMember",
        "terseLabel": "Switzerland Based Ewopharma [Member]"
       }
      }
     },
     "localname": "SwitzerlandBasedEwopharmaMember",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_TaxesonIncomeDetailsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income (Details) [Line Items]"
       }
      }
     },
     "localname": "TaxesonIncomeDetailsLineItems",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_TaxesonIncomeDetailsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes on Income (Details) [Table]"
       }
      }
     },
     "localname": "TaxesonIncomeDetailsTable",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "canf_TotalConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total consideration amount.",
        "label": "TotalConsiderationAmount",
        "terseLabel": "Total consideration amount (in Dollars)"
       }
      }
     },
     "localname": "TotalConsiderationAmount",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_TotalReceivedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total received amount.",
        "label": "TotalReceivedAmount",
        "terseLabel": "Total received amount (in Dollars)"
       }
      }
     },
     "localname": "TotalReceivedAmount",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_UnfrontPaymentAmount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unfront payment amount.",
        "label": "UnfrontPaymentAmount",
        "terseLabel": "Upfront payment amount"
       }
      }
     },
     "localname": "UnfrontPaymentAmount",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation rates property, plant and equipment.",
        "label": "UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments",
        "terseLabel": "Depreciation rates property, plant and equipment"
       }
      }
     },
     "localname": "UsefulLivesOrDepreciationRatesPropertyPlantAndEquipments",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "percentItemType"
    },
    "canf_VetbiolixMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "VetbiolixMember",
        "terseLabel": "Vetbiolix [Member]"
       }
      }
     },
     "localname": "VetbiolixMember",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "canf_WarrantsNetOfIssueExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, net of issue expenses.",
        "label": "WarrantsNetOfIssueExpenses",
        "terseLabel": "Warrants, net of issue expenses"
       }
      }
     },
     "localname": "WarrantsNetOfIssueExpenses",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3_Parentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "canf_WarrantsToPurchaseAdditionalSharesIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to purchase additional shares issued.",
        "label": "WarrantsToPurchaseAdditionalSharesIssued",
        "terseLabel": "Warrants to purchase additional shares"
       }
      }
     },
     "localname": "WarrantsToPurchaseAdditionalSharesIssued",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_WarrantsToPurchaseAggregateShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to purchase aggregate shares.",
        "label": "WarrantsToPurchaseAggregateShares",
        "terseLabel": "Warrants to purchase aggregate ADS shares"
       }
      }
     },
     "localname": "WarrantsToPurchaseAggregateShares",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "canf_WeightedAverageExercisePriceExercisableAtEndOfPerShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price, Exercisable at end of per shares.",
        "label": "WeightedAverageExercisePriceExercisableAtEndOfPerShares",
        "terseLabel": "Weighted average exercise price, Exercisable at end of year"
       }
      }
     },
     "localname": "WeightedAverageExercisePriceExercisableAtEndOfPerShares",
     "nsuri": "http://www.confite.com/20211231",
     "presentation": [
      "http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]",
        "terseLabel": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelEmailAddress": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Email address of contact personnel.",
        "label": "Contact Personnel Email Address",
        "terseLabel": "Contact Personnel Email Address"
       }
      }
     },
     "localname": "ContactPersonnelEmailAddress",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelFaxNumber": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fax Number of contact personnel.",
        "label": "Contact Personnel Fax Number",
        "terseLabel": "Contact Personnel Fax Number"
       }
      }
     },
     "localname": "ContactPersonnelFaxNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name",
        "terseLabel": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard",
        "terseLabel": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement",
        "terseLabel": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report",
        "terseLabel": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three",
        "terseLabel": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country",
        "terseLabel": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.confite.com/role/DocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r131",
      "r189",
      "r190",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r167",
      "r172",
      "r202",
      "r204",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r349",
      "r351",
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable",
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable",
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable",
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r167",
      "r172",
      "r202",
      "r204",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r349",
      "r351",
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable",
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable",
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable",
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r131",
      "r189",
      "r190",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmajorcustomerdataasapercentageoftotalrevenuesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r167",
      "r172",
      "r191",
      "r202",
      "r204",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r349",
      "r351",
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable",
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable",
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable",
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r167",
      "r172",
      "r191",
      "r202",
      "r204",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r349",
      "r351",
      "r363",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable",
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable",
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable",
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "OTHER ACCOUNTS PAYABLE"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/OtherAccountsPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Other accounts payable"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrent": {
     "auth_ref": [
      "r6",
      "r38"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Trade, Current",
        "terseLabel": "Trade payables"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r325",
      "r344"
     ],
     "calculation": {
      "http://www.confite.com/role/ScheduleofotheraccountspayableTable": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAccountsPayableAndAccruedLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofotheraccountspayableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r36",
      "r145"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r26",
      "r45",
      "r46",
      "r47",
      "r339",
      "r356",
      "r357"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r44",
      "r47",
      "r53",
      "r54",
      "r55",
      "r89",
      "r90",
      "r91",
      "r262",
      "r352",
      "r353",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r24",
      "r229",
      "r306"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r226",
      "r227",
      "r228",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments required to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvanceRoyalties": {
     "auth_ref": [
      "r319"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount paid to music publishers, record producers, songwriters, or other artists in advance of their earning royalties from record or music sales. Such an amount is based on contractual terms and is generally nonrefundable.",
        "label": "Advance Royalties",
        "terseLabel": "Royalties in a total amount (in Euro)"
       }
      }
     },
     "localname": "AdvanceRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total number of shares subject to outstanding unlisted options (in Shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r86",
      "r119",
      "r122",
      "r127",
      "r137",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r259",
      "r263",
      "r276",
      "r304",
      "r306",
      "r321",
      "r338"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r43",
      "r86",
      "r137",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r259",
      "r263",
      "r276",
      "r304",
      "r306"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r86",
      "r137",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r259",
      "r263",
      "r276",
      "r304"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total long-term assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r207",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankingAndThriftInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Banking and Thrift, Interest [Abstract]"
       }
      }
     },
     "localname": "BankingAndThriftInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r201",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r201",
      "r203",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsDescription": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents a description of such arrangements.",
        "label": "Business Combination, Contingent Consideration Arrangements, Description",
        "terseLabel": "Distribution and supply agreement, description"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r33",
      "r77"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r10",
      "r78"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r71",
      "r77",
      "r80"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash and cash equivalents at the end of the year",
        "periodStartLabel": "Cash and cash equivalents at the beginning of the year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r71",
      "r277"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format.",
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "terseLabel": "Expiring date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price per warrant (in Dollars per share)",
        "verboseLabel": "Warrant exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable",
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Purchase aggregate warrant"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Number of outstanding warrants"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofinformationregardingoutstandingwarrantstopurchasesharesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r152",
      "r326",
      "r343"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "CONTIGENT LIABILITIES AND COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r153",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "CONTINGENT LIABILITIES AND COMMITMENTS"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r154",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Legal and other contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r89",
      "r90",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Ordinary shares",
        "verboseLabel": "Ordinary Shares [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Ordinary shares, par value (in New Shekels per share)",
        "verboseLabel": "Par value (in New Shekels per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals",
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Ordinary shares, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Ordinary shares, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r23",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Ordinary shares, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet_Parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r23",
      "r306"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Ordinary shares of NIS 0.25 par value - Authorized: 5,000,000,000 and 1,000,000,000 shares at December 31, 2021 and December 31, 2020, respectively; Issued and outstanding: 815,746,293 shares as of December 31, 2021; 463,769,463 shares as of December 31, 2020"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r49",
      "r51",
      "r59",
      "r258",
      "r265",
      "r329",
      "r346"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r110",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtPolicyTextBlock": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy related to debt. Includes, but is not limited to, debt issuance costs, the effects of refinancings, method of amortizing debt issuance costs and original issue discount, and classifications of debt.",
        "label": "Debt, Policy [Policy Text Block]",
        "terseLabel": "Short-term bank deposits"
       }
      }
     },
     "localname": "DebtPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average interest rates"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue, Current",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue, Noncurrent",
        "terseLabel": "Deferred revenues"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsCapitalLossCarryforwards": {
     "auth_ref": [
      "r245",
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible capital loss carryforwards.",
        "label": "Deferred Tax Assets, Capital Loss Carryforwards",
        "terseLabel": "Carryforward losses amount (in Dollars)"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "terseLabel": "Deferred tax asset before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r245",
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Temporary differences mainly relating to Research and Development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r242"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "terseLabel": "Deferred tax asset, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r245",
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carry forward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r241"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofdeferredtaxassetsandliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepositsAssetsCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.",
        "label": "Deposits Assets, Current",
        "terseLabel": "Short-term deposits"
       }
      }
     },
     "localname": "DepositsAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r75",
      "r118"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation of property, plant and equipment and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationExpenseOnReclassifiedAssets": {
     "auth_ref": [
      "r142",
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the asset that is reclassified back to held and use from held-for-sale, the depreciation expense recognized when the asset is reclassified. This represents the difference between the carrying value at the time the decision to reclassify is made and the carrying amount that the asset would have had if it had never been classified as held for sale (including consideration of depreciation expense).",
        "label": "Depreciation Expense on Reclassified Assets",
        "terseLabel": "Depreciation expenses"
       }
      }
     },
     "localname": "DepreciationExpenseOnReclassifiedAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/PropertyPlantandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED PAYMENT TRANSACTIONS"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureTextBlockSupplementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Text Block Supplement [Abstract]"
       }
      }
     },
     "localname": "DisclosureTextBlockSupplementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Basic and diluted net loss per share (in Dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r104",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Basic and diluted net loss per share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashAndCashEquivalents": {
     "auth_ref": [
      "r277"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from the effect of exchange rate changes on cash and cash equivalent balances held in foreign currencies.",
        "label": "Effect of Exchange Rate on Cash and Cash Equivalents",
        "terseLabel": "Exchange differences on balances of cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Corporate tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r223"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Compensation costs not yet recognized (in Dollars)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r53",
      "r54",
      "r55",
      "r89",
      "r90",
      "r91",
      "r93",
      "r98",
      "r100",
      "r107",
      "r140",
      "r184",
      "r186",
      "r226",
      "r227",
      "r228",
      "r248",
      "r249",
      "r267",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r352",
      "r353",
      "r354",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r269",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r270",
      "r307",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r269",
      "r270",
      "r271",
      "r272",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r168",
      "r192",
      "r193",
      "r198",
      "r200",
      "r270",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r192",
      "r193",
      "r198",
      "r200",
      "r270",
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r270",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r200",
      "r307",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r273",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Functional currency, reporting currency and foreign currency"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnInvestments": {
     "auth_ref": [
      "r63",
      "r75",
      "r134"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) on investment.",
        "label": "Gain (Loss) on Investments",
        "terseLabel": "Other gain from short-term investment remeasurement"
       }
      }
     },
     "localname": "GainLossOnInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "negatedLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r141",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of long-lived assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r57",
      "r119",
      "r121",
      "r123",
      "r126",
      "r128",
      "r320",
      "r327",
      "r334",
      "r347"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before taxes on income"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r86",
      "r92",
      "r119",
      "r121",
      "r123",
      "r126",
      "r128",
      "r137",
      "r156",
      "r157",
      "r158",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r258",
      "r268",
      "r276"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Taxes on income"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r87",
      "r236",
      "r238",
      "r244",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "TAXES ON INCOME"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncome"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r52",
      "r233",
      "r234",
      "r238",
      "r239",
      "r243",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Taxes on income"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Increase (decrease) in trade payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "negatedLabel": "Interest on bank deposits"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Increase (decrease) in deferred revenues"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherAccountsPayable": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Increase (Decrease) in Other Accounts Payable",
        "terseLabel": "Increase (decrease) in other accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Decrease in operating lease right of use asset"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Decrease in operating lease liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Change in prepaid expenses, and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of interest income and expense, including, but not limited to, interest income and expense from investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Table Text Block]",
        "terseLabel": "Schedule of components of finance (income)"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/FinanceIncomeExpenseTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestIncomeAndInterestExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for interest income and interest expense for enterprises that derive a significant portion of their revenue from interest collected on investments, loans, and securities.",
        "label": "Interest Income and Interest Expense Disclosure [Text Block]",
        "terseLabel": "FINANCE INCOME (EXPENSE)"
       }
      }
     },
     "localname": "InterestIncomeAndInterestExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/FinanceIncomeExpense"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestIncomeDepositsWithFinancialInstitutions": {
     "auth_ref": [
      "r333",
      "r374",
      "r375"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest income derived from funds deposited with both domestic and foreign financial institutions including funds in money market and other accounts.",
        "label": "Interest Income, Deposits with Financial Institutions",
        "terseLabel": "Interest income on bank deposits"
       }
      }
     },
     "localname": "InterestIncomeDepositsWithFinancialInstitutions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of operating interest income (expense).",
        "label": "Interest Income (Expense), Net",
        "terseLabel": "Total financial income (expenses), net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r70",
      "r72",
      "r79"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid during the year for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTextBlock": {
     "auth_ref": [
      "r135",
      "r136",
      "r138",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investment.",
        "label": "Investment [Text Block]",
        "terseLabel": "SHORT-TERM INVESTMENT"
       }
      }
     },
     "localname": "InvestmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShortTermInvestment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IsraelTaxAuthorityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of Israel.",
        "label": "Israel Tax Authority [Member]",
        "terseLabel": "Israel [Member]"
       }
      }
     },
     "localname": "IsraelTaxAuthorityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of weighted average remaining lease terms and discount rate"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of maturities of lease liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/LeasesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r29",
      "r86",
      "r137",
      "r276",
      "r306",
      "r322",
      "r341"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r40",
      "r86",
      "r137",
      "r156",
      "r157",
      "r158",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r260",
      "r263",
      "r264",
      "r276",
      "r304",
      "r305",
      "r306"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r20",
      "r21",
      "r86",
      "r137",
      "r156",
      "r157",
      "r158",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r260",
      "r263",
      "r264",
      "r276",
      "r304",
      "r305"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total Long-term liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "NON-CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r71",
      "r73",
      "r76"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r1",
      "r48",
      "r50",
      "r55",
      "r58",
      "r76",
      "r86",
      "r92",
      "r94",
      "r95",
      "r96",
      "r97",
      "r99",
      "r100",
      "r102",
      "r119",
      "r121",
      "r123",
      "r126",
      "r128",
      "r137",
      "r156",
      "r157",
      "r158",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r268",
      "r276",
      "r328",
      "r345"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net losses"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow",
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome",
      "http://www.confite.com/role/GeneralDetails",
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently adopted and recently issued accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoninterestExpenseCommissionExpense": {
     "auth_ref": [
      "r332"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of fees incurred for commissions on mutual funds and insurance products.",
        "label": "Noninterest Expense Commission Expense",
        "terseLabel": "Commission Income Expense (in Euro)"
       }
      }
     },
     "localname": "NoninterestExpenseCommissionExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "terseLabel": "Total financial income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r119",
      "r121",
      "r123",
      "r126",
      "r128"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r288",
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": {
     "auth_ref": [
      "r106",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of income from operating lease.",
        "label": "Operating Lease, Lease Income [Table Text Block]",
        "terseLabel": "Operating lease"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r286"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofmaturitiesofleaseliabilitiesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current maturity of operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r286"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r285"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r291",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r290",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "weighted average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofleaseexpenseandsupplementalcashflowinformationrelatedtoleasesandweightedaverageremainingleasetermsanddiscountrateTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r2",
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "GENERAL"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/General"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ScheduleofotheraccountspayableTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred and payable to vendors for goods and services received classified as other, and expenses incurred but not yet paid, payable within one year or the operating cycle, if longer.",
        "label": "Other Accounts Payable and Accrued Liabilities",
        "totalLabel": "Other accounts payable"
       }
      }
     },
     "localname": "OtherAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofotheraccountspayableTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpenses": {
     "auth_ref": [
      "r62",
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense classified as other.",
        "label": "Other Expenses",
        "negatedLabel": "Other financial expense"
       }
      }
     },
     "localname": "OtherExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofcomponentsoffinanceincomeTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r61"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of general and administrative expense classified as other.",
        "label": "Other General and Administrative Expense",
        "terseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "OtherGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "non-cash financial expenses (income), net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsOfDividends": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of capital distributions and dividends to common shareholders, preferred shareholders and noncontrolling interests.",
        "label": "Payments of Dividends",
        "terseLabel": "Deemed Dividend"
       }
      }
     },
     "localname": "PaymentsOfDividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r69"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Issuance cost (in Dollars)"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireOtherInvestments": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investments classified as other.",
        "label": "Payments to Acquire Other Investments",
        "negatedLabel": "Investment in short-term deposits"
       }
      }
     },
     "localname": "PaymentsToAcquireOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherReceivablesNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and others"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofotheraccountsreceivableandprepaidexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r31",
      "r32"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses, and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement Warrants [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r67",
      "r225"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Issuance of share capital and warrants, net of issuance expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromOtherEquity": {
     "auth_ref": [
      "r67"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the issuance of equity classified as other.",
        "label": "Proceeds from Other Equity",
        "terseLabel": "Gross proceeds from offering (in Dollars)"
       }
      }
     },
     "localname": "ProceedsFromOtherEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r36",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r148",
      "r360",
      "r361",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY, PLANT AND EQUIPMENT, NET"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/PropertyPlantandEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r35",
      "r144"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r14",
      "r15",
      "r146",
      "r306",
      "r335",
      "r342"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "verboseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet",
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r34",
      "r146",
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r14",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/PropertyPlantandEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r14",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for classification and method of accounting for interest-only strips, loans, other receivables, or retained interests in securitizations that can be contractually prepaid or otherwise settled in a way that the holder would not recover substantially all of its recorded investment.",
        "label": "Receivables and Portions of Securitizations that can be Prepaid at Potential Loss, Policy [Policy Text Block]",
        "terseLabel": "Prepaid expenses, and other current assets"
       }
      }
     },
     "localname": "ReceivablesAndPortionsOfSecuritizationsThatCanBePrepaidAtPotentialLossPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RedeemablePreferredStockDividends": {
     "auth_ref": [
      "r101",
      "r184",
      "r186"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividends paid to preferred stock holders that is redeemable solely at the option of the issuer.",
        "label": "Redeemable Preferred Stock Dividends",
        "negatedLabel": "Deemed dividend"
       }
      }
     },
     "localname": "RedeemablePreferredStockDividends",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r199",
      "r299",
      "r300",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r299"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Aggregate amount of research and development expenses"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/TransactionswithRelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r297",
      "r298",
      "r300",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "TRANSACTIONS WITH RELATED PARTIES"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/TransactionswithRelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r232",
      "r317",
      "r365"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "negatedLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r232"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofexpensesTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and development expenditures"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r25",
      "r186",
      "r229",
      "r306",
      "r340",
      "r355",
      "r357"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r89",
      "r90",
      "r91",
      "r93",
      "r98",
      "r100",
      "r140",
      "r226",
      "r227",
      "r228",
      "r248",
      "r249",
      "r267",
      "r352",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetentionPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts owed to vendors and subcontractors that have been withheld because of retainage provisions in a contract.",
        "label": "Retention Payable",
        "terseLabel": "Additional payable"
       }
      }
     },
     "localname": "RetentionPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r83",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r56",
      "r86",
      "r116",
      "r117",
      "r120",
      "r124",
      "r125",
      "r129",
      "r130",
      "r131",
      "r137",
      "r156",
      "r157",
      "r158",
      "r160",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r276",
      "r334"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r289",
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Lease liabilities arising from obtaining right-of-use-assets"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Annual royalties (in Euro)"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares hold by company",
        "verboseLabel": "Sold an aggregate shares"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/ShortTermInvestmentDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of other accounts payable"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/OtherAccountsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/TaxesonIncomeTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of financial assets and liabilities measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r36",
      "r146"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofpropertyplantandequipmentnetTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Schedule of options outstanding classified by exercise price"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r187",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of weighted average exercise prices and modification in option plans of employees"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregation and reporting of combined amounts of individually immaterial business combinations that were completed during the period.",
        "label": "Series of Individually Immaterial Business Acquisitions [Member]",
        "terseLabel": "Business Combination [Member]"
       }
      }
     },
     "localname": "SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Severance pay expense"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedCashFlow": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based payment in exchange for services"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Weighted average period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Early Exercise Multiple (Suboptimal Factor) (in Dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were either cancelled or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Forfeitures and Expirations",
        "negatedLabel": "Number of Forfeited/expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price of options that were either forfeited or expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Forfeited/expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r210",
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Outstanding at end of year",
        "periodStartLabel": "Number of Outstanding at beginning of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted average exercise price, Outstanding at end of year",
        "periodStartLabel": "Weighted average exercise price, Outstanding at beginning of year"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price, Grants"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofweightedaverageexercisepricesandmodificationinoptionplansofemployeesTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r207",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based payment transactions"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "terseLabel": "Exercisable, Weighted average exercise price per share (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Options outstanding (in Shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in Dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r218",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofestimatedusingthebinomialoptionpricingmodelTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in Dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, Options exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price per share"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual life in years"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ScheduleofoptionsoutstandingclassifiedbyexercisepriceTable"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "netLabel": "Shares issued (in Shares)",
        "terseLabel": "Number of ordinary shares represent by each ADS (in Shares)",
        "verboseLabel": "Ordinary shares issued"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/GeneralDetails",
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance (in Shares)",
        "periodStartLabel": "Balance (in Shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Investment [Abstract]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShortTermInvestment"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r19",
      "r323",
      "r324",
      "r337"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investment"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet",
      "http://www.confite.com/role/ScheduleoffinancialassetsandliabilitiesmeasuredatfairvalueonarecurringbasisTable"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r81",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r42",
      "r53",
      "r54",
      "r55",
      "r89",
      "r90",
      "r91",
      "r93",
      "r98",
      "r100",
      "r107",
      "r140",
      "r184",
      "r186",
      "r226",
      "r227",
      "r228",
      "r248",
      "r249",
      "r267",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r352",
      "r353",
      "r354",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareBasedPaymentTransactionsDetails",
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r107",
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Ordinary shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r184",
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of share capital (in Shares)",
        "verboseLabel": "Ordinary shares issued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "terseLabel": "Issuance of share capital in exchange for services (in Shares)",
        "verboseLabel": "Aggregate shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r22",
      "r23",
      "r184",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of share capital",
        "verboseLabel": "Gross proceeds (in Dollars)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails",
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "terseLabel": "Issuance of share capital in exchange for services"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r22",
      "r23",
      "r186",
      "r206",
      "r214"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based payment"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockDividend": {
     "auth_ref": [
      "r42",
      "r184",
      "r186"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued to shareholders as a dividend during the period.",
        "label": "Stock Issued During Period, Value, Stock Dividend",
        "terseLabel": "Deemed dividends related to the warrants exercise"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockDividend",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionExercisePriceIncrease": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement.",
        "label": "Stock Option, Exercise Price, Increase",
        "terseLabel": "Exercise price per ADS (in Dollars per share)"
       }
      }
     },
     "localname": "StockOptionExercisePriceIncrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r23",
      "r27",
      "r28",
      "r86",
      "r133",
      "r137",
      "r276",
      "r306"
     ],
     "calculation": {
      "http://www.confite.com/role/ConsolidatedBalanceSheet": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet",
      "http://www.confite.com/role/ShareholdersEquityType2or3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "SHAREHOLDERS\u2019 EQUITY:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedBalanceSheet"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r85",
      "r171",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r186",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "SHAREHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "verboseLabel": "Supplemental cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedCashFlow"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r108",
      "r109",
      "r111",
      "r112",
      "r113",
      "r114",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/AccountingPoliciesByPolicy"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantExercisePriceDecrease": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share decrease in exercise price of warrant. Excludes change due to standard antidilution provision.",
        "label": "Warrant, Exercise Price, Decrease",
        "terseLabel": "Reduced exercise price (in Dollars per share)"
       }
      }
     },
     "localname": "WarrantExercisePriceDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ShareholdersEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted average number of ordinary shares used in computing basic and diluted net loss per share (in Shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.confite.com/role/ConsolidatedComprehensiveIncome"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124502072&loc=SL77927221-108306"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(10))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(11))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27405-111563"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "321",
   "URI": "http://asc.fasb.org/topic&trid=75115024"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "323",
   "URI": "http://asc.fasb.org/topic&trid=2196965"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "325",
   "URI": "http://asc.fasb.org/topic&trid=2197064"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=29634951&loc=d3e1756-110224"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2459-110228"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)-(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "http://asc.fasb.org/topic&trid=2175825"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473541&loc=d3e61799-108003"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.1-12)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.7)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r366": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r367": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r368": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r369": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r371": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r372": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r373": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r374": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r375": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r376": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r377": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4,6)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>84
<FILENAME>0001213900-22-014672-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-22-014672-xbrl.zip
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MRQ$>3IN=OB>X07_ZQ(J"D.)$;!0B%"#*@45)HA7]]] /D4OP(_:B1!&EYZ1
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M"J#\%TBDTL[)>T+R3%/U2'E)-$56S9.OE\3?J,DP].M1\@DUI'Y\]9K^+5\
MWUNN3\V5'U^%),+9&:H(XSPB+%2W!YD4*1V4J'?)5.MA608E<(!$P<*1Z9G/
M_L/LY4?D,M-^$IXC0G;T L"?]T%$(T9Y?T":$U:-GF9E)HABJPQ5)#C%6[:R
M@QRS(!*KIF1\,0G(IP:C1!YO&M:4VJK*1T91S8@#>L E)$(W-ZWABDP(PD2
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M%P/25;AE7$%6L#CWAK?J+V$%RX -5@>FAHFDV9?I0[J)C2_BD&[$&:0M#>7
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MKZ$P!;(Q#JCB)8K<4 U6-NW6FVRGJ)^S';=3> :EZ'ZB'O)3H@9HYIG=;@2
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M=5ZK*>SRPPD;GM7.9]K^_P%02P,$%     @ SDQX5,-9BX5_E@  +UT' !4
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MV:#&#IF, -F=(VUM_(+#%@E[SZ@L4-$W&_BQ98,#)PI\'WNCV$J8@^I$ 8L
M;A$$VA05;0W;2D0"*5RPO.4I8@  %6)KE%.B-ICN@*WJY#QYTV^>M&EL_;K%
MS.!Y(=[F*I1"MJ[)7[SU+O#',GFW!M1[ZC>GYY9;!H<I;3<#DS=/"+FHF8M2
M.,R;.\*5]3J2U/DCF]S0"RJD=W72@X$'PYM[2TR\';Z^WG&.^LN]Y7J9(C$Z
M3&J#:[T^BBB11@OME*N&)C<0&:'Q0--:N>*=\AZ*&Y(SZ=W[QXT;>\-UA-:
M>D^2YO0<5-"_P;N4=^\_>_P<Y;U,HH$GB1P!S)4I'">;T()<1_?'_6/@#19W
M?32MFT%M:IZ<TS8H;61.\V<R/9=L>R$#/^;+5WL'Z71&N? Q!]6I'[ (X+TX
MRYJBO*WA"Y]((,WONK6\(>9C*(<'[M# _I0F8ZID.1O)$"2<0G.(73=%8CM1
MVA/1KB<H[5Q-)FG<;B0CS[H5J9,9*@%YZ= _8L_[W@]>_'ML$6T$.\LH2D:+
MN^*-;@12'&+$:().IY^@%\J[H;2?:6MTA^3J"!*M71T\/P1>0E39D,:"A<,O
M)^Q133@M&C2(,5(T1FEK\^Y.CF#JF&"M4=D_D;TV2:,_00&*K7B$-P'"P0UX
M.]F4=!Q(V3.BHA-*>YF'B5AHC3.(O_)!+E":I@9>-#_C"RNVLFE& @YG< /
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MUD0[5&[GPPX$(1"UIJL2US1J!X<,([F%>Y/)S3Q,&I\^0FO(TU#+.SPKH$H
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M[2^>@N<WI"_%UR]?P8^GZ8\45/Q1]?G\N33PBN!F;5'6&/TC;?Y/(S>03KD
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M<=:OY# AC ]"^.,1CD=J^ '/#+SOW06>0[:X,'BFYVMT@T$SD3J^^H^J.5%
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M*A1E>:)<$C4X6EY\G!)NC2GT;VYU GC/$WT_(3?)D+8%!]]LD,,642TPO+W
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M,$FSQL%[P<W.\K/]I5+;4U*QF"C69U8KU!]*-*?ERVH !QK<,X>S?2Z<XVH
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M%/;!$28(W-%J8@Y^QEYPH,$,><"+R:<!(T&I7@%J.&>5=8J'"*^VEU'L[LF
MTVS2C2GTVY;J!/"*:D8TLR/.FYG>6-F"J>*&L:P!EA5X@A!XKD-5@C7YR3YN
M\&M\1GI]F@06P@FU9ZL7$,,+1 ]=WW8/'A0@V]+7*,4 IK$C(\M:YJ&NU2MO
M+U=!2"[D_GE"CGG?KFYOT<)WZ#^]5 G5 3EU:@Q<:)2)Y4:1^'966<C.QCPA
M9RVY\\34JYW]CIZZVW3NXI=&7XH/QE 5ZL.XJGA).K>B'1D=_@.VK&?+HR6O
M=6RR4C.;2! G0QCW:A2ERJ$-/^"RNU&8]A)R;?>59H7R'?TQU@$VUCSZM3T&
M%=Q,7F3O.P6K(WJT_$_DKG$((K=69-O(C9HKK?K=F;W, 2I@^JX&(FQ@+US#
MP0#&]:+6S*_IQKC96?&YY9_A-3D]+-=9$#IH#=OTXIX2I0-O4])KH,;Q9(OA
M*K!TA.):?4+WU !\*]G!'R.+FF7,?A :8%F_CD\K"'4S5MV[0/\OM^T2:J?]
MUF3GUK_?2U+&>RR7]T8>]#3LP^TIX2IL^[!A2+G%," 3Q4>(THS)]P$:"[7.
MZ=CPI2<W$<\L2QQW-TZ[GZ ##$#W8IP/83XE=R^A-W)TR[-%-4IWN2=;< BC
MKL(+-R)JG.6MMM<!^1KH0V%ZBNE J!(A!JY?*G3RWJ,60X$=S"-#G'KIP_P9
MZ Y#@%%%L3*_%*]L=_@9^PG. N=TF62[9]7O=>J@B%OBB_;+8SF-I5;M+<^Z
M)BJS>&7;[%WF9R.;\D7I9<O<3NE,$Z&L>UX3![@$75RTB3R6C@N/X<P:IWK(
MNHY .9:HGMM%V/X-T5<)DTJ]0(L[0'IV[=8 :=*Z\V3MRQ',GL6]A5VSV_=B
MB/H=^QS6 :&BL-W>N=&G\Q"3#QA^FLH+RIW/A%F>3PXW;*[2 S3 M >"+C/P
M@W8)L^$&%2Y>U?L3[/<NK?D'!J4T .\)^S:4P]+B9Y>>W@C@9*GCA@X_65[5
M<ED=PF2D4'^QU['8BR]*%1HPQ,B3=:PM\7'+K<+'[Z\YB8* %&ZUO:P'.EAF
MW-NR,JA4T1,O<O1G5>GK"@*_)=T7R467OLV>\&J@0L=,GB@)B125$CJE+UX!
MAO3*$%<B$F:064 -%-W/?KK9I:[#%0'O6BQ^O,GT>T)XI/#R:%JO$+OF(Y?V
M,VQC[A):S1HG6JAJUJ!: J*\5@"MR>=N7=O*X-JZ?O0[,P=/8C#?I *Y4ADJ
MB^+IR*Z-3)4Z]NU5_T$]%CK8Z2]56:N^1UY:(;Q,B]8X3"O":=@JN^;4?I)W
M$,1!+SG+7#LU];E> N^ ?1S3)SIEH@^CQCY)V=8>BTEP0AULM_AE8=OPO@,J
M(82!3WZT*:@U1@OU)D*WKZ,O@5QC-"A4WA%93G"@K]0)4L/\ERZM/8&L8B*H
M"%V9R;3)1A4J53 K,;*W&R6M?\:9)\U[L4@EH*(H* VL^=:M0B/O'1@/CT56
ME@S-1I6 (=(N2^:I<DU5L3UW#SL<WF#(LRF%O5H'S9BJSLVS.-,FZ!]IHW^:
M3(+)8FU9A+FY%&4![@+_Z?O$OR!<Z"/&=C?MF8O;-/"$"@W1I\1'#ODU2[C:
M9<OE>BEA]NJ4<PWBT,71:KOT'??9=1++\X[+/;SN"UW+.TLBU\=1M+!_2=R(
MA@-$+#2,98I3)4:_/4Z14IYZGW5 Y\'^D5S1Z%64M=D8L<D-A$C-,#>$;XJE
M&LYO[F^P0^ZW7I^-K-E)EV;.G)VW@=W<HZS=+'8O#J/+O8NU+#4E^/LCV08?
M@S6Y..Y[B)713?OYU*:!(]ZL(:(M&0+6+5\^SPL)<]:FE%C__L6-?\4A88E#
M3?F7+\$!QK5ZR+MK#*U?=0<Q/(=-V0O1;JCH-PM]5%),I4M1@@MJ>\(/.'YT
MR27FM0= FGUTER!LS,_!0-'*N%(@8G0A8M:B5*(%%A?W/419MM;KL"CFY=D9
M+N[G<#JWF%E:!VH+4#>YKD/WF6AR:\]*S0L3WA0X4QD()F)3PL_? 8U1T1H5
M1<^-'N]R$JP_L>$N6S%D;1F%%O8@+5>:IC\^3H@?[F0&/.@<4KBEV*"YZ9-?
M5F@U#[IHH0,"B=)4K1#H$?A0N"N #)C3.!.9,XU]VG@"L# IX)5FHVU1T1C]
M(VW^3Y,1BD)AU;R#W)4JF@%HY@5(B+JD*<1ATZ+/5.7N$;S..H0OI$"89P+:
MH[(#^@?M8E9Y[))#>5$0K5A=2RF&A6P6UZZ/ES&>+*\Z<ZKQM131EL$FHA]L
M%H\1S61M^K@1RZX> <A=M<I-A&;_SKQHT=HZTO?MTKL'O[<>*(B)X 5,T=#V
MO /*>K2W$.U145VB*,.=A"L>"P:<+:0'%.H[@S$P=.T-/$"8WASD)2-$1FN3
M4#Q?BE=CZ0/M+)K.6?EWD,PE=/TG".:*'OS@,<(A3?JR] \)+5CBVZ[G4N_/
MV9%VI\%Y$VJTDQ$[LF%5=,!-M0:>.0>:(=JNK5&;?>0X$>*8;R*G8'9OLV\4
MQO^BE?KD306D2^7S(/]J?AK-,34@N3$E3S>+">^BF'K[*C&Z+!#J1"%'!@ :
MUKJ47HVY3SZ-4/;C2B03A"NY.+K L>5ZT;V]PT[BX6![R+*_T)PVEN\4&6UZ
M7/?&G% #@$8GF@?!<@I4"9_+)T&?9=-\CDY1/A6\SSV($@VU5$KM-]()X%7>
M8L>6BIIO;"0R^BF[HT^J\;HT-NUZORB8%M%Y#1M[)H+=V)_7( L!''.WUAZO
MMC?6ST%XGD1QL,>AO-HNI9/P9]#S50AIX 4H98T,*\I2 LH5%O$:58W/O6"Z
MA\GM;'+'BBTKL@ANX3F%]43^'D/9RS#-U!1-I=4H$#%/3:?_0D;>JRD!**<
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M<%&?YOH_E$'HA?XZ;J<48*7SBF]DJN(H@ZV1+\Z5U&KR)]! \8=*/D3*Q0\
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M<BHSG/R#:QU,1[A!=%>=]V)UIKQ)@I1AIR"2'8FC&":WW)>JM=/@@MX[YUL
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MI;3(R"XH-D%"Q*V]M*H&<>0X' [1C$B-X/NLO2&0:E17I?A1/>J-RB*(1/&
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MFN=/<'="2$D(%U8^\U87&7N#U=6F>%2<Y*#O2(#XQ-HZ6,\OB^I9YQZJJCP
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MBC?8]<D]GK$UML4*C%>-$C$,PN_MAD&Q\1R;;0@7?X4DV"_9(*<>?2O(:L,
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M[TL[&O"&*_((=Q0QU?5"A@DSK*/J@!39>C1#D/37>0!52P$J1 Y&4]*;=])
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MF5733<35%V;.SM*\)""JYP-SIJT&OPX^358,[&>[;+?Z.TH:('G5^ ZIL:^
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M*FMR>P_VO"VHMK" !G)&Q-&J[=DML DK@/=_0/EIC -H)&CR"&O7Y'99PG;
MG?D482=+0V-P0"TQ,Y=<1:G4(@;>47)HFTS+:9</ U#U^ZQ6F-VR[O%!*C<H
MP/Q"0]R0F7&)=<?N07H<.>+D!R2I9E>,!*)@K;"40FP3>GQM,4,^\).R&5>>
MSWZD=+_R:.0HTA--*TQ],%9 H]@ET 1LX-W;?2CCCGD@P28);ET@RJO,92Y(
M*HJ8&6R?):3UBM1*5'U/K1DZ3<;@A;FR%#_E\=13 :\K3R;-.%']R"['SC*
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MWB],)7[=-$_3_-R%H.:(D&#4&1I&Q3(G(BGN>D[7Y+) (VJB$:=65EJ1GQ#
M04X.#TC_K1=HJ_OP&'C-EZ*Y%R#J**B%["R3"09 $M_Q XTP3J,5"%R.@I<3
M9<4",R83F?6U!?HFW&@.J'S6)AGVE5?L5T#<CQ_5K^#FHPTWT6_GUH?3[@O0
M)>Z_T;X W;8#%_8%N-L]4"2>H1P!KO#ACDV^Q#BWFA G)9A4F,Y$]@':""&!
M1#M=804Z?%V=*9/2TC:K(QK4EBZW;[>D*K2B'CQ4TX-:LD $^IGT2J,P^F+!
M6=/$E(A,X."91I_2P..356F);[;CDU"01 43QCB+=Y\^?3ARF$L*KTSS22UL
MGB@8J@#-2I6A(9NTR^]R%E?%9P8VH<HC^5:+H:I!L7GP:G=G=Q2#.YW'[[/\
M'$E 6WR=^)6]]E<"$L^19_'<CNU)XJ(-3?6M49"@@%L+!,&DN$M%7L_FCCR"
M(E(=O^P[N)().V>ONV4*&^Y;3.%?ZC$JB1P9MA!B'>?,:'2Z#W=4Y[+ZGO9F
MJ5;\#.'*2.3.R>MJJZ]B@)$>C=8A<G)A %K!KJQ@<WJUA&RL7YJYP5L.)39=
M1>YQH7K(="6/;V3LW:=R*1?Y![/@\M]_V]W;?HQAM%1>N;>S!]OZ;[L/MQ^V
M/M[A_6K\(J(_[3[=CO?IX2]A59"!)WX #^%'29D:7-MP9]>+FJ^@1$\Q/M,W
MH(=@!MKGT^2%B@I%"&P$35$61!O/0<Y%;49=^OSX%&Y]>*8_&$3 =3%)O^7(
MY+]8HDS&C=I3P(0EI,/)"($EQJHC'&>$KQ":"?DQXIV1^H>(+9;<'XU0JF!C
MPY_J";-GX7TL>T2_9PM()Q[T >^@8> OFYF_-D-\@J .K/J._ FGA?1D7MU;
MYM+[Q)4L@B<A7Z8+*S7O-9/X$K@*S_BYOKPAU,UY"#W=!@?WX"KN =?""M.%
M#FI$$%NVM;8!09N3'D4F+)S"[V2P0MU;X]D7\R('&?DD&2%D>P#R<C1.;O.'
MS?YF-MO15G,WIXP(4,&G7SCX1Z'<S35L\Z9N,YUIN/YMY760Y0A;%06\^,-6
M;^A6STVAP_)/7QT"_A4X8IE.G^&'P_YNYOXN<JK^/4?8=</#^2B8WC<>%CI:
M1_H=$8\$(BE;!BY2)[,+.L-@>& '35)PWCE-7,2>*Y.9*=9P+,NC;#,>21R"
M*PEN/S[*M898UQ<N/A3.3F9IM@]JE &NJ[0L866$'<$Y;(T?8@Q$Q?^J50%7
M?[K"J@#%S;W'JC0E.ZHF"U@-[/O%.\P"VH7&@YFX.0!L2*Z\R;G8PZPX6@-9
M9<!1.8^G:7X.(WL-+BNZO2.[\E1D6<8+F#/WN^1>Z.PTI]1$R7;.HO X/K#9
M'MD1N#.L1&74F&O%@407-I1PTAR>F*ZL>.A$&("Y&M73JL(DJ2NGXFXTG6BD
M? W3(=ABO<?J%D^M)3=1I\:(B,%E.L3/323;&>%F<NS94[/L4MB3H,53;/ N
M?CWR%DM,ALH1+2DGRH[/S[@025[(?I>7!Y[O:++@6H#AIP-@N ,8?C  AK_1
MH]'J@AS=7A?D^#I=D*-/[X)\MW-P%V0%(LP*T/WM+G+<1KC?:!OA9_\6YB!H
M'^=P/6TAA1<2JF+.FK^W^W#[42-C,-8IV23^9OO ^)C OG <.%Q.2W<<"H A
M=K] S#JH&Q2O#"8;5^<ZQ7L=EG%>>G()M/-P7"; $!+)V3Y;4L>:TP!9_ JY
MTO9VME[AJ"-F3/G U.8TX<8\^C+$/7P_;EX7Q/+C2Q-\V]$I1?KY!89"/?QZ
MZ=8G>8B@\Y]4@O8G&[$/2=#X9F1KZ' $8;=;;G#B4F=1VQ8GUY7.9HO5/F26
MQPP$]KML.D/<KBW(]SBR>5PHS.ILQ[;ZBC#F=35A9I!(N.W 44Y:R?MN.!SV
M62S!@.W)0[+0YLZ1N&05(R!EP0  C<E8E VU0(.S!/E"<TMQ]7K(B$Y69ZKE
M5YW8?-OY6]_CJ,5LPO& .FM,C;:8$*Y(N4=)/EL:'['I7.H@FH#;BS <7T)0
M9YSXA4G4S%8E?0KH2(4*?EIG"7S#)G=M;K9P^5M)\:*BUN/*'F1DQG+0:Q%\
M;V![KB%;"HU40[R%*1<P\[^"U&T!1C''2=I+9%OV8>"L>S5%4IXP56=Y06=-
M3'3GR'!_/S<DZX^(.Z.]5V>/O4U<!HJ)EJF3<LDM&8P'B$3$^'SG+Z"WCB?'
M&P"!/F?=[WO(+%!!B!B'*70\:W"$9D5?-Z&ZTZ=YQ(>S%H@&G\RRXHH!2<ZV
M&WU'#6U)0JG&"/) [8:5"+;=Y+K\6Q]*@W HQG6J]"JMV1"$<!\\E6C=8[*:
MKO VB*1Q.^(C.*ZXK@\Q+&-=E+4."7!+_F5(-X '.%*E>\["=B09V9Y9DNAV
MK;*\[A:?'L:K"^0Q7^?<MZ^N*^G3:*T^=4!*3TO55/"BV=$P<$0D5B9A8Z@!
M*&V2PW@U+M_6<.E.NN >&D[^)2?_TD,_8!APO;N^^[,XH ;?+"YO(OW%(\X:
M< TNCO'$H79+HJ []$7I[B_"HST(SV<3GB[/<%]\%H/F$A7W%T@D5OQZBSPT
M.*[0^7R0N+L@<2U#,_25RPID11R8UNT?6:,0\Q6&6%<9U]65.?9G5Z#>)H;;
MCA,F4$!A'>]V:F&,OF=(."89[B";=T$VR70??;J#P;Z!\Z^(\K(A=H,X;2HT
MH46!+V$8"H34XRV'/<I6ZZ_% 79T5U0)M7XN- @)>?I3$!O1*YC-UY.:P\5,
MLR_U?10\0TIH!AW8'S"EM(UO4]%?TF#'3?04?6LB-^EAR-TJI%:.R7<'!717
MA% :,+6BZ$&IE)GVJ*LHN,RHZ*R=6@AM^W8PJQ/+XM,PR-Q=DKE&>FP==LS:
MZJXE\KENMLMME#<- K2I5I,/VX^XT'#)X6B.(5// NF:36##(E^IE)039?)\
MX-/*R4BTUF!*;;! ..)/!,EP%;^J*N1=D(P4]V][;U+L1^&1W<.>;^:>!XH^
M3HW#Y]ID=ZK.R]I8?C*6AQ#_.>S['; >X'.!*S%Y"J8@)XRMR"TY%"+B+%2.
M:>3%>$!X4%CIXX$<:WHT#0;%79 IYXH[B$T+%G2>%^_QT]ZTJH CECD[UZZ)
M$T/@L6E%266#KMYH$*=O5YS"J PV*%G4BU[HK&"[.H+$'5WQUX308.7D\(_"
M>1:[EA/"Q=%E-CN02HU?:I/H6Y>ZS<))[+<P>$'94.2);RS9!@.TYWHQ(K84
MZJ9+T7N*>G QBJ!?$/"'F= *L7;;\2]$K6'+6T)4'+YPH=[KV%0Q(:,\$AO#
M)W49V>9J7B,YL&V;<MC"BFS[>DQ)$.Z?_L*LP,AH<J9*@4<*/7"SOQHA=GCV
MUNZ*K*LNSI5'(!+KGDI >C%EQJN(ZT%U7FX):4FXO@I\.ZJKP9(JARL<.X:^
MA(MN4[4:<:LB] +ASL9+/<(UAS=7NB\7..HK7N-C<Q4:(,H:9F0[+*ASQ=I:
M.8)A]@XP]@.D!"3R-\-)G5LF)!_R<G$PW$1>9Z.#$0<#(Q&310JAL5$CX+$.
MZ7K7H5#7*CS:W1DJCSJ51P^__<JC;_P,",%JEU*/S-V(Z, *<*CQ;FFB!IV>
M#V/X 49LK#(RAZ?4I"O5,_P-_3?R0]59Y?\8\).!^QX';;3H[Q&2/3F<;R,C
MX((_WDFC@5.Y"R'TD66M=87 _9#/,E2,U+2+2FQ<]QC,,F29T&J2>27@V"@8
MY;G0A'I(/?R(S$Z\T>!^DQ&=$VR^2>+I6;'#GJ7=^MZA7G3-<(ZE4LW7&D3>
MVEG%C':FPC1B1LV;E4YEE4_>BYU-)=0@3-V>5;FK;T+CA&0&# CX &1%^D3+
M@\-0090/]^QZ';.N0,36MB@\^&.3N0(=6^)"F6XN?+'5+I:;<-2N>AE]<G%+
M="K]#"2&)/C\]:67ZWD7F8K:Z04:JM<B7#_04QY)3Q!YC4*_,+8E>5QVF?AJ
M ?8X1)-3'5IJ8 R)K&7AZ@\T+)RF)6#WI$W1'_9_8$'?CE_"N*-0W4^]^3Z2
MEY[E6/(7$#S2XWU1G.U@368QI?(*=_AL9B\ Q&!W"D>SK":,9G#E#\SRAS_#
M)<4A- (OC?H LL@GJ>*O&VP5"GZ()03O["I[*79/U\M2=!59L@4402=YY]90
M!5-3L9R!>4DNT7H-$_=JF!$JGAG>-):VJ.QQ0]'M\E58Y';996C69URR*.LJ
MSL@9CC@+<TWOK>4<V1F&[AB=I3;^P#(SN.F[E;-E0R$IQ 75-\S"08?DW!#Y
M!QZ4@.0I?$Z./7%!W*^@V;]%?NP7MKZ<(@<.SAB]Y@XO7XV=\)69+7\$=*LK
M74674*Z&IY[U_"7\-X.5T5C?%J5M=.WU=>1 20[^>!_C;B:,1KX"74J0>W";
M@2J+1&N-+JJ5F!+#T*I/9P4\UW)QMF^(]=@7>J9%85G(<=G@3L*[(*"U\42Z
M7),N*^B#FR&D*X!PV441IJ7@B75&W0NX2MIEW8A#JL/>P^N KP!CD+HSP#),
M+--1>)\UFY477,I]2K6+:)0PEJC]=%>L[9%#S<)79>L[,;XYE,)]^ZF9H#*X
M"=;WW*["I,)]/YSVF&(,>H[NHAAYZ.X,F>&[("]A)E=G9Z;(,U1"P^;?A<UO
M)G(XB;2 VZGR?2BH[9U.*/V$MW&=@?\D1"%QJ:;:M@EU;"^8YU.3MA'ALG@&
M/LHQ.H$!0W#AP?-1,[SZT7)QD:Z^+AR#3'[K,MD*I) CAZ&EO!DX[P$U14'T
MA@(7+0)&8EXRN3,VR;1<JLPU2H$GY2&.G\FI**\99C('&?S699!0 I3WGZPL
MTYRM\0ZE<-27];;NT0"%NBNB@MU!K;IHNG%+:E=,B'[IJN=N68JJ;F%4=14M
MU8H<,YN,,YGE<'4::A3/M4HK3,%AG#T3=N(9_/$OZTYZ^N\4V_(D",TB[>CZ
MB [P*#N$=_-5"5NC,"R_A 7D5H6X*=6JL2NQL.UU#""TC&8._$21XCI#]UOP
MD>RFCV+0% QB*2AQNP )D,2'=<2493=R$A%;B2!.J:@;CPD#Z9=%5!K\;CUT
M1LL"IU:%22./AK(-IF@1(@0X->+A:UBJ,<,B^+ @,M,(ZSC:E0"7U(S.^%GI
MSIP\FS:%9ZX=2[RC,=RW_:@OBH-5\9DJ##)KE6*-3[U%WR(UZQ!J-0*/S<CE
MG0_L]B\Z'L+HXD6_SB)3J' =E1T18=G2L: %E-#/19YGL,/+&9*-^W2MY<M9
M"R04F JVTNL/0E&<4EJJ(9<:OBZ2;"[ZCT0AG[58Y#V%FIT<1:ZZV!-*P7IU
MUE%YW9BR#R6_ 8VTG@X.QAPT"5P7^?;/%P+2-N'D5$UT0%%/T5E>4I,AH3O1
M587]&ON<86;M[Q<M4HS<&(XU=4-D,%_N *Q4RXQB!:/%KH5EJ+_O^N&]'L9R
M=\!8=C"6CP:,Y8:?@2-,%"8,)[!*_=7+?:?RHJ!+"B/X;4_R4#_6U3P7^"'2
M<$LNJZN^R-8,HCT-2(7@3[#UAP]3HB;-"=L1]5UO<FOQ-^)Y#2O3N>?(X!0V
MV-9P3$DQ3J8?H8L)YX]*TY#I73&O-^9-XN_T]FQ[%#5:!*L8&Y:8*5,#R_V$
MJ"#_^3FBR^KQGT$73ZQ="#*%SK4CY E_^CVA7W#0L!E4D]%=]BA8=L2:,4Y%
MF,=A>HKW2RC(^I>NSR; VZ7)JVZ[H/IV.<'(HHL%@D%8/>S1O6/*.[R\%W#E
MA@X(<VROI"LRV!\HQ/A6S7Q7/%X:2] EI=!_LC'2J9_ @_:RJ&?Q?LA9@]]Z
M(QO"H)YF4CS*5%'DY]1;U<N.N#QEJYLM=H?5JC34( AQB-3>!K]S2>X=QY?@
MV!J)=U^CLD#6\V(4!9[:JPX)8GC(K1TI<[_\V;Y(B(T],C$TD8<G(H6A=1>-
M5XRGLKS,/G$-)A09*F$:@;:KH$L!O>0BJ$VT0F![V S>X#H@LO<0A$^PP\L?
M])J2, $J/]M>R?\> 5:%-&(?&(N;0SAM+E7(#1Y2/5(+JFZ=U[3/P+^);8GW
MTS(?,6K7+"+Y56#[CY#IG"Z!UF\MCLA6;&'W=AM$0F?,T45NQ^_ZX#\\K#Z/
M5U@N<7K4M0WOE7E^+AS>)46=@H2CRS/:*<-WEJ8B()5H O*'J;91&A"L(=ID
M9LRTLTK1JQQ3D@J14<+!DA<+S;4F)C%8K_9V.0?MG9I_@)LW(;WO/D&7.<O1
M@T8G;+F5HMH+/?/XW1S#?T='1S0<N9Q"FEA"9B3%:DNO=%RNLJ3 8!>L(I=D
M-+X*:TP[0TU.)#2]P"&ZE8(+9YF;S/)A,=Z+^MT)9 1T::9I<;C =P0/Y AH
MJ=%^@:=%G:>!V/A% "7/+.B="9.M@5:3G71;L.#][:DS/#PTJ&:IJF'H*G)K
MD.4XW KSQA.Z,TLXE6A9X>V+5:<6,WZ.O=*FL!_8@Z4ZUYHCL(UWTKM@]#,0
MF*6+>"S!\]+C7#Z5R*VL;A0N:IJ?$[0?#U:A\@G<SH6KCR?A.'K[KA40J,YS
MMR1C)Y9XN\\UF*M5#MNJ"A!A^'YI(\IM.N&(2G]\ 0()TD*#D04S^@!3 EGD
M@#7<+7Q]@YF19W@CEX)_H[E3?*7GQ4&<'+[Z^A2$&P^IK4E2DSGG]B,G=%8Z
M+#R1K1T\1%[J]P^.W[[8/Q7I5]-**KU1B5++G$P,51BJ 3N'@/(P<%-56M;S
MY>L#'UKG-H"*3$?I[1*)CH-AJ'15BI$EAC:WW,$V/C0"4(MN</?]J>P3S&4)
MH\%2W^:Q0_ENKT",J1MV4+"]$2IK;WQ/ZX+K8NWH1(_W#*.L9S.JL&@,1F%X
MWP,JN*LS;#+'C%8\6-D[;C* M-/H.&VQ4>:G E8@CV9!AI573S( LF 1L($*
M[=># UQK\5PDB7XP-VFR]0YU[0LXGKF5D3<@@V=P%&BP4U.4542ZP1_MJZ\B
M5I3CO8"W08V-A="/H(1,3F$L6(.Z.,.>4_:DPB'$A7/+.%[FRYHI4.Z\??(:
MS7H/A;"ZK0&>@".4P#.*E>]<0]TS0T5;ZFJL)N_9%[ RTK9GI)N.C?3*94ZI
MFY3S3!3B0I-4+AF\@"H4+>*#H!8X<&JXA,Y>+"8+&+%)>\(Y)O+KE*I[1F&-
MAE04E76)-9-<JS7J:_<B+>+H&6Q889T+VA=,88IH6VDP0GXN_L?AZWU?KG1)
M&(3<&.]ICMI%1%<I@J=:'DY#5KKK^M@(06<;<G'AV6EO/)N844>Q10:"A2#U
M;(UREBEGJWNR29(,#40CE9U Y8\SA.^".YW8JE)V#QM?Q])24[079.T\8]?0
MS^82TE74J0WCKF^>=]V52]YY%7"*]U_3I6\@_C%+01W0-,8?=&;[YH+>F&.U
MF-<:TDVM+6^D7B1G' A63W\;3%:OR9;)B-!6P7LS-.5=;1<Y4? 2=#'B7L?'
M==1N]-WMU&:-\)(QV/2LK'*ZABA"(^FZ2$D78KFKPZ-!7H=:>#A'DP.4,GEH
MEB7L 7B8!KV5<K$I]R96:2[!D'-28]2IF-!%%*19(M#[+XWZ<$(D8&'>;SO^
M VYB+?4!U6HIKI;L%[Z&[3^N+*7,DX2C@F?WQT0YX-:SQ)'MDW79VG+K3AD+
M**.)*HJ52XBY<.S*UV!8I '/QXTU)]O#7*F8[1L_Q ?^*(:-#5M[$Z]/]C)3
MCG3;6IO6!:V)+K#SJRJ\N3R# OZ<$3 ?S$2BNZSFZ?$17Z?-BZ6WU1I_T8>3
MF>IT=%&?%?C/^S"]/W4.RB:QEV;[1L6FVO;7'K_G[I8A;'B%<G@*0X]M2CUL
MH[2V2!4/<K=]CH-6A@%DVUAOR^=;)%Z-THLNRYT_[#:KT6]:1E+5=E$#P548
M16QD'#Q.:RW"X/*?(BH+-4D4XA[AD$V:E)1=T)M[-F'?&A>01(/H#WCMB*59
MY3GGQ?J1#GY,SZ*E@_WY,?@WDN(+8'JMS".U\ISF:9J?K^E2B]$#.UBON519
MUER1E0GO"G4V6/&@8UMU19<JJ\IPTC))GP]-./4Q7G78#VSJ)#A>9YYA=AH^
M%@%#L/*1E/736^P1MCYU VQ(?A_7,>H*S2%;JLX]7C03)=02Y/,8^G )*85%
MC#:,3)$JS"K"@"$B&A8708HL>01SW8!2X#M!ZC>WXW<<XFC51TI%BY2XK:M)
M=4N/N,*+6X#9YB9AI26%%[#=^/I6H[!S)&.!H'J$4N-V:T"((PK)8L@']ONZ
M1VEDH<GLS3EMF@7]RIK5#DUR(EOGB]#/9MB]^1RR5]&S/@NYR5WH%&Y4[/X]
MX1PZA9Q$(+%1KCRNV[BS*3G@R/K#.[J^5A&/EX6C"RD(:WTM2LR9!&&40\R#
M9@0W'(X3&V'6T#-3IKPVXSP)(BR_;Y]LBQW.'8-Q$UQ[4SQJ>>FP"9P@1\N>
M$B@>!4!$&0)"1\5?><I@L>?F*)SBQZ"V:R7+2T'GV@/>JH\.,N$]C;7W*XZ=
MXL7=@A9' ;18<CA8J.S"E.'"6$^ [8K 7;?9X<$8NQ%\VMZ 3^O@TQY_^_BT
M.WHVW@:MU)=FB41%.@)E-:;L9.[<Y(K\V: NT"?84+/^8E M5AH]%']%[3_8
M/QZ%J9<&1+="G2N]IGD$J:.V(B8BK:-%GNI)35VOK] 6M->,ARNT)PML2JY8
M05Y;&XAOP'NLH4<JV8^C%Y0==T'9]1!KZ1.MV(I61,0;?8)UCH8[7I,B'[A-
M*$AL\,SA]D-_1:?B],) 8+,YWUHNE$3).48RF['!X'>/KNRQR<BVM-C""*OW
M,!U&B'-$;RZK1JV9'<(UN]1NTX\XC@@F8SUAMC+.K6,F.G@M#RU"MZI(V"PL
MP(A#@JH% DCPYB>O@>?H9T36MBR!'>]5CHK8ULC/9MT>',]V*U_><TS6P-LH
M*HTC<#:./]4^38T:!=/I=+R#:3B#R]D^W?;!OF&K&-H8Z+ P"S 0)V!>-GJ"
MT'H$1Y=L/3F[H;UJ23J;M11]ZB#JF?B(@29Y*HTGB 9N=).*XH[>30<MR!/*
M%)&D!]XM&M5;Z!S4"^^?60IUVC?<:(8O83AU09XD9155J^*/^"LI:<MQU;*9
M 26?A*/"-DPL7D0H5A?L]+I$W=6#J5_!WM_F$'[MA9UC5JNYZU?=93F*-LK&
M 3VFOG(X<K@D<O(E&SU[?2^&[9#]K@''#B\'2FVC_+@@#T>&YF9LJBX2FS-S
M^41KO$I <3HT-^8)NKGH6+)7L7B17N!'D:V)PEX/^009GM$I11U)62=1[2[G
MY#G0P()'=B-B#,W!%[4TDKQ6S(@K:6@.^"VUZLR%:^ILRH"",:YYA4M=] %F
M,5HGZ>[QRI56#?1;&]RTJ\:^LV LZ\S>SQS'';IQ;>B&(G-Z.U <'[UYB2=6
MM-ZPMQNZM[;,23G@4DXIZ>'(;O2V!L# ,/T0^$E2K]"ZDX<-W] -AQ/L70H/
MHM)AY>&_:NSW40G'3M-['39^0S<^ !5B!$V VE1^V8#2R?>&?=[0?0YH1,*,
M+:*2$<O=@)MQ85ES_\M*+TM7)$2'7UH 38;#OZE"45(%%?KKF2<P(3YL*H84
MD$>A)T5M*L>-H[,B3U-/6SML_,9M?..ZE[;GKFS)=()GPSYOZ#Y;.YX)#5?Q
M69YBK$X+8,9M.1?H4<YSV/&-WO&F(<]UG'Z?;8?5U#EPB-/C0E!;'#AL_89N
M_=2G&;E$&)E)+4^S]"<DNANJYI)6MDU>TP[?2XPU>(,V^-:I=0/OP&3P654+
M*U"ASPPLR#C',BXN 3]^@3#5W$(4HVY%"6%X\DF>ENWBSU9E:%\YBHT*PWM&
M\<N3UR]&%HONXL0#R?/F*J>+)2R0JS[1<'(U**1O7"%Y,P;;UUNN9PN"=V+!
M/83-S&/ &\(5=82+2TJN(%N#COEVA2O016LD":\M4UGZ1).1@VPYF%:1[YQ9
M8-!L8;AN)^2\F^5Y4'"]1*,+BP;H,OOEX-W(,Q>L08P,8OBMBV&BQZKPU)6]
MHHC6$%(#.FDIS<*DJHB:5I7^,$EK^@>6JO55*JZ&'AF;;#[90$Z0CL-.N]+_
M@&FY=1_]R/9M6TJ;A0V\7@W/@Z&&IU/#\^3;K^'YQL^ [7Z+&9_":"9,M/SX
MD?1G3US "*/"/5"/BPMNZ:\%<Q,RX%;@MLPT@17"/EI%+&18VRL4=ODT<F#3
M[;C!"GG3;(_QU=@>H\_#]MA]&CLU;M;1YR)\C*]$^!C=/N%CW$OXV.%UC&Z$
MUS'NXW5\??J/?O+%<(@BNM%'L"]>RJD8?PRG8G0KG(KQ=3D5H]O@5(ROSZD8
MN74(RYANDF(QOB+%8C10+-YV!X5&^Y<\]+##T@LIU"F7EGVD4S'"!1!8*8%U
M^X9X1K!IB[#L<'4:W&X,>25ZCXE9*DFHUIF GM&)D8YRTH*F0"YX+IOK92N<
M&KHJV=*?&$\T%7P?=GUARM*F;9B+A%.XKE6YXWG+5DT.Q@Y354"_"-,A$OP^
M4@Y/GF&O=V;,D)(ZQY%B*^&:I4HMWJ(F&51DV1Z^FKJQKZR,[0_N$TY +1 U
M6#7+B>GA7),\3=4XYSZ$K,&0K5^*E-KL>;V$<9V[(J1SD9Z'[?+H4104!#'9
MY02KDH@LU#8]=H1\$D]C=F$[7NY>Q3H,OKMT5&9T2AN$E4SETR];47M.:^G5
MP@YY0Q>F9KFU+5V-I>$O1B93Y+JRI7!Y9F40=[&O [ GN64N.*FFH]T@>R9K
M=5T3!ASB+;+T0](MW;YBX40P\H]7)?4[Q),A0V*8XL7%RY<(=-R2YX"IAL?4
M[+ 8J9G"Q .VOBF#3J)$I2/W!#'BR#."3LO!"<"A%07";+FQ\D?.(O+'TDYA
MW.PD25U!*O6>IXEQ)&?$!3LRZGI\77;-KOK 0/<9,Z.5>4I<-KSK^7G6< 7Q
M+@P7R+>,L^$LX1AL]++4'_2DYC9$I0YK.=UK*;1^+G6!5%X9^3]:4N2)6J+>
MMJW9I)=F6+8ME#YC'?#<MFXY)L_1TF+46["N_Q]+%;A4F>-D;#Y/:A='^)J4
M#IR;JYV&[!]L-;NZR!OE#/_>_H7N^N]KT2.]"_$ER'?UL=HY)K=!2F=[RZ<E
MCE V*N1=?\-J-11G;E8<VJ4M5$MGB=;EBWINIL[;";BWT0J!PX5A H7\ND$G
MK,[%;&G+(RXY0!NB?1_94Z[ NP)/J( #.&&^<-<I'/^<@,HIR<L?\ +?J+R)
M05R $S'+*V-[V@G(2$N@IJFZR):HG:#568GA+:X97_FV3*Y+3_/6$U))3-BM
ME<]5\&>*_&55D:=ARE?!%3Z@6+Y1J9R08QQ>R1RW<915"@5 _!LT?2@(+&02
M HJSFFX2-=XS2,PW*3'H'("\Y%6CX-(:J13"LO>GI=3OOST'E?)M"HA<)JPH
MF,5[ N85^A'L!;9;2EC>8O(P;"M/;&^9S:*^YB)#)>\W(4&-;FS2D4<:[CD:
M'?; FI% [R 3@*A?$)E7/BUSZ2RP5"LK0PML*53E&2HH$["FA6ZY%4D.#EO"
MZB"&1Y$(&RKPOQPD<I,ELE^4.+AB$P*^-3531W&(#6G@#4>E3 &F4;IB8CS[
MKY'GKD;E%PTJ[!L6&$&C=)(58V2MY.(EW\P 6Q8VH'(44#1L2G%7<F=019(8
M<>3LHR8SN_!O,Z9$Q'00L&]4P)JN/C>Z+@W=4#9C[/GN?'YTY,0)Q>5?M<(;
M+>)( 86_QF%XFQ !TB>AB_@>I&HSI2JTUO4'U%*8YW 5ES5&E(AR'_6-BT\I
M[^AC]M$,=!J;+@=P>2PQ085RH H4 HN&JUD7J, ((JYA2WYN:W)'S6Q.T9NC
MCSH>'\<KN1TR^H/6^O>F.:BI?*72REGN94]%)A8-BR!*6HO@(*OF\Q'U0:GX
M2J[?")W08FRDN5Z0O <I@>U U:HXLQFKBC)EDL1T-[&O4!AD?S-E/]2!K<YV
M(FJ.GIV0=N@@4K]%13 !DYUAQU<O5)PG4@QQH:>OAGJ&3ZAG>#C4,W3J&7X8
MZADV_ SL9ZL65,$"@2*"8CNLC2/#D!R@H&D%KN'SUP[=_9$9;'09NXG)Z*J)
M20+%J*R)YB/@,9<PU^D4 W&89>]X*&%KQZ"/(V/;". 2>3.C#SW23G?VFA^"
MU0I[)$C@)O2L'( F:$CM%B 9X7H8UW//%==2.%MHP[&9GVY.DO\N."):ZB!V
MR;A<>BTE6L_1_*):E[$M1V@]# PI@OX&*]V/27) F09*YD*(#(&A' (89\Z7
M8-Y$-%&##D(N1'YU6@_VDNLP730M CZBG8=HAP 7U /GHL1B1@XJ@N,OZ.T:
M>7S8Y6C18/5[<%XHMXAE#KO6V6.$H6A.< V0WW58=A;$"<4(HJ AHD6X(S;/
MVU1Y?P-2$1B3$:L_MKT;@VC89H<C+TV(RYS)X77@+JO_V*^U%6.1 !D(SRYG
MG]M7%(LFC"[HDSUT@N\T]T7;E[>7.QCR_D;!_O8U:,>Z*;OM!#/=[VNUV;*X
MS[43'[Z\N"$K:5 > >5W4O->IXZ*(!Q)#UJ7+TG7[EG:#"NLU//5@1K[;I;<
ML%)ON4NGP36%!>\8>L6*=QB8U!/85J#C520$0/9SF EI5;2ZL&5'?R&%+5>
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MQ;8RI JG->D2&9@%X.2$-JXSQJC8,$^AJ;:7?%I,;A(_!I=56'QJ;KGTLPO
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MH%;< \/&*V/M2^R0W1 Y'II=BZ_+YK0=O0V)8$$1LLW&]?QM?L!@EM0E8Q3
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M?1SE'3T<C2)BUW>\49L]*_)SWY4T:44"@N[1W,:6_HZ_P=B6)04@+RY-KY8
MB2[K!MUH0S"T@^[?S+AO,Z/69A)[CRU.;CH5UE!UER%:EK:8D'ST..A;#%_F
M/6]81K;F&K:?FW%P 9N+B$;V-^(U\,.=_9QY2U-<QU03,PD1YBV1\D<L&DX
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MX3Y]0"A,WV2YC-1ZUKM-V)4T@,2G61 T@&16ZD8;QJUC$C90D Q]+^EK]V)
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MRC)+(W_\M?>[>*S]L^)0; J$><R^TU4:"9M@SAT&(7Z-PB&:'V[SYXH)B -
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MLU@" <]'TG+88QTG=#.G/HJ-4(/YPHF[(MI=-SEH?.1^(6OS$)WCC+LAU,#
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M6^T@>:T M#!*!U*,N5]%:X/Z/CIIB&69"_GL#DAQ&&S;T2!$WW )1D8V,R@
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MX<E7Z:^SEW\'.N:/\6'DCXG84BGPB-2J/#"*!FH#P.F#<=2)7+7RK:?,@L(
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M0#3FN1J)CX%_QBIBV2.&5^G'XCT[YXK: -47UN:5K,1HR.3SN-YGG[Q\>?Y
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M[*>'T6\F]B@ZYHL)(^PR)721,&R-\S#<_,C),V7\8JR[&GWW3S__[*LGCXB
M#"1D1#J#/WWVGWJZ[-I=O-)UVZV7K&;(32=$N$#3$DSIJ8JA!][)9I]U7.N5
MBMD6[B4&*;EDJAQ$8@1_\%(F$$2J.DW!W"@A<\2B3%H3S6?AN*43^#@,A<,H
MF"7.\&%F<%B2QP 5.91G/'!)ZS4*A#)5 5?JAY>D0GM BF@M63%1PPXN?9SW
M'\&_1J61<QVW/G)_S5O^$(>O)PE?Q<?3F?M]FKVXQ!F_\]%47C^R0O"/E544
M2/&HG1@Z[7V V&,EUHZWBM80!KN-DP[;EI!X"U):J'Q[\(8V+[@UF][H.;*[
M!4%IG3*E[$3&J&KYW_MXI* KD+(FHIH[L%-HK1#8AK1\:FOC94VL_?$2!U]E
M13SCT@^TK0@F[R:>KA4#;.\QM*MX+.J5-]']"W)/SNWH=1/L-?Z9KW@&5A:5
M8TXKA.,3721N74037S+'XH*O$X>@:Z/1!)]D4\9SIX0F;MEC<*+W5G472(0"
MK(UTQH;"5#N\Z=CJX_E4FIRD_H;.FT^4A+BC_,65V%)V($W+D!V[QGYXR [Q
MM@N64$&[Z_?_>/7BX>-G%.TAZ?J 0RC+A$T<46>S-\B$ 7N>Y;?D@.4.01M8
MFKS'SS[[LO T["&&MI0#:9M5M"4[<9-8[A&Y00NWW7S3UJ.<<SQTZHM+8E%G
M]-)EG&<: #Z4->25'TKK!&I)W=Y(T!V(#(Y!1PS4=%ZFW=YVQQZ"ODVW,'=S
M"+5RPS;8!T=/\J!Z<^] ^H*$&J4?R%5COCH.7S+9N+/9B[TIFUYSO0RP\$=Q
MN/V_'S^Q-K%^3^ZR?/Q9H>]&>5F&R*":2=BO;(K8F?A+N:$6SI(M95U&AZG=
M<_-QVC&\EU,8)LG#/Y?_+./BZ.HMNU?+].C^F1Y]KL\4W#/-;GBFZI]S$F6Z
MI.?Z6S4O&ZI&ONK798R>=K,WEW4=U^-['_A,1V)50G!9_QJ +IA0JN:30"*9
MRWHK:=^W^^X=0;Y>=6A\7EK>+%NZ,Q0H.X1N&3*-O%/&F\C.D KB,J!,N>8T
MZSL7*B,VH7;]':GR<F.(JHG2FSDC)RTE$K1DAZ*FF,SK=,?L671C\%1I4/94
M>H[3I]8='NN^H3JMO[^]I2Z";^OE,K[#R[+G@/2[MB,:CE47K\HI+.YA4$D6
MFZ-T'L/,$)HY#2&+@/M#FZS8F@RI2G_7;0)%Y%?.YY"I^$A.<VKW,P[";ERD
MI 'V)>UB,=#11RAQFJ2 1X: O0?;CT;OS)C+;($+.C.WE86=-#M/%$@% )N>
M@?_B;GO$5$W-?X)J.E6OR;3&-WE+-PW_3W36]/%9# R;F^GQ,WE ./69.J!G
M2GQ(07N@L#:O$(91'FLI<6%\.L0EZM*%Y7[G]# $$[2EA;'$FH@NT=GL-:=3
M>"=?7[8;RJ,LVS0\F&MR9G;PJ985E><%X]:5)+,;_TL6C!@XOD?/;:?43%+%
M'P39*W0\L7U!O0/2H6SH<1)$)R"N)HX\,\F<Z\N*4F'"!3\A89,[,+8&^WJW
MMQD1,YO'W=NI(> LAF=CUV-6QAFPR'1V(DO"FUB+#-H%*S3S LB264+J/S"Q
M&=]!HT6HH:0;@V6]5/[V;D&H])^J?>?A)\CRP ^RW_%&$OW0W![(4DQ[YWWC
MQ5@W9T1%H31SDDZQ03<B8L :H<)MH'6 7!G ^96C> "!.C=@R9(DQ.@5%[D$
M1"9R5WDV*9NHP4F3BP)IVTSPZ'QN.8%,R!5J9;!.,*-"/<CMZ\1K ^?8N/--
M_@'U'*YI)_N\VQ&FT(<)UY1J2M+/)<1RPZ'=ZUZI^[QO0 22I7TTCE+=<*6.
M%[6,(+K2-D(@B]?!H^Q[,^&WR$.&Y.1/'#S9$3,,D9TY9P+W=712XGB.G(U;
M'#7A^%%SW_>5E-D*,UMQ></@AV'814.J#6()0)"0>5(5$:&/)L6X\_:P:'=Q
MT[PAK"(2D>K$T0&^3F \FTG;CGB(D#\$_CAZ$D4-ZL4R_.X6 H)2)^:5V]B*
M57/;#*H]LF!<"C78"C.A<T(1],ZS.!EL0_Q4J46/\MPD.2'.LJPMSIJ8\_9_
M:=RJ'45=J*QNA%.GB\$(J^]P'WX<[Y[W\>,GCY1!BDN^;*,8D8.<_56+J52Q
MQ/[00WH1J&KQ">.TYESTE+G12F9<#.@A7AXW5"FZ)T?5"CC<@MB/W($8@%[5
MG?:?L8"KH\4#7H8YCT@6Y@*)\J%S[7LU>9NAQL>;>-]11?77J0%\-+G;CRR5
M_&&8SB]/F,XQIO/)[Q_3>4\WQ_=9EC)(X619]Y0N944 [XRC$]-)A:W2V1XM
MU3\K5M89AM\:M-_[<_9;.G6&(^9;#;^-B[^>?5-V\WCVU7(V/+^LJY56#P7/
M]8V=$M]SU:-@F?&I^)I$^3;QW2X+;>!GKBMT[U.NN>!N<%3,+65"AVQ''4A[
MZ$;M2,:>0GE&(_*A!Y?SLT>H3L252D^QXJYLFG Z^.'_&: UQG?<'\U< N;(
M.AH;6S,:>12Z*"7# VX2G-KT9$A^4%Z6"'I\!5L[<?-<V:'@BJ%SA5V&QD,K
MZ&X/]UONX\W'A%Y,T3P)PB.YCLX%:_HJV5#:A3,M^+-9OA,E(,KVXIS;]8->
MP>,,M),0[2/\=WKRP7J2!ANY9,J^.=+]VR(4G'M]'/+TT9BYC\SJ?BT2?:5N
MC3#,>6K'?.TB>BJ$(E6!Z$AE7@F:23*(2RJ#4!WV:/RL9?%+#NWC<I++'6:K
M-9$HR"' 1F*U/K4$(>@FB!N-*14^MP)O 3@K9!1+(&,BEH4]@[ D^>J#E33>
MUT+K\MVK.'/?&@&"8AX Q"8 ;66]<NZR=A6&"BZH2Q&P3292H=+4K1XB_L2O
MG,2!$9_*T4D-WE)C=XV9KLGDS8%J;QM2QV751+R.H/H2PP.;R>RN=:]DC1N8
M?7TZ>6_+3+A0;*I=EM/W"D!(C!.4'"X/P"#5^4Z9<?A& &=H=7JZ'2 E]Y6,
M";U#M N4JJ?CUZ?B+0%XY";83,_C^R^I2&=[]%J%$&6W^KM)HOK8#='3$%=H
M2Z@SP4<<>ZTX5VC4J8J@>7Q*.[JRZF6U1)<\L. "\IK.F,XZ23&9:0"1(+?A
M+-^/<IPZ.:1($I?5,V8IHX>/__M8&HPJI9XI\M.RD&4/F#L*W6CYL;4S]59<
M#!1XFZ<D2 $W. MH['D>G$TT1^5GV60=.ADRSB+.67%7"6U@T" /^A7\1,E&
M<FJXE^TU9=T*P^26RQAJQ3M!Y"N'YQX9[=.9>Y0?R6BD#5D1L'RXDE3RW/RT
M7UZ()*MBT0UNE.&+$J:H*3?:)!5MV3F[T3\P6VZ<]6_(!7_RZ.$W>?XI=5$$
M[29A9#V[BD9<V=QPZWM_-DOG2SR9E>UYZ8 +X=P0:2J'1=TGT[.XCE[][::1
M,Z&$FN+_78T[8@IA)J?;HYY!9^(N =.,*IT_ONTS>E3<3;>'96%8)"5H=4V'
MU.65%C=Z__K=>YXA8?O<XXA-'+QY0IQ1W*F. =M) JN$I%_FJK;Z&EY27,I[
M9%89D:YF$9Q+8'BMY<@=/0</=?J^;'-XO65C54#JM-\AE@,6>F@@$,VB.M?J
M::;X TY+ZQYE: @CVJ<'1G8W:S+S>Z;W"ZZY (I?]06+OBWT](F;@ 3#_/+^
M:"SK1V;H_PLN%1.9EI!=1': <9(LZTW5!>K.NT32P@)VKKSR(E&OAV8FA=E"
M :XI% &$.=<YW7<VO"]5QMQ=L>:Q#E)9[&3/Q_8<Y:#@IH/;G6X8:#4F;IR!
M//9C3[?QTTU?.!=U*;KF#Q6*_\O9.37,K/FBYXG()O@*JSY4?_-C_2N+9S9<
M/"Q*!<P*+:*';&AUW*3A+&_XR1<]4GZ#TNP!+GW)B2I.M,W 9-BB/Y#JO.UU
MV2V%I81_8MTR(1]A;F;O2%:R%HY$L"@1*)3 /*@Q&N,)KI5U@#O%6SJ3FPL<
M+EHE%.7X"R%0WU3<ZAG/VWR/$=_H#K(^)L=+TVS!5*GW3N2#;L8==5%J-&25
MWO'O5$-86G^#X'3CN45P;#U)%_^]KWN'?%"QGDIQ\%G0PHW>0!*ZN5/>RB&Q
M86[5+EL(3_;<[$T:GD"+,.1&B[P*D=R0Q!/2^_O=0O#Z^?7BP%=ZBFVW;=T(
M(0\G;^'.\,<;2^:JK\!TF>)9!/$L!G/OEQY%967= 5XP7G'BWE#F  W8M.XI
MJ"-3G3J.^+"MV<N)MX(=07^\X$M#K<(+R0')F(PXN!=!";^JE$W"XN6WPU^*
M(X&YW1+7 --"0V7.)HRJUE9+X4R!^D:RXT=FR](-Y-;(_F<06BM^UI$3QIF%
MC^:@_LC\AM?>&_4'#I_\,8JGUA!9[MJV 5GL./S5$@ K;'04/5AVM_'[?0:!
M6BKHJ+7S3<YZ94^(+ 0.10#E%V"?:'94@E$V:=YB,.EO>=6:-),+8/W:N/>^
M1CKY5"B(IEIYT/H@1KM(8G> #7=,N2(DN=Z8ZPG=2^I'A'UIZU_&3VG<_=7P
M9_+Q$P=QV^7&WX"VP8(NU^74YE2[H\/77D7.4#T'O:*6R089S9\I7>8900_R
M#K;0LX",5 HVXK*M05A!_+^$]7_Z:+:D?G<D(+<4 BV3TT-I/K%K>EG@??J2
M^U)64 ,@<DZJ.](WE*HW;J$P(%LGX12TZ\*_>6[(-YR\^CB?RN-,/ )0I0,+
M.F]WP_OBDI@WS&XEBV5T' ,)+VT+>'SNDDU2F\Y;Y08..PTW^WZG]["1.9M]
M&V/Z%CG"<D:BV]FBC!Y'-#+-6EB):;(0,DJR88&5UZG4@IN@9T^MD5KX&YF\
M1#R8KQP98ARE(@-BDXU3CTK97M/ _XUXEIY^\?39P\?/GCWS(JXF;*,;<?"C
MH9X%D2\]9O*EQ\.QA=\"MA;%Y"Y;6IA!@*^.((B=+4.)^^&CEU8B4S^[V9>^
MHAQPM=W)2-2^_9P\)-'*^DFA7_S;P#<P[-H,&P3%NR?_J2>]##U;ZYVY*ME4
M6"+<$&>%61#D-FX>E\#C,ONP<1'6"C%=2VLRKW;5:'R4_2#?1SFU0?15 GFG
M!*;C;!9: * YLH7VEFV*[,HH!)"AB/L#I-K2L]?7/S/ @6SH>@UQ>G,8,\V2
MP06W%1.SAIVP+O**IKX+^7U#239I%EC)@O5'^B=BZ[(-%D^=K;!IULWHMFKL
MO&_-'^'U^V"S9O:UKZIWF.:R)K/(<>*#>W^$?QBR[]D)V3=&]GWZ^T?V_<XW
M@30%,(Y+S])=^7-NO!C:A[:RU'.8.9O[)AH8YKV6L(%C_5$,>NWZ+W'*2$.]
M]/?X\X4>8T>L*@??"!"JGTD*$6<;G379U>&4N=<8]!?Z%R1_W>X8G9KV FIT
M\4\/5_'$DX-32[:]<=#$/<!-@+L070L$R'*YL]F/@SY?BP*&-R[IG!&?/7Y$
MNA-=AY,TR>-X,4F03=+X\UEAWV?:.29.U!+W.OJ\:\VB-*3]Q>VTVC&3L[#0
MR*560QQTURU8;88NKIZ!+ER4"CP'HB!%#EQSZI5SR <VVCZ;I$YRE[A++1W4
MH92<U6'[M X13U%_76ZSQ<A-+?FXIF0/G:EQZ["G@:"8798:\[JM.Y;EPDH0
MH</>\!DJ%M*TRH'FWE5?4%Z7,E+H28M.S[T_;#G'E:B1^C@;Z[+SS-\B[3+*
ME&A^9)@-$2,#B%#*G,3O>>;30Q)X47Z+["KIMX*8#$SACN#Z)D-&/4X5L4L]
M>?+HJQ=5O^CJK5\$W\-Q)LEW#=5$8?-(2> ,EWK\/TLT]-%P&U&[.^&WWD@*
M)*Z3\Q=O^M_6/YS_Z7_7-D1U]"CF$S[C__@#294KM9U:&UO@_G<SY 9^VS=B
M,7=<;Y%H4#@N>X?HU:0BB[Q6&>6=M2MS0N6B:B<;I<*2I9H1AS07+1GY$2S;
M"!)^V/=]S2RX?W]'I1Z"^7\T8_T133X<#1JFBW4[=W-'I2(" W8U8<CB6%]!
M80L("3F+%:V=1[>.80'$MVXVA58@Z8/'R>T,=G)T,L/$9%).ZYMJW@$#^N31
MDR>%3OFZC,OR$EA52D4]I,>I/(W65:G=EG:Q#%FXKIH+V/NE]75RR^'Q51?=
M *(Z7E-+0CQAEO$S.M8+#=?E6XW>49+KR@;"8^Z&-/.E?#HU30*3 V\V[9(Q
M*_6"B2+CS7=3FS&^I!5XB$V*1\O*A%MB'Z!NB^C3ZMP][^(**XW_17Q9.XRN
M"15&R@V[NM]1 R3(3PUG\H)4]/IW>):_[:.S&_^;N[%[-_8B=C;O$>/M_#SM
M"'+6&-!1?P G7EHN<E4)+O<F-D2FX%@38-EXW0>PH &/</(C4H.QHI)XP(K9
MU_&(Z?;BR_$0(;^;+:D"Z9*^?2CM(3H8K^-V6%<VZC_(H+GTE/U$Q^SH3YRW
MK:02G.7;4')6(?S\V(W#DRIL!^-FKOB;Z#!40D?RHQ%6OJ)9F)?-.]?:\Y;Z
M9#UW\>R3-S^^^N;M ]6MD1Y9O^)""N_R.4NSQ<$9X9VX 0;9=DX\_A$I+O!@
M@F- W\D6BR?Q9:"T4L&FNV'+C:DN4:YGT^?Z8-UPF4%LTH;U_;OXG'(L<?;7
M=70!E]+5.]B 10IQUX<8][YCR,%Q6BW&Q?FZ[&K?+(4'0:%Z5--)Z-Z5$-4)
MH\Y4JXQUYDYVS0C+Z+"!G<$M')TJ45;IO=+!3!2#64[S,39UC*W9:,M28$TL
M,J$LA6 M1V0EB%^W)H3!N:J$^BL9>^BF))/).S[9<"%7AJ.XA&<]/X:M#!Y;
M^3\59'UTM6<&-%#Y9DZU_0!BD)*9]LH=@>"9=X9K;26*:-"($IE2IDB6%A*)
MFN+R?OW-J^?<DI<!*PE?M>'P>+OO://#[M/A+MT#+ VK9T6@9$)T!%;T(.#I
MDBMSOYO4$JV;7I-/DDSLTP/$OT3+E0$9!B"M5N,(#L$+!!'%[$?T0!#A,[U5
M5SVD#1J7E'Y^[Z/S'U/;(1)NVKI+\Q1NNP!05RE_1IZ$ICSUV50U=O0G]8-4
M-/SBJ56N+CJ2V96KQATN0;6N4OZ#A,<T@Y_4\4+D!0B]C:L4VS4%&QV]"2;?
M816S:I9?%"@+6D95W*%:H!'!,[&:^0^H3PC_#G(!_E'=ZT@HI&QM397]-!;-
M)#&($*)JEG EN8P6/;GVH)3BG8ETP+]A1T =REI5K5,].,O*XH14SX'R<Z(\
M?)ETS^@,(=@8P$JHZW8U]\(>>7,=.M$HXW<,\17W]*!QA8!#8XY6W]Z7SC8$
ME&#/7JT-(;7V\NY9@4\X\831#8X4%[7B-Q!3*.J,TX\5AK:$UNH0L@0F:;$X
MI2<#V6F.5VO7\EY4[#=D/=?=_=5T49-TQS5% ,9X*@(X_*\BV+(L9T_B8K<B
MZ2>Z*!^@>PW$I6A *A?P9N^]-?I:4?_8R-&A.I".C/3F\2P5,D69'Z1BX_-J
M75=7[O"K!/+&RP![EMK$SF;:24O3CS_ILK*5(^'BBK&LHA:*J,&?N+/WG;BX
M^/B0%)/@C*:>DWAF[M:+NY6(C2L&AYI=!B7O+[++6=9>.I<R;.\UA7ZW.$YG
MV7$:TN<[2JN+&2? 0X\<4XS3YAS.B#%':$C.X? 1I ,F/C@9/;(D:[R\U#C4
MDO'PY1GX\.$/[CXO>R<[4=BAZ'1Q%'@%+9RS&(\*,SW9+/KH?^&8HS3$Q(O3
M??%&FFU&(8A!#'$%QYL>$CWS<% LM!R4;/3<&KPT:!7PWN%6[XT4" %AV2%[
M\!6?LXA>8-S=LTIZ3W*0^>K2F9.GXX2%('M6==<3_9W%1?S!M->@NT"6NPU9
M_#;O WMA7OA?X=;QH6]X:C+GJN8PWGQ]NHF;<=I/ NZ"3E9\8&UFI3^13@T'
M<(;P2,(EAMA2WU6^5+)7K.L\'0ZTV2\JN]22\@7+5,<2?=GTG(K='9;(\NB:
M7X&7H2([<;*!$6+*"CU7T@V)7Z5--'/,X]\P,Q#+[=4:;NJ=D(C4JRGKPE5,
M8HU#"Y:H0I'7&?;272.6 ZK1@$#R5XF&/"[<0JU''*/__^4W6-1R4?TE1:\/
M=^U#CF+U^WK#&)72#],#U*A?*_8[#,>2+(K;*@VW*_L['+O4:%K\I7"EJ6@D
MPP&&VO6V(<W3(/I%SS>=M-1/AC%X]<.;(J'Q>SN)4LC%J%/>9L,GLSW'PM%Z
MF:5>)@Q.T0(Y$8[==FT[HWJ.7'\TY49)BRIKM'$T^FUW;!#/1E< ; !V[S;F
M_8B5TW//2B0H_N8#-&'P8:9BH,PY9=AX0537.*D7W!+>Y@>]2Y7"LA2Y[+AP
M0;C@=O2VFW+YOA$+MNP^D0?5U(\NP >TUD?S03M5)B3;!\3I(9@W*1(8PE><
M9FYK0=X-4(^XYI!_"5]^_N0QG TH(< 3,G M9>&ZO?;1D^>T:^,<;T6)$!'/
MM<C8"Z5D XH\$O-KZG[L'P@SD%=!;JIJR?SSP%5E*$-]RAF>\A->ZB W,COJ
MT8GS2F##"1X<+] RBSQGGUC:4'/5@Z=[$*1[B<<8K:1,O&H"B=FPKX10<'3\
MR>>F?3'OZV5=(MNMFULP_BG(<='#J3_CEZ+]/GUT0ON-T7Z?_?[1?O=T<^3-
M2] 5O80PSVS9+O9))W;4UD02?'N6K?MWM#B%V[8XS4XM3O_.14$G5X(M!=?7
M^J\L@V((Q9*2KA!1-7:X,=8+1YZ?H2!2P,"IICG-DHEY0Y0<K3MB(MP0#-X]
MG/2U($=8;>K]1H.PFL/HL]GW&92!*8?(<PG2D\+YJNG^7[A]*GE$\/U=>7$!
M@-C7+36HQF^_2%U:_)B<&N;(?(YO(4U(%=:*Q6AZP49:@Q?Y/PCL6*L&=!-P
M>?&CA_ P:'-HH9!H2TQ6*CT3W\W<Q.GJ9]Y:VJHT>YS((+5MXI[;S $7$.IF
M<67&[QS]5.ZQ+L:-M$Y,GB63.4M?:[:-$\I43^4YG7/VC1!12&,;R;QP8ZT$
M-<A1 QS2.;5H4G=-KYZOQ"1\&WEL7@99E]:\2EK,X[>:0?U6>O%C9 E/C]N<
M[3[YR'BRLZK<3(P&+?I5MV<E;M]#C6[Z'>79N? Q;O^U.0J@V<0<P=A+'L?=
M? ZX]_'2][')?_]$WW>SFBV?41MIR-I(9[]]&VE(>BV_=1MIR+6"?K,VTC!H
M(YW]9FVD(6LT_,W:2$/6H/9;MY$&R87\YFVDOZQ=\M_01IK/SV_91AI<>^UO
MV48:N,K\,;21!FTCG?W&;:3!MY&F63NUD9XZZ$X==*<.NH^^@^Z>YNZ^=[!A
M 4\[..6@:6??]-#'PG$7-P/ !NKIQF>9'W*F,.@>L"SU'(R;/[/2=M6;@BV;
M*Q2?M*#1KEQ&PO(ZXOK?^P-C/&&S;,*"*>L.Y%/*YN;YNW'ZRGSV3/Z9V;.1
MA\67LQ@N]-1ML[-:EK/DT]%]CG64&==\%H$1-LQ'S2_%MF3?,PLWZSV#5*^O
M=KMU)4S*TC.1R'I&0"$Z!#13+&<NP!<M-$0JYH1D%03$8/.^[0A2[B-76"^.
MT':,T^<<B&5$Q*,,D[DK32UE8UR\;[IL:TQ.VB_;7E+2!"NOZ"B*RRSM"AB*
M[-77<>FM9RO5R.5WD =GIS,1XB.DY\NY2X1;C=ZQS-_;2^\4(17YR\8Q3(XC
M;S$$%RL66(GK"*E:Z0Q!19[H!3D;QIFUBVB[MVO:]82*3:!84XE+397""BN;
M@E>"<&[527Y-O7 2W03TUM[8C$&[I3+[OC%5YB/95]HCNQV! F5"<)8GN Q'
M5$VU+H+4CWT=Q<NU-$>DY^V1IMM,/IK#[R,[BU_UE)&0?'IJJJ(-0SJS*=V"
M#IBI%J=C:6>L\1SV<N\/TE$G=.)0I1P0,AFSI\6C1X_T_T9#2%4'\3F3ASYL
M,BH8%K6<??GX:?'%9Y\73YY].D);3N=-X,S+KQLT3)$[K:FMWG_U YX%I1"Z
MY+5"F\@R[;MX/$<K]>D77Q3//ONB^/RS]+Y!D\+8SJ9H8;^)/L!G3YX47XR'
MR#]BD4S)U$6^*+Y\]JQX^L73T36R:0J4,CS,KIBU-JYK^B_-HM#;-W&N9Y]S
M?O3>+_*W&; +*1JQ!V%JE&49DK70MKW&K1,.R$E9NZ?DYZ!]"A<VO8K!U0&-
MLTYS.H[6P#2?A2S?/-)D2^+IM5A';JP8V40J):1_Q;,_FD>EZ*>S-76NP+M;
MM6/+&!00./5B4O4;OA>9XJG7FOTH&RU5F!',DZ=#'AG][U490_Y][UP&I.T:
M>/*2[%3W@ZHH@S%P+:-';+S/-% "@S(M&H:C8V1 !^WBBLU<VACZ(M!/)>F:
MK*6((U/E<U63ST%UD>CQ] -=G-+:6/LJ+\A\-.?N1^8&?!C6[/$):S;&FCT]
M8<U^IYOC1Y,28VNC& UKA#35HJ$I) -'<BI:D%#$#EH(X4!$7R6>(8!^G#SG
M6\W!CE3-UF7'/L.VK)<(&1=E?WF+&6E:0@@Z/3J9RUM?PLI9M$_[2DYVUC0-
M/WK?/J'#)=P%W,5S+L#'J,J.>D)QAC%O @?U ]WSBZZ]%NX8>@+Y<;]K%T1^
MHAXMOBO-?BR'=#U8O/K"MWM9U/:IY[.F?MKSY!GE;8>3UPQ'KJD="X(;("A>
M9\7&(Z@DN(3RNV6UK; X]*%U!*>UY,,H&5 8@88DA@ 7+7@-$(!/TOQ:F.#Z
M0F)P42X,.$M''IC:H'K#B<2A0Y=!? CJLU63@(F!!%I\LUZ[NY/TU!%C,/,M
M ]R]O:MX\.'P'5B]4WN6SV;_-6&"RH"VOCB$@Z]S?80>$8]UTW.HYM2ZE8Y4
M2@]UUL<6WV+X*!^-3?_(CIBW@T1*F*:',)HY*FZY]APGW9B++*1$GN,X04*O
M,L2=@1'O_2'S]E(MJLP%:0$Q.T)0>,94NFN4@."(\NWYFY<6G/(>XC]\]U_Q
M#^>;^+"$/+IA*L&V)16,&L:.XT6YO:#1]DV7R G=T<$57C0<Q4.%L]:W>7Q;
M9&@S<Y8W/68HJ<H\9UDEL8<N\OM?O_XT\O\_^R).5#ZCZVJU&TSGPT=G3VY<
M4]Q2NHCV;4L'<G/Q?_[PZ _X=[\M%_KO7_C -P<7<3"7N\O_\X?'CQ[]9W3=
M=YW>!KF#1;G6]XI7^<.?PO_>+?4+^*&+V';+/TW]5=_\V>=?//MJ^*WAP/WA
M3V73M%08X)8)BIJKQ673KML+H4ELVBMQ0^()T,17%[81V \A-*5CL9>;_7'7
MT?^C$3XM@3NX!&165SE*-E68RFX7+6)_61.6/X8O#TVXF0R _]=/T,RBM!K+
M_?K<#U4!U0LC;I@:_L%I#=W5-0043:EM,2XVZ)F];H%J+"J+T5WGNC<<[61
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MWKL_MVUEZ:(_7_P5J,QXRJI+TGI8?B:IDF6[H^XXUHG=G3EUZ]8IB(1$M$F
M X!2F+_^K&\]]@, 93GM)!U+-34=2R*!_5A[[?7XUK=.SKN#UL*P\^RRJLFR
M@5,+J>8GN$4I5>8^Z8@&)HEO%A_XP6K)>XP-6]>V@@R#&%A#Y3GI;>3( S/
M(UI(Z%$_'8Y.6*NQSGAJ7CI>AT&ZI@"(^RF6R^<P2 >(UW<9(MJL *\.",<Y
M:@SFV6<I^0UY/<V:W%LX^/C':\=^TQ%_$JCUX1VHM0]J??+E@UK_!&>&_R<C
M%?7-5]G_V=T]A&AGW_[!T\'KQN?9LEALGMU(:(>G?O+^U9ODX235R9^43&4M
MYKQ$(32Q\(>JDANZ;?^&B__5MT>31!?W.V8X%^/H9="G40V,FR[T%^X?OW6
M3;!KPUH]SLKQZZ+-DQ=%=<KT\>GW[6P2-M1:HB([^(JQP^DW'4.<.M]9D*1C
M"B^V\ZT6\H(\YE^BD+W1";"!A6A(XK@%A&3%9U.Z"!^EMJO4V&YI[=(7]"O8
M'._(F,_;4?JWHM[07]YD;0;^GO0T;[/Y^'WQX3)+'SX]W'O\^$GTMI:\F]4<
M)/-:,$DS_G^?/MY/[Q_LI$_W'X[W]O8>W@5:E"[]O%J76DGX+E^U7)B6[.V-
MTKVG3]G!.R5?*J-;JYGSVT_GDY<3,?./YT5^GKYR6_I6H7'L;+B$FMB2)PO.
MPLZ[3\@*] ;8GK,>!8DM%E\3VO2]=4Y@+C)(_-O2 50? Z"ZN\?! 0D&RF'@
M1Y"CX)[2.326O\];_8*&V).!$+M"3>A?@V6!O?KPJ&K3%19NI6Y\_>+$'<RW
M[AW)_DCQQ@$BG(ZD+]*P;C#L0>3U8#+@6L+(_QVB@FFHKEQQ[RF_^X#?G0R]
M>RB9?Q-NRMM^&$_*J"AT#S$.9EP$>0)Z<XA^#8 P+-G-:EV.220E#B50>5=!
M4:WF[3Q;H)W%.4Q.3P5UA=#*,J]]#'(S2M_*QXO_IO-*]R_I=&Z:H8 E<!5S
M>ENZ&%0US6#L@#3TY)<Y.9X%G7"@?.E<O7'>]"@]*:<3//6'_#*;9>$S1YH8
MQAWEZ^U9+^E1&9)>E'^"H7.;9+T]_?ZDVQ"C616R5+U%O*!?2*0'Q0J+-<=M
MM<^8);/2=>.\W]-BNH G736T)K-Z?8%PP:S@B-N6I7?XA>_UL4?&2,:,.:\V
MN2@CJ""H2U,M=OT:) J/L0^KB\YF:\Z%7ZRN$*B=J0YJ 1N3@]G1131.]U)T
M5;&]YXZ,EBL^9\1S^N31Y/&]"#3E/L[QW"G:\4K\#,&TY)K5]N_Q2C84<$OP
M<+FS]-60( 5"3L&30N32UM<YZ/M-G\K2,,=)8:S;S]9FY,G^==/_ZYH^0F?V
M43B]FDR03&!2JS'B4(G%6!@C@_@_W3HD""<GOG=URV$=6H90PIP$,I>@&<07
MBVQ-2Y@I[RP9./SE$8I/.-;M0HU1;$W+LM',Q-_]KK,,WA*]VN@++T@5K5Q$
MB)?QK-+?^N+I)>0K+V>KJI!!T@;)77GR]G22?E=<S/$OQF[A3D;2F?Z.D2;1
ME*(Q7 %LPL,T/JG,Q>6 ?3_/VXT ;1:26<,7 F:3?+$@9U[#W1.R+1MW_S8N
MKFD1L%'BM[#)KK":Q1(!1Z%Q:>?8C2N8*,!TZH 5-\@/SB1<ZH+!OETM$^@T
M!IIAHN$W&0D.5]+L/0Z%!^R0&10C)@#^Q)D382O)\(J;^R!YU?UB?5[,UM,/
M4"5.Z[Q!_[<: Q"E\1/9[VE@]? '^9=6J.)44.'J\N3*6'2!>VS#<*2'E35G
M.;QZX]>=+L3 DV%T1Q6H0DD!<-!3/[.4SU3G23P/R41H&+V*Q\Y_"GX3EAO*
MHHYE4;<LHA/T9EU?%I>"QO"WH%JJRZ')L GJS:5'MK?!X"&>3OE-TJ-^%:Y;
M)MB04;LKO\U.*A>;9%4U[=B^)&B@K@*[9\\.[P1SZ,[=[0M\:Q>%[%_DJ\#"
M4;I!)0W""PREMGL8A8&NQ$QR.EKTLY L5:^5P+F_EKHW$3Y?T#UW60EP<XJ,
MU&+A:\>N,E $8G_P>!A89[3$<@ROQ(>-]SB\ =<1>WF\?/]YB'9<"\WASG*Y
M;HU*:LO3D_CI^!7GBM#.WG9CM:ZG? L$\Y9T)BIR0$N'_ED>DCRM<;?36!#2
M+W,_ E7"0L2#I_WGWN/#T>[NKCI/F;-G/!4JFF>AUG"QB8\O'Y\?3K[KT0>!
MQUJ'TC-CG!$5&1-* L3JS+":* \2O]]]%T=":, R876[W;X 0AC&N\[UU+0%
MG)LWVKY-#IH7H6I\F4]%V1Q(2:869K)\D^YY*K;T?Y)'0=(P2O]S_Q'^P7_^
MSP/YG=)UT>%!%2V_75&A@Z, );76YRYRQ;E[9UBQLS3W8K$1AO;&R7L JE>U
MLUJ[7JPF(%!&:QA$ AI&<I/C@+A 41DX,"9N7R(V7>X2JZ3G U&ZE9+TD_HM
MM*57^1F(R]+[7Q??SMMV]>S!@ZNKJPDIT7,$ &G10::XDV1JG)%)SZ9H2-B%
MGPU'7_A(N-89!J'Q*VY%ZT .]FY%1\UP[&<N%TQW("/Y2>\N-CYAV23-7"H[
MJY+A%1 @?=)(R&A%-?DB)DOY@_^L,1,<J_CJ6'&NBNVVNMU2K>$4IK(1^)U-
M,RX+?J\@ X,<A3-13LH1R&$%DI %BIVNN2-&6Z<_.K"'@]?^L6G2/W.FX(7+
M%%@A?OKV$K=)?G7;KPP?MU=?<MPPT\!94<4-99TUS]>YHE\1U&=GB3[NNIRD
MS1)FU)*4_'2]8%A.G:WX,;#3@4ANAGU3-LSH2 ACL]CHYXMLN92&&J11^%P*
MI3>BO/#<9IO&RN\F+@T!*TC'R 8K*$?/$5.AP^2J2N2-97:FP!TRC,J/#2T<
MT"C)UFU5X-+1F,HR;[,S5&B[L6H6@UZ)5Z=!S]XU6JC^(@R,Z5\**52"=O+<
M)$<'1S]*%4VXABW0;'2I\5^+A@N\R9BG:PW:2P)?\#@YP(WHP%DUVTBW^(!U
M(UA7:5.+^<FG9"Y,E@E//-4G0V/2HTLHZX5]LEE?7"A2B]N!"002)>N,'-%^
M*YG? 1F]D*V*@+EQ\O5[*4 C7;=BE3,6!_=)%"^3H'BS*>F%+=J?RRJX]R39
M!6G_1E&3)(\58#+T_B4)(#=H:70H%@G"<MY9D R:$P0]JJ*X1%'W6&L\12@9
MRM3$<H:5#J7#D_G!//QICM/JY$ >HYODJS^C" [7B)-KHC^/.GN9^+WT#SA^
M_0CL..2'T22D('Q>G!6M$9B(5N&>L-FJ(C&%;^D.>%_IJ)Q'\Y(*I/.:.0&!
MOZNYC;70:E^ZCLRY+I)C4( (-PS A0B/G-BY=9 PU3Q#;%,*C"_[D:JNWU\$
M"XU\D[SV3I39GN/KQNL16JLSA-N,H-/).A*']:2;L;R:6X4HNHAPR-G%7*LS
M.*19T,UQO42=,%T!=(5"JI#".K-0*6G.)2Q;5L8M!]N;44+FL4A3QGVOW$=A
M.O,+E^MFBCN4OV!%UW".I+MVTPDX/-KE@,U\C<PHO^HJ!\WVA&>G\W* 85<K
M0PX]FE IDP\"!-*>77X>'@S6DAY0,-4(BWQW_H76]>K7Y.RH<=TQ$K2?1G)6
ME$K)!7U.+O\BM]R4'BI6TPA^F=7,/3IT(J-PFFH%% U7 MGD\'T]9V& .[KC
M$IG*-EUP!3[DK(EU C^1*^N1)PN?9X?4KD5Q$.)SO_62&B5!\_GP1NQ<AZ/T
MFJ7CIY^?(R$=K:.1' ES'NAJJJMR#"1TMN35X=1"5C;6<Q3J_@IDK)[F%1:+
MZ5&.:9(X7M394N)/W#6#OC3B5<"J-EN657_-NMIJ'J(/;=KJ VSW27)L_Q2J
M$K&;&CWL$E +3!Z=?*X-%<1<4TBY+ST# E@;#W(U>R4R/&%'0=6(]JX@#8$S
MM^)#D81_\^Q<;K2&'I8!,<N)$1FHB7CK%?6GP5D/[^"L?3CKTR\?SOJ%'X+0
M6@FU^O'KO=V]48+_[+,J,_N6R3!99XN;JV0&\%EOZD='[&W#_K2\7FY2-'DJ
MDXZ-/L(M7Y1:,BMAU,9Q%9JM- M F8/N]:JI2)VRPM4Z$8E(H[B+' ;E=LH5
M'\4)\.3D)#U^^X^3E^.]IY^2 /??0?1ONA::;N%BL?'J'=;( NR'"X"U"GV2
MI&AZ&S'XWN^.C[U?C8MD!3H2OL9G.5^V?(G(=WE19QK*WDY]_FI-]U ^"0>4
M<!9;<RJOR10#23QIM/ =>B>]?GDDWD23HU(\9;O"CUF:GK2%9W%P.XRYP#9&
M_367@M7T'ODZ!RHVDR08$N?ML8 W6J<?CMY]-V(0($LI?TC,7C*K>,A,)Y3/
M]%W<0=;92/G/9$]-Y)2 3%B+3FAZ8TGM2]+/FUH=&,[@D(;.1MA3I)E#,')@
M&+.I0U&%CTB&'B&=%7(G=4V[GA6Y:P>3,>&0.1^<7(Q9,N$LH'&6"V/ IAM=
M/X4D.MZG V_O^ *T?MW("YNZJZK-E9#9U(ZHFT"[A!320_J'O# ?_?'?NRSJ
MZ&=S[3&IOQ[CSVOC83DCJ6XWM]Z$^@F7P:+(+_/822#!ZVZ>:_*"<Q\X0%JM
M53%1PAJ>0I=&+;-D"T=5OLO1!VE*0GHD! \2SG"*7*1&GTH'$:8%\B.BR<DM
MOJ+WS)%?G!R0[R))\C/@H?8/@\2.  07E_E)V<"1E;= _T3/EQ/WER=*0N5:
M6XS2O^1 "6]&Z6LAVDQ.V@S9HG<KLM-'Z=__-DK_FJVTS\7QG(S[G90K=9'9
ME,%*F[W_/)@\Z0ST\9W@*85\M6['"A00!(S+JR5]JX8UE+_>/.4WPT:=*E^M
MZV9-3WCV^6<H_SMY3'.XR63'NY/]:U>\%5P)F5(K*+WRXINO=K\2_W.53>WG
M7SGFZQT&NIEG[?R;K_9V=^^1.=[6]AK2Q9RXL:G14[[Z-OFZG=D'^(N!%];.
MOAWZJ\W\Z:/'3Y]W/S6P=E]]^W$;['ZQ$V@*@.J+%0RPTRCE)/$$^9-<:\=9
MF<VR$7V_V$FB!_PE/ZLK;E9LI;+\&_F:GO5W9,3\DM<+C@C0_Q^M.;+%C^L-
MZ,V[]$T^DQZ8>/.;=SH$J @THC5.O>_ 0_"W"F]]DTTSJ=5_GQ576;F#1U]V
MGORW#7WVK)*YIL?5Q /IHC_IT.EDS>GQM'KTL.ZS7EUIEBXY^HM ?.T7.EA:
M;]REKZ!XZU+M1;D[[U_2G&$%51DI8A3ELB&OQ!8<?2^6TJ[2L1E7F@>G@\OO
M_T?>GA7D)/\\$<%XT-;X'YR&NQ/[)SJQH;&^]<"*>1?D26"I\UF9\Q%8E^G+
MC/XQ>(C_]G*4].49Q\XY%0//?_W]RP?N+70BAPY@>OT!9%'G\ZT.6&(/O-%9
MX>\'BN,W%_0_W?T?7=K/6%(<2C7)RYH, >GL4GK?/3TAYUU\=BQ]=&$,>$]>
MZ2E&ETX&V[<&C7?6FA&;BT.KC(4)-UK8WU>!$X82ZWB+$D?$RK+!D45>[,#
MM@NO#"E\1:+.=!HO2G^\:3A>7DY/X^9&><8.&^.//S9(\:C)3A-6HBGO5&+#
MF@7CT?OJT[Q.R2;0QS $V15)='S$%8V\Z42NI)T0M?&KP1KF.J9A6\J:,U:(
MO" ;%*5G[E+_-(0WI).K2V5%,F\R+K9@-%L<_6/J?4[:R.GCLN%N2*&UA+=7
MVJACN:BJ62>[/?)?MJ*T$=H3K+1$@RE]C4$TT=[N&RMY8S02">*R0%;-8CW*
MFL5<Y55CK*Z:M!FECLB[:#48>I'!Z=5*R.6*I-Q%:YSQI:W\-!F8./&3W]!;
M#0V%S)<0+F+JB.B +4QZY0(.@%X7)1]CS>U*TECA+&WU,\ MTARIN,P58T'.
M^X+S<(Y2YM:+[_?%A[PCFV%45-!,@Q)7.!2;20YGBV,,E$D.GM!8["\X*,P[
MW94D5<8P/$1>0$N42Z,?#E_@^9N\E>Z?+J[IP[/E=4'8Z,JQ:*FU(0(29EXL
M9NDISL6+QS$FGYSR?-P[I@ACAHOF< (E#6N1+G.@>XMFR1>?ENWQ.N3(FP+O
MDX\]:[/DO>L\3S_D&\TF,[6QY9 EXV\U4@R8H>\Q-HZQM@HMDBO.FX+6+*G;
MQIYAXF5;C'O8-O[M>4'NX$5.,S9.3VO5@V6<)&^PP78YHJ H6"!27IGC$!U:
M(!\,%52?:AZ^;OCM&JCD7;_U1_4' )]IZ:',1]8?&[K04#EZ6+A;&/]!ZW7#
M-%+@ ,A'7.<J1MK4>2<?U4@%CG^ ^;ITM0D4W$+=B8]4[8C\> ,H>!671]!U
M0$O R@/H12ZL.'=-OU?K&A1B &>LVX S(:!'X_.M'U.;RGI@CY@B*Y/.&^XB
M\O RJ[60,>G=:Z%?/N]H6CN2;F@Q!HW7B544^ W/%D4S5XTG[8;P [>],-7#
MYMEJOFF*:0'^9SD[11V4@/@K,>.%Z>&"1W:W<:*DT""?@388/LM/ &F[/^10
M)J@O8;4]27[0AKK58+XTZ*7LM"GWFLH6S ,L+U"*P9&W2\0\]%\NJY#[!-_6
MG@U&XCH0U?S]X/F_.QA?TM/O8%'E%W<\.D@IZEJD$H<[6^.JS9+SM6F""R')
M)/D/(-\QA%Z!:5P^:,%S;8)MZ'KTJRCI]N4S(&ZETQP=E#W;$[B@SJM%4<%0
MIZG0-U1;,3J,*9$]$KN'*?^74/GI5E1^\I,CW<PCZNR06I83MVP?J 9C(VNA
M6'['!LIZ-<P=&-6G^[XJ.';!,]AS" P)M6LA#"[XKV:KW+V-8RU@YPXN41",
M:!]4R$"'L/ST;;GXN=B@^X3*EM?A%[$BOM+<H1!DZ&SE72RJ,QJ6<2BZ<6IN
MN,GS#QQ;X#I[^S0@D5KURZ]UP@+;MN%ZNC7K;N]D<X+<B8ULB?5%#Y6L%C*P
M5D4V#!GTJT8:O/V>"9J!VJ"[6.]-8KVBQ\-CJ/91[+)+%:9'!=AI?/Z'!?CO
M=OQ?VG&G8*/2JPB:X96IN'.FZ9P*,Y+Q 0_PSR47?\A@/@W?^N@.W]K#MQ[L
MWN%;[Q3F[Z0P'>7XD#VH)AIZ"HAU_>?2?W?;[+;90W^'(PG3!4(RK>*_U+27
MF(>SQIGG\$X _IP"D%U6!5QM[:NYD2Y <MR5_15M(3K.G):/FL5T!P>(AO#W
M1DY)T3A/4:CQLLL\40)(B9&XX.R6X\=&:K /H97*9$.760T.HB"X.U1M,$G?
M6;@C7_@F0%5 5>-#.9JAB^"+OX%O^RFE46=N5\\^WG/@-Q[).[=_X0K;<OKX
MC0LF]([/(%N$W*B#D2?;8PLQ8168XT%B[0*N$(<V">)*__IP1M)Y!8-R#W+!
M^<'R&0WXV\V0A#J"(R=:Z.'S#]R!)?3'W8WT+P?<_!(E[KE<?(Q6FT6IU:16
ML>/);WJG,,RI<&(&#^GD549I,<DGHR WKAVT&P/ 1%E9SB18+0PG]+H?#Q)L
M?VRJ[-_J]/U=Z9@ !:#[LI&62LFVB"2B?]) +/?A9=YI!_ O@@/E>R(ATX+@
MHO5VO,R'!$.$TB+321L2:C/G@@6TN<?KE-L,=4ZN$_=M<G=E["'-ILSK"T:@
MB+ P?S7JI]UBX-F)Y>(EX.T!Y*X6.N(1$UZ&<. DY$:_:6,0))OH(R%5]&UT
MP6NB?:#S<FZAM"3(U#'3$',?N^92VB](H[HRDL["*#%,9[=I<%(RKC5P7?(4
M_TF^'!>\D@DRJ--%)NV2;J[_?%LO'K-%F[DGU:"J"-3L&?<%Y3YG6BKBA"%I
MF;+9U'I'G@(-WJ()J)@ ^' NS1-CN^M.,<A(3AUGGJV>1?J$KT5S#])Z-4HK
MZ/%_&UV7 V>="95$]:.>G_GUI>6"NXKX39P_'7K/)'FK/:;*5C-F0_D@%Z$,
MQQV_0@OYP\*E5;7R?<(;=YGU=2)G7;R.0#(\JVNPA%JC:ESEL/LDK:&=-W'O
M,:-">'D##C1*D5U:XJ@RE4C1?."^R-J3EF_G\I^5\C9H:D9#J8G/1$^SE30(
M+?(FRGGE:(W*O?D:7V.7";8A7 !O)),&:-C@""9J)#ZRIM+K40U>3)@,%>20
MFERQ,!_H:W.@I!RXE<<X5,C+J0*7F/+Y<H._;,W2WQU>-Y+C8-7R<+F2Z#9D
M=*.OL6( 0R"Z[AKG$QAQLC8Y\U2GV[\L5^HBESX,@Z1O>CDR*"VK&2$_TEJ<
MJ QYT#)W$.BA:::?,DW7K[2>\7G2[O""O<MK/NX,T:A942EUJ&=X;+/F0_/,
MT.E!*;) GZ4W'4.D+X1]9:,H$JYBH(U? U##GQD%!Y@O>$!$> &T%ZE?A] K
M09EP]!Q =/3LIXI385]HBJ>=G*<!TXCKPIUK;PY>UW'HBO%(2",M:)/Z6QR8
MV%BE_AT^L+Q5W=F[;.![W,UQ<9E'BB?Y@S6LQ_HDH8;]%-V8_F:Z,?D7=..?
M'$5TJE,^U<3R;4<3@0M*HK(DE70PFEQ2M.K;690J9$(<X@GQ:$B.HHCM%%!(
MB!>2M6OV U#0_.\)0_V- M0:)$;LV65$R7=:9*LFQXT@__H**;ROVUHS>3YZ
MK-_@^/99-X'Z/-6ACB'ES]+](.LJO^GE7)_#SFOS,>9$[R^KJSI;#47WF>6V
M(04HTQ2;P13.T4IZ#=/^/GA);IL8-.W,#Y\F!MK;;[[:_^J&4_GHN"S9.S2R
MTSH?V^CZ@_D]!B#%47_\0FB1UN<8B/ZY!OO!;S12'MU),%Q.:%Q_%K9*]L!A
MN)E<'SDRW?%)$._LK:'3';_S[SH+L&U#O@J_^Z\LI.JLPR?WOKIN./JQ1W_J
M3SV\_E,?/P/RF,Y2?3XQWIWL[6])P/9$^=0%PL=Q9>O]O9WAV='+T1*IG.%.
MJNIG*4WAX-'A\?5K<GN^]>+ERT>O7OUK$G*SQ_YZB1D<W6U153=3\-]'_%"W
M5J__>LV"M!F[MWO/HZ+O^_MWBN57?>OERY=/CP_^%<5RISW^R /!^>/!$W%P
M\Q/Q^N#)HX>?+&\?_]8 KFGP&OI]'_5IU^N_@WAT)R^@LKL3$_M8PZMTTZOY
ME<%(7GH8"2YH,F&%2O/^PQL?*!*GPX]9:Y_TK7]I9[8[W%^RX/II'_SNT_[L
MPGDLO"]E5<S&TH6U0S'%DGK_\$Y"MVR5P7"W1Y<^Q2RYZ</OOOP;?/D:!_=3
MGNZ$YO<#+?\Y8_[719O(4F5#]:/N2/]_KXN%T6/##,D-S,$A=>I6_=C(V#ZJ
M+:[=M!M:0)\TM$_28C>-ZCP]?''P\O''W_C99_.V'%]4)*VW9)U?O,;__0'K
M?,K\?8+/N*KJ#[^E0KNVI&4HR_+O6'H3J<*/E=YL6?2A>IR/5N,,80 L"/ZQ
M\_"3<=Y$!(4W99%,KF61=/0R0M(H.%5AE&2JIVM9&:7D)_EZ>\W/W4[+3N_?
M>*>EC].OHN4<W.E!CC2&_O1I.=/MM)S2UV*>+<YOOOF?I=QO[P#*]T9$Q_+1
MW[CD_5>,Y].JWA_?5;WWJ][W[JK>?_/C<:>K15<??)*NWL)(/,R;K*5]28^3
MN$M)G'I*XKY.OKMV;[J5#S]I*W\-U_/1CT+F?B-JY[N-N^G&'7[2QOTZHNSD
M<Q!E?YH)]"<&+,?P'6Z&M_-O"9O]'8<0<RS#&4/M2,@FV"?'M"Z!'^T#F'D,
MX&#-\Z33*P#TS$*5/79%GB.M:TRBNL9.Z:/K',\%CT;H+(JN"1H-2[ZA^ABQ
M^55869:UL2\J+-+GV26-BX?2:>C-51N^GJM/8FR-Q#NMO\%J[FH;-F&O<^8V
MC!K3AL]+7'=:WUOM_0^OQ__U'T\?'CX?I2??CQ_QJ.@?>Z-T.L^7UF^7?OGF
MS2GJXS?6I!@*" S/K@^O/1)/S):KYQ^FF^<O^*NG?WOQX.AO[Z6I+FW'2(M$
MUBMK.DP+"&7EF^1&/=K[78,G),TYF9P7J ?9$PA]+"..HWG;LJ(YF9)0S]++
M(O-WG H%O5O9V%49"M/]P&#\N?QWZ*+[[Q#T^CW'\/79MU\72[)A%NTW7Y&]
M4$^_^8I^_C^[N_N3?ZXNOGKP[8TJ_C[Q]OCM%NMS7&/V2CLASV+]V3\3CN(O
M<11_M_["<V%#,8O\'97 6"*#.?,W5%BF+/=(0ZJ3V;B#)C;:A%P:E"\KE*+5
MU9(_/LOKI91(,R/^JI!?:*,)_')#4R_8W@.U/KI<E!5I=.ZG6?/KK%$]/82T
M\J(XQZ?R2?KRAR/L::/,]-'&RS.U+,\]WUJY&#6DTG6G S>(7!:X.X3C([Q1
MC(5_64SKZ@Q.XHH>2U,C!?Z>KP#?,'W[9ZTE/5= #W201V%C71M3L@XUL2(_
M]P5F7#BQGK]750T7Q\>&J^ETS?/-RX&&\;")T0^RE8'2SK39A]SOM#6=QTW-
M'0PN\I+GGS0YR)BK-5D^&5UNUA)!"]N;54[7RIJI#YAGH9W3FDP77/#E'SQ)
M?R!;'];-*'P=$S-<U-EL+7TL:&0TV0_XLM:0_ES0S',RBG)NF'(.<^8JSS_@
MB71@NL]BUK/5(IM*[2.-FI9JD6WRNK&Z6OZ*=&6EN<SS&1E+ZS;JDB(,_L&S
M6=31LW=&(U$1;];U.=X3/A:F(EI$D-AJ?69IHWV/UPG?]EHHI*7,G\3S U:<
MK!5810MTL*4)_,_ZCZXW_S?08.]9=<!I/.?^ 9N5T(&XC7J6R%*-THMUVVJK
M'G"3TS]6].0U5Q0SW= &9=JLDZ:\&<()A,B-A'J6(UWV2-\U^@EAEV&YL1XK
M7+Z4SM<\I*2AK=NX?231S24GH)TAZ+*U;M,01A.:0$VJ"A2-VQL(2Y<*('H=
MK$7/-2D7 $,1-05K4E%W%[1<#=JYH%?N B=G+,.5@2&M0-:F2)EK2P1N)>@0
M&S._4P=*YBF-&MG449HOSD"AC37X4.;6)0(]$I3E(BLW2<:-\N+J3JS1BI8Y
M6RQY&^<91VF:2ML4G.>Y5""CW4F;+>34V&E(N2 ;1PPP*[EXQ#FB [F  \1K
MA_+].A,"Q'SZ2[[,1D''371 @A;FHNB-=O25WA8Z:U$9#>V+S?V?5<&$;&A'
M87TE0,..HO^14!>@+P[Z];:.UJ;9+.G^6=Z=X=@*(:>LKM#+I@9I0<U5[E4I
ML3NY4)@WAYUNIH" @\A;O21K@51Y->5Z_ID[:I(18Z0(69XS!&/AI$$:7M/C
M\[KD%C]"U)/K#] H7NI%;//9*/E0@NF #KE(#-QL? -AP;:N5O/-2-N(<C\0
MTP@P24B(V1'3?:?3Y>;-)P/$*--LW>31?1Z)F+5G2N@[ P-QW4Z_Z%+[3TN_
M/;E+O_73;_M??OKM3RS@8:UY^D[C<<Q@$GJXM_W6P+U/BA(^ ^M)X9@@Q7B&
MN*;UV_)<JK*,FMXC-=Q;T- 6"?M$Z%<GZ9%GWK''<>,K_\RS#;B#QJ_9CBIG
M#ZHZ"7[E>ZHIGPO3^9R?%XOBC^>.^C?8T=.ASGU,T48>IB3AP 18"./.% XQ
ML^Q*-%5;>C/U#MP\#E:0+JW;K"B5H[3*&Z8PRB^K#[ETH"3K(0B%2Z<]/,D/
MH+2^B@D05&2&([R1E;YAC'8TY$^RR0 Z4K;9.;DDA%&<-7 9Y50ZW-+ YNLE
MFPHD=7<2P(PQNBMIIR$KYQJXA9FQ?\X" JS])V-RJT?ITUWY;U/\/":G#$TE
MT5:T*'/]D?MD+C*ZQ26^LF(JT"GB02LT')J-9U43C,+$ *WWLD7.\9_S'/\D
M>Y.^=C]^LZ8\].4[(VDL?Q^$7XM<'@U74;MWTX<^Y)MF\"%^S#N3]-4EAVRX
M$RQ2G?*@\Z'VTDV@G=#"%BX5+Q:38^$(5<VZUF@>MWLM$319S"078#$)#MCA
M+6M-"HB@=L_G*"''AA=+'"++Y[!BU'X#=$IOO62_TG5A#N1Z5E2763-%["$!
MX'=)KDFMB^:EF]LXELV4+S#T[:W74'VYEQL)*)*^0;X/+@^DS>*.)@6SG#XN
M[%]HL!LEY#IC 0W9K=^JO]!QZAU_;$WB+WKPZ4KS:&TLM82_1O<X:8EUJ[Q4
M39-M&IU0\2U]Y;(@%_'K!X7.\KZP2WMEM*/DP_2?^&N7O6\E<DOMD"C 8^2(
M<KF>+O)U(R_N2@'+%C< R"\RR24;AQ:I3XY.P$$6:TE;X%82W.00&7JZP<=$
MK!6SOO5B\F-N:>A+O2Z$GEH7/-%.JB[TP!O+5P;;"=G9&9+<LT*:7M?Y90ZJ
MXTOH3 D9VT8YG5K)%02K46^@<T!Y%FS"G)0J"BTR(M%0)'FB<L#4PV<EA]J5
MG/%<VI^ZP%0 9:!EFM8D:A7('%74FP^0%/P0/4::QIXU>7VI#+K<^/6"V_C)
MI9+L[:;+BP<?+IZG9*+EW)$="@EIENCB"!]S(%\)U)@+%@K80$URMO#X"N20
M; DO6OND<UB0#@2O##=*1O-UK KNOF"Z/$,2$NYT"6!#WJX1<\G$;'3#XDBK
M;"#BJ*7.]7XXV71/1[ZC5VTIW6 Y9I7+.2JS1>)4#>)96 E]\JT_8.;YPLQY
M>+B;YN4O&WXN>57Z;UE99O2<%BLAA!<V?Q)0<LBUGYLV/H!? #NHBV*1J!O?
MC<&+#'%2,!:H=HR9,Y$T)I W,2I*Q:/P)^M<=CKZW,1Y\J'C(NRE&=W!= OD
M2.S</_ZZ6:^^W7OX]0/\=Z=GXI$,-]%43/@1%,Q_ID%R74G3"$,GB?*Z1.+[
M FFL^$[@D./0HU)N=3!#_'M6T)DKSM:JP+AG,V*H6'1:4WIAOI(ORH%;).39
M7K++S6G%6R_&2-8,.;;<XR!,:0-6+&WD?3Q<S6[Z:R0&LQS!YDWN6\G+HX-D
MZD^!%E7]P^XP.G.L%RT\ .17\/3DN^PX>V_#(#E?GV5;(B3\?0]<@F(TO<:?
MYM2[,LOJ49QFS0H_*HAJI(%KM&(5:)(^#^@Z;7S_A7/%WL7V_M#87N\D(J^O
M23N5XBU036Y0L9K3<5J0(9=XY.:OB0RFGS,RB%PH&>>?0T8_AVS\7L.Q:)J=
MJ"2T&>[.TR"P.75Q-!'5&3/AU_D<M/3<3YO.@QCVZ66U6)=M#HL6/I_@D-!Q
MI5'C>^2:M0#AQ/ZAM[P$P5(Q77]>9]K Z?U5%45!]00^W$WFY &U\XU_*VPV
M#IQ))$KBJQ*EX]\X%W;0JBL:#X<XHROU#-85 $YS*>Y99C]SH#?V%:  BC)!
MD!<H'AKL'"3P.ZH9N&1R#-P9QZ-!68'/(5@G'U04P!(HGFS&0!.#_MY?U:2%
MR$YEC).W)VG>=0N[+M^)W9_$>5%A9"Y8$A;TO=T)W"K)7U^1@SF>9=PSQ3YP
MR'^G@<&["*]G_V+GXF13ZXO .@O^D1B/*$;]7^]E*R\=\(*-1;4@462<U:D*
M EL2WJJ,%YE_+4CH)L '8I-IU] 7H*JU5D>A5"8 ";/E,S4_+?^B6!9EE"8W
MZW7H&=$8) #+UPJF-&[69_\$,@67BL+.R23+:278V]1I--E2QI*$[W-Y!<,0
M,M:$3&?R:6NX\W+'=-H:.6.',6'Z66$VORP =\/%0B[H;'P.L$J<.;BOYM:,
M.T<P](Y.VDX<[.-A\PED#X<.+403+8S*M:P:O3E&S>*@K+C[-8M"C1L3TMJK
M39BA?T$C[3C:*G$7*$-O4_1(0OR!E!C+'-<8B ZA295A,58\+UU6/XY1H%%&
MZM\8Z_N2=!&9!(M,(R8/)[L)'83K72A(>A3(:XJ?4U,]'%5149#P:G]!>T]#
M:$S:3:%EWKBM%@Q*G246C0"]Q.K6.T)1DNT<8EY>R.E/3 9ZV05L*70;Z[64
M]1J[V"].7DI81DIC$"D2H.IZM0*<D_2"E.$4Z ;GI2QXA4KC;=^5(W<2Y5)2
ML@)6#UP)Z4D*FF'CBF%T#:KEBF8N&85L:L$YY\'2<PN410%]BX9W>A/@#4&_
M&>U),Y+ J1[2)-,\Q6Q39F1X:S&N!%@%C@PX[UDU9F1?Q0#9:5TU#7!>JEBD
M?Q;R^F@D1SIE7LU</\$9(M]H'RF02\$H=O./-%H6MKJ2T5S4F8(4>W:+HA*Y
M?1GI-%8GB.2J=I/Q8^C>GKJ:YPP([@>F,,%9OLAX,75YR5->573+:-,5[M=)
MJTQF2:/>!M#Q57D178[!_>W@I=T9X<[!I38VO[[[ZC1^=3+EF"=#W/1A<30Y
M+R^+NBJY#$X:#](GI:Y.K_:@<@Z=47%%%YR/<J_,ZGJ^:>?+(FLXTJT-;6A?
MXYLI$9N'C2@ SJOT8(S49B^SR3\W8ETI<89D2,]\PA-75BBK8]<>KJM#TO>\
MH6;0B#TD"0 \Q%Y&6_)/>4 <S,$8YAG''^W)BTU<-V>&9&>W5G-T_Y7(^9V3
M>./RL>OP@D_O\()]O.#!EX\7O*6'PV[WD=SSR<G) USU7-+J+OY>P/(NO')]
M>,7E?!-RM;SMZ:Q:1!?LMP_,M-JH!U\-F%R1A^BNG[ASO,,N^IJ0>IZO$;LL
MR(8R;/@HO5AD:QJA-#B<H5IXPU7C,S+%N<0\??GJW4A*E(/ZJG1O]'AWUX5*
MN\DD"\4,.$F=*O&D6R5N40ZYLM7D)Q.?K4/]Y1.KDCKIH)S85K0TND9.8#'1
M$\?F8M/5K!P2\V)%=WQ+SRJ33KUH-UXS2=^0NJHX2SWT"H1&AJ]KB9CPKEWB
M(/,?D2SKF8^C]&Q!_GF"0G08&MSAD?ZM&?Q)^EI*_%"1PKER5)WER[R^@"#H
M.EJU'=>9<&0O3%1+Y,,P"!5J=YC+,9"R(3&10D.7B>IY2W<'73+_+-KD_92S
MC.QM[@U)=MDFY4 CAPR\(Y"7LQ7*.#CLTG-(@[-.YR^ 2&0=A="#1O(YH>]P
M^TB)Q_#K!U_NNZDZ*9%NW9=*$2A-NEE"H@,23]3A+?SHLG@N<!H2+UI!=4K7
MA+_2ML >]A$=)[&[28AK.\9VA%VK="-R<4ZFI]ZPH*'I+6NBZ<-O]/%PII/T
M.UOYX-B?K[G\M&4T\;9-]9/"<O651M*=F 4(.;'O!F2SZRFH5FK=X.NF]Z6.
M3[A&W&OA5.Y.]J! .T*R$^BS)+QESD+)&]JO;1+!^,3EF45@.2+YYOU_CV0S
MG2RFVV6QF21!5(C>) CK+N4(!XRD,ZKKUGOST:.QK%>-,VG;B\!O1WB,;I&F
M,&;Q\61='(GU;^P>OT%-D)HFZ*47NT*[@ -,7SY#"7&6&&2=QI^3*[F8?527
M#$X;:B2?YMQ >W]W[V#2OY-Y05H)&80J291]$L5U7 ;& "WI?:Y6-4J:."(\
MS5;D"RMZON5Z<]S\+0^KR^FT-]D=I?MTZ^/#>OMW@R]D#>Q$!=CI?> E.!-@
MO:#S7E7LSFAX;? BZ,N!9^R$6_U@J\KET)@?C)WS)>I3 0OK;1-"1 S?CI4M
M)S^LCC^C:WRCA#"AC ?#:-879%G0"Z+!2!#,->45Y T"92J"/-A(!FWB8ULY
MFPHK9PO/AW?/-5>/&92)9H* Z0,(MFD'C*,P*V**CB<;A13U_''DO*?ZY+?;
M]'!UGG M,O35R=O3/[@E>^'LEN(/;LE>^$);#.89QR@EM(7"!K:UAQ6]W:>!
MP$/ -'4GW9X#A%.0Z/( :HB&2Z7%%YNG[>B1MB09&[K&7>0A>7W.)$_;X5VA
MD*A#63X6(%] \O>?0.I5"X=3,DJ+7 ^@/Q%)="*,0PE9,%RFXX@ZB<.[1=.L
M15F>OGAS+$^+3I]_]FUWG7\*G1,I3UDH&CZ)[R->7=(5K]9UM<HS,8A.FCHC
M2X&A9! ]"87AEKFL%LS ^?A1Y+%&AE(&9/"L0A?V&2IUUG1%C>FZ*V<CIVM\
M2B$1<#YDBTN/P)I6S:NZC2ZQT36WF-R?[M$,Q4[W]L?P;%$Q5E0"T315:WD#
MJPPYAPJ=;A)?DL;HUCC;'[\PO)3UHN[9(^XN:*MQ=)&.0:?1X1;7!(D,Q-EQ
M6N^S1/HFE_H\E$A4K=A]OM+]B/0(R4S)=R"LB!.2AY_39LH.+M)-1^].[$=[
MWRD2"M,B*YWQ_I=%=88VT9P[P?N2X E_.9('L*>#I+_L6%_S+.FR-O Y3\@;
MIL+?P49\F-(5IA .N.,*A_NS)/FK%)6NB+#$4C$N-J,ABRAVXIA@Y3H#'U'!
M(KLOPA,-%=$0O5UIC2_8=+R,5IR5D7K[ZYK+P]CO,?ER%8>\HG^1<D6_VIR7
MC\T/H!\TEB&:'N@[II*WI[AOIUSK0&_9V]=2!O'B0BL@V>+ZA$; MJG?Q!ZX
MO_JO1?M\=[*[NX>N3,VZ\0/F8,8W]+>#O43_IE_>Z<_;"9"?"LO._L'D\)Y]
MR!TA&QH?I>OF .!1KMXMG@X(R2X$=F^DKA1(XO6^W;WG[J7A21[NA*J"/:X(
MJJ!HG%! PH-OIQ-;R/J$)ATQ#NZ#CTDR@>QU<^6"5@?%L":M6N-B/W*O:E>>
M@9%]S@ONBR/O.[@C[U-A>Q9<$4X9GVTB/77;3:5W.4-:Z- *'#IC!07;$Y5+
MN(^253%M.4@"AD-WOXC).7BC*QI'4#,*B%,6IUBQ;5%J(]$BD9[%/9#L[?_!
M)_]K-)X+WZ>M]YZ$Z4-\Y@^F%_VD[/3#W;OL=#\[_?#+ST[?'16,<_@6?>AN
MT3_\!OV,*_D[#/;WO.B/0OO6+/[>M4''*HFNKJ$[B+GJ_]A0VA]Q8'Y5Y>'K
M_*Q>(SJZO[MW.(K*T9,LCB]_-!02H"M'DEY7$&\,W7;F6QREV!J62"1^\<G!
MB3!DS7&=&)6G_55(=@[V'T5^S]YC_U$?+V)?^>]E 6E[!YY06G\)-06!IA%F
M(H'$O=V#8*3L MD+HQ9;LC82*%(YKW,GUP@!/4J9Y85##LG^_L<>JZW;/O[<
M)_I<\1,'1G.E2!4ZE(@.G7/&"62JRR81F]$&XF(3SQ#G&HAL/;?#V?L]>]XB
M0%(GUW^H<W%Y"@V]6K)=59(7G!>Q=]9;WI)FYZBZW]LWC(A+*F8^W:*BJ $<
M$5%&PQ;+7N)%%BO<XN1J7@61ROV'\BK^@DLUNWYMA4*89_FTF$D2%(>G*->#
M/=FL7X3;6I@$03WAQB(>B?R$4MIJ6@F$F*RA4M]!.B"WD%FX//L>41-LASN%
M 10[TS DWG[@EI.#5;:.=G821TMQ?NT;.7$HB7LFR@@"H#'7 V,)F-M3-(:D
M4NL0A9*Y>%_J:7-&B0_X<T3J\6&J$0T-;8U\<,8GV1U%KFBP/)NQ&K(@VOY#
M"9OYW=4 [=W-<Z.;YTU6DY9TUTY6EM4:_:\2+]0?3YJR+; ]E=@);KF0) F
MQ>^\V#FIAZY(3%=$!]C!K7H* 8G5VL:M1R0.#IYMW(&)E<) +?+!@841?=V4
MBP[:#.B:6>0^#DLOG2I"OC/M( H+?7#X^%X8"MW1V_'*X G#:YG885"*^8'P
MH8;V9(I[CQA=OP]0">X5_R24D9QMQ)RC%0G5V(CDX5ZLV(+;@#$."<_F*=(H
MUBHE)G[)4@_JTS+ I_30Z<+8M)53?I$#6X&N.O) 3M>53JTRM3>8+<H+!0EQ
M2!IU!RCH3%@FG9G@TP)<KY)GC:Q%A"$*P7*Z^1&&T(DG#:99GS7,9*UB9@@
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M!=LB^X 2#9E<,%_>2^=#L#<<;A&B.EDS!X=*$E87P^/703<*B#3J"S:&C<P
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M#':CRK@;")!A@-6P98#[,[ 'YM7'[M#AYK_=MD_NLEXH3CA;K>B::-DLH"L
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MU\.\V@<.-^!V+>KB$\WS$M"@IVZM'WN/0\:>\,>>TP9<[J1[8QC,O<,BJQT
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MM_?J^'HH6Q0%U5%;-NF6#S4YO.G?R:!3)+0]\O+Z&21U0<^</-SSK!\X!L\
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M>7-\+%\\>OWCRV\M4R>ML _\27V#Z69_KZ'*3O))ON;??,S+R[QZ>.^MTNW
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MH^[[/OA[CU_L=-E=UF4?#)@PK;E,[(HNPFO@Z+9^M1ISMCJ);77N,1%\:Z=
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M?BKINN28%Y^!KBJX#XZ^A9Z(F71)XXYTC.JJ0L,S,%\\-I@9I8$YF D ))V
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M^-DA,_ USA2C[L*=XE-=46HKXJIY\'@Z4MJY"0 A%4CW^"8XN@?CD^@&%#H
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M)[$V(_8&#8? ;=TW>R?=(^->PE#V\BJ.KT0A#EK3C]<2S&T%!^F:&Z$##K]
M@0G"Q\6OG6>R"46BFASNOEICA [\3OF:P)/*96Z@/OD=6G!1'0E)+SV2J7.O
M47JL5T?Y!364)7B@#0 27>1E,0% TZ*M-Q0RE]6GTB)"Z;DI.#-6D"*2CB[R
M =&1T 8):N%;"$A^^(J>HL!R;88: G1+O$"-8O_)*"ACP#YJVWI2:O-&V*<
MVM=Z4L]=;X.8@C(]$1JNC3P%T,N[PU<XF25?_0RGD#'$=HH29E$B&]:>ETOK
MPX;UM3GW76XU;=;T4L_4U!3Q+/9FI3MK? *X3L#]E3K,5]Z6#JCG.53GHN #
M4DJRE%#@?,@$[S.9\P$G$:Q (P2*-JXSV+1V-L$%UB,5AN A=#7%9V:O6&$,
M"H-_R"#H0><\ [!/%&)),H:B(O_,Y6J70_CK$&VDM\&17G%DRGQ>62R0CH$P
MY>EXC:1?V[H.6+I/T",[+AR(D]N71 CTN_9;?MD3% X!/>-WOJG7TL)R65BU
M*35>@ $W$\I?^I2;B? -()8E58Z?\,PT3A\88T&C+!@@<5[SBMCNMW(K+*/X
M/ '\,=X5.U]?]<SGVP&OOML!K_K J\.O'WAUAP7\57514BRBC(4G,GU[9P[$
MB*['_U+O6LEADB+<K@S93XRTL890A*[YI;:I%&?:CMWA+T5'WAET)Y=R\I(\
M:H490/7G-A+E$I&H_!,(AG.D#YGOH&R+)/@%#,D:J5=Z?I)5%TS2CY9<:$&2
M-O^%'-@:""*&X.H$S[BE*H4+PL& O[_K1R"34.35>LFU"MK_7+LM$_$?!GF7
MO4&KV>%Q6?%9/D'<XSQUZ?Q>*@9%*98H.F+?J^(@V]9F$4_K8%_J:,5O1CHY
M;_1R)+T2A-A^RH&;&".HL[IB-)DY]9, [QVXZ$GHHL>GZ]0/<T#4 M7.L@5A
MW80/K;'=O+@0Q!Q=;CWQ^Q>M/LK48*O$G4@&G\C%72O>V>#*+MQB>C-FV9IK
M0[Z17$1R[$0J=$9%21M%"I!WDA72,120RG7CBY3KQOE"? KLJS9'=N#AKIKA
M"@?&$7*X53G':2UU1=!T2!^*^L@,[S\Q^?H@DO(23'H?SHM"6.K,$4<8%SCW
ML<Q%K^5["S^#%2=#C.>T\+7X?-HV+FT?G6N#A-27E&@+L;_B_@MKOS\A^13!
M=Q%0+ZRU:NF.8:(NYTJ!BOY >@+X%#<NP5M;MI^LMZ9EQ9@C1 J*'MQ52&\)
MO?IXK62;QH7?,\L:BF]96O^@OREW9KNO8UXPCH(F_Z3-6IJ&2%KYT;N[0Y\/
M'_8L?"GX6ABMT4,4A?4JOJ6P+'D,B?,"ID?BF)&:&TZE';[XGMZM>?GO:*,N
MRN)2/_J!M3I+\'MW6U[2:QF\HM]3I1(J"D;4^6?2+WZL/Y=5<HJR]FJD391?
ML[=][0;N'!.SDVP8C?R?:X8U)O@D*N_,O^_E"2.][.B$)\(1^,5I#"'.,_KE
M?+YAU!TXGCZ7\0R#('="_R2+T-K8(,U?*5TS:R(1<U,ZS([089-Z'ZR-LY$<
M9#J.K2R>:T0;NP8876R*6$;47;4P.BFFS!Z2C 'B6#;%GM),M[39"G1E$\--
M4(Z L-#,CC1.OEK#(&;ZL=UGV:!X?I8R(WYQ9IY,X#!*-QBRO/1Q.U>UVT1,
M^B":P"@ K@4):-7QLP1O@Z'KB[J2F[&-8 YI;.:_U]SZF9G2RX4I4GBYD3YF
M_:E):.&4Q+XFPA=!&^%H)5FAA2]>V A[./!1^IK, F>B8D4=RA7 !IZHPJOM
M-J\F79?8I<B!G> Q1;C<M,DOQ7EU_9V.$"9@XU:;V)0,_,%?T4*_0\H!;2O.
M6#U&=H@[.YQJ2'S/K&6L?;J(7M+<):7LW80SD5 .I!M'0FG3(I8#8X7ZI0\E
M9!F^@9PDT.OD(>WI*'W#J!.A?LH,;<DX>L: ;;MUP3W0W04(W0%\IX03;1/R
MS:3&HH3!0I)I,/TY!V*]HDGLG_HR1W?4F9-6X6@@'XMS_!3%R8OA^R3]L@P?
M6+BR,IUCCC%K[+\*E8GJ[G9MG*B#:L > V=Z+.68 J-L<JXG.G/A9(+'??%"
MZ8S"8U5*54X'BONII#/X.&0V57X)J1,ILVB]ZF)D\@7/^X4Y* &9K[-M[R[I
M;?A)-&HN1^UEGF_ZQ(S2,+J2?GGI0C"D77S)[FP14B-:E..NZTFS+E>)AVJM
M--NNG=D-@SI[OY,">8#PTIPQ'/_9*M2J\N.9UZC>IA7A>Z6?5RMQEND9?*3N
M&-!ZCV6!.^U'<V:<0&MXMV1,2?154KA70P[*F?.^U+@'PL';W$KS@TFS;VCB
M!^@9JB%9[(NX]N#;%H"_6-YIV(8-;;12W%A'720R!(D[MYFWT;\&P,C$L A3
MP@V5TR@]<K5/IGJ*6<HM>N'UJCK,2:7"71F#M\O".CUL02%5Z7ZK72O(#Y&L
MK5?G=2,)(8IW)-_S+YZ!PSZ9N4-:IQ"79E#!.E 6&F^8NJ98@)!:+(3K;M(\
MA;0(Q;S1K/<"7NN$B?&]=\OV$K,:Q06F*^9EZPO?D=^CI6)/N&,#0-U";. G
MA^>J#9W<V)>D*IYPSR I3IV_SLT"W@MJP(8'7]D>7ZYI=]0;:?J.YY@$#8KN
M*+J>,+LWW\G9GR!'E73R;]BBU=HRAG'RT_MP/'&%'X_WFQ;-LZ:"&:G^51=A
M7D%J_-[0.)+L>W^2CFA?%ER"U/@JZJS-$@E@2!3I[QI,&Y@@T.\J'UP59]LU
M)MU[^567]J)]NN]2]':@*YM]D^04 .R)@DUPFPL*5],CA31Q+V4QY=;GUW5-
MA_IEL];^X^.Z7?"80GSYP>N7QT</Q9@N>.B!=U'"R!%>\7I^9E2H3<&<+(*.
M$1=@IK>3%"X[&EM4CWHTF8XJUH#V'&A][1.(/)0@#H[U?1"GB+O!B\XO.Q43
M*,>Z8H<O9$[Q<Z/HA&:6_@BS%^1"SG.43_!GQ#@Y*+/)6:F;:?JI*);2TJTZ
M-),,[XICAT2R$;5PZ7:BME:0 /JOO?%FSYE)@ #NO>H,9^"N>&2.YE]T;>5?
MR1NY*%=-_3_?EKI@VN_@T_2BO @^+( E=RBSX.5[?S43JDZ4*9#[S9@/+,QT
MPO4H):<C3=>8(9<$8Q]SJ.DVI"CM^]D>&[?L/2/'[CP>A/V 7L6-#3O/\PE+
M2)JGRI##^N''TRBQ/DK_4=8NR6X><B<?E'$F"$Z+DB>CA4&B2-JU<AIMFSYN
MINZ !F<+A=TW!7L=M/11<L3Q5+!2SE>VI>_'"9]>#E+*768@X"WGK#72MS^]
M-%]&RW-A3!BWZP]>-(ESD6&92MZB)5$QM3-7T@K,=4,O'NY>2I !CFWI:U:G
M6.B0Q']]+0W\GKD62Z?MPQK.--^8V/B;<+QCX""C8 008SOBO:1SHZ!&?1*W
M(&EH#V9;IH_V:?&;5D-8+$9Y'S'T+J/ 1XG/N+L>614*^*W'3C?<32[OP$;+
M-LR=YOYC#&<:"3.% &PWW"N$.E3\I5013.Q$:Y71?R51Q.B16PFNA,0/.S[&
M9)=WUR5)V:L61X^]*N?Q,_'?W:"L>3F#I-YW97L[)-7S'9*JCZ1Z]/4CJ;[R
M0_#11A=D7+%W#B Z3BJ-Y)%++XJ])7/%Q /^7.W,>H 4OKYJB_FLHZ>J]:)H
M@,_H@EZDC<37E\)2#)M]/^Y6C7[GZ_  CD]M"*IKH35<+/G::*YE4^OJ<5UW
M5L<*Z/3C"9J^=3(@<^0D;S.E5>\FQ)FUR#R7S,^"@'<A&("-;AHH%.E$\I0!
MSDQ*>WC1]?P5\<),Z4U>*5%#+\?9^M6E;]]F5R\LZN]U""$WJ\UF;?!L+1WR
M$;AVP>+.U(>;<X&KV23%!1H\)KYA,2CV]9.CT9IOLFA)6>4\E"X8*!(.F>89
M]#=ZG-FZX9!+W>+ 0D:C@^5Q1\$ Q&!UTP*E ZEX(/Y!0[?/B\O$2ZMA(0[D
MH>HL$.Q5IN%^#26D>7HC=^N& 1:$,Z3Y8<(%!DXS!;KNLP5MH^0TK"E[[Q7N
M[HHU25/,BD;1+;D10;W]ATN\Z83.0+)%?&56 =Q!;J=QNQO413-UR&AK93:X
M=1S9<@93T9&'.C:27ND1$L0/HP,I')Z5'!C=5IY'B<MI\H9K9<C!?*2OF5]K
MT3 I,M<!>JH.*=6+7).>91MF 1EVJ$AY;)X-^9!1BU*O:M<3)+9F:S"D.SXJ
MW?_,R1PS?WCY\Q"%+35*[ $?EXUOA>)GY=G84TEZ,L">O%<Y!D P24J%W%D1
MJ;<5W6>UUE?RO@"6*/V^SINI(V%':G7F:&1-<WH=.^!-<YDJ3\^0S.#^#KF9
M0-KD")RXWR=\NRRUV=2,D4/Z@O6\U#9H$UMD8K?>R_SNNG)3%,\:L =$Y;7<
M9HW+&U);Q; LDZU$2>J97!K(N$I&2G*&62%>W(%_W[WIM[/X98@>I" QD>"[
M^Y8>L'"W$'F2;TX"OWW[4#5LL; QMJ((KTR-J=WQM3\['4SJSZI"AIHFC$I>
M:?,5Q,AB+9ZC5'QB$X%>^XB538GJ>I4(KHUR[WWN1KQ*=JXJ/$!0SB+;,K\*
MP2=S90>JPK3 -.[^TIV2TO5FRP/B$S>U=:VS53A/.>/C';;NF#ZBHX5O)/T7
MIAI*S0]=2=\YMD6.NE#._83*#KAL&$T-U<(MD[*SW)2D)4=_TWZDK<.A^6:2
MQI2[(4:/[L=/(0\INXYY4-R\AG>Q;$JN^/(O=CE$&#D=QFM'XR>F0$P"AR5B
M' RJ^J$1;FO'6PB3IZZ@R@[^"GR-9"#$+;GB&'JP&A@'G($*!9?.Q,]<,S]]
M^?-K-4<QX:$>1#78RIR5;ZP>'U;CZ'K(RV,[-0M$LITS:V4)4T!?VV5 6%2P
MHQ7>^5QAFR!?R)*A D6K4]G@ D^:<NR,O<\=1TG'S#,.U7/N%*GV?"@GY7*D
M T6I.R@G74;B)?L*J5U4;41%^!',FI->E).FEKQB!X15SX;\ U_E@>Y@NVYN
MLVL6UUW85J9)(KG=:H!&FI*$$]4J)B<X7HX)54C^[:"&D>'P"DQ]NT(*>Z$]
M?%K/_CGSX,]PVX&LPM_5Q+LV/4S  -9%?VH7J":T6W"=)4%QP<T10Z2S$C3H
MJN'"?V8 424/:[BS6)&!XEIYO<]/('H]X[T,<A)!"*I;K.\A$8,A[O!3S1"+
M>E!=THF^ XW&WGPPSMNYYQ(4+(3 5K0,3QG"?4?@1RX:2:*LO0I+SM;EE">Y
MMK)Z&4-Y5@N*%&@_>KFK\];3UDT5(*8^ID:)N:O^N4T1CT,GO(%*BK=9$&*\
M%YSCYV:+)%:DV.RHYU>VR'XG;+GZL )1*FMN"KKRY>C4$KZ$SX"LR%"WZ<&A
M/F<2/Z>W3,%96#'K\TXSJWU>\)N926$EJ <E*@0\ M)X)F6<.N9,LN3RCA9<
M/NG_67G&<O1@,;O8M$! 56CS3!-EX52%EKFV>XDZ:OF4P(XG[B?L,*C&RUR:
MQ4I?['M(64FPD5ICRUFIV#D,^ I$49Y; X\#4N%R<M(N<4,7XK<2XZL0<Q3.
ME'&.L3&\;:L^17]S!)9>\H5!V-<H)7KW]YC3QW&\N+X+H<N;DG/3RF),KP6A
MLOBSWO_B%C+M&#MW/4B<80FZ$B48#NNW9:BZ#5SE+LG^OGIE>96$VZG^4+GR
M*K#USGEL#CP(9Z!+<J!(VS<6K(<T$9MXR\$;VS)#1(1&B!Y1=;A+T)C;:#7>
M&!0YOFZON50G6YV$(5JGPL;]HVFXU/@9?SB.'_'>ZZJ3H&K06K )U9_PV/.)
M)5\M6*8_#I6$O60/S8>0HF9>12%?T (3"+BK<[I!1WK\N;IMQP3?"B,&M#0W
MBLF^\%HH0D4J)]:&:;F8%%F+M&'AQ#L_J+Z1F[*RC'6BIB_W]DZ'BNKE-><:
M0-/G&R%2F4JGIY;C-2<PG#MEZ'7>N(,2D 6%G9_&\:E:F59RU,H 5SZ%SIS'
MYT=L45=#J^T)WLR-[5 2V"&<M*;D+M7_U"*EM[1(R946*;:]MS-(MS-&27^'
M7O@&V'*E+A43()MQRHT2<F![G3!V[S9LL(+R51)X!WZS.U+2/R+BZ0:6);3J
M@\<DM"I\O 8-4'(KBQ-D--"74GTQFY.<.G>X9V=B3(C:])VA^7)+>.U8'K6[
MQC?1</M@#'8+7XNX66@L<8KJ@CLA02["Q2SNJ>90[[U1?O_H)X,<O_]1]%?G
MEP:)XBYS:U=3A%2BDN72PF$J>!IX,;BZJN:V=TR\9Z;1%7BYK9TI1HBU/ES-
MC289\7#G2S)0%ZK?5W'8A' Z@,-Y&4:XL+4%)>VIZ%?,"+(<WK20HS:19@F?
MQ\#]Q6:P#">!O8I3P$B9B_X.>K+Z[;_:B=]MFVMBE<$=06[F"XP+CW3I[FO"
MH$,=J;)RBQ9[/I_'3Z5S/Z2#PWI![3>C]!7*6LB!S^=FH5&"Q*-Y4(':E:;P
MQI]E,P%UO9(I&@0LS*?^M(N&;X?4HL7ND%H]I-;C'5+KCA^"#X"2S/+0:Y%T
M;B+*<PN8JI>.L[EP/.[%)\.A%Z%5435WW@\4$D,=@DB)+B1,INNENIV859(I
ME.&SI78Y-;7:=/RK41HP:G@\=M!DR6@66J*CKC=F!H<N=[T$D@-S;C!/96*P
M0V*=O*Q^!9VK'5V>A0'8 &[/G#"_9:E%V2WH#0N"G*T*^Y2-^X;=#)]VV23U
M4/<#5B:;6+81+..#($/2#DB>&6[1,<Y#^WH&<%H78M35C6S]5;A'W&;]=5M*
MG=5ROJ\#3P_T8&>QMS\8J2(?KU8ZJ/ Y5X<>A&O?)G(8OH9?Z*>XI#(%<5?R
MS%)B 1' A2,H[HK52VX'9A8KHQ?()(<F7;$!YFB(=2!++SFFNYZZ*.01N_>&
MF65(P%Z71NP03&TDL4D4:3'N\BE)([0!\GKHD')4C+(N*NUA&+6'^0]Q(ZNM
M&)%1,@38EX/L8W4^GMX?CALNG$95M<,DZT'$P;%K:6T/QL.R82%\_^KD0^:
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M.Q(B<)IZK3"3@/H-L)BP\S>R"E*FVO(*]7UU=H2A*&0S.$IT4R3<[+2JKL(
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M"Y/'.$;S58ZP<NAN86I984+N!74+D+ I,RX:KI( !Q)_$L%3!IZB ^;06X5
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MR=:M=05X>\GL<'"R!TEON)M@7GXJ *?.TC.CF0,4IYZ394M::PJMF9;;.!$
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M%[H3VM$V%MS@]4*6>"$+NTI\=0P,BYPEF=:3M;I"T33=7ID$U0VF.1CS..B
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M'2X#C'5(ZME4"'V=Z[;GVH@Y(GM;X??8$[S8>9%/!\U:HHZ=$B9_:V[;/=&
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M'I%R[]KUUA\1D#@VFIP%Q&+;V?H-VG7O&WT%IHG6W+#R%C4*JFS)7&1Q^*4
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M/DD;"B+"EP.4Z#KT6BW]:]U$!T6T$GY7NSCPND$:U!WS8ZUF+]/+ H&XB"O
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M3E58U' MT/Q.]T[?2E&=O[U!3520 )6.O@8_F*67,SJ=Y /NO0:-%G$]XQJ
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MC$<)IJ'KXC>"L7"6M?\^SKM)*\M!Q''(C.[N^QPY@"G6N6YA'I';O7!E]WB
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MKEN]F01,Y,!E9YB3$H>"[EP;200>AJ*T;[W-% .NAP,,;N0B1L9["J=(\\X
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M\&E!_Q?NO#B]>/K8F<%-.,TY NC&8%,\6!ICOO#Z#&%2!I@X+<>DY=70^:I
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M[8SE;H%VC:-<)D:V@0D0QQ],@J-DE[&9RJ7I@I#.-\,4, />CW5W#_?  I)
MW,0AP#D454VS09,Y[;3VS3* ((V8@?S\<61]='8I,![$\VG J,1-*SA6)H3
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M:J)5+6%^BV-M'=$@ 3F_<3X<@+2+<@XT[YL&329;TOCF2$-R4+GXA=6<2*H
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MLBVG>:DU)F$!WF2E38C^8=0DN, 0N_@.ZB2V!)^OF@:\[^)J2?\K][5,-,U
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M\%F=?,2_BV36(@"!FED@&8"R1"A[=!G@8!*8$P&-)/7PTC@/1%Q0DC$(7 5
M8PDQ+_02H)0\6<.=KOZO54,N$"7OF&[FUX % E]"K40RS=+JQG)9A-;C37@R
MR6I5I#D;#&3BE0#+KPE[E%8S@!H5N>BMH?2@18@TLT7>+FS**: /5=YKGHW
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MKX6=I:VJ/W>76.=Y-T^0"XT_*/M6W0#^_(0SOYZ5<P8_TXMTSTZ,(G?.EX:
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MD;N=5.)@3'6>*.#P$GB9H$D70#9X07_X1TFN*9W,8KXFSY2S!46Y*@@C!O=
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M(F-U?'E\0AP_5-K&_/WFX1$F!W6! OSAI[]_> .%<"4$S:*R@<JW!5S)9!)
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M?<$A+]5F/\)Q, %N!D.NZ(Y$HZAJ%Z=7O$<1TG*(#99WZ+2XR2,DX>"LH6[
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M^<W>:Z][">4VK5[''M*BXRB^I-),Z%[!Y1#K?W8A#/\P.ESSK%B,!,V*IJ3
MF+ZQAJCJ?@F'JZD+Z"Y8?I0U >A?*CD9I&'_I '</0(C1:;9I"9&RC&Z2;0)
M#!V)!32.K-$JR-)$PZ.'$.6N?+$Y5JJT;=N$LF)9"K6?!H)F8UHN@;X-!&(S
M[=CZ'GYXU-MSAVI-N*G;KK6,O17JF[3DX(?O;'3G'; XJ1N,%Z;%.:R=1PB-
M:@!AI*);O,+N@ <'^C@!32 @%6U(MQ7.=>(=_@I@@Y3@*A1EY&M$D<QO(0$4
M<43?VL"EIS0]#%1W';SP\-[;N+MA_X\'['\7^W_^_+'_S_P0W'L3-#E'A:%3
MCS(?N*&/NF:+66H*.ZUFTXV]C9:,6\J-8NJMJR7\)=+OXN'Z'3,G-B06R*UL
MK]=%'P1NJ[)5Z#=]Q>6I,*M?-2?"E;.H5\ZBS@O2Z.WE'(EWY#.'+PPGP)%6
MV$1IDZ<>4W_R!RV1N/_J,]W1^BTX(SB6H\NSYZ*@/1=SZZ(DIUJ5.OG(.$[-
M$;^F "A:)5WRC)O"=BBS#4?5+[ !$<32=$-S/V#D#C8#&\F4"0I3YMOF@-UV
M=!./C=LC];P61O+\4P1)KKPCC^UR2C?^C]S'MEQYLQ!?E4ITKJ5&&5PGI8D?
M^PPW :9^P^-/ZL(TX--MHD(QQDZ#Q)[.HFZN(J:X0E)3)?;>6SE77J_#EJH4
M-OB:T_FLI;4H7=D'676RI#UI,8YSMP4.5(!M,@&"/Y6VSR"V++4/M]%N&V8V
MUU WM3IW![^G9RJKH4#HF3P.?G]^BW9[S4Y5<AE8 L1 0)=/)?I(63*7H!D@
MG$7K:N/SMO>J7@K;?5&T-;S>DZK!MA'NB1U%[Q8;%^:>US9K3%E:6@,J \)B
MZ;Y&;CZ7PHX=8 ?41QOUT9OS;\,_!M3'#N9K?X""SZ/IR-N%W8#PVX_[,1F+
M3B/TD7HOJ6$::-E,7HHKU!^OW.:B@-:@+I&8%S$D SU#C:(W?9:<P:IL0(YH
M"UKT?ZO7DG9:VX#-< MT7ROELDK=6$=7&^[Z9*'^?B>S# DYW/<Q@%E-S!!9
MSMC*M( D+9>Q763^=5]KXT#B,!9%Z?@Q3'L6?@+_O8H[,*R666C97_S61YLF
MU[\]G22\;849P&4R6$AW'HAW,[7@/NPQMWKP317C@=B W' ].$UW"4(]U^ER
M[]8GH\1]#B^ ,%"B=[EI"!1W4]OF);FY4+9(H2@L-XU4+=&KJQB&).3SRRS4
MP))<U?VR>R,S%%T?_W=34"ET"!FAS2?73,/C41K4'(.XM&V+8CB5?$ZP<]AM
M01<(2JI1&JZ';D Q(IE6-73S4FIF2(?M@="&-&M;/*->\10!\80?H'?E8C;=
M+Y12^R+JD;9?=0<.6D+E?@=B-639? @@U6Q(:"!>L[7)EH4(!#O[+ )NPF@Z
MB>/ST!2;RG6!R3&#P8P]L(V)\H0!F[%P@[LM[[;MMU*A0FG"6FW)P>$,QP,5
M[]=M6@=NGL@(V[H8_$3?3]0$,MXQ'WR\^[!H 4=#<X_X99X(++JF;@LA0#M:
M\WWUZQI>.Y,KNLS4.^;X#,&=4?2S63MB;SG*R.I/;%_2JEO2Q?'U3CC3QH4#
M?3FMI<$1-FT<=^1(&]?6Z.4@]V#O/CO3 035\#2RH/6D[P:0W1X(@U(B<#LC
M.AI+0IOZ1GE!_Y*</(EFR0HNN$$8GKTP*&^TO 98R% __OQWNQWJT_8W02J\
MP"5U5*X=JFJA#0=T '3T,!1@&SR_SX&6G0S0LBZT[&* EGWCA^#*5Q6032/?
M3#LJ01\-FY*FRF'BW  'JKJ>T=XC.Z#"%#(6<X@96'A%<IND&6A@@4U\7'@6
M1IB(/A02;JW\ID]*@:#M:$GQ9G5C$%>69FFCP-8M9[/</</FZ<Z>"=^;U=D:
M=1V9N2/=JYZU]E;2_!]-*3ULS][ON)?MHF);$S)TUYD^=$\?WN ?\^*.+W.(
M16 @>*:< Q/J(VAE4\^*)<.TW&=0X!@1E=V'<S&_Z.+Y>MS.&)4!)G@Q$D.
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M5O=KF15@I-\?!_GB'N'C#?AZ%+WA;F #0](5!OQ>RQFIC^-Q'$V.)F/ P@I
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MST9]<9$2(!F(LZ#I9"EKYF$LY4*6  Y2JE4MS^Q&SANUXN/COT8+[+ECZ&>
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MF\9.WACN)6F&*^V%"VU'(2X4_.8>M1UE*G"*YOZ2)?G>=U+_'<)S*1K;3''
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M66!D30F^65!^ V"GB))4WT5@I'HF7$O@A)<IP2]BH>NP&,;!4!^]*G#Z,3<
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M*= [O9A+H)* G<)H%W7T8_M+B<._0: +>O;).W"@U2BUR\1[DZY0HN:2TV+
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M/<>G<,E2$+> ^R;E43ZY@KIQ5^0B6B6!EN<1+_3=J&HA*<P(Z9(M-5?V"!+
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ML183W45.X9Y?]^94P[RJ(*LU3DLMFU;5T%LXL>=^",X86_.*U3)HF5&BMVQ
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MLO:E"I+<,3C#(!8 'HX.1!0 : AWK)>_;2POK9@!=U=K2YR'M=.TTOWG;)
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M'[4)W1?M"T9%\#UE3@"2?&K# AUL%_3#L0$A@9F,RBZ']=7%5["5M_H!UG$
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M _6=N&3KC&AUPVQ_9Y/MK\GV[Z]_MO\)BSBZ/.\X'.YDG4X<4)[G?KU\N:S
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MU5IJ0;56DF*1&*&?-=9J@;<<F0:X8+=U^)-HVQ1ES4F9B^<NBG;+-'4KQB
MK]W0V]08D7I;1-OZ]N=EII6J?I\!9,@&I)FB =P[^A\>2A[P'A78);#)LMET
M/2X5W5+E<VP+,NIK)REA#\* #(>B@)=]35!ON1R0=XNZ<RFHF\Z02EFK6*<
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M#^)UB'$=1=8=O]KVH35JDC(%#Z5DW/1,\W<EVU5IM57&,<;A0"_YRF=BT7F
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MEH^<*EUU"_V/6<%\+5Q,49?T 5R8O)(V$"N]P:/2$E>;4:]A-W$%H-F&N %
MCQ\7N=E5OA+T3O,H ?L.^VW< ="2J(8!P$*.,Z)S3PTH3YD.CIZW?/(^F(_!
M_"R!^:A&,)\[QO$)%N'XJ!*.SW,_U'[7HQ=V &^\-G*&<DG1<HK^S1CJ ?9[
MJ/? 8Q<B>8BGLSPUSLHPR8LI.]F9DZ7SW@.N<*90 *KACFI(!+%'D1AA*LFM
M7/_M"N BN *>XVD#&220G+[+]*$[/.AV,*C6[VO=@F%% VR<","?_C[U?$RS
M5O 'M 6!2X?MAM>$M4CT9*:!:*BGG!1>>)!#"2X:<1K'[-9@*H9"ACB-N#1
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M21H717TP5(LUI@%-B32V.[I1ZC*$V!QKDIWZ(H4H=9!_C%)8.1,CI8,$Y>X
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MQTVT$9E[UQ]E3OS1@JX&=3W%!E80RQ&T]>*<X8,7>0R; VH.N']IM_*O\30
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MY>MTZX!T8#1 _8RP!'#[7";Q$(R1_@SIMS\2&YY'M2@HL;OMKG#V52G)X2^
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M4]-'.TF<.S3F%XX]9;KO\/ *\ ]2D929X?[AIK*%Y.,DIMK ,FJ4H;FQ):?
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M[5:@YP)]/4?;A2+%OX7;+@S6-A/8B;G4;5S;A<&PIQZ/Q^KQ27/QI[*3M &
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M5A?/-[%"(U.W]_'F2/!KD#'5$*^(:;-;VE7I6\Q'N\$6!Z]<\^02,P)!'BI
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MGFYB^M\FDQOI[J[VFK3B_>(>K9.H]A3>C5+]K3D/P:#8V>D?Y!-!/UQV/;L
MVLQQ3[**FOA3K3MV39Y'C>Y8V!6\\S"Y+ZL)'I6[Z0IP5U0NE^;:R\DUPV+,
M-CA(<9RD<E5=@5 NM?F,$J[!G:1K<)*$#V2S=$+$O APQY]K?[#PQ*DP"_V1
MCT91>-?UY[P39Z)+HA,9[(&9!GN.>NRR#*M06@B:@(B ;ELDAQZP0:CB+RB=
M(2C*5,(D$?$"&)Z<$R\='&"NZ8QFZ69\-48Z-4)7%TD1"YO28[B#GZ(:'.F&
MGHR!Y*"+,%Y&2F?H$=U1:<]X@;/##;T=J]NH!E'GI DY0&)TR5 ^B^@T'2TU
MX\_ ;YT%0<S#56GJ^=S9XYOH!J*,#]YQBL<ZP$B/4NPH8G<U1\K$I<K.M/JH
MF* 9YM3J,6<M#?N2^SJQ;HQ6XS<C 'L36MU<AH0[UBK_K,PU+L:3HS3EGY'Y
MZC(%-KJ_.P8!J7(WO;C2+2>YB* WIA<^N(9N:,[+D4(5A3)#,WB0M(^C62X/
M%D?ODJ#AYQC,8WJSKW@[4P_'Q8[B.*=Z^&H[#-YP1A$=.)V1W9I8.OUJ\B!L
M0=U1^ 6M8HG)]^FN%,M7D=Z,,7>QB6IH&P:?$;//^&8''^Y \ZQQ]>U*JYP4
M8^7C!*U2-O-*MV098J#IQ3['_=T4^_1V6>R3P+W$J:L,O),:H*KT<^4\?5J,
MIT]JX.E!:3Q=6DU2+SVQC+L-5C- ,"6=G"OP5\?V'Y\Z_Z,!Q9P7A5))>R=J
MXF.S\+Q36#"2FA0R %8T4:8ZK$"6)=T]L3^8&40BKB[O@A@$6+?BC:&/"K/=
M,$,%72KH23%@*.F)26"Y!!,:!B!;6U_)2TM:3# 25NKP2@1* A)Y_1T>*0VF
MSW\5*U!ESCTEF?)R!-N1'_XI*"U@Y,#"'-8E4A]Q3QA_K:O\Q/0Z[EBC["1R
M;;DND04]9YC<E[2<J+M0+AFFA(5-'CDJC3F^=)EH#"AES\&29=:SX=@6#6!8
MRL\G8_H4(ZNH1*LXN6ZSR&KTQ0+[AA417:<UB*YA::)KT)HC*19!?Y?F2'0G
MU327./#VYHO$KHV3I1S;)MHHO5[!I(-NFC^K# ZOW*2(SHIGMVHF3P#7&2H2
M\CIAY6PLQ0C#/L):0)U.VLEP0$\:\&*T)GC@Y$CY;EN,JO0"-U=D6 J<<>K@
M2;8Q:1Z5'4]Z$$J:AZ@.YTS#D ].!;-YPU0G'-C1*7^>(F^3NS/ERA;!E)-!
M-]#G8CL4N1_*=\WSF.,&=743TXPZX)1'S1 T$=4V,VE^A?,A-0ZJ=R[7*<BG
MN$\,:PD]-G?%$F8FFT9R.F+NQ<"IR-W1<Z#M$[-<M"[PW5B7''H@#2K&0:-$
M!J)0.'2TQ<*QP2R D<I1Z1M.SOYZ"WM%\XMZ><-)O!/7<@_J@G&E+(.U?L"8
M!M5WY0=,[6+9AI<R<UO!3*Y>/S7 E),=Z\$86>YRBF -3[;C47641&L0M38@
M^Y^9Z_&T"KH6B@P.'4XIDIN849;:X- \WQ!FY?D.9J?0-=%A03D(:!&3N;$L
M"<J_F,+K7 -II^)8#[Q4LQ.9:8E*9BV%:M4S-2PG*?.Y1*XIF)+5&^34;;=L
MRN HP%E#:_8&_:-@T5S/[M@43YJH?G/OX9">:=87=H.9508\>V-["&2BF5A.
MS)FOH$:L< JO0X_FV<]S]N 5W(>$1\O4I2Q4XLNJ2:P^1=ZO7Q(\N3U\[ET@
MJ<'RM_Z VPWADJ":7Y3R@GS2;_LWIDBMM'62_@E^X97'7-48/+<&BZ#EG2ZB
M=NA6A7J'_@27)P)"@#L8/;2"A$#?AQ^ZR7[LI"F%M\PYW.-,++Y>NL/B99?A
M3_AJ\R4 B4==^)-AR1'>;8$ML=K+D>F#V9%6AKE0%O"P_EV\=<)?*I&G;^'=
M >; 83^"-;" *^C!Y^[1:!4)_!TM$#YA1\K:W4NXQV-)K:H8LD\PWK&![?6
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MP(LAK#X8#-@\C=3,>>0W4BZ:.15?]%VI\US/T<AC25W%Y@SN8GIH9066!!I
MV H 6[])\), B8OKH1F8$=QNT"R+(+$$R%XM@<]F:J%^P6JC?G>C%DK2(=36
MY&[ZQ'3?9->S'[1GWW#+KF=@*4YHOU;BDB5SV* HA_7SJC3A!R'[=>&"1)8_
MQ708E]E9#MVFRD7N<%DM7EQ[(%'PAU\E]<&SSG \4_^DR*RBP.5WM)Q4%+P/
MUH?JY*\'_64:I+I6A<:*OS+)C'NW/-7$>24,5]M2,RTDB[/Y.^67_.7!^?-G
MI:1ER^K+2@Y/5@*ML\Y71ZINX*S$@+V"O7ET0!SJR,6V\U%Q'A_>][M#M3\X
M4?NCT8?T4N'QN_C^FVP&9^D;[Y"#73TCZA.4*3E\GF#CT%7@8%L_O*8N[[Z4
M&^^R5"'WWJV_$24.?9KRT-J$T\$XFG':S][C*JH"G*A!@!X+-U5$N^OR4'NK
M/0!3R9BT16O)4XSR&09>IKN,'KQ)LF?GT$P"*Y3L^"JX )X>C9<E>YJXR2QB
MMOMFT@G).I]UIVM-X"?/9*H5F:OO1J>1CV71*ACS8)=BKJ(#YPW3%6-7C^KW
MKKRK^'I>/FX0+X]7VR8>KB\Y&)PT:/J#U3J$F*-CYRRXGI2G32=E$<E1C5LI
MLY,W@Y^IANMVP8K_?B\M:%C@]EN'MR/9F)556OQ<,KV#,:<E#\^#YAJ1,!J5
M(,//L5 AI6^]#^N"*++B4EHAC[8\,>QJ'P.T$L$@C_>XY:7$,A"A?^C(-$5,
M5:,,-M.8!0'*R!IVUW9^=X>V:"N3O+U,+F&C# >I#-++<!>VJYG7LV^V]8@B
M3>?>H8)1BR)CMQ&,F/5B5%GK%>X/19&Q*RNZ<O5&%'@U,611L+Z^G]KS9$ON
MVW'P@:,Y8F<43!D.#U,*,M-@' (RA0&RFR! %JA156(O8G2=H5;"!AR\(:R$
M5L3(O>%,_3EFC4_I QWSW%DGB(%/-<?AV<A!\W !P>A%N]-B]C;6W,*Y/E)N
MY2\\O!]V(^'*BW0<SI4ZJ(#.#-);0/%IO-6R8[BV)3O"KIN# *64]6!6)/,E
MTAH]4(Y\!CQ+Q6.!JN7S.U(N9]B=^2F:-Q0F#G3XPWR/F*Y*#2MWC/\YR&-?
M65JD!?O#2P1/,F%YX9PH<8_I/-%_!J_JQ#*0Y,13RK[52-VW9<>/%^TT]MX-
M8?+#\H.W:"T4K"KMY^V1<LL[X=SR@X(3+PS?L6&@FNR ]69 RB'HI-D&*:XW
M- J2G&_E:?)_'66X:H?IA:*?D1-2_R._;).6WU[);TBUSZ_::V"A@I6F_:26
M)D691MY4\[#9;@J("\.:1BZ'@;IQ@PY;AM5)LARH((Z?FG%WK"KR %/=CRQ0
M$_534YBT#:<I[)6)(\!C 7HS-1(+*^F<56[HB%JRI10&UV.+B%6\C9;9P"'E
M$;S1Y=W]@N6C_<WEH]E9:)";Z7+G).Q8.7'>3E5/W:/^"NN7K:!ZN114B5=<
M81;R"MC *A<B0Z4;A90?JBS E"(DA@RS&]W8%$8M6'C1W]R:)3O;#7,S:EW8
MYJ^(4?N-8M0%<R@.@]9 6!;L1G"4B75;1@T8KF"&>W]SOY7L;#?*S:C#EE'S
M,LQ@1XQZ+@NCHGP:A4Y?P$6.M1P9Z*"">>[]S7GNV?EKG)LC1RU'YN6,X8XX
M<F)2\=PZ=I2^YJSZ%._(+0=+#BZ8KS](Z@Y2E(./<W/PN.7@O)PTVA$'1W:S
M$^DWC^$ONJ)JKKJ6?:D2"'YV1?RC?,;-"XJS"W=5#9*@8"K1("F5J*@D.,DM
M"8[WSTG<D4YB&>\D/ZTX%[AL@01&T)\\-HU(9([QX/.J^D>'L4@YO R%<M(3
M4A5R% )7!=_DS7<,CBOF+V!\R^L 11'[4YDQG#&LA[D>0E;'ZMT7$DI5<>P7
MS?1>PF+\MQ>,'!1,71HD]>XHRB2GN9GDI!YDCVCD(CR\G93#NQS2H*K_($A/
MX .!W6:;80;?HVWKE"[A,N?9F'* "[(*9PR!.Z0]*$<F)NFLFHVBX60\NA_G
M)4JW,%;R%!R")<;L@2CPA30P.7"$BAD"$F:<HYETL%J/CP.//+ GS9SQ]QH.
M@DPXA!?W7F0Z*)[VB[D?CI9:S-4#JKORSMUV'RD#Y&W8;4'>DD#>^BW(6];S
MML(5+=9;B_768KVU6&^YS<&"R;:#I&3;PEELW=QVY.DN[<C8):B3;D?R[-W
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M3P88M6"UOO"<"6OAP]GFB+Z6.-SQ]W+>G&N_C#G!%5)@A >7[0<T-5%7=<1
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MWA8^&?6*!/*'8Z<^&RYZ/HP9O \A7LF/9%B=2$/T0!#,$%?2QYJ_R+MT8X:
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M.83T>N&98;<S/%D5&\E<W[BY#/8SMZP)Z2W]#)R<]'*W84\E2S)W[>$^%.'
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MK)A@T0@#SY<\$2M.-ZO'B>@[*?39VQ*609TD/=U<!=$XA%AA* 8W]=<=JBS
M89&[U9)%+:#VX(1<V=9T"7=OY7 ,NIM+QMJP\G:L6]9>]3-DMS4H:%Q(4[=!
MGAJ%[9N"ELW'J[&.-NL<&&OT;C<_N[[Q^$[M>S08Y$=.WUO0V5H!S_A]-S?
MWZ@%^$L"^#MN ?XRGK>T>$@+Y]?"^344SJ^8N,X3X/NJ&0Z)U3#LD[V[HU2W
M:P>I/EAW_!$$RN3R5OG;Y-N/"^7[Q>3NQRT_196#]ZU)FBB*Y99M2R1,7]8-
MK"&3XM*BML$.;SM,&,F3NS/EI-]5$*:YW_V$D^W0;)7O'%F90S$3J'4X?_IV
M[U.\B:V 8@;>A ?<)]OQ#D&LSR.0SG&0YB/E+NE+'-<YC.9W1$/=;^R9F6!:
M:"Z]5?2UQ<"IM?#%4\&'+EQW7:9C&]M_^S:F?"Q@RQG)#8TW%>;0TCR1Q,!,
M&[R="=C"HQI/9#GX@ME.V2#7F>S7C(4?0(6'[83Y=I \-\-+01KJ-U %^RNC
M-P9QO>$(&# M[%1LN'@&1-MCCC5)+9'!="-$=L-"[')Q_-S5+Q)8^\=7>BJ&
MN4[%8&.*07P.85)!,#Y/T('[7N2B)\2-3JD\? ._X/[%LPRR*KQ27_H:4AO6
M.2-*BJ?VALL46..[S11RC2<V*.4%Y<L)K^XI3;^& G,>T?%-IVR1Z/+RS;*T
ML/6K''@;IW7^N$_B43H'H>X8"U1EZQSNTF]3>DI-:4SV%QPY)@QFVMPP7SYN
MLA7HNZ[Q'\8U UVB0H[EMR4<.VOX*.-\-P<YWAC-Q76C)7B]!.^W!*^7X(-:
M"%YNT9NPHD?]=VG;FBUI*'7D7NK *Q[;X)G33,]D?$T[_W;^^5_3$!C71+?>
M;E*+L@7!MP.K&&Y1YDBDN@=*A3TIUZ'\#?*7G38RXZN.;1FUV[*C;8D$KP]=
M-CTT?AT^&;K.X"O\7[!:IM[AJ'_P^5"X,5MJ;:36H%QJE5W4G+5;<LY\FLTE
M<UE]W"F/5^6>WC.?<6UNS$IJWI2=-L+9.](US .\YV[3_1NX=?0VU"73.GI;
M1^\;(7CKZ&T=O<DUG*U;MYU_.__6K;MC_^$VW1+R^0^/*ZH-?8V[LDVWA797
M:G!3#ENG;@YJC:IUZJXZ5QM9OI@GG?C,GL\-SKL32S^COSTR:[H=SEV^4:NO
MF#GY>,@)=G9]=7]Y]=O%U;WR[7+RY?+;Y?WEQ1V5J)U=?_]^>4]5-)T]K*(I
MN)&RK*;P.<CIF,].QXB??I/WW;,7J=>?X<GB5VB#.?SRU3TZW2#LQ-/]X>)7
MF=='[4B)WADSH4V5]_9(  8Q6Q?:B^+8+YJ)'WR,W65K#6>MJ]*HC1$&VS%"
M?R\8(?N1SWB?J^"03JBDCLJ);"H;6F@>%KN9QA0!D!3MT6$48($_:EZL9(X<
M*$R'^Q0\2O5XWQC6HBD_+ -(Y1K>"Z]T93 ?A$PPJ=X5CM 5]O7!Z%<?@U_=
M4U7Y^61,GQ3#5;39#'B&6B_2D/0T'3S-5"XM6+_G>[SLZ7<&O/2DO+^Z_/U#
MO)COI^8JCXY&:,D:PBY/3=_%LCFY*HF_[,//HER*KYL&=AE,'UXWA>'P.@KD
M,RP8@LAT]G7<[>.ZIG :-%P?<QS#LQTXLD=OG*N'VW%UB8#<QYEJ]O# 36FN
M E<[)J,[FBN*Z/:P>*[@%HRVV\%A37)YHU1.0DGL+TG:&@R0WH>H1*A3K(.8
M98<>? G/Q92Y+C\BL*O\1Q!S__U?)X/Q\%-VI/.<'HLKVS)(1;B>0#H_"]XO
M/DAT8##?.?C<7W5@!)@)GU;$;'E"ME'R=+P=-XY:;HPQ17]GW&C!L3!#S5('
M]]W2RUXV,EIOM>M(P&CP5<\PR3R:FH9%& .>8\!T2)00@M!;X<7C[7AQW/)B
MC"4&N^+%M0PWCB'W];,#Y-XP!P/*VB.[GL%EYPYX+?3.'_8C3+> XP&B:(7I
MWAVNG]F@IIFMPB"_0W%E,4]Q\5GE/9C%.IL9%EW]2#@$E\0/"&#!X*:E*P\O
MT2O9FQ$3)]N)B>.&BXD$AMHL-]*Y,)O7_(:NYA-YR"+9=U$/>?3,ISY0IB09
MAB)L.2U\LTA+H<F: YF!"M*]G(E@)5+B-C!L$*$(#I"'Z#?4KPIEA[_ NW46
M@V>KCJ#Z,R)#!7-)-WE.$CJMA39/@+TD'3P+QP9*NJX"Q(&[#%RL7"GXI#_)
M1?D:(._  [H_]5SIUD)P)_S<]1_^Q:9>W.,$<].9$Q>CJA)Q/2COC0^2>*-N
MQ#9;$'R4X8GF8C#JS1/,7;F$Z?@Z4. 3/!H^"XR?Y>'XT^'C_8R/1Y[';[XW
MGB.S7QZ"PUBA6TU;8+=O.#8/V/CQ!?3((_8AM1WXU8>'',-[.8KRVU)D<#=J
MI3Z]<KJ=7CDI0[P,LHN7NAST^V+NCG9E[E[.XJ(%79X@AX3@(J>G9MGHG2=W
M-[#>DBO=,$T4:,^&SA+\^^&55O,0O@Q.!@J#[+?:'):LN-'>:"]T_$/#=ITY
MFW"]?7>D3!30U(_,X?AJF DAY)A#PD?0XTD#UD)1;_^T8+U/QH*3 ^BE/##E
MV6 _,<"  (.(]09;2!2VETF.!C/PIN^ZTF2&35AH#GQ#6SRM!@UV&S+8M07=
MZVXGZD[+$'7#[**NCJC%4E/5[E$?OGGP>4(FAZPEZPQZHG&H9<L>/PIH93BK
MP+1P,<-D(!%6$PTCD?U7F+H<_,C-@9@BIS#Q&#8"0'S< H@G 8B?M #B+8!X
M"R#^.@'$<\GXF@AU520#\3U:%T>-HU(U]E5ORR3$;AD&UBB[@94[J: 2S(']
MR7I\.-IATF/D4"D<^'HICZR!J8\[O_%LFQ;<*X,CQ]DYLJ[$@N(<N>+CJ8GW
M>KODO4M+^:XYTR>X!?9&<3<..B?05X&.",\Q'GPZ(Z&+@BZ%9\8"_1XW8#;,
MM2GSB=JN\EZT5^!_%MT3/H"A2$Z,P-^1/+(J1R7/2? =F)EF'7XU/!;@YIM,
MTQ7=\1^5*0@.],@P5;DQIB9>3VT7!I59FQ[<"3SI:EFXMF,@F V)&^>)^7/-
MLPU8J^,].89G!,YZ>*.F&YKT.G,/-,4K%S12U.4LO-$-S.C<N;#:,G6[UR]#
M6!UG%U;CLOPSO53[[4<0PL$"4W?% RB9H#/7=(;>0G\Q<V FF&\JS_&/N_/U
M;M-Q$:@^<IS^L.AMPG$ZH;A<>NE@3^V?KJ8G*._/)KN?X%2C"8[7!? ^R$SV
M(,DW*A:/%.PC PH+'U*7'+7"S^WR7'?YK?^_O2]];MO(]OVNOP+/+WEEUY T
M >Z>*5?16A+%MJ21Y&0RM^X'B&R*2"B P2*+^>M?GV[L:.P[A5OWYEH2"73W
M6?JLOR/N3DPZ:4XVL\336-KOM4+=$>A]O>$P*IE)M.X#"BO+H#J0',)J*Z%G
M9'&CE?MTI3SW.T,SX_T'BW&UD[A@O_<84IQ"MFC_=!"L&_75KT"NTGVKX%V2
MFT$L,.XY7@RF@8['ENCWG$7\_*@(_3Y/KM]G5>IWETKWF%=;<;<[(7*F[6%B
M#]C&8*[@%4(I &2XS:H + W/:*?L:68(ICE)9N6$U6&"%XO9W)U*LHLOS=0Z
M?LU?AD1[;S@2UP*5I &V'SIAF3'$-B*+)"TOI'A3A1E%.\BTBU@,B#6/-GC-
M.C&87 O7#*AAL%?*T*#6,9#3(3E%D/(3D?M#D? N-!TA,M/(ZK5 'GN3%DD0
M3:5 "@(AJXJ"EEV$'$)]8ZYJ+P;@<[9I\"Q R=0RND@NH_/.80RK2:_98;Q>
MZ0KIQ!ORTRPNXU;!<OW9D+DS$?_#[SJ>*NI^X#B0G\\L[Y$HQXVA8_8TKV6L
M<^X4 S_RLX(U4G+O\O-9P+6\$I^42)]Q!ZE.<#.QF6-YAZZ7=QYB/NV4LVV%
MGQ2AG>PR@D2:K DNXN>S?/YA%LSP#/[AA.EP!%PN&^$6- NQ/_ OE\8C/A#X
MU<RK;&S_1 0S!ML>CN=A'<*)56QNUY7&'\FTQB/!#W@"HEI5H%")X91=X8TX
M;<DD8P!GF%6)P=D0U9549;6KP*,<-96SHX>?%J*F^!0UV\/R]532Z,B)$QWA
M@M&1>,F<51,=84IF<4&1U^R#Y.QTX6>%B$^:EH?"QE1WD8)DD8)62$<CJ@=G
M7?4@JWIPT54/=M6#7?5@5SW850\VI7HP9R,:7T@G&I^B%8T4')1L]EW+W 5Z
M4 T1FU+"!$#-^(7'[K.J7$[.W'',I2^8"K%,:"?"OUK3/ IZV8,\%A NN%K>
M_4S:<TW_Z01_WQ\']01@8340LW"2.H".Y?63:/N8*U.>P//+ DV=(28S96?&
M)2>X)K*B3!!U/H")>^+ODR%(=/00U]C$AL<-.#>8&'$K\:X4\"WQHR1]9S;8
M84J(LK;!A[Q7I16U]]>(G#Z8S1MLLVM;_%G+\(?Z GSZM ,8?^+$,<.YG6C(
MJRU)PBWQTW9!7G,%TS)&$K/@5&>J-&&1J!U>0SGPL#E;W_A">M_X%,UO)-O?
M9?:8"#?,S)[YCY+8^]H==Z?@FG-V5L^51",K4M&C:.* TMS[LV3AQ(D>V$RH
MG;%O&J(C16_N;._) 3I=Q9^_0X;P3 FD"?':!MP7?>TD"IT\X8 L+@!2&J@J
M]V[2POZ$WV$]ZFP ?]W04,^*K- K@.;Z)*SZ/7LCMRC<H/!>1=X=Z#FQ"DSA
MKU8>\1;M27LUG!R]24';E$IUMU+KDI"F*LW9Y2(4TN7"IVAS(449)=NIWH9A
M:_@D[Y4>;!#ABUU'V@DI@R1!O95U;KIC*(%[J*(G14>O^<K.V;LA5(7IGATI
MHP Q2-%; ME_B^1,F)?PJYLY(C?9\HJ$A8J!J:FPO@>; [^(,O%*Y\0I]1D#
MR(W@+7(>WQ2NQCMCO\<WF\]-_0E[N@KWL[(C-_)/3Y]^MB]N\B?K[N[1>YA\
MB'PEWHOU%^;>[44);_,.O_=OBA_>X[Y(:+7%--5T)-%E+@UX@)BU/Z1,  [@
M2H>=/S8"HD[("[Y?04#%R:/%,F7O) I,;C;TXX1]PNPG(TW#NW^09'*N]M;U
M4TC)X5>37R]5%1!@R %Y,.0\I2Z:Q]>WP+9Z0; K]()6=!L!A!A26\^(19#O
MT2PTJ9\U$]!6EJ]W0J,!-&E'RNB<W'0HB-@H!LD+EK8\O54>\.7OH'IY 6"#
ML@:= $SC&-X2^F9X1/#MI]=?+ZYO[U.\W2/IO1.">_: ].^ ?&*^?.8&3W,M
MBN]-W<NR@R[<1E(UW8K3'$@!@#\,P_UE@(:S,'TM]66Y#T@"(*&3P$K93H3J
MVH&)G<;8AN<,Z3FZ^&[<&PH3/\@:HA!K)O><V*T0ODIN9^>,Q# CB^T/<YGE
MG"Z48SF\[<*JYG)-3R"[L>)4%H6Q'C%@VI1!(F7N)PRH6G7=<6;D=1Y6648)
MZHJ$D<V]$&,7NW<0%Q-Z@'-'2K?HG14H7)N[GNC^.@FKC3"/F158(+6F-TW?
M:TOF((@76>=P@>KNG9R=)4)A2$OA]\X]RP\"(@+((U*?I17^$0*])]I>A895
MZ%C K+7'KU+66!R(3>2J?12F _) 3'?,<P0-$4+\ "$FKE80'Z408NY:9Q6_
MC32L ?.YBT#L%5BM7;209*4\RMCJ6Q-I5($7;=WJ2(')CU08"5YE,5Y;LV 2
MA9R=$4(WP<('7#BH";CPVE:ZTP2NRQ<:X.OAO^]VXH-"#3@B)Y$9MZ]WW%>T
M)I;%K_BW<'\Y\S7Q4S$/X9?8#0S.QSV-#*3RRK8-I+]M8R:^?3W49/+Z+;'I
M/9&BWZZ].3WRU>7%E[/W5OKO%&L!$>LANX;L9]+ @?_3X[Z**Y'>>/>B]%V4
MWPTXQPY/?<(A.:G8[-.,KR;[%-(Z&V>J$X/ :_.[TI_);7BWC<6PWLNQS=:*
M :IM+3U*>IBAELDP\_.ZCV>;AG$9:O@THAAPWA4#,HH!A6%7#-@5 W;%@,=9
M#-A5 !9U-,PL2'9WJNGN4/ZLNGD_5^1036MTJ'XQ=@<SZ>NO&4O4[?WY@/V$
M!X76;T#91L]7M^'^NY,&"L_Q].)R-MZBQ%ZR]D8NI-DVK(?<LVR8]0IZD(*_
MDRBNG;+R/(!<,QIMI\$&MS]UE6)3DJM-!S_N2?P3V5-4LM3OS;*,4<G@0<V8
M,$R>3N">62*4JUDP^W[2- N.>@)K/R[W+:H1L+Q*4*_0D>6$E(/:,>JP>E R
M\C@+0XUJ9"@2C/<< LN;3'!]^"-G89&TR-LVWQN+T^:SP#52P$T87E5( =3X
M*:M>2)1E3%:(/4FZJ[XP1&WZKA17:K]/)R^=?U=H":%=;IA0K?KC9*Q/T^@8
M7A#"[]((I^ZPDMJB/;Y$P*3!MPE$S[!PR?BXN+<_GYZ^H_$.!<L6"!Z-P#T%
M<$3@]9AQ\>FME*T"%8":CM^LD&>3L-Y;",*]2WT].0>R%Z6U#9Q)7J:BC2&O
MB8'F%VQ2'.%"2_@A6L0K0A<4V%J6$55C=1?$["$+ H8]+Q5!G1!^Y@VM_P_?
MPGC8&[/V8#8.A+:/QT3\R"]3T"@]EMZUG&0 )#]C8NBQHX7DXK&L)3>KDBMP
M*SZCL*H?L^R6G 3+?CK%IZ9BDI^+6(Q4F3LW5&4/]<5O3\_/WW$D=68')WUB
MCS_A^X!+S0Q<JX3^%I)QLU:%SQJ9_38A6@M_2,;*U&D",=$B;;%\$@\<; 1T
M)U%A4%GLQ;6EG=&5U@/7?5_-:W5[9,0)\\1WE[?Q'K-#,+?CN\5^1?J#A'7^
M2P]_&PL-?J)YFSUCM8)-.RA/P)_0$:FE-4UCR_=QORY1T@A?14CQX!O39]*$
M#-$/+I2 M?)(A0#S*Q;80#%]2!$]D6!2P>=LSWNO*Z0<BG2&&=@\@%H=X'6K
MV)X!M G/=YV(;Q^F2B!;_JYP!P3Q*6+^D>F)F#HBS6(0:.@US3Q0<!T=,X%K
MF63M)C !V-+*IH__%_^"A+<L; 1*6I+ !WM=TQ1,8LCWK?#"0+71>]GZ^ $B
MN=Q>T?!BGVDPC#S">2UZ 2X!PP+.P3D>Y8&X"^[.!8H.9.H,<O"R?_W8=U >
ML%R0)9GM=[:6$=->_Z _8ZZ7S&A)5XI\:Z_DV]YM#X1/X63: 58HLL=,JFGV
M[K"[#,5@J794]JBY$6/4G)E.Q)9 @$"V5T98P9G)AQ(8 K-*1^@QS('H8=6S
M>97K&[/./22Y:<:/ D$CHG1<FLG04#.\3"M+&IW#+-60,!?U8*^NRG1%NLSI
MHLN<LC*G?)<Y;5;"J4N==JG3PI8;F0H,ZXN #)ZGX/).5U9_;I4=)H]V_I<A
MZ8<K[*Y$=IN_X1"^E?=PF:D&\@=4$C^P@*I>)W.[L#*W=UB8SG^^_G)V?GMG
MHF]PY__^=GG_.V>3H8IKTRI <M=[9RV*34\CJSLQ"W6;F_F%>6M5%\**-08P
MOF+/CQ^RTK9HLT$K4D+N&E=-(EK /W8_C1>$AEN>W1&W%,( 8.T2%66ZVE"[
M&-E0M?!8[$'&.B7KN)1O806>MJFW_#OR:A7MH<2=M@:"I_]6>!=8#,F60:3-
MW@FLC/V(K:3J!^[M:!AXS("[P H9OF&NL><Z'?/$MB(-^&EX5^:!DJ'>\,(^
MUN?]C;31Z0AE,IZ /$[;[R0=7]/83X<?+64/_R:! 9,,&[P8F23J-!W[\6;C
M-(TP2BI^XHYX][(";08D7&H.:]95A0 I0C6_N :V D]1H:$*VFV O6%Z!C0\
MH*+-CD#5^/;':#<IL=VQC'Z3],IKE%GM%=;;.)D.9J$38(!M_ Q/J$_C&K2T
MX,0BMR3K5B02>[Q[13-C5R2LX'T,G-P&J30 13?^H=[VHDKH/<Y,[PZ_II&C
M#._=29D'N-6>22<&K42'PY/V6'.2*">6$-8E]XAD! DDL_T1OPQ['=!3)8.(
MD69P$@=2>Y9"=MX(5\TSYARBTWT2IGR7*9PNO/B9*&ZS21!^$;,*]^+7S1L=
M49F"GF06V*H:M-HGL+6.DO$(K!G:YC#K0/8'6RK2AO8L0IICC598ZDQAUEG?
M>U!D0[/N1<]7[3+"URP\T\S"TPWN38?65H?P^*ZW0"E"B$\G:AJRNLUV$N:&
M-6&V5RPFL\QB,FV\F 0B(*]AMOREIAFDK,"\&<BU( )(B^E44X>7!&81(70M
ML^:#F;+:&A C\FA%2]L\L[3-&AQIA.N(P8GQH4?&E\IRS6(DL-25N-!7^#DK
M0 F%23M$(Y38WY(TVK:_EE2(52F;#2U\IUT"4".$UZP;9N&'1%KQ%>RA[0U5
M Z@=N"!IQ8]$,D8FDNDCP)?J*+IJ8CYT5R4,4U6'0M7D]8;P]I4!T![X!Z*$
MB$Y:7\KW4-=/WVK7*@Q=I0I496'2C1<]83@-5KXLS^XT;U@S>C-\CLW -NC"
MST@1U0V))](-8=J3/VF1VQCWQK-ICV<-"@]$8#V-[. FPTY6AJH2Y"M5>@;*
M[7?BBE&$)I%56I5J%C_@];AXR;X"W(5HA7,"B7;_9K[J7KDQ7^1TF+CYH;$L
M4-PNDG, #5N[Q=2F$FV"2=*",L_> V2]UMKL#;PTJD)]Q*I,>TOJ'DG=)# E
ME'B2.L'R5F^)JU4-9>J?2_/MIU"D&%&E+LP#FWA'VY1L@2$A9U+22>L6T]!C
ME+[$R]K0Z0X[*]<;DPVOU5MP?<[--1#JV'_4S+]J/),9\4ZQ[K(%:S%@UN73
MO$R/ -9*3T]H+5'$+G/;Q/0@\?27/;Z6N(WT3'^&_,]6W&W\E:@V_:$0U=OY
M19J^3*7E45*V?L-B0,J&64K+(R28"BDHD.X&8%+ OMA@.AC!M#L5=SNT_G3P
M$R-2,<QZXRF#"FF5VSC'_994APG"J#?G&8OU:S"SH8-D"&G/CMDX8)/1+/_
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M:Y;P @&[ 2\+KSE5S0M9 :R-K(>\P!5\/JHRF*4-8K'!5X%,T"[LT]%(77@
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MCJ>]T3@XJKP=$M/ ^ $30+CE]U!4@(&,#&F>3-477UC,A[WI-(B W0Z):F"
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MKXFEH5\!&QKJ0;'?:97K@?_9(>GY!8(O&@-_6%W=IUU_225P)^$U$E)3!%B
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M9JZSR7"80L[1R8T_S$F5AYESGFP!\7.F-KE".H=]$XT6'V('?PM8T":NV<Z
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MJ&\UP^!J1FQT+FOP+@M/ W]B9T!DY0;JLQ5YJ>NJ]& 0/_Q>N<(^)OZ2JNS
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MK&NV7%H>>URI(=YL"91K;4SI0I14 J;UZ4"Z_4]WHF92C< U?!$?%%6$\91
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M]K@<1JN@WP?Y'PS1[XK^!U!+ P04    " #.3'A44_I"O!4'  "],P  '0
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M\'78(K"E;#]-EM\J[2?-OP!02P,$%     @ SDQX5":-@^HP!    10  !T
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ML>ETT*8YP\$#ZE28!^8DA1"[9L/:%I8XM]RD):#&SP77N*7LY-;H?^P_9B=
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M;:Q?S499J5;FOY)X/?L)K_JF9S_]_0M02P,$%     @ SDQX5/.DX#7^ P
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M((=)D&TI7AW4WWZ+4%4?/21?0:B/)?X&4$L#!!0    ( ,Y,>%2@<C70"0(
M $ '   <    9C(P9C(P,C%E>#@M,5]C86YF:71E8FEO+FAT;=55T6Z;,!1]
MK]1_N&+JGIJ02(NT)A0I"63-1%.4\-)' P[<#6QDG*7=U\^&L*(I94-:)XT'
MP/:]]CG'Y]K677#OV9<7UIT[=]07]&,%Z\!S;<NLOVK4/ U;BP?G$7;!H^?>
M&GO.Y!3&HT)"@#DM84./L.4Y8==UQS7LJ,"]H1)5JM\W;P8Y$0FR*>C0T0PD
M?9(#DF&BN@0FJ31L:V&[3RF&*.'C<&R9"X7:?XOU(LHD%8;]GH5E,7OC112K
MW2$L,48BGH'O84G88(62P@*YGQ*1$_!D//QO^2*+J<X?#2?(##M(*>QYEO$C
ML@0D"3,*)96EZA0R!:F&&<DI$!;#EX/ ,L9((F>7%TH;9!$7!1=$]VBQ^$%
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M,ZLW$YJJ3@=%>[S!(1)3^V$/0N1STP,F)O25EU%88^1ER"1:KC2%UG=DYU-
M!(OM?*!$+K'LM9FMRXQ;D ODTCRQR6=@5#_?_TXAQD43E0'!QDFF\:-RH><?
MJ((KI9G=US4GO#$F3JX-:F[4;;5K%?GU0E,U[/+H\40$>&PP?C)@97B2J'X
MFT7(GNQ\(,VRZYQV7-+&Y+D_=70]O#;_M3,G8/]P%P7KK<Z_% 9&3@F-E0.4
M7V27-S<JO2Q/WZ@]JU&(:9W \:2,Z2L;IF$&F95QR/[9QL2A-RJ#?Y>\U='#
M;D,NAV&^F5.%8WKB M)&&+EDH??%)>"24F$[0H(H(&.P4N'0_DA/3S92^QV1
MC-E?%N_QD&BNTX)6_K&M3B>&E-&[FHBWAV1(=2*I#WV/S08C-B_K@OK;@OTQ
MD:;',5EZ12*CA!$[^H3F2D+"S3ZXTT74"U--U$+/D+#6]KT%=\XSMFZ.>;GM
M@?LWP".F,Q43KV!_> S'(3D"$V%8NGHUI@Q3:*$5%V5SSAJ^-=\-D K:Z<G#
M]QA>N-'+0^$LTLS":N_9Q]M^!H:$9_P'4^ZFYQ0$F]BA6FBM85OKO=0I!T>O
M6-$=JSN)#56U35;;)!S+10&[+7]D%-'$.'&]LAP@:_LY1R7'/AKUA8;@TKJK
MOY/^\/U2N&H(F\D2KGSV3B+A%$\9J5NG+#^S9@@3WH,/W;;KMY:T:GYE-AUS
M,,/@G5(J^]KD07O^9F3$L0?XH#,35\!Y.RQZAF--\C8<'V"O*%'DW7+V34NO
M'*EOL=AO%-GP\:8,$J/1&J^B*3EE NU^F%O_QJ^WR,6RI(7B((ZK-Z:"<A\O
M/OP^$#<1.\U2'1FO[*)NU<^M4(7).^*'3J&C?%Q\L$_.)!!%5!9S.GL!&,5H
M[CZAWSO!\E6NJ?J210?,N()2ZJ%G."N?WI^))'JEM,FD''D_C'>8P[6)IEXP
M"5,\B!^-889I_<WH#OENZ4@'Z2:B>;BUQ8MABD;GH_/<TOOM7%RN("E7/!]H
MMVD2C'N9Y38@4TD;*'?H3U!+ P04    " #.3'A4L\8<3"7, 0#BT@$ "P
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MR IHDX[LD7>TO'%!4&N[S&15F$QK*]ZT:X>#A97XU>@E!9FX\KRFGTHN,<E
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M<?7V)M_GFGR*SL;\Y#E<LE<Y0%VT@B>0'BFER\U,3'?0!&Q[<V;@16Y'?L<
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MV)$JQ",@%X.T*7=].:KTDM(?'_I[7C?I9JQE3/K%/=M2T[Y:'D-'D6!^6;H
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MVCF.W7EQE0.L:!KR%+ 8KY_G6\\Z?!TF]]W-7''5?7-SFQT__T&7OJG2207
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M[/CTGG=8;:7'B<W_(N6LPJ* NGX_"-("TD@J($J'=(NTA'0/TD@W0PV-M("
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MM\(WLA@M[:H)OM5F-#3?^=AX9USB>X6!@S%KJM19.MV7/,3R @CV[J[X >
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M&R.%P*^"1)+LJ]N&$D).M#0]@'6"0./NH+\3=J<'(ZA:V3?R^E)3XG#<?8#
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M/^QY'T7JN"L)?!%CL$[9@RN&T!CD_DZ-:+MJ,O'5>'.]<'UNL))7Q:WA;D9
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MW8ZTYK.S6])66D>#N<[LMMTNE(I;DL] 5W]#4-Z(H < Q*[]2<N-Z,)AS0-
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M[WK#&3CM%'D[0CDY4M?[?G[^18GS69>8E#=';J5,>C$#+\_&C0SEX5H_K<$
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MXOWNHQU]A#@92W^S:.OR;!JNZG?2<"LA^1LDP@=E&&@\5<B>_&Z^MPG>TZW
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MM"W<[)?C_36OJ8$)[#,F"4 L/0ZFKO6SAJN;&QJCN>(#"Z"2O8;U7U08C21
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MN7#J-5[%<-#UL](>*@9=^'092=G1.!2^:LMGU$O3<*1RN98LV_.:']K1[YZ
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M_1"<<>^KPM1E&S#G^OJ4D+, /]S\SZ82B'53C.IL^Y92KB_P)X;U7?.$XJ+
M"OU,N^JPA38YZ9(E/T 6)R)59>P]X=7ENY;CF;"U)04+=.FBB6,(TQ_R&_5Z
MQV[D8K:_ CSR-3UD-7*98#<DUZ7'6 *N]'51UT_5(;O&=ZFXL.YT;PIQ=%\W
M=>H$C IYCG[V '#::V=#X];PSD1?;!VJTKWS)&,[D;-2Z<<BV-E+^/  ( 1V
M+W@GVKL'J3+6[8IF!AVP^1YG="ZS60%L9?V@GA[],#)@?"[S \"!F<"_&"%+
M>!XLVM/^]%@(6%<9<Z+H55X8(<)"4EJ8Y:.;V)LAAEUH<1?;X=("7E ;@C\
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M2E6+[?QO2%[%@LR(@YN"?"N[KC319?F8D_H'K9_S*X%[-9"Y0*B%4KT5&EB
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MM-"&,B7M# PGK3O64=@2)CWX/-2-'/57[PX-P]&B@>M+8!(56&))TJ/'62@
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MQG%?I[\8X)H_!GBN>YF2,VDTUS*H^98W:5B@5CRI(SC&.*]$FMO 7@G0=/\
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M>WDTD1O%ANH)$M+,  E7&(F<# W'Y<G@ Y/&:X7399)K^5Y%9?LZP1%%X'.
MX&W&-Q&#V;()SGCK=,OX["YD;RWB\P@;U7)#'&'*X(<KUPP/([UZF*RV33M\
M5FD]];/EM\[=?T/X#6:/+W]9PSYH2WO=^Z]^^MFV?>7P_P!+^WP:;=65WJ&C
M12)!)-9!@$=05)5E4C)(XR%W ''6OT>^'MMI.J6D%E:PF"P+VSW#7!V7#R(
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MR#7]ZGP(\;Z-\1/ /ASQ1X<O_MFG:OIMMJBN;A9A')=0(6CQEC\C,<+G"]<
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M5L%5 .$4G_='^%0M6NNJ\^OS"C\"=_O\F^ICSK"+>5DM7F5B(@ ,GYR1OZ'
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MW!=_""\\;>(ITU.PO%>Q35[Z&3=),[ QXM4M1MPV5XVXQD5ZO\7_ /@J];^
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M6A"P=&/(3/!Q@9P.F3T ]J# 3(SC'( '0X STY& <]* 'Q1KY2HZJP\I%8,
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M%FRJ,7.=N2% &>0*^-M1.I:1>7.G^(-,N-$UY=T4EM=VTD<17ID!P%CS@X<
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MT=^R+^S:W@;37\7^+]DOB#4[IY4DNP@-M8S-E8 )0678K81%PJ$#:H&#3?\
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MMM4B??)%?Q02202QKT9GF"I@]2PR<U_&]?ZIKD/B2\.HZKKMVWA^Y-O.;AY
M\EW]J:*ZCD);<?)CVE1SL .,5Z&&XOR_'1Y\1+DJ-65U9\SVOL]^]G:Q_:WA
M7C\9Q'P]+*:+E.C2P]2-2[E)1I^SDIO5NUHWULF?K&VM:=:#1_/#ZG:B&ZG6
MXC+.8HHL1KYI!+,B@X / [8[6V\0Z59KYVE7*7,DGS>0(I&,1/.P@DXQR.G3
MZ"OU%_8)_8V^#?Q;^"7@/QMK$VI7]SK=I>6ESM+21VI<@MN#;L!64 Y!SN&.
M17Z.:+_P3K_9LLI(+A/#TDC6+!9_/(5+HCYLL HSDX.26)Z=.*C-/$# X>C1
MPL6U*ERN\>MGI=IJ^VVOFNI_-/B%@<)@.)L7@XM7ISFK6^U!M;-:NZ5VT][W
M/YG;36=4UIF$/AVY!'RK(MM*1,W(^0?Q9'3'MST->C^%?@O\:?B /[/\/?#_
M %W$K;8KHVMTD;,^=A,H&%4L .N.=IR#7]1VE_LR? G0HK=[3X?:9(8]L?S6
MR.4"  2 >6!D8&6&#DDYYKV#3-$\.^&+-8-'TFWMH JJEM9P*CJ R@+N1!\R
MCYP23@KP<FOF,9XDMQFJ<9<]FH)M13>J3LI.^NMK+FMNCXBR[+[E_D?SK_"W
M_@E]\9O$\;7?BW5;71K.6(17UK(S-/;3L0S1A =X*K@[1P.3UZ_IW\&/^"=G
MP;^':V=SK6EZ?XEOH;1(OM-Q C!KH?-)N9T9@P&?FZY'Y?H7#Y*E!;PM&UPQ
M>7>/WF_!RY;DE@ 1O)+$<=.*TE$.P^45*@\@'C/3ICKGJ3SW-?(8WB[-<;S1
ME*4(23C)Q;3Y9+57;Z:[+9V\QG&^'_"FC>%K)-+\-Z)INE0QA%B\F!$)"D$9
M=8QD;1W'7&.M;,GGB:5+C4"N4_U:0@J>#QNQG(/8GGCN:V22![#''XCM^H]Z
MIW%N'D5VSL)RV,@GTY&#UZ=?YU\W7<\1.-1SD[24G>4I7L[_ &I-]-OE8#-A
MF$"P6X%PPE<[9"A6(;<MST SM(SSS@>E="_2/_/1>*JS,J^5$B'83U.<+CD#
M'0>GX@'FKV 0F0#]?]TTP(=N_P"4]P1SSC@U''#MWL% ;G' Y/Y=L#W]JMX'
MH/RHX&3T]:B4%*,HV2YDU>R6Z'=I63:79-V_,YR>SGE: A,@2;B.HYR<\<9.
M.OM^%<UXL\,)X@L=0T^YM(+J"YLKFU>&9$*!;B(Q.5W#",58\@9/(.>!7=S
MN0-Q48/W21@CD=",>WKS^.9=3E+RR20[21)A2=JR$*<;L$!B#R 0<GGKBM\+
M4EADHZ7VU[W7X?U?N4L3+*I/%0DU-R333:?-=65TUUOU6[U[_P ^WQ@_8W_8
MU_99\>>)/CCXTTZT;4M:U>WU*]M-5DBGL0\0WNL=M,KHI<D[ JJ"=HYKY[^"
M_P#P6(T>]_:(\,_#:'P?:^#_ (,:G?\ ]F:!K@B$%O=1";R89(V54B*L^T#
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MM3PP_=>-MM:EZ*SIE>L# "ZM/+".8@7XZNZQY.'=!=S@/$AR^_WC.*[<!D!
M'F+$?^J9M,<O^=I??:_D8]M^]'0#-EPGW11VG-41WE$"+<5I-Y"&EF8"(^P8
M:MS M@4W$N CP*]*;#:( ,2U26N=S!_O%('U[;*'B@F'6N(>FZ.V)5R!][.T
M>H'D_N[;%\.*4^.ZU,,'S3FB"XGG#5QPRM9Y]EO/,-&\&!^.\R:<F6154?'3
MF?@'9<-O-*JQ10=IZY91JHW39N#=50N,NJ2PG9"46_B"P+2,XPZ/-,^'Z#!,
M(*D@-F___<5"R91K? -5U(W(+,"<5R'M"72O2WHY;Y+O**9A)T^PH(>8([LR
M42D^]XV+'X&9KBH11SR1-A5'XQG5@&D5,F:QUZ?%?-E_.NCZ,KMI_N0:76D^
M;$?P2WZ8 ,3P+5B:$>@Y)?E0 ZMX#V"">N  @>Y)RJVO-ISHQQ;IV[WH.R3I
M9Y>_9 Q*,V$V^KG'2V2[KK5]J5V#W4AF.J,XIH[SD!:#7?5=/>LP0X4FI&Z,
M/Q-BD"7^J)<>1]]RP6F3D0];5]+:\J7A#NPSV'*KA<[PVA81!'T$6$G&=I$]
MD/N3H6*]X1.^QF_ZSQ 7AN&&#A=311.T:]%<1:9UBN6_ZLN8.+=)0^?N193M
MR$YVILC<AT(%E6D4OXE+*6A@3&'^.,F4G^%TA"<:+"\;=#=&DA)0(&5D%/$<
M'PRJB7*_BSR-5'6#/#55:3(T5&X3"\R>VG$87# EVYCKL@I:-NZR67VG^^<!
M;Q^R*>[<PVLW_=QI^B#)@L,Y?X RQ6UIM&):JIL$_T5+]7P'TW4+,F(O7(+>
M7P;!>GRWE?O,+D=R3H/+5'Z>\]KT@%)C/-83?.TU7$K &7^G.B ]:_;LGL%!
MY?4DAQ_9C,=-$S&XUK!><)>:&7?)._:C@M?0^FN]^#WP3.2>8@,))OUW)\L0
M4%.][:;>1W_,N^90+"B)E(0!-,%WL-/AZX=&4DH)_4K2W1WO_>^M 9G>76L*
MLQ>?9%3Y3QZH.JJ2&U(? 80).B;3]&+%,PT')H;LGF)4.8Z\=GI?+#TUS_O'
MM7A30F7BN]+J8U+6(60;GS#"+3="^S_*^Q' X^'0W=J/<Y6L+]I_+7^O9^NT
MA5E(X=YENT(M,18*'16YJB!N.XM9D7$QZ,4-('&\BYHX\G+7!_UJ!I_;H4VL
M;3WPI&NL,TJI9PMQ=%_%S0VS<UCBZ&C[Z\F[E8;<SOPM]]UG&P,"B-@#6GX,
MPLC)YGAOU/.$RM(MOJ0;(]&0<<,U(2,!LYII/?:%[,?M\_Z+Q621VUHU5R@\
M99*#Y);KF_':*D_LB&X*?L\39AOA(<T(X2'WF0X=/JI?>A!SF,YVRNWYZ/+?
MS]05?/TC]K>?D[U:9S)8*BKN_K%='VIJJ/5-./^MLT#LG9BBO(%@^S>%AJ\D
M!<["*[@@"W$B=].OZ]1!]F]>H-H,6Z<O5935!--(PQQ![AL30,=45@>KZ*%1
M7,:;)^UOKBM1V?"SN/47GH\ #'W\5;X^@Z>SC0B3 VO3!E7M)3*EFMK4=?3[
M>QSQ+PR<A[GX[::;D=.[OUHZ6YI_Q5EUM+6:E<P/82ON<+J#VC">Z:7I] "#
M'6[?]4N(36QJ*SPI'-VA@G%5KG:.&5\OG$I6@YD1,U'();<ABT(<(8J49&B+
M4V,"K[.?0^')=D(G?Q<0MO+-4R'&SEE ,7GM[Q:VE28C!BVS(K<;I$=<GF]D
M:('AF1<J5N-7SAHD_ .(9QQ$H-H]UFYY3L@W]3%'U>%\;R.^)@A^D-OKQ;(E
M8C;[LHEGF0G\1X7SX$7SFH1'-+YS4@@#F\@&S?T*2AQQ+?D,Y;1&S12OHD3%
MR&?T/J:2B8W@,T<:5T*KVD2.]-DARAD\(]+O;F&QU.G067K5I6RW@O17UU<C
MNGM/03RHRO/50^D.PI5ZT]A6OG@M3OJ^<7HK!A=^NP.5_":UI@4(M+[KI]](
MYLFZNU(/B:"BFOIQ):"#0S!"\]52+] :X$3T" #WT.&473(E&+1V*,P&B3[D
M]&["P_KD7Q-#*VG/"^GHOY=4W:")=E;DF;<L"[T=CJROZF:JEAU_Q"LF 81I
MHS"+$=<EQ483),$BFD.?3JDDU6%5+PA];1: ]T'/;-*'S=T49!3$W:&[K;+O
MMI-&M@D[1 ,]1/'(\C:(@X/:<N"_$]1U$M[E*HTG"SED"-8\>V5.Z8K?[+%A
M1IAMI^_U_W\[M7#BOSK3QR<WO;),=E,(] 5:S"S#%EFMW2>))+/==84^O:(T
M^#I2V(=Y$J_S-80'!\HBY>::F"]RDL,^^-?&+.V"IPGR,V+'4B1127(G0YRH
MB.^!.=WJYLTY9A#(?63(!.TY!#_0MCZW'#9O&Z953QB%B-!^1<:+XVZU'%7*
M58(S6-*42Z&:U(SR>DSQ9"-VUEZOA'M_@$:W,4)21JJ"WB,70AN.DFP*?<K[
M8.%ND;)-"1J1#OM79)\$6GPLP9' (E7%;JRKPGRUB<\/6)/<KE_)S]B:RXW%
M&JRL&U8K&X[M3!:-#\M+ENU_+V6#W^+MIC(.*HBP"H,(V^F;!P(_!"X&(92G
MPDSKBU*K)5(^VFR>?8$5ILXLHJ+4HIG:(ZT!H%[;5%8KS3:, HX+&RA!8$68
MG[N%Y_5WBCLM;[@'\; ^=R6VUU?_30AP;R$K6(KK(WG'K!#/(^"'O>&3XU1\
MS@][NU@;OV1:@"YZT/BY.0(%#@AS:V.\X)RGL6@'_?%5;2#W)$HS+8=$.V!O
M=,5>Q=U4+8!UKS-!;C=A/!?%JH8F'9*]C^NDJ8S83O+)'ZJSYPNR=5@P9&Z_
MXQOV<D[[<#$^VN[XF1:S^,>];9/>/',3M RR4^()^*C8PP2T "(3QC)WOK @
M/6D-O])XC.S$*N9;MK>T?5 [-:Z)M ;R,+TF]!'@%&KR#>WH_Z!28/\BN;;/
M<Z<,S+BA2-Y*(OS\4$%8N (I &=)@33.'WCNG^:L<JHZ9.]^'M".';H8@RFK
M?E9R=!>SFV"W;6^MJU#X1I+.(O N47A0>L.3P0^GB>'/"5!:UFK$MM._9@S@
M,PF?"8LGVIQP6^ UL;NAJ/VY:EJ!>()LXRQW9F1LGQ1Y)?XC6.I0@2GK8*1$
M;_=5+5O:\1>X749[M5!8S;!8ZQ, YIF9QZ3(<=N;EJ"DW>\?,63(SQ4!)&["
M8-><U=>L\5)1-\/!9MO5HV^E]UB!<(9"-V^#M'I0ZZ^&F=RI>)_V[ZA%6L4/
MJ=P7V+<QN#=QS?\N\%*ISMT)I5":!E^%3N/^^2&3NZ'J=MD("=LP)X839:*J
MGR:F#]/PT2NC/.)M<E6^1"T7(G&_OUK?:0CJIY]42&T#=[Y@XH#V0#94<+"%
MP-B[ !J\@H90$?[R3[_D/U-<0Q0 H?U\W.<%D<+:0%_MW,81WU]&2AHPO)L"
M)#BW/<$\+2*?FEE9B0R(D90T4X(CI:0 "FJ%IK&2D&D<I3*B%X>GU%Q<!TR[
M-Z"^EX>X5:+KVAUI?LHBG]9]DOI4ZE.)RWATG "WH<C<K5>M".QS]V'U\[T0
ME/??RQ\X?^1>;K_P?>$N1;:S>0Y@]G:$%[DG2Q)V-I?QCG!8Z9O:'9(E!K@.
M=1(=Z,;W!W>>*T[BB8B B9,_#[IGCG5\UEBC_KDR:8D)R$H\QCC+LDC)"?V9
M7P^ZDZL9!$^K/UBGK__HLTVFF]I]2BTIJ$?BIO6Q>1M!R(L'C-E%*Y?M9XK7
MM"')YGTEHAV<!29.3N:ZHU,999 A*6F<&V8$ISA4(_#"SK9TM=KO&BW-D;2T
M8OI.509&@)]DW!FL='IF%Y,N1.\?B-"6J)FM7%CZ4" ($9]2>4B#T_<&Q[Z(
M2TVSAE?>T\)!XJ!B^L-H)2GOMR6]Q#+W^8[V7 RPNWK8SBY$B)*9VPZ4K%/[
MQWZEI4D'LIJDT_[+^]K-;K5P%#;G7:?KF/L!K7_?6;__9@:"$LKK@W-L-_LY
M1+/&"1I6X%AZ$[,3$BIB#8LPNKDX[ 68PIM.-+>*[E0+@^PVC^P,/=Y*]TG3
M7F.^CDWJ8<0<,K'+- UK%]MLX1<;>_-\Z4!!=^ECOC&@Z/SZ'S&U9/T,=ZXG
MONM=LB80C6_E/A_]V^N3_(%YNHB+3-V_9!Z=7"BLX76YFLB3R'$Y+H0[='A9
MJ,%>[9TQPG*<[I7]"##M1R S.CF2C= KT8(S*5X7NAW9;<QS5\)PN#-,0]B)
MTQ*Y$F[_-'!X5P8"V(NT67FK1]ZS$<_37=E!"+].2B8Z'@E\]5[ L&C)_L((
MPABW?5<KR,Q)+CQ"!7@@K\[G3JH<<R@UD'N]+/T2P\J\Q\7U6QCP]8V8Z[ZO
M;M4!!4RV%2J:95GQB[?;D/$3"6)\J+9*9$I<(K4RD+IW.E_'!4H:S@QJL6@U
MW;R;X#V<(AW3.(%-Z2RC'W3WFUJ.@FK.AJK)4>7]OGL]4U^:U">V<C%'6HWE
M]:F>FX5ST<I.]G<*V5#OY71PC$M^8FLPK(8Q;18F?.>PFS8$Z38J8I(I1[Z>
MD>MB:S8IQ-:S (48=?6?8?CDRG9( A\(VS$')$CUBEIK4C/9&CIZ8F^/"-<;
MRK VK2^D<"[V D%H_5K4KZXG8(OG5\&H\NLZ9S@=24]&SJA5DKK9N9M7_X]D
M:88W6  UR9P N4WDPSP[6Z_1!!<WG*.2(BTP4/$Z(8;A ?=H\R#(=IT2[=Z(
M^EX!,_29TG2(^ W/5#R)/*^%./*["LN8?OR@K[J>V:6$ED0T]4G0(BXE*% .
M/ZLC=15NP=JE(-=!S\\OGYK8-$=;?+9,3-8:'E\<IKNX1/\ER Q(_?JKU\IP
MS)8;>A=MZTP/GE1\((N+7I^AICY4^:A2L/+TN=,1>59<M@R_W)(OZE"*BO$1
M0)N5J#@R0GZEQ==5T:.^&]02L#-Z_*_<31NR)+>>=3$'17,Y!E3OMC*('AHP
MMU9 _)P6! _P>VQ*97[T8;9H4.BHQYV.NHQ[TU7.M^L.FCS]XQG&G5MM*P/)
MX6-N;"HN,+5+9D-@<=[Y][5YN1DEU9MWMLQ[#)\44=@_R&=[OAJ1R!H^-WQ>
MMGZ@S.FS#-)_J457,.P^7,TW?XE7O=D2B=-<9P@AK[1Y]RP?EF?!.KX-&?NT
M[WXRX5M?HD")/W%7#;&M2 _J:\SV H].NY04-F1?^GYZ!$PUN<-U4,Z5^E_J
MU_'04DBAR&/6)+/FIOC#W1?$T9R6Q.]#OK[@U:/OS&9-W^0N;E)OFFL/J+;G
MZ4:0I\&N/9--OZ;T3B7WTZMI'F4M--IG.JZV9V;/#0QFGG'BTV>3_53<3OUM
MEFAQB]_D3ZBWO9")ZKTS^H/&J%C3MS6HA_7V+CR]? 2P1Q-C.Y9-96!OE5]@
M9OEWX)'O?QA]J_J\4_<\P7/GH@:*U :"\EBVYWY6W?S>.WT@MDLGUC?Q\1OH
M?/E'P$%;F[))4TDA8_:,B^6S_UOW*;H /V>\P-\,#)(V7;0H?Y\%PR!:?WZS
M7^LJQ'>R!U@5(98KQDM*\O%M(=V@0,F43NK[UNKZ1P ^*E(M^H9/_RAMC;/Y
M#W\ ,7G$<:;O"ODZI[V4M2F7YN<Q3!:,/K.'[W$R,T-!V*?^FH7+^,("=$^H
M/QR^IU#6SUD?U_](8KE-+BQ[=%/3/2@RJ1:NIY-'=2'J-!^NX33FD=:54?EL
ML1![-_<U*GMYQF$5W=ZAMMH59<+^&_UQ,TYH0 +XC+_2?.'$-0/78>!S#&1G
M_.1NX@=I\,0L $?I!/I],]#73?(M'\KW+A.5?HVEHO4PU4IT/7%DNEK9CQSP
M&-7Z;F71""9-+I."J;J\Q1;5A9T05!3(=M/? HESY$6FJAL".6(+K_R-#;SO
M5 )6N\0%3GV_^:(/%/P. AX!U>T=&"S"YY#[M<]7$VK:E>%YKMQKO!@?,(ZE
MP(19#RP5\PIZZG)D@/]M:&F46@F#+&:@UZ5VM'E_&7:DJ)ORTM7:1\!+QMY@
M<\Z@-Q<3@<Z'H$> K:E;$/S\J.41D'-FFN_[Y7FQO52-YK58,"[H!;CQX&!8
M';6P>YIGJW)_<&'ZO2WE)@%]'60/N+/8Y 2A)-6$P$UNZSS"0*MXR'V PY_3
M_D#/&K9_"A(3OLN@HG6_4:."TV?S&!'UNJ5+X,Z,E[Y*)G1ODUCM@9]O>U>_
M-W__W>"M'L&IL/!)TI!J]L55E96\LITD&G]OA4=GP+%H2FYI];IQ -(2! I6
M'#("/H"AN1<G+)N["9=>W=NNW=0G@S@7)SKOL;+[GZRO,9+>[@DXM?[/\^"W
M9&7+])_*YZ\=8R<? 3I+5\N# 0'N.7Q'ZPV&1W(X>2>*UAYAHRDY& ?#(WOQ
M+8< ^-_Y@)T5=6EW\<%9*4D?0P#5;Z=/33]+0!M9&)E=WM0DR^,0XGY<SQ'&
M;3,*.D*>V3V&!'H[I*H#<J.:1*V -<._E6X_!C2EL$JK],/-Z"4C.?4AWS#Y
M4(:Y143/14"53O6"[-5,];B/\ 7< N^($I3IK"PB9Q= 7NV8,"D),[P^_HTF
MEZC9=,8J6%@#U;12N$(L<S_)0X"RA)=C3V]#5HCH4=61[<QW!F@MI$2Q:SYJ
M03/@S0!%>K5 /0^X9L OC^.T(7Z5?)8V&' !9+=(^):U<9V+*T&&"NI?R!&9
M>V-Z$L@<&2#/SM3RS"K\-KYL%$30-[I1LA$*,"+0C4;KH;PYZ;D03M]_IL;V
M'_'_86FP_ZD_S7->H?LL?WSPI)UG(^=;]4X.W[A[A;Q99]'N@JC2=*;OJ.3:
M@NJ"Y*]FAI>;9?I,.6)+?JH0";M>DF3_A+3SKX9S)S:[@1$HOJV;.+1>HY>H
M3HWP+.;0;N\1RZ[8[-.[I;UBZ80JCDOGS>S<Z,IZRUFP>DEZLO3Y<@3S[^O5
MK*;WKBC/ZN0N*Z(0E8U[2M6%JWE'Y_ZFQ((F(@^O B81[SC0"F\P7Q5@#_-7
M==>KX$X*<L*,#1?=Z@]$P)M[7]>_-T\^\LQT#^JM.5FFW&1]A^B?L?PM]O1;
M]C,U[0'+#FZDB?J 22+35=6AFATP!]F<[-/JF=(\K$WM L+S/,TYOF'JH^4F
M?S^/*CZC9.4VL<7\>%F[O$QR%U7RG;@D(^^G>J5P+.)+@5494#2!%4!]$8!#
M]TO2)#^^,T-H?N?FLSU?Y$LI !]A< @T.8CS;];"VNZB;FPOJ'KT<D=-65R"
MKG%9^5*"E"-]SHJ2V4^XP_,/1*)I1L4C(# HRD >^H"%:H#O^YO4P@IW=F;3
M;NIZB6 O6U;RPIHYUX/<2(>%E^,Y:.$!"Y%<]881,Z=;':*K3>FO#A9S#F&V
M^1R?:(1'_"SX\RCDC8 \(E@8IA5=Q)TX/II;O-%7RAXJ[]E9%//E4F-*%Y,5
M*<<Y$GF:3S#!WM5BB*;C$,29S)RS@%^VV,F"T-&G4'89%3(5TE).$CE/*J8L
M0C&+)OAM%":GM>#I"_LC'[DEDWOS*U,NQ_R#.T+MH80W1;.LHG8LLR\U7..F
M6V\LV"KGT8T.QE4^#,=B=Q)VG22_'25>V:?]?A,-EL;:W<+[DVAXL$-5_F71
MS.C;H#:RN7.FV8WC\INJ#E8VYS8L6!K F&HEK+?#E-@/?&N!(M8X@%'D%A[,
MS]/(05T';$NQ"7^3DT4PEE Q6C"[8&!2#4H=4#RO*<GZH=(L#. 6WI0" EUX
MUJFHJW_[6$0B6F0_511:U2J;1->G+%R<2W)NM=_0YEJ_H=H1D=?TUOCNZ^Z0
M_]U0R*G1MRI6=%+$T4A6EQUL\MF-5S;8"9>(%:/-A4AIKNDS]; E/%Y-^!%
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ME 1ORE5G6^I0&I#S5A$+2CPCL>)9L,"[<U:\QB[& NM(^=V#9(EVV'I._PB
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M?N:U([04*UAQ$K"]=T6[<3.D(K;5F?29)<[C+X&@NC+=6FH A_RU"M-@1=5
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M L>!\Y-8#Y[W''8;-O5<QH,[3QOC?#9Z>4,#R7@;><D")@/)3KXK)2C.G%K
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M8O1&8,/90,49[K(^TG%;ZU=% LD!65.N(U/GK*Y5,RD>/26-[FZH:&B$'51
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M^]@<QQPBQWX8PL^^W(G#UX(=C0[;J?6(EXD7TWZATII\/ 4B%,BK\_9R;<S
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M5-21T^P3X'AW/Y&,QE0N[C.'Y3(<UC@6]&UWRJNWAZHX)2W+) WK4+(#M%.
M\/)2ZD$^6^%MDL%<#)3A9#6:H>A\\<B0YIL-)\MD*-$CX#K@G/#]Z.]DIA1
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M3]MX9J+F$LQ?RJG-QO//YZL<JV4 U,FW8G 8-R^QH4 '4<UR2<!?P(0^QAA
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MX:Y#.9@Q6T_&UB-+=:RNRZSM+=*:-#:T5Z6_D_T-?Z6P%[OY39\2Q"8F)R$
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MW.9+Y:<R?GOF%( IG&K0"FOB&*56OJHX]FU .3CT*59.R6DLK3NDREW8=4Q
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MR&;!R8\>\3XUX.E\"<^RW04H^7U<>GT11K8&N<H&QU S';F3<^-6S2+)-M%
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M&[/(433@=O]:%\EL<B_FQP"?Z*-1L?$/5)D\SI\YN>+L.7H3@X][+:H():<
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M^;31?(D4>KXW@46C<WWT0;._[24@<K@3E>8E]5#NK^(CCJPK@3U.FXP0&'*
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MVLZ&NV8V(59?5F@#BN (RA4/0)A.+BT&C\G\\W6T8_N-SIP&N3-XN/X2P"E
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MDM@G*_V>,F>]KJ4\XL:=\&59;W?00VS=8KSUU5*2%"65<4B:AJ"C_VKD#?<
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M^V2];/?DB6NN1_'G+?ASI>D"MW"GX,_.M*8=^_7-+X*K%N/.]$F13FY1Z>7
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MW^,#L:QEX8XZQC.'QRGVM7T"_.F.QKT9MQQP%)@HXDU=;.P.:O_U)J[,NZR
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M)P?H67PADT=POLRO'TXLI/DU<71D*<?JRUXP-1?1"E*<U>&F:I(S46R&:>Q
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MTA]5^'XV66<DT"?F!/8$VDE>&R9%1;ZQD)<T\EPQ'_-BK[-WU%.K^?E0F)N
MM"SLW5;Q3\NT',>RCQ1T$IWX<I6131'IO$2.5AXZ_GPY6!^;^SS0@OV%0-NB
MK)&;55!(^&+7@[@0J8I^X"H+'_)#EE^78J^[L4[N:"]I-,'&'8 XZ2?R3,CW
M\:R*8.S7S9$!T*_7M:6+AZE-K0EJX- 8L'?UJ&63N:?]#DTX%7CO&8ZNZL,/
MOWKROP8E O/84I6$AVC"U=2Y.6G5Z[4M3B(X?&Y\W6*"GN FXG\>A.(D?R'B
ME@9\K(L/Y<ZZ?7,'Z'+9[5L# 1$3A2V4+U/0;05<-W#!PJ9+A@N>_W<FDLC]
M/T7QA1E8S8K8WNMH*U?/V<N]>T2 ]D'SGE#]AU%.TL6.$5H#$5,&O)1"QMP
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M7[]A^_%:C7F0P-'L"7.6(T$N'WXZ*\FZ+<>^*S25'M>&BJ<Z+=%+/%WV_ Y
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M5;I -Y(%PK\#.%B2KFW7CWFZ-.L[5J3O]?>1NMHG&?KJ<O@G/_V0?D*]:7/
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MZNK/_*STCE0>Q#>-YS_R,G21E_WUX85TSR",C@4":%=H_ONU;<*DH/NSLFZ
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M$V^?!MJIFHNCUV"2VV^[@NVHAFSYIMUP]*,A?%%>+ZU FO&#9)*_.)>$!WJ
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M$ESP4$Z+<?10:UZ/DH'1&8?]SDW:,WN!UD 1&IX*5P;2I4J6XJ9NRT#M"'2
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MW(9:[8I"YY3Y"V%DYO<_=.I6:OX^-7] !Y]GT^6N:=#D3=/[ TRUQ0,XB@:
MH(S;]:7S(?<6R*79M2%!8>)M92CW:0=1AU]!ZQ@<M([(AS7S<>;_=6'0:4G8
MDXC9^JICMUQ)*#<5I@7#.^=4D.;))Y?4&-D![R;T]_"_L1&O;UJ86J!"\D\
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M@Y4 1*U-<H!?BOC5SSJF.P E[EL\.X ^%+>@=_/:Y$;^;</\KS..YCF%TUG
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MM3=(('K[=(_6AK95]+N3,6E('2=@(F ,XXCC^EC'SC[#C],@R2-LDLJ@CR2
M!SX55AH594I2G?:L$-+IO9H?*;/C@[O\;;G7NOF$-$E,A%^S8"/@=$IL6-8'
M][2&U-XCE!#L#"CGCZ:VP?'XWB92MS$&Q,,9FR("[D\WA;EAYT -*="P9V&_
M-G[T(*@V.\8EYQ3)_X(HQ5V#!W+GN[XM!S@,FK[K*IVFC[:5S'%_/.+/^4^[
MLI*3<HR9VE14%/+*[]G>RZV?T0*(_(BH81R>YM #L1O))3N37FO;0-9'?D]P
M)[%MG3_Z1$5.B0][Z9:E.=CS0$@M\%+']O3A'R2//C)V6(NGGXD]&0-&X0YB
MQ?^$B&W6T?[+78CQL0"9S^UES4R_PLX:IE%M9HLJPRG3L_1_5M3-XE\)U&8V
M2')%I0980&G)97J!,(5GO(<UVR\L4@21Q8V?TF(61+\:0PN2U9GC>^6\PX6O
MTO6;\T*BPV/,C^PMACZ>2P^KN8\OAXMU2A-_AYXV=I8&>: )KRFP33X&TX[J
M+Z&/I3RBPI17+EO2@[UD8+AI%F3_WPZ?5LUQ&_]YFCUWNJ]3) N#QM3"N.SV
M!\-$L(W9W.NL_[4^ZW&EN!*?7B;\X/Y?J]X6DO8.\.6Z4.'O_^SRZ4X'7F2_
M>&5"E(+E+XIZ0W7$RV+,R^$@$*[,42A],%K7QKE2[W<B+'/9>[QZO3!@A=0F
M)L'V;C28AS\%(4OER26__XQ\3\./ PJXWNO>)20)K4\&L(1[1B3G;(?S_=2$
M^QF(I/?6 ;$704+RA6TCM7S45X*Y__K-U&N.]-9V0H@OA!W,Z<<.4@$V%)QU
MC,/C[")0968\ZCXT'BZ4Q1>>#XE^U+2J; >-!NK0"A(JB;9RX?3NA8N$3-J%
MKF@]2O:.\B 7FSMCN;F9Q=QG(<AT8>8=((*@67&BYW28YEP'4B"41KDY0*]F
M+DBX'Z$$[';K6A]Y=5W=FQKJ,>@A!RNR59UT%)4=*HN!4I:R4#.G=T2, DXC
M^@X2%EU" (9$%/([;/GP$LAY903'%(E2N71?TAAFP"9<#"]WG]/'U%#L]Q,9
M>389O'MZK=&]RET^BWV=*'H'H.U^RY%<]!2X2BZ2+);/DK!RP@&[%/'\FZ#0
M 7!Z+4Q)F,% UAH255<+%L>!<LTO')GL5Q42W^C*^TIC/*]G&.;U$91.^==K
MPF.*Q9OYN4O" U%Q-H3U'# 4'/.T?N@A::/AB0?D#S<XC/A)/"<0@9@)%[66
M/:F*<OU:^8_4B")_Y_9(?64:#IU[U(352'QEFS&=-W8Q!2$/GI_I<Z5_[?>S
M+&;&6 3/=X1G#A>M;[,^"_KG.@?_'#^&EW].EAR$%<<IV+NGU-/=TCO QK7?
MK7V,Y3B87^V1V_=2<L!^*E&O_/5VL_PGL+KMM!N%U52J6:WHK^?'X4'!(>L?
M<3[$FAHPUYPEONUD82S44PTT3_<<D9G6G<W_S=7^B\U<<MDL)^2"<-I^%,]U
MI3 J*I]-;A,I-:B3G'K/5R%W@//])'?<]K&=83L= V+=$W@%V^!Y,>F[#%-?
M@QO!C\:NPX+>,2MC*QCSB]'IVF<,H6%/.%:<R*TX^"8$PI#2> 2NJX4Y5R-?
M78IOA'<"A5.#=I7O[QD&%-]H4"H'.7R0YDC7 6FK2M$D;V@O%I-[[?5?7&\<
MSBP9 WW)%"VDC*,%+W%I46.D:;7*ZZ2O;9<#<:;(C0A/-.^)"OF28C&O7W*#
MH+H11!"0L+ZRZ3 "8<9 D*^2K/LEV!G1,,33VI6 PAV&=/C +XF=1-MW4SW"
MI,]QI@\C$H!81"=$+$9.AZ*H]H*3,*/O$/(LTLQX=Y5M62;+FF[B_8/,L2L3
M8@Y>@:P1/5%'7)20P?W\),<.,DW%;M_2NW(.(5_6!>R&!&Y9O)K5ISPH(C^7
MTQSNZ)KME)(F=6LLL-P++&LUZQ,OU%V.9B!5V.@M0KY*6?+>&AD^)L'.%)(C
MF^N_8+R1VDGE 9 7J*&8^O^'HO,,9.MMXW",4GO5'K&UM3=%8M2J6OW7+FF+
M$L2H%16[]J9&J=%:M??>>]-:J2U!U:J$(@A>[_?SX9SGOG_W?5U?GK/EQ+S&
M51-YD/%!8(6_0=M@@1L$6WI\[]-%KFUUYK=N8_J?1@I6\#G0P78S\+-/3HE2
M*D7/+]7A+BKY XF#XPDZ8G+:UYQC,7+?3:>PC:I$5%,$BHHC)+R"#=_,$I:&
M#[4=U>L9ZP%Q+5Y&'",]*5M;&?RAICFW  8\B>._>7?)[=C/TM-"I"Q<Y=.L
M'!RFZ.6>"HNWJCHFRG9OM "]_($*HZ<E+&^%0"_]3H_GOIRI*!F1*O'?\!B]
MZBUL,7EA/G[3&=UK+_0#$08>S#/@.'96#?R[_#P^PRZ%IJ&>_O.]"!)#52VE
M1*=5*QV 43J&-K91@_OB0<HO2#F]82"44KCUA+%&"I"@3K7MGZ P14W*Z9=/
MF2S8!G@$+4KJ5Y2GA!_&A1SE%8GGH*D7/AB=GTPS5HENV"0-_Z"$;<;XIC([
MVI+6]NXO=U<";/URN8,Z9/Y,28?PR05HL23.8HMELI:?//*7#B[Z%$'N+C2B
M_.\W2%MA1YEM1:XW2O2!?MRFCX'TBJ?.ZU@?RX?U<70UMGF!G0^)'NA6C/A2
M6(O4$.@Q[Q$H$/%O=J,2/.(>/4'^!RVZW)D:_J<PO-"D'.OU0K,M5YO\\_[^
M]+;A\9MIVJ$GMN__7<9M8O(II4%-8;S+NL.(E1OSC0]Y8QF';+L*Q_^2<R6$
M1EEW@PT5#N[_;K)9>$3"RCW<X @N4AKE^S;<X$6H@ WY([>S7@EX4^\\_ Y6
ML04(E2#Y0=JBT,L))J]U<_82'SQ%IM)?J(-%=10S.,V(3PZ180L- QY?*?F>
MUP+P+<#0L) +D\@8>8 4AD5J,[Y">@1_Z7663S#UDC%)\ ,]*3A7\M6L[';X
M]D3M[N]#H5_R5K3\"OSX"P52_DTB(OZ04:%BR5*C0COQYWF805.HU(S8 @GO
M5Q8[@B^>O;T +BD:93; X)/<ZHBI6.[_!ORR/0^')R )'(BB#S0=TCV%D49=
M/'/0)TD/W2M5^H 2">_;X:Q"1$(EKO.M6^&**Q>OR91J]Q,R2RG)4>^/,00L
M/BP*9T-!;( !YLNOMX!,_1^74V&W /M"^?,-NS^7T7RIL6G<>:^I/7)['#C+
MG4<>OQ<(5 -*-^]..QF3 '@M? F^9(SM<'WTNOQ!(K1\RD%R,]AQO:'4V_:J
M:HTYF%J>4)?#$RG3[=IU"\@'%>"L!<&47S9GE1=*@PD-,Q===<WX2JK SY*L
M2@$7J>])\0U@E"I+\>554V+I#;-QD&FA?%LTL6"R?\L_>>;[8R77<\KG',E3
M*OONR^+X?QE8V'JZ]H.(19WASQ*7.MK;PP\(IFX!CD[)M2<RGU=>8RGC&79^
M-8_!571[\(YL$:61?)ISF*?^:AW!F]O$(1&KLU62J<A*KW>+U%+'V+Q-Q1U,
MOM7W*?Z,LMRRP#\]>SF22,5)@.?ZTH<D(9_HTI.XMUYO9G,C8S(AZ[0T9Z!B
M*8);0&)F+R<V#OMO$-9@#8;W[WE<P"@N?V>*'ONE=6^(1N!IP(E-CD243F;;
M9X+Q[F0[.\D)AE6'16I$+7P<)\^06<W\N_)/O?M6\X6^!(.C $$&G?M?)>((
MNM02,CTO3K(TR)/C9QR0_@[[N].!#XDHUR'A]$%V-A<?$3^O\UEZ.:4 XX%$
M7!?%[#E:CGU=J3*VE/^YQ+;)>7/7N/KURTDI* @V!TZT3G^6GYU0P-<:2)2R
MB/-PA8\",YX!CJ=IX6!-K/$/6ZQAJ%<WW31JO&A!6=H;K42A8M$0$$BL)*L'
M4>&P@FBP2VGZLM(_$FYL4=QRNR''2R[("$]3.G7?0[ &H *L!HQQW48_2V8:
MANHZL2+2%3]QZ7]7K+YG#.B#N/35\@Y?/$[F]E8J_T-'&*Q>7V7P_OZ(PC"'
M+\?+=S/2O7Y1Z[]M)Y1!<ENV362;Q7[[,0 L*4X<4WLZ?L0TCG'H]<0U&\^*
MRCA/>C1PRA\VMX%RERM<Q/YJMOKE-S^^_[&L $ D1\/>!<2D)Z-8W X10AN<
MXOW&3LC0J_\2G\YX78NM&W402UM;][_]J353:_TU]'W+^BSC7O$JG&";A06M
M=>V9%6?)K?0QU2$7,6W3W;^N_(/D4<>\>_8__R2?X'N=*X[YU !O_C>=$:HL
MK"IAWF6Y[+HM]@ICC2L!TNL<6]Z;+55A8S8@A\WK;[J7.^#B1\IYE\X29S0]
MEQZJ+"]>[;GDBZ5R<]MFYX,Y@@U9#X_B?G]ESDH>\H+IOR<#V"P?_D=ZV<CZ
MWL,C!>2R81LT&><EN&J^-0XNN9P!IS^\DG(0*.1/,D]G?:OX8EU<P(#\^O\-
M^>T68*2< S1]==*PIDJ^];[SO;MGJ+_'#_(:;XK.]NZZ4\)^ '>.UGN/%(_$
M3^_]1A4'81>D';,.K90%H"WB_3B:_ ==SVX!@1JW "(9@E"QHY/PGSOCE$E(
M<U?/WI&=KT=A.N)'XXIL(FB#,)'[O:A6(8X$O .VLA<6,9+E]O6U*GY0?/&"
M?U)R-2Y^@UI%0OKF[EO5+Z\A9-^L*>.^&)1)Z4Y7<U >*W$]J@PH?4U0M*YS
M ^?7]F0Q%"X==7W?TF.<ZW=YE.W-G2CUYB^_(K (Z#!,:!%ZQ_(2K.=3TGG%
MTFO!$EVK@5])SS0OME+;MG6)<X,3"KX"TY2N-%Y.&20^NFS[I\RE)J2P.VQL
M%>3 $7CV)BSO-,^@PS\H]^[0;@'3NMU'J#L7 /1?^12QWL_2/(BJ%R:%%DRG
MJZY(#' 0Z@!.<&Q:G9WV.>]FA(YS6/V$PT?XA!11GE^^CQQ:Z=\G)=3]$#2M
M<:0##/K2SL]J4_X%.TR<:[BA, EPV#4>=2OYGFE7ZG,_P<%./=!D@X3X/7E(
M^!^RROR>,SX5*4E<@%.L>MQ7R-3C$0+CJ(N=%".BU/W<?JRG0TAV6+2Z1U@/
MZ^C(EB<.'2PZ1A;?L]^ ' <WY=(<?+Y2(Z0@P" '7NFH K&'<S!%%JX+?/F>
MNU21[B9[ #;.\Y=\-4MU.ABFTOW_WYVQNKQ&R&!9=Y '*Q^,2!.#>E40%L[V
M5Q2!H[144MOATSTT1.O#+(^N&E(-5+7_:[%CHFSA*PH(=]O<E_\XD6Y&_L#-
M*T.8[ZN"6;A5U;-3/E(.0DE(7A#&4%SN_(SU.A86.LYQV=V;2 5]$K#$+&6Y
M: 7MYC^:_OM".?YCZ5LR(OXPR&-XP0VY/OJ:X@Y9Z<<0(,Q1?!<;0A0WMTXN
M,A0O<-@<>PM <?TXB+M1Q!7_[&=M;,'LA)LRLWV4GWZ0^FPQO ^K"FS2'F[*
M'H Y>+E2?EOB8Y:<Y!/#-IISK4L0!VOY;3*RP??D)<-C+B8F]NGTG-WCC&-J
MJ&>"?9*T_D9R-5ZDHMR6#-'- ]61@52XP0U]/M1..(@#KXZ+M2W "V"F$QO]
M*A&033=RF]5AF"?:6H!?TT^6TW))\??/?\%'_,8I,SEEO9W  4A#4W)1X +X
M?I!=(@W.'1?Y'[8Z$@]!N[' BQ>P[/TWQ&']'E93;0(_A*:>% TT4Q=%V%(6
M:1E($)R_QZLVB:A#+S^6C"@LTX=3?J:^"J-]R>BJI;9)'/<R"%-3V2_RG]5(
MW+(!HZXBM\3JD&=BYR^O?1O34K[1<GW':6?BI[NQK.GJ6#I!_<FVU).*/ FC
MY5C7HS#($T3 ]3>70"9GR\00A%168#566Q_G4(;7FT?-D3<E?L5!=.M7.0>O
MZ+)A&L;=QQ4NE=M*585)!Z;Y-"W?L*L5463)L63SP)'_A+GI/QM@'@1' (=)
M@7V_<CJ\7>N2%AA$E*+B/U6](L)S!Z"U[B_=Y\XI1'<_Z1"Z@N!E9T$<. H+
MW$\T!9 &;XS5#N?'FD5W,**NY:#Y%JX-XSGJPH_LHA<KBAM_HORB<OX[KW]*
MGL;CG'6=>0MPT8,L":$U=T+L9EV]ZJO@O(91-QR8F5WD@C1.NT^.X3JTWQ0I
M:U% 5^[T-]:7,U8BW<O[..KNK6<)L-0_M)6+E_:VWV2_%:C5D'$DG7JG=0M(
MCV$AZGGUA5KGP18NA'*73^W=P???%J_*P^OK.&2G2EJ""DIMPT7#^4.%?W>S
MX%_C()C9ES\/$?YHEG^3&H.^SXZ<;6U%SZK+EEOH+*WW/LBV^ZT!ZW) =BUY
M7$[RG\."M2?62;IA>43P*[3\X#01_&0P2RRD^,^:[/P_FH^1!@UVC=B,4+RH
MO9M'%?NA?:TKI[C0L>C,]OB(+2R[MB$X,'-X<]_T%F#A%IX)K$OC.^^A&Q&*
MDYB:<6<)^.&I?PL(#WE;QJ;TJ/\AR,6I58@O@EUM!.C7PN][E!CN#5P6/[.K
MR3J>?86]ON[ZGE6<]M7&L>F#R@KS6=OJ@?J^SJPHCV1MTEY--5[ON>A--HL?
M\_C]!\=GP"9D'RP K^V!>M0X?D2)4T('1=RPP9L'GDQF0P]]T6 6.KFT;W^,
M]1O6#&U=QC)JXX]8J>LH3U2!W^CQ&HTQ@I\/MYW=N'7/&@AUTM7'"!F-!B1?
MF(NM8#Q-P2A0_8@:[ 3V7\1&TTO.\3A"=D6NL$H_@V^B,E;MOSOG1&2RE7@(
M&N>/JBH.9,P+Y]1'8= RBFAZ0834=Y/'!SA.Z0P=5Y[:D'\7O O5.V$OP@P[
MX?0JH%N ::[(+ZOR)59IYVYVUP?W[#DDIW1(BX/Z^H-YDG:1!F&^?'R4)<G3
M+Q19B&3J\6H-D;8J19-=!@[RI'3Y0T;4)3O/)::I<I]XXJ:"7-:7RCC!9YE(
M;_ ]/'<M)N-@N-(<YVS1%F#@!S'&BN5_CM5K;(OG$E[,SW+F-J7+ VFX/10I
M[OJ"D3],QBA9X32AF]WL\!.]YOE_XS!9$/^2E?F8S?" NVC'4DY$7O%WY](W
M4=85HOQ&+0(:G&&\P: ;PR@?>8JK[X5Q'/AC?)%JSTI^L-_TV/ VGU")S"#V
ML!7<WM@B]CIGQ.=%S[($]P:'1"OE<RNU%0D")6IE4@CV%A"F#-X0SHNYO*G)
M"NIGIR*<'I9?$TCY.;<,?W)$LBC89&]Q#_NB;*%7GM&;QS,% 5&[KNE^M\X,
M7>/%<N5M7H@RJS77=775M=2GK+]*U.UHD@_DG&\H)U-?,2PVI'C8GL#R^2+@
M8( -<)43R+TT^B@>5D))B59^?9%KKDJ.#3O_53L]WISRZ,[@<_HD[$)-R-CJ
M_9['\P@![BPH7>$7P3C 8\H#L_;YRBYPXO)OMQO*6AY=B'R2LKALK>\C\ZZF
M8>90K, _//<2BN60<A+0+[,PV'4W__J2?:$RJ-\R<-J4C:D$?:@W^+M??U;6
M0EFIU#'#5%[N<D6>F8=W]E2CN /F+9HUV2%2T_<'L: TLJ1*NFP[7".2^* I
M@W)#\7XLA=1CF,C@TX])1#1S)S$?<;< @V3*Y"IC^V-^D[X5Y9:W3^]3(TW(
M?3?CXG(+P(2K@<O@NJH<3S\H\T"V5:6M0>U<(_M5I?2S.7'1@2[FF@!GLQG1
MXH>E H-#G]G5C=X4=#J^MDWO_3D#=JD.EE\CQ<@/5%K]-]?!6H*;]X(%J=;.
M_UNT^N^'2X>FUX(E+=9%5?Y,\&N X%6KR]\Y7:I05A]"*D# /$UBI6!/<^A%
MS=>T-06?&L7-H[@O=@QX?H [E&: 78+S9M+#A3'84T2U+&59U>>%B6_R\%4_
MD1 CYB;O"G(SQ;PFVHJQKQZT$E:QJ!#OT"CNG.]X 64;_"A/ _,KLW1VC"6V
M9'L5PIG3Z^[PI:V$(N:4)N(6P*#,@/75F6\$1F3-#\?*Q L-R(/8L,KGZ;-+
M8[(C$6;ZC2>FP"<*WTCL.J+QG5_-.>R2: H3$]]HPTV!Z[U,%R[JS;F>)T?\
MF'PM#534A8''($B<JU?A1?I)%?8X_1<!-Z'/CA/HYVCO$,'T!]RLY77)#<#Q
M0T+KM\G-]%8(I=6^[ZQ^<?21'=:D.;PRZ\3ZAT@U7UQ _8NZXZWZ%EI)\RV3
MNT,P=3A8Q/H.!G'><(@/79OI-V&:^[J9?^VM\>+\B@W?'6ZR!]'LFGGVO>NJ
M?5]\+VMAM4C76C'>UZ-5!W %!?%"T<^?O$K)3RFKH9$&/WQ,L4-0'_HDSQ5*
MFO@Z;JANX&#&OH:6XJ/J\+U?1*[?'Q :X#>+#?3O@+][&7QFBST<^I;+C O=
ME_IS#($NR%LJ]0M6>64WS[K1?*QV>"K_PF8MZ&N'QC3A-D?$<K#4*7@Y^\R_
M$6L3LI%#8X(EJ:W&90$9-3V=BQRE(=!<BBZ,ZZ>EA"*AA)>/!TO4Z[\WI[]S
M)WO_DF0DG^:'-O;Z>P*S8PYG\9(MWWE<YTM: E87]X(4@$+/=A)"M:'E9#OB
MD5S!?5/I(;OU".60T,@RS*_#F:X'==<5((9^E'CD9=[ -#/TDCE:V;,( @\=
M&N\GNC)=&M:K7Q5HJO7FYZY,JSCS&)70FWYLWG>]8*2[I:Q]%10X=@/$_*U$
M"QMRV, 3EK7#^GV16;Z1,J5_Q:K?8EUKK\-0T0WC:7'%U;[E3L'#?O?:ZJUZ
MZCB_&TD"KEG=HDR_'Q,X>W^4EY),2]JV'1I\D7]/[<16^1^Q5_FCS2B[I)J0
M'WYRS4 '1&QE?7(Z<7PLV2N.9IM8R$.$$FX>,X[.;40'\*'.HZB+*N R%R"1
MV=^QP-<=;>%V&?VS1Z.))N0SM'&TA%_ETDVK@M!YP]6D>"%<2 E.;PC$-^LE
M3K,,5Q=GA7>;MH;GGFACL%^LH&>_7^^<%V_X^5MK;1X7K\0 KNXXP?293R9_
MC.@Y5#E5"LW'NO)9^-Q=2LI _H%Q^FO*/$R>5;1R4\.7;R,\4%KZ[.$Q$]T1
M$4,"/Q'_U\B=NW@A;D;8/L\]A3#RRC5)V#15I3K61W6-%UJ-ECDQ%#19_-VJ
MOU(9&R#K,6FVEY+XSGR&N4X7;?"WNM9&"]8["0: ^F;&;^BNBN=.)QTL'BN#
M0=EO*%^\ND :-?CZDN\]I?N2E.].<$F9J]2P3!&5 :6G'+OB2'O?\KH'T8,!
M;%U+D&ML_E'-]HZKH+/8-/$F45M^VT2C>#?PT9VV9TW7.0V?[3J0-SS\QA;F
M3ED?+6-VFSTMGWNU:"ZT?^5=YN._X9\Y7"(#Z@?K\;HF%R+BQ&71U4O=J( *
MMGL980C#DKU<_CEO%38K?_]^CS-=!"M:V,_[88<:3&R=I[IA4DRNI2M.QW+I
MM7%M'("F<WB PH^.W^I1KJ* W $!<=^O<5?6L21)Y&R,,99DR3QR$;:X-369
M=_S#-@[55+I['KV\Y[S1*7\V<_WIU"IV''S'?$T=>A3.UOKY5P(#5-7/SM]#
M1SWR5Q3HG'R;/WS+9-:/3XLC^^VF6F&%#*3!V^&<K]1VF;E$<!IHX3P6QQJG
MK(P(,6_SAE:97S+5C- ,DH4C]7:K\.>O+%?*-?FC[/1'/I1. @(4<E6:4_YS
M2;>,:B&OHM!VV^XFKAN^FLAS>9T\HD 2@3U,F,A^-)_9D#QD,,LK3JDZ/$$P
MS<?-=;&/ >5=V2*HY[UO 3$V''/>-'26XYC8 2S<&=)J+;J5,61YO.B*%>B*
MK*'Y1T.-.'DU:B=(I\F@-*'+VQ6&&8[!2V]":/ZLJ6#RHBI.ITD@NR_VVR#1
ME=L)HF)(M1I>)61+NHE) HN?<P1WFLYZ@:<JU]J-LOIL?H-WC$):<SGB#WN*
MKB)%2.\T9\!]&D.@1<<7D=\K@$H)6BGJ@8PU I=3%E)@&D+)_\KL9NI)8%[9
MBA.$OJ+B'YBZ7^5OB:=_B2&_C<"LF+>D7=9.A+A&>.=L^#*%O_FG9R<W)^F/
MA4<0GE?N./IQ0YQ^!8)EOA)A@HHW0XN>Q6.?_;T%/$M9VNGOHO]Y$#+?* P3
M= R</W-,-R\\^?4I7I<_5 - ,YO9$4!<DT:G*]L37I3&&_L./,/&;4LJLL'[
M-3GCL3S1_G_R"8<>?)^"Q"<H&JAZ@KY%2X;,D?1R>[1O[V==('N[Z?",6+Z7
M&7HX6)58HURR0Q$\5#"-JH(>;F4AI5MHZ. 1PK& -+"PBR^4=C,Q%4XCFNKP
MO-)"R&$J;P$#;L2<[Z9OF*:#09Q[0%K7#D&3KD'&R%3Q,\C9_!3Y[HP3<TRZ
M^]!?#<F^K?< T!A(,6(U=/+>94US]*^ 7/KNUD^5 V'GP55JIG9"[L;MCARS
MR\/I U(UN:M\2PBD.>BM^Q@U/X^>EY$JY:+QR&"@*U[FNLIK/P>LX9;(G,N*
M<:V_!=RW+HGROI8W2% +L$6O,Q#YP3;TQ09"D<UU?T+$+=V'O0PJV+\@&=%N
MN(<T?= N'@03A!P7VO\"I[$)[S#\#K\:N!Q*.FN+2+0OFF9*_@IE\DG?Y6].
M?;5/^)]@F6JHN'@2:@H -KES6W#\)][=R[!G9,DQ0V65-)BV&I$BG?UI5E;.
MQQI8DF'^3+&7=,'%]!;FWI0O<]H-CC*#"[TVL,>D?8:)>=0W<K@"='4DB M4
M7V:%%T=6= B5PL,/BVMGCL0%F^OF7-_,6@\M%T<L[)+\68D?&_STL#=O8)TK
MD SN/(0$D2\$<N^F/UE-^*J27MATQ)]NJ=4&TU]+0ZV:[JG\4$::KJN@(T[0
M*U(,*0!02S/VM**.\=C^HG:;.A"!;^5X3^21&K)B6_GT!AS,KT\I3^_6:F4;
M'DG0#.,3Y5;V?4M"LS:(*,4D;A[UW0(222T24>#80JS^=-B1:-$":+2H@\E'
M<IQ/4S0M;2M?^_O#)!("JR! 6,P6XK\KT\!I$#%VH1PS/ BF2PC95)$>>**5
M4VJN5Q#][>?IH:[R,CM[>W UO;:_6]?9Z>KP(OHBY-5[@K-=['S5:9R:!X_;
M75>JNIOEWP*L?M &9O[;)[8!U7WY;-O8:JX\P0IZ%3\3D#-'&6SPHQY 1O0W
M,3OL>#TT4 '!CT5&G]*0X:0'33\T1S=4R@7X&"71.53C'%=D*Q?*4?;V%K)*
MCB4KE1[4J'!883B_(VY]DZ8O+QRR*'<CBV7Z6C)>*AOQM<2132M-KKI4NV <
M_ NT7M[K:JE'H9T4F>) SL?JL*L*?)8(7.8=?I"T^GF)CP66%-6QKE F+9'Z
MW2@_!"D4MQ6IOWGE_YZR">GX7"#NM]1"%1'U6\UQ4I5^#ML2#K/?).%7;_:8
M;Q2PSRTK2\+_)48*8YV-,1DA;G]M6[I@5GUWR<XVPXK'Y*0('*.:6N@U1/Y,
M<-\O3^JM7UR[688 3@VI<6$O<-J;L6[,N S]1LQ6DR7LWWNU@G7QZ%,+K_9W
ML49?^'G>M-Q!88'H ZN8#7P^\!O-9N8;:ON&5@M8YL7/5Z/WFDPZ*F3\O[@:
M"<3/EB;1,_"SE0L-6)EOTUU(@U=97\,P[TGD6OI=_Y"]Z5V1N(<(!3O> D)U
MJVX!?9)!FXX9 W)9@;MN!GF^'JBC!T[]XS>S,_]RG$>O! :OTRY"Q_J$?=[Y
MT@NE,SLG*F"!A]I0-) #3X,+PACL]0\U=RGBTJIP\L,+7-RSS^6Y@#,=2@RK
M3F8CVXEG ?-E95;C?$P:)\4].C($EP^[%)NA71,+,QJ/D^+)/'Z3#*G1,VS3
M]O]-&?8E*:>)8@KY;+FPE<XW)N+NS@\(2U($T'K$?=GD1DX!&0)%$'*X_XIW
MF]>DD4'U__(8]O51W?<7-1GD.BOVC<9*O1V*IU2M_^JRO4%0A+:;O$IR'MRY
MK@;1_0'Q8@^;8_&Z5)'A'5SIR4N9HL6)@]I,?>>6=R"N_TG:<AUN<T_*&?#7
MP4P_JF*3&^@O/T!A/0,4]*9=$:'__OC^I_"^E%_;=0"B:N.L+ B'5IGYXE0L
MGXQQO0)@I)"P)/>^$*L"*W_<!K)G] H6.,8,7CR71!A%_ U ['XH_EQDL8L\
MEV>KRJM>+<H+E\V(ZJEVOG<I4J\'>V1AZWC20I1ZR$6*:\=,HW]_12L%170)
MI XLY+)U)EZYGJVQ\L;JS1]:F![II\BQHY//Z7N/>_XI< 0'\.;1NN3!K?Q8
M"ITFI!NJM*34]O0(21'8,'T(E\;CBVC*W=K:K98H9KXO3**M:IQD0_ I8;1;
M'!B(D,3L#/JNTQR*PNZ6+2?<']4<'2@#;QMSCBZ8Q;-O!% _$M*;IGV6;4K<
M^4F#.MOUF/6O0^9'+9.=#7'*6T#O"X1A@6/7?:S0X-''A5S^&9  _HDA"\[-
M&,/!<!VIBW5M1S-\Q0%10R4\<2)9:Z5$R^LKR>G'9*]5J52!;07#/^G-E[LT
M[LEEOI'[Z]&(H2VGI-7C,GSU-JN;%O9%\4HF,_%-LH&O(-JGE%)5_/A+R,C^
MB@,ZB 2WN6F.2[PK./[Y/(AQV=QIC=*- 3?>_X$3K8%E0,69K3MD&$:^F'W5
MVE47KQ-^ZF4HH.,Y$I<:C@&?Y<QV*>+?7A<%<N)\M0.$^H'UAS>IJ)--:$FB
MT2S>OWS?J'+F%73-B.7J@=/+"P?V^B35.Y;Y#>)6U?&N;S=?\G"].K0(] C?
MY'?@WZ [;Z=_K-L1\,"-CUVIL#F2/7-@:I@[0;EFA2@N8BO >?L6P(1WP#EO
M3 ,=URD[?-%>L\I^Z$K2&WHP)<[I[>B[2X2NDC4\Y>^.,'"Q 7=XKGL_V5SB
MI>N'XX7N1N8><UF*=NE-_];J ]=[A9)Z4)4R^)E_MEEG"Q>3+E% &=) AT-?
M1FEVVYZ?D@UPI73#D&D,\>XHC#I<YDG#_G[$G5.8W"+LP"<0L=;YADNEV4[Z
M,3C]7JW 5K-&)"4+3(IY5&'3U1-)V,69=]9VG>G2> L@QWEW"65;FPU@Q!J+
MU* EX[YN 6]DIATKRU:J_AR(N+AV>XI.'!**5#86]@SZKI'CIC'=Z,!6M"$%
M3MHT<2#W,88=ZALHBMGN3-)7.3REM:W+>(8D$16;__PQ^X6VF_06?VX^T#@O
M2H).0NY<[O<2]W%%+:FK+L\4M4]=&A\1P)^+#A]$FH($ONVDBU0C?Q0JE\ZL
M.JJPRL,KM4*O_6U'2/8B%3M^-@3YV 7&(D/PBE_-<5G]&TWQJ$Z]36!,XW*8
MF^S\3GPCRZ&,&Q'N]=&B8"OT07[F3XT'\2.V-M=7ZGB+6!2XQY ) <5T-F6@
M89#^+)*(-KE(N2(GF\W_D*Z53.L:+^NAGJ7JS<\0&1,QMJO<RC](D2GPM=4E
MF:=I=O"N'R,LKB1(40^7S9RJE\4'B9^\CV).$)JU.AW]C/-=:$"'?82>G$O(
M]H9NZD,6=C/B +2$\+8A.<*L/ALM%H[)'L@*J&Q._!O(  UB$G-!M[E?OIFK
MK.29JS"'_><S\VJU_MESI\%OWD9E83*!8@C'F2Z:/1O"V!?68KW*UF76Z\Y-
MQ_EML6JXH*_F.I=Y43.D6^TZ"0/Q4T6*_]WU:>0M@.STZUBL7J1#JA, Y$);
M)MD#D(ZP5^0C#H#F86I$?CTEEHK>#H\V07./Y[[O8>++!YS,=/%@D(?^5_+P
M(H36&@LN4[85\8@IV_]]W>+D;US,N'ETM<QGO)#SMLCLJJY;LN\6GX@_P2NB
M$&W]ZWJP_:K> '3CRBTZ8[QL=7?2ST_V)E8L#8KR?P@.H-_/R*"[!>1/EX[>
M1+)-O':3S*!(507Z:&-))C=]Z49,":YVW@(^)7S[A6$=UMK+Q_Z:I4E$K8TT
M7<;JM.O&+?7 [:E;A<7<7QYK>8SP\24FB-X"H+> 8%]+E;GT-44:M_PUI_3S
M2Z?%CJRJ\#/"\V;FRX^JL+E_,K.CG\6-HCHVM[:D*9LUKXM! %SDBR>@9"R/
MJS=% !<-XR "EC4U?4-7:4*A[5NI_42K#9*BJB=R]&ZE?\?%B'21#TW5^FZ9
M..(I)2L)(DY(9!G;[QG9R\U!N9-U47_6CGWOG%=G=D@E4)1>).*!$$,6.6XU
MA@N\\VCL(>CE%N<&^/*1L))TE%M>UP0Y5()[0?)8F_A-OZ,23$1J*:NR+-6G
M^C6G)U.?&6S,UZP4->$-_JUS:@(3(6_==Z <;"@\;!/(CM>_V\I^>!-<!I9\
MUN"'LLEFT.+)(!=?=O\'D;<Z!PVGZ18-\=8_R1]:'*3Q282R5*N:TP-D;P&O
M-?R$#NY= 4=15_NX1E&-,P1FPM*GDJINM=_Y+$=L;V5%]N,WQ0)XX"SC@%L-
M^#-Y,/L7&)[N^A-"&-._(10+(MA#&N,UW+BL<&B::!O9F*FE_J% WD2TRN
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MH7CG9(/H=1*XM%N/9PUSYZ35?TCSV1L8CEIV']9C,P8_E/2)Q]VM@9L0E5M
MB R8'6&0@?H;B7[$T(OL(D*>[OQ D)%&G=H1]@6X7CZ<*N",?9@%7GT:584#
M?^TF KM86YVE8ZLC*VZ8$>!9U\ '>_K^^;CEH0@LU?G'TTZQ06\JF]V&C/AW
MMP#UU(G:^L_#GRS!LG,/60!%F.$SVA\(/NRSX4WY 2"7$Y"A0^/_<<B5SS"
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M[B7'*.MBM3:B_M?$SZ/F!.6) ;9=;\CR\% 65Q$ZD1@7MG&6Z(S50]V1T"V
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MME.\ .0L6'0 BRC5P'H"9Q9&.4VJ5QG3E4D/5^]16MAP+WAXS]'&?Y_GE7N
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MX_O/M#$"(TWMHJS2V("5-)!^&)([Y&S6V5IT!?(6E>F6H@<%]'3^*,(U'MG
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MT_E-T.QD_OO0D[ZX7@G^L4ZBZ;WA(S4:T E*]8*"((S+6[-;A,"QO*\LH()
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MH]NM)4-7(## OC+()X3;+ZI6S!MY"GB4 ]WL[EY<2*]A?R7LBD$P=:FC;KX
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MTGLKJ/39IM,:P$^GC_B72K;%'1&LNL) RI&%PM.T']H;]A?PO>ZIJ/ACXM?
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M\444B"(?M:_LC1O"T7[2_P -61]S+'+X@EG.\YRWSH0!@?+D\<C@U+_PUO\
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M111BJ2B[1E)*,5+IJWWT^X#_V5!+ P04    " #.3'A4,PZ_9@?W 0#S]P$
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M+0I,/T.D[!?\DW>KEU\$EVKT%FD5ECT=:!8B/9-VTM??LNH^%\.A921DM+J
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MK#?8A+#$B4O&&0=*VR:(*6<I?![L?V(\-WV@\R[1B[Z7)F,YWXQ1*FQE.Y*
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MT*684I_\A05V3U:HLXY(A@JLR4E/I8);%,.IF\'H<H"D\\>*BPJ%9AQM47:
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M.N9RRA36BT6F.&H^>G)Y0!DCL1 42^(0V28>X+G#UCB@=D10QL<8^YX_<'_
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MJFE/Q"?O'BJ8G5DTP:JG'E$SXQG$QS).EB9N7*K9O<)"\"=6::N!!!8;-BB
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M5ILW;,]M?=AV)1FMU>^V=U3F%3CW >^5_L,8;' R[F:O\5!<,62KICU2VL*
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M*XNE&ZA.45?[-KZV5KV>FKT/J</P11HOFJU?:1TM&35EL^ENS\_D?B3\!?\
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M8)2T0XW39S*-N'Z>M?Z!_@GP-)X?\!Z)X:TZVCTJ^-E8SW,:1J8YPEM"TL7
M41B0JRXY"9'I72Z\J+C44Y)QM*][--=M7?1+7=[^KJ0IP5XQC%KFLU:^WG_D
M?YR?[3/[(7Q#_9EUC5]0ET35+KPI;NEE)=);EDB4SO)+*JJK'<B*3D$ +G/
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M7\4BZ49IMKW;1=VVM+O5K7SZ>MQLNGVJ30PQW,GF>6,HP*C=D\ LH!YZ '/
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MMF.Z7S9052=U'\)9@5SMR1BL;P[%9:CI=C)=V:>8EE]H+J,,"H)\L@H"S \
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M]^+2U<4[]+:-];?U\C^3KQ]X*\2>-/B:'U@SW-]XSF@\16T:Q.)Y3>7B2M/
MAPSP_:&*[E&TC+ [>:_ME_83_94\,?#S]G+P9K&N1VXNX_#0UBX-PB0S"00J
MY5O.*\H<@;<Y//I7X^3?LYZ=\0_^"CG@'X-^ M)BFTOX>Z-HL-[J,< :.QT*
MT1;JXAN'4 #_ $E6B.\Y SD8K^B3]NCXE>$OV6?V7_$.HPQM)>7WAK_A!?!]
ME$F96\1WL$EI:R10*NZ2!IRA\R,$  <YKVZ,9U(X>5-V5-^]/I'371ZZWMHG
MN8.K&F]US6=EKV?Z?>?S;?LJ_!"+]HW_ (+%>*-=%K=OX1\ ZG=WJW8B'V7[
M;+<[;16EX7:9(RH<?*F/WA48K^U^+0HY[BU1 DHL'BLI=J,2@0+& >#NRJ_,
M5R!WQ7XY?\$2/V+?$WP>^%VO_&CXO6=V?'7Q::YUR6^N65A9V>JLUU:(C2'S
M MM<>7A5*L ^T8ZU^\FE6<*6KW2P/'(6E%WM7RV-Z5,  # Y#3,90XR"G YY
MK3$1J>W<Y5/:1E%*+U2NG?9^77\3QL7BFIQE?2+=^OW[Z_UZ^5:E864<U]!=
M6L M'L[F'S6&U9%,3*\9S@J9 =HR "> 3P3_ !J:I\,F^!W_  7+\"3:1!-9
MZ;XBN_/MYHT)MY;?4Y3+*"\9((C9N%."2Y.TU_:-JQA19+J?)MQ*MNWFJ)E+
MYV2ED R <YWG&W!-?S1?M*^#+KQ/_P %=?V?H=%LWFN-#M8]8U%[%D83VL5Y
M!&JR*,D*B!I,'.U=P89((FFU&:;=EK?^D>Q@:OM:/->[5WV]VRL_3?STVV/Z
M.]83RDCVQ6T]Q(!<SNCH6$4F I9=P=2.00>>^,9KB]6T=7L;V&?3K'4M)U.&
M6TUFRU22&:TFM9&9I (9ESM",RA5# #C.*]F\1:%%;W3FUDC0O-;6]XT,9E+
M0&UWO(JA28]K9#(V3N7/2O,-9TJ9'T^+<SVHD,D\LCJ^8\[@61<"+,?/SY"]
M"  :^DR?,\9@\7"I1J-TK12]'TW375+LCQ\SPRQCFK72<K>:2>U[=5^I_%E_
MP6V_X)M67[/7B.P_:E^ MF?^%2^/_$?E_$=+(M+%X9\2RPM<VB&T@0,EG-+D
M&81F. 8#NIR*_GIE>>3;>O(/,<&Y(0$C=,Q^9F'!5D5"ISC!Y]O]0/X]_";P
MI\:O@S\7?A)XCM=/U7PU\0?#&N11Z7%!&S6NK):,VEW5C"5)^UQ/'B6>$KUW
MJ H-?YF7Q.\$:C\*_B+X\^'6H$&_\+>)-1\/&%?G"6^FW$B6KQMDY4P,%8\_
M.A!/! _K/PSXCJ9C1]A4=IT+J$7??E:=G:RT\_F?B/%67>QKN27O+9*VMW;>
M_:_;16.$/VB9A,)&=F7RRF3Q&>&))PN#]><"M!!#% 4V*&"D#E<D@8'3([=,
MGCBLO=<6C@$>6MP N&!RQ[@<X'IT/7-7;<GH\2/C(/7(QD=3D$\9SP,_05^S
M4)U*E7V;7O)*27D]/ZU/AZR:BTUKV]%UM_6IK6D8)>4GI$&?@'$84ASCVXX
M)YX!K^L;_@URTR.Y^)GQL\131[K;2]*>"4I=W$63<0,D(:+H_P RX! ;;N.<
M#FOY/K-<R70 RODDJO0D;>5'OCKVQDC/0_U_?\&N%JD6E_M(:DC[7C>WA?\
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M6XUP*L#KN D^8$=,R(W4<C&>^,]C5.YCT74K:VNHV%V\0G62 ;2J;9?E#+R
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M_P!Y=G681.9B2QQEB#EOF Y.<'CVXYZ56@.UB1LC"JVYR.N1@*23C)/W??\
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M<YXGV;Y92<O)-?UN>I2PRDN;DLEO>_YIV#Q'J)T#PM_PD\EE'8W$D<EG:.X
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MW+*ZAH"KQ)L_?@;8R,G,9.1WZ\?QORM<$W"W+1?-&AA: HDUUD%DB:4 X92
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M5UM-(M;&35&9&O()8T\N&*5W1902"X4';@<$'./48KTL/%0;A%6C&Z2\M?\
M,Y*_M*C>B2OIH[Z;=?4ZRTOOM3>7)>1$+\J8&6+-PN,<\G!/.,59N;E+2"V2
MZ7[1)-=&,2D'Y<<<'!)Y^7VZ\#D^;Z#K.DW$^^)F(A=&F)5D\LJP)&2 ,G&.
M1R>![]OKE^D$>EA )5DN#<0AE(5T<9#%SD)C@9(KU)S;IQA96I[=_G]_0XXR
M<(N*V=[OK\ON-R:SBVQ3*^4>;S48#); "F-AC< NW/( ]?6L?5(9Y+^2X$3"
M,QCGC()QVSR!D8Q_*HEU2ZC $D1:,>8R@<*"I#?*<<C#@;L8X.1G($_VFXG2
M6=O,$6%1F RJD#.1CJ!GVQ[XR,)24E9QCUUMKKYBIJ$)RG*4O>5M7I>]]-/Z
M1S]C:RSQ78N+ATACN"H98X@^X-GY>P /!/'!..2*HZK9 ((;42Q2S,(DU)68
M3)N^7;CH@(/)'  Y)'%=.R"*)E12RN&=F7 ^=1NSC/\ $<#&>/TK(M)KJ_@G
MMO(+,?,6,84,IQA9-Q/1.I'<=P>:\VM0I\T?=U3YU)?%?U2VTO8[*%:E&H]F
MI1Y7?6RUVVU/'/$?ARP\6>&O&O@/7--TK6])\3>'=6\/W>FZO;17%M=/<VD\
M46I!9!\]VKR-L<9(,:GOFO\ +8_;E_9SU;]E3]KGXL_"(EH=#TOQ'-JNEI<Q
M*LCZ3J]W/.BHH'*QJVU0N< #BO\ 4^\3:5)<ZE!F>>TNK: ?9I8/G6>>)RTG
MF%77RPN3DMNX./>OX>?^#GCX%/X;_:>^&'QGL5C6#QYX=T_2=3N8V!2:[LHM
MK;]@VR,S$G/&#WYK]\\&\]K4,>L$JGN/E33<FXZK2/O62UVMY'Y9XDY=2JX.
MI6HQ:FI-Z)<MFKMM6NO70_FDOK194=X[ABJ[#L9%(;?ADX0Y/RXZ [>0V!FL
MR))U,C/&$4J4*J,<?WN.N<].H[U?=/.BA,+,/(,UM<MG!62-R8V.> &08'<Y
MSFLV226-MBN"3P=\@(//08 []?P'%?W)@]<-";UE/5MZ]$].U_G]Y_.G(K-:
M[-_<F^WEU5_0T()+>UCBG9!(\89/+?Y=WF#&>1@!<]1@'M4:;1\\,X8J"@ZK
ME6!QC..V1@YR..V2L]JSVJ-.40GL'4?+@?-@>I.#S[X!IL5GY<1(!(."ISP1
MU!Z'.>#P>>QK:CAZ<\1"4N:_O6V_EOM;Y$45STZDWO&5K+:REWZ^O4]5_9F1
M5_:C_9M^^/\ B\'A3[J%FQ_:< &%(YSSGICTR*_VI/"$<K^$?"3*BK$/#&CA
MY&>1)(_^);;\JBD EA@G.<>W K_%=_9F$W_#4/[-SB8(R_%[PF3\A)7&J0\9
M+8.3U...I%?[5?@@X\'^%9'E+@^&=()4CAP--MCP/QQCGIZ&OY_\1H16:22T
M]YJW7=O_ (>^GS/U3AEWP%/RFU^$=_O-5U.V"6U6VFD14@>:=RN+9V;SMF"-
MK* !S\QW8YK\N/\ @M8(X_\ @F/^UE)<,1!!\/+Z17MAYK!%\H(9-P(.6(W>
MW(K]2F<RQ!8+4/O94:,CR!&"3F3+!L@ #H/FZ9Q@'\KO^"V'FM_P2[_:WBE5
M;6,_#K4HI0KART$<L10AL+RQ5,\=%P,9 'P6"7)C\+-;ITTKO2W,OGL]-NB/
M>Q\$\.XN_OIM[:?Y:K=[>>Y_CVVTTDD 8_NQ-M8A3P/WDY&"/0X'KVZYK!UF
M^%NNU/D:3*L_<@#C P.A)/7/' ZFMFQD22RA977:=J[BP49\RX+=3QM&3WR/
MKQSNJ1V]PMS+)O9+4;E90=K G&0P]>, 9(YR>>/W6OC8T,J<E+:&\GW:6R:U
MU/C,%AN;'3BXNRD]K;V;6Z]+[_YY%C:W.HRV^GV[2W%[J][!86\1C5U+3R*J
M!21YF>2#_"!@\5_8A_P3U^!</PW^!'@BRO(VAU34@U]J=J@VNLGE1'D#E@06
M8[<G ['I_+Y^R)\+]0^*G[0O@/0+2W>YL],U*UU2\P,*(XY%D4XZ,6VXVY[9
MST%?W)_"WPY;Z'I&@V!L+I#$%(E\@[H4AB$3Q\$ K(1G(V@*>F<5_,?&^/E4
MK5W"I)OFFVG)M)-/97OO]Q^G992<(1NK)6M96U2U^2\DCL+33O,M884@6(3R
MR9?+@A8<^4<-Q\T8'7D9P<$XKI]/2WMA']H#QB%C(C*>79>Q Y)QCMT)K8U&
MV,,=JL2#9\[LQ&P*-K=SQT [\],"J!N+9HX4A7SW\U0^%) !QD C()/([<#I
M7Y[E]"G"$JKBISJMMN=I)72^'MKJKM_,^CJ/FC&+VY5Y/KU/0K*Z2X6VDA#2
M).JO(3)(K DX;" YY !&1SGGFNWM+]H@T0C 11L0ECG&"H)R=Q..O<X^@'#Z
M;-9VRG(*RA0(U$9P@P-HQR200<G(ZC@5KP3EXGD9MI*DC(P6)'U[YZ#..,GO
M7;[./FO2VGIH8>RBEMLO+\=#I+1Y+V21KB4Q1VK *,9$P+!0><@8SN^;D<<D
M]+7C3PV;K28=:M5>4V8CD#811OAP54D8X&,Y8 8/'2I-*CBGBMUVX5BJ7.".
MK'"\\8^;'KCTX->PII236Y\-B%VAU&PD$+#[K3M&=@>3!\OYCP<G)SZ5O0I3
ME'F2O26DF]7IM9^MMT<4ZO)44791=[M+5=M?7R'^ -0F?1].OX[:2XO;E%26
M*(Y1"P17=G!"YP,'!. .!D\^HWVCQBXL[T>8;F/#/A4<Q#()C)!R=O*D]3@G
M->5?"E+?PW=7NA:ROD26I\E#//A2Y8X6'Y0'.,8QD\CUQ7T]HMM8R13&0[#(
MY\EIU959&)VX9C\V2?EYY^E?08.C"4;NZLD]&ONV(JUJ?(_>;^:_R1+I>H6]
MPGV<1&$M"%>4*WS @@Y^7/(/.>,$]*Q-96?[/+?P[9XM/'EA7PNY<@?*6QM(
MY)Q].>A]&E%O9VN([&*.4P;!*RA488P63(Y^7..>.#SBO,=5M)+E)X+2?=8R
MQAKTK)\L1W9+''H1R.,@]A7=6TIV[*WX'D1DI5+QU2=OQO\ J?D%_P %--5G
MB^$OBF^2ZGLD:WD;R]\87/EG+*6.22#T4'IZ]/XT]*,_BKQUJNJ2/$Z^&VCN
MQ*QD#W49Y(<<#<,8(^[R,#'3^OW_ (*L:9+J'PTGTK3W"V_DM+,YF&[RT)BD
MW* ,KMP0.,C(%?R8>!;&._\ $?BFUTTPR6\%K^_:.(H93;R,NUWW'<20<G'.
M. 2:\2I5A0O)-\TD[I]]4[;6W?<^BR^*G-)W2OY=$O71ZF_X$\&IXL\4OJ;H
MWER7+/#"%WX7+ @J,D8/3CH<CIFOL[5?@HNIV%E8S:=?VB,3)YUC"LDEQNC"
MQH^02HW8<YP.#G'%:O[+'PSM/$7B6SV0MM2*-I$1"L*R&3#*23CVS^'K7ZX:
M!\.+":2ZMH--^T26,@B+3'8$\M>D;]&)(.3CY0!@'->!B:T5*Z<WO9+=Z>:_
M+I]Q])*K3C3<5:VFO7='XS^+_ D.C?#V[\+^(-):22VLH]FKFUB;4IK=2T0D
M94#2%D9T0 C<0"^-HR/BKX&> [OP5^T'IWAV[F.F0W=['-!<#'FS23$2Z8(V
MSA996:'SFCR-S$ YQ7](GC7X#6&K6=]=S:?NEC@DN0)'#QM$IQ):AR.'?(>/
MJ/E*A23FO@SQ_P#L3'XBR0ZAX-U62Q^)OAZ:XU#PU;2XL6O#AI(XKF9@OEK:
M85;8NS@E5(9<Y'E5,76J3Y(1DK/7F3OKHMK:EQ5-PO'WG+>]K);Z>?0_=K]G
M+XLZ'=^%=.\+:U8-;>.X+:TTZYMKJ0;-3L(451<;I.'*A6=5!)0C+ #./OF[
MM[FW\+VR#3KHHZ(Z-&,IY/'^CJ%SA ."<8 [Y(K^?#]AO7-&^(-]'\./CGXP
M?P%\8_ >H1Z+97%T6MAK10^6@2]FV171D((+J\H^;KS7]&'@;PGXMT&VTZQG
MUM?$^F60CMS-$JS)M4;B69,@*8V7#%GW8.  ,5[^6T\34M"R<7)MNS<KNUU>
M^ENAYF-PDIIRIRA&-M5+>^MVMM#Y/\:?"#7O&MQ/JO@J>73M8M[-[,6S!<!;
MDD.I?ACD$D\[1QBM']G[]CB7P?XDN?&7C:WM9]<-S;QQK-$KP2,R@^9)O+ %
MW.YF'8Y[&OT$T718FO-2:VTE;4%K-C=)B,EGD,;E2"#A>#@*1U%=[]DL[S[;
M:0!+EK6*Q>[:XD92OGHT+/"2,,T91I$'(8[5R,9KZ-Y=S1BII^ZE>UMUJ_ZL
MOD<-/$/#P]G[KE"+@WW=GJM=M3D-&\'6=CJ%I>S6RB_LB\B;54VYBV_)%&A)
M4,G5$/S8 ('0UV4\LD3W8>65KG$]TUS(O'E1*ADL4VCC*LH8="#QG!-36VGW
M,S^9)))Y<92X0K\SRSPKY,:8!R!+&.GJ=QR*ADC,EOL#M)<1SL]S;,I%P IS
M> *<DG8T!50/F(P.QKHHPA&44HRULKR1Y\JTY24G:ZO96=M5;57"T:UFAN)&
M\RT%S:QR^1$H98A'D* ><G<<]>^>1D5LVEQ(D$,-L(;U7VHXN4VNCC ?9L&2
M4.2KGY20#TJW:V%D;;#LB22PH8XYF\F4Q[6PA1LD.<@E2<@C!R34-O;"T6*0
MR)'(B30N"2RL=I08. !(Y& G56.">]=&+5.A**Z-7UWO9/\ 45**<Y2=[VOI
MZG/M;&29)9E+1X&XLQ18U^T;2 PR2<$8 SNX(&,UK):Z?<-'&7=6G&H0RW+
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M9-K,3P:O<1EC<@6VR8!/(,;Y&XG&, D< ]#QS4FH:@J64!6&&*=;=461L$G
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MD9YS71%GT6+4\R3:E<M@W5L886 2/=@QD@G(!Y;OP.H%>1:UH::+<1W_ (2
MMKV2YC66,9,LRASED"C:-P8@-R1C.<5ZEITLD<'FW&F7K:M+;2I,LTJM'FX7
M(9@QVYC 8QCG' 7OCV8**2:23>[TN_Q.:>(IPE*+4?=T>W;U\_4\GT^Z?6H=
M5.E1SVL:7R231W BBD94E1F4HP4D8!R 0,=^#7L]KK5EKT%CIYMX$-G&2TS<
M)E(\>6<_*RE@<*#UP>U?/.K6.J:?>7EU+,M[#+*96LK2)H9B5&^W4RQ@%@R
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M:'4)"C'S!Y=JI9E5R00K,3\W &.AYYK^?<3B9TZEJ=VI1YI6=M6[=6NB]3]
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MXR3T()& ,C/%<^-QJ@VI2L_OOZ6_X<Y</"A37OR:M=;-Z6?D=M#=>8@RB#:
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MOV78?ES^^91NFW\AG'' YXQSQ7 P^(KFTW,TYN4.Y#'(/EC 8DO&#D+A,J%
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M:XO2KF:!4C:;:DDF[+(IPV1G)Z\^G'?&16CK=Q++;F\%T#$7\A(_.MU_?%#
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MA=1:AHZ)?*ZB'^SKEU18X%B& BP!BEP2!B4$28;BOB,SI>SE)/23F[0ZVO\
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MDN71NWGV/4],FN(X(;JR_?6[D;R$)0*< X)'.,9/3CGG(->@B&XNM)U2UC,
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M2QS'2XD6.&)A+]NW*,[0?OD C(]/4&M;4)HWLXD.AQKJ>LRB9Y1&OG1^7_K
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MRL6R(UQAH0CG)8FODCP5K$:36JW4+2H]NIR@SN*_>//7YL!CTZ@GM7T_X<U
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M;^S)R[HMQ$&EACX1F ^\0I W-QN^G/K7O%A%8R[3&9DWQAF"%@<LNYL8)/T
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MW5S#.(8?]((3]W&57$13J8DZ$=2.>M?->QOBE+FTE-:6?1W[_P!=#] RZ?\
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M5\M]B=Y%3EXP <+(. &/89/;D<UJ>();:X\1ZW.\4NT,2=P   (.[J>%ZGU
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MBI1E=6C9:IIW5[;/TO;R/T,U'6I=/M)K,Q#6)X;-8%F2$*&8CY5!!R57@%\
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MKSUJF9+: F282&-H@CA%&[>N"QP6 P,\'J?3M4WE_:)=D =(@ PWC!))(/'
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M24?: %^412CY@PY).,;17@/_  35^%)U.7Q)X[O+266ROI[2PM84C(\I[:5
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M4RX2",>C9*C!( ;@AO0^N3CZ0\-[5L+9G9PXN6C,3##%U< C!)!!/&<G(ZX
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MO;K_ $Y"+A+=UBNU8E@FX.BLAP  F QYQSCD<]=%;I/=Q231[V VCD@;>0,
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M2*,K%/;^;D?N1<(BQX&[]Z">5Q@ CDU]X:2;&(RILLWDMSNFF<2"XBV\MC(
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M'1V@L8([='MXIU%P=L&Y<@DOL_A 8C=M4#J<#!Q7KVF1F]N;123(I 3)&PL
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MQ^@KAIX%XF7-?DC9WB_=6B;6CLEK9+=WV._"5Y4G&HVY.-M')MMNRVO=[_\
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M.(HQ2M&4VDDM[M75N^WG]Y9ANH1:7-O>W<YO"@-G<VD1NB8R,BQ>0,@1,?(
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MS:LKI^K7=7/4RBI&->K%O5O33O:VO]:'S!^R'XSM)?A'X+CNT,MQ8QK#$ R
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M"6=8A*5+9S@;A@8.>1]*]9T]6BD::6,R?9I8/,CD;>%@9?.9X0#@2Q%<1YP
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MEVX4^2#.6SAF]@",CMD9./PJM8);IJ%K))LMC)&56602/;QG^](J*S$\_*.
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M2QP'C0@9<!N3C@ X)XS]H:/=QKHDMGLMP+2%I'MLA9)R!D*J@A@I) '?<1D
M#-?(7A%ETG4)?#20K:7<TNZ&.%ML<D3# #7(PL4B\$'[N1M(R<5UVJ6^N^%[
M&YU$W]X9KB5K6SF8M-Y$K'<LDK#Y9451@ C.[!/ Y_-%.5.C%)VG&IR3;5UL
MGI?\U]Q]=.+Q+G..L')VW[;75SP7]JSQE'>:-KVKS>7I$NF:?=V]I9S-^]E
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MKY4\H8[R3AE.,AB4R<#(P,UX2MQK>FPJ\EF+6YB=[PR3W/VL7BRD!XGMP?\
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MW:W%N26MD:S*84,2.-_!RH/*[<'&,U_1.'WI^K>W]UH_&L9'ZO5?-M*,6O\
M$Y7?]?\  .O_ &<;?/[3G[-0Q"A'Q<\))D0J&)_M.#[Q'!'!R.IK_:8\#1D>
M#_"+97 \,Z&IPH7&-/MN<]P<' ]>>]?XM7[.DC']J7]FT, J_P#"W/"4B,1D
M$G5(>O?&.A&.3C/K_M*^#8UE\%>%8R_RMX7T0[ER""=-M_F'7@9((.3TK^:_
M%)\N;-K?VC3TZ-O3[GI^!^N<&S4LONMM?/2Z6ANW[JEM</*CR0#:S>2[>9C=
M@D  <+@'[V3GD8'/Y2_\%L1#)_P2Z_:N\F5P)?AI>I;[E8DIOBR&R"Q(12=Q
M/4#T%?JNAEA>"!$+P/O,DQ(89 X7:>O !)/J?3G\I_\ @MSY+_\ !+K]KC=O
M0_\ "N=0$,D1*^4RR1_/&"=H!YW*1C!(QG%?GN"DYXZC0IO]ZZM/D=M'>45J
MKOY^G=GT=:$94TVMU)[OJWK^3\C_ !V[" '1;.YRS")KV-8MIQ(WFW*K,1C!
M*(3S][.,#(S6/>*L90X.UK=G(SSO&>G., @$^U=3I5P[:%;C$#"*>[MP"IPZ
MM \Y=@"") TK %<#"KQG.>>UB-DBMRJAB8N=I&0')X.3GOQ^O2OV_'Y=4_L^
M/,M%!7:5GI;JON[]-#Y2,Y3QLX/:,G97Z-==-[Z^I0\.7S:7XD\,WS%XH5U6
MTDDDAD\II#;W"2&*1UQOB(VJ48@<GL17];?P$UR[\2>$=&NY5#W#M#):VT$C
M)%_9K6R$)M''EH,%1R!MQG&*_D(N))$-N?+S!:7&_)D17#$IE@.@/(YP>1SP
M#7].O[%OBF]USX1^$M:LV<RVVE2VLQ#[U#P+&J)E26^:,$-D\?PCI7X/Q+"5
M&I473F:5U\]]S]!R=MTW'5I035GM[S\_3^D?M-\#];G>*"WB2-"\SQ7#RS,2
M(1F-D P1P,E,D '!QD5]BZ'!9S-<>9!YBV[[H<X(D1><9!/S$C&3@=.?3X$^
M$%^K&P73$CMY##/+,\RN[AIE5H%VJP5O,43=<G**1_$*_0#PO)+-INR.<>;;
MVRW%WYL2Q B,_,J\ D,,A1DMR#DUQY4I<L*LK<B7+>VMUK9/IJ]?(ZL=LM_A
MZN_5GCWQ2U.XBTC7;:"SBMVU?3KZU/FNH$%HEM,[2LI.U9-P7:V[D9R1QC^#
MS]H*Z.H?M#?$X>)I%C,>O7FR:SA CC:-7B63S 2/*D3@8^8@\@9X_N-_:M\;
M:/X'^'VKW5[+;(WB* :?I3 $W45Q=9A<Q8.1G?AL# !&.Y/\?7_!1'X-:A\)
M->\.^+Q!_P 2?XC 7.H31(%E>5D12WG.A5/,1BY!R0Y^7 KT*]7GQ4(?\NI>
M]9;]]]UL^G?N>0H5%/VL&E))V=DU9IK57]=3=_8T_;Q^(7[-&NZ5IOB&!_%7
MP_N]6@M8YX+R6>#3M,+^61);[@(S% W E*_, 5.:_K(^ ?[1?PN^-OA^SUOX
M;^,K#4FE8W5[HTMPA6QEA!D\S[/*PWF$L552>J'''7^".SO9;1XXK6%8;!(@
M(;96)@N$88WW W$2SX.YVR I&5 (%>S?#7XF>/?ACJD&M?#[Q%J?A>\CF$FV
MPO)8K,R'++YMNK[9(V(8,K<8.>_&F+RVCC(RE1IZI)IWOU5WMZIG'#,*F%J1
MA6FN6[NK+71^>^S/]!?1-=G>)[BZM[/4DG^;^TA<R-<Q@,?GCM8B-@3&%C4'
M![G->AZ9=VMT$>%?M E&[=,?*=OE!+,LA#(6P?E.6!P" :_F)_9+_P""TUEX
M;.B>#?V@?#T[Q7<5MI\GCFVMUAMH)YYTMO/<[FRD8_>$]V;-?T(_!GX]?!_X
MQ:7;:G\//&^@>+8;>*.:YM8KJWCU"5)(Q(-J^8IW$9WDHQ!).!V^.QF78FE*
M473YXIOE459IZZMK?Y^OD>U1S'#54DOB?][]#W*[U=K4)!<M'#;,-R(3F(E
M6'(YW*1D =_SJ73I8=6>.0DKMW&,$E5< <DJ3G;@#:<<G/;%<9XJGMY[98I;
M>738'8SVUY(7:  D-L5PF,Q#J6.UCT'(S%I-S=L+.2QNDU1E MEDMVV;ER,F
M1">&4$8( R1["O+C&I"ZJ0<)7=D][:6?Z';;9]&KKT/6V6XE6**W>2-BV!)"
MV'4>XS@#T['))P:V=/M+S$",UU/);RW9$DJ.-Q&[=O)^\#R5*Y&<$8&*YNS#
MB:*UMKLM>!=\T+C]Y'P,*K*,%NN<@@''!KM=(N+^: 3SR7 AL)GA90X$C.&*
ML2,8*9&>G(X)ZU1C*;3:NK*YK6[.+)!*%6&:/<Y;*R !MJX YR7QSTQ@^M,2
MS>V@,4$9:3?YZ, 2S+(1\K;@"2 ,#&>_UJ\VG7DSP3N4VJA,2<@&)VR#(HPN
M<].!COSTV(FGBO8;F2-9%CC6/R$X3OSCEB21CK^0Q6V'BY5H)6N[VOKT?<Q5
M>"=UH^]_^#V9#;7TCQI"]@P8 !FP%;<1@DX/0?YQ6E';&X 86A#*P 8C^('(
M;//&>?UZUK#3[J9H[J!( LLJ@Q/*JL@R/NKUS@G!/<=.M>BZ7IUH)$LY89EE
MVJV^2/=#)@?=611CY\8#' ^8,1BO6CAJLKV4=/[J[^NF_P#5C"M.,VFKWZZM
MK;L]C@;?19I6621]H&0"$#KO)PGRX&3DC!_A/M6\UG)$B1H\\1$,KR%HH$:9
MP% "LQ9N">-HR,_-U%=CJO\ PC]B);6:\M;*Y:(-;VTK9+2XRNZ0*8R!D$]R
M!@')!KD;25)2D$L::G-\Z!X+9VA!D*_*D@!VMA0.2!USGI732H5:?_+IR=]T
MM.FEE=/Y_H<TJD8NS]3I-$5+*X DM[J F&,.;O#B5\'+PD#.U\C;D# ';OW=
MG)$T,AD5IAYQ*JQP5&_*X .,#C /7 '3FN-5;2%&_MP#22B"2!KZ[2V@6)5^
M9G>1N$ &1@@@ \$ 8\W\9?M-_LZ_"JV2[\<_&?P!H-FD_P!GD^T^(+)Y0X0X
M4*DA/F%AMW,.O)&3S]'A,-.K3AS12;@M-K:/1Z[_ (_KS2KT^9J^M[=-7\WW
M\CZ?LIX;8;_-$?F';LD)/RO\I#*N21USC.!US6S9M;RSM>H3'+;;4^T623,P
M7YL;65=T?3# ###C/&*_";XY?\%Z/V&OA+/=V&CZ]J'Q$O[7S5C;PT@N;-9X
M<@>?<1AE6 M]YP-H Y-?D+\8?^#FGXKZL[Z7\"_AM;Z1:332K+J6I7%M<^7
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M?MGXR_X*>C]H;]M6QU&QL5T'P+J5O!8:5'<*89+FY679;EG(#9R05"L2>C
MFOZ+O@WK-O=:0DJ7YD\Z"&X\L3-CY@0R [2<J<$]!MQSGK_G[Z1>:E%XQ\*:
MWX<TV[U;7O#NJVVMW-K8Q23'2]/AG0SR7#P!@\ C#GY&!7'+#)K^W;]B7Q*O
MC;X8Z)XI^9+JYTRW@&G2EA/+YBM(UX QR$2$))(IPWS#'%?-8S")U:=2":DY
M1@]7:R;MI:U]7=GU^6XF7+:#5IIJ5U=[*Z3?K]Y^O'A2:&]LH+01D':5SNW
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M]X(^,?PU^)GAA=7\"_$+P=XEM6AA<VVG:K!<ZO,+D;DNYK8L9$AXV[=QQDG
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MHV7JT0+<]006KZC">&&BG*7*FKJZM;5[W5NB_K?Q/];KR?+)/6UHSOVOL_\
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M+!E(G8!3*%SM"Y&>YXQD5WBZ=9W>H20Z1K$,&EO9P-YKME(V1E(C<<L-[_*
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MW(//?!/4 @'N*_.<QKSKU9SGJWK][_,_4LF@L+[&%/1-I?=;R[=#^6+X"!_
M?B'Q]\(]=>2TU+PYXDN/[(2X/_(1LX[R0!K8MR\3Q2><@X&U"3CC/V=H!:>&
M%E?")=7*]P5;J3@>PZ?3CU^,OC$3:?M_?$V&V/DPB700L2<1QB6(F3RT.5BW
M_P 7EA<C(Z$BOL[PV K7J*,*MQ(R@= 2PR1Z$]Z^8J_&S]04W4P*;W6GW)/[
MCVO1KHQ3Z>"\S;(PV!$&W("=Q4C@!?3[PKV/PI,+R]"F(ET:6^B#\>>MN^P#
M:#Q*I/S;L <>U>+Z9QJ6A@$@-I6J%@"0"51"I(!P2,GGWKVWP> )M.<<./$>
ME6H;G/V>XL9))XL_W)7 9AW(SQ7O<*_\C6G_ (OUA_F?!<248O 5)/K)OYV[
MG\V?_!S#X<F@;]GGQ=-:F>.XNY--N'0 B(AL^6W &%[[>.N.M?S ?:]/*1S6
MJ.FZ2:VR>RKEACD<!CCVZ9S7]:__  <GHA^&_P " 5!"Z[.X!R0'( +#.>2"
M?Y]:_D>MU4Q1H5!0>:X7 P&,A!;ZD<5_HSX._P"YXC_#?[K'\8>(_P#R,8^3
M9K07UYITT%]#,UQY4+VXB4,Q'F_=^0C!!.0,9(-6[I?[0%W>7D9L[NUFM(!'
ML*$;HR3E1TVY^88SDGJ*R& \TQ\A-@?"DK\RG(.5(/!Y'-:%K<336<QED:0O
M"KLSG<S.#@,S'YBW'4G/O7[A2_BT_67_ *2S\QG\/S1WO[-41?\ :K_9I0E0
MZ_%CPSAS]TXUB#IWZ#J1D_K7^T-X19+;P7X5:8IM.@Z+&2Q&"9;"V4 <<]L_
M7ZX_Q>OV<QG]J7]F;W^*_AG/O_Q.+?K7^T7X*CC/@WPHC(K+_P (]I+890PW
M)I]LRGY@>5))'O\ 05_-'BI_R-*G^)W_ / I'ZYP?_N\?^O;:\M4OS-IV#;U
ML_+5[:9(61B H# ,H!Z'@]!EN.!TK\J/^"V[LW_!+[]K/ST99&^'UY%;K"&<
MR3R2QI!$ H8LS2 # !R"%Z]?U4NHT>!=RCFZMY#@;29"2"Q*X). !SQP/2O+
M/B?X9\/^,?!?BWPYXKT>P\0Z!JUUIEEJ6CZO;I?:=>6LES KPS6DX>%E978$
MA V2"&! (_,,NERXVG+^51E_X#*_Z'U]?6%GLTUIYW7Y'^'[I-ZR:'':7.FZ
MK'JJWLPNH3IEX#'Y?FN6 \K(!W[-O52"&KE=66[O7+1V&K?NRQ5?[,NB6.<<
MAHL8P.,9YY(XK_:VC_X)Q?L)(%V_LJ_!G,RNTK'PA9M)(Q<,2TC9D)) .=V>
MHZ$Y9)_P3:_8,*@G]E+X,YW'G_A$K7T'^U7Z34X\QDL+'"0IN,7'ED]-EV2E
M9ZQZV_0YX9304XRLK7;22VWT_KR/\22ZAU"58UETO5X9(FW(JZ;.JL1C#L @
M'S=#QV->^_LMZSJ7AOXX>%M1DMM4@6^<Q7$,>GWD<UQ"73<(DBB+2';D;R<$
MG.>1C_9@3_@FO^P4Y#/^RA\%V(4<MX1M#TQCJW3D\=*LVO\ P3D_85TRZBOM
M/_98^#UG>6Y9[>Z@\*VZ3P,V<F*4/OC!_NH0OM7P>:8RIC'5G4=[ZJZVOZ-]
M#T:;=%QA#9.R^7X]3^)'X2:U:Z]96MU96NJ7,0L[2$NNEZFZ:=;&,"3[8/(.
MV3R\KR#EV !]/LS3=7L9+&2\/]M1VHMTGM2FF:AO1(REJBMM@ W;T:53RH5N
M1G-?U\6_[,?[/VBV9M-)^$?@G3K>1H4DBL]'B@61>%VR%"&<8)^^3USUYK9@
M_9[^"<(,47PR\)I$B;%C&FIL"X+;=I8J1D9Y!Y^IKSWIAX+^XO\ VYG55J^T
M<6[Z14=?)O\ S/\ .,_X*2:@-!^+OPAUE+35]4N7N8H8]2MM/O&CMK!PC!;M
M_*SN)DE# 9()^;BOHGX6>)K&\_L"#3['5M)@MEAU&:\6POQ!>1K())GW",KM
M#N4 .#N/ P1G^\#Q/^R3^S1XMGBN/$OP4\ :U-:[FMGO]$BF,)!CP4!8*"/I
MZ>@I(?V6OV=[7-E;?![P/!:H5B2"'1XHT2)E\PQJ%8%4+J&V@@9%?.8SXO\
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M;0 8 &@8_O<%P/\Q:&CIZ!D8F9A96-G.%E1Q ;0T='2T]'0,#/3T9[/!9_,
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M[8!7;/PYUL1&4@>91&>S/5?; V[\WDH49257'NSXJ>&#+ IS9SU^K^]M8]U
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MOF"KEX>7I*]KI& ]Z9"U&U/H9X=AYCW2=.]_:GT4\VX1=DQ4)&B#I>&M(.K
M U*WA@CC8U,:I-PWNI\;9I#UA\>:32B>1I;IDFM/['5GIR/BN715UYE*7=8.
M'5EX'AK>_%-@SRD?KGX.T. F("M_#KBG)-OX;TA:/\/J+BV%RK?@MG- '^ +
M_YU,&T;7(A?<*USMUS(?5'] H7[X<<P=TO^YI&DQ!M.9$'IX%,^9+\A4JG9F
MVM#?G[XZE\G\F%0/U0-@@OCX77$!)5.;]@N'" \I>:"X>MZ=07NFCDDBD;)$
M?4.S71C2"JU CDBU\)T"A/<=F_G^&D2_K9,K<\2SYXT2V(BD%Y\!^>9]\)7.
M=55TT5*6'CL];8\J:*6:*:T^BB9:0B&<YI\*7@19]D+@\( CQ<#>3U6*(?C]
M48B($]U2]4D4'*;LF$26/+\<29_>]9JF:RMUF-0N??(>#H.H.+1PP20\9M\1
M#<!XM,;8J'P(.0J3%8E82M4T1',@F53[ X.OCN%0<"B\(U1+[Q2($CM!ZG]
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M35]2#[V<\$A?G45^)Q%/4X$8+7^]%*Y*>7]#LC;5DSL'F+_R.Y[S6!NWN]O
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MI(SV"[/7#'<BFXO[4!E<=]P@$AK.V'LM'W<ZK9RJ$!)E[S:+6]\XZT[MF@Z
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M!+_6T;6[+7'O/8I3'W^A:E(PY7<;9VYJ+LLOO,!;UZ.,^VOF(/XC 37]C5P
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M+X_I4_9@YQ(ED'6EE3NIK:6.5/TS@ )T>5_^;WP__<-R;S^_QZHNKNJ3NV?
M"V%O?CQ-W3:[ZI!U5'[4"YNLEW5IFK[%AZ^2*L<5T%V86J,#YX!<+33E]XHU
MYP3![\1EJ98=L:U]2(9Q/;@5"I?Z<4ZB;&6(K!ED'WA+4,B#> Z,?AFZ<5>O
M17ITP54_VYUF;^5.[#>M=UP[GDA>\G11>-')(+S/^_LD",Z+H@N]3.3_,49X
M0[K-U2HSE((A5D_O \Z=#>KK% EMP;93/[S5%SYK,:YX)_%&/6&O6P)%^,T7
M>T3-.%JH=+>RD)?R;B/Z\KM4:!6V85M]J)V)/O34+[9I'Y5MI$F=7\O/??Y
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M=<A^8&/AS)7]?<@GB("F]I /_.66\B@2L)2/]E==2^PHE9$3-9<^^#+[]Y=
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M;B5+M?A1X O;S1BL2GS#I\\4)12AR8&+G#E6(]OZ'?@O^S'\!?V<-&T_P_\
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MR.>M6?M=T I\KSED .U54"/V#$@$=P3CUSS7X]:U_P %&OB3XOO_ .Q?@U\
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M12.,+)*JF4*I.TN "-HKI5"6FNG_  W]?\/87MXUKJ&C[K?;RM;TTZ^9R/\
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M> ?"ZK'H'@WPYHZ6\2"+[%IEG$\:HN !,L>XD  94CID"K]I27V8R:W]U?\
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MQ^F?QKY.\=HI^-_PY9;D32"ZERJDD;=\G;IP?;MFOJX#]Z_.<NQ^GM_7\<T
M?+?[&20G]G_P?B%5 M.0 <-P#SST!S^!KZ0N;=4N-/E1]J#W.WH.>23WZYKY
MQ_8P:8_L]^"6G5$D-IDHF#U"C!'OC(]L^]?25Y#EK!L94'!AZ#L?KU.,9ZT
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M[WJMM+]==(//L;41+'(EO;H"[0I$(@!(,Q!MB@YC!P.>Q!)Q6U:W,913D/D
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M<]!S5(R;)A;_ &20.^6:5%PH!.>),X( ZGL0<^WXY7W_  4X\=^/A)IOPM^
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M5DP 2,@]Q]<']A8/"GA6R19H?#6C*,#!BL8& 7&%<,8V&"N#GT.,U?BTS1W
M>/3-+0 G;BR@##!(QE8QT.<>U>8JT:+E.45RR;=G9K=Z6>EE\MNNI@]WZO\
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M&>7?/77>KJ\3&9 LZ*UI\17J&UHZP<-%?L(\T:7<XGJ_QCXR? UBH1 (-RP
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M!%N<5:+ZR&6A"V@8A9"%#\,!G%VXPOIOW,^.^)ER&9._KZGTM_Z$:V"< 5$
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M#Y ,"E>K+><(_;$J1K"YNL?KD1BRUEQN,!#3J9R[J\(XX[6@)D2EDN!W'K8
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M$>7JPX;6;WL6N*A9_7%DXWE\6HL:;5AEW77&2^O<A11G)4F,28[$1-!N'_F
MEDE6X- ]+H%42C\#PA"4,04D@D8##_[P%L 2W +G-(9F[<N5F)%7=\)@JR01
M9L0(3PU3N0./?OPMD%BEA94.,T\VR.!"'29DX^-$)X_AN1$I?-Z2,K0PTAJR
MYJL*--VYY[_3*0[K9.X0J<I_2L&&3N:U-PJ?+A?H#R0'*_J\O1%\<@O<C0BP
M_\,B%G1D!3V9QAR<AVD#-%LH>7,G%@?B%^U3%Z+'C_\_&XAKE!YC3*G,Q>X>
M_:G"> E5$,A(3UT:##.0/+301Y6O_9AB-[SKQ[ZKSCNN_0*Z6"K&ZP(:%O&9
M#N<O]=ZF(<++:@L!=T5(R$+*]&M5<V;:L*#C%JS$%CPU5Q.$NPQ 2DN+CZYD
M!M*2R@[?WPDG _5(R8V0$PX)7L#H FL!:K*,QNB_?0:Z_]9HN 7N?"RMWD</
M^)W2"0M::Z\O99I?_%C\5>!%"'2QQ"FQ08IH(&_T[TJFA9_I*;EP"]RI5;;)
M>[_)2;UO_?])KF+'75&!#"24DBSD5<;R;Q&!TF5&K("\,PJ6BGEB>/CU)9L;
MUQW@&$DIEH"S&_XOM5_F,W6;JF=L&CGH.-##J.>5XG>R3.*4Y2WS88SEO9<Q
MFQ].5[G,@&C2/>:Q#MF9J>AHXC:N@J@"@FY99(8:;6E$,L_$H5Z1=YG4QRF^
M)NRWX5L@;A7E.9H2L:J$HB.VNC,K/GH1&Y\D;%(ZZ9['LK&BXW$UWT>4I?W4
M&KS^= O(\==TF&T?U'RBS\VH-LD<YRE_EIQKP]@AP.EV5\Q8_M9$@+X\SI_G
M7<!6)LZ8[S_G'__13E=#EP)Y2"4F/6-[T$H4^S[N%LAY&PEOWLWG_UK"%"8^
M7[>'22C-2K$LW0^U?K6T^_>\<Y8-SBJ"TM_7\21*"%.MV!GGD/ABO4!_CR.6
M+/JSGEAEW%B7^I-H+>5V5?K1C]!%%Z63MS<'DC/C&BRRVYG.7UH<4#HSF%19
M&((GT"-P9O!V]G]02P,$%     @ SDQX5'K/5GG@30$ "U !  L   !I;6=?
M,# V+FIP9Z2Z>SS3\?LW_IYAE!R3R9@RAR(YE<UII)PJD@HE9(I2CCD?-L>B
MF5.D6IM".A+)H9.S43)%"&5L+.?-<8SM7I_O[W'_[N_COO_X/7[W>W_M_7J]
MK^OU?+VNZ_F\KNW-'^33 &D'&WL;  0" =Z"#\ ?!JS_??N_NOX9^;^U >(W
M C)BH/-"!\"@O8"0# @L ^*W G   (G\UP3@_[E 0F!A$5&(F/BV[8()[Z0!
M(1 8+"0,%A$1%A:,Q@O& 6$9$=D]^E:B<LZ7('M#=AHDYCP64SM2V21_^CL+
M8>@3FB2^;9<"5'&WNH:FUK[]1H<.&R-1)M9'C]G8VMD[N)PY>\[5S?T\QO?R
M%3__J]?";H9'1$9%QR2GI*;=NIV>D9MW-[_@7N']!T^*2TJ?ECU[_J+J;?6[
MFMJZ^O?-+:UM[92.SB\_>OM^]@\,_AH:&Z<S)B:9?Z>FV8M+RRNK:YSUC7^X
M0 #X?T+_/^*2$> 2$A8&"T/^X0()1?Z;(",LLD=?5-;*&7(I1&ZO0:+8SB,Y
MCRN;Q-4,3[/D?4*_;]N%,!I39_^#]A]D_]^ )?W_0O8_@?V_N(8 "3!(<'A@
M&0 -;,UNI?$!&A%=16X;_75A[-:=S6-C>T'5QD0^X$$D8"66B*[];_A DQH?
M\'$RG6-Q=$(;?!&P)*= T1C8<EOD*.L$_.V?A':LA&O6V_@\PI80X5?'%&>Y
MXO,>.2L):7?U#T3?K1(:-]L6M=#N%#BH"B>B67_YP.!3-U:"2@LZ;JL,G18:
MLD*?^DOEW R:M>(#1]M'5_C MBT]H>B=Z9?%HL<'B(2B/ YSN<U]7&O=4!KB
MR0?ZI)A4!FC]%A^0S-I*Q_Z]3Z;R@==V6%K.:*4,_!/'6VD)CFLF8A3G'FP9
M+[WF \QZ/H#.=")O!&U@5_Z"E[;SE#6YLMCO!O <@2^O?ZYM!:[;L.P%5D5O
MO2\86GC0LV58D0^LQ/PXKG4[3$ME$-+@.8E#ZV/'OC=4PK?DY/D I:$YBW,3
M.^N\AAUSR])4-AQ%+G<;4AWS-R*)#?<F!:L+&55Y%$-?9@X5D8(T>1>6ITW6
M%OKX@.-=T'J^8)BPE=X>5Y&V7Q(-IM:I-)"-L"W%#3Y9QCS[[*FI4>4PPB?V
MU$);PL/HAN61! P?2'_^_BOO0TT(96(*O\K[> HRJ;EIXK*JN10F0-&*)<6;
MT/$K"_8"RWE;Z>B_]Z4Z^$!J HD/?/5:VIK6N/?U=A?$BOK4<(&74 U:3_WO
M\PYNFABO"@[ZB4\#9XWC.D7+EI8B?L2O>/$T\'R@%]O+!RHLX858UM_1P2Q>
M>@8?H(^.V?_W(_!Z^OE:AYUH@JE4H.'P0.UKH:#?ZRU$WS B+9SZV=9B&;3^
M^#\/9 B<9G4)G,H(@@N!]@E&<GRE'FNJ_"'?>MZ60 3GIVP0>=X_Y#JW5LTK
M>U>*I+H,^8"P8+$&8:R.\&7TV/^&L??*W:-[VT7=)(G>68'W!0\X<6Z29P73
MCG8DV&[ND]J4=5G=LV23H)C D41>3QP&!^I/)7N5_;Y6W;N^=Y>R7WP*D\A#
M\0&U"C-<PN6O F^$K0PUX9$X8P5PC8$EU8*>V'?ZF^#V_:V,[:\&X#MX/2\
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M_79[AB!)6E)F\N9%_86F.KI"%ZMD0=3G2#AS9L:NO$K-1^=VI_.C,E,+CZQ
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M >  P=A/H&Y/#PMR; 9/5CB$<,WM63C2A+R([ 6Q8?'?6\\OSC/>- I_.>/
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MV57;RH!D+46EL=OZO'P9M#;=&+F8C14*P)+A*>2Z A?:KZFUMU#M'+^W/\1
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M@*9XP2S8RV!GGYN1D<_7J,UD2:GHMK<S)+J-K;SR(2[-=J!$"."(Y&VL<\X
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MTR<"JP5(@(8U8-,!M9B7V[N0"6)Z9 SZ@\4U(1$K1LTCN2<OYC[<]_ES@>P
M'I0 ^ZWO% OEC:S)E<GC@8 (Y&!WSG-?C5_P4#MH4^*6A +<\Z%*2!(^T9N4
MZ<GCL/8"OV.NXYMML(YN5*CJ".W8^WY<?2OQ]_;]C0_$_0O,N[T.-"E#!+>
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MHZ@8.>/4=*?(@9@XR'&.5.,D=2>@S_A[U%.Y0H8L9F(60XSD8"GKT/\ 7ZT
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M3['%,$)8AIY(\\9P^.0.O7&[UZ=!59HA"MM)N=R9B,;B5VECC ]<8R1UY[4
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M&&+[2)'B>-7B4;E8  LW4,&R<AN#CZC%68RV-TJ^7GG)(8$DG@#H..@[=.U
M$3W"EE4Q2L6)*NJ_=!Z<CK@=QUJ=0P4.RE\ %1G!QVR/7&,^_M59#=GS1YD9
M#,YB.X A-V4QC_9QQZ9Z8%2Q"7:R&3$F,$M\RELD' .#@GIC^M $+S+,P22-
MHC_!)GA>ZD\?_JSVJ55\N&7<Q?EOG(^]U^;@]^IP>.@%+EHT(G*R,>G&#VZ'
MG '!]N!Z4Q&,D+K)PO8#C Z 9Q[=<?6@" J&6W=264,A())YP._]?\C\>?\
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M0!SP,CI]:J0SQ-%E'246Y+QKY@$A)YP[$<@< C QZG%"WUFGFSL=TLP(? R
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M)(4Y]^O?'OG% "JTDV^2"-HY2,;GQM./0<=>HY[GM3H%G7JIR.3SWZ=/T [
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M7=HE&\J>,YVCGCDG_P#7VJ-&$B$R0 J#N7 P3SD$_7'^- $:M';J0[RNA.0
MC' ZC!'8 <'T[<FI&5S)$5G94*J0I !"XR <\Y //ZTI-U(/E18E']]@RXY
MP, CL/I^JJ(G92X.], [>%)''0YX.">O XH B66='=9VV1AFPV,';N.#G.1D
M<Y^E-$&PF5[PA')=0<#"ORO.>H!X]>ISCB21%1RSOYH;++ V"Q!)V[>F!S@
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MGP9X@_8V^#=W\8?@UINK72F?4K#^VHT@O(=[ #<T<P< ."23@;<^H.<_I_\
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M.@("Y]..13XOW(;S)59&4%=W)R><-S@\\# '')J-06<222)[*<[0.W!/\O\
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M!Z\]_P .]  0B1JK?O&50-TF&8<>H"].<'&2>E-"QD ^H';_ .M3A$LC%27
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M2S'HYG)D8LWC^\'G(;W<<CN<QII%@L=<-8H8&BS1Q .JTR-[:Y<Q C,8GH#
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M9=NJ^<LH]3-/(Z9Y*2(PRB_O+=3GAAC02($'L,-C(LL)Q=R%NT#@U_MZG_0
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M[@/"J*.4>^\!I O_[@%D4APT2Y;H[+>?JB0'U,V]S^S"FO$Y!ZN8#JT+ ZV
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MS$/S&,/4[A(ZZ='[.HT0\OD4/%=*KWN YH1^!6Y93OHR5:K?0."6?U72T3W
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M2QM!B_!N)X^.GL.<S>8'MU>K6&S= RSN 1+8T#$N;CM\S&#DO]![@*#3\D/
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M, _@ZQ/=+@Y2F%O>?R2;*8R[(5+(_]KY [Q^[%XQ4"9\'ZZDC0IDP#&5+[9
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M@B?@=R-( /N7XQ<<>J7?C28\G#HZC 97D]BZOYHBDY]U\[S,XN;?(F7_Z#\
MV IA=@ZN_+8AV1-L8E(T.#Z8SP[:++X"S@U><C16]7AH7XV"A0Y;E/R["HW1
M)@2 #Y&$59O==,VP1I%NU7#W&G3IP#-2<::PX32235E.IQR.+S3C#^Q$CR^B
M/+OGV$O ^M>_BP67G?!W;&W<"=A<P431Q[;Y/HSCWB"[:&B^')VMV]=?MS4,
M2ZDZY(S)XN3JA,529_!8B$M5M-)SJ,8!4-^!ID_SS!'*;<R9:N)P$IW4R^8K
MNVM9#F/%,BXN\WSN%)EXFT3=++9<\%_Q>SL?8^!F,2TKMJ<V\-(@T.N@,WD0
MX@.:_-WE( K4@%HD D9AADP'$J>(=)7ATA*[($'4L$1#G]@O:J/79+F1\=5(
M_+0]N:V+2K6K#:_>MEMG1VNZ?\=>$ENUEFJLC^LBHWJW[::AT84"UZT/0%CR
M@%RZ,&?=2!AC/80 #+<E>Z?BGRPP>BM08/]IE(Z(+V-'6!1'\( 184^*8ILG
MS1;]8_?\\[/IK?B@L(I!37/_;VV-<ZV:G<58Z*S"%_S*=/J8W*%DP[Y/Z3ZL
M(!Y3XZ,RJBS$MSI\5'4<0)6?E%VNTS2G/R)0Y,0^.GJ9]=9XQQA#O;]I/*B<
M L';.JD:@ D%$#D83IG(MQ[.$T?U$7#RXV]Y@S-O7GH*I1_K9KQ;X=F0_"]=
M3=F/:KA+:/QD',>='1L5G<*DM1< KM(W*PT,+5.:]9J!H>W"-V]?Q!N8DL_P
MB.WA<")3U7SVY-_ENP!WZ;Z+!8/P(V,^3%/\X*H,^5NK9#*2[[CR;_B,P>I'
M)H=_)I()>*)M,-77P_.<,7N-CW!'H282"M@L1M!$OA@W2C7_,JEI'#8Q9"0M
MQ]AK$[[:Y7,47G8R=7D/:([!/G/FV:HEE61Z0>8F(,- =#7$23\>1)6JH[$!
MLSNR,S0/X&2M]7H.-IC'^?Y/1]<++'""Q!+CL4V&Z?\-U :H_AC1$TMY O[[
MY=T:IYW<Q<V<PLH-;"SR7U[U^2);-H9F4RUCX)UKB%1%2HP7S\G[NI7P)KW&
MT ">MWYJ7$SN.#F5RYNK,)I.HC!%U-R@]2*?\43G4W1;_RKEWX"*@"HE)E"L
M%U6T0UGKZO> 1M@+_Q+<5+Q8H\_GECG1UHW6*%T1O%T()0R1Q\Z"2NI=+6 7
M16VO9.4#TUO:_7Q_$(H/IVL, C9S$',[EV4/)8H?7421)"AU#R "3[:N)A6
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MQ3LZ)XS7N ?8P-#/^C^[S]X#6.I?#F:T[0QSY>QX(E.*)<.-">\!ROR8[7O
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M/H>^A/!1;=]Z86US A:GYIE<V[ #HMO%G\7=G:A:9.[81"^9S;08X2-"0JX
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M>39E,GPY'PN 9^/I%ECBLB=<_A[,O/0#/L#\>WQ^\\\&YZ=GLD1'A\7,$I@
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MM%9"QR9@L_SAWFYSU^!90D(GM7NMHERTW,/=+2J6FW];/^6H4)=N9G#N([+
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M58]X,K8.H*L?#0R$_U5:O.@%0HF(\<4GZ'8W$M.%X&YN)S=OMS5[W5(N^\O
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MC'A\'^%8>^C4"T?@:Q4]O<-T A/>O JNQ*JOYC%2 \/4@>'#2,P$8FS5R79
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MC3&%-UWJ'=ZF!'7JC7D,:HC;R",0,RVK.N7.>FWQ0>%C\20>4DOD/:A]E9[
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ME'\D8T2=]^RB#?GL6%:7-'X;YKM2JYR^QYSQ1J%Y]T_S?\Z@N[3*K@"XB2M
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M?$TH:?$IW<@2  D85]0S5CS9ADN).]P3N9\G U26GAD2^MS6K!7Y,FH,%#G
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M+FAT;5!+ 0(4 Q0    ( ,Y,>%13^D*\%0<  +TS   =              "
M 3,R!0!F,C!F,C R,65X,3(M,E]C86YF:71E8FEO+FAT;5!+ 0(4 Q0    (
M ,Y,>%1=LJ>U/00  -D4   =              "  8,Y!0!F,C!F,C R,65X
M,3,M,5]C86YF:71E8FEO+FAT;5!+ 0(4 Q0    ( ,Y,>%0FC8/J, 0   $4
M   =              "  ?L]!0!F,C!F,C R,65X,3,M,E]C86YF:71E8FEO
M+FAT;5!+ 0(4 Q0    ( ,Y,>%3SI. U_@,  #,A   =              "
M 69"!0!F,C!F,C R,65X,34M,5]C86YF:71E8FEO+FAT;5!+ 0(4 Q0    (
M ,Y,>%2@<C70"0(  $ '   <              "  9]&!0!F,C!F,C R,65X
M."TQ7V-A;F9I=&5B:6\N:'1M4$L! A0#%     @ SDQX5"_R-D\F"0  O D
M  L              ( !XD@% &EM9U\P,#$N:G!G4$L! A0#%     @ SDQX
M5+/&'$PES $ XM(!  L              ( !,5(% &EM9U\P,#(N:G!G4$L!
M A0#%     @ SDQX5(E4:[P^40$ 45D!  L              ( !?QX' &EM
M9U\P,#,N:G!G4$L! A0#%     @ SDQX5#,.OV8']P$ \_<!  L
M     ( !YF\( &EM9U\P,#0N:G!G4$L! A0#%     @ SDQX5*3PXD4K/0$
ML#\!  L              ( !%F<* &EM9U\P,#4N:G!G4$L! A0#%     @
MSDQX5'K/5GG@30$ "U !  L              ( !:J0+ &EM9U\P,#8N:G!G
64$L%!@     2 !( IP0  '/R#     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
